

Europäisches Patentamt European Patent Office

Office européen des brevets

Bescheinigung

Certificate

Attestation

REC'D 2 1 MAY 2004

WIPO PCT

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

7001014

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°


03450087.6



Der Präsident des Europäischen Patentamts; Im Auftrag

For the President of the European Patent Office Le Président de l'Office européen des brevets p.o.

R C van Dijk





Anmeldung Nr:

Application no.:

03450087.6

Demande no:

Anmeldetag:

Date of filing:

Date de dépôt:

15.04.03

Anmelder/Applicant(s)/Demandeur(s):

Intercell Biomedizinische Forschungs- und Entwicklungs AG Campus Vienna Biocenter 6 1030 Vienna AUTRICHE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention: (Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung. If no title is shown please refer to the description. Si aucun titre n'est indiqué se referer à la description.)

S. pneumoniae antigens

In Anspruch genommene Prioriät(en) / Priority(ies) claimed /Priorité(s) revendiquée(s) Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/ Classification internationale des brevets:

C07K14/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR LI

The present invention relates to isolated nucleic acid molecules, which encode antigens for *Streptococcus pneumoniae*, which are suitable for use in preparation of pharmaceutical medicaments for the prevention and treatment of bacterial infections caused by *Streptococcus pneumoniae*.

Streptococcus pneumoniae (Pneumococcus) is a lancet-shaped, gram-positive, facultative anaerobic bacterium. It is only the encapsulated organism that is pathogenic for humans and experimental animals. Capsules are antigenic and form the basis for classifying pneumococci by serotypes. Ninety serotypes have been identified, based on their reaction with type-specific antisera. Most S. pneumoniae serotypes have been shown to cause serious disease, and the ten most common serotypes are estimated to account for about 62% of invasive disease worldwide. The ranking and serotype prevalence differs by age group and geographic area.

Pneumococci are common inhabitants of the respiratory tract, and may be isolated from the nasopharynx of 5% to 70% of normal adults. Rates of asymptomatic carriage vary with age, environment, and the presence of upper respiratory infections. Only 5%-10% of adults without children are carriers. In schools and orphanages, 27% to 58% of students and residents may be carriers. On military installations, as many as 50% to 60% of service personnel may be carriers. The duration of carriage varies and is generally longer in children than adults (reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book).

The relationship of carriage to the development of natural immunity is poorly understood. In addition, the immunologic mechanism that allows disease to occur in a carrier is poorly understood.

Streptococcus pneumoniae is an important agent of human disease at the extremities of age and in those who have underlying disease. Pneumococcal disease kills more people – in the US 40,000 or more each year – than all other vaccine preventable diseases combined. The major clinical syndromes of pneumococcal disease include pneumonia, bacteremia, and meningitis. The disease most often occurs when a predisposing condition exists, particularly pulmonary disease. It is a common bacterial complication of antecedent viral respiratory infection such as influenza and measles, and of chronic conditions such as chronic obstructive pulmonary disease, diabetes, congestive heart failure, renal failure, smoking and alcoholism. Pneumococcal infections are more common during the winter and in early spring when respiratory diseases are more prevalent. Immunodeficiency (splenic dysfunction, iatrogen, etc.) is a risk factor for development of fatal pneumococcal infections, because of decreased bacterial clearance and lack of antibodies. The incubation period is short, 1-3 days. Symptomes include an abrupt onset of fever and shaking chills or rigor, productive cough, pleuritic chest pain, dyspnoe, tachycardia and hypoxia.

5. pneumoniae is responsible for 88% of bacteremia infections in the US. Pneumonia is the most common form of invasive pneumococcal diseases: 150.000-570.000 cases per year (US). 36% of adult community-acquired and 50% of hospital-acquired pneumonia is caused by S. pneumoniae (US). The incidence of disease among adults aged 65 years and older has been reported to be ~60 cases/100.000. Case fatality rates for this disease increase from 1.4% for those aged two or younger to as high as 20.6% among those aged 80 or older. Diseases caused by influenza and Pneumococcus are together the fifth leading cause of death for persons aged 65 and older. Mortality attributable to these pathogens is more than 90% in this age group. Bacteremia occurs in about 25-30% of patients with pneumonia. The overall mortality rate of bacteremia is about 20%, but may be as high as 60% in elderly people. In 1998, 51% of all deaths attributable to invasive pneumococcal diseases occurred in age group above 65 years. Pneumococci cause 13%-19% of all cases of bacterial meningitis in the United States. An estimated 3,000 to 6,000 cases of pneumococcal meningitis occur each year. One-quarter of patients with pneumococcal meningitis also have pneumonia. The clinical symptoms, spinal fluid profile and neurologic complications are similar to other forms of purulent bacterial meningitis (reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book).

In children, Pneumococci are a common cause of acute otitis media, and are detected in 28%-55% of middle ear aspirates. By age 12 months, 62% of children have had at least one episode of acute otitis media. Middle ear infections are the most frequent reasons for pediatric office visits in the United States, resulting in over 20 million visits annually. Complications of pneumococcal otitis media may include mastoiditis and meningitis. Bacteremia without a known site of infection is the most common invasive clinical presentation among children <2 years of age, accounting for approximately 70% of invasive disease in this age group. Bacteremic pneumonia accounts for 12%-16% of invasive pneumococcal disease among children 2 years of age. With the decline of invasive Hib disease, S. pneumoniae has become the leading cause of bacterial meningitis among children <5 years of age in the United States. Children <1 year have the highest rates of pneumococcal meningitis, approximately 10 cases per 100,000 population. The burden of pneumococcal disease among children <5 years of age is significant. An estimated 17,000 cases of invasive disease occur each year, of which 13,000 are bacteremia without a known site of infection and about 700 are of meningitis. An estimated 200 children die every year as a result of invasive pneumococcal disease. Although not considered invasive disease, an estimated 5 million cases of acute otitis media occur each year among children <5 years of age (reviewed Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book).

A definitive diagnosis of infection with *Streptococcus pneumoniae* generally relies on isolation of the organism from blood or other normally sterile body sites. Tests are also available to detect capsular polysaccharide antigen in body fluids.

Penicillin is the drug of choice for treatment. However, successful implementation of anti-infective therapy has become increasingly difficult because of widespread antimicrobial resistance. Resistance to penicillin is rising, and according to recent reports it reaches ~ 25% in the US {Whitney, C. et al., 2000}. The proportion of macrolide-resistant strains reached ~ 20 % {Hyde, T. et al., 2001}. Use of antimicrobial agents is highly correlated with the increase in resistance of *S. pneumoniae* to @-lactams and macrolides {McCormick, A. et al., 2003}.

However, even with effective antibiotic therapy (sensitive strains), the case fatality rate of invasive disease is high with an average of 10% in the developed world and can be much higher with certain serotypes, in elderly patients and in cases of bacteremia or meningitis (up to 80%).

Thus, there remains a need for an effective treatment to prevent or ameliorate spneumoococcal infections. A vaccine could not only prevent infections by streptococci, but more specifically prevent or ameliorate colonization of host tissues (esp. in nasopharynx), thereby reducing the incidence of upper respiratory infections and other suppurative infections, such otitis media. Elimination of invasive diseases - pneumonia, bacteremia and meningitis, and sepsis - would be a direct consequence of reducing the incidence of acute infection and carriage of the organism. Vaccines capable of showing cross-protection against the majority of *S. pneumoniae* strains causing human infections would also be useful to prevent or ameliorate infections caused by all other streptococcal species, namely groups A, B, C and G.

A vaccine can contain a whole variety of different antigens. Examples of antigens are whole-killed or attenuated organisms, subfractions of these organisms/tissues, proteins, or, in their most simple form, peptides. Antigens can also be recognized by the immune system in form of glycosylated proteins or peptides and may also be or contain polysaccharides or lipids. Short peptides can be used since for example cytotoxic T-cells (CTL) recognize antigens in form of short usually 8-11 amino acids long peptides in conjunction with major histocompatibility complex (MHC). B-cells can recognize linear epitopes as short as 4-5 amino acids, as well as three-dimensional structures (conformational epitopes). In order to obtain sustained, antigen-specific immune responses, adjuvants need to trigger immune cascades that involve all cells of the immune system. Primarily, adjuvants are acting, but are not restricted in their mode of action, on so-called antigen presenting cells (APCs). These cells usually first

encounter the antigen(s) followed by presentation of processed or unmodified antigen to immune effector cells. Intermediate cell types may also be involved. Only effector cells with the appropriate specificity are activated in a productive immune response. The adjuvant may also locally retain antigens and co-injected other factors. In addition the adjuvant may act as a chemoattractant for other immune cells or may act locally and/or systemically as a stimulating agent for the immune system.

Efforts to develop effective pneumococcal vaccines began as early as 1911. However, with the advent of penicillin in the 1940s, interest in the vaccine declined, until it was observed that many patients still died despite antibiotic treatment. By the late 60s, efforts were again being made to develop a polyvalent vaccine. The first pneumococcal vaccines contained purified capsular polysaccharide antigen from 14 different types of pneumococcal bacteria. In 1983, a 23-valent polysaccharide vaccine (PPV23) was licensed and replaced the 14- valent vaccine, which is no longer produced. PPV23 contains polysaccharide antigen from 23 types of pneumococcal bacteria which cause 88% of bacteremic pneumococcal disease. In addition, cross-reactivity occurs for several capsular types which account for an additional 8% of bacteremic disease. Two polysaccharide vaccines are available in the United States (Pneumovax 23, Merck, and Pnu-Immune 23, Wyeth-Lederle). Both vaccines contain 25 μg of each antigen per dose and include either phenol or thimerosal as a preservative.

The first pneumococcal conjugate vaccine (PCV7, Prevnar) was licensed in the United States in 2000. It includes purified capsular polysaccharide of 7 serotypes of S. pneumoniae (4, 9V, 14, 19F, 23F, 18C, and 6B) conjugated to a nontoxic variant of diphtheria toxin known as CRM197. The serotypes included in Prevnar accounted for 86% of bacteremia, 83% of meningitis, and 65% of acute otitis media among children <6 years of age in the United States during 1978-1994 (reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book). Additional pneumococcal polysaccharide conjugate vaccines containing 9 and 11 serotypes of S. pneumoniae are being developed. The vaccine is administered intramuscularly. After 4 doses of Prevnar vaccine, virtually all healthy infants develop antibody to all 7 serotypes contained in the vaccine. Prevnar has also been shown to be immunogenic in infants and children, including those with sickle cell disease and HIV infection. In a large clinical trial, Prevnar was shown to reduce invasive disease caused by vaccine serotypes, and reduce invasive disease caused by all serotypes, including serotypes not in the vaccine. Children who received Prevnar had fewer episodes of acute otitis media and underwent fewer tympanostomy tube placements than unvaccinated children. The duration of protection following Prevnar is currently unknown. Immunization with Prevnar reduces the rate of nasopharyngeal carriage of the vaccine serotypes, while the overall carriage rate is unaffected. Unfortunately, it has also been shown to induce serotype redistribution, that is the replacement of vaccine serotypes by strains, which are not covered by Prevnar (Pelton, S. et al., 2003).

Pneumococcal vaccine is recommended to be administered routinely to i., all children as part of the routine shildhood immunization schedule, ii., adults 65 years of age and older and iii., persons aged >2 years with normal immune systems who have chronic illnesses, including cardiovascular disease, pulmonary disease, diabetes, alcoholism, cirrhosis, or cerebrospinal fluid leaks. In the elderly population the target groups for pneumococcal vaccine and influenza vaccine overlap. These vaccines can be given at the same time at different sites without increased side effects.

High mortality is observed among high-risk individuals (with underlying disease – mainly viral respiratory infection, immunocompromise) even with effective antibiotic therapy. The mAb approach targets patients with serious disease and provides immediate immune enhancement for the clearance of the bacteria. Through opsonization bacteria are killed within phagocytic cells and not lysed in the blood by antibiotics. This mechanism of action can help to eliminate the release of toxins (such as pneumolysin and other cytotoxins), which worsen the clinical condition of septic patients. Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy.

Immunoglobulins are an extremely versatile class of antimicrobial proteins that can be used to prevent and treat emerging infectious diseases. Antibody therapy has been effective against a variety of diverse microorganisms reviewed in {Burnie, J. et al., 1998}.

Although capsular specific antibodies have been shown to be highly protective, it remains unclear what concentration of these serotype-specific antibodies protect against disease and more recently it has become clear that opsonic activity and avidity of these antibodies are more critical determinants of protection than concentration.

Protein conjugate vaccines are no doubt a great new addition to the amarmatorium in the battle against pneumococcal disease, but the vaccine contains a limited number of pneumococcal serotypes and given adequate ecological pressure, replacement disease by non-vaccine serotypes remains a real threat, particularly in areas with very high disease burden.

During the last decade the immunogenicity and protective capacity of several pneumococcal proteins have been described in animal models and these are now being explored for the development of species-common protein based vaccines. Such proteins are the Pneumococcal surface protein A (PspA, [McDaniel, L. et al., 1991]; {Roche, H. et al., 2003}), Pneumococcal surface adhesin A (PsaA, {Talkington, D. et al., 1996}), Choline binding protein A (CbpA, [Rosenow, C. et al., 1997]), LytB glucosaminidase, LytC muramidase, PrtA serine protease, PhtA (histidine triad A) and Pneumococcal vaccine antigen A (PvaA) {Wizemann, T. et al., 2001}; {Adamou, J. et al., 2001}.

Certain proteins or enzymes displayed on the surface of gram-positive organisms significantly contribute to pathogenesis, and might be involved in the disease process caused by these pathogens. Often, these proteins are involved in direct interactions with host tissues or in conceiling the bacterial surface from the host defense mechanisms [Navarre, W. et al., 1999]. S. pneumoniae is not an exception in this regard. Several surface proteins are characterized by as virulence factors, important for pneumococcal pathogenicity reviewed in [Jedrzejas, M., 2001]. If antibodies to these proteins could offer better protection to humans, they could provide the source of a novel, protein-based pneumococcal vaccine to be used in conjunction with or in place of the more traditional capsular polysaccharise vaccine. The use of some of the above-described proteins as antigens for a potential vaccine as well as a number of additional candidates reviewed in [Di Guilmi, A. et al., 2002] resulted mainly from a selection based on easiness of identification or chance of availability. There is a demand to identify relevant antigens for S. pneumoniae in a more comprehensive way.

The present inventors have developed a method for identification, isolation and production of hyperimmune serum reactive antigens from a specific pathogen, especially from Staphylococcus aureus and Staphylococcus epidermidis (WO 02/059148). However, given the differences in biological property, pathogenic function and genetic background, Streptococcus pneumoniae is distinctive from Staphylococcus strains. Importantly, the selection of sera for the identification of antigens from S. pneumoniae is different from that applied to the S. aureus screens. Three major types of human sera were collected for that purpose. First, healthy adults below <45 years of age preferably with small children in the household were tested for nasopharyngeal carriage of S. pneumoniae. A large percentage of young children are carriers of S. pneumoniae, and they are considered to be a source for exposure for their family members. Based on correlative data, protective (colonization neutralizing) antibodies are likely to be present in exposed individuals (children with high carriage rate in the household) who are not carriers of S. pneumoniae. To be able to select for relevant serum sources, a series of ELISAs measuring anti-S. pneumoniae IgG and IgA antibody levels were performed with bacterial lysates and culture supernatant proteins. Sera from high titer non-carriers were included in the genomic-based antigen identification. This approach for selection of human sera is basically very different from that used for S. aureus, where carriage or non-carriage state couldn't be associated with antibody levels. Second, serum samples from

convalescent phase patients with invasive pneumococcal diseases were characterized and selected in the same way. The third group of sera, containing longitudinally collected samples were also obtained from individuals with invasive disease and were used mainly for validation purposes. The main value of this collection is that one can follow the changes in antigen-specific antibody levels before diase (prae-), at the time of onset (acute) and during recovery (convalescent). This latter group helps in the selection of epitopes, which induce antibodies during disease and missing in the prae-disease state.

The genomes of the two bacterial species S. pneumoniae and S. aureus by itself show a number of important differences. The genome of S. pneumoniae contains app. 2.16 Mb, while S. aureus harbours 2.85 Mb. They have an average GC content of 39.7 and 33%, respectively and approximately 30 to 45% of the encoded genes are not shared between the two pathogens. In addition, the two bacterial species require different growth conditions and media for propagation. While S. pneumoniae is a strictly human pathogen, S. aureus can also be found infecting a range of warm-blooded animals. A list of the most important diseases, which can be inflicted by the two pathogens is presented below. S. aureus causes mainly nosocomial, opportunistic infections: impetigo, folliculitis, abscesses, boils, infected lacerations, endocarditis, meningitis, septic arthritis, pneumonia, osteomyelitis, scalded skin syndrome (SSS), toxic shock syndrome. S. pneumoniae causes mainly community aquired infections: upper (pharyngitis, otitis media) and and lower respiratory infections (pneumonia), as well as bacteremia, sepsis and meningitis.

The complete genome sequence of a capsular serotype 4 isolate of *S. pneumoniae*, designated TIGR4 was determined by the random shotgun sequencing strategy (GenBank accession number AE005672; see www.tigr.org/tigrscripts/CMR2/CMRHomePage.spl). This clinical isolate was taken from the blood of a 30-year-old male patient in Kongsvinger, Norway, and is highly invasive and virulent in a mouse model of infection.

The problem underlying the present invention was to provide means for the development of medicaments such as vaccines against *S. pneumoniae* infection. More particularly, the problem was to provide an efficient, relevant and comprehensive set of nucleic acid molecules or hyperimmune serum reactive antigens from *S. pneumoniae* that can be used for the manufacture of said medicaments.

Therefore, the present invention provides an isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence, which is selected from the group consisting of:

- a) a nucleic acid molecule having at least 70% sequence identity to a nucleic acid molecule selected from Seq ID No 1, 101-144.
- b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
- c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
- d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b), or c)
- e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid molecule defined in a), b), c) or d).

According to a preferred embodiment of the present invention the sequence identity is at least 80%, preferably at least 95%, especially 100%.

Furthermore, the present invention provides an isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence selected from the group consisting of

 a nucleic acid molecule having at least 96% sequence identity to a nucleic acid molecule selected from Seq ID No 2-6, 8, 10-16, 18-23, 25-31, 34, 36, 38-42, 44, 47-48, 51, 53, 55-62, 64, 67, 71-76, 78-79, 81-94, 96-100.

- b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
- c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid-molecule of a)
  - d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b) or c),
  - e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

According to another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of

- a) a nucleic acid molecule selected from Seq ID No 9, 17, 24, 32, 37, 43, 52, 54, 65-66, 70, 80.
- b) a nucleic acid molecule which is complementary to the nucleic acid of a),
- c) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

Preferably, the nucleic acid molecule is DNA or RNA.

According to a preferred embodiment of the present invention, the nucleic acid molecule is isolated from a genomic DNA, especially from a S. pneumoniae genomic DNA.

According to the present invention a vector comprising a nucleic acid molecule according to any of the present invention is provided.

In a preferred embodiment the vector is adapted for recombinant expression of the hyperimmune serum reactive antigens or fragments thereof encoded by the nucleic acid molecule according to the present

The present invention also provides a host cell comprising the vector according to the present invention.

According to another aspect the present invention further provides a hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to the present invention.

In a preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of Seq ID No 145, 245-288.

In another preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of Seq ID No 146-150, 152, 154-160, 162-167, 169-175, 178, 180, 182-186, 188, 191-192, 195, 197, 199-206, 208, 211, 215-220, 222-223, 225-238, 240-244.

In a further preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of Seq ID No 153, 161, 168, 176, 181, 187, 196, 198, 209-210, 214, 224.

According to a further aspect the present invention provides fragments of hyperimmune serum-reactive antigens selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa" and "location of identified immunogenic region" of Table 1; the serum reactive epitopes of Table 2, especially peptides comprising amino acids 4-11, 35-64, 66-76, 101-108, 111-119 and 57-114 of Seq ID No 145; 5-27, 32-64, 92-102, 107-113, 119-125, 133-139, 148-162, 177-187, 195-201, 207-214, 241-251, 254-269, 285-300, 302-309, 317-324, 332-357, 365-404, 411-425, 443-463, 470-477, 479-487, 506-512, 515-520, 532-547, 556-596, 603-610, 616-622, 624-629, 636-642, 646-665, 667-674, 687-692, 708-720, 734-739, 752-757, 798-820, 824-851, 856-865 and 732-763 of Seq ID No 146; 14-21, 36-44, 49-66, 102-127, 162-167, 177-196, 45-109 and 145-172 of Seq ID No 147; 17-35, 64-75, 81-92, 100-119, 125-172, 174-183, 214222, 230-236, 273-282, 287-303, 310-315, 331-340, 392-398, 412-420, 480-505, 515-523, 525-546, 553-575, 592-598, 603-609, 617-625, 631-639, 644-651, 658-670, 681-687, 691-704, 709-716, 731-736, 739-744, 750-763, 774-780, 784-791, 799-805, 809-822, 859-870, 880-885, 907-916, 924-941, 943-949, 973-986, 1010-1016, 1026-1036, 1045-1054, 1057-1062, 1082-1088, 1095-1102, 1109-1120, 1127-1134, 1140-1146, 1152-1159, 1169-1179, 1187-1196, 1243-1251, 1262-1273, 1279-1292, 1306-1312, 1332-1343, 1348-1364, 1379-1390, 1412-1420, 1427-1436, 1458-1468, 1483-1503, 1524-1549, 1574-1588, 1614-1619, 1672-1685, 1697-1707, 1711-1720, 1738-1753, 1781-1787, 1796-1801, 1826-1843, 132-478, 508-592 and 1753-1810 of Seq ID No 148; 15-43, 49-55, 71-77, 104-110, 123-130, 162-171, 180-192, 199-205, 219-227, 246-254, 264-270, 279-287, 293-308, 312-322, 330-342, 349-356, 369-377, 384-394, 401-406, 416-422, 432-439, 450-460, 464-474, 482-494, 501-508, 521-529, 536-546, 553-558, 568-574, 584-591, 602-612, 616-626, 634-646, 653-660, 673-681, 688-698, 705-710, 720-726, 736-749, 833-848, 1-199, 200-337, 418-494 and 549-647 of Seq ID No 149; 9-30, 65-96, 99-123, 170-178 and 1-128 of Seq ID No 150; 7-32, 34-41, 96-106, 127-136, 154-163, 188-199, 207-238, 272-279, 306-312, 318-325, 341-347, 353-360, 387-393, 399-406, 434-440, 452-503, 575-580, 589-601, 615-620, 635-640, 654-660, 674-680, 696-701, 710-731, 1-548 and 660-691 of Seq ID No 151; 4-19, 35-44, 48-59, 77-87, 93-99, 106-111, 130-138, 146-161 and 78-84 of Seq ID No 152; 24-30, 36-43, 64-86, 93-99, 106-130, 132-145, 148-165, 171-177, 189-220, 230-249, 251-263, 293-300, 302-312, 323-329, 338-356, 369-379, 390-412 and 179-193 of Seq ID No 153; 30-39, 61-67, 74-81, 90-120, 123-145, 154-167, 169-179, 182-197, 200-206, 238-244, 267-272 and 230-265 of Seq ID No 154; 14-20, 49-65, 77-86 and 2-68 of Seq ID No 155; 4-9, 26-35, 42-48, 53-61, 63-85, 90-101, 105-111, 113-121, 129-137, 140-150, 179-188, 199-226, 228-237, 248-255, 259-285, 299-308, 314-331, 337-343, 353-364, 410-421, 436-442 and 110-144 of Seq ID No 156; 36-47, 55-63, 94-108, 129-134, 144-158, 173-187, 196-206, 209-238, 251-266, 270-285, 290-295, 300-306, 333-344, 346-354, 366-397, 404-410, 422-435, 439-453, 466-473, 515-523, 529-543, 554-569, 571-585, 590-596, 607-618, 627-643, 690-696, 704-714, 720-728, 741-749, 752-767, 780-799, 225-247 and 480-507 of Seq ID No 157; 16-25, 36-70, 80-93, 100-106 and 78-130 of Seq ID No 158; 18-27, 41-46, 50-57, 65-71, 79-85, 93-98, 113-128, 144-155, 166-178, 181-188, 201-207, 242-262, 265-273, 281-295, 303-309, 318-327 and 36-64 of **Seq ID No** 159; 7-29, 31-44, 50-59, 91-96, 146-153, 194-201, 207-212, 232-238, 264-278, 284-290, 296-302, 326-353, 360-370, 378-384, 400-405, 409-418, 420-435, 442-460, 499-506, 529-534, 556-562, 564-576, 644-651, 677-684, 687-698, 736-743, 759-766, 778-784, 808-814, 852-858, 874-896, 920-925, 929-935, 957-965, 1003-1012, 1021-1027, 1030-1044, 1081-1087, 1101-1111, 1116-1124, 1148-1159, 1188-1196, 1235-1251, 1288-1303, 1313-1319, 1328-1335, 1367-1373, 1431-1437, 1451-1458, 1479-1503, 1514-1521, 1530-1540, 1545-1552, 1561-1568, 1598-1605, 1617-1647, 1658-1665, 1670-1676, 1679-1689, 1698-1704, 1707-1713, 1732-1738, 1744-1764, 1-70, 154-189, 922-941, 1445-1462 and 1483-1496 of Seq ID No 160; 6-51, 81-91, 104-113, 126-137, 150-159, 164-174, 197-209, 215-224, 229-235, 256-269, 276-282, 307-313, 317-348, 351-357, 376-397, 418-437, 454-464, 485-490, 498-509, 547-555, 574-586, 602-619 and 452-530 of Seq ID No 161; 25-31, 39-47, 49-56, 99-114, 121-127, 159-186, 228-240, 253-269, 271-279, 303-315, 365-382, 395-405, 414-425, 438-453 and 289-384 of Seq ID No 162; 9-24, 41-47, 49-54, 68-78, 108-114, 117-122, 132-140, 164-169, 179-186, 193-199, 206-213, 244-251, 267-274, 289-294, 309-314, 327-333, 209-249 and 286-336 of Seq ID No 163; 9-28, 53-67, 69-82, 87-93, 109-117, 172-177, 201-207, 220-227, 242-247, 262-268, 305-318, 320-325 and 286-306 of Seq ID No 164; 4-10, 26-39, 47-58, 63-73, 86-96, 98-108, 115-123, 137-143, 148-155, 160-176, 184-189, 194-204, 235-240, 254-259, 272-278 and 199-283 of Seq ID No 165; 4-26, 33-39, 47-53, 59-65, 76-83, 91-97, 104-112, 118-137, 155-160, 167-174, 198-207, 242-268, 273-279, 292-315, 320-332, 345-354, 358-367, 377-394, 403-410, 424-439, 445-451, 453-497, 511-518, 535-570, 573-589, 592-601, 604-610 and 202-242 of Seq ID No 166; 8-30, 36-45, 64-71, 76-82, 97-103, 105-112, 134-151, 161-183, 211-234, 253-268, 270-276, 278-284, 297-305, 309-315, 357-362, 366-372, 375-384, 401-407, 409-416, 441-455, 463-470, 475-480, 490-497, 501-513, 524-537, 552-559, 565-576, 581-590, 592-600, 619-625, 636-644, 646-656 and 316-419 of Seq ID No 167; 4-17, 52-58, 84-99, 102-110, 114-120, 124-135, 143-158, 160-173, 177-196, 201-216, 223-250, 259-267, 269-275 and 1-67 of Seq ID No 168; 6-46, 57-67, 69-80, 82-133, 137-143, 147-168, 182-187, 203-209, 214-229, 233-242, 246-280 and 53-93 of Seq ID No 169; 7-40, 50-56, 81-89, 117-123, 202-209, 213-218, 223-229, 248-261, 264-276, 281-288, 303-308, 313-324, 326-332, 340-346, 353-372, 434-443, 465-474, 514-523, 556-564, 605-616, 620-626, 631-636, 667-683, 685-699, 710-719, 726-732, 751-756, 760-771, 779-788, 815-828, 855-867, 869-879, 897-902, 917-924, 926-931, 936-942, 981-1000, 1006-1015, 1017-1028, 1030-1039, 1046-1054, 1060-1066, 1083-1092, 1099-1112, 1122-1130, 1132-1140, 1148-1158, 1161-1171, 1174-1181, 1209-1230, 1236-1244, 1248-1254, 1256-1267, 1269-1276, 1294-1299, 1316-1328, 1332-1354, 1359-1372, 1374-1380, 1384-1390, 1395-1408, 1419-1425, 1434-1446, 1453-1460, 1465-1471, 1474-

1493, 1505-1515, 1523-1537, 1547-1555, 1560-1567, 1577-1605, 1633-1651, 1226-1309, 1455-1536 and 1538--1605 of Seq ID No 170, 4-10, 31-39, 81-88, 106-112, 122-135, 152-158, 177-184, 191-197, 221-227, 230-246, 249-255, 303-311, 317-326, 337-344, 346-362, 365-371, 430-437, 439-446, 453-462, 474-484 and 449-467 of Seq ID No 171; 9-15, 24-35, 47-55, 122-128, 160-177, 188-196, 202-208, 216-228, 250-261, 272-303, 318-324, 327-339, 346-352, 355-361, 368-373, 108-218 and 344-376 of Seq ID No 172; 6-14, 17-48, 55-63, 71-90, 99-109, 116-124, 181-189, 212-223, 232-268, 270-294, 297-304, 319-325, 340-348, 351-370, 372-378, 388-394, 406-415, 421-434 and 177-277 of Seq ID No 173; 21-39, 42-61, 65-75, 79-85, 108-115 and 11-38 of Seq ID No 174; 4-17, 26-39, 61-76, 103-113, 115-122, 136-142, 158-192, 197-203, 208-214, 225-230, 237-251 and 207-225 of Seq ID-No-175; 5-11; 27-36, 42-53, 62-70, 74-93, 95-104, 114-119, 127-150, 153-159, 173-179, 184-193, 199-206, 222-241, 248-253, 257-280, 289-295, 313-319, 322-342, 349-365, 368-389, 393-406, 408-413, 426-438, 447-461, 463-470, 476-495, 532-537, 543-550 and 225-246 of Seq ID No 176; 4-29, 68-82, 123-130, 141-147, 149-157, 178-191, 203-215, 269-277, 300-307, 327-335, 359-370, 374-380, 382-388, 393-400, 410-417, 434-442, 483-492, 497-503, 505-513, 533-540, 564-569, 601-607, 639-647, 655-666, 693-706, 712-718, 726-736, 752-758, 763-771, 774-780, 786-799, 806-812, 820-828, 852-863, 884-892, 901-909, 925-932, 943-948, 990-996, 1030-1036, 1051-1059, 1062-1068, 1079-1086, 1105-1113, 1152-1162, 1168-1179, 1183-1191, 1204-1210, 1234-1244, 1286-1295, 1318-1326, 1396-1401, 1451-1460, 1465-1474, 1477-1483, 1488-1494, 1505-1510, 1514-1521, 1552-1565, 1593-1614, 1664-1672, 1677-1685, 1701-1711, 1734-1745, 1758-1770, 1784-1798, 1840-1847, 1852-1873, 1885-1891, 1906-1911, 1931-1939, 1957-1970, 1977-1992, 2014-2020, 2026-2032, 2116-2134, 1-348, 373-490, 573-767, 903-1043, 1155-1198, 1243-1482, 1550-1595, 1682-1719, 1793-1921 and 2008-2110 of Seq ID No 177; 10-35, 39-52, 107-112, 181-188, 226-236, 238-253, 258-268, 275-284, 296-310, 326-338, 345-368, 380-389, 391-408, 410-418, 420-429, 444-456, 489-505, 573-588, 616-623, 637-643, 726-739, 741-767, 785-791, 793-803, 830-847, 867-881, 886-922, 949-956, 961-980, 988-1004, 1009-1018, 1027-1042, 1051-1069, 1076-1089, 1108-1115, 1123-1135, 1140-1151, 1164-1179, 1182-1191, 1210-1221, 1223-1234, 1242-1250, 1255-1267, 1281-1292, 1301-1307, 1315-1340, 1348-1355, 1366-1373, 1381-1413, 1417-1428, 1437-1444, 1453-1463, 1478-1484, 1490-1496, 1498-1503, 1520-1536, 1538-1546, 1548-1570, 1593-1603, 1612-1625, 1635-1649, 1654-1660, 1670-1687, 1693-1700, 1705-1711, 1718-1726, 1729-1763, 1790-1813, 1871-1881, 1893-1900, 1907-1935, 1962-1970, 1992-2000, 2006-2013, 2033-2039, 2045-2051, 2055-2067, 2070-2095, 2097-2110, 2115-2121, 2150-2171, 2174-2180, 2197-2202, 2206-2228 and 1526-1560 of Seq ID No 178; 4-17, 35-48, 54-76, 78-107, 109-115, 118-127, 134-140, 145-156, 169-174, 217-226, 232-240, 256-262, 267-273, 316-328, 340-346, 353-360, 402-409, 416-439, 448-456, 506-531, 540-546, 570-578, 586-593, 595-600, 623-632, 662-667, 674-681, 689-705, 713-724, 730-740, 757-763, 773-778, 783-796, 829-835, 861-871, 888-899, 907-939, 941-955, 957-969, 986-1000, 1022-1028, 1036-1044, 1068-1084, 1095-1102, 1118-1124, 1140-1146, 1148-1154, 1168-1181, 1185-1190, 1197-1207, 1218-1226, 1250-1270, 1272-1281, 1284-1296, 1312-1319, 1351-1358, 1383-1409, 1422-1428, 1438-1447, 1449-1461, 1482-1489, 1504-1510, 1518-1527, 1529-1537, 1544-1551, 1569-1575, 1622-1628, 1631-1637, 1682-1689, 1711-1718, 1733-1740, 1772-1783, 1818-1834, 1859-1872, 1-64 and 128-495 of Seq ID No 179; 8-28, 32-37, 62-69, 119-125, 137-149, 159-164, 173-189, 200-205, 221-229, 240-245, 258-265, 268-276, 287-293, 296-302, 323-329 and 1-95 of Seq ID No 180; 9-18, 25-38, 49-63, 65-72, 74-81, 94-117, 131-137, 139-146, 149-158, 162-188, 191-207, 217-225, 237-252, 255-269, 281-293, 301-326, 332-342, 347-354, 363-370, 373-380, 391-400, 415-424, 441-447 and 75-107 of Seq ID No 181; 4-24, 64-71, 81-87, 96-116, 121-128, 130-139, 148-155, 166-173, 176-184, 203-215, 231-238, 243-248, 256-261, 280-286, 288-306, 314-329 and 67-148 of Seq ID No 182; 4-10, 19-37, 46-52, 62-81, 83-89, 115-120, 134-139, 141-151, 168-186, 197-205, 209-234, 241-252, 322-335, 339-345, 363-379, 385-393, 403-431, 434-442, 447-454, 459-465, 479-484, 487-496 and 404-420 of Seq ID No 183; 10-35, 46-66, 71-77, 84-93, 96-122, 138-148, 154-172, 182-213, 221-233, 245-263, 269-275, 295-301, 303-309, 311-320, 324-336, 340-348, 351-359, 375-381 and 111-198 of Seq ID No 184; 14-25, 30-42, 47-61, 67-75, 81-91, 98-106, 114-122, 124-135, 148-193, 209-227 and 198-213 of Seq ID No 185; 5-18, 45-50, 82-90, 97-114, 116-136, 153-161, 163-171, 212-219, 221-227, 240-249, 267-281, 311-317, 328-337, 375-381, 390-395, 430-436, 449-455, 484-495, 538-543, 548-554, 556-564, 580-586, 596-602 and 493-606 of Seq ID No 186; 9-25, 28-34, 37-44, 61-68, 75-81, 88-96, 98-111, 119-133, 138-150, 152-163, 168-182, 186-194, 200-205, 216-223, 236-245, 257-264, 279-287, 293-304, 311-318, 325-330, 340-346, 353-358, 365-379, 399-409, 444-453 and 303-391 of Seq ID No 187; 16-36, 55-61, 66-76, 78-102, 121-130, 134-146, 150-212, 221-239, 255-276, 289-322, 329-357 and 29-59 of Seq ID No 188; 8-27, 68-74, 77-99, 110-116, 124-141, 171-177, 202-217, 221-228, 259-265, 275-290, 293-303, 309-325, 335-343, 345-351, 365-379, 384-394, 406-414, 423-437, 452-465, 478-507, 525-534, 554-560, 611-624, 628-651, 669-682, 742-747, 767-778, 782-

792, 804-812, 820-836, 79-231 and 359-451 of Seq ID No 189; 5-28, 39-45, 56-62, 67-74, 77-99, 110-117, 124-141, 168-176, 200-230, 237-244, 268-279, 287-299, 304-326, 329-335, 348-362, 370-376, 379-384, 390-406, 420-429, 466-471, 479-489, 495-504, 529-541, 545-553, 561-577, 598-604, 622-630, 637-658, 672-680, 682-688, 690-696, 698-709, 712-719, 724-736, 738-746, 759-769, 780-786, 796-804, 813-818, 860-877, 895-904, 981-997, 1000-1014, 1021-1029, 1-162, 206-224, 254-350, 414-514 and 864-938 of Seq ID No 190; 4-11, 19-49, 56-66, 68-101, 109-116, 123-145, 156-165, 177-185, 204-221, 226-234, 242-248, 251-256, 259-265, 282-302, 307-330, 340-349, 355-374, 377-383, 392-400, 422-428, 434-442, 462-474 and 266-322 of Seq ID No 191; 14-43, 45-57, 64-74, 80-87, 106-127, 131-142, 145-161, 173-180, 182-188, 203-210, 213-219, 221-243, 245-254, 304-311, 314-320, 342-348, 354-365, 372-378, 394-399, 407-431, 436-448, 459-465, 470-477, 484-490, 504-509, 531-537, 590-596, 611-617, 642-647, 723-734, 740-751, 754-762, 764-774, 782-797, 807-812, 824-831, 838-845, 877-885, 892-898, 900-906, 924-935, 940-946, 982-996, 1006-1016, 1033-1043, 1051-1056, 1058-1066, 1094-1108, 1119-1126, 1129-1140, 1150-1157, 1167-1174, 1176-1185, 1188-1201, 1209-1216, 1220-1228, 1231-1237, 1243-1248, 1253-1285, 1288-1297, 1299-1307, 1316-1334, 1336-1343, 1350-1359, 1365-1381, 1390-1396, 1412-1420, 1427-1439, 1452-1459, 1477-1484, 1493-1512, 1554-1559, 1570-1578, 1603-1608, 1623-1630, 1654-1659, 1672-1680, 1689-1696, 1705-1711, 1721-1738, 1752-1757, 1773-1780, 1817-1829, 1844-1851, 1856-1863, 1883-1895, 1950-1958, 1974-1990, 172-354, 384-448, 464-644, 648-728 and 1357-1370 of Seq ID No 192; 8-27, 68-74, 77-99, 110-116, 124-141, 169-176, 201-216, 220-227, 258-264, 274-289, 292-302, 308-324, 334-342, 344-350, 364-372, 377-387, 399-407, 416-429, 445-458, 471-481, 483-500, 518-527, 547-553, 604-617, 621-644, 662-675, 767-778, 809-816, 15-307, 350-448 and 496-620 of Seq ID No 193; 4-17, 24-29, 53-59, 62-84, 109-126, 159-164, 189-204, 208-219, 244-249, 274-290, 292-302, 308-324, 334-342, 344-350, 378-389, 391-397, 401-409, 424-432, 447-460, 470-479, 490-504, 521-529, 538-544, 549-555, 570-577, 583-592, 602-608, 615-630, 635-647, 664-677, 692-698, 722-731, 733-751, 782-790, 793-799, 56-267, 337-426 and 495-601 of Seq ID No 194; 12-22, 49-59, 77-89, 111-121, 136-148, 177-186, 207-213, 217-225, 227-253, 259-274, 296-302, 328-333, 343-354, 374-383, 424-446, 448-457, 468-480, 488-502, 507-522, 544-550, 553-560, 564-572, 587-596, 604-614, 619-625, 629-635, 638-656, 662-676, 680-692, 697-713, 720-738, 779-786, 833-847, 861-869, 880-895, 897-902, 911-917, 946-951, 959-967, 984-990, 992-.1004, 1021-1040, 1057-1067, 1073-1080 and 381-403 of Seq ID No 195; 4-10, 26-31, 46-56, 60-66, 70-79, 86-94, 96-102, 109-118, 132-152, 164-187, 193-206, 217-224 and 81-149 of Seq ID No 196; 4-21, 26-37, 48-60, 71-82, 109-117, 120-128, 130-136, 142-147, 181-187, 203-211, 216-223, 247-255, 257-284, 316-325, 373-379, 395-400, 423-435, 448-456, 479-489, 512-576, 596-625, 641-678, 680-688, 692-715 and 346-453 of Seq ID No 197; 10-16, 25-31, 34-56, 58-69, 71-89, 94-110, 133-176, 186-193, 208-225, 240-250, 259-266, 302-307, 335-341, 376-383, 410-416 and 316-407 of Seq ID No 198; 11-29, 42-56, 60-75, 82-88, 95-110, 116-126, 132-143, 145-160, 166-172, 184-216 and 123-164 of Seq ID No 199; 11-29, 54-63, 110-117, 139-152, 158-166, 172-180, 186-193, 215-236, 240-251, 302-323, 330-335, 340-347, 350-366, 374-381 and 252-299 of Seq ID No 200; 18-27, 35-42, 50-56, 67-74, 112-136, 141-153, 163-171, 176-189, 205-213, 225-234, 241-247, 253-258, 269-281, 288-298, 306-324, 326-334, 355-369, 380-387 and 289-320 of Seq ID No 201; 7-15, 19-41, 56-72, 91-112, 114-122, 139-147, 163-183, 196-209, 258-280, 326-338, 357-363, 391-403, 406-416 and 360-378 of Seq ID No 202; 11-18, 29-41, 43-49, 95-108, 142-194, 204-212, 216-242, 247-256, 264-273 and 136-149 of Seq ID No 203; 18-24, 33-40, 65-79, 89-102, 113-119, 130-137, 155-161, 173-179, 183-203, 205-219, 223-231, 245-261, 267-274, 296-306, 311-321, 330-341, 344-363, 369-381, 401-408, 415-427, 437-444, 453-464, 472-478, 484-508, 517-524, 526-532, 543-548 and 59-180 of Seq ID No 204; 5-13, 52-65, 67-73, 97-110, 112-119, 134-155 and 45-177 of Seq ID No 205; 6-28, 34-43, 57-67, 75-81, 111-128, 132-147, 155-163, 165-176, 184-194, 208-216, 218-229, 239-252, 271-278, 328-334, 363-376, 381-388, 426-473, 481-488, 492-498, 507-513, 536-546, 564-582, 590-601, 607-623, 148-269, 420-450 and 610-648 of Seq ID No 206; 4-12, 20-38, 69-75, 83-88, 123-128, 145-152, 154-161, 183-188, 200-213, 245-250, 266-272, 306-312, 332-339, 357-369, 383-389, 395-402, 437-453, 455-470, 497-503 and 1-112 of Seq ID No 207; 35-59, 74-86, 111-117, 122-137 and 70-154 of Seq ID No 208; 26-42, 54-61, 65-75, 101-107, 123-130, 137-144, 148-156, 164-172, 177-192, 213-221, 231-258 and 157-249 of Seq ID No 209; 29-38, 61-67, 77-87, 94-100, 105-111, 118-158 and 1-97 of Seq ID No 210; 7-21, 30-48, 51-58, 60-85, 94-123, 134-156, 160-167, 169-183, 186-191, 216-229, 237-251, 257-267, 272-282, 287-298 and 220-243 of Seq ID No 211; 6-29, 34-47, 56-65, 69-76, 83-90, 123-134, 143-151, 158-178, 197-203, 217-235, 243-263, 303-309, 320-333, 338-348, 367-373, 387-393, 407-414, 416-427, 441-457, 473-482, 487-499, 501-509, 514-520, 530-535, 577-583, 590-602, 605-612, 622-629, 641-670, 678-690, 37-71 and 238-307 of Seq ID No 212; 7-40, 121-132, 148-161, 196-202, 209-215, 221-235, 248-255, 271-280, 288-295, 330-339, 395-409, 414-420, 446-451, 475-487, 556-563, 568-575, 580-586, 588-595,

633-638, 643-648, 652-659, 672-685, 695-700, 710-716, 737-742, 749-754, 761-767, 775-781, 796-806, 823-835, 850-863, 884-890, 892-900, 902-915, 934-941 and 406-521 of Seq ID No 213, 9-18, 24-46, 51-58, 67-77, 85-108, 114-126, 129-137, 139-146, 152-165, 173-182, 188-195, 197-204, 217-250, 260-274, 296-313, 343-366, 368-384, 427-434, 437-446, 449-455, 478-484, 492-506, 522-527, 562-591, 599-606, 609-618, 625-631, 645-652 and 577-654 of Seq ID No 214; 13-20, 26-37, 41-53, 56-65, 81-100, 102-114, 118-127, 163-188, 196-202, 231-238, 245-252, 266-285, 293-298, 301-306 and 19-78 of Seq ID No 215; 10-23, 32-42, 54-66, 73-91, 106-113, 118-127, 139-152, 164-173, 198-207, 210-245, 284-300, 313-318, 330-337, 339-346, 354-361, 387-393, 404-426, 429-439, 441-453, 467-473, 479-485, 496-509, 536-544, 551-558, 560-566, 569-574, 578-588, 610-615, 627-635, 649-675, 679-690, 698-716, 722-734, 743-754, 769-780, 782-787 and 480-550 of Seq ID No 216; 6-39, 42-50, 60-68, 76-83, 114-129, 147-162, 170-189, 197-205, 217-231, 239-248, 299-305, 338-344, 352-357, 371-377, 380-451, 459-483, 491-499, 507-523, 537-559, 587-613, 625-681, 689-729, 737-781, 785-809, 817-865, 873-881, 889-939, 951-975, 983-1027, 1031-1055, 1063-1071, 1079-1099, 1103-1127, 1151-1185, 1197-1261, 1269-1309, 1317-1333, 1341-1349, 1357-1465, 1469-1513, 1517-1553, 1557-1629, 1637-1669, 1677-1701, 1709-1725, 1733-1795, 1823-1849, 1861-1925, 1933-1973, 1981-2025, 2029-2053, 2061-2109, 2117-2125, 2133-2183, 2195-2219, 2227-2271, 2275-2299, 2307-2315, 2323-2343, 2347-2371, 2395-2429, 2441-2529, 2537-2569, 2577-2601, 2609-2625, 2633-2695, 2699-2737, 2765-2791, 2803-2867, 2889-2913, 2921-2937, 2945-2969, 2977-2985, 2993-3009, 3023-3045, 3073-3099, 3111-3167, 3175-3215, 3223-3267, 3271-3295, 3303-3351, 3359-3367, 3375-3425, 3437-3461, 3469-3513, 3517-3541, 3549-3557, 3565-3585, 3589-3613, 3637-3671, 3683-3747, 3755-3795, 3803-3819, 3827-3835, 3843-3951, 3955-3999, 4003-4039, 4043-4115, 4123-4143, 4147-4171, 4195-4229, 4241-4305, 4313-4353, 4361-4377, 4385-4393, 4401-4509, 4513-4557, 4561-4597, 4601-4718, 4749-4768, 74-171, 452-559 and 2951-3061 of Seq ID No 217; 16-22, 30-51, 70-111, 117-130, 137-150, 171-178, 180-188, 191-196 and 148-181 of Seq ID No 218; 6-19, 21-46, 50-56, 80-86, 118-126, 167-186, 189-205, 211-242, 244-267, 273-286, 290-297, 307-316, 320-341 and 34-60 of Seq ID No 219; 5-26, 33-43, 48-54, 58-63, 78-83, 113-120, 122-128, 143-152, 157-175, 185-192, 211-225, 227-234, 244-256, 270-281, 284-290, 304-310, 330-337, 348-355, 362-379, 384-394, 429-445, 450-474, 483-490, 511-520, 537-546, 548-554, 561-586, 590-604, 613-629, 149-186, 285-431 and 573-659 of Seq ID No 220; 5-26, 49-59, 61-67, 83-91, 102-111, 145-157, 185-192, 267-272, 279-286, 292-298, 306-312, 134-220, 235-251 and 254-280 of Seq ID No 221; 5-19, 72-79, 83-92, 119-124, 140-145, 160-165, 167-182, 224-232, 240-252, 259-270, 301-310, 313-322, 332-343, 347-367, 384-398, 416-429, 431-446, 454-461 and 1-169 of Seq ID No 222; 8-17, 26-31, 56-62, 75-83, 93-103, 125-131, 135-141, 150-194, 205-217, 233-258, 262-268, 281-286 and 127-168 of Seq ID No 223; 6-12, 69-75, 108-115, 139-159, 176-182, 194-214 and 46-161 of Seq ID No 224; 6-13, 18-27, 39-48, 51-59, 66-73, 79-85, 95-101, 109-116, 118-124, 144-164, 166-177, 183-193, 197-204, 215-223, 227-236, 242-249, 252-259, 261-270, 289-301, 318-325 and 12-58 of Seq ID No 225; 4-10, 26-32, 48-60, 97-105, 117-132, 138-163, 169-185, 192-214, 219-231, 249-261, 264-270, 292-308, 343-356, 385-392, 398-404, 408-417, 435-441 and 24-50 of Seq ID No 226; 10-40, 42-48, 51-61, 119-126 and 1-118 of Seq ID No 227; 5-17, 40-58, 71-83, 103-111, 123-140, 167-177, 188-204 and 116-128 of Seq ID No 228; 4-9, 11-50, 57-70, 112-123, 127-138 and 64-107 of Seq ID No 229; 9-39, 51-67 and 1-101 of Seq ID No 230; 5-14, 17-25, 28-46, 52-59, 85-93, 99-104, 111-120, 122-131, 140-148, 158-179, 187-197, 204-225, 271-283, 285-293 and 139-155 of Seq ID No 231; 42-70, 73-90, 92-108, 112-127, 152-164, 166-172, 181-199, 201-210, 219-228, 247-274, 295-302, 322-334, 336-346, 353-358, 396-414, 419-425, 432-438, 462-471, 518-523, 531-536, 561-567, 576-589, 594-612, 620-631, 665-671, 697-710, 718-731, 736-756, 765-771, 784-801 and 626-653 of Seq ID No 232; 8-28, 41-51, 53-62, 68-74, 79-85, 94-100, 102-108, 114-120, 130-154, 156-162, 175-180, 198-204, 206-213, 281-294, 308-318, 321-339, 362-368, 381-386, 393-399, 407-415 and 2-13 of Seq ID No 233; 4-39, 48-65, 93-98, 106-112, 116-129 and 10-36 of Seq ID No 234; 25-32, 35-50, 66-71, 75-86, 90-96, 123-136, 141-151, 160-179, 190-196, 209-215, 222-228, 235-242, 257-263, 270-280 and 209-247 of Seq ID No 235; 5-29, 31-38, 50-57, 62-75, 83-110, 115-132, 168-195, 197-206, 216-242, 249-258, 262-269, 333-340, 342-350, 363-368, 376-392, 400-406, 410-421, 423-430, 436-442, 448-454, 460-466, 471-476, 491-496, 511-516, 531-536, 551-556, 571-576, 585-591, 599-605, 27-70, 219-293, 441-504 and 512-584 of Seq ID No 236; 4-12, 14-34, 47-75, 83-104, 107-115, 133-140, 148-185, 187-196, 207-212, 224-256, 258-265, 281-287, 289-296, 298-308, 325-333, 345-355, 365-371, 382-395, 424-435, 441-457, 465-472, 483-491, 493-505, 528-534, 536-546, 552-558, 575-584, 589-600, 616-623 and 576-591 of Seq ID No 237; 4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771 and 313-329 of Seq ID No

238; 7-38, 44-49, 79-89, 99-108, 117-123, 125-132, 137-146, 178-187, 207-237, 245-255, 322-337, 365-387, 398-408, 445-462, 603-608, 623-628, 644-650, 657-671, 673-679 and 111-566 of Seq ID No 239; 6-20, 22-35, 39-45, 58-64, 77-117, 137-144, 158-163, 205-210, 218-224, 229-236, 239-251, 263-277, 299-307, 323-334, 353-384, 388-396, 399-438, 443-448, 458-463, 467-478, 481-495, 503-509, 511-526, 559-576, 595-600, 612-645, 711-721, 723-738, 744-758, 778-807 and 686-720 of Seq ID No 240; 10-33, 35-41, 72-84, 129-138, 158-163, 203-226, 243-252, 258-264, 279-302, 322-329, 381-386, 401-406, 414-435 and 184-385 of Seq ID No 241; 4-9, 19-24, 41-47, 75-85, 105-110, 113-146 and 45-62 of Seq ID No 242; 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-279, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389 and 1-285 of Seq ID No 243; 14-32, 38-50, 73-84, 93-105, 109-114 and 40-70 of Seq ID No 244; 5-26 and 22-34 of Seq ID No 245; 23-28 and 13-39 of Seq ID No 246; 8-14 and 21-34 of Seq ID No 247; 4-13, 20-29, 44-50, 59-74 and 41-69 of Seq ID No 248; 4-9, 19-42, 48-59, 71-83 and 57-91 of Seq ID No 249; 4-14 and 10-28 of Seq ID No 250; 22-28, 32-42, 63-71, 81-111, 149-156, 158-167, 172-180, 182-203, 219-229 and 27-49 of Seq ID No 251; 17-27 and 23-32 of Seq ID No 252; 18-24 and 28-38 of Seq ID No 253; 9-15 and 13-27 of Seq ID No 254; 13-22 and 18-29 of Seq ID No 255; 17-26 and 2-11 of Seq ID No 256; 4-33 and 16-32 of Seq ID No 257; 4-10, 37-43, 54-84, 92-127 and 15-62 of Seq ID No 258; 4-14, 20-32, 35-60, 69-75, 79-99, 101-109, 116-140 and 124-136 of Seq ID No 259; 2-13 of Seq ID No 260; 4-13, 28-42 and 42-57 of Seq ID No 261; 4-14, 27-44 and 14-35 of Seq ID No 262; 4-12 and 1-27 of Seq ID No 263; 4-18, 39-45, 47-74 and 35-66 of Seq ID No 264; 8-20, 43-77 and 17-36 of Seq ID No 265; 4-30, 35-45, 51-57 and 35-49 of Seq ID No 266; 4-24, 49-57 and 15-34 of Seq ID No 267; 4-22 and 8-27 of Seq ID No 268; 13-25, 32-59, 66-80 and 21-55 of Seq ID No 269; 4-10, 24-33, 35-42, 54-65, 72-82, 98-108 and 15-30 of Seq ID No 270; 8-19 and 17-47 of Seq ID No 271; 12-18, 40-46 and 31-52 of Seq ID No 272; 4-20, 35-78, 83-102, 109-122 and 74-86 of Seq ID No 273; 7-17, 21-41, 46-63 and 2-20 of Seq ID No 274; 30-37 and 2-33 of Seq ID No 275; 4-13, 17-25 and 1-15 of Seq ID No 276; 17-31, 44-51 and 20-51 of Seq ID No 277; 20-30 and 5-23 of Seq ID No 278; 13-33, 48-71 and 92-110 of Seq ID No 279; 4-9, 50-69, 76-88, 96-106, 113-118 and 12-34 of Seq ID No 280; 4-24 and 6-26 of Seq ID No 281; 7-26 and 14-30 of Seq ID No 282; 9-39, 46-68, 75-82, 84-103 and 26-44 of Seq ID No 283; 4-30, 33-107 and 58-84 of Seq ID No 284; 4-12 and 9-51 of Seq ID No 285; 12-18, 29-37 and 6-37 of Seq ID No 286; 4-21, 33-52; 64-71 and 16-37 of Seq ID No 287; 9-19 and 2-30 of Seq ID No 288; 20-37 of Seq ID No 245; 8-27 of Seq ID No 246; 10-27 of Seq ID No 247; 42-59 and 52-69 of Seq ID No 248; 63-80 and 74-91 of Seq ID No 249; 11-28 of Seq ID No 250; 28-49 of Seq ID No 251; 15-32 of Seq ID No 252; 4-20 of Seq ID No 253; 10-27 of Seq ID No 254; 17-34 of Seq ID No 255; 1-18 of Seq ID No 256; 16-33 of Seq ID No 257; 16-36, 30-49 and 43-62 of Seq ID No 258; 122-139 of Seq ID No 259; 1-18 of Seq ID No 260; 41-58 of Seq ID No 261; 15-35 of Seq ID No 262; 2-27 of Seq ID No 263; 18-36 of Seq ID No 265; 34-51 of Seq ID No 266; 9-27 of Seq ID No 268; 22-47 of Seq ID No 269; 18-36 and 29-47 of Seq ID No 271; 32-52 of Seq ID No 272; 72-89 of Seq ID No 273; 3-20 of Seq ID No 274; 3-21 and 15-33 of Seq ID No 275; 1-18 of Seq ID No 276; 6-23 of Seq ID No 278; 93-110 of Seq ID No 279; 13-34 of Seq ID No 280; 7-26 and 9-26 of Seq ID No 281; 16-33 of Seq ID No 282; 27-44 of Seq ID No 283; 67-84 of Seq ID No 284; 10-33 and 26-50 of Seq ID No 285; 7-25 and 19-37 of Seq ID No 286; 17-37 of Seq ID No 287; 3-20 and 13-30 of Seq ID No 288; 62-80 and 75-93 of Seq ID No 145; 92-108 of Seq ID No 147; 332-349, 177-200 and 1755-1777 of Seq ID No 148; 109-133, 149-174, 260-285 and 460-485 of Seq ID No 149; 26-47 and 42-64 of Seq ID No 150; 22-41, 35-54, 115-130, 306-325, 401-420 and 454-478 of Seq ID No 151; 22-45 of Seq ID No 155; 156-174, 924-940, 1485-1496, 1447-1462 and 1483-1498 of Seq ID No 160; 457-475 of Seq ID No 161; 302-325 of Seq ID No 163; 288-305 of Seq ID No 164; 244-266 and 260-282 of Seq ID No 165; 204-225 and 220-241 of Seq ID No 166; 324-345, 340-361, 356-377, 372-393 and 388-408 of Seq ID No 167; 39-64 of Seq ID No 168; 54-76 and 70-92 of Seq ID No 169; 1227-1247, 1539-1559, 1554-1574, 1569-1589, 1584-1604, 1242-1262, 1272-1292, 1287-1308, 1456-1477, 1472-1494, 1488-1510 and 1505-1526 of Seq ID No 170; 351-368 of Seq ID No 172; 179-200, 195-216, 211-232, 227-248 and 243-263 of Seq ID No 173; 13-37 of Seq ID No 174; 208-224 of Seq ID No 175; 42-64, 59-81, 304-328, 323-348, 465-489, 968-992, 1399-1418, 1412-1431 and 2092-2111 of Seq ID No 177; 1528-1547 and 1541-1560 of Seq ID No 178; 184-200, 367-388, 382-403, 409-429, 425-444 and 438-457 of Seq ID No 179; 27-50 and 45-67 of Seq ID No 180; 114-131 and 405-419 of Seq ID No 183; 113-134, 129-150, 145-166, 161-182 and 177-198 of Seq ID No 184; 495-515 of Seq ID No 186; 346-358 of Seq ID No 187; 208-224 of Seq ID No 190; 178-194, 202-223, 217- 238, 288-308 and 1355-1372 of Seq ID No 192; 57-78 of Seq ID No 194; 347-369, 364-386, 381-403, 398-420, 415-437 and 432-452 of Seq ID No 197; 347-372 of Seq ID No 198;

147-163 of Seq ID No 199; 263-288 of Seq ID No 200; 361-377 of Seq ID No 202; 82-104, 99-121, 116-138, 133-155 and 150-171 of Seq ID No 204; 110-130 and 125-145 of Seq ID No 205; 613-631, 626-644 and 196-213 of Seq ID No 206; 78-100, 95-117, 112-134 and 129-151 of Seq ID No 208; 158-180, 175-197, 192-214, 209-231 and 226-248 of Seq ID No 209; 30-50, 45-65 and 60-79 of Seq ID No 210; 431-455 and 450-474 of Seq ID No 213; 579-601, 596-618, 613-635 and 630-653 of Seq ID No 214; 920-927, 98-119, 114-135, 130-151, 146-167 and 162-182 of Seq ID No 217; 36-59 of Seq ID No 219; 194-216 and 381-404 of Seq ID No 220; 236-251 and 255-279 of Seq ID No 221; 80-100 and 141-164 of Seq ID No 222; 128-154 of Seq ID No 223; 82-100, 95-116 and 111-134 of Seq ID No 224; 55-76, 71-92 and 87-110 of Seq ID No 227; 91-106 of Seq ID No 229, 74-96 of Seq ID No 230; 140-157 of Seq ID No 231; 4-13 of Seq ID No 233; 41-65 and 499-523 of Seq ID No 236; 122-146, 191-215, 288-313, 445-469 and 511-535 of Seq ID No 239; 347-368 of Seq ID No 241; 46-61 of Seq ID No 242; 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 and 236-258 of Seq

The present invention also provides a process for producing a S. pneumoniae hyperimmune serum reactive antigen or a fragment thereof according to the present invention comprising expressing one or more of the nucleic acid molecules according to the present invention in a suitable expression system.

Moreover, the present invention provides a process for producing a cell, which expresses a S pneumoniae hyperimmune serum reactive antigen or a fragment thereof according to the present invention comprising transforming or transfecting a suitable host cell with the vector according to the present

According to the present invention a pharmaceutical composition, especially a vaccine, comprising a hyperimmune serum-reactive antigen or a fragment thereof as defined in the present invention or a nucleic acid molecule as defined in the present invention is provided.

In a preferred embodiment the pharmaceutical composition further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at least two LysLeuLys motifs, especially KLKLLLLKLK, neuroactive compounds, especially human growth hormone, alumn, Freund's complete or incomplete adjuvants or combinations thereof.

In a more preferred embodiment the immunostimulatory substance is a combination of either a polycationic polymer and immunostimulatory deoxynucleotides or of a peptide containing at least two LysLeuLys motifs and immunostimulatory deoxynucleotides.

In a still more preferred embodiment the polycationic polymer is a polycationic peptide, especially

According to the present invention the use of a nucleic acid molecule according to the present invention or a hyperimmune serum-reactive antigen or fragment thereof according to the present invention for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against S. pneumoniae infection, is provided.

Also an antibody, or at least an effective part thereof, which binds at least to a selective part of the hyperimmune serum-reactive antigen or a fragment thereof according to the present invention, is provided herewith.

In a preferred embodiment the antibody is a monoclonal antibody.

In another preferred embodiment the effective part of the antibody comprises Fab fragments.

In a further preferred embodiment the antibody is a chimeric antibody.

In a still preferred embodiment the antibody is a humanized antibody.

The present invention also provides a hybridoma cell line, which produces an antibody according to the present invention.

Moreover, the present invention provids a method for producing an antibody according to the present invention, characterized by the following steps:

- initiating an immune response in a non-human animal by administrating an hyperimmune serum-reactive antigen or a fragment thereof, as defined in the invention, to said animal,
- removing an antibody containing body fluid from said animal, and
- producing the antibody by subjecting said antibody containing body fluid to further purification steps.

Accordingly, the present invention also provides a method for producing an antibody according to the present invention, characterized by the following steps:

- initiating an immune response in a non-human animal by administrating an hyperimmune serum-reactive antigen or a fragment thereof, as defined in the present invention, to said animal,
- removing the spleen or spleen cells from said animal,
- producing hybridoma cells of said spleen or spleen cells,
- selecting and cloning hybridoma cells specific for said hyperimmune serum-reactive antigens or a fragment thereof,
- producing the antibody by cultivation of said cloned hybridoma cells and optionally further purification steps.

The antibodies provided or produced according to the above methods may be used for the preparation of a medicament for treating or preventing *S. pneumoniae* infections.

According to another aspect the present invention provides an antagonist, which binds to a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention.

Such an antagonist capable of binding to a hyperimmune serum-reactive antigen or fragment thereof according to the present invention may be identified by a method comprising the following steps:

- a) contacting an isolated or immobilized hyperimmune serum-reactive antigen or a fragment thereof according to the present invention with a candidate antagonist under conditions to permit binding of said candidate antagonist to said hyperimmune serum-reactive antigen or fragment, in the presence of a component capable of providing a detectable signal in response to the binding of the candidate antagonist to said hyperimmune serum reactive antigen or fragment thereof; and
- b) detecting the presence or absence of a signal generated in response to the binding of the antagonist to the hyperimmune serum reactive antigen or the fragment thereof.

An antagonist capable of reducing or inhibiting the interaction activity of a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention to its interaction partner may be identified by a method comprising the following steps:

- a) providing a hyperimmune serum reactive antigen or a hyperimmune fragment thereof according to the present invention,
- providing an interaction partner to said hyperimmune serum reactive antigen or a fragment thereof, especially an antibody according to the present invention,
- allowing interaction of said hyperimmune serum reactive antigen or fragment thereof to said interaction partner to form an interaction complex,

- d) providing a candidate antagonist,
- e) allowing a competition reaction to occur between the candidate antagonist and the interaction
  - determining whether the candidate antagonist inhibits or reduces the interaction activities of the hyperimmune serum reactive antigen or the fragment thereof with the interaction partner.

The hyperimmune serum reactive antigens or fragments thereof according to the present invention may be used for the isolation and/or purification and/or identification of an interaction partner of said\_\_\_\_\_\_ hyperimmune serum reactive antigen or fragment thereof.

The present invention also provides a process for in vitro diagnosing a disease related to expression of a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention comprising determining the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen or fragment thereof according to the present invention or the presence of the hyperimmune serum reactive antigen or fragment thereof according to the present invention.

The present invention also provides a process for in vitro diagnosis of a bacterial infection, especially a S. pneumoniae infection, comprising analyzing for the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen or fragment thereof according to the present invention or the presence of the hyperimmune serum reactive antigen or fragment thereof according to the present invention.

Moreover, the present invention provides the use of a hyperimmune serum reactive antigen or fragment thereof according to the present invention for the generation of a peptide binding to said hyperimmune serum reactive antigen or fragment thereof, wherein the peptide is an anticaline.

The present invention also provides the use of a hyperimmune serum-reactive antigen or fragment thereof according to the present invention for the manufacture of a functional nucleic acid, wherein the functional nucleic acid is selected from the group comprising aptamers and spiegelmers.

The nucleic acid molecule according to the present invention may also be used for the manufacture of a functional ribonucleic acid, wherein the functional ribonucleic acid is selected from the group comprising ribozymes, antisense nucleic acids and siRNA.

The present invention advantageously provides an efficient, relevant and comprehensive set of isolated nucleic acid molecules and their encoded hyperimmune serum reactive antigens or fragments thereof identified from S. pneumoniae using an antibody preparation from multiple human plasma pools and surface expression libraries derived from the genome of S. pneumoniae. Thus, the present invention fulfils a widely felt demand for S. pneumoniae antigens, vaccines, diagnostics and products useful in procedures for preparing antibodies and for identifying compounds effective against S. pneumoniae infection.

An effective vaccine should be composed of proteins or polypeptides, which are expressed by all strains and are able to induce high affinity, abundant antibodies against cell surface components of S. pneumoniae. The antibodies should be IgG1 and/or IgG3 for opsonization, and any IgG subtype and IgA for neutralisation of adherence and toxin action. A chemically defined vaccine must be definitely superior compared to a whole cell vaccine (attenuated or killed), since components of S. pneumoniae, which crossreact with human tissues or inhibit opsonization can be eliminated, and the individual proteins inducing protective antibodies and/or a protective immune response can be selected.

The approach, which has been employed for the present invention, is based on the interaction of pneumococcal proteins or peptides with the antibodies present in human sera. The antibodies produced against S. pneumoniae by the human immune system and present in human sera are indicative of the in

vivo expression of the antigenic proteins and their immunogenicity. In addition, the antigenic proteins as identified by the bacterial surface display expression libraries using pools of pre-selected sera, are processed in a second and third round of screening by individual selected or generated sera. Thus the present invention supplies an efficient, relevant, comprehensive set of pneumoococcal antigens as a pharmaceutical composition, especially a vaccine preventing infection by *S. pneumoniae*.

In the antigen identification program for identifying a comprehensive set of antigens according to the present invention, at least two different bacterial surface expression libraries are screened with several serum pools or plasma fractions or other pooled antibody containing body fluids (antibody pools). The antibody pools are derived from a serum collection, which has been tested against antigenic compounds of *S. pneumoniae*, such as whole cell extracts and culture supernatant proteins. Preferably, two distinct serum collections are used: 1. With very stable antibody repertoire: normal adults, clinically healthy people, who are non-carriers and overcame previous encounters or currently carriers of *S. pneumoniae* without acute disease and symptoms, 2. With antibodies induced acutely by the presence of the pathogenic organism: patients with acute disease with different manifestations (e.g. *S. pneumoniae* pharyngitis, pneumonia, bacteraemia, peritonitis, meningitis and sepsis). Sera have to react with multiple Pneumococcus-specific antigens in order to be considered hyperimmune and therefore relevant in the screening method applied for the present invention.

The expression libraries as used in the present invention should allow expression of all potential antigens, e.g. derived from all secreted and surface proteins of *S. pneumoniae*. Bacterial surface display libraries will be represented by a recombinant library of a bacterial host displaying a (total) set of expressed peptide sequences of *S. pneumoniae* on two selected outer membrane proteins (LamB and FhuA) at the bacterial host membrane (Georgiou, G., 1997); {Etz, H. et al., 2001}. One of the advantages of using recombinant expression libraries is that the identified hyperimmune serum-reactive antigens may be instantly produced by expression of the coding sequences of the screened and selected clones expressing the hyperimmune serum-reactive antigens without further recombinant DNA technology or cloning steps necessary.

The comprehensive set of antigens identified by the described program according to the present invention is analysed further by one or more additional rounds of screening. Therefore individual antibody preparations or antibodies generated against selected peptides, which were identified as immunogenic are used. According to a preferred embodiment the individual antibody preparations for the second round of screening are derived from patients who have suffered from an acute infection with *S. pneumoniae*, especially from patients who show an antibody titer above a certain minimum level, for example an antibody titer being higher than 80 percentile, preferably higher than 90 percentile, especially higher than 95 percentile of the human (patient or healthy individual) sera tested. Using such high titer individual antibody preparations in the second screening round allows a very selective identification of the hyperimmune serum-reactive antigens and fragments thereof from *S. pneumoniae*.

Following the comprehensive screening procedure, the selected antigenic proteins, expressed as recombinant proteins or *in vitro* translated products, in case it can not be expressed in prokaryotic expression systems, or the identified antigenic peptides (produced synthetically) are tested in a second screening by a series of ELISA and Western blotting assays for the assessment of their immunogenicity with a large human serum collection (minimum ~150 healthy and patients sera).

It is important that the individual antibody preparations (which may also be the selected serum) allow a selective identification of the most promising candidates of all the hyperimmune serum-reactive antigens from all the promising candidates from the first round. Therefore, preferably at least 10 individual antibody preparations (i.e. antibody preparations (e.g. sera) from at least 10 different individuals having suffered from an infection to the chosen pathogen) should be used in identifying these antigens in the second screening round. Of course, it is possible to use also less than 10 individual preparations,

however, selectivity of the step may not be optimal with a low number of individual antibody. preparations. On the other hand, if a given hyperimmune-serum-reactive-antigen-(or-an antigenic fragment thereof) is recognized by at least 10 individual antibody preparations, preferably at least 30, especially at least 50 individual antibody preparations, identification of the hyperimmune serum-reactive antigen is also selective enough for a proper identification. Hyperimmune serum-reactivity may of course be tested with as many individual preparations as possible (e.g. with more than 100 or even with more

Therefore, the relevant portion of the hyperimmune serum-reactive antibody preparations according to the method of the present invention should preferably be at least 10, more preferred at least 30, especially at least 50 individual antibody preparations. Alternatively (or in combination) hyperimmune serumreactive antigens may preferably be also identified with at least 20%, preferably at least 30%, especially at least 40% of all individual antibody preparations used in the second screening round.

According to a preferred embodiment of the present invention, the sera from which the individual antibody preparations for the second round of screening are prepared (or which are used as antibody preparations), are selected by their titer against S. pneumoniae (e.g. against a preparation of this pathogen, such as a lysate, cell wall components and recombinant proteins). Preferably, some are selected with a total IgA titer above 2,000 U, especially above 4,000 U, and/or an IgG titer above 5,000 U, especially above 12,000 U (U = units, calculated from the OD405nm reading at a given dilution) when the whole organism (total lysate or whole cells) is used as antigen in the ELISA.

The antibodies produced against streptococci by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and their immunogenicity. The recognition of linear epitopes recognized by serum antibodies can be based on sequences as short as 4-5 amino acids. Of course it does not necessarily mean that these short peptides are capable of inducing the given antibody in vivo. For that reason the defined epitopes, polypeptides and proteins are further to be tested in animals (mainly in mice) for their capacity to induce antibodies against the selected proteins in

The preferred antigens are located on the cell surface or are secreted, and are therefore accessible extracellularly. Antibodies against cell wall proteins are expected to serve multiple purposes: to inhibit adhesion, to interfere with nutrient acquisition, to inhibit immune evasion nand to promote phagocytosis {Hornef, M. et al., 2002}. Antibodies against secreted proteins are beneficial in neutralisation of their function as toxin or virulence component. It is also known that bacteria communicate with each other through secreted proteins. Neutralizing antibodies against these proteins will interrupt growthpromoting cross-talk between or within streptococcal species. Bioinformatic analyses (signal sequences, cell wall localisation signals, transmembrane domains) proved to be very useful in assessing cell surface localisation or secretion. The experimental approach includes the isolation of antibodies with the corresponding epitopes and proteins from human serum, and the generation of immune sera in mice against (poly)peptides selected by the bacterial surface display screens. These sera are then used in a third round of screening as reagents in the following assays: cell surface staining of S. pneumoniae grown under different conditions (FACS or microscopy), determination of neutralizing capacity (toxin, adherence), and promotion of opsonization and phagocytosis (in vitro phagocytosis assay).

For that purpose, bacterial E. coli clones are directly injected into mice and immune sera are taken and tested in the relevant in vitro assay for functional opsonic or neutralizing antibodies. Alternatively, specific antibodies may be purified from human or mouse sera using peptides or proteins as substrate.

Host defence against S. pneumoniae relies mainly on opsonophagocytic killing mechanism. Inducing high affinity antibodies of the opsonic and neutralizing type by vaccination helps the innate immune system to eliminate bacteria and toxins. This makes the method according to the present invention an optimal tool

for the identification of pneumococcal antigenic proteins.

The skin and mucous membranes are formidable barriers against invasion by streptococci. However, once the skin or the mucous membranes are breached the first line of non-adaptive cellular defence begins its co-ordinate action through complement and phagocytes, especially the polymorphonuclear leukocytes (PMNs). These cells can be regarded as the cornerstones in eliminating invading bacteria. As Streptococcus pneumoniae is a primarily extracellular pathogen, the major anti-streptococcal adaptive response comes from the humoral arm of the immune system, and is mediated through three major mechanisms: promotion of opsonization, toxin neutralisation, and inhibition of adherence. It is believed that opsonization is especially important, because of its requirement for an effective phagocytosis. For efficient opsonization the microbial surface has to be coated with antibodies and complement factors for recognition by PMNs through receptors to the Fc fragment of the IgG molecule or to activated C3b. After opsonization, streptococci are phagocytosed and killed. Antibodies bound to specific antigens on the cell surface of bacteria serve as ligands for the attachment to PMNs and to promote phagocytosis. The very same antibodies bound to the adhesins and other cell surface proteins are expected to neutralize adhesion and prevent colonization. The selection of antigens as provided by the present invention is thus well suited to identify those that will lead to protection against infection in an animal model or in humans.

According to the antigen identification method used herein, the present invention can surprisingly provide a set of comprehensive novel nucleic acids and novel hyperimmune serum reactive antigens and fragments thereof of *S. pneumoniae*, among other things, as described below. According to one aspect, the invention particularly relates to the nucleotide sequences encoding hyperimmune serum reactive antigens which sequences are set forth in the Sequence listing Seq ID No: 1-144 and the corresponding encoded amino acid sequences representing hyperimmune serum reactive antigens are set forth in the Sequence Listing Seq ID No 145-288.

In a preferred embodiment of the present invention, a nucleic acid molecule is provided which exhibits 70% identity over their entire length to a nucleotide sequence set forth with Seq ID No 1, 101-144. Most highly preferred are nucleic acids that comprise a region that is at least 80% or at least 85% identical over their entire length to a nucleic acid molecule set forth with Seq ID No 1, 101-144. In this regard, nucleic acid molecules at least 90%, 91%, 92%, 93%, 94%, 95%, or 96% identical over their entire length to the same are particularly preferred. Furthermore, those with at least 97% are highly preferred, those with at least 98% and at least 99% are particularly highly preferred, with at least 99% or 99.5% being the more preferred, with 100% identity being especially preferred. Moreover, preferred embodiments in this respect are nucleic acids which encode hyperimmune serum reactive antigens or fragments thereof (polypeptides) which retain substantially the same biological function or activity as the mature polypeptide encoded by said nucleic acids set forth in the Seq ID No 1, 101-144.

Identity, as known in the art and used herein, is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. Identity can be readily calculated. While there exist a number of methods to measure identity between two polynucleotide or two polypeptide sequences, the term is well known to skilled artisans (e.g. Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity are codified in computer programs. Preferred computer program methods to determine identity between two sequences include, but are not limited to, GCG program package (Devereux, J. et al., 1984), BLASTP, BLASTN, and FASTA {Altschul, S. et al., 1990}.

According to another aspect of the invention, nucleic acid molecules are provided which exhibit at least 96% identity to the nucleic acid sequence set forth with Seq ID No 2-6, 8, 10-16, 18-23, 25-31, 34, 36, 38-42,

According to a further aspect of the present invention, nucleic acid molecules are provided which are identical to the nucleic acid sequences set forth with Seq ID No 9, 17, 24, 32, 37, 43, 52, 54, 65-66, 70, 80.

The nucleic acid molecules according to the present invention can as a second alternative also be a nucleic acid molecule which is at least essentially complementary to the nucleic acid described as the first alternative above. As used herein complementary means that a nucleic acid strand is base pairing via Watson-Crick base pairing with a second nucleic acid strand. Essentially complementary as used herein means that the base pairing is not occurring for all of the bases of the respective strands but leaves a certain number or percentage of the bases unpaired or wrongly paired. The percentage of correctly pairing bases is preferably at least 70 %, more preferably 80 %, even more preferably 90 % and most preferably any percentage higher than 90 %. It is to be noted that a percentage of 70 % matching bases is considered as homology and the hybridization having this extent of matching base pairs is considered as stringent. Hybridization conditions for this kind of stringent hybridization may be taken from Current Protocols in Molecular Biology (John Wiley and Sons, Inc., 1987). More particularly, the hybridization conditions can be as follows:

- Hybridization performed e.g. in 5 x SSPE, 5 x Denhardt's reagent, 0.1% SDS, 100 g/mL sheared DNA at 68°C
- Moderate stringency wash in 0.2xSSC, O.1% SDS at 42°C
- High stringency wash in 0.1xSSC, 0.1% SDS at 68°C

Genomic DNA with a GC content of 50% has an approximate  $T_M$  of 96°C. For 1% mismatch, the  $T_M$  is reduced by approximately 1°C.

In addition, any of the further hybridization conditions described herein are in principle applicable as well.

Of course, all nucleic acid sequence molecules which encode the same polypeptide molecule as those identified by the present invention are encompassed by any disclosure of a given coding sequence, since the degeneracy of the genetic code is directly applicable to unambiguously determine all possible nucleic acid molecules which encode a given polypeptide molecule, even if the number of such degenerated nucleic acid molecules may be high. This is also applicable for fragments of a given polypeptide, as long as the fragments encode a polypeptide being suitable to be used in a vaccination connection, e.g. as an active or passive vaccine.

The nucleic acid molecule according to the present invention can as a third alternative also be a nucleic acid which comprises a stretch of at least 15 bases of the nucleic acid molecule according to the first and second alternative of the nucleic acid molecules according to the present invention as outlined above. Preferably, the bases form a contiguous stretch of bases. However, it is also within the scope of the present invention that the stretch consists of two or more moieties, which are separated by a number of bases.

The present nucleic acids may preferably consist of at least 20, even more preferred at least 30, especially at least 50 contiguous bases from the sequences disclosed herein. The suitable length may easily be optimized due to the planned area of use (e.g. as (PCR) primers, probes, capture molecules (e.g. on a (DNA) chip), etc.). Preferred nucleic acid molecules contain at least a contiguous 15 base portion of one or more of the predicted immunogenic amino acid sequences listed in tables 1 and 2, especially the sequences of table 2 with scores of more than 10, preferably more than 20, especially with a score of more than 25. Specifically preferred are nucleic acids containing a contiguous portion of a DNA sequence of any sequence in the sequence protocol of the present application which shows 1 or more, preferably more

than 2, especially more than 5, non-identical nucleic acid residues compared to the published Streptococcus pneumoniae strain TIGR4 genome ({Tettelin, H. et al., 2001}; GenBank accession AE005672) and/or any other published S. pneumoniae genome sequence or parts thereof, especially of the strain R6 ({Hoskins, J. et al., 2001}; GenBank accession AE007317). Specifically preferred non-identical nucleic acid residues are residues, which lead to a non-identical amino acid residue. Preferably, the nucleic acid sequences encode for polypeptides having at least 1, preferably at least 2, preferably at least 3 different amino acid residues compared to the published S. pneumoniae counterparts mentioned above. Also such isolated polypeptides, being fragments of the proteins (or the whole protein) mentioned herein e.g. in the sequence listing, having at least 6, 7, or 8 amino acid residues and being encoded by these nucleic acids are preferred.

The nucleic acid molecule according to the present invention can as a fourth alternative also be a nucleic acid molecule which anneals under stringent hybridisation conditions to any of the nucleic acids of the present invention according to the above outlined first, second, and third alternative. Stringent hybridisation conditions are typically those described herein.

Finally, the nucleic acid molecule according to the present invention can as a fifth alternative also be a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to any of the nucleic acid molecules according to any nucleic acid molecule of the present invention according to the first, second, third, and fourth alternative as outlined above. This kind of nucleic acid molecule refers to the fact that preferably the nucleic acids according to the present invention code for the hyperimmune serum reactive antigens or fragments thereof according to the present invention. This kind of nucleic acid molecule is particularly useful in the detection of a nucleic acid molecule according to the present invention and thus the diagnosis of the respective microorganisms such as *S. pneumoniae* and any disease or diseased condition where this kind of microorganims is involved. Preferably, the hybridisation would occur or be preformed under stringent conditions as described in connection with the fourth alternative described above.

Nucleic acid molecule as used herein generally refers to any ribonucleic acid molecule or deoxyribonucleic acid molecule, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, nucleic acid molecule as used herein refers to, among other, single-and doublestranded DNA, DNA that is a mixture of single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be singlestranded or, more typically, double-stranded, or triple-stranded, or a mixture of single- and doublestranded regions. In addition, nucleic acid molecule as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term nucleic acid molecule includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "nucleic acid molecule" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are nucleic acid molecule as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term nucleic acid molecule as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of nucleic acid molecule, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia. The term nucleic acid molecule also embraces short nucleic acid molecules often referred to as oligonucleotide(s). "Polynucleotide" and "nucleic acid" or "nucleic acid molecule" are often used interchangeably herein.

Nucleic acid molecules provided in the present invention also encompass numerous unique fragments,

S. pneumoniae coding regions, which can be generated by standard cloning methods. To be unique, a fragment must be of sufficient size to distinguish it from other known nucleic acid sequences, most readily determined by comparing any selected S. pneumoniae fragment to the nucleotide sequences in computer databases such as GenBank.

Additionally, modifications can be made to the nucleic acid molecules and polypeptides that are encompassed by the present invention. For example, nucleotide substitutions can be made which do not affect the polypeptide encoded by the nucleic acid, and thus any nucleic acid molecule which encodes a hyperimmune serum reactive antigen or fragments thereof is encompassed by the present invention.

Furthermore, any of the nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof provided by the present invention can be functionally linked, using standard techniques such as standard cloning techniques, to any desired regulatory sequences, whether a *S. pneumoniae* regulatory sequence or a heterologous regulatory sequence, heterologous leader sequence, heterologous marker sequence or a heterologous coding sequence to create a fusion protein.

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA or cRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The DNA may be triple-stranded, double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

The present invention further relates to variants of the herein above described nucleic acid molecules which encode fragments, analogs and derivatives of the hyperimmune serum reactive antigens and fragments thereof having a deducted *S. pneumoniae* amino acid sequence set forth in the Sequence Listing. A variant of the nucleic acid molecule may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.

Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or additions. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Preferred are nucleic acid molecules encoding a variant, analog, derivative or fragment, or a variant, analogue or derivative of a fragment, which have a *S. pneumoniae* sequence as set forth in the Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid(s) is substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the *S. pneumoniae* polypeptides set forth in the Sequence Listing. Also especially preferred in this regard are conservative substitutions.

The peptides and fragments according to the present invention also include modified epitopes wherein preferably one or two of the amino acids of a given epitope are modified or replaced according to the rules disclosed in e.g. {Tourdot, S. et al., 2000}, as well as the nucleic acid sequences encoding such modified epitopes.

It is clear that also epitopes derived from the present epitopes by amino acid exchanges improving, conserving or at least not significantly impeding the T cell activating capability of the epitopes are covered by the epitopes according to the present invention. Therefore the present epitopes also cover epitopes, which do not contain the original sequence as derived from S. pneumoniae, but trigger the same or preferably an improved T cell response. These epitope are referred to as "heteroclitic"; they need to

have a similar or preferably greater affinity to MHC/HLA molecules, and the need the ability to stimulate the T cell receptors (TCR) directed to the original epitope in a similar or preferably stronger manner.

Heteroclitic epitopes can be obtained by rational design i.e. taking into account the contribution of individual residues to binding to MHC/HLA as for instance described by {Rammensee, H. et al., 1999}, combined with a systematic exchange of residues potentially interacting with the TCR and testing the resulting sequences with T cells directed against the original epitope. Such a design is possible for a skilled man in the art without much experimentation.

Another possibility includes the screening of peptide libraries with T cells directed against the original epitope. A preferred way is the positional scanning of synthetic peptide libraries. Such approaches have been described in detail for instance by {Hemmer, B. et al., 1999} and the references given therein.

As an alternative to epitopes represented by the present derived amino acid sequences or heteroclitic epitopes, also substances mimicking these epitopes e.g. "peptidemimetica" or "retro-inverso-peptides" can be applied.

Another aspect of the design of improved epitopes is their formulation or modification with substances increasing their capacity to stimulate T cells. These include T helper cell epitopes, lipids or liposomes or preferred modifications as described in WO 01/78767.

Another way to increase the T cell stimulating capacity of epitopes is their formulation with immune stimulating substances for instance cytokines or chemokines like interleukin-2, -7, -12, -18, class I and II interferons (IFN), especially IFN-gamma, GM-CSF, TNF-alpha, flt3-ligand and others.

As discussed additionally herein regarding nucleic acid molecule assays of the invention, for instance, nucleic acid molecules of the invention as discussed above, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the nucleic acid molecules of the present invention. Such probes generally will comprise at least 15 bases. Preferably, such probes will have at least 20, at least 25 or at least 30 bases, and may have at least 50 bases. Particularly preferred probes will have at least 30 bases, and will have 50 bases or less, such as 30, 35, 40, 45, or 50 bases.

For example, the coding region of a nucleic acid molecule of the present invention may be isolated by screening a relevant library using the known DNA sequence to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the present invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine to which members of the library the probe hybridizes.

The nucleic acid molecules and polypeptides of the present invention may be employed as reagents and materials for development of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to nucleic acid molecule assays, *inter alia*.

The nucleic acid molecules of the present invention that are oligonucleotides can be used in the processes herein as described, but preferably for PCR, to determine whether or not the *S. pneumoniae* genes identified herein in whole or in part are present and/or transcribed in infected tissue such as blood. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained. For this and other purposes the arrays comprising at least one of the nucleic acids according to the present invention as described herein, may be used.

The nucleic acid molecules according to the present invention may be used for the detection of nucleic acid molecules and organisms or samples containing these nucleic acids. Preferably such detection is for diagnosis, more preferable for the diagnosis of a disease related or linked to the present or abundance of

Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, infected with S. pneumoniae may be identifiable by detecting any of the nucleic acid molecules according to the present invention detected at the DNA level by a variety of techniques. Preferred nucleic acid molecules candidates for distinguishing a S. pneumoniae from other organisms can be obtained.

The invention provides a process for diagnosing disease, arising from infection with S. pneumoniae, comprising determining from a sample isolated or derived from an individual an increased level of expression of a nucleic acid molecule having the sequence of a nucleic acid molecule set forth in the Sequence Listing. Expression of nucleic acid molecules can be measured using any one of the methods well known in the art for the quantitation of nucleic acid molecules, such as, for example, PCR, RT-PCR, Rnase protection, Northern blotting, other hybridisation methods and the arrays described herein.

Isolated as used herein means separated "by the hand of man" from its natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring nucleic acid molecule or a polypeptide naturally present in a living organism in its natural state is not "isolated," but the same nucleic acid molecule or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. As part of or following isolation, such nucleic acid molecules can be joined to other nucleic acid molecules, such as DNAs, for mutagenesis, to form fusion proteins, and for propagation or expression in a host, for instance. The isolated nucleic acid molecules, alone or joined to other nucleic acid molecules such as vectors, can be introduced into host cells, in culture or in whole organisms. Introduced into host cells in culture or in whole organisms, such DNAs still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment. Similarly, the nucleic acid molecules and polypeptides may occur in a composition, such as a media formulations, solutions for introduction of nucleic acid molecules or polypeptides, for example, into cells, compositions or solutions for chemical or enzymatic reactions, for instance, which are not naturally occurring compositions, and, therein remain isolated nucleic acid molecules or polypeptides within the meaning of that term as it is employed herein.

The nucleic acids according to the present invention may be chemically synthesized. Alternatively, the nucleic acids can be isolated from S. pneumoniae by methods known to the one skilled in the art.

According to another aspect of the present invention, a comprehensive set of novel hyperimmune serum reactive antigens and fragments thereof are provided by using the herein described antigen identification method. In a preferred embodiment of the invention, a hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by any one of the nucleic acids molecules herein described and fragments thereof are provided. In another preferred embodiment of the invention a novel set of hyperimmune serum-reactive antigens which comprises amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 145, 245-288 and fragments thereof are provided. In a further preferred embodiment of the invention hyperimmune serum-reactive antigens which comprise amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 146-150, 152, 154-160, 162-167, 169-175, 178, 180, 182-186, 188, 191-192, 195, 197, 199-206, 208, 211, 215-220, 222-223, 225-238, 240-244 and fragments thereof are provided. In a still preferred embodiment of the invention hyperimmune serum-reactive antigens which comprise amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 153, 161, 168, 176, 181, 187, 196, 198, 209-210, 214, 224 and fragments thereof are provided.

The hyperimmune serum reactive antigens and fragments thereof as provided in the invention include

any polypeptide set forth in the Sequence Listing as well as polypeptides which have at least 70% identity to a polypeptide set forth in the Sequence Listing, preferably at least 80% or 85% identity to a polypeptide set forth in the Sequence Listing, and more preferably at least 90% similarity (more preferably at least 90% identity) to a polypeptide set forth in the Sequence Listing and still more preferably at least 95%, 96%, 97%, 98%, 99% or 99.5% similarity (still more preferably at least 95%, 96%, 97%, 98%, 99%, or 99.5% identity) to a polypeptide set forth in the Sequence Listing and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 4 amino acids and more preferably at least 8, still more preferably at least 30, still more preferably at least 50 amino acids, such as 4, 8, 10, 20, 30, 35, 40, 45 or 50 amino acids.

The invention also relates to fragments, analogs, and derivatives of these hyperimmune serum reactive antigens and fragments thereof. The terms "fragment", "derivative" and "analog" when referring to an antigen whose amino acid sequence is set forth in the Sequence Listing, means a polypeptide which retains essentially the same or a similar biological function or activity as such hyperimmune serum reactive antigen and fragment thereof.

The fragment, derivative or analog of a hyperimmune serum reactive antigen and fragment thereof may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid residues includes a substituent group, or 3) one in which the mature hyperimmune serum reactive antigen or fragment thereof is fused with another compound, such as a compound to increase the half-life of the hyperimmune serum reactive antigen and fragment thereof (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the mature hyperimmune serum reactive antigen or fragment thereof, such as a leader or secretory sequence or a sequence which is employed for purification of the mature hyperimmune serum reactive antigen or fragment thereof or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

The present invention also relates to antigens of different *S. pneumoniae* isolates. Such homologues may easily be isolated based on the nucleic acid and amino acid sequences disclosed herein. There are more than 90 serotypes in more than 40 serogroups distinguished to date and the typing is based on serotype specific antisera. The presence of any antigen can accordingly be determined for every serotype. In addition it is possible to determine the variability of a particular antigen in the various serotypes as described for the *S. pyogenes* sic gene {Hoe, N. et al., 2001}. The contribution of the various serotypes to the different pneumococcal infections varies in the different age groups and geographical regions {Gray, B. et al., 1979}; {Gray, B. et al., 1986}; {Orange, M. et al., 1993}, reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book). It is an important aspect that the most valuable protective antigens are expected to be conserved among various clinical strains.

Among the particularly preferred embodiments of the invention in this regard are the hyperimmune serum reactive antigens set forth in the Sequence Listing, variants, analogs, derivatives and fragments thereof, and variants, analogs and derivatives of fragments. Additionally, fusion polypeptides comprising such hyperimmune serum reactive antigens, variants, analogs, derivatives and fragments thereof, and variants, analogs and derivatives of the fragments are also encompassed by the present invention. Such fusion polypeptides and proteins, as well as nucleic acid molecules encoding them, can readily be made using standard techniques, including standard recombinant techniques for producing and expression of a recombinant polynucleic acid encoding a fusion protein.

Among preferred variants are those that vary from a reference by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another,

among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues-Asn-and-Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe and Tyr.

Further particularly preferred in this regard are variants, analogs, derivatives and fragments, and variants, analogs and derivatives of the fragments, having the amino acid sequence of any polypeptide set forth in the Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the polypeptide of the present invention. Also especially preferred in this regard are conservative substitutions. Most highly preferred are polypeptides having an amino acid sequence set forth in the Sequence Listing without substitutions.

The hyperimmune serum reactive antigens and fragments thereof of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

Also among preferred embodiments of the present invention are polypeptides comprising fragments of the polypeptides having the amino acid sequence set forth in the Sequence Listing, and fragments of variants and derivatives of the polypeptides set forth in the Sequence Listing.

In this regard a fragment is a polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the afore mentioned hyperimmune serum reactive antigen and fragment thereof, and variants or derivative, analogs, fragments thereof. Such fragments may be "freestanding", i.e., not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. Also preferred in this aspect of the invention are fragments characterised by structural or functional attributes of the polypeptide of the present invention, i.e. fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta-amphipathic regions, flexible regions, surface-forming regions, substrate binding regions, and high antigenic index regions of the polypeptide of the present invention, and combinations of such fragments. Preferred regions are those that mediate activities of the hyperimmune serum reactive antigens and fragments thereof of the present invention. Most highly preferred in this regard are fragments that have a chemical, biological or other activity of the hyperimmune serum reactive antigen and fragments thereof of the present invention, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for viability of S. pneumoniae or the ability to cause disease in humans. Further preferred polypeptide fragments are those that comprise or contain antigenic or immunogenic determinants in an animal, especially in a human.

An antigenic fragment is defined as a fragment of the identified antigen, which is for itself antigenic or may be made antigenic when provided as a hapten. Therefore, also antigens or antigenic fragments showing one or (for longer fragments) only a few amino acid exchanges are enabled with the present invention, provided that the antigenic capacities of such fragments with amino acid exchanges are not severely deteriorated on the exchange(s), i.e., suited for eliciting an appropriate immune response in an individual vaccinated with this antigen and identified by individual antibody preparations from

Preferred examples of such fragments of a hyperimmune serum-reactive antigen are selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa", and "Location of identified immunogenic region" of Table 1; the serum reactive epitopes of Table 2, especially peptides comprising amino acid 4-11, 35-64, 66-76, 101-108, 111-119 and 57-114 of Seq ID No

145; 5-27, 32-64, 92-102, 107-113, 119-125, 133-139, 148-162, 177-187, 195-201, 207-214, 241-251, 254-269, 285-300, 302-309, 317-324, 332-357, 365-404, 411-425, 443-463, 470-477, 479-487, 506-512, 515-520, 532-547, 556-596, 603-610, 616-622, 624-629, 636-642, 646-665, 667-674, 687-692, 708-720, 734-739, 752-757, 798-820, 824-851, 856-865 and 732-763 of Seq ID No 146; 14-21, 36-44, 49-66, 102-127, 162-167, 177-196, 45-109 and 145-172 of Seq ID No 147; 17-35, 64-75, 81-92, 100-119, 125-172, 174-183, 214-222, 230-236, 273-282, 287-303, 310-315, 331-340, 392-398, 412-420, 480-505, 515-523, 525-546, 553-575, 592-598, 603-609, 617-625, 631-639, 644-651, 658-670, 681-687, 691-704, 709-716, 731-736, 739-744, 750-763, 774-780, 784-791, 799-805, 809-822. 859-870, 880-885, 907-916, 924-941, 943-949, 973-986, 1010-1016, 1026-1036, 1045-1054, 1057-1062, 1082-1088, 1095-1102, 1109-1120, 1127-1134, 1140-1146, 1152-1159, 1169-1179, 1187-1196, 1243-1251, 1262-1273, 1279-1292, 1306-1312, 1332-1343, 1348-1364, 1379-1390, 1412-1420, 1427-1436, 1458-1468, 1483-1503, 1524-1549, 1574-1588, 1614-1619, 1672-1685, 1697-1707, 1711-1720, 1738-1753, 1781-1787, 1796-1801, 1826-1843, 132-478, 508-592 and 1753-1810 of Seq ID No 148; 15-43, 49-55, 71-77, 104-110, 123-130, 162-171, 180-192, 199-205, 219-227, 246-254, 264-270, 279-287, 293-308, 312-322, 330-342, 349-356, 369-377, 384-394, 401-406, 416-422, 432-439, 450-460, 464-474, 482-494, 501-508, 521-529, 536-546, 553-558, 568-574, 584-591, 602-612, 616-626, 634-646, 653-660, 673-681, 688-698, 705-710, 720-726, 736-749, 833-848, 1-199, 200-337, 418-494 and 549-647 of Seq ID No 149; 9-30, 65-96, 99-123, 170-178 and 1-128 of Seq ID No 150; 7-32, 34-41, 96-106, 127-136, 154-163, 188-199, 207-238, 272-279, 306-312, 318-325, 341-347, 353-360, 387-393, 399-406, 434-440, 452-503, 575-580, 589-601, 615-620, 635-640, 654-660, 674-680, 696-701, 710-731, 1-548 and 660-691 of Seq ID No 151; 4-19, 35-44, 48-59, 77-87, 93-99, 106-111, 130-138, 146-161 and 78-84 of Seq ID No 152; 24-30, 36-43, 64-86, 93-99, 106-130, 132-145, 148-165, 171-177, 189-220, 230-249, 251-263, 293-300, 302-312, 323-329, 338-356, 369-379, 390-412 and 179-193 of Seq ID No 153; 30-39, 61-67, 74-81, 90-120, 123-145, 154-167, 169-179, 182-197, 200-206, 238-244, 267-272 and 230-265 of Seq ID No 154; 14-20, 49-65, 77-86 and 2-68 of Seq ID No 155; 4-9, 26-35, 42-48, 53-61, 63-85, 90-101, 105-111, 113-121, 129-137, 140-150, 179-188, 199-226, 228-237, 248-255, 259-285, 299-308, 314-331, 337-343, 353-364, 410-421, 436-442 and 110-144 of Seq ID No 156; 36-47, 55-63, 94-108, 129-134, 144-158, 173-187, 196-206, 209-238, 251-266, 270-285, 290-295, 300-306, 333-344, 346-354, 366-397, 404-410, 422-435, 439-453, 466-473, 515-523, 529-543, 554-569, 571-585, 590-596, 607-618, 627-643, 690-696, 704-714, 720-728, 741-749, 752-767, 780-799, 225-247 and 480-507 of Seq ID No 157; 16-25, 36-70, 80-93, 100-106 and 78-130 of Seq ID No 158; 18-27, 41-46, 50-57, 65-71, 79-85, 93-98, 113-128, 144-155, 166-178, 181-188, 201-207, 242-262, 265-273, 281-295, 303-309, 318-327 and 36-64 of Seq ID No 159; 7-29, 31-44, 50-59, 91-96, 146-153, 194-201, 207-212, 232-238, 264-278, 284-290, 296-302, 326-353, 360-370, 378-384, 400-405, 409-418, 420-435, 442-460, 499-506, 529-534, 556-562, 564-576, 644-651, 677-684, 687-698, 736-743, 759-766, 778-784, 808-814, 852-858, 874-896, 920-925, 929-935, 957-965, 1003-1012, 1021-1027, 1030-1044, 1081-1087, 1101-1111, 1116-1124, 1148-1159, 1188-1196, 1235-1251, 1288-1303, 1313-1319, 1328-1335, 1367-1373, 1431-1437, 1451-1458, 1479-1503, 1514-1521, 1530-1540, 1545-1552, 1561-1568, 1598-1605, 1617-1647, 1658-1665, 1670-1676, 1679-1689, 1698-1704, 1707-1713, 1732-1738, 1744-1764, 1-70, 154-189, 922-941, 1445-1462 and 1483-1496 of Seq ID No 160; 6-51, 81-91, 104-113, 126-137, 150-159, 164-174, 197-209, 215-224, 229-235, 256-269, 276-282, 307-313, 317-348, 351-357, 376-397, 418-437, 454-464, 485-490, 498-509, 547-555. 574-586, 602-619 and 452-530 of Seq ID No 161; 25-31, 39-47, 49-56, 99-114, 121-127, 159-186, 228-240, 253-269, 271-279, 303-315, 365-382, 395-405, 414-425, 438-453 and 289-384 of Seq ID No 162; 9-24, 41-47, 49-54, 68-78, 108-114, 117-122, 132-140, 164-169, 179-186, 193-199, 206-213, 244-251, 267-274, 289-294, 309-314, 327-333, 209-249 and 286-336 of Seq ID No 163; 9-28, 53-67, 69-82, 87-93, 109-117, 172-177, 201-207, 220-227, 242-247, 262-268, 305-318, 320-325 and 286-306 of Seq ID No 164; 4-10, 26-39, 47-58, 63-73, 86-96, 98-108, 115-123, 137-143, 148-155, 160-176, 184-189, 194-204, 235-240, 254-259, 272-278 and 199-283 of Seq. ID No 165; 4-26, 33-39, 47-53, 59-65, 76-83, 91-97, 104-112, 118-137, 155-160, 167-174, 198-207, 242-268, 273-279, 292-315, 320-332, 345-354, 358-367, 377-394, 403-410, 424-439, 445-451, 453-497, 511-518, 535-570, 573-589, 592-601, 604-610 and 202-242 of Seq ID No 166; 8-30, 36-45, 64-71, 76-82, 97-103, 105-112, 134-151, 161-183, 211-234, 253-268, 270-276, 278-284, 297-305, 309-315, 357-362, 366-372, 375-384, 401-407, 409-416, 441-455, 463-470, 475-480, 490-497, 501-513, 524-537, 552-559, 565-576, 581-590, 592-600, 619-625, 636-644, 646-656 and 316-419 of Seq ID No 167; 4-17, 52-58, 84-99, 102-110, 114-120, 124-135, 143-158, 160-173, 177-196, 201-216, 223-250, 259-267, 269-275 and 1-67 of Seq ID No 168; 6-46, 57-67, 69-80, 82-133, 137-143, 147-168. 182-187, 203-209, 214-229, 233-242, 246-280 and 53-93 of Seq ID No 169; 7-40, 50-56, 81-89, 117-123, 202-209, 213-218, 223-229, 248-261, 264-276, 281-288, 303-308, 313-324, 326-332, 340-346, 353-372, 434-443,

465-474, 514-523, 556-564, 605-616, 620-626, 631-636, 667-683, 685-699, 710-719, 726-732, 751-756, 760-771, 779-788, 815-828, 855-867, 869-879, 897-902, 917-924, 926-931, 936-942, 981-1000, 1006-1015, 1017-1028, 1030-1039, 1046-1054, 1060-1066, 1083-1092, 1099-1112, 1122-1130, 1132-1140, 1148-1158, 1161-1171, 1174-1181, 1209-1230, 1236-1244, 1248-1254, 1256-1267, 1269-1276, 1294-1299, 1316-1328, 1332-1354, 1359-1372, 1374-1380, 1384-1390, 1395-1408, 1419-1425, 1434-1446, 1453-1460, 1465-1471, 1474-1493, 1505-1515, 1523-1537, 1547-1555, 1560-1567, 1577-1605, 1633-1651, 1226-1309, 1455-1536 and 1538-1605 of Seq ID No 170; 4-10, 31-39, 81-88, 106-112, 122-135, 152-158, 177-184, 191-197, 221-227, 230-246, 249-255, 303-311, 317-326, 337-344, 346-362, 365-371, 430-437, 439-446, 453-462, 474-484 and 449-467 of Seq ID No 171; 9-15, 24-35, 47-55, 122-128, 160-177, 188-196, 202-208, 216-228, 250-261, 272-303, 318-324, 327-339, 346-352, 355-361, 368-373, 108-218 and 344-376 of Seq ID No 172; 6-14, 17-48, 55-63, 71-90, 99-109, 116-124, 181-189, 212-223, 232-268, 270-294, 297-304, 319-325, 340-348, 351-370, 372-378, 388-394, 406-415, 421-434 and 177-277 of Seq ID No 173; 21-39, 42-61, 65-75, 79-85, 108-115 and 11-38 of Seq ID No 174; 4-17, 26-39, 61-76, 103-113, 115-122, 136-142, 158-192, 197-203, 208-214, 225-230, 237-251 and 207-225 of Seq ID No 175; 5-11, 27-36, 42-53, 62-70, 74-93, 95-104, 114-119, 127-150, 153-159, 173-179, 184-193, 199-206, 222-241, 248-253, 257-280, 289-295, 313-319, 322-342, 349-365, 368-389, 393-406, 408-413, 426-438, 447-461, 463-470, 476-495, 532-537, 543-550 and 225-246 of Seq ID No 176; 4-29, 68-82, 123-130, 141-147, 149-157, 178-191, 203-215, 269-277, 300-307, 327-335, 359-370, 374-380, 382-388, 393-400, 410-417, 434-442, 483-492, 497-503, 505-513, 533-540, 564-569, 601-607, 639-647, 655-666, 693-706, 712-718, 726-736, 752-758, 763-771, 774-780, 786-799, 806-812, 820-828, 852-863, 884-892, 901-909, 925-932, 943-948, 990-996, 1030-1036, 1051-1059, 1062-1068, 1079-1086, 1105-1113, 1152-1162, 1168-1179, 1183-1191, 1204-1210, 1234-1244, 1286-1295, 1318-1326, 1396-1401, 1451-1460, 1465-1474, 1477-1483, 1488-1494, 1505-1510, 1514-1521, 1552-1565, 1593-1614, 1664-1672, 1677-1685, 1701-1711, 1734-1745, 1758-1770, 1784-1798, 1840-1847, 1852-1873, 1885-1891, 1906-1911, 1931-1939, 1957-1970, 1977-1992, 2014-2020, 2026-2032, 2116-2134, 1-348, 373-490, 573-767, 903-1043, 1155-1198, 1243-1482, 1550-1595, 1682-1719, 1793-1921 and 2008-2110 of Seq ID No 177; 10-35, 39-52, 107-112, 181-188, 226-236, 238-253, 258-268, 275-284, 296-310, 326-338, 345-368, 380-389, 391-408, 410-418, 420-429, 444-456, 489-505, 573-588, 616-623, 637-643, 726-739, 741-767, 785-791, 793-803, 830-847, 867-881, 886-922, 949-956, 961-980, 988-1004, 1009-1018, 1027-1042, 1051-1069, 1076-1089, 1108-1115, 1123-1135, 1140-1151, 1164-1179, 1182-1191, 1210-1221, 1223-1234, 1242-1250, 1255-1267, 1281-1292, 1301-1307, 1315-1340, 1348-1355, 1366-1373, 1381-1413, 1417-1428, 1437-1444, 1453-1463, 1478-1484, 1490-1496, 1498-1503, 1520-1536, 1538-1546, 1548-1570, 1593-1603, 1612-1625, 1635-1649, 1654-1660, 1670-1687, 1693-1700, 1705-1711, 1718-1726, 1729-1763, 1790-1813, 1871-1881, 1893-1900, 1907-1935, 1962-1970, 1992-2000, 2006-2013, 2033-2039, 2045-2051, 2055-2067, 2070-2095, 2097-2110, 2115-2121, 2150-2171, 2174-2180, 2197-2202, 2206-2228 and 1526-1560 of Seq ID No 178; 4-17, 35-48, 54-76, 78-107, 109-115, 118-127, 134-140, 145-156, 169-174, 217-226, 232-240, 256-262, 267-273, 316-328, 340-346, 353-360, 402-409, 416-439, 448-456, 506-531, 540-546, 570-578, 586-593, 595-600, 623-632, 662-667, 674-681, 689-705, 713-724, 730-740, 757-763, 773-778, 783-796, 829-835, 861-871, 888-899, 907-939, 941-955, 957-969, 986-1000, 1022-1028, 1036-1044, 1068-1084, 1095-1102, 1118-1124, 1140-1146, 1148-1154, 1168-1181, 1185-1190, 1197-1207, 1218-1226, 1250-1270, 1272-1281, 1284-1296, 1312-1319, 1351-1358, 1383-1409, 1422-1428, 1438-1447, 1449-1461, 1482-1489, 1504-1510, 1518-1527, 1529-1537, 1544-1551, 1569-1575, 1622-1628, 1631-1637, 1682-1689, 1711-1718, 1733-1740, 1772-1783, 1818-1834, 1859-1872, 1-64 and 128-495 of Seq ID No 179; 8-28, 32-37, 62-69, 119-125, 137-149, 159-164, 173-189, 200-205, 221-229, 240-245, 258-265, 268-276, 287-293, 296-302, 323-329 and 1-95 of Seq ID No 180; 9-18, 25-38, 49-63, 65-72, 74-81, 94-117, 131-137, 139-146, 149-158, 162-188, 191-207, 217-225, 237-252, 255-269, 281-293, 301-326, 332-342, 347-354, 363-370, 373-380, 391-400, 415-424, 441-447 and 75-107 of Seq ID No 181; 4-24, 64-71, 81-87, 96-116, 121-128, 130-139, 148-155, 166-173, 176-184, 203-215, 231-238, 243-248, 256-261, 280-286, 288-306, 314-329 and 67-148 of Seq ID No 182; 4-10, 19-37, 46-52, 62-81, 83-89, 115-120, 134-139, 141-151, 168-186, 197-205, 209-234, 241-252, 322-335, 339-345, 363-379, 385-393, 403-431, 434-442, 447-454, 459-465, 479-484, 487-496 and 404-420 of Seq ID No 183; 10-35, 46-66, 71-77, 84-93, 96-122, 138-148, 154-172, 182-213, 221-233, 245-263, 269-275, 295-301, 303-309, 311-320, 324-336, 340-348, 351-359, 375-381 and 111-198 of Seq ID No 184; 14-25, 30-42, 47-61, 67-75, 81-91, 98-106, 114-122, 124-135, 148-193, 209-227 and 198-213 of Seq ID No 185; 5-18, 45-50, 82-90, 97-114, 116-136, 153-161, 163-171, 212-219, 221-227, 240-249, 267-281, 311-317, 328-337, 375-381, 390-395, 430-436, 449-455, 484-495, 538-543, 548-554, 556-564, 580-586, 596-602 and 493-606 of Seq ID No 186; 9-25, 28-34, 37-44, 61-68, 75-81, 88-96, 98-111, 119-133, 138-150, 152-163, 168-182, 186-194, 200205, 216-223, 236-245, 257-264, 279-287, 293-304, 311-318, 325-330, 340-346, 353-358, 365-379, 399-409, 444-453 and 303-391 of Seq ID No 187; 16-36, 55-61, 66-76, 78-102, 121-130, 134-146, 150-212, 221-239, 255-276, 289-322, 329-357 and 29-59 of Seq ID No 188; 8-27, 68-74, 77-99, 110-116, 124-141, 171-177, 202-217, 221-228, 259-265, 275-290, 293-303, 309-325, 335-343, 345-351, 365-379, 384-394, 406-414, 423-437, 452-465, 478-507, 525-534, 554-560, 611-624, 628-651, 669-682, 742-747, 767-778, 782-792, 804-812, 820-836, 79-231 and 359-451 of Seq ID No 189; 5-28, 39-45, 56-62, 67-74, 77-99, 110-117, 124-141, 168-176, 200-230, 237-244, 268-279, 287-299, 304-326, 329-335, 348-362, 370-376, 379-384, 390-406, 420-429, 466-471, 479-489, 495-504, 529-541, 545-553, 561-577, 598-604, 622-630, 637-658, 672-680, 682-688, 690-696, 698-709, 712-719, 724-736, 738-746, 759-769, 780-786, 796-804, 813-818, 860-877, 895-904, 981-997, 1000-1014, 1021-1029, 1-162, 206-224, 254-350, 414-514 and 864-938 of Seq ID No 190; 4-11, 19-49, 56-66, 68-101, 109-116, 123-145, 156-165, 177-185, 204-221, 226-234, 242-248, 251-256, 259-265, 282-302, 307-330, 340-349, 355-374, 377-383, 392-400, 422-428, 434-442, 462-474 and 266-322 of Seq ID No 191; 14-43, 45-57, 64-74, 80-87, 106-127, 131-142, 145-161, 173-180, 182-188, 203-210, 213-219, 221-243, 245-254, 304-311, 314-320, 342-348, 354-365, 372-378, 394-399, 407-431, 436-448, 459-465, 470-477, 484-490, 504-509, 531-537, 590-596, 611-617, 642-647, 723-734, 740-751, 754-762, 764-774, 782-797, 807-812, 824-831, 838-845, 877-885, 892-898, 900-906, 924-935, 940-946, 982-996, 1006-1016, 1033-1043, 1051-1056, 1058-1066, 1094-1108, 1119-1126, 1129-1140, 1150-1157, 1167-1174, 1176-1185, 1188-1201, 1209-1216, 1220-1228, 1231-1237, 1243-1248, 1253-1285, 1288-1297, 1299-1307, 1316-1334, 1336-1343, 1350-1359, 1365-1381, 1390-1396, 1412-1420, 1427-1439, 1452-1459, 1477-1484, 1493-1512, 1554-1559, 1570-1578, 1603-1608, 1623-1630, 1654-1659, 1672-1680, 1689-1696, 1705-1711, 1721-1738, 1752-1757, 1773-1780, 1817-1829, 1844-1851, 1856-1863, 1883-1895, 1950-1958, 1974-1990, 172-354, 384-448, 464-644, 648-728 and 1357-1370 of Seq ID No 192; 8-27, 68-74, 77-99, 110-116, 124-141, 169-176, 201-216, 220-227, 258-264, 274-289, 292-302, 308-324, 334-342, 344-350, 364-372, 377-387, 399-407, 416-429, 445-458, 471-481, 483-500, 518-527, 547-553, 604-617, 621-644, 662-675, 767-778, 809-816, 15-307, 350-448 and 496-620 of Seq. ID No 193; 4-17, 24-29, 53-59, 62-84, 109-126, 159-164, 189-204, 208-219, 244-249, 274-290, 292-302, 308-324, 334-342, 344-350, 378-389, 391-397, 401-409, 424-432, 447-460, 470-479, 490-504, 521-529, 538-544, 549-555, 570-577, 583-592, 602-608, 615-630, 635-647, 664-677, 692-698, 722-731, 733-751, 782-790, 793-799, 56-267, 337-426 and 495-601 of Seq ID No 194; 12-22, 49-59, 77-89, 111-121, 136-148, 177-186, 207-213, 217-225, 227-253, 259-274, 296-302, 328-333, 343-354, 374-383, 424-446, 448-457, 468-480, 488-502, 507-522, 544-550, 553-560, 564-572, 587-596, 604-614, 619-625, 629-635, 638-656, 662-676, 680-692, 697-713, 720-738, 779-786, 833-847, 861-869, 880-895, 897-902, 911-917, 946-951, 959-967, 984-990, 992-1004, 1021-1040, 1057-1067, 1073-1080 and 381-403 of Seq ID No 195; 4-10, 26-31, 46-56, 60-66, 70-79, 86-94, 96-102, 109-118, 132-152, 164-187, 193-206, 217-224 and 81-149 of Seq ID No 196; 4-21, 26-37, 48-60, 71-82, 109-117, 120-128, 130-136, 142-147, 181-187, 203-211, 216-223, 247-255, 257-284, 316-325, 373-379, 395-400, 423-435, 448-456, 479-489, 512-576, 596-625, 641-678, 680-688, 692-715 and 346-453 of Seq ID No 197; 10-16, 25-31, 34-56, 58-69, 71-89, 94-110, 133-176, 186-193, 208-225, 240-250, 259-266, 302-307, 335-341, 376-383, 410-416 and 316-407 of Seq ID No 198; 11-29, 42-56, 60-75, 82-88, 95-110, 116-126, 132-143, 145-160, 166-172, 184-216 and 123-164 of Seq ID No 199; 11-29, 54-63, 110-117, 139-152, 158-166, 172-180, 186-193, 215-236, 240-251, 302-323, 330-335, 340-347, 350-366, 374-381 and 252-299 of Seq ID No 200; 18-27, 35-42, 50-56, 67-74, 112-136, 141-153, 163-171, 176-189, 205-213, 225-234, 241-247, 253-258, 269-281, 288-298, 306-324, 326-334, 355-369, 380-387 and 289-320 of Seq ID No 201; 7-15, 19-41, 56-72, 91-112, 114-122, 139-147, 163-183, 196-209, 258-280, 326-338, 357-363, 391-403, 406-416 and 360-378 of Seq ID No 202; 11-18, 29-41, 43-49, 95-108, 142-194, 204-212, 216-242, 247-256, 264-273 and 136-149 of Seq ID No 203; 18-24, 33-40, 65-79, 89-102, 113-119, 130-137, 155-161, 173-179, 183-203, 205-219, 223-231, 245-261, 267-274, 296-306, 311-321, 330-341, 344-363, 369-381, 401-408, 415-427, 437-444, 453-464, 472-478, 484-508, 517-524, 526-532, 543-548 and 59-180 of Seq ID No 204; 5-13, 52-65, 67-73, 97-110, 112-119, 134-155 and 45-177 of Seq ID No 205; 6-28, 34-43, 57-67, 75-81, 111-128, 132-147, 155-163, 165-176, 184-194, 208-216, 218-229, 239-252, 271-278, 328-334, 363-376, 381-388, 426-473, 481-488, 492-498, 507-513, 536-546, 564-582, 590-601, 607-623, 148-269, 420-450 and 610-648 of Seq ID No 206; 4-12, 20-38, 69-75, 83-88, 123-128, 145-152, 154-161, 183-188, 200-213, 245-250, 266-272, 306-312, 332-339, 357-369, 383-389, 395-402, 437-453, 455-470, 497-503 and 1-112 of Seq ID No 207; 35-59, 74-86, 111-117, 122-137 and 70-154 of Seq ID No 208; 26-42, 54-61, 65-75, 101-107, 123-130, 137-144, 148-156, 164-172, 177-192, 213-221, 231-258 and 157-249 of Seq ID No 209; 29-38, 61-67, 77-87, 94-100, 105-111, 118-158 and 1-97 of Seq ID No 210; 7-21, 30-48, 51-58, 60-85, 94-123, 134-156, 160-167, 169-183, 186-191, 216-229, 237-251.

257-267, 272-282, 287-298 and 220-243 of Seq ID No 211; 6-29, 34-47, 56-65, 69-76, 83-90, 123-134, 143-151, 158-178, 197-203, 217-235, 243-263, 303-309, 320-333, 338-348, 367-373, 387-393, 407-414, 416-427, 441-457, 473-482, 487-499, 501-509, 514-520, 530-535, 577-583, 590-602, 605-612, 622-629, 641-670, 678-690, 37-71 and 238-307 of Seq ID No 212; 7-40, 121-132, 148-161, 196-202, 209-215, 221-235, 248-255, 271-280, 288-295, 330-339, 395-409, 414-420, 446-451, 475-487, 556-563, 568-575, 580-586, 588-595, 633-638, 643-648, 652-659, 672-685, 695-700, 710-716, 737-742, 749-754, 761-767, 775-781, 796-806, 823-835, 850-863, 884-890, 892-900, 902-915, 934-941 and 406-521 of Seq ID No 213; 9-18, 24-46, 51-58, 67-77, 85-108, 114-126, 129-137, 139-146, 152-165, 173-182, 188-195, 197-204, 217-250, 260-274, 296-313, 343-366, 368-384, 427-434, 437-446, 449-455, 478-484, 492-506, 522-527, 562-591, 599-606, 609-618, 625-631, 645-652 and 577-654 of **Seq ID No** 214; 13-20, 26-37, 41-53, 56-65, 81-100, 102-114, 118-127, 163-188, 196-202, 231-238, 245-252, 266-285, 293-298, 301-306 and 19-78 of Seq ID No 215; 10-23, 32-42, 54-66, 73-91, 106-113, 118-127, 139-152, 164-173, 198-207, 210-245, 284-300, 313-318, 330-337, 339-346, 354-361, 387-393, 404-426, 429-439, 441-453, 467-473, 479-485, 496-509, 536-544, 551-558, 560-566, 569-574, 578-588, 610-615, 627-635, 649-675, 679-690, 698-716, 722-734, 743-754, 769-780, 782-787 and 480-550 of Seq ID No 216; 6-39, 42-50, 60-68, 76-83, 114-129, 147-162, 170-189, 197-205, 217-231, 239-248, 299-305, 338-344, 352-357, 371-377, 380-451, 459-483, 491-499, 507-523, 537-559, 587-613, 625-681, 689-729, 737-781, 785-809, 817-865, 873-881, 889-939, 951-975, 983-1027, 1031-1055, 1063-1071, 1079-1099, 1103-1127, 1151-1185, 1197-1261, 1269-1309, 1317-1333, 1341-1349, 1357-1465, 1469-1513, 1517-1553, 1557-1629, 1637-1669, 1677-1701, 1709-1725, 1733-1795, 1823-1849, 1861-1925, 1933-1973, 1981-2025, 2029-2053, 2061-2109, 2117-2125, 2133-2183, 2195-2219, 2227-2271, 2275-2299, 2307-2315, 2323-2343, 2347-2371, 2395-2429, 2441-2529, 2537-2569, 2577-2601, 2609-2625, 2633-2695, 2699-2737, 2765-2791, 2803-2867, 2889-2913, 2921-2937, 2945-2969, 2977-2985, 2993-3009, 3023-3045, 3073-3099, 3111-3167, 3175-3215, 3223-3267, 3271-3295, 3303-3351, 3359-3367, 3375-3425, 3437-3461, 3469-3513, 3517-3541, 3549-3557, 3565-3585, 3589-3613, 3637-3671, 3683-3747, 3755-3795, 3803-3819, 3827-3835, 3843-3951, 3955-3999, 4003-4039, 4043-4115, 4123-4143, 4147-4171, 4195-4229, 4241-4305, 4313-4353, 4361-4377, 4385-4393, 4401-4509, 4513-4557, 4561-4597, 4601-4718, 4749-4768, 74-171, 452-559 and 2951-3061 of Seq ID No 217; 16-22, 30-51, 70-111, 117-130, 137-150, 171-178, 180-188, 191-196 and 148-181 of Seq ID No 218; 6-19, 21-46, 50-56, 80-86, 118-126, 167-186, 189-205, 211-242, 244-267, 273-286, 290-297, 307-316, 320-341 and 34-60 of Seq ID No 219; 5-26, 33-43, 48-54, 58-63, 78-83, 113-120, 122-128, 143-152, 157-175, 185-192, 211-225, 227-234, 244-256, 270-281, 284-290, 304-310, 330-337, 348-355, 362-379, 384-394, 429-445, 450-474, 483-490, 511-520, 537-546, 548-554, 561-586, 590-604, 613-629, 149-186, 285-431 and 573-659 of Seq ID No 220; 5-26, 49-59, 61-67, 83-91, 102-111, 145-157, 185-192, 267-272, 279-286, 292-298, 306-312, 134-220, 235-251 and 254-280 of Seq ID No 221; 5-19, 72-79, 83-92, 119-124, 140-145, 160-165, 167-182, 224-232, 240-252, 259-270, 301-310, 313-322, 332-343, 347-367, 384-398, 416-429, 431-446, 454-461 and 1-169 of Seq ID No 222; 8-17, 26-31, 56-62, 75-83, 93-103, 125-131, 135-141, 150-194, 205-217, 233-258, 262-268, 281-286 and 127-168 of Seq ID No 223; 6-12, 69-75, 108-115, 139-159, 176-182, 194-214 and 46-161 of Seq ID No 224; 6-13, 18-27, 39-48, 51-59, 66-73, 79-85, 95-101, 109-116, 118-124, 144-164, 166-177, 183-193, 197-204, 215-223, 227-236, 242-249, 252-259, 261-270, 289-301, 318-325 and 12-58 of Seq ID No 225; 4-10, 26-32, 48-60, 97-105, 117-132, 138-163, 169-185, 192-214, 219-231, 249-261, 264-270, 292-308, 343-356, 385-392, 398-404, 408-417, 435-441 and 24-50 of Seq ID No 226; 10-40, 42-48, 51-61, 119-126 and 1-118 of Seq ID No 227; 5-17, 40-58, 71-83, 103-111, 123-140, 167-177, 188-204 and 116-128 of Seq ID No 228; 4-9, 11-50, 57-70, 112-123, 127-138 and 64-107 of Seq ID No 229; 9-39, 51-67 and 1-101 of Seq ID No 230; 5-14, 17-25, 28-46, 52-59, 85-93, 99-104, 111-120, 122-131, 140-148, 158-179, 187-197, 204-225, 271-283, 285-293 and 139-155 of Seq ID No 231; 42-70, 73-90, 92-108, 112-127, 152-164, 166-172, 181-199, 201-210, 219-228, 247-274, 295-302, 322-334, 336-346, 353-358, 396-414, 419-425, 432-438, 462-471, 518-523, 531-536, 561-567, 576-589, 594-612, 620-631, 665-671, 697-710, 718-731, 736-756, 765-771, 784-801 and 626-653 of Seq ID No 232; 8-28, 41-51, 53-62, 68-74, 79-85, 94-100, 102-108, 114-120, 130-154, 156-162, 175-180, 198-204, 206-213, 281-294, 308-318, 321-339, 362-368, 381-386, 393-399, 407-415 and 2-13 of Seq ID No 233; 4-39, 48-65, 93-98, 106-112, 116-129 and 10-36 of Seq ID No 234; 25-32, 35-50, 66-71, 75-86, 90-96, 123-136, 141-151, 160-179, 190-196, 209-215, 222-228, 235-242, 257-263, 270-280 and 209-247 of Seq ID No 235; 5-29, 31-38, 50-57, 62-75, 83-110, 115-132, 168-195, 197-206, 216-242, 249-258, 262-269, 333-340, 342-350, 363-368, 376-392, 400-406, 410-421, 423-430, 436-442, 448-454, 460-466, 471-476, 491-496, 511-516, 531-536, 551-556, 571-576, 585-591, 599-605, 27-70, 219-293, 441-504 and 512-584 of Seq ID No 236; 4-12, 14-34, 47-75, 83-104, 107-115, 133-140, 148-185, 187-196, 207-212, 224-256, 258-265, 281-287, 289-296,

298-308, 325-333, 345-355, 365-371, 382-395, 424-435, 441-457, 465-472, 483-491, 493-505, 528-534, 536-546, 552-558, 575-584, 589-600, 616-623 and 576-591 of Seq ID No 237; 4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771 and 313-329 of Seq ID No 238; 7-38, 44-49, 79-89, 99-108, 117-123, 125-132, 137-146, 178-187, 207-237, 245-255, 322-337, 365-387, 398-408, 445-462, 603-608, 623-628, 644-650, 657-671, 673-679 and 111-566 of Seq ID No 239; 6-20, 22-35, 39-45, 58-64, 77-117, 137-144, 158-163, 205-210, 218-224, 229-236, 239-251, 263-277, 299-307, 323-334, 353-384, 388-396, 399-438, 443-448, 458-463, 467-478, 481-495, 503-509, 511-526, 559-576, 595-600, 612-645, 711-721, 723-738, 744-758, 778-807 and 686-720 of Seq ID No 240; 10-33, 35-41, 72-84, 129-138, 158-163, 203-226, 243-252, 258-264, 279-302, 322-329, 381-386, 401-406, 414-435 and 184-385 of Seq ID No 241; 4-9, 19-24, 41-47, 75-85, 105-110, 113-146 and 45-62 of Seq ID No 242; 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-279, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389 and 1-285 of Seq ID No 243; 14-32, 38-50, 73-84, 93-105, 109-114 and 40-70 of Seq ID No 244; 5-26 and 22-34 of Seq ID No 245; 23-28 and 13-39 of Seq ID No 246; 8-14 and 21-34 of Seq ID No 247; 4-13, 20-29, 44-50, 59-74 and 41-69 of Seq ID No 248; 4-9, 19-42, 48-59, 71-83 and 57-91 of Seq ID No 249; 4-14 and 10-28 of Seq ID No 250; 22-28, 32-42, 63-71, 81-111, 149-156, 158-167, 172-180, 182-203, 219-229 and 27-49 of Seq ID No 251; 17-27 and 23-32 of Seq ID No 252; 18-24 and 28-38 of Seq ID No 253; 9-15 and 13-27 of Seq ID No 254; 13-22 and 18-29 of Seq ID No 255; 17-26 and 2-11 of Seq ID No 256; 4-33 and 16-32 of Seq ID No 257; 4-10, 37-43, 54-84, 92-127 and 15-62 of Seq ID No 258; 4-14, 20-32, 35-60, 69-75, 79-99, 101-109, 116-140 and 124-136 of Seq ID No 259; 2-13 of Seq ID No 260; 4-13, 28-42 and 42-57 of Seq ID No 261; 4-14, 27-44 and 14-35 of Seq ID No 262; 4-12 and 1-27 of Seq ID No 263; 4-18, 39-45, 47-74 and 35-66 of Seq ID No 264; 8-20, 43-77 and 17-36 of Seq ID No 265; 4-30, 35-45, 51-57 and 35-49 of Seq ID No 266; 4-24, 49-57 and 15-34 of Seq ID No 267; 4-22 and 8-27 of Seq ID No 268; 13-25, 32-59, 66-80 and 21-55 of Seq ID No 269; 4-10, 24-33, 35-42, 54-65, 72-82, 98-108 and 15-30 of Seq ID No 270; 8-19 and 17-47 of Seq ID No 271; 12-18, 40-46 and 31-52 of Seq ID No 272; 4-20, 35-78, 83-102, 109-122 and 74-86 of Seq ID No 273; 7-17, 21-41, 46-63 and 2-20 of Seq ID No 274; 30-37 and 2-33 of Seq ID No 275; 4-13, 17-25 and 1-15 of Seq ID No 276; 17-31, 44-51 and 20-51 of Seq ID No 277; 20-30 and 5-23 of Seq ID No 278; 13-33, 48-71 and 92-110 of Seq ID No 279; 4-9, 50-69, 76-88, 96-106, 113-118 and 12-34 of Seq ID No 280; 4-24 and 6-26 of Seq ID No 281; 7-26 and 14-30 of Seq ID No 282; 9-39, 46-68, 75-82, 84-103 and 26-44 of Seq ID No 283; 4-30, 33-107 and 58-84 of Seq ID No 284; 4-12 and 9-51 of Seq ID No 285; 12-18, 29-37 and 6-37 of Seq ID No 286; 4-21, 33-52, 64-71 and 16-37 of Seq ID No 287; 9-19 and 2-30 of Seq ID No 288; 20-37 of Seq ID No 245; 8-27 of Seq ID No 246; 10-27 of Seq ID No 247; 42-59 and 52-69 of Seq ID No 248; 63-80 and 74-91 of Seq ID No 249; 11-28 of Seq ID No 250; 28-49 of Seq ID No 251; 15-32 of Seq ID No 252; 4-20 of Seq ID No 253; 10-27 of Seq ID No 254; 17-34 of Seq ID No 255; 1-18 of Seq ID No 256; 16-33 of Seq ID No 257; 16-36, 30-49 and 43-62 of Seq ID No 258; 122-139 of Seq ID No 259; 1-18 of Seq ID No 260; 41-58 of Seq ID No 261; 15-35 of Seq ID No 262; 2-27 of Seq ID No 263; 18-36 of Seq ID No 265; 34-51 of Seq ID No 266; 9-27 of Seq ID No 268; 22-47 of Seq ID No 269; 18-36 and 29-47 of Seq ID No 271; 32-52 of Seq ID No 272; 72-89 of Seq ID No 273; 3-20 of Seq ID No 274; 3-21 and 15-33 of Seq ID No 275; 1-18 of Seq ID No 276; 6-23 of Seq ID No 278; 93-110 of Seq ID No 279; 13-34 of Seq ID No 280; 7-26 and 9-26 of Seq ID No 281; 16-33 of Seq ID No 282; 27-44 of Seq ID No 283; 67-84 of Seq ID No 284; 10-33 and 26-50 of Seq ID No 285; 7-25 and 19-37 of Seq ID No 286; 17-37 of Seq ID No 287; 3-20 and 13-30 of Seq ID No 288; 62-80 and 75-93 of Seq ID No 145; 92-108 of Seq ID No 147; 332-349, 177-200 and 1755-1777 of Seq ID No 148; 109-133, 149-174, 260-285 and 460-485 of Seq ID No 149; 26-47 and 42-64 of Seq ID No 150; 22-41, 35-54, 115-130, 306-325, 401-420 and 454-478 of Seq ID No 151; 22-45 of Seq ID No 155; 156-174, 924-940, 1485-1496, 1447-1462 and 1483-1498 of Seq ID No 160; 457-475 of Seq ID No 161; 302-325 of Seq ID No 163; 288-305 of Seq ID No 164; 244-266 and 260-282 of Seq ID No 165; 204-225 and 220-241 of Seq ID No 166; 324-345, 340-361, 356-377, 372-393 and 388-408 of Seq ID No 167; 39-64 of Seq ID No 168; 54-76 and 70-92 of Seq ID No 169; 1227-1247, 1539-1559, 1554-1574, 1569-1589, 1584-1604, 1242-1262, 1272-1292, 1287-1308, 1456-1477, 1472-1494, 1488-1510 and 1505-1526 of Seq ID No 170; 351-368 of Seq ID No 172; 179-200, 195-216, 211-232, 227-248 and 243-263 of Seq ID No 173; 13-37 of Seq ID No 174; 208-224 of Seq ID No 175; 42-64, 59-81, 304-328, 323-348, 465-489, 968-992, 1399-1418, 1412-1431 and 2092-2111 of Seq ID No 177; 1528-1547 and 1541-1560 of Seq ID No

178; 184-200, 367-388, 382-403, 409-429, 425-444 and 438-457 of Seq ID No 179; 27-50 and 45-67 of Seq ID No 180, 114-131 and 405-419 of Seq ID No 183; 113-134, 129-150, 145-166, 161-182-and 177-198 of Seq ID No 184; 495-515 of Seq ID No 186; 346-358 of Seq ID No 187; 208-224 of Seq ID No 190; 178-194, 202-223, 217- 238, 288-308 and 1355-1372 of Seq ID No 192; 57-78 of Seq ID No 194; 347-369, 364-386, 381-403, 398-420, 415-437 and 432-452 of Seq ID No 197; 347-372 of Seq ID No 198; 147-163 of Seq ID No 199; 263-288 of Seq ID No 200; 361-377 of Seq ID No 202; 82-104, 99-121, 116-138, 133-155 and 150-171 of Seq ID No 204; 110-130 and 125-145 of Seq ID No 205; 613-631, 626-644 and 196-213 of Seq ID No 206; 78-100, 95-117, 112-134 and 129-151 of Seq ID No 208; 158-180, 175-197, 192-214, 209-231 and 226-248 of Seq ID No 209; 30-50, 45-65 and 60-79 of Seq ID No 210; 431-455 and 450-474 of Seq ID No 213; 579-601, 596-618, 613-635 and 630-653 of Seq ID No 214; 920-927, 98-119, 114-135, 130-151, 146-167 and 162-182 of Seq ID No 217; 36-59 of Seq ID No 219; 194-216 and 381-404 of Seq ID No 220; 236-251 and 255-279 of Seq ID No 221; 80-100 and 141-164 of Seq ID No 222; 128-154 of Seq ID No 223; 82-100, 95-116 and 111-134 of Seq ID No 224; 55-76, 71-92 and 87-110 of Seq ID No 227; 91-106 of Seq ID No 229; 74-96 of Seq ID No 230; 140-157 of Seq ID No 231; 4-13 of Seq ID No 233; 41-65 and 499-523 of Seq ID No 236; 122-146, 191-215, 288-313, 445-469 and 511-535 of Seq ID No 239; 347-368 of Seq ID No 241; 46-61 of Seq ID No 242; 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 and 236-258 of Seq ID No 243, and fragments comprising at least 6, preferably more than 8, especially more than 10 aa of said sequences. All these fragments individually and each independently form a preferred selected aspect of the present invention.

All linear hyperimmune serum reactive fragments of a particular antigen may be identified by analysing the entire sequence of the protein antigen by a set of peptides overlapping by 1 amino acid with a length of at least 10 amino acids. Subsequently, non-linear epitopes can be identified by analysis of the protein antigen with hyperimmune sera using the expressed full-length protein or domain polypeptides thereof. Assuming that a distinct domain of a protein is sufficient to form the 3D structure independent from the native protein, the analysis of the respective recombinant or synthetically produced domain polypeptide with hyperimmune serum would allow the identification of conformational epitopes within the individual domains of multi-domain proteins. For those antigens where a domain possesses linear as well as conformational epitopes, competition experiments with peptides corresponding to the linear epitopes may be used to confirm the presence of conformational epitopes.

It will be appreciated that the invention also relates to, among others, nucleic acid molecules encoding the aforementioned fragments, nucleic acid molecules that hybridise to nucleic acid molecules encoding the fragments, particularly those that hybridise under stringent conditions, and nucleic acid molecules, such as PCR primers, for amplifying nucleic acid molecules that encode the fragments. In these regards, preferred nucleic acid molecules are those that correspond to the preferred fragments, as discussed

The present invention also relates to vectors, which comprise a nucleic acid molecule or nucleic acid molecules of the present invention, host cells which are genetically engineered with vectors of the invention and the production of hyperimmune serum reactive antigens and fragments thereof by recombinant techniques.

A great variety of expression vectors can be used to express a hyperimmune serum reactive antigen or fragment thereof according to the present invention. Generally, any vector suitable to maintain, propagate or express nucleic acids to express a polypeptide in a host may be used for expression in this regard. In accordance with this aspect of the invention the vector may be, for example, a plasmid vector, a single or double-stranded phage vector, a single or double-stranded RNA or DNA viral vector. Starting plasmids disclosed herein are either commercially available, publicly available, or can be constructed from available plasmids by routine application of well-known, published procedures. Preferred among vectors, in certain respects, are those for expression of nucleic acid molecules and hyperimmune serum reactive antigens or fragments thereof of the present invention. Nucleic acid constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

Alternatively, the hyperimmune serum reactive antigens and fragments thereof of the invention can be synthetically produced by conventional peptide synthesizers. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA construct of the present invention.

Host cells can be genetically engineered to incorporate nucleic acid molecules and express nucleic acid molecules of the present invention. Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtillis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, Hela, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

The invention also provides a process for producing a *S. pneumoniae* hyperimmune serum reactive antigen and a fragment thereof comprising expressing from the host cell a hyperimmune serum reactive antigen or fragment thereof encoded by the nucleic acid molecules provided by the present invention. The invention further provides a process for producing a cell, which expresses a *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof comprising transforming or transfecting a suitable host cell with the vector according to the present invention such that the transformed or transfected cell expresses the polypeptide encoded by the nucleic acid contained in the vector.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N- or C-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, regions may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability or to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize or purify polypeptides. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobin molecules together with another protein or part thereof. In drug discovery, for example, proteins have been fused with antibody Fc portions for the purpose of high-throughout screening assays to identify antagonists. See for example, {Bennett, D. et al., 1995} and {Johanson, K. et al., 1995}.

The S. pneumoniae hyperimmune serum reactive antigen or a fragment thereof can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention can be produced by chemical synthesis as well as by biotechnological means. The latter comprise the transfection or transformation of a host cell with a vector containing a nucleic acid according to the present invention and the cultivation of the transfected or transformed host cell under conditions, which are known to the ones skilled in the art. The production method may also comprise a purification step in order to purify or isolate the polypeptide to be manufactured. In a preferred embodiment the vector is a vector according to the present invention.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention may be used for the detection of the organism or organisms in a sample containing these organisms or polypeptides derived thereof. Preferably such detection is for diagnosis, more preferable for the diagnosis

of a disease, most preferably for the diagnosis of a diseases related or linked to the presence or abundance of Gram-positive bacteria, especially bacteria selected from the group-comprising-streptococci, staphylococci and lactococci. More preferably, the microorganisms are selected from the group comprising Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus mutans, especially the microorganism is Streptococcus pyogenes.

The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of the hyperimmune serum reactive antigens and fragments thereof of the present invention in cells and tissues, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for detecting over-expression of the polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example, and to identify the infecting organism. Assay techniques that can be used to determine levels of a polypeptide, in a sample derived from a host are well known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Among these, ELISAs frequently are preferred. An ELISA assay initially comprises preparing an antibody specific to the polypeptide, preferably a monoclonal antibody. In addition, a reporter antibody generally is prepared which binds to the monoclonal antibody. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, such as horseradish peroxidase

The hyperimmune serum reactive antigens and fragments thereof according to the present invention may also be used for the purpose of or in connection with an array. More particularly, at least one of the hyperimmune serum reactive antigens and fragments thereof according to the present invention may be immobilized on a support. Said support typically comprises a variety of hyperimmune serum reactive antigens and fragments thereof whereby the variety may be created by using one or several of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and/or hyperimmune serum reactive antigens and fragments thereof being different. The characterizing feature of such array as well as of any array in general is the fact that at a distinct or predefined region or position on said support or a surface thereof, a distinct polypeptide is immobilized. Because of this any activity at a distinct position or region of an array can be correlated with a specific polypeptide. The number of different hyperimmune serum reactive antigens and fragments thereof immobilized on a support may range from as little as 10 to several 1000 different hyperimmune serum reactive antigens and fragments thereof. The density of hyperimmune serum reactive antigens and fragments thereof per cm<sup>2</sup> is in a preferred embodiment as little as 10 peptides/polypeptides per cm<sup>2</sup> to at least 400 different peptides/polypeptides per cm<sup>2</sup> and more particularly at least 1000 different hyperimmune serum reactive antigens and fragments thereof per cm2.

The manufacture of such arrays is known to the one skilled in the art and, for example, described in US patent 5,744,309. The array preferably comprises a planar, porous or non-porous solid support having at least a first surface. The hyperimmune serum reactive antigens and fragments thereof as disclosed herein, are immobilized on said surface. Preferred support materials are, among others, glass or cellulose. It is also within the present invention that the array is used for any of the diagnostic applications described herein. Apart from the hyperimmune serum reactive antigens and fragments thereof according to the present invention also the nucleic acid molecules according to the present invention may be used for the generation of an array as described above. This applies as well to an array made of antibodies, preferably monoclonal antibodies as, among others, described herein.

In a further aspect the present invention relates to an antibody directed to any of the hyperimmune serum reactive antigens and fragments thereof, derivatives or fragments thereof according to the present invention. The present invention includes, for example, monoclonal and polyclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of a Fab expression library. It is within the present invention that the antibody may be chimeric, i. e. that different parts thereof stem from different species or at least the respective sequences are taken from different species.

Antibodies generated against the hyperimmune serum reactive antigens and fragments thereof corresponding to a sequence of the present invention can be obtained by direct injection of the hyperimmune serum reactive antigens and fragments thereof into an animal or by administering the hyperimmune serum reactive antigens and fragments thereof to an animal, preferably a non-human. The antibody so obtained will then bind the hyperimmune serum reactive antigens and fragments thereof itself. In this manner, even a sequence encoding only a fragment of a hyperimmune serum reactive antigen and fragments thereof can be used to generate antibodies binding the whole native hyperimmune serum reactive antigen and fragments thereof. Such antibodies can then be used to isolate the hyperimmune serum reactive antigens and fragments thereof from tissue expressing those hyperimmune serum reactive antigens and fragments thereof.

For preparation of monoclonal antibodies, any technique known in the art, which provides antibodies produced by continuous cell line cultures can be used (as described originally in {Kohler, G. et al., 1975}.

Techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to immunogenic hyperimmune serum reactive antigens and fragments thereof according to this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies to immunogenic hyperimmune serum reactive antigens and fragments thereof according to this invention.

Alternatively, phage display technology or ribosomal display could be utilized to select antibody genes with binding activities towards the hyperimmune serum reactive antigens and fragments thereof either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing respective target antigens or from naïve libraries {McCafferty, J. et al., 1990}; {Marks, J. et al., 1992}. The affinity of these antibodies can also be improved by chain shuffling {Clackson, T. et al., 1991}.

If two antigen binding domains are present, each domain may be directed against a different epitope – termed 'bispecific' antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the hyperimmune serum reactive antigens and fragments thereof or purify the hyperimmune serum reactive antigens and fragments thereof of the present invention by attachment of the antibody to a solid support for isolation and/or purification by affinity chromatography.

Thus, among others, antibodies against the hyperimmune serum reactive antigens and fragments thereof of the present invention may be employed to inhibit and/or treat infections, particularly bacterial infections and especially infections arising from *S. pneumoniae*.

Hyperimmune serum reactive antigens and fragments thereof include antigenically, epitopically or immunologically equivalent derivatives, which form a particular aspect of this invention. The term "antigenically equivalent derivative" as used herein encompasses a hyperimmune serum reactive antigen and fragments thereof or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or hyperimmune serum reactive antigen and fragments thereof according to the present invention, interfere with the interaction between pathogen and mammalian host. The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the interaction between pathogen and mammalian host.

The hyperimmune serum reactive antigens and fragments thereof, such as an antigenically or

immunologically equivalent derivative or a fusion protein thereof can be used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability—to—the-hyperimmune serum reactive antigens and fragments thereof. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein, for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively, an antigenic peptide comprising multiple copies of the protein or hyperimmune serum reactive antigen and fragments thereof, or an antigenically or immunologically equivalent hyperimmune serum reactive antigen and fragments thereof, may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.

Preferably the antibody or derivative thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized", wherein the complimentarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in [Jones, P. et al., 1986] or [Tempest, P. et al., 1991].

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscle, delivery of DNA complexed with specific protein carriers, coprecipitation of DNA with calcium phosphate, encapsulation of DNA in various forms of liposomes, particle bombardment (Tang, D. et al., 1992); {Eisenbraun, M. et al., 1993} and in vivo infection using cloned retroviral vectors (Seeger, C. et al., 1984).

In a further aspect the present invention relates to a peptide binding to any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, and a method for the manufacture of such peptides whereby the method is characterized by the use of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and the basic steps are known to the one skilled in the art.

Such peptides may be generated by using methods according to the state of the art such as phage display or ribosome display. In case of phage display, basically a library of peptides is generated, in form of phages, and this kind of library is contacted with the target molecule, in the present case a hyperimmune serum reactive antigen and fragments thereof according to the present invention. Those peptides binding to the target molecule are subsequently removed, preferably as a complex with the target molecule, from the respective reaction. It is known to the one skilled in the art that the binding characteristics, at least to a certain extent, depend on the particularly realized experimental set-up such as the salt concentration and the like. After separating those peptides binding to the target molecule with a higher affinity or a bigger force, from the non-binding members of the library, and optionally also after removal of the target molecule from the complex of target molecule and peptide, the respective peptide(s) may subsequently be characterised. Prior to the characterisation optionally an amplification step is realized such as, e. g. by propagating the peptide encoding phages. The characterisation preferably comprises the sequencing of the target binding peptides. Basically, the peptides are not limited in their lengths, however, preferably peptides having a lengths from about 8 to 20 amino acids are preferably obtained in the respective methods. The size of the libraries may be about 102 to 1018, preferably 108 to 1015 different peptides, however, is not limited thereto.

A particular form of target binding hyperimmune serum reactive antigens and fragments thereof are the so-called "anticalines" which are, among others, described in German patent application DE 197 42 706.

In a further aspect the present invention relates to functional nucleic acids interacting with any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, and a method for the manufacture of such functional nucleic acids whereby the method is characterized by the use of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and the basic steps are known to the one skilled in the art. The functional nucleic acids are

Aptamers are D-nucleic acids, which are either single stranded or double stranded and which specifically interact with a target molecule. The manufacture or selection of aptamers is, e.g. described in European patent EP 0 533 838. Basically the following steps are realized. First, a mixture of nucleic acids, i. e. potential aptamers, is provided whereby each nucleic acid typically comprises a segment of several, preferably at least eight subsequent randomised nucleotides. This mixture is subsequently contacted with the target molecule whereby the nucleic acid(s) bind to the target molecule, such as based on an increased affinity towards the target or with a bigger force thereto, compared to the candidate mixture. The binding nucleic acid(s) are/is subsequently separated from the remainder of the mixture. Optionally, the thus obtained nucleic acid(s) is amplified using, e.g. polymerase chain reaction. These steps may be repeated several times giving at the end a mixture having an increased ratio of nucleic acids specifically binding to the target from which the final binding nucleic acid is then optionally selected. These specifically binding nucleic acid(s) are referred to as aptamers. It is obvious that at any stage of the method for the generation or identification of the aptamers samples of the mixture of individual nucleic acids may be taken to determine the sequence thereof using standard techniques. It is within the present invention that the aptamers may be stabilized such as, e. g., by introducing defined chemical groups which are known to the one skilled in the art of generating aptamers. Such modification may for example reside in the introduction of an amino group at the 2'-position of the sugar moiety of the nucleotides. Aptamers are currently used as therapeutical agents. However, it is also within the present invention that the thus selected or generated aptamers may be used for target validation and/or as lead substance for the development of medicaments, preferably of medicaments based on small molecules. This is actually done by a competition assay whereby the specific interaction between the target molecule and the aptamer is inhibited by a candidate drug whereby upon replacement of the aptamer from the complex of target and aptamer it may be assumed that the respective drug candidate allows a specific inhibition of the interaction between target and aptamer, and if the interaction is specific, said candidate drug will, at least in principle, be suitable to block the target and thus decrease its biological availability or activity in a respective system comprising such target. The thus obtained small molecule may then be subject to further derivatisation and modification to optimise its physical, chemical, biological and/or medical characteristics such as toxicity, specificity, biodegradability and bioavailability.

Spiegelmers and their generation or manufacture is based on a similar principle. The manufacture of spiegelmers is described in international patent application WO 98/08856. Spiegelmers are L-nucleic acids, which means that they are composed of L-nucleotides rather than D-nucleotides as aptamers are. Spiegelmers are characterized by the fact that they have a very high stability in biological systems and, comparable to aptamers, specifically interact with the target molecule against which they are directed. In the process of generating spiegelmers, a heterogeonous population of D-nucleic acids is created and this population is contacted with the optical antipode of the target molecule, in the present case for example with the D-enantiomer of the naturally occurring L-enantiomer of the hyperimmune serum reactive antigens and fragments thereof according to the present invention. Subsequently, those D-nucleic acids are separated which do not interact with the optical antipode of the target molecule. But those D-nucleic acids interacting with the optical antipode of the target molecule are separated, optionally identified and/or sequenced and subsequently the corresponding L-nucleic acids are synthesized based on the nucleic acid sequence information obtained from the D-nucleic acids. These L-nucleic acids which are identical in terms of sequence with the aforementioned D-nucleic acids interacting with the optical antipode of the target molecule, will specifically interact with the naturally occurring target molecule rather than with the optical antipode thereof. Similar to the method for the generation of aptamers it is also possible to repeat the various steps several times and thus to enrich those nucleic acids specifically interacting with the optical antipode of the target molecule.

In a further aspect the present invention relates to functional nucleic acids interacting with any of the nucleic acid molecules according to the present invention, and a method for the manufacture of such

functional nucleic acids whereby the method is characterized by the use of the nucleic acid molecules and their respective sequences according to the present invention and the basic steps are known to the oneskilled in the art. The functional nucleic acids are preferably ribozymes, antisense oligonucleotides and

Ribozymes are catalytically active nucleic acids which preferably consist of RNA which basically comprises two moieties. The first moiety shows a catalytic activity whereas the second moiety is responsible for the specific interaction with the target nucleic acid, in the present case the nucleic acid coding for the hyperimmune serum reactive antigens and fragments thereof according to the present invention. Upon interaction between the target nucleic acid and the second moiety of the ribozyme, typically by hybridisation and Watson-Crick base pairing of essentially complementary stretches of bases on the two hybridising strands, the catalytically active moiety may become active which means that it catalyses, either intramolecularly or intermolecularly, the target nucleic acid in case the catalytic activity of the ribozyme is a phosphodiesterase activity. Subsequently, there may be a further degradation of the target nucleic acid, which in the end results in the degradation of the target nucleic acid as well as the protein derived from the said target nucleic acid. Ribozymes, their use and design principles are known to the one skilled in the art, and, for example described in [Doherty, E. et al., 2001] and [Lewin, A. et al.,

The activity and design of antisense oligonucleotides for the manufacture of a medicament and as a diagnostic agent, respectively, is based on a similar mode of action. Basically, antisense oligonucleotides hybridise based on base complementarity, with a target RNA, preferably with a mRNA, thereby activating RNase H. RNase H is activated by both phosphodiester and phosphorothioate-coupled DNA. Phosphodiester-coupled DNA, however, is rapidly degraded by cellular nucleases with the exception of phosphorothioate-coupled DNA. These resistant, non-naturally occurring DNA derivatives do not inhibit RNase H upon hybridisation with RNA. In other words, antisense polynucleotides are only effective as DNA RNA hybride complexes. Examples for this kind of antisense oligonucleotides are described, among others, in US-patent US 5,849,902 and US 5,989,912. In other words, based on the nucleic acid sequence of the target molecule which in the present case are the nucleic acid molecules for the hyperimmune serum reactive antigens and fragments thereof according to the present invention, either from the target protein from which a respective nucleic acid sequence may in principle be deduced, or by knowing the nucleic acid sequence as such, particularly the mRNA, suitable antisense oligonucleotides may be designed base on the principle of base complementarity.

Particularly preferred are antisense-oligonucleotides, which have a short stretch of phosphorothioate DNA (3 to 9 bases). A minimum of 3 DNA bases is required for activation of bacterial RNase H and a minimum of 5 bases is required for mammalian RNase H activation. In these chimeric oligonucleotides there is a central region that forms a substrate for RNase H that is flanked by hybridising "arms" comprised of modified nucleotides that do not form substrates for RNase H. The hybridising arms of the chimeric oligonucleotides may be modified such as by 2'-O-methyl or 2'-fluoro. Alternative approaches used methylphosphonate or phosphoramidate linkages in said arms. Further embodiments of the antisense oligonucleotide useful in the practice of the present invention are P-methoxyoligonucleotides, partial P-methoxyoligodeoxyribonucleotides or P-methoxyoligonucleotides.

Of particular relevance and usefulness for the present invention are those antisense oligonucleotides as more particularly described in the above two mentioned US patents. These oligonucleotides contain no naturally occurring 5'→3'-linked nucleotides. Rather the oligonucleotides have two types of nucleotides: 2'-deoxyphosphorothioate, which activate RNase H, and 2'-modified nucleotides, which do not. The linkages between the 2'-modified nucleotides can be phosphodiesters, phosphorothioate or Pethoxyphosphodiester. Activation of RNase H is accomplished by a contiguous RNase H-activating region, which contains between 3 and 52'-deoxyphosphorothioate nucleotides to activate bacterial RNase H and between 5 and 10 2'- deoxyphosphorothioate nucleotides to activate eucaryotic and, particularly,

mammalian RNase H. Protection from degradation is accomplished by making the 5' and 3' terminal bases highly nuclease resistant and, optionally, by placing a 3' terminal blocking group.

More particularly, the antisense oligonucleotide comprises a 5' terminus and a 3' terminus; and from position 11 to 59 5'→3'-linked nucleotides independently selected from the group consisting of 2'-modified phosphodiester nucleotides and 2'-modified P-alkyloxyphosphotriester nucleotides; and wherein the 5'-terminal nucleoside is attached to an RNase H-activating region of between three and ten contiguous phosphorothioate-linked deoxyribonucleotides, and wherein the 3'-terminus of said oligonucleotide is selected from the group consisting of an inverted deoxyribonucleotide, a contiguous stretch of one to three phosphorothioate 2'-modified ribonucleotides, a biotin group and a P-alkyloxyphosphotriester nucleotide.

Also an antisense oligonucleotide may be used wherein not the 5' terminal nucleoside is attached to an RNase H-activating region but the 3' terminal nucleoside as specified above. Also, the 5' terminus is selected from the particular group rather than the 3' terminus of said oligonucleotide.

The nucleic acids as well as the hyperimmune serum reactive antigens and fragments thereof according to the present invention may be used as or for the manufacture of pharmaceutical compositions, especially vaccines. Preferably such pharmaceutical composition, preferably vaccine is for the prevention or treatment of diseases caused by, related to or associated with S. pneumoniae. In so far another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal, which comprises inoculating the individual with the hyperimmune serum reactive antigens and fragments thereof of the invention, or a fragment or variant thereof, adequate to produce antibodies to protect said individual from infection, particularly streptococcal infection and most particularly S. pneumoniae infections.

Yet another aspect of the invention relates to a method of inducing an immunological response in an individual which comprises, through gene therapy or otherwise, delivering a nucleic acid functionally encoding hyperimmune serum reactive antigens and fragments thereof, or a fragment or a variant thereof, for expressing the hyperimmune serum reactive antigens and fragments thereof, or a fragment or a variant thereof *in vivo* in order to induce an immunological response to produce antibodies or a cell mediated T cell response, either cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise.

A further aspect of the invention relates to an immunological composition which, when introduced into a host capable of having induced within it an immunological response, induces an immunological response in such host, wherein the composition comprises recombinant DNA which codes for and expresses an antigen of the hyperimmune serum reactive antigens and fragments thereof of the present invention. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.

The hyperimmune serum reactive antigens and fragments thereof of the invention or a fragment thereof may be fused with a co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. This fused recombinant protein preferably further comprises an antigenic co-protein, such as Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilise the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

Also, provided by this invention are methods using the described nucleic acid molecule or particular

fragments thereof in such genetic immunization experiments in animal models of infection with S. pneumoniae. Such fragments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. This approach can allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of S. pneumoniae infection in mammals, particularly humans.

The hyperimmune serum reactive antigens and fragments thereof may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue and mucosal tissues caused e.g. by viral infection (esp. respiratory, such as the flu) mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.

The present invention also includes a vaccine formulation, which comprises the immunogenic recombinant protein together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, intradermal intranasal or tramsdermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unitdose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in a freezedried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in-water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

According to another aspect, the present invention relates to a pharmaceutical composition comprising such a hyperimmune serum-reactive antigen or a fragment thereof as provided in the present invention for S. pneumoniae. Such a pharmaceutical composition may comprise one or more hyperimmune serum reactive antigens or fragments thereof against S. pneumoniae. Optionally, such S. pneumoniae hyperimmune serum reactive antigens or fragments thereof may also be combined with antigens against other pathogens in a combination pharmaceutical composition. Preferably, said pharmaceutical composition is a vaccine for preventing or treating an infection caused by S. pneumoniae and/or other pathogens against which the antigens have been included in the vaccine.

According to a further aspect, the present invention relates to a pharmaceutical composition comprising a nucleic acid molecule encoding a hyperimmune serum-reactive antigen or a fragment thereof as identified above for S. pneumoniae. Such a pharmaceutical composition may comprise one or more nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof against S. Optionally, such S. pneumoniae nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof may also be combined with nucleic acid molecules encoding antigens against other pathogens in a combination pharmaceutical composition. pharmaceutical composition is a vaccine for preventing or treating an infection caused by S. pneumoniae Preferably, said and/or other pathogens against which the antigens have been included in the vaccine.

The pharmaceutical composition may contain any suitable auxiliary substances, such as buffer substances, stabilisers or further active ingredients, especially ingredients known in connection of pharmaceutical composition and/or vaccine production.

A preferable carrier/or excipient for the hyperimmune serum-reactive antigens, fragments thereof or a

coding nucleic acid molecule thereof according to the present invention is an immunostimulatory compound for further stimulating the immune response to the given hyperimmune serum-reactive antigen, fragment thereof or a coding nucleic acid molecule thereof. Preferably the immunostimulatory compound in the pharmaceutical preparation according to the present invention is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory nucleic acids molecules, preferably immunostimulatory deoxynucleotides, alum, Freund's complete adjuvants, Freund's incomplete adjuvants, neuroactive compounds, especially human growth hormone, or combinations thereof.

It is also within the scope of the present invention that the pharmaceutical composition, especially vaccine, comprises apart from the hyperimmune serum reactive antigens, fragments thereof and/or coding nucleic acid molecules thereof according to the present invention other compounds which are biologically or pharmaceutically active. Preferably, the vaccine composition comprises at least one polycationic peptide. The polycationic compound(s) to be used according to the present invention may be any polycationic compound, which shows the characteristic effects according to the WO 97/30721. Preferred polycationic compounds are selected from basic polyppetides, organic polycations, basic polyamino acids or mixtures thereof. These polyamino acids should have a chain length of at least 4 amino acid residues (WO 97/30721). Especially preferred are substances like polylysine, polyarginine and polypeptides containing more than 20 %, especially more than 50 % of basic amino acids in a range of more than 8, especially more than 20, amino acid residues or mixtures thereof. Other preferred polycations and their pharmaceutical compositions are described in WO 97/30721 (e.g. polyethyleneimine) and WO 99/38528. Preferably these polypeptides contain between 20 and 500 amino acid residues, especially between 30 and 200 residues.

These polycationic compounds may be produced chemically or recombinantly or may be derived from natural sources.

Cationic (poly)peptides may also be anti-microbial with properties as reviewed in {Ganz, T., 1999}. These (poly)peptides may be of prokaryotic or animal or plant origin or may be produced chemically or recombinantly (WO 02/13857). Peptides may also belong to the class of defensins (WO 02/13857). Sequences of such peptides can be, for example, found in the Antimicrobial Sequences Database under the following internet address:

## http://www.bbcm.univ.trieste.it/~tossi/pag2.html

Such host defence peptides or defensives are also a preferred form of the polycationic polymer according to the present invention. Generally, a compound allowing as an end product activation (or down-regulation) of the adaptive immune system, preferably mediated by APCs (including dendritic cells) is used as polycationic polymer.

Especially preferred for use as polycationic substances in the present invention are cathelicidin derived antimicrobial peptides or derivatives thereof (International patent application WO 02/13857, incorporated herein by reference), especially antimicrobial peptides derived from mammalian cathelicidin, preferably from human, bovine or mouse.

Polycationic compounds derived from natural sources include HIV-REV or HIV-TAT (derived cationic peptides, antennapedia peptides, chitosan or other derivatives of chitin) or other peptides derived from these peptides or proteins by biochemical or recombinant production. Other preferred polycationic compounds are cathelin or related or derived substances from cathelin. For example, mouse cathelin is a peptide which has the amino acid sequence NH2-RLAGLLRKGGEKIGEKLKKIGOKIKNFFQKLVPQPE-COOH. Related or derived cathelin substances contain the whole or parts of the cathelin sequence with at least 15-20 amino acid residues. Derivations may include the substitution or modification of the natural

amino acids by amino acids which are not among the 20 standard amino acids. Moreover, further cationic residues may be introduced into such cathelin molecules. These cathelin molecules are preferred to be combined with the antigen. These cathelin molecules surprisingly have turned out to be also effective as an adjuvant for an antigen without the addition of further adjuvants. It is therefore possible to use such cathelin molecules as efficient adjuvants in vaccine formulations with or without further

Another preferred polycationic substance to be used according to the present invention is a synthetic peptide containing at least 2 KLK-motifs separated by a linker of 3 to 7 hydrophobic amino acids (International patent application WO 02/32451, incorporated herein by reference).

The pharmaceutical composition of the present invention may further comprise immunostimulatory nucleic acid(s). Immunostimulatory nucleic acids are e. g. neutral or artificial CpG containing nucleic acids, short stretches of nucleic acids derived from non-vertebrates or in form of short oligonucleotides (ODNs) containing non-methylated cytosine-guanine di-nucleotides (CpG) in a certain base context (e.g. described in WO 96/02555). Alternatively, also nucleic acids based on inosine and cytidine as e.g. described in the WO 01/93903, or deoxynucleic acids containing deoxy-inosine and/or deoxyuridine residues (described in WO 01/93905 and PCT/EP 02/05448, incorporated herein by reference) may preferably be used as immunostimulatory nucleic acids for the present invention. Preferablly, the mixtures of different immunostimulatory nucleic acids may be used according to the present invention.

It is also within the present invention that any of the aforementioned polycationic compounds is combined with any of the immunostimulatory nucleic acids as aforementioned. Preferably, such combinations are according to the ones as described in WO 01/93905, WO 02/32451, WO 01/54720, WO 01/93903, WO 02/13857 and PCT/EP 02/05448 and the Austrian patent application A 1924/2001, incorporated herein by reference.

In addition or alternatively such vaccine composition may comprise apart from the hyperimmune serum reactive antigens and fragments thereof, and the coding nucleic acid molecules thereof according to the present invention a neuroactive compound. Preferably, the neuroactive compound is human growth factor as, e.g. described in WO 01/24822. Also preferably, the neuroactive compound is combined with any of the polycationic compounds and/or immunostimulatory nucleic acids as afore-mentioned.

In a further aspect the present invention is related to a pharmaceutical composition. Such pharmaceutical composition is, for example, the vaccine described herein. Also a pharmaceutical composition is a pharmaceutical composition which comprises any of the following compounds or combinations thereof: the nucleic acid molecules according to the present invention, the hyperimmune serum reactive antigens and fragments thereof according to the present invention, the vector according to the present invention, the cells according to the present invention, the antibody according to the present invention, the functional nucleic acids according to the present invention and the binding peptides such as the anticalines according to the present invention, any agonists and antagonists screened as described herein. In connection therewith any of these compounds may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a hyperimmune serum reactive antigen and fragments thereof of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intratracheal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1 % to about 98 % by weight of the formulation; more usually they will constitute up to about 80 % by weight of the formulation.

In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.05-5  $\mu$ g antigen / per kg of body weight, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks.

With the indicated dose range, no adverse toxicological effects should be observed with the compounds of the invention, which would preclude their administration to suitable individuals.

In a further embodiment the present invention relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. The ingredient(s) can be present in a useful amount, dosage, formulation or combination. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.

In connection with the present invention any disease related use as disclosed herein such as, e. g. use of the pharmaceutical composition or vaccine, is particularly a disease or diseased condition which is caused by, linked or associated with Streptococci, more preferably, S. pneumoniae. In connection therewith it is to be noted that S. pneumoniae comprises several strains including those disclosed herein. A disease related, caused or associated with the bacterial infection to be prevented and/or treated according to the present invention includes besides others bacterial pharyngitis, otitis media, pneumonia, bacteremia, meningitis, peritonitis and sepsis in humans.

In a still further embodiment the present invention is related to a screening method using any of the hyperimmune serum reactive antigens or nucleic acids according to the present invention. Screening methods as such are known to the one skilled in the art and can be designed such that an agonist or an antagonist is screened. Preferably an antagonist is screened which in the present case inhibits or prevents the binding of any hyperimmune serum reactive antigen and fragment thereof according to the present invention to an interaction partner. Such interaction partner can be a naturally occurring interaction partner or a non-naturally occurring interaction partner.

The invention also provides a method of screening compounds to identify those, which enhance (agonist) or block (antagonist) the function of hyperimmune serum reactive antigens and fragments thereof or nucleic acid molecules of the present invention, such as its interaction with a binding molecule. The

For example, to screen for agonists or antagonists, the interaction partner of the nucleic acid molecule and nucleic acid, respectively, according to the present invention, maybe a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, may be prepared from a cell that expresses a molecule that binds to the hyperimmune serum reactive antigens and fragments thereof of the present invention. The preparation is incubated with labelled hyperimmune serum reactive antigens and fragments thereof in the absence or the presence of a candidate molecule, which may be an agonist or antagonist. The ability of the candidate molecule to bind the binding molecule is reflected in decreased binding of the labelled ligand. Molecules which bind gratuitously, i. e., without inducing the functional effects of the hyperimmune serum reactive antigens and fragments thereof, are most likely to be good antagonists. Molecules that bind well and elicit functional effects that are the same as or closely related to the hyperimmune serum reactive antigens and fragments thereof are good agonists.

The functional effects of potential agonists and antagonists may be measured, for instance, by determining the activity of a reporter system following interaction of the candidate molecule with a cell or appropriate cell preparation, and comparing the effect with that of the hyperimmune serum reactive antigens and fragments thereof of the present invention or molecules that elicit the same effects as the hyperimmune serum reactive antigens and fragments thereof. Reporter systems that may be useful in this regard include but are not limited to colorimetric labelled substrate converted into product, a reporter gene that is responsive to changes in the functional activity of the hyperimmune serum reactive antigens and fragments thereof, and binding assays known in the art.

Another example of an assay for antagonists is a competitive assay that combines the hyperimmune serum reactive antigens and fragments thereof of the present invention and a potential antagonist with membrane-bound binding molecules, recombinant binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. The hyperimmune serum reactive antigens and fragments thereof can be labelled such as by radioactivity or a colorimetric compound, such that the molecule number of hyperimmune serum reactive antigens and fragments thereof bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a hyperimmune serum reactive antigen and fragments thereof of the invention and thereby inhibit or extinguish its acitivity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds to the same sites on a binding molecule without inducing functional activity of the hyperimmune serum reactive antigens and fragments thereof of the invention.

Potential antagonists include a small molecule, which binds to and occupies the binding site of the hyperimmune serum reactive antigens and fragments thereof thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules.

Other potential antagonists include antisense molecules (see {Okano, H. et al., 1991}; OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION; CRC Press, Boca Ration, FL (1988), for a description of these molecules).

Preferred potential antagonists include derivatives of the hyperimmune serum reactive antigens and fragments thereof of the invention.

As used herein the activity of a hyperimmune serum reactive antigen and fragment thereof according to the present invention is its capability to bind to any of its interaction partner or the extent of such capability to bind to its or any interaction partner.

In a particular aspect, the invention provides the use of the hyperimmune serum reactive antigens and fragments thereof, nucleic acid molecules or inhibitors of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particular the molecules of the invention may be used: i) in the prevention of adhesion of *S. pneumoniae* to mammalian extracellular matrix proteins at mucosal surfaces and on in-dwelling devices or to extracellular matrix proteins in wounds; ii) to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial proteins which mediate tissue damage or invasion iii) or lead to evasion of immune defense; iv) to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques, e.g. through inhibiting nutrient acquisition {Brown, J. et al., 2001}.

Each of the DNA coding sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein upon expression can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The antagonists and agonists may be employed, for instance, to inhibit diseases arising from infection with Streptococcus, especially *S. pneumoniae*, such as sepsis.

In a still further aspect the present invention is related to an affinity device such affinity device comprises as least a support material and any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, which is attached to the support material. Because of the specificity of the hyperimmune serum reactive antigens and fragments thereof according to the present invention for their target cells or target molecules or their interaction partners, the hyperimmune serum reactive antigens and fragments thereof allow a selective removal of their interaction partner(s) from any kind of sample applied to the support material provided that the conditions for binding are met. The sample may be a biological or medical sample, including but not limited to, fermentation broth, cell debris, cell preparation, tissue preparation, organ preparation, blood, urine, lymph liquid, liquor and the like.

The hyperimmune serum reactive antigens and fragments thereof may be attached to the matrix in a covalent or non-covalent manner. Suitable support material is known to the one skilled in the art and can be selected from the group comprising cellulose, silicon, glass, aluminium, paramagnetic beads, starch and dextrane.

The present invention is further illustrated by the following figures, examples and the sequence listing, from which further features, embodiments and advantages may be taken. It is to be understood that the present examples are given by way of illustration only and not by way of limitation of the disclosure.

In connection with the present invention

Figure 1 shows the characterization of S. pneumoniae specific human sera.

Figure 2 shows the characterization of the small fragment genomic library, LSPn-70, from *Streptococcus pneumoniue* serotype 4.

Figure 3 shows the selection of bacterial cells by MACS using biotinylated human IgGs.

Figure 5 shows examples of changes in epitope-specific antibody levels in the different age groups and during the course of pneumococcal disease.

Figure 6 shows examples for cell surface staining with epitope-specific antisera by flow cytometry.

Figure 7 shows the determination of bactericidal activity of antibodies induced by selected epitopes in an in vitro assay.

Table 1 shows the summary of all screens performed with genomic *S. pneumoniae* libraries and human serum.

Table 2 shows the summary of epitope serology analysis with human sera.

Table 3 shows the summary of the gene distribution analysis for the identified antigens in 50 S.

Table 4 shows the summary of the surface staining and bactericidal activity measurements.

The figures to which it might be referred to in the specification are described in the following in more details.

Figure 1 shows the characterization of human sera for anti-S. pneumoniae antibodies ass measured by immune assays. Total anti-S. pneumoniae IgG and IgA antibody levels were measured by standard ELISA using total bacterial lysates or culture supernant fractions prepared from S. pneumoniae serotype 4 capsule negative mutant strain as coating antigens. 97 serum samples from convalescing patients with inasive diseases or 50 sera from healthy adults without nasopharyngeal carriage of S. pneumoniae were analysed at three different serum dilutions. Results of representative experiments are shown with (A) patients' sera with bacterial lysate and (B) healthy adult sera with culture superntant proteins. Data are expressed as ELISA units calculated from absorbance at 405nm at a serum dilution in the linear range of detection (10.000X for IgA, 50,000 for IgG). 2x5 sera from both donor groups were selected and pooled for antigen identification by bacterial surface display. Selected sera included in the two patient (PSPn3-IgG,-IgA and PSPn7-IgG) and two healthy pools (NSPn4-IgG,-IgA and NSPn5-IgG) are indicated by circules. (C) Immunoblot analysis was performed on sera pre-selected by ELISA in order to ensure multiple immune reactivity with protein antigens. Results of a representative experiment using total bacterial lysate prepared from S. pneumoniae serotype 4 capsule negative mutant strain and selected patients' sera at 5.000X dilution are shown. Not selected, low titer sera were included as negative controls. Mw: molecular weigth markers. (D) Surface staining of S. pneumoniae serotype 4 capsule negative mutant strain was performed by FACS to compare antibody binding to surface located antigens. Human sera were used at different concentrations (0.5-5%). Representative data are shown with patients' sera used at 0.5% final concentration. Signal was detected with FITC-labeled anti-human IgGFab and analysed with the computer program CELLQuest. (E) Correlation between IgG titers measured by ELISA using total bacterial lysates and surface staining of whole living S. pneumoniae with serum IgGs is shown. IgG titer is expressed as ELISA units, while surface staining is expressed as mean fluorescence of stained bacteria calculated by the computer program CELLQuest.

Figure 2 (A) shows the fragment size distribution of the *Streptococcus pneumoniae* type 4 small fragment genomic library, LSPn-70. After sequencing 609 randomly selected clones sequences were frimmed to eliminate vector residues and the number of clones with various genomic fragment sizes were plotted. (B) shows graphic illustration of the distribution of the same set of randomly sequenced clones of LSPn-70 over the *S. pneumoniae* chromosome (according to the TIGR4 genome data). Circles indicate matching

sequences to annotated ORFs and rectangles represent fully matched clones to non-coding chromosomal sequences in +/+ or +/- orientation. Diamonds position all clones with chimeric sequences. Numeric distances in base pairs are indicated over the circular genome for orientation. Partitioning of various clone sets within the library is given in numbers and percentage at the bottom of the figure.

Figure 3 (A) shows the MACS selection with biotinylated human IgGs. The LSPn-70 library in pMAL9.1 was screened with 10  $\mu$ g biotinylated IgG (PSPn3-IgG, purified from human serum). As negative control, no serum was added to the library cells for screening. Number of cells selected after the 1<sup>st</sup> and 2<sup>nd</sup> elution are shown for each selection round (upper and lower panel, respectively). (B) shows the reactivity of specific clones (1-26) selected by bacterial surface display as analysed by immunoblot analysis with the human serum IgG pool (PSPn7-IgG,  $4\mu$ g/ $\mu$ l) used for selection by MACS at a dilution of 1:3,000. As a loading control the same blot was also analysed with antibodies directed against the platform protein LamB at a dilution of 1:5,000 of hyperimmune rabbit serum. LB, Extract from a clone expressing LamB without foreign peptide insert.

Figure 4 (A) shows the representation of different serotypes of *S. pneumoniae* clinical isolates analysed for the gene distribution study. (B) shows the PCR analysis for the gene distribution of SP1604 with the respective oligonucleotides. The predicted size of the PCR fragments is 470 bp. 1-50, *S. pneumoniae* strains, clinical isolates as listed under A; -, no genomic DNA added; +, genomic DNA from *S. pneumoniae* serotype 4, which served as template for library construction.

Figure 5 shows the ELISA measurement of epitope-specific human serum IgG antibody levels during pneumococcal disease. Three serum samples were collected longitudinally from patients with invasive pneumococcal disease, before disease occurred (pre), in the acute and convalescent phases. Representative experiments are shown with two sets of sera from two different patients, (A) P1147 and (B) P1150 reacted with peptides representing the identified antigens SP0069, SP0082, SP0117, SP1175, SP1937, SP2190 and SP2216, as indicated. Biotin-labeled peptides were reacted with human serum samples at 200X and 1.000X dilutions and data are expressed as ELISA units.

Figure 6 shows the detection of specific antibody binding on the cell surface of Streptococcus pneumoniae by flow cytometry. In Figure 5A preimmune mouse sera and polyclonal sera raised against S. pneumoniae serotype 4 lysate were incubated with S. pneumoniae strain serotype 4 and analysed by flow cytometry. Control shows the level of non-specific binding of the secondary antibody to the surface of S. pneumoniae cells. The histograms in figure 5B indicates the increased fluorescence due to specific binding of anti-SP2216, anti-SP0117, anti-SP0454 and anti-CRF1992 antibodies in comparison to the control sera against the platform protein LamB.

Figure 7 shows the bactericidal activity of epitope specific antibodies as determined in *in vitro* killing assay. The killing activity of immune sera is measured parallel with and calculated relative to the appropriate control sera. Data are expressed as percentage of killing, that is the reduction on bacterial cfu numbers as a consequence of the presence of antibodies in hyperimmune (HI) polyclonal mouse sera generated with *S. pneumoniae* lysate (A), in immune sera generated with SP0117 epitopes expressed in the LamB platform protein (B), and in mouse immune sera generated with SP1287 epitopes expressed in the FhuA platform protein (C). The control sera represent preimmune sera (PI), sera induced with Lamb or FhuA expressing *E. coli* clones without *S. pneumonia*-derived epitopes. *S. pneumonaie* serotype 4 cells were incubated with mouse phagocytic cells for 60 min, and surviving bacteria were quantified by counting cfus after plating on blood agar.

# Table 1: Immunogenic proteins identified by bacterial surface display.

A, 300bp library in fhuA with NSPn4-IgA (362), B, 300bp library in fhuA with NSPn4-IgG (832), C, 300bp library in fhuA with NSPn5-IgG (872), D, 300bp library in fhuA with PSPn3-IgA (361), E, 300bp library in fhuA with PSPn3-IgG (575), F, 300bp library in fhuA with PSPn7-IgG (795), G, 70bp library in lamB with

NSPn4-IgA (1043), H,-70bp library-in lamB with NSPn4-IgG (929), I, 70bp library in lamB with NSPn5-IgG (527), K, 70bp library in lamb with PSPn3-IgA (1121), L, 70bp library in lamb with PSPn3-IgG (1242), M, 70bp library in lamB with PSPn7-IgG (514); \*, prediction of antigenic sequences longer than 5 amino acids was performed with the program ANTIGENIC (Kolaskar, A. et al., 1990).

## Table 2: Epitope serology with human sera.

Immune reactivity of individual synthetic peptides representing selected epitopes with individual human sera is shown. Extent of reactivity is pattern/grey coded; white: - (<50U), light grey: + (50-119U); dark ---gery: ++ (120-199U), black: +++ (200-500U) and vertically crossed: ++++ (> 500U). ELISA units (U) are calculated from OD405nm readings and the serum dilution after correction for background. S stands for score, calculated as the sum of all reactivities (addition of the number of all +); P1 to P13 sera are measured to be high titer and are from patients with invasive penumococcal diseases and N1 to N10 sera are from healthy adults with high anti-S. pneumoniae titers. S stands for score. Which is the sum of immune reactivities: - =0; + =1; ++ =2; +++ =3 and ++++ =4. Location of synthetic peptides within the antigenic ORFs according to the genome annotation of TIGR4 strain are given in columns from and to indicating the first and last amino acid residues, respectively. Peptide names: SP0117.1-7 present in annotated ORFSP0117; ARF0408.1, potential novel ORF in alternative reading-frame of SP0408; CRF0129.1, potential novel ORF on complement of SP0129.

## Table 3: Gene distribution in S. pneumoniae strains.

Fifty S. pneumoniae strains as shown in Figure 4A were tested by PCR with oligonucleotides specific for the genes encoding relevant antigens. The PCR fragment of one selected PCR fragment was sequenced in order to confirm the amplification of the correct DNA fragment. \*, number of amino acid substitutions in a serotype 14 strain as compared to S. pneumoniae TIGR4 (serotype 4). #, alternative strain used for sequencing, because gene was not present in the serotype 14 strain.

Table 4: Surface location of antigenic epitopes and the functionality of the epitope-specific antibodies. 45 S. pneumoniae antigens were tested for surface localization in the way described and presented in Figure 6 by using mouse sera generated by immunization with E. coli clones harboring plasmids encoding the platform proteins LamB or FhuA fused to a S. pneumoniae peptide. Data are summarized in the column labeled FACS. The very same immune reagents were used in an in vitro killing assay, as shown in Figure 7 for the examples, and presented for all antigens tested positive by FACS in column PK (phagocytic killing). -: negative result, +: not consistently positive in all assays performed, ++ and +++ are consistently positive relative to control reagents.

#### EXAMPLES

Example 1: Characterization and selection of human sera based anti-S. pneumoniae antibodies, preparation of antibody screening reagents

#### Experimental procedures

Enzyme linked immune assay (ELISA).

ELISA plates (Maxisorb, Millipore) were coated with 5-10 µg/ml total protein diluted in coating buffer (0.1M sodium carbonate pH 9.2). Three dilutions of sera (2,000X, 10,000X, 50,000X) were made in PBS-BSA. Highly specific Horse Radish Peroxidase (HRP)-conjugated anti-human IgG or anti-human IgA secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (dilution: 1,000x). Antigen-antibody complexes were quantified by measuring the conversion of the substrate (ABTS) to colored product based on OD405nm readings by automatic ELIAS reader (TECAN SUNRISE).

Preparation of bacterial antigen extracts

Total bacterial lysate: Bacteria were grown overnight in THB (Todd-Hewitt Broth) and lysed by repeated freeze-thaw cycles: incubation on dry ice/ethanol-mixture until frozen (1 min), then thawed at 37°C (5 min): repeated 3 times. This was followed by sonication and collection of supernatant by centrifugation (3,500 rpm, 15 min, 4°C).

Culture supernatant: After removal of bacteria by centrifugation, the supernatant of overnight grown bacterial cultures was precipitated with ice-cold ethanol by mixing 1 part supernatant with 3 parts abs. ethanol and incubated overnight at -20°C. Precipitates were collected by centrifugation (2,600 g, for 15 min). Dry pellets were dissolved either in PBS for ELISA, or in urea and SDS-sample buffer for SDS-PAGE and immunoblotting. The protein concentration of samples was determined by Bradford assay.

## Immunoblotting

Total bacterial lysate and culture supernatant samples were prepared from *in vitro* grown *S. pneumoniae* serotype 4 uncapsulated mutant strain. 10 to 25µg total protein/lane was separated by SDS-PAGE using the BioRad Mini-Protean 3 Cell electrophoresis system and proteins transferred to nitrocellulose membrane (ECL, Amersham Pharmacia). After overnight blocking in 5% milk, human sera were added at 2,000x dilution, and HRPO labeled anti-human IgG was used for detection.

## Surface staining of bacteria

Flow cytometric analysis was carried out as follows. S. pneumoniae serotype 4 uncapsulated mutant strain was grown in Todd-Hewitt broth overnight until early stationary phase. Cells were collected and washed twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted to approximately 1 X 106 CFU in 100µl HBSS with 0.5% BSA based on OD600 nm readings. After incubation with human sera at 0,5 and 2% final concentration for 60 min at 4°C, unbound antibodies were washed away by centrifugation in excess HBSS, 0.5% BSA. For detection fluorescein (FITC) labeled secondary goat antihuman IgG (F(ab')2 fragment specific) was incubated with the cells at 4°C for 30 min. After washing the cells, cells were fixed with 2% paraformaldehyde. Surface staining antibodies were detected using a Becton Dickinson FACScan flow cytometer and data further analyzed with the computer program CELLQuest.

Purification of antibodies for genomic screening. Five sera from both the patient and the healthy group were selected based on the overall anti-streptococcal titers for a serum pool used in the screening procedure. Antibodies against *E. coli* proteins were removed by incubating the heat-inactivated sera with whole cell *E. coli* cells (DH5alpha, transformed with pHIE11, grown under the same condition as used for bacterial surface display). Highly enriched preparations of IgGs from the pooled, depleted sera were generated by protein G affinity chromatography, according to the manufacturer's instructions (UltraLink Immobilized Protein G, Pierce). IgA antibodies were purified also by affinity chromatography using biotin-labeled anti-human IgA (Southern Biotech) immobilized on Streptavidin-agarose (GIBCO BRL). The efficiency of depletion and purification was checked by SDS-PAGE, Western blotting, ELISA and protein concentration measurements.

#### Results

The antibodies produced against *S. pneumoniae* by the human immune system and present in human sera are indicative of the *in vivo* expression of the antigenic proteins and their immunogenicity. These molecules are essential for the identification of individual antigens in the approach as described in the present invention, which is based on the interaction of the specific anti-streptococcal antibodies and the corresponding *S. pneumoniae* peptides or proteins. To gain access to relevant antibody repertoires, human sera were collected from

I. convalescent patients with invasive *S. pneumoniae* infections, such as pneumonia, bacteraemia and meningitis. (*S. pneumoniae* was shown to be the causative agent by medical microbiological tests),

Il healthy adults without carriage at the time of sampling. S. pneumoniae colonization and infections are common, and antibodies are present as a consequence of natural immunization from

97 serum samples from patien and 50 sera from healthy adults were characterized for anti-S. pneumoniae antibodies by a series of immune assays. Primary characterization was done by ELISA using two different antigen preparations, such as total bacterial extract and culture supernatant proteins prepared from S. pneumoniae serotype 4 uncapsulated mutant strain. It is an important aspect that we analysed uncapsulated strain, since we avoided the reactivities coming from serotype specific abundant anticapsular polysaccharide antibodies.

Recently it was reported that not only IgG, but also IgA serum antibodies can be recognized by the FcRIII receptors of PMNs and promote opsonization (Phillips-Quagliata, J. et al., 2000); {Shibuya, A. et al., 2000}. The primary role of IgA antibodies is neutralization, mainly at the mucosal surface. The level of serum IgA reflects the quality, quantity and specificity of the dimeric secretory IgA. For that reason the serum collection was not only analyzed for anti-streptococcal IgG, but also for IgA levels. In the ELISA assays highly specific secondary reagents were used to detect antibodies from the high affinity types, such as IgG and IgA, but avoided IgM. Production of IgM antibodies occurs during the primary adaptive humoral response, and results in low affinity antibodies, while IgG and IgA antibodies had already undergone affinity maturation, and are more valuable in fighting or preventing disease. Antibody titers were compared at given dilutions where the response was linear (Fig. 1A and 1B.). Sera were ranked based on the IgG and IgA reactivity against the two complex antigenic mixtures, and the highest ones were selected for further testing by immunoblotting. This analysis confirmed a high antibody reactivity of the pre-selected sera against multiple pneumococcal proteins, especially when compared to not selected, low-titer sera (Fig 1C). ELISA ranking of sera also correlated very well with surface staining of the same S. pneumoniae strain (Fig. 1D and 1E) suggesting that the majority of the antibodies detected by ELISA corresponded to surface antigens. This extensive antibody characterization approach has led to the unambiguous identification of anti-pneumococcal hyperimmune sera.

Selected sera, 2x5 from both the patient and healthy donor groups were pooled to further enrich for abundant antibodies, but still having a representation of antibody repertoires of different individuals. IgG and IgA antibodies were purified from pooled sera by affinity chromatography and depleted of E. coli -reactive antibodies to avoid background in the bacterial surface display screen.

Example 2: Generation of highly random, frame-selected, small-fragment, genomic DNA libraries of Streptococcus pneumoniae

## Experimental procedures

Preparation of streptococcal genomic DNA. 50 ml Todd-Hewitt Broth medium was inoculated with S. pneumoniae serotype 4 (clinical isolate, typed with conventional serotyping) bacteria from a frozen stab and grown with aeration and shaking for 18 h at 37°C. The culture was then harvested, centrifuged with 1,600x g for 15 min and the supernatant was removed. Bacterial pellets were washed 3 x with PBS and carefully re-suspended in 0.5 ml of Lysozyme solution (100 mg/ml). 0.1 ml of 10 mg/ml heat treated RNase A and 20 U of RNase T1 were added, mixed carefully and the solution was incubated for 1 h at 37°C. Following the addition of 0.2 ml of 20 % SDS solution and 0.1 ml of Proteinase K (10 mg/ml) the tube was incubated overnight at 55°C. 1/3 volume of saturated NaCl was then added and the solution was incubated for 20 min at 4°C. The extract was pelleted in a microfuge (13,000 rpm) and the supernatant transferred into a new tube. The solution was extracted with PhOH/CHCla/IAA (25:24:1) and with CHCla/IAA (24:1). DNA was precipitated at room temperature by adding 0.6x volume of Isopropanol, spooled from the solution with a sterile Pasteur pipette and transferred into tubes containing 80% ice-cold ethanol. DNA was recovered by centrifuging the precipitates with 10-12,000x g, then dried on air and dissolved in ddH<sub>2</sub>O.

fragments ranging in size between 150 and 300 bp using a cup-horn sonicator (Bandelin Sonoplus UV 2200 sonicator equipped with a BB5 cup horn, 10 sec. pulses at 100 % power output) or into fragments of size between 50 and 70 bp by mild DNase I treatment (Novagen). It was observed that sonication yielded a much tighter fragment size distribution when breaking the DNA into fragments of the 150-300 bp size range. However, despite extensive exposure of the DNA to ultrasonic wave-induced hydromechanical shearing force, subsequent decrease in fragment size could not be efficiently and reproducibly achieved. Therefore, fragments of 50 to 70 bp in size were obtained by mild DNase I treatment using Novagen's shotgun cleavage kit. A 1:20 dilution of DNase I provided with the kit was prepared and the digestion was performed in the presence of MnCl2 in a 60  $\mu$ l volume at 20°C for 5 min to ensure double-stranded cleavage by the enzyme. Reactions were stopped with 2  $\mu$ l of 0.5 M EDTA and the fragmentation efficiency was evaluated on a 2% TAE-agarose gel. This treatment resulted in total fragmentation of genomic DNA into near 50-70 bp fragments. Fragments were then blunt-ended twice using T4 DNA Polymerase in the presence of 100  $\mu$ M each of dNTPs to ensure efficient flushing of the ends. Fragments were used immediately in ligation reactions or frozen at -20°C for subsequent use.

Description of the vectors. The vector pMALA.31 was constructed on a pASK-IBA backbone {Skerra, A., 1994} with the beta-lactamase (bla) gene exchanged with the Kanamycin resistance gene. In addition the bla gene was cloned into the multiple cloning site. The sequence encoding mature beta-lactamase is preceded by the leader peptide sequence of ompA to allow efficient secretion across the cytoplasmic membrane. Furthermore a sequence encoding the first 12 amino acids (spacer sequence) of mature beta-lactamase follows the ompA leader peptide sequence to avoid fusion of sequences immediately after the leader peptidase cleavage site, since e.g. clusters of positive charged amino acids in this region would decrease or abolish translocation across the cytoplasmic membrane {Kajava, A. et al., 2000}. A Smal restriction site serves for library insertion. An upstream Fsel site and a downstream NotI site, which were used for recovery of the selected fragment, flank the Smal site. The three restriction sites are inserted after the sequence encoding the 12 amino acid spacer sequence in such a way that the bla gene is transcribed in the -1 reading frame resulting in a stop codon 15 bp after the NotI site. A +1 bp insertion restores the bla ORF so that beta-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMAL9.1 was constructed by cloning the *lamB* gene into the multiple cloning site of pEH1 {Hashemzadeh-Bonehi, L. et al., 1998}. Subsequently, a sequence was inserted in *lamB* after amino acid 154, containing the restriction sites *FseI*, *SmaI* and *NotI*. The reading frame for this insertion was constructed in such a way that transfer of frame-selected DNA fragments excised by digestion with *FseI* and *NotI* from plasmid pMAL4.31 yields a continuous reading frame of *lamB* and the respective insert.

The vector pMAL10.1 was constructed by cloning the *btuB* gene into the multiple cloning site of pEH1. Subsequently, a sequence was inserted in *btuB* after amino acid 236, containing the restriction sites *FseI*, *XbaI* and *NotI*. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with *FseI* and *NotI* from plasmid pMAL4.31 yields a continuous reading frame of *btuB* and the respective insert.

The vector pHIE11 was constructed by cloning the *fhuA* gene into the multiple cloning site of pEH1. Thereafter, a sequence was inserted in *fhuA* after amino acid 405, containing the restriction site *FseI*, *XbaI* and *NotI*. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with *FseI* and *NotI* from plasmid pMAL4.31 yields a continuous reading frame of *fhuA* and the respective insert.

Cloning and evaluation of the library for frame selection. Genomic S. pneumoniae DNA fragments were ligated into the Smal site of the vector pMAL4.31. Recombinant DNA was electroporated into DH10B electrocompetent E. coli cells (GIBCO BRL) and transformants plated on LB-agar supplemented with Kanamycin (50 µg/ml) and Ampicillin (50 µg/ml). Plates were incubated over night at 37°C and colonies collected for large scale DNA extraction. A representative plate was stored and saved for collecting

colonies for colony PCR analysis and large-scale sequencing. A simple colony PCR assay was used to initially determine the rough fragment size distribution as well as insertion efficiency. From sequencing data the precise fragment size was evaluated, junction intactness at the insertion site as well as the frame selection accuracy (3n+1 rule).

Cloning and evaluation of the library for bacterial surface display. Genomic DNA fragments were excised from the pMAL4.31 vector, containing the S. pneumoniae library with the restriction enzymes FseI and NotI. The entire population of fragments was then transferred into plasmids pMAL9.1 (LamB) or pHIE11 (FhuA), which have been digested with FseI and NotI. Using these two restriction enzymes, which recognise an 8 bp GC rich sequence, the reading frame that was selected in the pMAL4.31 vector is maintained in each of the platform vectors. The plasmid library was then transformed into E. coli DH5alpha cells by electroporation. Cells were plated onto large LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C at a density yielding clearly visible single colonies. Cells were then scraped off the surface of these plates, washed with fresh LB medium and stored in aliquots for library screening at -80°C.

#### Results

Libraries for frame selection. Two libraries (LSPn70 and LSPn300) were generated in the pMAL4.31 vector with sizes of approximately 70 and 300 bp, respectively. For each library, ligation and subsequent transformation of approximately 1 µg of pMAL4.31 plasmid DNA and 50 ng of fragmented genomic *S. pneumoniae* DNA yielded 4x 10<sup>5</sup> to 2x 10<sup>6</sup> clones after frame selection. To assess the randomness of the libraries, approximately 600 randomly chosen clones of LSPn70 were sequenced. The bioinformatic analysis showed that of these clones only very few were present more than once. Furthermore, it was shown that 90% of the clones fell in the size range between 25 and 100 bp with an average size of 52 bp (Figure 2). Allmost all sequences followed the 3n+1 rule, showing that all clones were properly frame selected.

Bacterial surface display libraries. The display of peptides on the surface of E. coli required the transfer of the inserts from the LSPn libraries from the frame selection vector pMAL4.31 to the display plasmids pMAL9.1 (LamB) or pHIE11 (FhuA). Genomic DNA fragments were excised by FseI and NotI restriction and ligation of 5ng inserts with 0.1µg plasmid DNA and subsequent transformation into DH5alpha cells resulted in 2-5x 10<sup>6</sup> clones. The clones were scraped off the LB plates and frozen without further amplification.

Example 3: Identification of highly immunogenic peptide sequences from S. pneumoniae using bacterial surface displayed genomic libraries and human serum

## Experimental procedures

MACS screening. Approximately 2.5x  $10^8$  cells from a given library were grown in 5 ml LB-medium supplemented with 50  $\mu$ g/ml Kanamycin for 2 h at 37°C. Expression was induced by the addition of 1 mM IPTG for 30 min. Cells were washed twice with fresh LB medium and approximately  $2x 10^7$  cells resuspended in  $100 \mu$ l LB medium and transferred to an Eppendorf tube.

10  $\mu g$  of biotinylated, human IgGs purified from serum was added to the cells and the suspension incubated overnight at 4°C with gentle shaking. 900  $\mu l$  of LB medium was added, the suspension mixed and subsequently centrifuged for 10 min at 6,000 rpm at 4°C (For IgA screens, 10  $\mu g$  of purified IgAs were used and these captured with biotinylated anti-human-IgG secondary antibodies). Cells were washed once with 1 ml LB and then re-suspended in 100  $\mu l$  LB medium. 10  $\mu l$  of MACS microbeads coupled to streptavidin (Miltenyi Biotech, Germany) were added and the incubation continued for 20 min at 4°C. Thereafter 900  $\mu l$  of LB medium was added and the MACS microbead cell suspension was loaded

onto the equilibrated MS column (Miltenyi Biotech, Germany) which was fixed to the magnet. (The MS columns were equilibrated by washing once with 1 ml 70% EtOH and twice with 2 ml LB medium.)

The column was then washed three times with 3 ml LB medium. After removal of the magnet, cells were eluted by washing with 2 ml LB medium. After washing the column with 3 ml LB medium, the 2 ml eluate was loaded a second time on the same column and the washing and elution process repeated. The loading, washing and elution process was performed a third time, resulting in a final eluate of 2 ml.

A second round of screening was performed as follows. The cells from the final eluate were collected by centrifugation and re-suspended in 1 ml LB medium supplemented with 50  $\mu$ g/ml Kanamycin. The culture was incubated at 37°C for 90 min and then induced with 1 mM IPTG for 30 min. Cells were subsequently collected, washed once with 1 ml LB medium and suspended in 10  $\mu$ l LB medium. 10  $\mu$ g of human, biotinylated IgGs were added again and the suspension incubated over night at 4°C with gentle shaking. All further steps were exactly the same as in the first selection round. Cells selected after two rounds of selection were plated onto LB-agar plates supplemented with 50  $\mu$ g/ml Kanamycin and grown over night at 37°C.

Evaluation of selected clones by sequencing and Western blot analysis. Selected clones were grown overnight at  $37^{\circ}$ C in 3 ml LB medium supplemented with 50  $\mu$ g/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany) or in collaboration with TIGR (U.S.A.).

For Western blot analysis approximately 10 to 20 µg of total cellular protein was separated by 10% SDS-PAGE and blotted onto HybondC membrane (Amersham Pharmacia Biotech, England). The LamB or FhuA fusion proteins were detected using human serum as the primary antibody at a dilution of approximately 1:5,000 and anti-human IgG or IgA antibodies coupled to HRP at a dilution of 1:5,000 as secondary antibodies. Detection was performed using the ECL detection kit (Amersham Pharmacia Biotech, England). Alternatively, rabbit anti-FhuA or rabbit anti-LamB polyclonal immune sera were used as primary antibodies in combination with the respective secondary antibodies coupled to HRP for the detection of the fusion proteins.

## Results

Screening of bacterial surface display libraries by magnetic activated cell sorting (MACS) using biotinylated Igs. The libraries LSPn70 in pMAL9.1 and LSPn300 in pHIE11 were screened with pools of biotinylated, human IgGs and IgAs from patient sera or sera from healthy individuals (see Example 1: Preparation of antibodies from human serum). The selection procedure was performed as described under Experimental procedures. Figure 3A shows a representative example of a screen with the LSPn-70 library and PSPn3-IgGs. As can be seen from the colony count after the first selection cycle from MACS screening, the total number of cells recovered at the end is drastically reduced from 2x107 cells to approximately 5x 104 cells, whereas the selection without antibodies added showed a reduction to about 2x103 cells (Figure 3A). After the second round, a similar number of cells was recovered with PSPn3-IgGs, while fewer than 10 cells were recovered when no IgGs from human serum were added, clearly showing that selection was dependent on S. pneumoniae specific antibodies. To evaluate the performance of the screen, 26 selected clones were picked randomly and subjected to immunoblot analysis with screening IgG pool (PSPn7) (Figure 3B). This analysis revealed that ~90% of the selected clones showed reactivity with antibodies present in the relevant serum whereas the control strain expressing LamB without a S. pneumoniae specific insert did not react with the same serum. In general, the rate of reactivity was observed to lie within the range of 35 to 90%. Colony PCR analysis showed that all selected clones contained an insert in the expected size range.

Subsequent sequencing of a larger number of randomly picked clones (600 to 1200 per screen) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the human serum antibodies used for screening. The frequency with which a specific clone is selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. In that regard it is striking that clones derived from some ORFs (e.g. SP2216, SP0117, SP0641, SP2136, SP2190, SP0107, SP0082) were picked more than 100 times, indicating their highly immunogenic property. Table 1 summarizes the data obtained for all 12 performed screens. All clones that are presented in Table 1 have been verified by with the pool of human serum used in the respective screen. As can be seen from Table 1, distinct regions of the identified ORF are identified as immunogenic, since variably sized fragments of the proteins are displayed on the surface by the platform proteins.

It is further worth noticing that most of the genes identified by the bacterial surface display screen encode proteins that are either attached to the surface of *S. pneumoniae* and/or are secreted. This is in accordance with the expected role of surface attached or secreted proteins in virulence of *S. pneumoniae*.

Example 4: Assessment of the reactivity of highly immunogenic peptide sequences with individual human sera.

## Experimental procedures

## Peptide synthesis

Peptides were synthesized in small scale (4 mg resin; up to 288 in parallel) using standard F-moc chemistry on a Rink amide resin (PepChem, Tübingen, Germany) using a SyroII synthesizer (Multisyntech, Witten, Germany). After the sequence was assembled, peptides were elongated with Fmoc-epsilon-aminohexanoic acid (as a linker) and biotin (Sigma, St. Louis, MO; activated like a normal amino acid). Peptides were cleaved off the resin with 93%TFA, 5% triethylsilane, and 2% water for one hour. Peptides were dried under vacuum and freeze dried three times from acetonitrile/water (1:1). The presence of the correct mass was verified by mass spectrometry on a Reflex III MALDI-TOF (Bruker, Bremen Germany). The peptides were used without further purification.

## Enzyme linked immune assay (ELISA).

Biotin-labeled peptides (at the N-terminus) were coated on Streptavidin ELISA plates (EXICON) at 10  $\mu$ g/ml concentration according to the manufacturer's instructions. Highly specific Horse Radish Peroxidase (HRP)-conjugated anti-human IgG secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (dilution: 1,000x). Sera were tested at two serum dilutions, 200X and 1,000X. Following manual coating, peptide plates were processed and analyzed by the Gemini 160 ELISA robot (TECAN) with a built-in ELISA reader (GENIOS, TECAN).

Approximately 110 patients and 60 healthy adult sera were included in the analysis. Following the bioinformatic analysis of selected clones, corresponding peptides were designed and synthesized. In case of epitopes with more than 26 amino acid residues, overlapping peptides were made. All peptides were synthesized with a N-terminal biotin-tag and used as coating reagents on Streptavidin-coated ELISA plates.

The analysis was performed in two steps. First, peptides were selected based on their reactivity with the individual sera, which were included in the serum pools used for preparations of IgG and IgA screening reagents for bacterial surface display. A summary for serum reactivity of 224 peptides representing *S. pneumoniae* epitopes from the genomic screen analysed with 20 human sera (representing 4 different pools of five sera) used for the antigen identification is shown in Table 2. The peptides were compared by

the score calculated for each peptide based on the number of positive sera and the extent of reactivity. Peptides range from highly and widely reactive to weakly positive ones. Among the most reactive ones there are known antigens, some of them are also protective in animal challenge models for nasopharyngeal carriage or sepsis (e.g. PspA/SP0117, serine protease/SP0641, histidine triad protein/SP1175). Peptides not displaying a positive reaction were not included in further, more detailed studies.

Second, a large number of not pre-selected individual sera from patients with invasive pneumococcal disease or from healthy adults and children were tested against the peptides showing specific and high reactivity with the screening sera. Seroconversion during disease was tested for highly positive peptides by using three serial serum samples collected longitudinally from patients with invasive pneumococcal disease, the first before disease occurred (pre), the second in the acute phase (within 5 days after onset) and the third in the convalescent phase (> 3 weeks after onset) of the disease. Two representative ELISA experiments are shown with two different patients, displaying seroconversion to multiple peptides, suggesting that epitope-specific antibody levels were low before disease occurred, and were induced in the acute and convalescent phase (Fig. 5). The antigens showing this antibody profile are especially valuable for vaccine development (e.g. SP2216, SP2109, SP1175, SP0117, SP0082).

# Example 5: Gene distribution studies with highly immunogenic proteins identified from S. pneumoniae.

## Experimental procedures

Gene distribution of pneumococcal antigens by PCR. An ideal vaccine antigen would be an antigen that is present in all, or the vast majority of strains of the target organism to which the vaccine is directed. In order to establish whether the genes encoding the identified Streptococcus pneumoniae antigens occur ubiquitously in S. pneumoniae strains, PCR was performed on a series of independent S. pneumoniae isolates with primers specific for the gene of interest. S. pneumoniae isolates were obtained covering the serotypes most frequently present in patients as shown in Figure 4A. Oligonucleotide sequences as primers were designed for all identified ORFs yielding products of approximately 1,000 bp, if possible covering all identified immunogenic epitopes. Genomic DNA of all S. pneumoniae strains was prepared as described under Example 2. PCR was performed in a reaction volume of 25 µl using Taq polymerase (1U), 200 nM dNTPs, 10 pMol of each oligonucleotide and the kit according to the manufacturers instructions (Invitrogen, The Netherlands). As standard, 30 cycles (1x: 5min. 95°C, 30x: 30sec. 95°C, 30sec. 56°C, 30sec. 72°C, 1x 4min. 72°C) were performed, unless conditions had to be adapted for individual primer pairs.

#### Results

All identified genes encoding immunogenic proteins were tested by PCR for their presence in 50 different strains of *S. pneumoniae* (Figure 4A). As an example, figure 4B shows the PCR reaction for SP1604 with all indicated 50 strains. As clearly visible, the gene is present in all strains analysed. The PCR fragment from a type 14 strain was sequenced and showed that of 414 bp, 6 bp are different as compared to the *S. pneumoniae* type 4 strain, resulting in three amino acid difference between the two isolates.

From a total of 50 genes analysed, 31 were present in all strains tested, while 9 genes were absent in more than 10 of the tested 50 strains (Table 3). Several genes (SP0667, SP0930) showed variation in size and were not present in all strain isolates. Some genes showed variation in size, but were otherwise conserved in all tested strains. Sequencing of the generated PCR fragment from one strain and subsequent comparison to the type 4 strain confirmed the amplification of the correct DNA fragment and revealed a degree of sequence divergence as indicated in Table 3. Importantly, many of the identified antigens are well conserved in all strains in sequence and size and are therefore novel vaccine candidates to prevent

Example 6: Characterization of immune sera obtained from mice immunized with highly immunogenic proteins/peptides from S. pneumoniae displayed on the surface of E. coli.

## Experimental procedures

Generation of immune sera from mice

E. coli clones harboring plasmids encoding the platform protein fused to a S. pneumoniae peptide, were grown in LB medium supplemented with 50μg/ml Kanamycin at 37°C. Overnight cultures were diluted 1:10, grown until an ODco of 0.5 and induced with 0.2 mM IPTG for 2 hours. Pelleted bacterial cells were suspended in PBS buffer and disrupted by sonication on ice, generating a crude cell extract. According to the ODco measurement, an aliquot corresponding to 5x10° cells was injected into NMRI mice i.v., followed by a boost after 2 weeks. Serum was taken 1 week after the second injection. Epitope specific antibody levels were measured by peptide ELISA.

## In vitro expression of antigens

Expression of antigens by in vitro grown S. pneumoniae serotype 4 was tested by immunoblotting. Different growth media and culture conditions were tested to detect the presence of antigens in total lysates and bacterial culture supernatants. Expression was considered confirmed when a specific band corresponding to the predicted molecular weight and electrophoretic mobility was detected.

## Cell surface staining

Flow cytometric analysis was carried out as follows. Bacteria were grown under culture conditions, which resulted in expression of the antigen as shown by the immunoblot analysis. Cells were washed twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted to approximately 1 X 106 CFU in 100µl HBSS, 0.5% BSA. After incubation for 30 to 60 min at 4°C with mouse antisera diluted 50 to 100-fold, unbound antibodies were washed away by centrifugation in excess HBSS, 0.5% BSA. Secondary goat anti-mouse antibody (F(ab')2 fragment specific) labeled with fluorescein (FITC) was incubated with the cells at 4°C for 30 to 60 min. After washing, cells were fixed with 2% paraformaldehyde. Bound antibodies were detected using a Becton Dickinson FACScan flow cytometer and data further analyzed with the computer program CELLQuest. Negative control sera included mouse pre-immune serum and mouse polyclonal serum generated with lysates prepared from IPTG induced *E. coli* cells transformed with plasmids encoding the genes *lamB* or *fhuA* without *S. pneumoniae* genomic insert.

## Bactericidal (killing) assay

Murine macrophage cells (RAW246.7 or P388.D1) and bacteria were incubated and the loss of viable bacteria after 60 min was determined by colony counting. In brief, bacteria were washed twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted to approximately 1X 10<sup>5</sup> CFU in 50µl HBSS. Bacteria were incubated with mouse sera (up to 25%) and guinea pig complement (up to 5%) in a total volume of 100µl for 60min at 4°C. Pre-opsonized bacteria were mixed with macrophages (murine cell line RAW264.7 or P388.D1; 2X 10<sup>6</sup> cells per 100µl) at a 1:20 ratio and were incubated at 37°C on a rotating shaker at 500 rpm. An aliquot of each sample was diluted in sterile water and incubated for 5 min at room temperature to lyse macrophages. Serial dilutions were then plated onto Todd-Hewitt Broth agar plates. The plates were incubated overnight at 37°C, and the colonies were counted with the Countermat flash colony counter (IUL Instruments). Control sera included mouse pre-immune serum and mouse polyclonal serum generated with lysates prepared from IPTG induced *E. coli* transformed with plasmids harboring the genes *lamB* or *fhuA* without *S. pneumoniae* genomic insert.

## Results

In vitro expression of antigens. The expression of the antigenic proteins was analyzed in vitro in S.

pneumoniae serotype 4 by using sera raised against *E. coli* clones harboring plasmids encoding the platform protein fused to a *S. pneumoniae* peptide. First, the presence of specific antibodies was determined by peptide ELISA and/or immunoblotting using the *E. coli* clone expressing the given epitope embedded in LamB or FhuA platform proteins. Positive sera were then analysed by immunblotting using total bacterial lysates and culture supernatants prepared from *S. pneumoniae* serotype 4 strain (data not shown). This analysis served as a first step to determine whether a protein is expressed at all, and if, under which growth conditions, in order to evaluate surface expression of the polypeptide by FACS analysis. It was anticipated based on literature data that not all proteins would be expressed under *in vitro* conditions.

Cell surface staining of S. pneumoniae. Cell surface accessibility for several antigenic proteins was subsequently demonstrated by an assay based on flow cytometry. Streptococci were incubated with preimmune and polyclonal mouse sera raised against S. pneumoniae lysate or E. coli clones harboring plasmids encoding the platform protein fused to a S. pneumoniae peptide, follow by detection with fluorescently tagged secondary antibody. As shown in Fig. 6A, antisera raised against S. pneumoniae lysate contains antibodies against surface components, demonstrated by a significant shift in fluorescence of the S. pneumoniae serotype 4 cell population. Similar cell surface staining of S. pneumoniae sertype 4 cells was observed with polyclonal sera raised against peptides of many of the pneumococcal antigens identified (Fig. 6B and Table 4.). In some instancies, a subpopulation of the bacteria was not stained, as indicated by the detection of two peaks in the histograms (Fig. 6B). This phenomenon may be a result of differential expression of the gene products during the growth of the bacterium, insufficient antibody levels or partial inhibition of antibody binding caused by other surface molecules or plasma proteins.

In vitro bactericidal activity. Opsonophagocytic killing is the cornerstone of host defense against extracellular bacteria, such as *S. pneumoniae*. Cell surface binding of antibodies to bacterial antigens are opsonizing and induce killing (bactericidal) by phagocytic cells (macrophages and neutrophiligranulocytes) if the antibodies induced by the particular antigens can bind activated complement components (C3bi). It has been shown that anti-pneumococcal bactericidal activity of human sera measured in *in vitro* assays can be correlated with *in vivo* protection of vaccinated individuals {Romero-Steiner, S. et al., 1999}. In Figure 7 examples are shown and in Table 4 a summary is presented on bactericidal activity measured by antigen-specific antibodies generated in mice with corresponding epitopes. According to these data, several of the novel pneumococcal antigens induce functional antibodies (e.g. SP0082, SP2216, SP2136, SP0454, SP0069, SP0369, etc.). Importantly, a well-known protective pneumoniae antigen, PspA (SP0117) is proved to be strongly positive in the very same assay.

These experiments confirmed the bioinformatic prediction that many of the proteins are exported due to their signal peptide sequence and in addition showed that they are present on the cell surface of *S. pneumoniae* serotype 4. They also confirm that these proteins are available for recognition by human antibodies with functional properties and make them valuable candidates for the development of a vaccine against pneumococcal diseases.

and the second of the companies of the c

Adamou, J., et al. (2001). Infect Immun 69: 949-58.

Altschul, S., et al. (1990). Journal of Molecular Biology 215: 403-10.

Bennett, D., et al. (1995). J Mol Recognit 8: 52-8.

Brown, J., et al. (2001). Infect Immun 69: 6702-6.

Burnie, J., et al. (1998). <u>I Antimicrob Chemother</u> 41: 319-22.

-Clackson, T., et al. (1991). Nature 352: 624-8.

Devereux, J., et al. (1984). Nucleic acids research 12: 387-95.

Di Guilmi, A., et al. (2002). EMBO Rep 3: 728-34.

Doherty, E., et al. (2001). Annu Rev Biophys Biomol Struct 30: 457-475.

Eisenbraun, M., et al. (1993). DNA Cell Biol 12: 791-7.

Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing (The Pink Book). The Pink Book is published by the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.

Etz, H., et al. (2001). <u>I Bacteriol</u> 183: 6924-35.

Ganz, T. (1999). Science 286: 420-421.

Georgiou, G. (1997). Nature Biotechnology 15: 29-34.

Gray, B., et al. (1979). <u>I Infect Dis</u> 140: 979-83.

Gray, B., et al. (1986). Pediatr Infect Dis 5: 201-7.

Hashemzadeh-Bonehi, L., et al. (1998). Mol Microbiol 30: 676-678.

Hausdorff, W., et al. (2001). Lancet 357: 950-2.

Heinje, von G. (1987) e.g. Sequence Analysis in Molecular Biology, Acedimic Press

Hemmer, B., et al. (1999). Nat Med 5: 1375-82.

Hoe, N., et al. (2001). I Infect Dis 183: 633-9.

Hornef, M., et al. (2002). Nat Immunol 3: 1033-40.

Hoskins, J., et al. (2001). <u>I Bacteriol</u> 183: 5709-17.

Hyde, T., et al. (2001). <u>JAMA</u> 286: 1857-62.

Jedrzejas, M. (2001). Microbiol Mol Biol Rev 65: 187-207.

Johanson, K., et al. (1995). I Biol Chem 270: 9459-71.

Jones, P., et al. (1986). Nature 321: 522-5.

Kajava, A., et al. (2000). <u>I Bacteriol</u> 182: 2163-9.

Kohler, G., et al. (1975). Nature 256: 495-7.

Kolaskar, A., et al. (1990). FEBS Lett 276: 172-4.

Lewin, A., et al. (2001). Trends Mol Med 7: 221-8.

Marks, J., et al. (1992). Biotechnology (N Y) 10: 779-83.

McCafferty, J., et al. (1990). Nature 348: 552-4.

McCormick, A., et al. (2003). Nat Med 9: 424-30.

McDaniel, L., et al. (1991). Infect Immun 59: 222-8.

Navarre, W., et al. (1999). Microbiol Mol Biol Rev 63: 174-229.

Okano, H., et al. (1991). I Neurochem 56: 560-7.

Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression; CRC Press, Boca Tation, FL (1988) for a description of these molecules

Orange, M., et al. (1993). Pediatr Infect Dis J 12: 244-6.

Pelton, S., et al. (2003). Vaccine 21: 1562-71.

Phillips-Quagliata, J., et al. (2000). <u>I Immunol</u> 165: 2544-55.

Rammensee, H., et al. (1999). Immunogenetics 50: 213-9.

Roche, H., et al. (2003). Infect Immun 71: 1033-41.

Romero-Steiner, S., et al. (1999). Clin Infect Dis 29: 281-8.

Rosenow, C., et al. (1997). Mol Microbiol 25: 819-29.

Seeger, C., et al. (1984). Proc Natl Acad Sci USA 81: 5849-52.

Shibuya, A., et al. (2000). Nature Immunology 1: 441-6.

Skerra, A. (1994). Gene 151: 131-5.

Talkington, D., et al. (1996). Microb Pathog 21: 17-22.

Tang, D., et al. (1992). Nature 356: 152-4.

Tempest, P., et al. (1991). Biotechnology (N Y) 9: 266-71.

Tettelin, H., et al. (2001). Science 293: 498-506.

Tourdot, S., et al. (2000). Eur J Immunol 30: 3411-21.

Whitney, C., et al. (2000). N Engl J Med 343: 1917-24.

Wiley, J., et al. (1987) Current Protocols in Molecular Biology.

Wizemann, T., et al. (2001). Infect Immun 69: 1593-8.

- 57a - Table 1: Immunogenic proteins identified by bacterial surface display.

. .....

Spneumonii	e-Putative-function-	predicted immunogenic aa**-	-No. of	Location of	-Seq:-
antigenic	(by homology)	-	selected	identified	ID
protein				immunogenic	
			ORF and	region (aa)	Prot.)
-			screen		- 10,
SP0008	hypothetical protein	4-11,35-64,66-76,101-108,111-119	G:15	57-114	1, 145
SP0032	DNA polymerase I	5-27,32-64,92-102,107-113,119-125,133-139,148-		732-763	2, 146
	(polA)	162,177-187,195-201,207-214,241-251,254-269,285-	L:2	732-703	2, 140
•		300,302-309,317-324,332-357,365-404,411-425,443-		[	
		463,470-477,479-487,506-512,515-520,532-547,556-			
		596,603-610,616-622,624-629,636-642,646-665,667-			
		674,687-692,708-720,734-739,752-757,798-820,824-	ļ		
		851,856-865			
SP0069	Choline binding	14-21,36-44,49-66,102-127,162-167,177-196	G:1, H:2,	<b>45-109</b>	2 147
	protein I		L:1, K:44,	145-172	3, 147
			L:3, M:1	143-172	
SP0071	immunoglobulin A1	17 25 (4 75 01 00 100 110 110 110	A:3, C:1,	132-478	4 440
	protease (iga-1)	200 000 006 000 000 000 000 000 000 000	1	508-592	4, 148
		000 400 400 400		1753-1810	
		TOO COO COO COT COT COT	I:34, K:61,	1755-1610	
		687,691-704,709-716,731-736,739-744,750-763,774-	L:20, M:2		
		780,784-791,799-805,809-822,859-870,880-885,907-	L.20, 1V1.2		
		916,924-941,943-949,973-986,1010-1016,1026-	ĺ		
		1036,1045-1054,1057-1062,1082-1088,1095-1102,1109-			
		1120,1127-1134,1140-1146,1152-1159,1169-1179,1187-			
		1196,1243-1251,1262-1273,1279-1292,1306-1312,1332-			1
		1343,1348-1364,1379-1390,1412-1420,1427-1436,1458-			
		1468,1483-1503,1524-1549,1574-1588,1614-1619,1672-			
		1685,1697-1707,1711-1720,1738-1753,1781-1787,1796-			
		1801,1826-1843			
P0082	Cell wall surface	15-43,49-55,71-77,104-110,123-130,162-171,180-	C:9, E:4,	1-199	5, 149
		100 100 005 010 005 044 054 044 054		200-337	3, 149
		***	L:4, M:67	1	
		406,416-422,432-439,450-460,464-474,482-494,501-		549-647	
	ľ	508,521-529,536-546,553-558,568-574,584-591,602-		01.	
	1	612,616-626,634-646,653-660,673-681,688-698,705-			ļ
	1	710,720-726,736-749,833-848			
P0107			A :3, B :16,	1-128	
			C :15, D :1,	120	6, 150
• •			E :5,		l
			F :178,		
			M:1		
	J		174.1		ľ

		- 57b -			
S. pneumoniae		predicted immunogenic aa**	No. of	Location of	Seq.
antigenic	(by homology)		selected	identified	ID
protein			clones per	immunogenic	(DNA,
			ORF and	region (aa)	Prot.)
			screen		
SP0117	pneumococcal surface	7-32,34-41,96-106,127-136,154-163,188-199,207-	A:13, B:11,	1-548	7, 151
	protein A (pspA)	238,272-279,306-312,318-325,341-347,353-360,387-	C:10, D:4,	660-691	
'		393,399-406,434-440,452-503,575-580,589-601,615-	E:31, F:6,		
1		620,635-640,654-660,674-680,696-701,710-731	G:33,		
			H:13, I:9,		
			K:64, L:32,		
		•	M:46		
SP0191	hypothetical protein	4-19,35-44,48-59,77-87,93-99,106-111,130-138,146-161	E:1, I:2	78-84	8, 152
SP0197	dihydrofolate	24-30,36-43,64-86,93-99,106-130,132-145,148-165,171-	L :9	179-193	9, 153
	synthetase, putative	177,189-220,230-249,251-263,293-300,302-312,323-			
		329,338-356,369-379,390-412			
SP0212	Ribosomal protein L2	30-39,61-67,74-81,90-120,123-145,154-167,169-179,182-	L:10	230-265	10, 154
		197,200-206,238-244,267-272			,
SP0222	Ribosomal protein S14	14-20,49-65,77-86	H:14, L:8,	2-68	11, 155
			M:3		
SP0239	Conserved	4-9,26-35,42-48,53-61,63-85,90-101,105-111,113-	L:2, M:1	110-144	12, 156
	hypothetical protein	121,129-137,140-150,179-188,199-226,228-237,248-			
		255,259-285,299-308,314-331,337-343,353-364,410-			
		421,436-442			
SP0251	formate	36-47,55-63,94-108,129-134,144-158,173-187,196-	G:2, H:7,	225-247	13, 157
<u> </u>	acetyltransferase,	206,209-238,251-266,270-285,290-295,300-306,333-	I:1, M:5	480-507	
	putative	344,346-354,366-397,404-410,422-435,439-453,466-			
		473,515-523,529-543,554-569,571-585,590-596,607-	•		
		618,627-643,690-696,704-714,720-728,741-749,752-			
		767,780-799			
SP0295	ribosomal protein S9	16-25,36-70,80-93,100-106	I:4	78-130	14, 158
	(rpsI)				
SP0330	sugar binding	18-27,41-46,50-57,65-71,79-85,93-98,113-128,144-	G:1, H:1,	36-64	15, 159
	transcriptional	155,166-178,181-188,201-207,242-262,265-273,281-	L:4		
	regulator RegR	295,303-309,318-327			
SP0368	cell wall surface	7-29,31-44,50-59,91-96,146-153,194-201,207-212,232-	D:1, H:3,	1-70	16, 160
	anchor family protein	238,264-278,284-290,296-302,326-353,360-370,378-	I:1, L:1,	154-189	
į		384,400-405,409-418,420-435,442-460,499-506,529-	M:3	922-94ī	
		534,556-562,564-576,644-651,677-684,687-698,736-		1445-1462	
		743,759-766,778-784,808-814,852-858,874-896,920-		1483-1496	
		925,929-935,957-965,1003-1012,1021-1027,1030-			
		1044,1081-1087,1101-1111,1116-1124,1148-1159,1188-			
		1196,1235-1251,1288-1303,1313-1319,1328-1335,1367-			
		1373,1431-1437,1451-1458,1479-1503,1514-1521,1530-			
L	<del></del>	<u> </u>		L	L.

<u> </u>	T	57c <b>-</b>			
S. pneumonia		predicted immunogenic aa**	No. of	Location of	Seq
antigenic	(by homology)	and Subtract on a company of the contract of t	selected	identified	ID
protein			clones pe	immunogenic	
			ORF and		Prot
			screen	Tegion (aa)	FIOT
		1540,1545-1552,1561-1568,1598-1605,1617-1647,1658		<del> </del>	
	_	1665,1670-1676,1679-1689,1698-1704,1707-1713,1732			
والمساوسة والمستدو		. 1738,1744-1764			ĺ
SP0369	Penicillin binding	6-51,81-91,104-113,126-137,150-159,164-174,197-		V: 6	
	protein 1A	209,215-224,229-235,256-269,276-282,307-313,317-	B:1, E:1,	452-530	17, 1
		348,351-357,376-397,418-437,454-464,485-490,498-	L:13, M:1		
		509,547-555,574-586,602-619			
SP0374	hypothetical protein		<u></u>		
	ny pouteucur protent	25-31,39-47,49-56,99-114,121-127,159-186,228-240,253	E:4, L:1,	289-384	18, 16
SP0377	Challe 1	269,271-279,303-315,365-382,395-405,414-425,438-45	L:3		
	Choline binding	9-24,41-47,49-54,68-78,108-114,117-122,132-140,164-	G:5, H:4,	209-249	19, 10
	protein C	169,179-186,193-199,206-213,244-251,267-274,289-	I:1, K:88,	286-336	
		294,309-314,327-333	L:3, M:8		
	choline binding	9-28,53-67,69-82,87-93,109-117,172-177,201-207,220-	K:47, L:6,	286-306	20, 16
	protein J (cbpJ)	227,242-247,262-268,305-318,320-325	M:5		20, 10
SP0390	choline binding	4-10,26-39,47-58,63-73,86-96,98-108,115-123,137-	G:1, K:69,	100 202	20
	protein G (cbpG)	143,148-155,160-176,184-189,194-204,235-240,254-	M:6	199-283	21, 16
		259,272-278	141.0		
P0454	hypothetical protein	4-26,33-39,47-53,59-65,76-83,91-97,104-112,118-	77.7.7		
		137,155-160,167-174,198-207,242-268,273-279,292-		202-242	22, 16
		315,320-332,345-354,358-367,377-394,403-410,424-	L:6		
		439,445-451,453-497,511-518,535-570,573-589,592-		ł	
		601,604-610			
P0463	cell wall surface	8 20 26 45 64 77 76 00 07 co			
1		8-30,36-45,64-71,76-82,97-103,105-112,134-151,161-	A:1, B:2,	316-419	23, 16
ľ	atestor ranning protein		C:4, E:1,		
[			F:4,		
		455,463-470,475-480,490-497,501-513,524-537,552-		1	
70.151		559,565-576,581-590,592-600,619-625,636-644,646-656			
P0466 s	ortase, putative	4-17,52-58,84-99,102-110,114-120,124-135,143-158,160-	E:1, M:2 1	-67	24, 168
		173,177-196,201-216,223-250,259-267,269-275			, 200
P0468 S	ortase, putative	6-46,57-67,69-80,82-133,137-143,147-168,182-187,203-	G:24, 5	3-93	E 160
		209.214-229.233-242.244.200	H:20, L:1		25, 169
?0498 e	ndo-beta-N-	7-40,50-56,81-89,117-123,202-209,213-218,223-229,248		226-1309 2	
а	cetylglucosaminidas	261 264-276 281 289 202 203 020 020 021		1-	6, 170
		346 353-372 434 442 465 474 774 774 770		455-1536	
1		616,620-626,631-636,667-683,685-699,710-719,726-	G:2 1.	538-1605	
		732,751-756,760-771,779-788,815-828,855-867,869-			
			. [		
		879,897-902,917-924,926-931,936-942,981-1000,1006-			
		1015,1017-1028,1030-1039,1046-1054,1060-1066,1083-		j	
		1092,1099-1112,1122-1130,1132-1140,1148-1158,1161-		ĺ	I

S. pneumoniae	Putative function	predicted immunogenic aa**	No. of	Location of	Seq.
antigenic	(by homology)		selected	identified	ID
protein			clones ver	immunogenic	
			ORF and	region (aa)	Prot.)
			screen	8	
<del></del>		1171,1174-1181,1209-1230,1236-1244,1248-1254,1256-			
		1267,1269-1276,1294-1299,1316-1328,1332-1354,1359-			
V		1372,1374-1380,1384-1390,1395-1408,1419-1425,1434-			
		1446,1453-1460,1465-1471,1474-1493,1505-1515,1523-			
	•	1537,1547-1555,1560-1567,1577-1605,1633-1651			
SP0509	type I restriction-	4-10,31-39,81-88,106-112,122-135,152-158,177-184,191-	I:2	449-467	27, 171
		197,221-227,230-246,249-255,303-311,317-326,337-			
		344,346-362,365-371,430-437,439-446,453-462,474-484			
SP0519	dnaJ protein (dnaJ)	9-15,24-35,47-55,122-128,160-177,188-196,202-208,216-	A:1, D:2,	108-218	28, 172
		200 000 001 000 000 000 000		3 <del>44-</del> 376	,
		361,368-373			
SP0529	BlpC ABC transporter	6-14,17-48,55-63,71-90,99-109,116-124,181-189,212-	A:1, B:3,	177-277	29, 173
	(blpB)	223,232-268,270-294,297-304,319-325,340-348,351-	C:3, D:1,		
		370,372-378,388-394,406-415,421-434	F:4,		
SP0564	hypothetical protein	21-39,42-61,65-75,79-85,108-115	H:3	11-38	30, 174
SP0609	amino acid ABC	4-17,26-39,61-76,103-113,115-122,136-142,158-192,197-	I:3	207-225	31, 175
	transporter, amino	203,208-214,225-230,237-251			
	acid-binding protein				
SP0613	metallo-beta-	5-11,27-36,42-53,62-70,74-93,95-104,114-119,127-	I:12	225-246	32, 176
	lactamase superfamily	150,153-159,173-179,184-193,199-206,222-241,248-			
	protein	253,257-280,289-295,313-319,322-342,349-365,368-			
		389,393-406,408-413,426-438,447-461,463-470,476-			
		495,532-537,543-550			
SP0641	Serine protease	4-29,68-82,123-130,141-147,149-157,178-191,203-	A:19, B:72,	1-348	33, 177
		215,269-277,300-307,327-335,359-370,374-380,382-	C:34, D:5,	373-490	
		1	E:21, F:86,	573-767	
		513,533-540,564-569,601-607,639-647,655-666,693-	G:26,	903-1043	
			H:86, I:17,	1155-1198	
			L:130,	1243-1482	
			M:29	1550-1595	
		1068,1079-1086,1105-1113,1152-1162,1168-1179,1183-		1682-1719	
		1191,1204-1210,1234-1244,1286-1295,1318-1326,1396-		1793-1921	
		1401,1451-1460,1465-1474,1477-1483,1488-1494,1505-		2008-2110	
		1510,1514-1521,1552-1565,1593-1614,1664-1672,1677-	i		
		1685,1701-1711,1734-1745,1758-1770,1784-1798,1840-		į	
		1847,1852-1873,1885-1891,1906-1911,1931-1939,1957-			
		1970,1977-1992,2014-2020,2026-2032,2116-2134			
SP0648	beta-galactosidase	10-35,39-52,107-112,181-188,226-236,238-253,258-	C:1, E:1,	1526-1560	34, 178
	(bgaA)	268,275-284,296-310,326-338,345-368,380-389,391-	F:1, G:1,		

	ae Putative function	predicted immunogenic aa**	No. of	Location of	16
antigenic	(by homology)		selected		
protein-					
		1		immunogeni	c (D
			ORF and	region (aa)	Pr
		408,410-418,420-429,444-456,489-505,573-588,616-	screen	<u> </u>	
		623,637-643,726-739,741-767,785-791,793-803,830-	H:4, I:1,		
			M:2		
		847,867-881,886-922,949-956,961-980,988-1004,1009-			
		1018,1027-1042,1051-1069,1076-1089,1108-1115,1123-	1	1	
- [		1135,1140-1151,1164-1179,1182-1191,1210-1221,1223-	·		
		1234,1242-1250,1255-1267,1281-1292,1301-1307,1315-	-		
	1	1340,1348-1355,1366-1373,1381-1413,1417-1428,1437-		ŀ	
		1444,1453-1463,1478-1484,1490-1496,1498-1503,1520-	.]		
		1536,1538-1546,1548-1570,1593-1603,1612-1625,1635-			1
		1649,1654-1660,1670-1687,1693-1700,1705-1711,1718-		<b>[</b>	
		1726,1729-1763,1790-1813,1871-1881,1893-1900,1907-			
	İ	1935,1962-1970,1992-2000,2006-2013,2033-2039,2045-			
1		2051,2055-2067,2070-2095,2097-2110,2115-2121,2150-			j
		2171,2174-2180,2197-2202,2206-2228			l
SP0664	Zinc metalloprotease		A-0. P.05		_
	ZmpB, putative	156 169-174 217 226 222 242 and and and		1-64	35,
f		328 340-246 252 260 400 400 400	C:13, D:7,	128-495	
	j	531.540-546.570-578.586.500.505.600.505	E:14, F:77,		l
		667,674-681,689-705,712,724,720,740,740	G:12,		
		779 702 704 000 000 044 000	H:10,		
		778,783-796,829-835,861-871,888-899,907-939,941-	K:67, L:13,		
1			M:6		ļ
		1084,1095-1102,1118-1124,1140-1146,1148-1154,1168-			
ĺ		1181,1185-1190,1197-1207,1218-1226,1250-1270,1272-	1		
Į.		1281,1284-1296,1312-1319,1351-1358,1383-1409,1422-	1		
		1428,1438-1447,1449-1461,1482-1489,1504-1510,1518-	ļ		
		1527,1529-1537,1544-1551,1569-1575,1622-1628,1631-	I		
		1637,1682-1689,1711-1718,1733-1740,1772-1783,1818-	ļ		
		1834,1859-1872	}	j	
SP0667	pneumococcal surface	8-28,32-37,62-69,119-125,137-149,159-164,173-189,200-	4:72, B:80, 1	-95	36, 1
1	protein, putative	205 221 220 240 245 250 250 250	C:90, D:20,		JO, 1
		302 323-320	3:12, F:53	l l	
SP0688	UDP-N-	0.18 25.29 40 62 65 50 54 04 04 04		5-107	
	acetylmuramoylalanin	146,149-158,162-188,191-207,217-225,237-252,255-	- Y	2-10/	37, 1
	eD-glutamate ligase	269,281-293,301-326,332-342,347-354,363-370,373-	1		
		380,391-400,415-424,441-447		1	
SP0749		4-24,64-71,81-87,96-116,121-128,130-139,148-155,166-			
1.	acid ABC transporter	173,176-184,203-215,231-238,243-248,256-261,280-	:2, I:8, 67	7-148	38, 18
		L/ U/A/ UT 104./115-/ 15 73 1.2338 3/3 5/6 5/2 6/4 6/4 6.4			
		286,288-306,314-329	:8	1	

6		- 57f -			
S. pneumoniae		predicted immunogenic aa**	No. of	Location of	Seq.
antigenic	(by homology)		selected	identified	ID
protein			clones per	immunogenic	(DNA
·			ORF and	region (aa)	Prot.
			screen		1
	ATP-binding protein	151,168-186,197-205,209-234,241-252,322-335,339-	<del> </del>		<del></del>
		345,363-379,385-393,403-431,434-442,447-454,459-	[		ĺ
		465,479-484,487-496		[	ŀ
SP0785	conserved	10-35,46-66,71-77,84-93,96-122,138-148,154-172,182-	C:1, E:2,	111-198	40, 18
	hypothetical protein	213,221-233,245-263,269-275,295-301,303-309,311-	I:1	170	40, 10
		320,324-336,340-348,351-359,375-381			
SP0914	nodulin-related	14-25,30-42,47-61,67-75,81-91,98-106,114-122,124-	L.2	198-213	41 10
	protein, truncation	135,148-193,209-227		170-213	41, 18
SP0930	choline binding	5-18,45-50,82-90,97-114,116-136,153-161,163-171,212-	R.4 C:2	402.606	
	protein E (cbpE)	219 221 227 240 240 247 247 247 244	H:1, I:2,	493-606	42, 186
		381 300 305 430 436 440 455 404 405	K:5		
		554,556-564,580-586,596-602	K.3	·	
SP0943	Gid protein (gid)	9-25,28-34,37-44,61-68,75-81,88-96,98-111,119-133,138-	50.00		
	,	150,152-163,168-182,186-194,200-205,216-223,236-	E:2, L:24	303-391	43, 187
		245,257-264,279-287,293-304,311-318,325-330,340-			
		346,353-358,365-379,399-409,444-453			
SP0952	alanine				
	dehydrogenase,	16-36,55-61,66-76,78-102,121-130,134-146,150-212,221- 239,255-276,289-322,329-357	G:3, H:4	29-59	44, 188
	authentic frameshift				
1	(ald)				
	conserved	8-27 68-74 77 99 110 116 124 141 186 487 262 267			
		8-27,68-74,77-99,110-116,124-141,171-177,202-217,221-		- 4	45, 189
	(PAT)		1	359-451	
]	-		E:13, F:3,	ł	
			M:2		
SP1004		747,767-778,782-792,804-812,820-836			
			A:5, B:4,	1-162	46, 190
ľ	-	205 040 040 050		206-224	
		484 480 400 100		254-350	
			H:3, I:1,	114-514	
ļ			L:1 8	864-938	
		709,712-719,724-736,738-746,759-769,780-786,796-	1		
		804,813-818,860-877,895-904,981-997,1000-1014,1021-	ĺ		
Dito		1029		]	
[		4-11,19-49,56-66,68-101,109-116,123-145,156-165,177-	M:1 2	66-322	47, 191
G		185,204-221,226-234,242-248,251-256,259-265,282-	1	1	
		302,307-330,340-349,355-374,377-383,392-400,422-	1	1	
		428,434-442,462-474			
P1154	gA1 protease	14-43,45-57,64-74,80-87,106-127,131-142,145-161,173-	A:6, B:2, 1	72-354	18, 192
ŀ		180,182-188,203-210,213-219,221-243,245-254,304-		84-448	,,

\_\_\_\_ **-** 57g -

S. pneumonia	e Putative function	- 57g - predicted immunogenic aa**	No. of	Location of	T	7
antigenic	(by homology)		selected		Seq.	
protein		Management of the second secon		identified	<u>ID</u>	- 12. /
			ORF and	immunogenic	1 '	
				region (aa)	Prot.)	l
		311,314-320,342-348,354-365,372-378,394-399,407-	screen			
	Ì	431,436-448,459-465,470-477,484-490,504-509,531-	E:4, F:2,	464-644		ĺ
		537 500 506 611 617 640 647 700		648-728		
		762,764-774,782-797,807-812,824-831,838-845,877-	I:13, L:12 .	1357-1370 .		
		885,892-898,900-906,924-935,940-946,982-996,1006-				
	ļ	1016,1033-1043,1051-1056,1058-1066,1094-1108,1119-				
		1126,1129-1140,1150-1157,1167-1174,1176-1185,1188-				
						!
		1201,1209-1216,1220-1228,1231-1237,1243-1248,1253-				
		1285,1288-1297,1299-1307,1316-1334,1336-1343,1350-				
	_	1359,1365-1381,1390-1396,1412-1420,1427-1439,1452-				
	,	1459,1477-1484,1493-1512,1554-1559,1570-1578,1603-				
		1608,1623-1630,1654-1659,1672-1680,1689-1696,1705-				
		1711,1721-1738,1752-1757,1773-1780,1817-1829,1844-				
P1174		1851,1856-1863,1883-1895,1950-1958,1974-1990				
		8-27,68-74,77-99,110-116,124-141,169-176,201-216,220-	B:14, C:17,	15-307	49, 193	
	, ,	227,258-264,274-289,292-302,308-324,334-342,344-	D:6, E:18,	350-448	1	
		350,364-372,377-387,399-407,416-429,445-458,471-	F:16, I:1,	496-620		
			K:5, L:1,	Ì		
Diagra			M:8	ļ	1	
1			A:1, B:4,	56-267	50, 194	
			C:3, D:3,	337-426		
			E:9, F:2,	195-601		
			H:2, M:4		- [	
}		592,602-608,615-630,635-647,664-677,692-698,722-			1	
		731,733-751,782-790,793-799	}			
21221	ype II restriction	12-22,49-59,77-89,111-121,136-148,177-186,207-	G:2, H:1,	81-403	51, 195	
e	endonuclease	213 217-225 227-252 250 274 204 205 205 205	K:1, L:4	]	31, 195	
ļ		354,374-383,424-446,448-457,468-480,488-502,507-			İ	
		522,544-550,553-560,564-572,587-596,604-614,619-		i		
		625,629-635,638-656,662-676,680-692,697-713,720-		1	ŀ	
		738,779-786,833-847,861-869,880-895,897-902,911-		[		
		917,946-951,959-967,984-990,992-1004,1021-1040,1057-	l			
	Tr.	1067,1073-1080		j		
1227	NA-binding	1-10,26-31,46-56,60-66,70-79,86-94,96-102,109-118,132-E	11 1.2 0	1-149		
r		52,164-187,193-206,217-224	, 2.3	1-147	2, 196	
1241 a		101 06 07 40 60 71 00 100	2 61	16.450		
tı		47 181-187 203-211 216 222 047 077 077	1	16-453 5	3, 197	
1		25,373-379,395-400,423-435,448-456,479-489,512-	:2, I:1			
				1	I	

C manus min	Destations (c. 12)	- 3/II -			
S. pneumoniae	!	predicted immunogenic aa**	No. of	Location of	Seq.
antigenic	(by homology)		selected	identified	ID
protein			clones per	immunogenic	(DNA
			ORF and	region (aa)	Prot.
			screen		
	signal recognition	10-16,25-31,34-56,58-69,71-89,94-110,133-176,186-	B :8, G :8,	316-407	54, 19
	particle protein (ffh)	193,208-225,240-250,259-266,302-307,335-341,376-	H:3, M:1		
		383,410-416		İ	
SP1330	N-	11-29,42-56,60-75,82-88,95-110,116-126,132-143,145-	L:45	123-164	55, 19
	acetylmannosamine-	160,166-172,184-216		1	00, 15
	6-P epimerase,				İ
	putative (nanE)				ł
SP1374	Chorismate sythetase	11-29,54-63,110-117,139-152,158-166,172-180,186-	G:1, L:29,	252-299	56, 200
	(aroC)	193,215-236,240-251,302-323,330-335,340-347,350-	M:14	22,7	30, 200
		366,374-381			
SP1378	conserved	18-27,35-42,50-56,67-74,112-136,141-153,163-171,176-	H-2	289-320	55.00
	hypothetical protein	189,205-213,225-234,241-247,253-258,269-281,288-		209-320	<b>57, 20</b> 1
		298,306-324,326-334,355-369,380-387			
SP1429		7-15,19-41,56-72,91-112,114-122,139-147,163-183,196-	T.T. A	260.072	
		209,258-280,326-338,357-363,391-403,406-416	11:4	360-378	58, 202
SP1478		11-18,29-41,43-49,95-108,142-194,204-212,216-242,247	77.11	104.440	
		256,264-273	14:11	136-149	59, 203
	family				
SP1518	conserved	18-24,33-40,65-79,89-102,113-119,130-137,155-161,173	1 10 7		
	9	179,183-203,205-219,223-231;245-261,267-274;296-		59-180	60, 204
	_	306,311-321,330-341,344-363,369-381,401-408,415-	G:5, H:1		
	1	427,437-444,453-464,472-478,484-508,517-524,526-			
		532.543-548			
SP1522	conserved domain				
	protein	2 20,02-00,07-7 3,57-110,112-119,134-155		45-177	61, 205
			E:1, H:7,		
SP1527	oligopeptide ABC	6 29 24 42 FB 68 FB 01 444 400 400 400	L:3		
JA 102,				148-269	62, 206
	_	176,184-194,208-216,218-229,239-252,271-278,328-		420- <b>4</b> 50	
		E10 F06 F46 me4 mea and a second	1	610-648	
			H:18, I:10,		
SP1573	4.0		L:2, M:1		
5P1573			A:40, B:27,	1-112	63, 207
		188,200-213,245-250,266-272,306-312,332-339,357-	C:24, D:2,		
		369,383-389,395-402,437-453,455-470,497-503	E:6, G:11,		
			K:1		
SP1604	hypothetical protein	35-59,74-86,111-117,122-137	A:1, C:3,	70-154	64, 208
			E:1, G:1,		
			I:1		
P1661	cell division protein	26-42,54-61,65-75,101-107,123-130,137-144,148-	E :2	157-249	65, 209

---------

ſ,	C manusaria	a Protesting Co. at	- 57i -			
ľ	S. pneumoniae antigenic		Language intitution and and	· No. of	Location of	Seq.
. :=	rea maligina s	(by homology)	r   n www.arananan.com wallan hawanan.com wallanan.com wallanan.com wallanan.com wallanan.com wallanan.com wallanan	selected	identified	ID
	protein	·		clones pe	rimmunogenic	(DNA,
				ORF and	region (aa)	Prot.)
 				screen	·	
		DivIVA	156,164-172,177-192,213-221,231-258			
P	P1664	ylmF protein (ylmF)	29-38,61-67,77-87,94-100,105-111,118-158	B:1, C:42,	1-97	66, 210
				E:3	······································	
S	P1676		7-21,30-48,51-58,60-85,94-123,134-156,160-167,169-	H:2	220-243	67, 211
L		lyase, putative	183,186-191,216-229,237-251,257-267,272-282,287-298			
S	P1687	neuraminidase B	6-29,34-47,56-65,69-76,83-90,123-134,143-151,158-	B:3, E:2,	37-71	68, 212
		(nanB)	178,197-203,217-235,243-263,303-309,320-333,338-	L:1, M:2	238-307	,
			348,367-373,387-393,407-414,416-427,441-457,473-			
			482,487-499,501-509,514-520,530-535,577-583,590-	İ		
L			602,605-612,622-629,641-670,678-690			
SI	P1693	neuraminidase A	7-40,121-132,148-161,196-202,209-215,221-235,248-	C:3, D:5,	406-521	69, 213
	4	(nanA)	255,271-280,288-295,330-339,395-409,414-420,446-	E:3, F:1,		03, 213
			451 475-487 554 542 540 555 500 500 500	G:7, H:1,		
			638 643 648 652 650 670 605 605	I:3, K:20,		
			742.749-754.761-767.775 701 704 004 004 004	L:4		
L			863,884-890,892-900,902-915,934-941			İ
SF	P1732	serine/threonine	9-18,24-46,51-58,67-77,85-108,114-126,129-137,139-	E:2, H:1	577-654	70, 214
l		protein kinase	146,152-165,173-182,188-195,197-204,217-250,260-			70, 214
1			274,296-313,343-366,368-384,427-434,437-446,449-			İ
			455,478-484,492-506,522-527,562-591,599-606,609-	i		1
L			618,625-631,645-652			
SP		methionyl-tRNA	13-20,26-37,41-53,56-65,81-100,102-114,118-127,163-	K:13, M:13	19-78	71, 215
	ŀ	formyltransferase	188,196-202,231-238,245-252,266-285,293-298,301-306			71,213
L		(fmt)				
SP	1759	preprotein	10-23,32-42,54-66,73-91,106-113,118-127,139-152,164-	I:6. L:2.	480-550	72, 216
	t	translocase, SecA	173 198-207 210-245 284 200 242 242 242	M:2		/2, 216
	İs		346,354-361,387-393,404-426,429-439,441-453,467-		ľ	
			473,479-485,496-509,536-544,551-558,560-566,569-			
ŀ			574,578-588,610-615,627-635,649-675,679-690,698-			1
L			716,722-734,743-754,769-780,782-787			}
SP	21772 c	cell wall surface	6-39,42-50,60-68,76-83,114-129,147-162,170-189,197-	3:9, C:1,	74-171	72 217
	а	anchor family protein	205 217 221 220 242 222 222 222	D:1, F:13,	1	73, 217
			277 290 451 450 400 401 400		2951-3061	
			613 625-681 680-720 727 727 727 727 227 227	:1, L:1,	201-0001	
1			881 880-020 057 075 000 5000 4004	л, Бл, И:2		
1					1	
	1		1071,1079-1099,1103-1127,1151-1185,1197-1261 1260		1	. !
			1071,1079-1099,1103-1127,1151-1185,1197-1261,1269- 1309,1317-1333,1341-1349,1357-1465,1469-1513 1517-		•	
			1071,1079-1099,1103-1127,1151-1185,1197-1261,1269- 1309,1317-1333,1341-1349,1357-1465,1469-1513,1517- 1553,1557-1629,1637-1669,1677-1701,1709-1725,1733-			

- 57i -

		<u> </u>			
S. pneumoniae		predicted immunogenic aa**	No. of	Location of	Seq.
antigenic	(by homology)		selected	identified	ID
protein			clones per	immunogenic	(DNA,
•			ORF and	region (aa)	Prot.)
			screen		
i		2053,2061-2109,2117-2125,2133-2183,2195-2219,2227-			<b></b> -
<u>.</u>		2271,2275-2299,2307-2315,2323-2343,2347-2371,2395-		•	
1		2429,2441-2529,2537-2569,2577-2601,2609-2625,2633-			
		2695,2699-2737,2765-2791,2803-2867,2889-2913,2921-			
·		2937,2945-2969,2977-2985,2993-3009,3023-3045,3073-			
		3099,3111-3167,3175-3215,3223-3267,3271-3295,3303-			
		3351,3359-3367,3375-3425,3437-3461,3469-3513,3517-			
		3541,3549-3557,3565-3585,3589-3613,3637-3671,3683-			
		3747,3755-3795,3803-3819,3827-3835,3843-3951,3955-			
		3999,4003-4039,4043-4115,4123-4143,4147-4171,4195-			
		4229,4241-4305,4313-4353,4361-4377,4385-4393,4401-			
		4509,4513-4557,4561-4597,4601-4718,4749-4768			
SP1804	general stress protein	16-22,30-51,70-111,117-130,137-150,171-178,180-	L:4	148-181	74, 218
	24, putative	188,191-196			,
SP1888	oligopeptide ABC	6-19,21-46,50-56,80-86,118-126,167-186,189-205,211-	H:1	34-60	75, 219
	transporter, ATP-	242,244-267,273-286,290-297,307-316,320-341			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	binding protein AmiE				
SP1891	oligopeptide ABC	5-26,33-43,48-54,58-63,78-83,113-120,122-128,143-	A:2, B:3,	149-186	76, 220
	transporter,	152,157-175,185-192,211-225,227-234,244-256,270-	E:1, F:1,	285-431	,
		281,284-290,304-310,330-337,348-355,362-379,384-	G:13, H:8	5 <b>73-</b> 659	
		394,429-445,450-474,483-490,511-520,537-546,548-			
		554,561-586,590-604,613-629			
SP1937	Autolysin (lytA)	5-26,49-59,61-67,83-91,102-111,145-157,185-192,267-	D:3, F:1,	134-220	77, 221
		272,279-286,292-298,306-312	G:1, H:2,	235-251	,
	·		K:11, M:1	254-280	
SP1954	serine protease,	5-19,72-79,83-92,119-124,140-145,160-165,167-182,224-	C:43, E:6,	1-169	78, 222
	subtilase family,	727 740 050 050 050 000	I:4, K:21,		,
	authentic frame	367,384-398,416-429,431-446,454-461	L:50	ļ	
SP1980	cmp-binding-factor 1	8-17,26-31,56-62,75-83,93-103,125-131,135-141,150-	H:9	127-168	79, 223
	(cbf1)	194,205-217,233-258,262-268,281-286			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SP1992	cell wall surface	6-12,69-75,108-115,139-159,176-182,194-214	B:5, C:1,	46-161	80, 224
	anchor family protein		F:4, I:1		00, 224
SP1999	catabolite control	6-13,18-27,39-48,51-59,66-73,79-85,95-101,109-116,118-		12-58	91 225
		124,144-164,166-177,183-193,197-204,215-223,227-			81, 225
		236,242-249,252-259,261-270,289-301,318-325			
SP2021		4-10,26-32,48-60,97-105,117-132,138-163,169-185,192-	T.:3	24-50	90.75
		214,219-231,249-261,264-270,292-308,343-356,385-		-1-00	82, 226
		392,398-404,408-417,435-441			- 1
SP2027		10.40.40.40.	A.1 77.7	1110	
			A:1, E:1,	1-118	83, 227

S. pneumonia	e Putative function	predicted immunogenic aa**	No. of	Torrette de	1 ~
antigenic	(by homology)		selected	Location of	Se
—protein—	Tantul, Lumarene	The state of the first the state of the stat		identified	<u>_n</u>
		İ	clones per ORF and		1
	1	1	İ	region (aa)	Pro
	hypothetical protein		screen		
			G:19,	1	
	1		H:12, I:16,	l .	
SP2039	conserved	5-17 40-58 71-82 102 111 102 140 467	L:5:	· .	
	hypothetical protein	5-17,40-58,71-83,103-111,123-140,167-177,188-204	G:1, L:3	116-128	84,
SP2048	Conserved	4.0.11 50 57 70 310 300			
	hypothetical protein	4-9,11-50,57-70,112-123,127-138	I:1, L:4	64-107	85,
SP2051	<del>- </del>				
3F2U31	Conpetence protein	9-39,51-67	D:1, G:3,	1-101	86,
OPPOSE	CglC		I:8, L:26		
SP2092	UTP-glucose-1-	· ·	H:2	139-155	87,
	phosphate	131,140-148,158-179,187-197,204-225,271-283,285-293			
	uridylyltransferase				
	(galU)				
SP2099	Penicillin binding	42-70,73-90,92-108,112-127,152-164,166-172,181-	A:1, B:9,	626-653	88, 2
	protein 1B	199 201 210 210 220 247 074 227 227	C:11, D:1,		00,
		346 353 358 306 414 410 405 400 400 400	E:6, F:1,		
		E22 E21 E24 E44 E44	H:4, K:1		
		671,697-710,718-731,736-756,765-771,784-801			
SP2108	Maltose ABC	9 20 41 51 50 60 60 74 70 40	G:10, H:1,	2.12	00.
	transporter	120 120 154 156 160 175 100 100 100 100	L:10, M:1	2-13	89, 2
		294,308-318,321-339,362-368,381-386,393-399,407-415	2.10, 141.1		
SP2120	hypothetical protein	4 00 40 (7 00 00 00 00	I:2	10-36	
SP2128	transketolase, N-	DE 22 25 50 ( 71 75 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			90, 2
	terminal subunit	179,190-196,209-215,222-228,235-242,257-263,270-280	Π:Z	209-247	91, 2
SP2136		5 20 21 20 50 50 50 00 00 00 00 00			
	1	206 216 242 240 250 262 262 202 242 243	I		92, 2
		200 270 000 400 404 440 440		219-293	
		454 460 466 471 472 401 404 514 514 514	H:32, I:13,		
		EEC E71 F77 F08 804 F88 4		512-584	
P2141			L:34, M:18		
		4-12,14-34,47-75,83-104,107-115,133-140,148-185,187-	L:3	576-591	93, 2
		196,207-212,224-256,258-265,281-287,289-296,298-			
		308,325-333,345-355,365-371,382-395,424-435,441-			
		457,465-472,483-491,493-505,528-534,536-546,552- 	[		
		558,575-584,589-600,616-623			
			:3	313-329	94, 23
		223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-			-, -A
		377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-	ŀ		
		484, 494-512, 516-523, 538-552, 559-566, 571-577, 579- 596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-			
		759, 761-771	1	1	

C munum nus! =	ol Protesting C 41	- 571 -			
S. pneumonia	1	predicted immunogenic aa**	No. of	Location of	Seq.
antigenic	(by homology)		selected	identified	ID
protein			clones pe	immunogenic	(DNA,
			ORF and	region (aa)	Prot.)
onorton			screen		
SP2190	choline binding	7-38,44-49,79-89,99-108,117-123,125-132,137-146,178	- A:6, B:12,	111-566	95, 239
	protein A (cbpA)	187,207-237,245-255,322-337,365-387,398-408,445-	C:9, D:6,		}
		462,603-608,623-628,644-650,657-671,673-679	E:30, F:8,		
			G:65,		
			H:72, I:76,		
			K:222,		
· · · · · · · · · · · · · · · · · · ·			L:99, M:37		•
SP2194	ATP-dependent Clp	6-20,22-35,39-45,58-64,77-117,137-144,158-163,205-	H:1	686-720	96, 240
	protease, ATP-	210,218-224,229-236,239-251,263-277,299-307,323-			
	binding subunit	334,353-384,388-396,399-438,443-448,458-463,467-			
		478,481-495,503-509,511-526,559-576,595-600,612-			
		645,711-721,723-738,744-758,778-807			
SP2201	choline binding	10-33,35-41,72-84,129-138,158-163,203-226,243-	B:4, C:3,	184-385	97, 241
	protein D (cbpD)	252,258-264,279-302,322-329,381-386,401-406,414-435	D:1, E:7,		'
			F:1, G:1,		<b> </b> 
			H:2, K:26,		
			M:1		
SP2204	ribosomal protein L9	4-9,19-24,41-47,75-85,105-110,113-146	H:3, L:4	45-62	98, 242
SP2216	secreted 45 kd protein	4-25,52-67,117-124,131-146,173-180,182-191,195-	A:130,	1-285	99, 243
	homology to glucan	206,215-221,229-236,245-252,258-279,286-291,293-	B:414,		77,52
	binding protein	302,314-320,327-336,341-353,355-361,383-389	C:450,		
	(GbpB) S.mutant		D:162,	'	
			E:166,		
			F:284,		
			G:90,		(
			H:16, I:4,		
			K:10, L:29,		
			M:11		
SP-NRF1	Choline binding	14-32,38-50,73-84,93-105,109-114	H:1	40-70	100, 244
	protein				
ARF0408	Hypothetical protein	5-26	L:3	22-34	101, 245
ARF0441	Hypothetical protein	23-28			102, 246
ARF0690	Hypothetical protein	8-14			103, 247
ARF0878	Hypothetical protein	4-13,20-29,44-50,59-74			
ARF0921	Hypothetical protein	4 0 40 40 40 40			104, 248
	Hypothetical protein	4.14			105, 249
		22-28,32-42,63-71,81-111,149-156,158-167,172-180,182-			106, 250
ARF1515	Hypothetical protein		G:4, H:5	27-49	107, 251
	protent			1	- 1

S. pneum	noniae Putative function	- 5/m -				
antige		predicted immunogenic aa**	No. of	Location of	Seq.	
prote			selected	identified	_ip	· ·
1	_		clones pe	1	DNA,	
			ORF and	region (aa)	Prot.)	
ARF1519	Hypothetical protein	17.27	screen			
ARF1905			H:3	23-32	108, 252	
ARF2044	71 Freezen		H:2	28-38	109, 253	
ARF2155	<del></del>		G:2, H:5 ··	13-27	110; 254	<b></b>
ARF2199	71 Freedom	- <del></del>	H:3	18-29	111, 255	
CRF0129	71 Protein	<u>_i</u>	M:3	2-11	112, 256	
CRF0200	January Protein	<u>_  </u>	L:4	16-32	113, 257	
		4-10,37-43,54-84,92-127	H:5, L:1	15-62	114, 258	
CRF0236		4-14,20-32,35-60,69-75,79-99,101-109,116-140	L:3	124-136	115, 259	
CRF0394	Hypothetical protein		H:7	2-13	116, 260	
CRF0408	Hypothetical protein		L:11	42-57	117, 261	
CRF0430	Hypothetical protein	1 7	G:4, H:8	14-35	118, 262	
CRF0498	Hypothetical protein	4-12	H:4	1-27	119, 263	
CRF0519	Hypothetical protein		G:5, H:3	35-66	120, 264	
CRF0573	Hypothetical protein	8-20,43-77	I:3, L:9	17-36	121, 265	
CRF0713	Hypothetical protein	4-30,35-45,51-57	L:3	35-49	122, 266	
CRF0722	Hypothetical protein	4-24,49-57	G:18		123, 267	
CRF0764	Hypothetical protein	4-22	L:4		124, 268	
CRF1079	Hypothetical protein	13-25,32-59,66-80			125, 269	
CRF1248	Hypothetical protein	4-10,24-33,35-42,54-65,72-82,98-108	H:1	15-30	126, 270	
CRF1398	Hypothetical protein	8-19	H:1, L:3	15.	127, 271	
CRF1412	Hypothetical protein	12-18,40-46			128, 272	
CRF1467	Hypothetical protein	4-20,35-78,83-102,109-122			129, 273	
CRF1484	Hypothetical protein	7-17,21-41,46-63		2.53	· ·	
		30-37			130, 274	
CRF1587	Hypothetical protein		L:4		131, 275	
CRF1606	Hypothetical protein	4-13,17-25		1-15	122 276	
CRF1623	Hypothetical protein	17-31,44-51			132, 276	
CRF1625	Hypothetical protein	20-30			133, 277	
CRF1640	Hypothetical protein	13-33,48-71			134, 278	
CRF1702	Hypothetical protein	4-9,50-69,76-88,96-106,113-118			135, 279	
CRF1825	Hypothetical protein	4-24			136, 280	
CRF1883	Hypothetical protein	7-26			137, 281	
CRF1991		9-39,46-68,75-82,84-103	H:61, L:77		38, 282	
CRF1992		4-30,33-107			39, 283	
CRF2004	Hypothetical protein	4-12			40, 284	
	7			9-51	41, 285	
	1	12-18,29-37	H:5, L:1,	5-37	42, 286	

S. pneumoniae	Putative function	predicted immunogenic aa**	No. of	Location of	Seq.
antigenic	(by homology)		selected	identified	ID
protein			clones per ORF and	immunogenic	
			screen		
CRF2065	Hypothetical protein	4-21,33-52,64-71	I:1, M:6	16-37	143, 287
CRF2232	Hypothetical protein	9-19	L:3	2-30	144, 288

- 570 - Table 2. Immunogenicity of epitopes in peptide ELISA

Peptides	- P1	·P2	Р3	P4	P5	P6	-P7	P8	- P9	240		<del></del>	ī		<u> </u>	<u></u>		<del>;; ;</del>	·			···· ·	<del></del>	<del>,</del>	 	<del>1217.2.7</del>	<u>25 14 -</u>
ARF0408.1	nd	+-		253	282	+-	"	-	P9	P10	P11	P12	P13	'N1'	'N2	'N3	N4	N5	N6	N7	*N8	.N9.	N10	-s-	from	to	- Seq ID
ARF0441.1	nd	-	124			nd	52Z	nd				17474	2192			XX		<u>.</u>		2				15	20	37	245
ARF0690.1	nd	┢	252	€ <b>8</b>	\$15.6 01.000	nd		nd				13.5		_									,	26	8	27	246
ARF0878.1	526	Link		S P		nd		nd		10.5		5		-W5 To						12.	٠, ٢	3	5.	20	10	27	247
ARF0878.2		55,81	400	1		nd		Ž.				nd	nd	7								7		22	42	59	248
ARF0921.1	1.12	20.3	-	-		nd				RUESA		nd	nd											11	52	69	248
ARF0921.1	100	4.5.5	44.7	_		nd						nd	nd											15	63	80	249
ARF1153.1	nd	┡		***	217	nd		<u> </u>	2770			nd	nd										90	14	74	91	249
ARF1515.1	nd	145 S	-			nd		nd			M									17				19	11	28	250
ARF1519.1	nd					nd	<u> </u>	nd			8									TA .				18	28	49	251
ARF1905.1	nd	<b>2000</b>	25			nd	\$0%7¢	nd				1-27/-22												15	15	32	252
ARF2044.1	nd	66.00	<b>37</b> (2)			nd		nd					Name:			. 4							, 100	21	4	20	253
ARF2155.1	+	┝	-			nd		nd									隧			i i		MY,		18	10	27	254
ARF2199.1	nd	<del> </del>				nd		nd	(MA)	<u>सुरुक्तात</u>		16 W.Sr.												15	17	34	255
CRF0129.1	nd	$\vdash$	1000			nd	器	nd															٧,,,	19	1	18	256
CRF0129.1	nd	-		(1) (1)		nd		nd												J.	脈			15	16	33	257
CRF0200.1	nd nd	<del> </del> —		ER.		nd	<u> </u>	nd		<u> </u>		Щ											翻	12	16	36	258
CRF0200.2	nd	-	-		(COM	nd	<u> </u>	nd		<u> </u>			$oxed{oxed}$											9	30	49	258
CRF0236.1	200	14023	0.24	2523		nd	SC-SC	nd	ATTA	gener.				SULLE									27	10	43	62	258
CRF0394.1	323		發薬		e.	nd		23.2				nd	nd		1 10 1000 20									19	122	139	259
CRF0408.1	nd	-	-			nd		nd					彌		3							710	7	20	1	18	260
CRF0430.1	nd	-		朝的		nd		nd		Ø ()			噩										4.2	19	41	58	261
CRF0498.1	nd	<u> </u>	77/20%	irinz-		nd		nd	SAVER				term to the									No.		15	15	35	262
CRF0573.1	nd					nd		nd															14	21	2	27	263
CRF0713.1	200	100	No.			nd			meenn			nd	nd		P. ADIMA						44,450		3.0	22	18	36	265
CRF0713.1	nd		6582	<b>基</b> 拉		nd		nd															1	20	34	51	266
CRF1079.1	nd	\$11.70		ace se		nd		nd										WAY						16	9	27	268
CRF1398.1	nd		1			nd		nd				ervic		700			!							27	22	47	269
CRF1398.2	nd nd				郡市	nd		nd																24	18	36	271
CRF1412.1	III	_				nd		nd		·														21	29	47	271
CRF1467.1	-	-				nd	5865					nd	nd						70					9	32	52	272
CRF1484.1	nd		$\vdash$	77 FE		nd		nd	24.34	ara B			esau.	IS THE ST										11	72	89	273
CRF1587.1	nd	<b>1999</b>	95%			nd		nd				55,82,								7.7				20	3	20	274
CRF1587.1	nd			136		nd		nd		iesis a	蘊										1	N.		23	3	21	275
CRF1606.1	nd nd					nd	TO COM	nd					580es											21	15	33	275
CRF1625.1	nd					nd		nd		製製														22	1	18	276
CRF1640.1	nd					nd		nd		2170									1					23	6	23	278
CRF1702.1	H	Diver				nd	474	nd Busse											200					18	93	110	279
CRF1825.1	Med	<b>WAR</b>				nd						nd Regard	nd		732	<b>30</b>	1							18	13	34	280
CRF1825.1	nd	-				nd		nd			謎		200			SALE.			1			Ŋ,	7	24	7	26	281
CRF1883.1	nd			4. F. V		nd		nd			no al	्राह्म-१ <u>५</u>	智事											24	9	26	281
CRF1883.1	nd	<u> इ</u>		<u>स्यक्ति ड</u>		nd		nd		製料						_								20	16	33	282
CRF1991.1	nd	独		CON.		nd		nd															7	24	27	44	283
CRF2004.1	nd			X(55H)				nd			nd				. 1.									19	67	84	284
CRF2004.1	nd	X 100				nd		nd														1311		20	10	33	285
CRF2004.2						nd		nd		: Signi									Y	燃			湖	22	26	50	285
CRF2030.1	nd			49		nd	塑	_			200									77			* :	21	7	25	286
CRF2030.2	nd				核	nd		nd	33			Y S						37	1		41	35	73	20	19	37	286
																	-12:51	-11-12-11-11-11-11-11-11-11-11-11-11-11-		- 1	- 27	1 - 41.	انت			٥١_	200

CRF2065.1	nd					nd		nd				题:			贈		THE STATE OF	47			100	14.7	1	21	17	37	28
CRF2232.1	nd					nd	73	nd	187		1 3		缩					10.1		7.17		(7.7	7	23	3	20	28
CRF2232.2	nd	1				nd		nd			7			3,5	VIE				15-113	17.			-	19	13	30	28
P0008.1									77.7		nd	nd	nd			7.24							<del></del>	28	62	80	14
P0008.2											nd	nd	nd		Mil			297.7					::: <u>*</u>	21	75		╄
P0069.1	额	製		UŠ		nd			12.23		377	nd	nd		CHICA						أتما		$\vdash$	17		93	14
P0071.1	nd			17.32		nd		nd		227.117.5			31	30.57	-		1	GE E				Ties.	33	15	92	108	14
P0071.2						nd						nd	nd	智家	-	392	Date:	14.5	-		3.1		<b>39</b> 🖓	<u> </u>	332	349	14
SP0071.3						nd	17,24,5				3500	nd	nd	45.50				35.44	-			AL PARTIE		13	177	200	1.
P0082.1						nd			<b></b>	_		nd	nd	-	<del> </del>		-	-			-			4	1755	1777	1
P0082.2	nd	444	1			nd		nd	2	1	1	134		7.5	reg		-	166	43.4%			43	2 0.0	4	109	133	1
P0082.3	nd			SCHOOL STREET		nd		nd				22.44			217		AA.		17)760 5,14		12.00 A			24	149	174	1
P0082.4						nd				144.4		nd	nd	2015					100 Y			BANE	TATE	26	260	285	1
SP0107.1	nd		35-41				More	nd			nd	-							_	ek e				20	460	485	1.
P0107.2	nd	<u> </u>	<del>                                     </del>			Ţ,	-	nd			nd	-		-		TYV.			70112	-	_		EA.52	10	26	47	1
SP0117.1							<b>200</b>		2521611		nd	nd	nd	- 18 E						PAGE	SH212	ROUE		11	42	64	1
P0117.2	1(12)				新学	祖子经	0.21.6			田建設	nd	nd	nd.	621	接張	7.1			_		部	į:	20003	18	22	41	1
SP0117.3		Gi.		ACCES,				. :			nd	nd	nd	5									6,	57	35	54	1
P0117.4	722			H.A.						<b>1</b>	nd	nd	-	-		NG.	125			NY TE		S-20		64	115	130	1
P0117.5	╁╴	┢╌	566.50	-							nd	<del></del>	nd						1000				e rec	17	306	325	1
SP0117.6		I	-		223	1432	4		# Ve	地區	nd	nd	nd	200						以於				15	401	420	1
P0222.1						nd	20.00		類葉	13.00	110 110	nd	nd	802 SE				151000		WAR				68	454	478	1
P0368.1	23		1	-		nd		_	鱼是			nd	nd	型產	ana can	PRIZE	Kerese				10050			15	22	45	1
P0368.2	(9)					3		191.4°				nd	nd					N.		C 10104				22	156	174	1
SP0368.2b		301		F113-7		nd	数数	200		III.	nd	nd	nd	9250							1	DFF Time		32	924	940	1
SP0368.3	10	-	M.	-		nd			<b>新型</b>	16.207		nd	nd			<u> </u>	ļ							12	1485	1496	1
SP0368.4	13	-	19.5	╫		nd	10/3	-	数膜	100		nd	nd			├	<u> </u>							14	1447	1462	1
SP0369.1		-		-		nd	+	$\vdash$	┝	W		nd	nd			<u> </u>	3533G						रक्षा क	11	1483	1498	1
SP0377.1	協	-	1036	<del> </del>		nd	╀	├—	$\vdash$			nd	nd		_							di.		16	457	475	1
SP0378.1		1	20	1600		nd	200	7 111	-	-		nd	nd			10000			<u> </u>					11	302	325	1
SP0390.1		-	2360			nd	347			_		nd	nd				_				L			17	288	305	1
SP0390.2	nd	C BA	SME			-	A Per		MARK	NA CO		nd	nd		anna	SU PREZ	Mactaus I		STORAGE		-			11	244	266	1
SP0454.1	III			No.		nd	200	nd	Mar.				200				200						· (y	24	260	282	1
SP0454.2		<b>河</b>	HIS CO						10275	j. ·	nd	-	nd					Diversa		th them	i in form			64	204	225	1
SP0454.2 SP0463.1	nd	543	733								<b></b>	nd	nd		ENTER.	: 	Transmiss		IN COLUMN			445		38	220	241	1
SP0463.1	+	547			1.00	∄ :	435.3	nd		F-415-28	nd	HONAC											7.1	20	324	345	1
SP0463.3	nd		_		1355	a)	. 施到	nd			nd				i ne									26	340	361	1
	nd		-	-		(1) (1) (1)	e -	nd			nd		1905											19	356	377	1
SP0463.4	nd	$\vdash$	├	├—	23/20			nd			nd					i ç								.9	372	393	1
SP0463.5	nd	3597	V PA	137376			2430	nd			nd	_					erates.							13	388	408	1
SP0466.1	nd	協	763	200		nd		nd		remova				,							it i		1000	22	39	64	1
SP0468.1	nd		1			nd		nd				<u></u>												21	54	76	1
SP0468.2	nd	9.7				nd		nd								極							N <sub>o</sub>	24	70	92	1
SP0498.1	nd	-	上	<u> </u>			-	nd	1717		nd													13	1227	1247	1
SP0498.2	nd	_	$\vdash$	स्टब्स			<u> </u>	nd			nd	L										-44		8	1539	1559	1
SP0498.3	nd	↓_	_				_	nd			nd	L				:								16	1554	1574	1
SP0498.4	nd	1_	12302					nd			nd										$\vdash$		1.5	13	1569	1589	1
SP0498.5	nd						70	nd			nd					38		-	1			T.	स्मानिक स्थादक	15	1584	1604	1
SP0498.6	nd			_				nd			nd							$\sqcap$		100	27.84	1	7 ·	11	1242	1262	1
SP0498.8	nd				月	繼		nd	J.		nd	77	쀓		E I	25:38		PO	12	172			<u></u>	24	1272	1292	-
SP0498.9	nd							nd			nd	16,00			20			10 N.S.	120			24		9	1272		1
SP0498.10	nd	4						nd			nd		5 V.		(C)4436			_	ENT	iL				63	1456	1308	1

C			7											- 5	<b>7</b> q	-							•			•		
-	P0498.11 P0498.12:	nd			. :	HAVR	g:-::	- AHR	nd	PAIN-	IV IV	nd	3000												59	1472	1494	170
$\vdash$		nd				2	Jeu-	100	nd	1	100	nd		膠	. :	腦		W.	1						20	1488	1510	170
$\vdash$	P0498.13 P0519.1	nd	235	2.566	स्वस्था	2		4	nd	X 77.		nd		驟											10	1505	1526	170
-		nd	3-0)	C (e	3712		nd	<u> </u>	nd												3.77 3.44	歌	116	1.3	25	351	368	172
-	P0529.1	nd	74.0K	AFFECT				1283	nd			nd								T	1.72	25.	3012		6	179	200	17:
-	P0529.2	nd		32		en en			nd			nd							100	将		<u> </u>		nort.	23	195	216	173
-	P0529.3	nd			, c				nd			nd							1	2.11.	<b>(3)</b>		_	814	7	211	232	173
$\vdash$	P0529.4	nd		EL CO	ज्यार स				nd			nd		7											8	227	248	173
-		nd		ŧ.	180		9		nd		-	ñd								10 E.V	· · · · ·			-	18	243	263	173
-	P0564.1				ASST.	} ! !!	r.				· France	nđ	nd	nd				E-48CF-1	: ::	21000					63	13	37	174
-	P0609.1	nd		27 <b>73</b> 25			nd		nd										No.						16	208	224	175
$\vdash$	P0641.1	W.						39				nd	nd	nd						95 E	era hira	HICSEL	18 h		34	42	64	177
$\vdash$	P0641.2											nd	nd	nd					111.5-44						61	59	81	177
-	P0641.3				Z 12 A 24			P8772 8				nd	nd	nd			T							2.15.2	0	304	328	177
-	P0641.4						1					nd	nd	nd							N.	1994		┢	36	323	348	177
-	P0641.5					'n				_		nd	nd	nd			H		10 (212		F.	Augus		-	76	465	489	177
-	P0641.6	<sub>2</sub> ;	Nº 50 SE SI	Arrens		,						nd	nd	nd		$\frac{t_{\rm t} t_{\rm s}}{-}$	, N. M. M. C.		1		I II II II				64	968	992	177
-		, e				2000 TO 1000	1111111			*,	r.	nd	nd	nd							y - 5			到的	52	1399	1418	177
-	P0641.8		÷ ,		THE COURT							nd	nd	nd						識					25	1412	1431	177
-	P0641.9	nd					nd		nd			翼								243416					18	2092	2111	177
-	P0648.1	nd	WZ (la)	Parts.			nd		nd													-			11	1528	1547	178
-	P0648.2	nd					nd		nd			100								46	12.27.24				24	1541	1560	178
-	P0664.1	nd			Pierro		nd		nd								M			-				格公	28	184	200	179
-	P0664.2	nd					nd		nđ			44.				avie	1119		3 <b>0 49 F</b>				E-7666		18	367	388	179
-	P0664.3	nd		The section			nd		nd													123			15	382	403	179
-	P0864.4	nd			eré-les		nd	题	nd					W.7.								-			14	409	429	-
-	P0664.5	nd					nd		nd						攤							X			20	425	444	179
-	P0664.6	nd					nd		nd							2017	-				1.	32.00P		. 20	17	438	457	179
SI	P0667.1	nd							nd			nd			A STAN									104	22	27	50	179
$\vdash$	P0667.2	nd							nd			nd												230	16	45	67	180
SI	P0749.2	nd		, i			nd		nd							CSIXI		H.P.				WA126	1		24	114		180
SI	20770.1	nd			in .		nd		nd								HEAR		(CARTIN			-			17	405	131	182
SI	20785.1	nd							nd			nd	-3.5						劉隆					26.21	11	113	419	183
-		nd							nd			nd				i SMIT			CONTRACT OF			25 (A)			10	129	134	
SI	P0785.3	nd							nd			nd								100					8		150	184
SI	20785.4	nd							nd			nd						22344							11	145	166	184
-		nd							nd			nd								45 E681	WEIS.	四次位			8	161	182	184
SI	0930.1	nd					nd		nd				ZEASSI!												30	177	198	184
-		nd					nd		nd					- CO					e-13/42		200				19	495	515	186
-	21004.1	nd					nd		nd														HARD.		21	346	358	187
SF	21154.1	nd					nd	岩	nd	74111			754PL												_	208	224	190
SF	21154.2	nd		31			nd		nd		110,414									齫				洲夏	33	178	194	192
SF	1154.3	nd					nd		nd						BUCK				WHAT I				_		28	202	223	192
SI	1154.4	nd					nd	-II CAW	nd					**************************************											_	217	238	192
SI	P1154.5	nd					nd		nd						4.45					12/2/2					19	288		192
SF	1175.1	nd					nd	额	nd	32 AS	LOW PUTP	us (s)	mubi.			<b>兴</b> 英兴	判服	ES			超高	安計	響		16	1355	$\overline{}$	192
SF	1241.1	nd	<b>以</b>						nd			nd	48						¥ 20				i		56	57	78	194
SF	1241.2	nd						*****	nd	湖底	(G-3- ES)	nd	30,725	With his	·							<u>स्थ</u>		Tempo	26	347		197
SF	1241.3	nd			स्टब्स	a PRI			nd		<b>-</b>	nď				N. A.		211	是是			3.5	_		18	364		197
SF	1241.4	nd		ككنت			;-;-		nd		12002	nd		<b>***</b>		:		सुङ्का		Mala	taker)		ACHE:		25	381		197
la.	1241.5	nd	_	_			. :		nd	B-7317	-52.041	nd	1	地拉				IWH		of cont				然類	21	398	420	197

07/0// 0	т.				12 '		7797							<b>3</b> /	r	-											
SP1241.6	nd	1474.53	2892	E1202			14.00	nd		Sec. 8	nd		<b>W</b>	1					KQ.					16	432	452	197
SP1287.1	nd	17.7				nd	_	nd						N.				7.510	1	34	4.7	455		20	347	372	198
SP1330.1	nd	_				nd	L	nd						1						V.		74	1	18	147	163	199
SP1374.1	nd	U 513	12.03			nd		nd										_			捌			15	263	288	200
SP1429.1	nd		, in			nd		nd										-						20	361	377	202
SP1518.1	nd		/2000					nd			nd					24.96.1	213.312		3			112.45	E	19	82	104	204
SP1518.2	nd	溪						nd			nd	100			T-H-H-M-C				5455	27		16.3	7	28	99	121	-
SP1518.3	nd							nd			nd								M.			雅	1	21	116	138	204
SP1518.4	nd				3			nd			nd						123.50				133	The C	٠	26	133	155	204
SP1518.5	nđ			业				nd			nd						201				Yes.		33	19	150	171	204
SP1522.1	nd			攤		nd		nd										2399437.	GO:		100	2.0	\$75	12	110	<del> </del> -	204
SP1522.2	nd					nd		nd						厂	7.16							16 m	2 440	13	125	130	205
SP1527.1	nd					nd		nd	25						377	united (	E STA				3.6	233	1.0	22	613	145	205
SP1527.2	nd					nd		nd													<b>3</b> /2	<del> </del>	ř.	20	626	631	206
SP1527.3	nđ					nd		nd					SIGHE	941		HARE		15.25	Rate !			2005		<del>-</del>	<del></del>	644	206
SP1604.1	nd		4					nd			nd					罪				363.	16.183			16	196 78	213	206
SP1604.2	nd							nd			nd						area.			異統	数数	-	731	├		100	208
SP1604.3	nd				E.			nd	11.10/45		nd	E.S.L.	ental.	-	N7197					が続		-		20	95	117	208
SP1604.4	nd		鯔					nd			nd					46-56	D) IS			-			Triet	15 25	112	134	208
SP1661.1	nd							nd			nd			-											129	151	208
SP1661.2	nd							nd	1		nd	- United								-	-	-	6363	18	158	180	209
SP1661.3	nd							nd			nd		337 JH	$\vdash$						-	_		2. 50	13	175	197	209
SP1661.4	nd							nd			nd											-		16	192	214	209
SP1661.5	nd							nd			nd	653,53314	ı	-			<b>CHAP</b>				1.24	-	<b>美宝</b>		209	231	209
SP1664.1	nd							nď			nd				NEUR	ninge.	司福			THE ST	-	248	1729	12	226	248	209
SP1664.2	nđ						a. <b></b>	nd	270445124		nd										-			24	30	50	210
SP1684.3	nd							nd			nd	2447		2.357			₩.Q.#.E			المادة المادة	_			26	45	65	210
SP1693.1	nd	溢				nd		nd					1501=3	40%							18.60	52	142	11	60	79	210
SP1693.2	nd					nd		nd	臟		쨦		_							7.88				20	431	455	213
SP1732.1	nd							nd		S. S. P. 149.14	nd			1916585	100,1970	DIE.				436	1100			18	450	474	213
SP1732.2	nđ							nd	- PA		nd	7393E												25	579	601	214
SP1732.3	nd							nd			nd			_						_		30		15	596	618	214
SP1732.4	nd							nd	******	-	nd	1000			99-6921						_			19	613	635	214
SP1772.1	nd					nd		nd						Retail.								ZNI	<b>339</b>	_	630	653	214
SP1772.1b	nd						-	nd	E		nd		1 53.47				100	13第至					35.	27	920	927	217
SP1772.2	nd							nd			nd			—				20		10			3474	12	98	119	217
SP1772.3	nd							nd	1303-1		nd	45(0)		7			er.	4121	建築	0.5				20	114	135	217
SP1772.4	nd							nd			nd				505030	Sec.	<b>33</b>							11	130	151	217
SP1772.5	nd							nd			nd									100	<b>#</b>			30	146	167	217
SP1888.1	nd					nd		nd				341571	AK 1855A			150		(\$385)	RECH					19	162	182	217
SP1891.1	nd		53			nd		nd	T PASY4	1002				i Z.F.	THE STATE OF					10				16	36	59	219
SP1891.2	nd		7			nd		nd				10 TO		-				200			: Z.E.C.		2.71	14	194	216	220
SP1937.1	nd					nd	36	nd		302				231					-		395		-	12	381	404	220
SP1937.2	nd	1010		-MC-13		nd	N K S G	nd			的影響						e en				压(2) 化行:	<b>1</b>		20	236	251	221
SP1954.1	nd					nd	_	nd					_	HOLES E	17/23							i Diga		26	255	279	221
SP1954.2	nd				쀖	nd		nd				SHIPPE F		魏坚			214.F	W.X.						15	80	100	222
SP1980.1	nd					nd		nd									雅					11 (1) 17 (1)		14	141	164	222
SP1992.1	nd						<b>國籍</b>	nd	灩	<b>લ્સક</b> ો	nd nd				5733		建設	SALT.	2514	##			翼	18	128	154	223
SP1992.2	nd							nd			nd	a track	STATE OF							गुजाङ		6.2		20.	82	100	224
SP1992.3	nd	****	27.2	M				nd			nd				的祖		gest							23	95	116	224
SP2027.1	nd		Н		讖	nd	44##J	nd	:DEST					्रम् जुलार				KILT.					19.3	20	111	134	224
			لــــا	<u></u>	200	لت				in''S [1]	U.S.		لـــا		$\sqcup$		松山							12	55	76	227

		_			-							_	5	7s	_											•		
SP2027.2	nd	T				nd		nd	100				1	1	4		6.23	1	Τ-	-A-F	147.	गरः व		- 1			,	
SP2027.3	nd	Ī	13		170	nd	48	nd	数		拔		-				ded.		-		墾	1		<u>: 1</u>	16	71	92	22
SP2048:1-		쨣	1 2		- 13	nd	-	=				1443	nd				٠ -				533			2	1.1	··-87 =-	·· 110	22
SP2051.1						nd		69	NO.		體	nd	nd		1874	DALT.	Tiest.	1147						2	1	91	106	22
SP2092.1	nd					nd		nd							1				-	P.	LA.	趣	13	2	5	74	96	230
SP2108.1	nd			7.5		nd	120	nd	櫏				9242		1		20 A	X-1	$\vdash$	4	7	\$		2	2	140	157	23
SP2136.1	nd			1	11100	nd	1	nd	11472	1112	323	23.0	-					├		E. T.		_		1	3	4	13	233
SP2136.2	nd					nd	12	nd				35E	1833 E	Ç.	136			E137			22.55		1	1:	5	41	65	236
SP2190:1 -	- nd			-	W.	nd	-	nd	1,554				200	in it.	£309		Sie			20.00	V .			3	-	499	523	236
SP2190.2	nd					nd		nd				441			GI 2		開度	ने के किया है। जिल्ला			उक्रप्ट	E- Y-1-		1	-+	122	146	239
SP2190.3	nd					nd	721.01	nd			VE 15	<b>300</b>				器膜	12.0						0	2	4	191	215	239
SP2190.4	nd				10716-0	nd	一	nd			egi.				200		1	EIAM	P###					2	6	288	313	239
SP2190.5	nd	1				nd	+-	nd				<b>新春秋</b>				TO SEC.	1513U			Vani		EVENEN	8	3	В	445	469	239
SP2201.1	nd			Mary 1	ZARAZI	nd	福記	nd	瓣		- -		unis	12.5				Lists		:	<u>.</u>			ž 2	4	511	535	239
SP2204.1	nd	YOU T				nd	153.53	nd		117		1133				ner.			- 8	LIL TO	ere kir	lencas		3	4	347	368	241
SP2216.1						nd	Žiti.		800 E			nd	nd	33			38	31955			***		12	10	5	46	61	242
SP2216.2	12371					nd		1735				nd	nd						0.95					10	3	15	37	243
SP2216.3		ZMZ		20120		nd						_	nd		網網							9E-1	遂	(f 2)	3	32	57	243
SP2216.4						nd		ЕЙ				-	nd										jî.	§ 14	1	101	121	243
SP2216.5	NT SATE					nd							nd							2 .		20såe	F76.11	31		115	135	243
SP2216.6		er-called)	2-1-1-7	102101		nd			1931A2															22	-1-	138	158	243
SP2216.7						nd				北流	27.7		nd	TRAFF.	(Care	23:5020			99 10 10		Bar as	<b>1</b>	76.75.7	12	-	152	172	243
SP2216.8		13.144				<del> </del>								125	F 21		i.	e iza	1		7.5	Arces.		46	1	220	242	243
	E-97:47				3-		KIV S	4.4	ي			nd	nd					7	2	5,		4	٠.	- 12	:	236	258	243

٠,٠

ORF	Common name	Gene distribution	Amino acid	Homology ()	Seq.
		(present of 50)	substitutions (in		ID (DNA
			serotype 14 strain)*		Prot.)
SP0008	hypothetical protein	n.d.	n.d.		1, 145
SP0032	DNA polymerase I (polA)	n.d.	n.d.	<del></del>	2, 146
SP0069	Choline binding protein I	7	0/166#		3, 147
SP0071	immunoglobulin A1 protease (iga-1)	7	0/477#	<del></del>	4, 148
SP0082	Cell wall surface anchor	50	5/385		5, 149
SP0107	LysM domain protein	50	1/173		6, 150
SP0117	pneumococcal surface protein A	n.d.	n.d.		7, 151
	(pspA)				
SP0191	hypothetical protein	n.d.	n.d.		8, 152
SP0197	dihydrofolate synthetase, putative	n.d.	n.d.		9, 153
SP0212	Ribosomal protein L2	50	0/232		10, 154
SP0222	Ribosomal protein S14	n.d.	n.d.		11, 155
SP0239	Conserved hypothetical protein	n.d.	n.d.		12, 156
SP0251	formate acetyltransferase, putative	n.d.	. n.d.		13, 157
SP0295	ribosomal protein S9 (rpsI)	50	1/121		14, 158
SP0330	sugar binding transcriptional	n.d.	n.d.		15, 159
	regulator RegR				
SP0368	cell wall surface anchor family	46	4/422#		16, 160
	protein				
SP0369	Penicillin binding protein 1A	50	1/346	- , , , , , , , , , , , , , , , , , , ,	17, 161
SP0374	hypothetical protein	n.d.	n.d.		18, 162
SP0377	Choline binding protein C	29	0/114	· · · · · · · · · · · · · · · · · · ·	19, 163
SP0378	choline binding protein J (cbpJ)	50	2/104	· · · · · · · · · · · · · · · · · · ·	20, 164
SP0390	choline binding protein G (cbpG)	50	3/171#	·	21, 165
SP0454	hypothetical protein	48	1/303#		22, 166
SP0463	cell wall surface anchor family	10	0/298#		23, 167
	protein				
SP0466	sortase, putative	44	4/243#		24, 168
SP0468	Sortase, putative	18	0/254#	· · · · · · · · · · · · · · · · · · ·	25, 169
SP0498	endo-beta-N-acetylglucosaminidase,	50	4/334	*** ·	26, 170
	putative				
SP0509	type I restriction-modification	n.d.	n.d.		27, 171
	system, M subunit				
SP0519	dnaJ protein (dnaJ)	50	2/312		28, 172
SP0529	BlpC ABC transporter (blpB)	50	6/306		29, 173
SP0564	hypothetical protein	50	1/127		30, 174
SP0609	amino acid ABC transporter, amino	50	0/232		31, 175

. •

OTT	lo-	<u> - 5/u</u>			
ORF	Common name	Gene distribution	Amino acid	Homology ()	Seq.
	A Contract of the contract of	(present of 50)	substitutions (in		ID (DNA,
	acid-binding pro		serotype 14 strain)*		Prot.)
SP0613		<del></del>			
DI 0015	metallo-beta-lactamase superfamily protein	n.d.	n.d.		32, 176
SP0641	Serine protease	n.d.	n.d.		33, 177
SP0648	beta-galactosidase (bgaA)		-0/304		
SP0664	Zinc metalloprotease ZmpB, putative	n.d.	n.d.		34, 178 35, 179
SP0667	pneumococcal surface protein,	45	18/297		
	putative		10/297		36, 180
SP0688	UDP-N-acetylmuramoylalanineD-	n.d.	n.d.		37, 181
	glutamate ligase				0,,101
SP0749	branched-chain amino acid ABC	50	4/303	<del></del>	38, 182
j	transporter				33, 332
SP0770	ABC transporter, ATP-binding	50	0/307		39, 183
	protein				,
SP0785	conserved hypothetical protein	50	0/304		40, 184
SP0914	nodulin-related protein, truncation	n.đ.	n.d.		41, 185
SP0930	choline binding protein E (cbpE)	47	17/294		42, 186
SP0943	Gid protein (gid)	n.d.	n,d,		43, 187
SP0952	alanine dehydrogenase, authentic	n.d.	n.d.		44, 188
	frameshift (ald)				
SP1003	conserved hypothetical protein (PAT)	n.d.	n.d.		45, 189
SP1004	Conserved hypothetical protein	n.d.	n.d.		46, 190
SP1124	glycogen synthase (glgA)	n.d.	n.d.	······································	47, 191
SP1154	IgA1 protease	28	13/470; 80 missing		48, 192
SP1174	conserved domain protein (PAT)	n.d.	n.d.		49, 193
SP1175	conserved domain protein	n.d.	n.d.		50, 194
SP1221	type II restriction endonuclease	n.d.	n.d.		51, 195
SP1227	DNA-binding response regulator	n.d.	n.d.		52, 196
SP1241	amino acid ABC transporter, amino	50	0/285		53, 197
	acid-binding protein				
SP1287	signal recognition particle protein	49	0/300		54, 198
	(ffh)				
SP1330	N-acetylmannosamine-6-P	14	0/211#		55, 199
	epimerase, putative (nanE)				
SP1374	Chorismate sythetase (aroC)	50	0/289		56, 200
SP1378	conserved hypothetical protein	n.d.	n.d.		57, 201
SP1429	peptidase, U32 family	50	8/305		58, 202
SP1478	oxidoreductase, aldo/keto reductase	n.d.	n.d.		59, 203
	family				
SP1518	conserved hypothetical protein	50	4/313; 3 additional		60, 204

ORF	Common name	Gene distribution	Amino acid	Homology ()	Seq.
		(present of 50)	substitutions (in	<b>37</b>	ID (DNA
			serotype 14 strain)*		Prot.)
SP1522	conserved domain protein	n.d.	n.d.		61, 205
SP1527	oligopeptide ABC transporter	50	0/463		62, 206
SP1573	lysozyme (lytC)	n.d.	n.d.		63, 207
SP1604	hypothetical protein	50	3/138		64, 208
SP1661	cell division protein DivIVA	50	3/236		65, 209
SP1664	ylmF protein (ylmF)	50	0/164		66, 210
SP1676	N-acetylneuraminate lyase, putative	n.d.	n.d.		67, 211
SP1687	neuraminidase B (nanB)	n.d.	n.d.		68, 212
SP1693	neuraminidase A (nanA)	n.d.	n.d.		69, 213
SP1732	serine/threonine protein kinase	49	2/293		70, 214
SP1735	methionyl-tRNA formyltransferase	n.d.	n.d.		71, 215
	(fmt)				
SP1759	preprotein translocase, SecA subunit	n.d.	n.d.		72, 216
	(secA-2)				
SP1772	cell wall surface anchor family	23	12/253#		73, 217
	protein		,		
SP1804	general stress protein 24, putative	n.d.	n.d.		74, 218
SP1888	oligopeptide ABC transporter, ATP-	n.d.	n.d.		75, 219
	binding protein AmiE		<u> </u>	·	
SP1891	oligopeptide ABC transporter,	n.d.	n.d.		76, 220
SP1937	Autolysin (lytA)	50	0/275		77, 221
SP1954	serine protease, subtilase family,	12	0/305#		78, 222
	authentic frame				
SP1980	cmp-binding-factor 1 (cbf1)	n.d.	n.d.		79, 223
SP1992	cell wall surface anchor family	50	4/197		80, 224
SP1999	protein				
<u> </u>	catabolite control protein A (ccpA)	n.d.	n.d.		81, 225
SP2021	glycosyl hydrolase	n.d.	n.d.		82, 226
SP2027	Conserved hypothetical protein	n.d.	n.d.		83, 227
SP2039	conserved hypothetical protein	n.d.	n.d.		84, 228
SP2048	Conserved hypothetical protein	50	8/134		85, 229
SP2051	Conpetence protein CglC	50	8/92		86, 230
SP2092	UTP-glucose-1-phosphate	n.d.	n.d.	İ '	87, 231
enage	uridylyltransferase (galU)				
SP2099	Penecillin binding protein 1B	n.d.	n.d.		88, 232
SP2108	Maltose ABC transporter	50	1/279		89, 233
SP2120	hypothetical protein	n.d.	n.d.		90, 234
SP2128	transketolase, N-terminal subunit	n.d.	n.d.		91, 235
SP2136	choline binding protein PcpA	45	1/382	,	92, 236

ORF	Common name	Gene distribution	Amino acid	Homology ()	Seq.	İ
		(present of 50)	substitutions (in	• • • • •	ID (DNA,	
			serotype 14 strain)*		Prot.)	
SP2141	glycosyl hydrolase-related protein	n.d,	n.d.		93, 237	
SP2180	conserved hypothetical protein	n.d.	n.d.	~	94, 238	
SP2190	choline binding protein A (cbpA)	47	for: 48,8%; rev: 2 /17#		95, 239	
SP2194	ATP-dependent Clp protease, ATP-	50	1/262		96, 240	
	binding subunit	ىيى بىرى مەسەر بەسەرىد دە			٠٠.٠ حمد ١٠٠٠	• •
SP2201	choline binding protein D (cbpD)	50	7/384		97, 241	
SP2204	ribosomal protein L9	n.d.	n.d.		98, 242	
SP2216	secreted 45 kd protein - homology to	50	0/347		99, 243	
	glucan binding protein (GbpB)					
CD NOTE	S.mutant					
SP-NRF1	Choline binding protein	n.d.	n.d.		100, 244	
ARF0408	II					
	Hypothetical protein	n.d.	n.d.		101, 245	
ARF0441 ARF0690	Hypothetical protein	n.d.	n.d.		102, 246	
ARF0878	Hypothetical protein	n.d.	n.d.		103, 247	
ARF0921	Hypothetical protein	n.d.	n.d.		104, 248	
ARF1153	Hypothetical protein  Hypothetical protein	n.d.	n.d.		105, 249	
ARF1515	Hypothetical protein	n.d.	n.d.		106, 250	
ARF1519	Hypothetical protein	n.d.	n.d.		107, 251	
ARF1905	Hypothetical protein	n.d.	n.d.		108, 252	
ARF2044	Hypothetical protein	n.d.	n.d.		109, 253	
ARF2155	Hypothetical protein	n.d.	n.d.		110, 254	·
ARF2199	Hypothetical protein	n.d.	n.d.	·	111, 255	
CRF0129	Hypothetical protein	n.d.	n.d.		112, 256	
CRF0200	Hypothetical protein	n.d.	n.d.		113, 257	
CRF0236	Hypothetical protein	n.d.	n.d.		114, 258	
CRF0394	Hypothetical protein	n.d.	n.d.		115, 259	
CRF0408	Hypothetical protein	n.d.	n.d.		116, 260	
CRF0430	Hypothetical protein	n.d.	n.d.		117, 261 118, 262	
CRF0498	Hypothetical protein	n.d.	n.d.		119, 263	
CRF0519	Hypothetical protein	n.d.	n.d.		120, 264	
CRF0573	Hypothetical protein	n.d.	n.d.		121, 265	
CRF0713	Hypothetical protein	n.d.	n.d.		122, 266	
CRF0722	Hypothetical protein	n.d.	n.d.		123, 267	
CRF0764	Hypothetical protein	n.d.	n.d.		123, 267	ļ
CRF1079	Hypothetical protein	n.d.	n.d.		125, 269	
CRF1248	Hypothetical protein	n.d.	n.d.		126, 270	
CRF1398	Hypothetical protein	n.d.	n.d.		127, 271	
L	1	l		L	127, 2/1	]

ORF	Common name	Gene distribution	Amino acid	Homology ()	Seq.
		(present of 50)	substitutions (in		ID (DNA,
_			serotype 14 strain)*		Prot.)
CRF1412	Hypothetical protein	n.d.	n.d.		128, 272
CRF1467.1	Hypothetical protein	n.d.	n.d.		129, 273
CRF1484	Hypothetical protein	n.d.	n.d.		130, 274
CRF1587	Hypothetical protein	n.d.	n.d.		131, 275
CRF1606	Hypothetical protein	n.d.	n.d.		132, 276
CRF1623	Hypothetical protein	n.d.	n.d.		133, 277
CRF1625	Hypothetical protein .	n.d.	n.d.		134, 278
CRF1640	Hypothetical protein	n.d.	n.d.		135, 279
CRF1702	Hypothetical protein	n.d.	n.d.		136, 280
CRF1825	Hypothetical protein	n.d.	n.d.		137, 281
CRF1883	Hypothetical protein	n.d.	n.d.	<del></del>	138, 282
CRF1991	Hypothetical protein	n.d.	n.d.		139, 283
CRF1992	Hypothetical protein	n.d.	n.d.		140, 284
CRF2004	Hypothetical protein	n.d.	n.d.	*	141, 285
CRF2030	Hypothetical protein	n.d.	n.d.		142, 286
CRF2065	Hypothetical protein	n.d.	n.d.		143, 287
CRF2232	Hypothetical protein	n.d.	n.d.		144, 288
					1

ORF	Common Name		
ARF0878	hypothetical protein	FACS	PK
ARF0921	hypothetical protein	+	nd
CRF0236	hypothetical protein	+	nd
CRF0573	hypothetical protein	++	-
CRF1412	hypothetical protein	+	nd
CRF1702	hypothetical protein	+	nd
CRF1992	hypothetical protein	+	nd
SP0008	hypothetical protein	++	++
SP0069		+	•
SP0082	Choline binding protein I	++	++
SP0117	Cell wall surface anchor	+	•
SP0212	pneumococcal surface protein A (pspA)	+++	+++
SP0212	Ribosomal protein L2	+	++
SP0368	ribosomal protein S9 (rpsl)	++	+++
SP0369	cell wall surface anchor family protein	++	+++
	Penecillin binding protein 1A	++	++
SP0377	Choline binding protein C	++	++
SP0378	choline binding protein J (cbpJ)	++	nd
SP0390	choline binding protein G (cbpG)	++	+
SP0454	hypothetical protein	++	+++
SP0463	cell wall surface anchor family protein	+	++
SP0466	sortase, putative	++	++
SP0468	Sortase, putative	++	++
SP0519	dnaJ protein (dnaJ)	++	+
SP0609	amino acid ABC transporter, amino acid-bind	++	+
SP0641	Serine protease	+	<del></del>
SP0664	Zinc metalloprotease ZmpB	+	++
SP0749	branched-chain amino acid ABC transporter	+	+
SP0770	ABC transporter, ATP-binding protein	++	++
SP1154	IgA1 protease	++	++
SP1287	signal recognition particle protein (ffh)	+	++
SP1330	N-acetylmannoseamine-6-P	++	
SP1429	peptidase, U32 family	+	++
SP1527	oligopeptide ABC transporter	+	++
	preprotein translocase, SecA subunit (wrong clone!!!)	+	
P1772	cell wall surface anchor family protein	+	<u> </u>
P1891	oligopeptide ABC transporter	+	+
P1937	Autolysin (lytA)	+	++
	serine protease, subtilase family, auth frame	+	-
P1980	cmp-binding-factor 1 (cbf1)		++
	Maltose ABC transporter	+	
	choline binding protein PcpA	+	++
	choline binding protein A (cbpA)	+	++
	ATP-dependent Clp protease, ATP-bind subu	+	++
	choline binding protein D (cbpD)	++	++
	wive and the property of the contract of the c	+	++

### Claims:

- 1. An isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence, which is selected from the group consisting of:
  - a) a nucleic acid molecule having at least 70% sequence identity to a nucleic acid molecule selected from Seq ID No 1, 101-144.
  - b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
  - c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
  - d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b), or c)
  - e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid molecule defined in a), b), c) or d).
- 2. The isolated nucleic acid molecule according to claim 1, wherein the sequence identity is at least 80%, preferably at least 95%, especially 100%.
- 3. An isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence selected from the group consisting of
  - a) a nucleic acid molecule having at least 96% sequence identity to a nucleic acid molecule selected from Seq ID No 2-6, 8, 10-16, 18-23, 25-31, 34, 36, 38-42, 44, 47-48, 51, 53, 55-62, 64, 67, 71-76, 78-79, 81-94, 96-100.
  - b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
  - c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
  - d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b) or c),
  - e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).
- 4. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of
  - a) a nucleic acid molecule selected from Seq ID No 9, 17, 24, 32, 37, 43, 52, 54, 65-66, 70, 80,
  - b) a nucleic acid molecule which is complementary to the nucleic acid of a),
  - c) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).
- 5. The nucleic acid molecule according to any one of the claims 1, 2, 3 or 4, wherein the nucleic acid is DNA.
- 6. The nucleic acid molecule according to any one of the claims 1,2, 3, 4, or 5 wherein the nucleic acid is RNA.
- 7. An isolated nucleic acid molecule according to any one of claims 1 to 5, wherein the nucleic acid molecule is isolated from a genomic DNA, especially from a S. pneumoniae genomic DNA.
- 8. A vector comprising a nucleic acid molecule according to any one of claims 1 to 7.
- A vector according to claim 8, wherein the vector is adapted for recombinant expression of the
  hyperimmune serum reactive antigens or fragment thereof encoded by the nucleic acid molecule
  according to any one of claims 1 to 7.

or representations of the property of the contraction of the contracti

- 10.—A-host-cell-comprising-the-vector-according-to-claim-8-or-9.—
- 11. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 1, 2, 5, 6 or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 145, 245-288.
- 12. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 3, 5, 6, or 7 and fragments thereof, wherein the amino acid suequece is selected from the group consisting of Seq ID No 146-150, 152, 154-160, 162-167, 169-175, 178, 180, 182-186, 188, 191-192, 195, 197, 199-206, 208, 211, 215-220, 222-223, 225-238, 240-244.
- 13. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 4, 5, 6, or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 153, 161, 168, 176, 181, 187, 196, 198, 209-210, 214, 224.
- Fragments of hyperimmune serum-reactive antigens selected from the group consisting of peptides 14. comprising amino acid sequences of column "predicted immunogenic aa" and "location of identified immunogenic region" of Table 2; the serum reactive epitopes of Table 2, especially peptides comprising amino acid 4-11, 35-64, 66-76, 101-108, 111-119 and 57-114 of Seq ID No 145; 5-27, 32-64, 92-102, 107-113, 119-125, 133-139, 148-162, 177-187, 195-201, 207-214, 241-251, 254-269, 285-300, 302-309, 317-324, 332-357, 365-404, 411-425, 443-463, 470-477, 479-487, 506-512, 515-520, 532-547, 556-596, 603-610, 616-622, 624-629, 636-642, 646-665, 667-674, 687-692, 708-720, 734-739, 752-757, 798-820, 824-851, 856-865 and 732-763 of Seq ID No 146; 14-21, 36-44, 49-66, 102-127, 162-167, 177-196, 45-109 and 145-172 of Seq ID No 147; 17-35, 64-75, 81-92, 100-119, 125-172, 174-183, 214-222, 230-236, 273-282, 287-303, 310-315, 331-340, 392-398, 412-420, 480-505, 515-523, 525-546, 553-575, 592-598, 603-609, 617-625, 631-639, 644-651, 658-670, 681-687, 691-704, 709-716, 731-736, 739-744, 750-763, 774-780, 784-791, 799-805, 809-822, 859-870, 880-885, 907-916, 924-941, 943-949, 973-986, 1010-1016, 1026-1036, 1045-1054, 1057-1062, 1082-1088, 1095-1102, 1109-1120, 1127-1134, 1140-1146, 1152-1159, 1169-1179, 1187-1196, 1243-1251, 1262-1273, 1279-1292, 1306-1312, 1332-1343, 1348-1364, 1379-1390, 1412-1420, 1427-1436, 1458-1468, 1483-1503, 1524-1549, 1574-1588, 1614-1619, 1672-1685, 1697-1707, 1711-1720, 1738-1753, 1781-1787, 1796-1801, 1826-1843, 132-478, 508-592 and 1753-1810 of Seq ID No 148; 15-43, 49-55, 71-77, 104-110, 123-130, 162-171, 180-192, 199-205, 219-227, 246-254, 264-270, 279-287, 293-308, 312-322, 330-342, 349-356, 369-377, 384-394, 401-406, 416-422, 432-439, 450-460, 464-474, 482-494, 501-508, 521-529, 536-546, 553-558, 568-574, 584-591, 602-612, 616-626, 634-646, 653-660, 673-681, 688-698, 705-710, 720-726, 736-749, 833-848, 1-199, 200-337, 418-494 and 549-647 of Seq ID No 149; 9-30, 65-96, 99-123, 170-178 and 1-128 of Seq ID No 150; 7-32, 34-41, 96-106, 127-136, 154-163, 188-199, 207-238, 272-279, 306-312, 318-325, 341-347, 353-360, 387-393, 399-406, 434-440, 452-503, 575-580, 589-601, 615-620, 635-640, 654-660, 674-680, 696-701, 710-731, 1-548 and 660-691 of Seq ID No 151; 4-19, 35-44, 48-59, 77-87, 93-99, 106-111, 130-138, 146-161 and 78-84 of Seq ID No 152; 24-30, 36-43, 64-86, 93-99, 106-130, 132-145, 148-165, 171-177, 189-220, 230-249, 251-263, 293-300, 302-312, 323-329, 338-356, 369-379, 390-412 and 179-193 of Seq ID No 153; 30-39, 61-67, 74-81, 90-120, 123-145, 154-167, 169-179, 182-197, 200-206, 238-244, 267-272 and 230-265 of Seq ID No 154; 14-20, 49-65, 77-86 and 2-68 of Seq ID No 155; 4-9, 26-35, 42-48, 53-61, 63-85, 90-101, 105-111, 113-121, 129-137, 140-150, 179-188, 199-226, 228-237, 248-255, 259-285, 299-308, 314-331, 337-343, 353-364, 410-421, 436-442 and 110-144 of Seq ID No 156; 36-47, 55-63, 94-108, 129-134, 144-158, 173-187, 196-206, 209-238, 251-266, 270-285, 290-295, 300-306, 333-344, 346-354, 366-397, 404-410, 422-435, 439-453, 466-473, 515-523, 529-543, 554-569, 571-585, 590-596, 607-618, 627-643, 690-696, 704-714, 720-728, 741-749, 752-767, 780-799, 225-247 and 480-507 of Seq ID No 157; 16-25, 36-70, 80-

93, 100-106 and 78-130 of Seq ID No 158; 18-27, 41-46, 50-57, 65-71, 79-85, 93-98, 113-128, 144-155, 166-178, 181-188, 201-207, 242-262, 265-273, 281-295, 303-309, 318-327 and 36-64 of Seq ID No 159; 7-29, 31-44, 50-59, 91-96, 146-153, 194-201, 207-212, 232-238, 264-278, 284-290, 296-302, 326-353, 360-370, 378-384, 400-405, 409-418, 420-435, 442-460, 499-506, 529-534, 556-562, 564-576, 644-651, 677-684, 687-698, 736-743, 759-766, 778-784, 808-814, 852-858, 874-896, 920-925, 929-935, 957-965, 1003-1012, 1021-1027, 1030-1044, 1081-1087, 1101-1111, 1116-1124, 1148-1159, 1188-1196, 1235-1251, 1288-1303, 1313-1319, 1328-1335, 1367-1373, 1431-1437, 1451-1458, 1479-1503, 1514-1521, 1530-1540, 1545-1552, 1561-1568, 1598-1605, 1617-1647, 1658-1665, 1670-1676, 1679-1689, 1698-1704, 1707-1713, 1732-1738, 1744-1764, 1-70, 154-189, 922-941, 1445-1462 and 1483-1496 of Seq ID No 160; 6-51, 81-91, 104-113, 126-137, 150-159, 164-174, 197-209, 215-224, 229-235, 256-269, 276-282, 307-313, 317-348, 351-357, 376-397, 418-437, 454-464, 485-490, 498-509, 547-555, 574-586, 602-619 and 452-530 of Seq ID No 161; 25-31, 39-47, 49-56, 99-114, 121-127, 159-186, 228-240, 253-269, 271-279, 303-315, 365-382, 395-405, 414-425, 438-453 and 289-384 of Seq ID No 162; 9-24, 41-47, 49-54, 68-78, 108-114, 117-122, 132-140, 164-169, 179-186, 193-199, 206-213, 244-251, 267-274, 289-294, 309-314, 327-333, 209-249 and 286-336 of Seq ID No 163; 9-28, 53-67, 69-82, 87-93, 109-117, 172-177, 201-207, 220-227, 242-247, 262-268, 305-318, 320-325 and 286-306 of Seq ID No 164; 4-10, 26-39, 47-58, 63-73, 86-96, 98-108, 115-123, 137-143, 148-155, 160-176, 184-189, 194-204, 235-240, 254-259, 272-278 and 199-283 of Seq ID No 165; 4-26, 33-39, 47-53, 59-65, 76-83, 91-97, 104-112, 118-137, 155-160, 167-174, 198-207, 242-268, 273-279, 292-315, 320-332, 345-354, 358-367, 377-394, 403-410, 424-439, 445-451, 453-497, 511-518, 535-570, 573-589, 592-601, 604-610 and 202-242 of Seq ID No 166; 8-30, 36-45, 64-71, 76-82, 97-103, 105-112, 134-151, 161-183, 211-234, 253-268, 270-276, 278-284, 297-305, 309-315, 357-362, 366-372, 375-384, 401-407, 409-416, 441-455, 463-470, 475-480, 490-497, 501-513, 524-537, 552-559, 565-576, 581-590, 592-600, 619-625, 636-644, 646-656 and 316-419 of Seq ID No 167; 4-17, 52-58, 84-99, 102-110, 114-120, 124-135, 143-158, 160-173, 177-196, 201-216, 223-250, 259-267, 269-275 and 1-67 of Seq ID No 168; 6-46, 57-67, 69-80, 82-133, 137-143, 147-168, 182-187, 203-209, 214-229, 233-242, 246-280 and 53-93 of Seq ID No 169; 7-40, 50-56, 81-89, 117-123, 202-209, 213-218, 223-229, 248-261, 264-276, 281-288, 303-308, 313-324, 326-332, 340-346, 353-372, 434-443, 465-474, 514-523, 556-564, 605-616, 620-626, 631-636, 667-683, 685-699, 710-719, 726-732, 751-756, 760-771, 779-788, 815-828, 855-867, 869-879, 897-902, 917-924, 926-931, 936-942, 981-1000, 1006-1015, 1017-1028, 1030-1039, 1046-1054, 1060-1066, 1083-1092, 1099-1112, 1122-1130, 1132-1140, 1148-1158, 1161-1171, 1174-1181, 1209-1230, 1236-1244, 1248-1254, 1256-1267, 1269-1276, 1294-1299, 1316-1328, 1332-1354, 1359-1372, 1374-1380, 1384-1390, 1395-1408, 1419-1425, 1434-1446, 1453-1460, 1465-1471, 1474-1493, 1505-1515, 1523-1537, 1547-1555, 1560-1567, 1577-1605, 1633-1651, 1226-1309, 1455-1536 and 1538-1605 of Seq ID No 170; 4-10, 31-39, 81-88, 106-112, 122-135, 152-158, 177-184, 191-197, 221-227, 230-246, 249-255, 303-311, 317-326, 337-344, 346-362, 365-371, 430-437, 439-446, 453-462, 474-484 and 449-467 of Seq ID No 171; 9-15, 24-35, 47-55, 122-128, 160-177, 188-196, 202-208, 216-228, 250-261, 272-303, 318-324, 327-339, 346-352, 355-361, 368-373, 108-218 and 344-376 of Seq ID No 172; 6-14, 17-48, 55-63, 71-90, 99-109, 116-124, 181-189, 212-223, 232-268, 270-294, 297-304, 319-325, 340-348, 351-370, 372-378, 388-394, 406-415, 421-434 and 177-277 of Seq ID No 173; 21-39, 42-61, 65-75, 79-85, 108-115 and 11-38 of Seq ID No 174; 4-17, 26-39, 61-76, 103-113, 115-122, 136-142, 158-192, 197-203, 208-214, 225-230, 237-251 and 207-225 of Seq ID No 175; 5-11, 27-36, 42-53, 62-70, 74-93, 95-104, 114-119, 127-150, 153-159, 173-179, 184-193, 199-206, 222-241, 248-253, 257-280, 289-295, 313-319, 322-342, 349-365, 368-389, 393-406, 408-413, 426-438, 447-461, 463-470, 476-495, 532-537, 543-550 and 225-246 of Seq ID No 176; 4-29, 68-82, 123-130, 141-147, 149-157, 178-191, 203-215, 269-277, 300-307, 327-335, 359-370, 374-380, 382-388, 393-400, 410-417, 434-442, 483-492, 497-503, 505-513, 533-540, 564-569, 601-607, 639-647, 655-666, 693-706, 712-718, 726-736, 752-758, 763-771, 774-780, 786-799, 806-812, 820-828, 852-863, 884-892, 901-909, 925-932, 943-948, 990-996, 1030-1036, 1051-1059, 1062-1068, 1079-1086, 1105-1113, 1152-1162, 1168-1179, 1183-1191, 1204-1210, 1234-1244, 1286-1295, 1318-1326, 1396-1401, 1451-1460, 1465-1474, 1477-1483, 1488-1494, 1505-1510, 1514-1521, 1552-1565, 1593-1614, 1664-1672, 1677-1685, 1701-1711, 1734-1745, 1758-1770, 1784-1798, 1840-1847, 1852-1873, 1885-1891, 1906-1911, 1931-1939, 1957-1970, 1977-1992, 2014-2020, 2026-2032, 2116-2134, 1-348, 373-490, 573-767, 903-1043, 1155-1198, 1243-1482, 1550-1595, 1682-1719, 1793-1921 and 2008-2110 of Seq ID No 177; 10-35, 39-52, 107-112, 181-188, 226-236, 238-253,

258-268, 275-284, 296-310, 326-338, 345-368, 380-389, 391-408, 410-418, 420-429, 444-456, 489-505, 573-588,\_616-623,\_637.643,\_726-739,\_741-767,\_785-791,\_793-803,\_830-847,\_867-881,\_886-922,\_949-956, 961-980, 988-1004, 1009-1018, 1027-1042, 1051-1069, 1076-1089, 1108-1115, 1123-1135, 1140-1151, 1164-1179, 1182-1191, 1210-1221, 1223-1234, 1242-1250, 1255-1267, 1281-1292, 1301-1307, 1315-1340, 1348-1355, 1366-1373, 1381-1413, 1417-1428, 1437-1444, 1453-1463, 1478-1484, 1490-1496, 1498-1503, 1520-1536, 1538-1546, 1548-1570, 1593-1603, 1612-1625, 1635-1649, 1654-1660, 1670-1687, 1693-1700, 1705-1711, 1718-1726, 1729-1763, 1790-1813, 1871-1881, 1893-1900, 1907-1935, 1962-1970, 1992-2000, 2006-2013, 2033-2039, 2045-2051, 2055-2067, 2070-2095, 2097-2110, 2115-2121, 2150-2171, 2174-2180, 2197-2202, 2206-2228 and 1526-1560 of Seq ID No 178; 4-17, 35-48, 54-76, 78-107, 109-115, 118-127, 134-140, 145-156, 169-174, 217-226, 232-240, 256-262, 267-273, 316-328, 340-346, 353-360, 402-409, 416-439, 448-456, 506-531, 540-546, 570-578, 586-593, 595-600, 623-632, 662-667, 674-681, 689-705, 713-724, 730-740, 757-763, 773-778, 783-796, 829-835, 861-871, 888-899, 907-939, 941-955, 957-969, 986-1000, 1022-1028, 1036-1044, 1068-1084, 1095-1102, 1118-1124, 1140-1146, 1148-1154, 1168-1181, 1185-1190, 1197-1207, 1218-1226, 1250-1270, 1272-1281, 1284-1296, 1312-1319, 1351-1358, 1383-1409, 1422-1428, 1438-1447, 1449-1461, 1482-1489, 1504-1510, 1518-1527, 1529-1537, 1544-1551, 1569-1575, 1622-1628, 1631-1637, 1682-1689, 1711-1718, 1733-1740, 1772-1783, 1818-1834, 1859-1872, 1-64 and 128-495 of Seq ID No 179; 8-28, 32-37, 62-69, 119-125, 137-149, 159-164, 173-189, 200-205, 221-229, 240-245, 258-265, 268-276, 287-293, 296-302, 323-329 and 1-95 of Seq ID No 180; 9-18, 25-38, 49-63, 65-72, 74-81, 94-117, 131-137, 139-146, 149-158, 162-188, 191-207, 217-225, 237-252, 255-269, 281-293, 301-326, 332-342, 347-354, 363-370, 373-380, 391-400, 415-424, 441-447 and 75-107 of Seq ID No 181; 4-24, 64-71, 81-87, 96-116, 121-128, 130-139, 148-155, 166-173, 176-184, 203-215, 231-238, 243-248, 256-261, 280-286, 288-306, 314-329 and 67-148 of Seq ID No 182; 4-10, 19-37, 46-52, 62-81, 83-89, 115-120, 134-139, 141-151, 168-186, 197-205, 209-234, 241-252, 322-335, 339-345, 363-379, 385-393, 403-431, 434-442, 447-454, 459-465, 479-484, 487-496 and 404-420 of Seq ID No 183; 10-35, 46-66, 71-77, 84-93, 96-122, 138-148, 154-172, 182-213, 221-233, 245-263, 269-275, 295-301, 303-309, 311-320, 324-336, 340-348, 351-359, 375-381 and 111-198 of Seq ID No 184; 14-25, 30-42, 47-61, 67-75, 81-91, 98-106, 114-122, 124-135, 148-193, 209-227 and 198-213 of Seq ID No 185; 5-18, 45-50, 82-90, 97-114, 116-136, 153-161, 163-171, 212-219, 221-227, 240-249, 267-281, 311-317, 328-337, 375-381, 390-395, 430-436, 449-455, 484-495, 538-543, 548-554, 556-564, 580-586, 596-602 and 493-606 of Seq ID No 186; 9-25, 28-34, 37-44, 61-68, 75-81, 88-96, 98-111, 119-133, 138-150, 152-163, 168-182, 186-194, 200-205, 216-223, 236-245, 257-264, 279-287, 293-304, 311-318, 325-330, 340-346, 353-358, 365-379, 399-409, 444-453 and 303-391 of Seq ID No 187; 16-36, 55-61, 66-76, 78-102, 121-130, 134-146, 150-212, 221-239, 255-276, 289-322, 329-357 and 29-59 of Seq ID No 188; 8-27, 68-74, 77-99, 110-116, 124-141, 171-177, 202-217, 221-228, 259-265, 275-290, 293-303, 309-325, 335-343, 345-351, 365-379, 384-394, 406-414, 423-437, 452-465, 478-507, 525-534, 554-560, 611-624, 628-651, 669-682, 742-747, 767-778, 782-792, 804-812, 820-836, 79-231 and 359-451 of Seq ID No 189; 5-28, 39-45, 56-62, 67-74, 77-99, 110-117, 124-141, 168-176, 200-230, 237-244, 268-279, 287-299, 304-326, 329-335, 348-362, 370-376, 379-384, 390-406, 420-429, 466-471, 479-489, 495-504, 529-541, 545-553, 561-577, 598-604, 622-630, 637-658, 672-680, 682-688, 690-696, 698-709, 712-719, 724-736, 738-746, 759-769, 780-786, 796-804, 813-818, 860-877, 895-904, 981-997, 1000-1014, 1021-1029, 1-162, 206-224, 254-350, 414-514 and 864-938 of Seq ID No 190; 4-11, 19-49, 56-66, 68-101, 109-116, 123-145, 156-165, 177-185, 204-221, 226-234, 242-248, 251-256, 259-265, 282-302, 307-330, 340-349, 355-374, 377-383, 392-400, 422-428, 434-442, 462-474 and 266-322 of Seq ID No 191; 14-43, 45-57, 64-74, 80-87, 106-127, 131-142, 145-161, 173-180, 182-188, 203-210, 213-219, 221-243, 245-254, 304-311, 314-320, 342-348, 354-365, 372-378, 394-399, 407-431, 436-448, 459-465, 470-477, 484-490, 504-509, 531-537, 590-596, 611-617, 642-647, 723-734, 740-751, 754-762, 764-774, 782-797, 807-812, 824-831, 838-845, 877-885, 892-898, 900-906, 924-935, 940-946, 982-996, 1006-1016, 1033-1043, 1051-1056, 1058-1066, 1094-1108, 1119-1126, 1129-1140, 1150-1157, 1167-1174, 1176-1185, 1188-1201, 1209-1216, 1220-1228, 1231-1237, 1243-1248, 1253-1285, 1288-1297, 1299-1307, 1316-1334, 1336-1343, 1350-1359, 1365-1381, 1390-1396, 1412-1420, 1427-1439, 1452-1459, 1477-1484, 1493-1512, 1554-1559, 1570-1578, 1603-1608, 1623-1630, 1654-1659, 1672-1680, 1689-1696, 1705-1711, 1721-1738, 1752-1757, 1773-1780, 1817-1829, 1844-1851, 1856-1863, 1883-1895, 1950-1958, 1974-1990, 172-354, 384-448, 464-644, 648-728 and 1357-1370 of Seq ID No 192; 8-27, 68-74, 77-99, 110-116, 124-141, 169-

176, 201-216, 220-227, 258-264, 274-289, 292-302, 308-324, 334-342, 344-350, 364-372, 377-387, 399-407, 416-429, 445-458, 471-481, 483-500, 518-527, 547-553, 604-617, 621-644, 662-675, 767-778, 809-816, 15-307, 350-448 and 496-620 of Seq ID No 193; 4-17, 24-29, 53-59, 62-84, 109-126, 159-164, 189-204, 208-219, 244-249, 274-290, 292-302, 308-324, 334-342, 344-350, 378-389, 391-397, 401-409, 424-432, 447-460, 470-479, 490-504, 521-529, 538-544, 549-555, 570-577, 583-592, 602-608, 615-630, 635-647, 664-677, 692-698, 722-731, 733-751, 782-790, 793-799, 56-267, 337-426 and 495-601 of Seq ID No 194; 12-22, 49-59, 77-89, 111-121, 136-148, 177-186, 207-213, 217-225, 227-253, 259-274, 296-302, 328-333, 343-354, 374-383, 424-446, 448-457, 468-480, 488-502, 507-522, 544-550, 553-560, 564-572, 587-596, 604-614, 619-625, 629-635, 638-656, 662-676, 680-692, 697-713, 720-738, 779-786, 833-847, 861-869, 880-895, 897-902, 911-917, 946-951, 959-967, 984-990, 992-1004, 1021-1040, 1057-1067, 1073-1080 and 381-403 of Seq ID No 195; 4-10, 26-31, 46-56, 60-66, 70-79, 86-94, 96-102, 109-118, 132-152, 164-187, 193-206, 217-224 and 81-149 of Seq ID No 196; 4-21, 26-37, 48-60, 71-82, 109-117, 120-128, 130-136, 142-147, 181-187, 203-211, 216-223, 247-255, 257-284, 316-325, 373-379, 395-400, 423-435, 448-456, 479-489, 512-576, 596-625, 641-678, 680-688, 692-715 and 346-453 of Seq ID No 197; 10-16, 25-31, 34-56, 58-69, 71-89, 94-110, 133-176, 186-193, 208-225, 240-250, 259-266, 302-307, 335-341, 376-383, 410-416 and 316-407 of Seq ID No 198; 11-29, 42-56, 60-75, 82-88, 95-110, 116-126, 132-143, 145-160, 166-172, 184-216 and 123-164 of Seq ID No 199; 11-29, 54-63, 110-117, 139-152, 158-166, 172-180, 186-193, 215-236, 240-251, 302-323, 330-335, 340-347, 350-366, 374-381 and 252-299 of Seq ID No 200; 18-27, 35-42, 50-56, 67-74, 112-136, 141-153, 163-171, 176-189, 205-213, 225-234, 241-247, 253-258, 269-281, 288-298, 306-324, 326-334, 355-369, 380-387 and 289-320 of Seq ID No 201; 7-15, 19-41, 56-72, 91-112, 114-122, 139-147, 163-183, 196-209, 258-280, 326-338, 357-363, 391-403, 406-416 and 360-378 of Seq ID No 202; 11-18, 29-41, 43-49, 95-108, 142-194, 204-212, 216-242, 247-256, 264-273 and 136-149 of Seq ID No 203; 18-24, 33-40, 65-79, 89-102, 113-119, 130-137, 155-161, 173-179, 183-203, 205-219, 223-231, 245-261, 267-274, 296-306, 311-321, 330-341, 344-363, 369-381, 401-408, 415-427, 437-444, 453-464, 472-478, 484-508, 517-524, 526-532, 543-548 and 59-180 of Seq ID No 204; 5-13, 52-65, 67-73, 97-110, 112-119, 134-155 and 45-177 of Seq ID No 205; 6-28, 34-43, 57-67, 75-81, 111-128, 132-147, 155-163, 165-176, 184-194, 208-216, 218-229, 239-252, 271-278, 328-334, 363-376, 381-388, 426-473, 481-488, 492-498, 507-513, 536-546, 564-582, 590-601, 607-623, 148-269, 420-450 and 610-648 of Seq ID No 206; 4-12, 20-38, 69-75, 83-88, 123-128, 145-152, 154-161, 183-188, 200-213, 245-250, 266-272, 306-312, 332-339, 357-369, 383-389, 395-402, 437-453, 455-470, 497-503 and 1-112 of Seq ID No 207; 35-59, 74-86, 111-117, 122-137 and 70-154 of Seq ID No 208; 26-42, 54-61, 65-75, 101-107, 123-130, 137-144, 148-156, 164-172, 177-192, 213-221, 231-258 and 157-249 of Seq ID No 209; 29-38, 61-67, 77-87, 94-100, 105-111, 118-158 and 1-97 of Seq ID No 210; 7-21, 30-48, 51-58, 60-85, 94-123, 134-156, 160-167, 169-183, 186-191, 216-229, 237-251, 257-267, 272-282, 287-298 and 220-243 of Seq ID No 211; 6-29, 34-47, 56-65, 69-76, 83-90, 123-134, 143-151, 158-178, 197-203, 217-235, 243-263, 303-309, 320-333, 338-348, 367-373, 387-393, 407-414, 416-427, 441-457, 473-482, 487-499, 501-509, 514-520, 530-535, 577-583, 590-602, 605-612, 622-629, 641-670, 678-690, 37-71 and 238-307 of Seq ID No 212; 7-40, 121-132, 148-161, 196-202, 209-215, 221-235, 248-255, 271-280, 288-295, 330-339, 395-409, 414-420, 446-451, 475-487, 556-563, 568-575, 580-586, 588-595, 633-638, 643-648, 652-659, 672-685, 695-700, 710-716, 737-742, 749-754, 761-767, 775-781, 796-806, 823-835, 850-863, 884-890, 892-900, 902-915, 934-941 and 406-521 of Seq ID No 213; 9-18, 24-46, 51-58, 67-77, 85-108, 114-126, 129-137, 139-146, 152-165, 173-182, 188-195, 197-204, 217-250, 260-274, 296-313, 343-366, 368-384, 427-434, 437-446, 449-455, 478-484, 492-506, 522-527, 562-591, 599-606, 609-618, 625-631, 645-652 and 577-654 of Seq ID No 214; 13-20, 26-37, 41-53, 56-65, 81-100, 102-114, 118-127, 163-188, 196-202, 231-238, 245-252, 266-285, 293-298, 301-306 and 19-78 of Seq ID No 215; 10-23, 32-42, 54-66, 73-91, 106-113, 118-127, 139-152, 164-173, 198-207, 210-245, 284-300, 313-318, 330-337, 339-346, 354-361, 387-393, 404-426, 429-439, 441-453, 467-473, 479-485, 496-509, 536-544, 551-558, 560-566, 569-574, 578-588, 610-615, 627-635, 649-675, 679-690, 698-716, 722-734, 743-754, 769-780, 782-787 and 480-550 of Seq ID No 216; 6-39, 42-50, 60-68, 76-83, 114-129, 147-162, 170-189, 197-205, 217-231, 239-248, 299-305, 338-344, 352-357, 371-377, 380-451, 459-483, 491-499, 507-523, 537-559, 587-613, 625-681, 689-729, 737-781, 785-809, 817-865, 873-881, 889-939, 951-975, 983-1027, 1031-1055, 1063-1071, 1079-1099, 1103-1127, 1151-1185, 1197-1261, 1269-1309, 1317-1333, 1341-1349, 1357-1465, 1469-1513, 1517-1553, 1557-1629, 1637-1669, 1677-1701, 1709-1725,

1733-1795, 1823-1849, 1861-1925, 1933-1973, 1981-2025, 2029-2053, 2061-2109, 2117-2125, 2133-2183, 2195-2219, 2227-2271, 2275-2299, 2307-2315, 2323-2343, 2347-2371, 2395-2429, 2441-2529, 2537-2569, 2577-2601, 2609-2625, 2633-2695, 2699-2737, 2765-2791, 2803-2867, 2889-2913, 2921-2937, 2945-2969, 2977-2985, 2993-3009, 3023-3045, 3073-3099, 3111-3167, 3175-3215, 3223-3267, 3271-3295, 3303-3351, 3359-3367, 3375-3425, 3437-3461, 3469-3513, 3517-3541, 3549-3557, 3565-3585, 3589-3613, 3637-3671, 3683-3747, 3755-3795, 3803-3819, 3827-3835, 3843-3951, 3955-3999, 4003-4039, 4043-4115, 4123-4143, 4147-4171, 4195-4229, 4241-4305, 4313-4353, 4361-4377, 4385-4393, 4401-4509, 4513-4557, 4561-4597, 4601-4718, 4749-4768, 74-171, 452-559 and 2951-3061 of Seq ID No 217; 16-22, 30-51, 70-111, 117-130, 137-150, 171-178, 180-188, 191-196 and 148-181 of Seq ID No 218, 6-19, 21-46, 50-56, 80-86, 118-126, 167-186, 189-205, 211-242, 244-267, 273-286, 290-297, 307-316, 320-341 and 34-60 of Seq ID No 219; 5-26, 33-43, 48-54, 58-63, 78-83, 113-120, 122-128, 143-152, 157-175, 185-192, 211-225, 227-234, 244-256, 270-281, 284-290, 304-310, 330-337, 348-355, 362-379, 384-394, 429-445, 450-474, 483-490, 511-520, 537-546, 548-554, 561-586, 590-604, 613-629, 149-186, 285-431 and 573-659 of Seq ID No 220; 5-26, 49-59, 61-67, 83-91, 102-111, 145-157, 185-192, 267-272, 279-286, 292-298, 306-312, 134-220, 235-251 and 254-280 of Seq ID No 221; 5-19, 72-79, 83-92, 119-124, 140-145, 160-165, 167-182, 224-232, 240-252, 259-270, 301-310, 313-322, 332-343, 347-367, 384-398, 416-429, 431-446, 454-461 and 1-169 of Seq ID No 222; 8-17, 26-31, 56-62, 75-83, 93-103, 125-131, 135-141, 150-194, 205-217, 233-258, 262-268, 281-286 and 127-168 of Seq ID No 223; 6-12, 69-75, 108-115, 139-159, 176-182, 194-214 and 46-161 of Seq ID No 224; 6-13, 18-27, 39-48, 51-59, 66-73, 79-85, 95-101, 109-116, 118-124, 144-164, 166-177, 183-193, 197-204, 215-223, 227-236, 242-249, 252-259, 261-270, 289-301, 318-325 and 12-58 of Seq ID No 225; 4-10, 26-32, 48-60, 97-105, 117-132, 138-163, 169-185, 192-214, 219-231, 249-261, 264-270, 292-308, 343-356, 385-392, 398-404, 408-417, 435-441 and 24-50 of Seq ID No 226; 10-40, 42-48, 51-61, 119-126 and 1-118 of Seq ID No 227; 5-17, 40-58, 71-83, 103-111, 123-140, 167-177, 188-204 and 116-128 of Seq ID No 228; 4-9, 11-50, 57-70, 112-123, 127-138 and 64-107 of Seq ID No 229; 9-39, 51-67 and 1-101 of Seq ID No 230; 5-14, 17-25, 28-46, 52-59, 85-93, 99-104, 111-120, 122-131, 140-148, 158-179, 187-197, 204-225, 271-283, 285-293 and 139-155 of Seq ID No 231; 42-70, 73-90, 92-108, 112-127, 152-164, 166-172, 181-199, 201-210, 219-228, 247-274, 295-302, 322-334, 336-346, 353-358, 396-414, 419-425, 432-438, 462-471, 518-523, 531-536, 561-567, 576-589, 594-612, 620-631, 665-671, 697-710, 718-731, 736-756, 765-771, 784-801 and 626-653 of Seq ID No 232; 8-28, 41-51, 53-62, 68-74, 79-85, 94-100, 102-108, 114-120, 130-154, 156-162, 175-180, 198-204, 206-213, 281-294, 308-318, 321-339, 362-368, 381-386, 393-399, 407-415 and 2-13 of Seq ID No 233; 4-39, 48-65, 93-98, 106-112, 116-129 and 10-36 of Seq ID No 234; 25-32, 35-50, 66-71, 75-86, 90-96, 123-136, 141-151, 160-179, 190-196, 209-215, 222-228, 235-242, 257-263, 270-280 and 209-247 of Seq ID No 235; 5-29, 31-38, 50-57, 62-75, 83-110, 115-132, 168-195, 197-206, 216-242, 249-258, 262-269, 333-340, 342-350, 363-368, 376-392, 400-406, 410-421, 423-430, 436-442, 448-454, 460-466, 471-476, 491-496, 511-516, 531-536, 551-556, 571-576, 585-591, 599-605, 27-70, 219-293, 441-504 and 512-584 of Seq ID No 236; 4-12, 14-34, 47-75, 83-104, 107-115, 133-140, 148-185, 187-196, 207-212, 224-256, 258-265, 281-287, 289-296, 298-308, 325-333, 345-355, 365-371, 382-395, 424-435, 441-457, 465-472, 483-491, 493-505, 528-534, 536-546, 552-558, 575-584, 589-600, 616-623 and 576-591 of Seq ID No 237; 4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771 and 313-329 of Seq ID No 238; 7-38, 44-49, 79-89, 99-108, 117-123, 125-132, 137-146, 178-187, 207-237, 245-255, 322-337, 365-387, 398-408, 445-462, 603-608, 623-628, 644-650, 657-671, 673-679 and 111-566 of Seq ID No 239; 6-20, 22-35, 39-45, 58-64, 77-117, 137-144, 158-163, 205-210, 218-224, 229-236, 239-251, 263-277, 299-307, 323-334, 353-384, 388-396, 399-438, 443-448, 458-463, 467-478, 481-495, 503-509, 511-526, 559-576, 595-600, 612-645, 711-721, 723-738, 744-758, 778-807 and 686-720 of Seq ID No 240; 10-33, 35-41, 72-84, 129-138, 158-163, 203-226, 243-252, 258-264, 279-302, 322-329, 381-386, 401-406, 414-435 and 184-385 of Seq ID No 241; 4-9, 19-24, 41-47, 75-85, 105-110, 113-146 and 45-62 of Seq ID No 242; 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-279, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389 and 1-285 of Seq ID No 243; 14-32, 38-50, 73-84, 93-105, 109-114 and 40-70 of Seq ID No 244; 5-26 and 22-34 of Seq ID No 245; 23-28 and 13-39 of Seq ID No 246; 8-14 and 21-34 of

Seq ID No 247; 4-13, 20-29, 44-50, 59-74 and 41-69 of Seq ID No 248; 4-9, 19-42, 48-59, 71-83 and 57-91 of Seq ID No 249; 4-14 and 10-28 of Seq ID No 250; 22-28, 32-42, 63-71, 81-111, 149-156, 158-167, 172-180, 182-203, 219-229 and 27-49 of Seq ID No 251; 17-27 and 23-32 of Seq ID No 252; 18-24 and 28-38 of Seq ID No 253; 9-15 and 13-27 of Seq ID No 254; 13-22 and 18-29 of Seq ID No 255; 17-26 and 2-11 of Seq ID No 256; 4-33 and 16-32 of Seq ID No 257; 4-10, 37-43, 54-84, 92-127 and 15-62 of Seq ID No 258; 4-14, 20-32, 35-60, 69-75, 79-99, 101-109, 116-140 and 124-136 of Seq ID No 259; 2-13 of Seq ID No 260; 4-13, 28-42 and 42-57 of Seq ID No 261; 4-14, 27-44 and 14-35 of Seq ID No 262; 4-12 and 1-27 of Seq ID No 263; 4-18, 39-45, 47-74 and 35-66 of Seq ID No 264; 8-20, 43-77 and 17-36 of Seq ID No 265; 4-30, 35-45, 51-57 and 35-49 of Seq ID No 266; 4-24, 49-57 and 15-34 of Seq ID No 267; 4-22 and 8-27 of Seq ID No 268; 13-25, 32-59, 66-80 and 21-55 of Seq ID No 269; 4-10, 24-33, 35-42, 54-65, 72-82, 98-108 and 15-30 of Seq ID No 270; 8-19 and 17-47 of Seq ID No 271; 12-18, 40-46 and 31-52 of Seq ID No 272; 4-20, 35-78, 83-102, 109-122 and 74-86 of Seq ID No 273; 7-17, 21-41, 46-63 and 2-20 of Seq ID No 274; 30-37 and 2-33 of Seq ID No 275; 4-13, 17-25 and 1-15 of Seq ID No 276; 17-31, 44-51 and 20-51 of Seq ID No 277; 20-30 and 5-23 of Seq ID No 278; 13-33, 48-71 and 92-110 of Seq ID No 279; 4-9, 50-69, 76-88, 96-106, 113-118 and 12-34 of Seq ID No 280; 4-24 and 6-26 of Seq ID No 281; 7-26 and 14-30 of Seq ID No 282; 9-39, 46-68, 75-82, 84-103 and 26-44 of Seq ID No 283; 4-30, 33-107 and 58-84 of Seq ID No 284; 4-12 and 9-51 of Seq ID No 285; 12-18, 29-37 and 6-37 of Seq ID No 286; 4-21, 33-52, 64-71 and 16-37 of Seq ID No 287; 9-19 and 2-30 of Seq ID No 288; 20-37 of Seq ID No 245; 8-27 of Seq ID No 246; 10-27 of Seq ID No 247; 42-59 and 52-69 of Seq ID No 248; 63-80 and 74-91 of Seq ID No 249; 11-28 of Seq ID No 250; 28-49 of Seq ID No 251; 15-32 of Seq ID No 252; 4-20 of Seq ID No 253; 10-27 of Seq ID No 254; 17-34 of Seq ID No 255; 1-18 of Seq ID No 256; 16-33 of Seq ID No 257; 16-36, 30-49 and 43-62 of Seq ID No 258; 122-139 of Seq ID No 259; 1-18 of Seq ID No 260; 41-58 of Seq ID No 261; 15-35 of Seq ID No 262; 2-27 of Seq ID No 263; 18-36 of Seq ID No 265; 34-51 of Seq ID No 266; 9-27 of Seq ID No 268; 22-47 of Seq ID No 269; 18-36 and 29-47 of Seq ID No 271; 32-52 of Seq ID No 272; 72-89 of Seq ID No 273; 3-20 of Seq ID No 274; 3-21 and 15-33 of Seq ID No 275; 1-18 of Seq ID No 276; 6-23 of Seq ID No 278; 93-110 of Seq ID No 279; 13-34 of Seq ID No 280; 7-26 and 9-26 of Seq ID No 281; 16-33 of Seq ID No 282; 27-44 of Seq ID No 283; 67-84 of Seq ID No 284; 10-33 and 26-50 of Seq ID No 285; 7-25 and 19-37 of Seq ID No 286; 17-37 of Seq ID No 287; 3-20 and 13-30 of Seq ID No 288; 62-80 and 75-93 of Seq ID No 145; 92-108 of Seq ID No 147; 332-349, 177-200 and 1755-1777 of Seq ID No 148; 109-133, 149-174, 260-285 and 460-485 of Seq ID No 149; 26-47 and 42-64 of Seq ID No 150; 22-41, 35-54, 115-130, 306-325, 401-420 and 454-478 of Seq ID No 151; 22-45 of Seq ID No 155; 156-174, 924-940, 1485-1496, 1447-1462 and 1483-1498 of Seq ID No 160; 457-475 of Seq ID No 161; 302-325 of Seq ID No 163; 288-305 of Seq ID No 164; 244-266 and 260-282 of Seq ID No 165; 204-225 and 220-241 of Seq ID No 166; 324-345, 340-361, 356-377, 372-393 and 388-408 of Seq ID No 167; 39-64 of Seq ID No 168; 54-76 and 70-92 of Seq ID No 169; 1227-1247, 1539-1559, 1554-1574, 1569-1589, 1584-1604, 1242-1262, 1272-1292, 1287-1308, 1456-1477, 1472-1494, 1488-1510 and 1505-1526 of Seq ID No 170; 351-368 of Seq ID No 172; 179-200, 195-216, 211-232, 227-248 and 243-263 of Seq ID No 173; 13-37 of Seq ID No 174; 208-224 of Seq ID No 175; 42-64, 59-81, 304-328, 323-348, 465-489, 968-992, 1399-1418, 1412-1431 and 2092-2111 of Seq ID No 177; 1528-1547 and 1541-1560 of Seq ID No 178; 184-200, 367-388, 382-403, 409-429, 425-444 and 438-457 of Seq ID No 179; 27-50 and 45-67 of Seq ID No 180; 114-131 and 405-419 of Seq ID No 183; 113-134, 129-150, 145-166, 161-182 and 177-198 of Seq ID No 184; 495-515 of Seq ID No 186; 346-358 of Seq ID No 187; 208-224 of Seq ID No 190; 178-194, 202-223, 217-238, 288-308 and 1355-1372 of Seq ID No 192; 57-78 of Seq ID No 194; 347-369, 364-386, 381-403, 398-420, 415-437 and 432-452 of Seq ID No 197; 347-372 of Seq ID No 198; 147-163 of Seq ID No 199; 263-288 of Seq ID No 200; 361-377 of Seq ID No 202; 82-104, 99-121, 116-138, 133-155 and 150-171 of Seq ID No 204; 110-130 and 125-145 of Seq ID No 205; 613-631, 626-644 and 196-213 of Seq ID No 206; 78-100, 95-117, 112-134 and 129-151 of Seq ID No 208; 158-180, 175-197, 192-214, 209-231 and 226-248 of Seq ID No 209; 30-50, 45-65 and 60-79 of Seq ID No 210; 431-455 and 450-474 of Seq ID No 213; 579-601, 596-618, 613-635 and 630-653 of Seq ID No 214; 920-927, 98-119, 114-135, 130-151, 146-167 and 162-182 of Seq ID No 217; 36-59 of Seq ID No 219; 194-216 and 381-404 of Seq ID No 220; 236-251 and 255-279 of Seq ID No 221; 80-100 and

141-164 of Seq ID No 222; 128-154 of Seq ID No 223; 82-100, 95-116 and 111-134 of Seq ID No 224; 55-76, 71-92 and 87-110 of Seq ID No 227; 91-106 of Seq ID No 229; 74-96 of Seq ID No 230;-140-157 of Seq ID No 231; 4-13 of Seq ID No 233; 41-65 and 499-523 of Seq ID No 236; 122-146, 191-215, 288-313, 445-469 and 511-535 of Seq ID No 239; 347-368 of Seq ID No 241; 46-61 of Seq ID No 242; 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 and 236-258 of Seq ID No 243.

- A process for producing a S. pneumoniae hyperimmune serum reactive antigen or a fragment thereof according to any one of the claims 11 to 14 comprising expressing the nucleic acid molecule according to any one of claims 1 to 7.
- A process for producing a cell, which expresses a S. pneumoniae hyperimmune serum reactive 16. antigen or a fragment thereof according to any one of the claims 11 to 14 comprising transforming or transfecting a suitable host cell with the vector according to claim 8 or claim 9.
- A pharmaceutical composition, especially a vaccine, comprising a hyperimmune serum-reactive *17.* antigen or a fragment thereof, as defined in any one of claims 11 to 14 or a nucleic acid molecule according to any one of claims 1 to 7.
- A pharmaceutical composition, especially a vaccine, according to claim 17, characterized in that it 18. further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at least two LysLeuLys motifs, neuroactive compounds, especially human growth hormone, alumn, Freund's complete or incomplete adjuvants or combinations thereof.
- Use of a nucleic acid molecule according to any one of claims 1 to 7 or a hyperimmune serum-19. reactive antigen or fragment thereof according to any one of claims 11 to 14 for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against S. pneumoniae
- An antibody, or at least an effective part thereof, which binds at least to a selective part of the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to
- An antibody according to claim 20, wherein the antibody is a monoclonal antibody. 21.
- An antibody according to claim 20 or 21, wherein said effective part comprises Fab fragments. 22.
- An antibody according to any one of claims 20 to 22, wherein the antibody is a chimeric antibody. 23.
- An antibody according to any one of claims 20 to 23, wherein the antibody is a humanized 24. antibody.
- A hybridoma cell line, which produces an antibody according to any one of claims 20 to 24. 25,
- A method for producing an antibody according to claim 20, characterized by the following steps: 26.
  - initiating an immune response in a non-human animal by administrating an hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of the claims 11 to 14, to said animal,
  - removing an antibody containing body fluid from said animal, and
  - producing the antibody by subjecting said antibody containing body fluid to further purification steps.


- 27. Method for producing an antibody according to claim 21, characterized by the following steps:
  - initiating an immune response in a non-human animal by administrating an hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of the claims 12 to 15, to said animal,
  - removing the spleen or spleen cells from said animal,
  - producing hybridoma cells of said spleen or spleen cells,
  - selecting and cloning hybridoma cells specific for said hyperimmune serum-reactive antigens or a fragment thereof,
  - producing the antibody by cultivation of said cloned hybridoma cells and optionally further purification steps.
- 28. Use of the antibodies according to any one of claims 20 to 24 for the preparation of a medicament for treating or preventing *S. pneumoniae* infections.
- An antagonist, which binds to the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14.
- 30. A method for identifying an antagonist capable of binding to the hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 comprising:
  - a) contacting an isolated or immobilized hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 with a candidate antagonist under conditions to permit binding of said candidate antagonist to said hyperimmune serum-reactive antigen or fragment, in the presence of a component capable of providing a detectable signal in response to the binding of the candidate antagonist to said hyperimmune serum reactive antigen or fragment thereof; and
  - b) detecting the presence or absence of a signal generated in response to the binding of the antagonist to the hyperimmune serum reactive antigen or the fragment thereof.
- 31. A method for identifying an antagonist capable of reducing or inhibiting the interaction activity of a hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 to its interaction partner comprising:
  - a) providing a hyperimmune serum reactive antigen or a hyperimmune fragment thereof according to any one of claims 11-14,
  - b) providing an interaction partner to said hyperimmune serum reactive antigen or a fragment thereof, especially an antibody according to any one of the claims 20 to 24,
  - c) allowing interaction of said hyperimmune serum reactive antigen or fragment thereof to said interaction partner to form a interaction complex,
  - d) providing a candidate antagonist,
  - e) allowing a competition reaction to occur between the candidate antagonist and the interaction complex,
  - f) determining whether the candidate antagonist inhibits or reduces the interaction activities of the hyperimmune serum reactive antigen or the fragment thereof with the interaction partner.
- 32.. Use of any of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14 for the isolation and/or purification and/or identification of an interaction partner of said hyperimmune serum reactive antigen or fragment thereof.
- 33. A process for in vitro diagnosing a disease related to expression of the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 comprising determining the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen and fragment according to any one of claims 1 to 7 or the presence of the hyperimmune

- 34. A process for in vitro diagnosis of a bacterial infection, especially a S. pneumoniae infection, comprising analysing for the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen and fragment according to any one of claims 1 to 7 or the presence of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14.
- 35. Use of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14 for the generation of a peptide binding to said hyperimmune serum reactive antigen or fragment thereof, wherein the peptide is selected from the group comprising anticalines.
- 36. Use of the hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 for the manufacture of a functional nucleic acid, wherein the functional nucleic acid is selected from the group comprising aptamers and spiegelmers.
- 37. Use of a nucleic acid molecule according to any one of claims 11 to 14 for the manufacture of a functional ribonucleic acid, wherein the functional ribonucleic acid is selected from the group comprising ribozymes, antisense nucleic acids and siRNA.

## Summary:

S. pneumoniae antigens

The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from *S. pneumoniae*, methods for isolating such antigens and specific uses thereof.







Fig. 1






Fig.1





Fig.1







Fig. 2







Fig. 3







Fig. 4







Fig. 5






Fig. 6




Fig. 7

# str pneumoniae patentin.ST25 SEQUENCE LISTING

<110>	Intercell AG	•
<120>	S. pneumoniae antigens	
<130>	SPN	
<160>	288	
<170>	PatentIn version 3.1	
<2.10>	1	
<211>	366	•
<212>	DNA	
<213>	Streptococcus pneumoniae	
<400> atgtcta	1 aaaa atattgtaca attgaataat tcttttattc aaaatgaata ccaacgtcgt	60
cgctaco	ctga tgaaagaacg acaaaaacgg aatcgtttta tgggaggggt attgattttg	120
attatgo	ctat tatttatctt gccaactttt aatttagcgc agagttatca gcaattactc	180
caaagad	cgtc agcaattagc agacttgcaa actcagtatc aaactttgag tgatgaaaag	240
gataagg	gaga cagcatttgc taccaagttg aaagatgaag attatgctgc taaatataca	300
cgagcga	aagt actattattc taagtcgagg gaaaaagttt atacgattcc tgacttgctt	360
caaagg		366
<210>	2	
_	2631	
	DNA	
<213>	Streptococcus pneumoniae	
<400>	2	
	aga aaaaattatt attgattgat gggtcttctg tagcttttcg ggcgtttttt	60
gcgctgt	atc agcagttgga ccgttttaag aatgtggctg gtttgcatac caatgcgatt	120
tatggtt	ttc agttgatgtt gagtcattta ttggagcggg ttgagccgag tcatattttg	180
gtggctt	ttg atgcgggaaa gacgaccttc cggacagaga tgtatgcgga ctataagggt Page 1	240

## str pneumoniae patentin.ST25

	Jacobega	egageeeege	yaycaattt	rctttcattc	tgagttgctg	300
gatcatatgg	ggattcgtca	ctatgatctg	gctcagtato	aggcggatga	a catcattggg	360
acgctggata	agctagcaga	gcaggatggt	tttgatatta	ctattgtcag	tggggacaag	420
gatttgattc	agctgacgga	tgagcatacg	gtggttgaaa	tttccaagaa	aggtgtggct	480
gagtttgagg	cctttacgcc	agattacctc	atggaagaaa	_tgggcctcac	accageteag	. 540
tttatcgatc	tcaaggcgct	catgggtgat	aagtcggata	atatccctgg	ggtgaccaaa	600
gtcggtgaaa :	agacgggtat	taagctcttg	ctggagcatg	gttcgcttga	ggggatttat	660
gaaaatattg a	atggaatgaa	gacttctaag	atgaaggaaa	atctcatcaa	tgacaaggaa	720
caggcctttt	tgtctaaaac	actagcgacc	attgatacca	aggcaccgat	tgcgattggt	780
ttagaggact 1	tggtctatag	tggtccagat	gttgaaaatc	ttgggaaatt	ctacgatgag	840
atgggcttca a	aacagctaaa	gcaggcttta	aatgtgtcgt	cagctgatgt	gtctgagagt	900
ttggatttta (	ctattgttga	ccaaatcagt	caagatatgc	tgagtgaaga	gtctatcttc	960
cactttgagc 1	tttttggtga	gaattaccat	acggataatt	tggttggatt	tgtctggtct	1020
tgtggggata a	agctctatgc	cacagacaag	cttgagctgt	tgcaagaccc	gattttcaag	1080
gatttcttag a	aaaaaacatc	tctgagagtt	tatgacttta	agaaggttaa	agttcttttg	1140
caacgttttg g	gtgtggattt	gcaggcgcct	gcttttgaca	tccgtttggc	taaatacctc	1200
ctttcgactg 1	tggaggacaa	tgaaattgcg	accatcgcta	gtctttatgg	tcagacttac	1260
ttggttgatg a	atgaaacttt	ctacggtaag	ggtgttaaaa	aggccattcc	tgaacgtgag	1320
aaattcttgg a	aacacttagc	ttgtaaactt	gctgttttgg	tagaaacaga	gcctatttta	1380
cttgaaaaac t	tcagcgaaaa	tgggcaatta	gagcttcttt	atgatatgga	gcaacctctg	1440
gcttttgtcc t	ttgccaagat	ggaaattgct	gggattatgg	tcaagaaaga	gaccttgctt	1500
gagatgcagg c	ctgaaaatga	gcttgtcatt	gaaaaactga	ctcaagagat	ttacgagctg	1560
gctggtgagg a	agtttaatgt	caactcgcct	aagcagttgg	gcgtgcttct	ctttgagaaa	1620
ttgggacttc c	tctagaata	cactaagaaa	accaagacag	gttattcgac	agcagtggat	1680
gttttagagc g	tctcgctcc	tattgctccg	attgttaaga	aaatcctgga	ttaccgtcaa	1740
attgctaaga t	tcaatctac	ttatgtaatt	ggcttgcagg	actggatttt	ggctgatgga	1800
aagattcata c	tcgctatgt	gcaggatttg	acccagaccg	ggcgtttgtc	tagtgtggat	1860
ccaaacttgc a	aaatattcc	tgcccgattg	gaacaggggc	gcttgattcg	gaaggctttt	1920
gtgccagagt g						1980
gttttggcgc a						2040
atccatactt c	gacagccat	gcgggtcttt	ggcattgagc	gtcctgatga	tgtgactgca	2100
aacgaccgtc g	caatgccaa	ggcagttaac	tttggagtgg	tttatgggat	ttcagacttt	2160
ggcttgtcta a	taatttggg :	aattagtcgt	aaggaagcca	aagcctacat	tgatacctac	2220
tttgaacgtt t	tccaggtat	taaaaactac	atggatgaag Page 2	tggtgcggga	ggcgcgtgat	2280

str pneumoniae patentin.ST25							
aagggctatg tagagaccct ctttaagcgt cgccgtgagt tgccagatat caattcgcgc	2340						
aacttcaata ttcgtggttt tgcggagcga actgctatca actcacctat ccagggttcg	2400						
gcagcagata ttctcaagat tgccatgatt cagctggata aagccttggt tgcaggtggt	2460						
tatcagacta agatgctgtt acaagtgcac gatgaaatcg tccttgaagt gcctaaatct	2520						
gaattggtag agatgaaaaa attggtgaaa caaaccatgg aagaagccat tcaactcagt	2580						
gttcctctta tcgcagatga gaatgaaggg gcaacctggt acgaggctaa a	2631						
<210> 3							
<211> 633							
<212> DNA							
<213> Streptococcus pneumoniae							
•							
<400> 3							
atggggatgg cagcttttaa aaatcctaac aatcaataca aagctattac aattgctcaa	60						
actctaggtg atgatgcttc ttcagaggaa ttggctggta gatatggttc tgctgttcag	120						
tgtacagaag tgactgcctc aaacctttca acagttaaaa ctaaagctac ggttgtagaa	180						
aaaccactga aagattttag agcgtctacg tctgatcagt ctggttgggt ggaatctaat	240						
ggtaaatggt atttctatga gtctggtgat gtgaagacag gttgggtgaa aacagatggt	300						
aaatggtact atttgaatga cttaggtgtc atgcagactg gatttgtaaa attttctggt	360						
agctggtatt acttgagcaa ttcaggtgct atgtttacag gctggggaac agatggtagc	420						
agatggttct actttgacgg ctcaggagct atgaagacag gctggtacaa ggaaaatggc	480						
acttggtatt accttgacga agcaggtatc atgaagacag gttggtttaa agtcggacca	540						
cactggtact atgcctacgg ttcaggagct ttggctgtga gcacaacaac accagatggt taccgtgtaa atggtaatgg tgaatgggta aac	600						
· · · · · · · · · · · · · · · · · · ·	633						
<210> 4							
<211> 5568							
<212> DNA							
<213> Streptococcus pneumoniae							
<400> 4 atgagccgaa aaagcattgg tgagaaacgc catagtttct cgatgagaaa gttgtcagtg	50						
ggattggtat cagttactgt atctagtttc tttttgatga gtcaagggat tcaatcggta	60 130						
tcggccgata atatggaaag tccaattcat tataagtata tgaccgaggg taaattgaca	120.						
gacgaggaaa aatccttgct ggtagaggcc cttccacaac tggctgaaga atcagatgat	180						
acttattact tggtttatag atctcaacag tttttaccga atacaggttt taacccaact	240						
Page: 3	300						

str	pneumoniae	patentin.sT25

					atentin.st2		
	-greggeact	t-teetttta	c-tgcaggatt	g-agcttgtta	g ttttattggt	ttctaaaagg	<del></del> 360
	gaaaatggaa	a agaaacgac	t tgttcattt	t ctgctgttga	a ctagcatggg	agttcaatto	420
	ttgccggcca	a gtgcttttg	g gttgaccag	c cagatttta	t ctgcctataa	tagtcagc++	480
	tctatcggag	g töggggaaca	a tttaccaga	g cctctgaaaa	a tcgaaggtta	tcaatatatt	540
-	ggttatatca	<u>a aaactaag</u> aa	a acaggataa	t <u>acagagctt</u> i	caaggacagt	_tgatgggaaa_	~===600 <b></b>
	Lactetgete	c aaagagatag	y tcaaccaaa	tctacaaaa	catcagatgt	agttcattca	660
	gctgatttag	j aatggaacca	a aggacagggg	aaggttagtt	: tacaaggtga	agcatcaggg	720
	gatgatggad	: tttcagaaaa	atcttctata	ı gcagcagaca	atctatcttc	taatgattca	780
	ttcgcaagtc	: aagttgagca	gaatccggat	: cacaaaggag	ı aatctgtagț	tcgaccaaca	840
	gtgccagaac	: aaggaaatco	tgtgtctgct	acaacggtgc	: agagtgcgga	agaggaagta	900
	ttggcgacga	caaatgatcg	accagagtat	aaacttccat	tggaaaccaa	aggracacaa	960
	gaacccggtc	: atgagggtga	agccgcagto	cgtgaagact	taccagtcta	Cactaageca	1020
	ctagaaacca	aaggtacaca	aggacccgga	catgaaggtg	aagctgcagt	tracaageea	1020
	gaaccagctt	acacagaacc	gttagcaacg	aaaggcacgc	aagagccagg	tratgaggg	
	aaagctacag	tccgcgaaga	gactctagag	tacacggaac	cggtagcgac	aaaaaacaca	1140
	caagaacccg	aacatgaggģ	cgaagcggca	gtagaagaag	aacttccggc	tttagaggtc	1200 1260
	actacacgaa	atagaacgga	aatccagaat	attccttata	caacagaaga	aattcagget	1320
	ccaacacttc	tgaaaaatcg	tcgtaagatt	gaacgacaag	ggcaagcagg	gacacutaca	1380
	attcaatatg	aagactacat	cgtaaatggt	aatgtcgtag	aaactaaaga	antintracas	
	actgaagtag	ctccggtcaa	cgaagtcgtt	aaagtaggaa	cacttgtgaa	anttaaacet	1440 1500
	acagtagaaa	ttacaaactt	aacaaaagtt	gagaacaaaa	aatctataac	totaaottat	
	aacttaatag	acactacctc	agcatatgtt	tctgcaaaaa	cgcaagtttt	Catagaaa	1560
	aagctagtta	aagaggtgga	tatagaaaat	cctgccaaag	agcaagtaat	atcaggt++>	1620
	gattactaca	caccgtatac	agttaaaaca	cacctaactt	ataatttggg	toasastast	1680
	gaggaaaata	ctgaaacatc	aactcaagat	ttccaattag	agtataagaa	aatagaga++	1740
	aaagatattg	attcagtaga	attatacggt	aaagaaaatg	atcgttatcg	tagatattt	1800
	agtctaagtg	aagcgccgac	tgatacggct	aaatacttto	taaaagtgaa	atcacatoca	1860
	ttcaaagaaa	tgtacctacc	tgtaaaatct	attacagaaa	atacggatgg	accagatege	1920
	gtgacggtag	ccgttgatca	acttgtcgaa	gaaggtacag	acggttacaa	aacytataa	1980
	acatttactg	tagctaaatc	taaagcagag	caaccaggag	tttacacatc	ayatyattac	2040
	ctggtaacag	ccatgcaaaq	caatctgtct	qqtqtctata	cattggcttc	cccaaacag	2100
	gcagatgagg	tgagcttagg	cgataagcag	acaanttato	tcacaggtgc a	ayatatgacc	2160
	agcttgatcg	gttctgatgg	aacaaaatca	tatorce+++	atgatttgaa	attacaggg	2220
	tttgatacat	taaatootor	tacaattaaa	datttaases	ttaaaactgt	gaaaccatta	2280
				Page 4	ccaaaactgt 1	ttctgctgat	2340

	atgtcgcagc					2400
	gaaaaatctc					2460
	tagaaaacag					2520
	atactggagg					2580
	tagatgcctt					2640
	gtagattaga					2700
	gtcaaggata					2760
	ataatgttgt					2820
	cagcagcaga					2880
	ctacaaaatt					2940
	ctcttgatga					3000
	taaataaagc					3060
	tctacaataa					3120
	acactacaga					3180
	ataataagaa					3240
	acctagatgt					3300
	caggaaaaga					3360
	ataacgtact					3420
	taggagcagc					3480
	ttaaagctaa					3540
	ctacaggaga					3600
	ttatgctagg					3660
	caaaagattt					3720
	atactattgt					3780
	gtttatatgc					3840
	aagcgtatag					3900
	caaaggcata					3960
	caccaacagc					4020
	gggggcataa					4080
	catcgaatat					4140
	gagttattct					4200
	cgaaaaggca				_	4260
gcttcaaaag	aaaaactttt	ccgttctgtg	atagtttatg	atggattcaa	tgtaaaagat	4320
gagacaggaa	gaacttattg	ggcaaggtta	acggataaaa	acatcggctc	tattaaagaa	4380

Page 5

	str pneumoniae patentin.ST25	
_	ttetteggae etgetgggaa atggtatgag tataatagta gtgcaggage gtatgcgaat	4440
	ggaagtttaa cgcactttgt gttagataga ttattagatg cttatggaac gtcggttat	4500
	actcatgaaa tggttcataa ttctgattct gcaatctact ttgaaggaaa tggtagacgt	4560
	gaaggattgg gagcggagtt atacgcactt ggtttactgc aatctgtaga tagtgtaaat	4620
-	tctcatattt tagctttaaa tacgttatat_aaagcagaaa aagatgattt-gaatagattg-	4680 · · · · · · · -
	Catacatata atccggtgga acgtttcgat tcggatgagg cgcttcaaag ttatatgcat	4740
	ggatcatatg atgtaatgta tacacttgat gcgatggaag caaaagcgat attagctcaa	4800
	aataatgatg ttaagaaaaa atggtttaga aaaatagaaa attattacgt tcgtgatact	4860
	agacataata aagatacaca tgcaggaaat aaagtccgtc cattaacaga tgaagaagta	4920
	gctaacttaa catcgttaaa ctcattaatc gacaacgaca tcataaatag acgtagctat	4980
	gatgatagta gagaatataa acgaaatggc tactatacta	5040
	tacgcagcgc taagcaattc gaaaggtgct cctggagata ttatgtttag aaaaatagct	5100
	tatgaattac ttgcggaaaa aggttatcac aaaggattcc taccttatgt ttctaatcag	5160
	tacggagcag aagcatttgc cagcggaagc aaaacattct catcatggca tggaagagat	5220
	gttgctttag tgacagatga tttagtattt aagaaagtat tcaatggtga gtactcatca	5280
	tgggctgatt tcaaaaaagc aatgtttaaa caacgtatag ataaacaaga taatctgaaa	5340
	ccaataacaa ttcaatacga attaggtaat cctaatagta caaaagaagt aactataaca	5400
	acggctgcac aaatgcaaca attaattaat gaagcggctg cgaaagatat tactaatata	5460
	gatcgtgcaa cgagtcatac cccagcaagt tgggtgcatt tattaaaaca aaaaatctat	5520
	aatgcatatc ttcgcactac agatgacttt agaaattcta tatataaa	5568
	<210> 5	
	<211> 2571	,
	<212> DNA	
	<213> Streptococcus pneumoniae	
	<400> 5	
	atgaaattca atccaaatca aagatatact cgttggtcta ttcgccgtct cagtgtcggt	60 .
	gttgcctcag ttgttgtggc tagtggcttc tttgtcctag ttggtcagcc aagttctgta	120
	cgtgccgatg ggctcaatcc aaccccaggt caagtcttac ctgaagagac atcgggaacg	180
	aaagagggtg acttatcaga aaaaccagga gacaccgttc tcactcaagc gaaacctgag	240
	ggcgttactg gaaatacgaa ttcacttccg acacctacag aaagaactga agtgagcgag	300
	gaaacaagcc cttctagtct ggatacactt tttgaaaaaag atgaagaagc tcaaaaaaaat	360
	ccagagctaa cagatgtctt aaaagaaact gtagatacag ctgatgtgga tgggacacaa gcaagtccag cagaaactac tcctgaacaa gtagaaggtg gartaga	420
	T DESTROY SUNGODING III III AACAA OTSSSSSSSAAAA AAAAA	

gcaagtccag cagaaactac tcctgaacaa gtaaaaggtg gagtgaaaga aaatacaaaa Page 6

gacagcatco	atottectoe	tacttatctt	<b>6333333564</b>			
			gaaaaagctg			540
			ctattcgctg			600
			tggtctgaca			660
			gggaaatact			720
			ttaattgatc			780
			ggaaataaag			840
aatctagttg	ctactaaaaa	tgtagacatc	aacatcaatg	gattagttgc	taaagaaaca	900
gttcaaaaag	ccgttgcaga	caacgttaaa	gacagtatcg	atgttccagc	agcctaccta	960
gaaaaagcca	agggtgaagg	tccattcaca	gcaggtgtca	accatgtgat	tccatacgaa	1020
ctcttcgcag	gtgatggcat	gttgactcgt	ctcttgctca	aggcatctga	caaggcacca	1080
tggtcagata	acggcgacgc	taaaaaccca	gccctatctc	cactaggcga	aaacgtgaag	1140
accaaaggtc	aatacttcta	tcaagtagcc	ttggacggaa	atgtagctgg	caaagaaaaa	1200
caagcgctca	ttgaccagtt	ccgagcaaat	ggtactcaaa	cttacagcgc	tacagtcaat	1260
gtctatggta	acaaagacgg	taaaccagac	ttggacaaca	tcgtagcaac	taaaaaagtc	1320
actattaaca	taaacggttt	aatttctaaa	gaaacagttc	aaaaagccgt	tgcagacaac	1380
gttaaagaca	gtatcgatgt	tccagcagcc	tacctagaaa	aagccaaggg	tgaaggtcca	1440
ttcacagcag	gtgtcaacca	tgtgattcca	tacgaactct	tcgcaggtga	tggtatgttg	1500
actcgtctct	tgctcaaggc	atctgacaag	gcaccatggt	cagataacgg	tgacgctaaa	1560
			gtgaagacca			1620
ttagccttgg	acggaaatgt	agctggcaaa	gaaaaacaag	cgctcattga	ccagttccga	1680
			gtcaatgtct			1740
			aaagtcacta			1800
			gacaacgtta			1860
			ggtccattca			1920
			atgttgactc			1980
			gctaaaaacc			2040
			tatcaagtag			2100
			ttccgagcaa			2160
			ggtaaaccag		_	2220
			aaagaaacat			2280
			actccgatga			2340
			acaagttcta			2400
			gatacgatga	•		2460
			atggcaagta			
	. 33 -3334-		Page 7	Liggittet	caaacccaca	2520

str pneumoniae patentin.ST25	
cttgcaggtt-tactcggtgg-tctaggtttg-aaaaacaaaa aagaagaaaa c	2571
<210> 6	23, 2
<211> 585	
<212> DNA	
<213> Streptococcus pneumoniae	· · · · · · · · · · · · · · · · · · ·
<400> 6 atgaaatcaa taactaaaaa gattaaagca actcttgcag gagtagctgc cttgtttgca gtatttgctc catcatttgt atctgctcaa gaatcatcaa cttacactgt taaagaaggt	60
gatacacttt cagaaatcgc tgaaactcac aacacacaa cttacactgt taaagaaggt	· <b>120</b>
gatacacttt cagaaatcgc tgaaactcac aacacaacag ttgaaaaatt ggcagaaaac	180
aaccacattg ataacattca tttgatttat gttgatcaag agttggttat cgatggcct	240
gtagcgcctg ttgcaacacc agcgccagct acttatgcgg caccagccgc tcaagatgaa	300
actgtttcag ctccagtagc agaaactcca gtagtaagtg aaacagttgt ttcaactgta	360
agcggatctg aagcagaagc caaagaatgg atcgctcaaa aagaatcagg tggtagctat	420
acagctacaa atggacgtta tatcggacgt taccaattaa cagattcata cctgaacggt	480
gactactcag ctgaaaacca agaacgtgta gcagatgcct acgttgcagg acgttacggt	540
tcatggactg ctgctaaaaa cttctggctt aacaatggct ggtat	585
<210> 7	•
<211> 2232 .	
<212> DNA	
<213> Streptococcus pneumoniae	
<pre>&lt;400&gt; 7 atgaataaga aaaaaatgat tttaacaagt ctagccagcg tcgctatctt aggggctggt</pre>	60
tttgttacgt ctcagcctac ttttgtaaga gcagaagaat ctccacaagt tgtcgaaaaa	120
tcttcattag agaagaaata tgaggaagca aaagcaaaag ctgatactgc caagaaagat	180
tacgaaacgg ctaaaaagaa agcagaagac gctcagaaaa agtatgaaga tgatcagaag	240
agaactgagg agaaagctcg aaaagaagca gaagcatctc aaaaattgaa tgatgtggcg	300
cttgttgttc aaaatgcata taaagagtac cgagaagttc aaaatcaacg tagtaaatat	
aaatctgacg ctgaatatca gaaaaaatta acagaggtcg actctaaaat agagaaggct	360
aggaaagagc aacaggactt gcaaaataaa tttaatgaag taagagcagt tgtagttcct	420
gaaccaaatg cgttggctga gactaagaaa aaagcagaag aagctaaagc agaagaaaaa	480
gtagctaaga gaaaatatga ttatgcaact ctaaaggtag cactagcgaa gaaagaagta	540
gaggctaagg aacttgaaat tgaaaaactt caatatgaaa tttctacttt ggaacaagaa	600
Page 8	660

				•		
grrgctacto	ctcaacatca	agtagataat	ttgaaaaaac	ttcttgctgg	tgcggatcct	720
gatgatggca	cagaagttat	agaagctaaa	ttaaaaaaag	gagaagctga	gctaaacgct	780
aaacaagctg	agttagcaaa	aaaacaaaca	gaacttgaaa	aacttcttga	cagccttgat	840
cctgaaggta	agactcagga	tgaattagat	aaagaagcag	aagaagctga	gttggataaa	900
aaagctgatg	aacttcaaaa	taaagttgct	gatttagaaa	aagaaattag	taaccttgaa	960
atattacttg	gaggggctga	tcctgaagat	gatactgctg	ctcttcaaaa	taaattagct	1020
gctaaaaaag	ctgagttagc	aaaaaaacaa	acagaacttg	aaaaacttct	tgacagcctt	1080
gatcctgaag	gtaagactca	ggatgaatta	gataaagaag	cagaagaagc	tgagttggat	1140
aaaaaagctg	atgaacttca	aaataaagtt	gctgatttag	aaaaagaaat	tagtaacctt	1200
gaaatattac	ttggaggggc	tgattctgaa	gatgatactg	ctgctcttca	aaataaatta	1260
gctactaaaa	aagctgaatt	ggaaaaaact	caaaaagaat	tagatgcagc	tcttaatgag	1320
ttaggccctg	atggagatga	agaagaaact	ccagcgccgg	ctcctcaacc	agagcaacca	1380
gctcctgcac	caaaaccaga	gcaaccagct	ccagctccaa	aaccagagca	accagctcct	1440
gcaccaaaac	cagagcaacc	agctccagct	ccaaaaccag	agcaaccagc	tccagctcca	1500
aaaccagagc	aaccagctaa	gccggagaaa	ccagctgaag	agcctactca	accagaaaaa	1560
ccagccactc	caaaaacagg	ctggaaacaa	gaaaacggta	tgtggtattt	ctacaatact	1620
gatggttcaa	tggcaatagg	ttggctccaa	aacaacggtt	catggtacta	cctaaacgct	1680
aacggcgcta	tggcaacagg	ttgggtgaaa	gatggagata	cctggtacta	tcttgaagca	1740
tcaggtgcta	tgaaagcaag	ccaatggttc	aaagtatcag	ataaatggta	ctatgtcaac	1800
	ctatggcgac					1860
	atatggcgac					1920
	atatggcgac					1980
	ctatggctac					2040
	caatggcaac					2100
gcatcaggtg	ctatgaaagc	aagccaatgg	ttcaaagtat	cagataaatg	gtactatgtc	2160
	gtgcccttgc					2220
ggtgaatggg						2232

·<210> 8

<211> 567

<212> DNA

<213> Streptococcus pneumoniae

str pneumoniae patentin.ST25	
aaaaaagaaa ctggaccagc tacaaaaaca gaaaaagata cgcttcagtc ggcattgcca	120
gttattgaaa atgctgagaa gaatacagtt gtaactaaga ctttggtctt gcccaagtca	180
gatgatggta gccagcagac acaaacaatt acttacaaag acaagacttt tttgagtcta	240
gctatccaac aaaaacgtcc agtctctgat gagttgaaga cttatattga ccaacatgga	300
grggaggaaa ctcaaaaagc <del>tcttc</del> ttgaa gcggaggaga-aggataagtctatcattgaa	360
gctcgtaaat tggcaggttt caaacttgaa acaaaactat tgagcgcaac ggaacttcaa	420
acaacgacta gttttgattt tcaagttctg gatgtcaaga aggcttccca gttggaacat	480
ctgaagaata ttggtttgga aaatcttttg aaaaatgaac caagcaaata tatttcagat	540
agattggcaa atggcgcgac agaacaa	567
<210> 9	
<211> 1248	
<212> DNA	
<213> Streptococcus pneumoniae	
<400> 9	
atgittgaag tagaagaatg gctccatagt cggattggtt tgaattitcg atcaggtttg	60
ggtcgaatgc agcaagcggt ggatttgtta ggaaatcctg agcagtctta ccctattatc	120
cacgtaacag ggactaatgg gaaaggatct accattgctt ttatgaggga attattatg	180
gggcatggca aaaaagttgc gacctttacc tcccctcata tcgtctctat caatgaccga	240
atctgcatta atgggcagcc tatagcagac gcagacttta tccgtttgac tgatcaggtc	300
aaggagatgg agaaaacgct tctgcaaact cctgcccagt tgtccttttt tgaattgctg	360
accttggttg cttttcttta ttttagggag caggaggtgg atttggttt attagaagtg	420
ggaattggtg gcttacttga cacgaccaat gtggtaactg gagagtttgc tgtcatcacc	480
tccattgggc ttgaccatca agaaaccttg ggtgatagtc tagaagcaat tgcagagcag	540
aaagctggta ttttcaaggc tggtaagaag gcagtgattg cgaaattgcc tccagaagct	600
aggettgeet gteagaaaaa ageegaatet ttagetgtta acetttatea ggeaggteaa	660
gatttttaa tgctgaatgg tgattttca agctctttac taaatctttc acagctgaac	720
ataggettag aaggagteta teageaggag aatgeageet tggegttgea aactttett	780
ctttttatga gagaaagaaa ggaagctgtt gatgaacagg ctgtaagaaa ggccttggaa	840
cagacccatt gggctggtcg cttggagcgt attcgcccac agatttattt ggatggtgct	900
cataacctcc ctgccttgac tcgcttggct gagtttatca aagaaaaaga gcaggaaggc	960
tatcgacctc aaatcctctt tggatccttg aaacgtaagg attatcaagg gatgttgggt	1020
tatctgactg aaaaattgcc tcaggtggaa ctcaaggtga ccggctttga ctatcagggg	1080
gctttggacg aaagggatgt gacaggttac gatatagttt cttcttaccg agaatttatc Page 10	1140

### str pneumoniae patentin.ST25 agcgattttg aagaaagggc agacgctcaa gacttgctgt tcgttacagg gtctctctat 1200 tttatctcag aagtacgggg ctacctgctg gaccgtgagc agataaat 1248 <210> 10 <211> 831 <212> DNA <213> Streptococcus pneumoniae <400> 10 gtgggaattc gtgtttataa accaacaaca aacggtcgcc gtaatatgac ttctttggat 60 ttcgctgaaa tcacaacaag cactcctgaa aaatcattgc ttgttgcatt gaagagcaag 120 gctggtcgta acaacaacgg tcgtatcaca gttcgtcacc aaggtggtgg acacaaacgt 180 ttctaccgtt tggttgactt caaacgtaat aaagacaacg ttgaagcagt tgttaaaaca 240 300 aaagcataca tcatcgctcc aaaaggtctt gaagtaggtc aacgtatcgt ttcaggtcca 360 gaagcagata tcaaagtcgg aaacgctctt ccacttgcta acatcccagt tggtactttg 420 attcacaaca tcgagttgaa accaggtcgt ggtggtgaat tggtacgtgc tgctggtgca 480 tctgctcaag tattgggttc tgaaggtaaa tatgttcttg ttcgtcttca atcaggtgaa 540 gttcgtatga ttcttggaac ttgccgtgct acagttggtg ttgtcggaaa cgaacaacat 600 ggacttgtaa accttggtaa agcaggacgt agccgttgga aaggtatccg cccaacagtt 660 cgtggttctg taatgaaccc taacgatcac ccacacggtg gtggtgaagg taaagcacca 720 gttggtcgta aagcaccatc tactccatgg ggcaaacctg ctcttggtct taaaactcgt 780 aacaagaaag cgaaatctga caaacttatc gttcgtcgtc gcaacgagaa a 831 <210> 11 <211> 267 <212> DNA <213> Streptococcus pneumoniae <400> 11 atggctaaaa aatcaatggt agctagagag gctaaacgcc aaaaaattgt tgaccgttat 60. gctgaaaaac gtgctgcatt aaaggcggca ggggactacg aaggtttatc taaattacct 120 cgcaacgcct caccgactcg tttacataat cgttgtaggg ttacggggcg cccacattca 180 gtttaccgca aatttggtct gagtcgtatc gcttttcgcg aacttgcgca taaaggtcaa

attcctggtg taacaaaagc atcttgg

240

<210> 12 str pneumoniae patentin.st25	an samuela se con esta on esta o
<211> 1335	
<212> DNA	
<213> Streptococcus pneumoniae	
<400> 12	The second section of the second section of the second section of the second section of the second section of the second section secti
atggatatta gacaagttac tgaaaccatc gccatgattg aggagcaaaa cttcgatatt	60
agaaccatta ccatggggat ttctcttttg gactgtatcg atccagatat caatcgtgct	120
gcggagaaaa tctatcaaaa aattacgaca aaggcggcta atttagtagc tgttggtgat	180
gaaattgcgg ctgagttggg aattcctatc gttaataagc gtgtatcggt gacacctatt	240
tctctgattg gggcagcgac agatgcgacg gactacgtgg ttctggcaaa agcgcttgat	300
aaggctgcga aagagattgg tgtggacttt attggtggtt tttctgcctt agtacaaaaa	360
ggttatcaaa agggagatga gattctcatc aattccattc ctcgcgcttt ggctgagacg	420
gataaggtct gctcgtcagt caatatcggc tcaaccaagt ctggtattaa tatgacggct	480
gtggcagata tgggacgaat tatcaaggaa acagcaaatc tttcagatat gggagtggcc	540
aagttggttg tattcgctaa tgctgttgag gacaatccat ttatggcggg tgcctttcat	600
ggtgttgggg aagcagatgt tatcatcaat gtcggagttt ctggtcctgg tgttgtgaaa	660
cgtgctttgg aaaaagttcg tggacagagc tttgatgtag tagccgaaac agttaagaaa	720
actgccttta aaatcactcg tatcggtcaa ttggttggtc aaatggccag tgagagactg	780
ggtgtggagt ttggtattgt ggacttgagt ttggcaccaa cccctgcggt tggagactct	840
gtggcacgtg tccttgagga aatggggcta gaaacagttg gcacgcatgg aacgacggct	900
gccttggccc tcttgaacga ccaagttaaa aagggtggag tgatggcctg caaccaagtc	960
ggtggtttat ctggtgcctt tatccctgtt tctgaggatg aaggaatgat tgctgcagtg	1020
caaaatggct ctcttaattt agaaaaacta gaagctatga cggctatctg ttctgttgga	1080
ttggatatga ttgccatccc agaagatacg cctgctgaaa ctattgcggc tatgattgcg	1140
gatgaagcag caatcggtgt tatcaacatg aaaacaacag ctgttcgtat cattcccaaa	1200
ggaaaagaag gcgatatgat tgagtttggt ggtctattag gaactgcacc cgttatgaag	1260
gttaatgggg cttcgtctgt cgacttcatc tctcgcggtg gacaaatccc agcaccaatt	1320
catagtttta aaaat	1335
<210> 13	
<211> 2436	
<212> DNA	
<213> Streptococcus pneumoniae	

<400> 13		str pn	eumoniae pa	tentin.ST25	; -	
atggtaaata	cagaagtagc	aagaacaaca	atcaagacag	aatattttgg	cagccttact	60
gaaaggatga	acaaatatcg	agaagatgtt	ttaaataaaa	aaccttatat	tgatgctgag	120
agagcagttc	tagcaacacg	cgcctatgaa	cgatacaagg	aacaacctaa	tgtcctaaaa	180
cgtgcatata	tgctgaaaga	aattttggaa	aatatgacta	tctatattga	agaagaatct	240
atgattgcgg	gaaatcaagc	ttcttccaat	aaagatgctc	ctatttttcc	ggaatatacg	300
ctagaatttg	ttctcaatga	gttggatctt	tttgaaaagc	gtgatggaga	tgttttctat	360
attacagaag	aaacaaaga	acaacttaga	agtattgctc	cgttttggga	aaataataat	420
ttacgtgcta	gagctggtgc	cttattacct	gaagaagtgt	ctgtttatat	ggaaacagga	480
ttcttcggta	tggaaggtaa	gatgaattct	ggagatgctc	acttagcagt	taactatcag	540
aaacttttgc	aatttggttt	aagaggtttt	gaagagcggg	ctcgtaaagc	aaaagtagct	600
					tatatttatc	660
gtaatcgatg	ctattaaagt	atatgcaaag	cgctttgttg	ctcttgctaa	aagtttagcc	720
					ttgctctaga	780
					gtttattcaa	840
tgtattttac	aaattgaatc	taatggccac	tctctttcat	atggccgttt	tgatcaatat	900
atgtatccat	atatgaaggc	tgatttagaa	agtggtaaag	aaacagaaga	tagcattgtt	960
gaacgtctga	caaatctttg	gattaagaca	attacaatta	ataaggttcg	cagtcaatca	1020
					tggacagact	1080
					agttgcacaa	1140
acccatctac	cgcaacctaa	tctaactgta	cgttaccatg	caggtttaga	tgctcgtttc	1200
					taataatgat	1260
gagattatta	ttccttcttt	tattgcaaaa	ggagtattgg	aagatgatgc	ttatgattac	1320
					ttgcacaggt	1380
					aattgatccg	1440
gcttcgggta	aacggtttgc	accaagcttt	ggtcgtttta	aggatatgaa	gaacttttct	1500
gaattagaaa	atgcttggga	taaaacacta	agatatttga	cacgaatgag	tgttattgtt	1560
gaaaattcta	ttgatttatc	attggaacga	gaagttcctg	atattctatg	ttcagcattg	1620
actgatgatt	gtattggtcg	tggaaaacac	cttaaagaag	gtggagcagt	atatgattat	1680
atatcaggat	tgcaagttgg	aattgcaaat	ttgtcggatt	cattagctgc	aattaaaaaa	1740
ttggtgtttg	aggaagaacg	tataagccca	agtcagcttt	ggcatgcact	ggaaacagat	1800
tatgccggag	aagaaggtaa	ggtcattcaa	gaaatgttga	ttcatgatgc	acctaagtat	1860
	atgattatgc					1920
gaaattgcta	aatatcctaa	tacacgttat	ggaagagggc	ctattggagg	aattcgttat	1980
tcaggaacat	cttctatctc	agccaacgta	gggcagggac	gtggaacatt	agcaactcca	2040
			Page 13			

str pneumoniae patentin.sT25 gatggacgca acgcgggtac accgttagca gagggttgtt caccatcaca taata caacacggcc ctacatctgt tttaaaatct gtttcaaaat taccaacaga tgaaa	itggat 2100
caacacggcc ctacatctgt tttaaaatct gtttcaaaat taccaacaga tgana	itcota 2160
5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 -	gcu 2100
ggtggggttc tcttaaatca gaaagtaaat cctcaaacgt tagccaaaga agaag	ataaa 2220
ttaaaaactaa ttgctttgtt acgaacattc tttaatcgtt tacatgggta ccata	ttcaa 2280
tacaatgttg_tttccagaga gacgctgatt gacgcteaga~aacatcctga~aaaac	acaga2340
gacttaattg ttcgtgttgc aggatactct gcattcttca atgttctttc taagg	caacc 2400
caagatgaca ttataggacg tactgagcat actttg	2436
<210> 14	
<211> 390	
<212> DNA	
<213> Streptococcus pneumoniae	
<400> 14	
atgtcacaag cacaatatgc aggtactgga cgtcgtaaaa acgctgttgc acgcg	ttcgc 60
cttgttccag gaactggtaa aatcactgtt aacaaaaaag atgttgaaga gtaca	tccca 120
cacgctgacc ttcgtcttgt catcaaccaa ccattcgcag ttacttcaac tgtagg	gttca 180
tacgacgttt tcgttaacgt tataggtggt ggatacgctg gtcaatcagg agcta	tccgt 240
cacggtatcg ctcgtgccct tcttcaagta gacccagact tccgcgattc attga	aacgc 300
gcaggacttc ttacacgtga ctcacgtaaa gttgaacgta agaaaccagg tcttaa	agaaa 360
gctcgtaaag catcacaatt tagtaaacgt	390
<210> 15	
<211> 999	
<212> DNA	
<213> Streptococcus pneumoniae	·
<400> <b>1</b> 5	
ttggagaaga aactgaccat aaaagacatt gcggaaatgg ctcagacctc gaaaac	aacc 60
gtgtcatttt acctaaacgg gaaatatgaa aaaatgtccc aagagacacg tgaaaa	gatt 120
gaaaaagtta ttcatgaaac aaattacaaa ccgagcattg ttgcgcgtag cttaaa	ctcc 180
aaacgaacaa aattaatcgg tgttttgatt ggtgatatta ccaacagttt ctcaaa	ccaa 240
attgttaagg gaattgagga tatcgccagc cagaatggct accaggtaat gatagg	aaat 300
agtaattaca gccaagagag tgaggaccgg tatattgaaa gcatgcttct cttggg	
gacggcttta ttattcagcc gacctctaat ttccgaaaat attctcgtat catcga	tgag 420
aaaaagaaga aaatggtctt ttttgatagt cagctctatg aacaccggac tagctg Page 14	ggtt 480

aaaaccaata	actatgatgc	cgtttatgac	atgacccagt	cctgtatcga	aaaaggttat	540
gaacattttc	tcttgattac	agcggatacg	agtcgtttga	gtactcggat	tgagcgggca	600
agtggttttg	tggatgcttt	aacagatgct	aatatgcgtc	acgccagtct	aaccattgaa	660
gataagcata	cgaatttgga	acaaattaag	gaatttttac	aaaaagaaat	cgatcccgat	720
gaaaaaactc	tggtatttat	ccctaactgt	tgggccctac	ctctagtctt	taccgttatc	780
aaagagttga	attataactt	gccacaagtt	gggttgattg	gttttgacaa	tacggagtgg	840
acttgctttt	cttctccaag	tgtttcgacg	ctggttcagc	cctcctttga	ggaaggacaa <sup>.</sup>	900
caggctacaa	agattttgat	tgaccagatt	gaaggtcgca	atcaagaaga	aaggcaacaa	960
gtcttggatt	gtagtgtgaa	ttggaaagag	tcgactttc			999

<210> 16

<211> 5301

<212> DNA

<213> Streptococcus pneumoniae

<400> 16						
atgaataaag	gattatttga	aaaacgttgt	aaatatagta	ttcggaaatt	ttcattaggt	60
gttgcttctg	ttatgattgg	agctgcattc	tttgggacaa	gtccggttct	tgcagatagc	120
gtgcagtctg	gttccacggc	gaacttacca	gctgatttag	ctactgctct	tgcaacagca	180
aaagagaatg	atgggcgtga	ttttgaagcg	cctaaggtgg	gagaagacca	aggttctcca	240
gaagttacag	atggacctaa	gacagaagaa	gaactattag	cacttgaaaa	agaaaaacco	300
gctgaagaaa	aaccaaaaga	ggataaacct	gcagctgcta	aacctgaaac	acctaagacg	360
gtaacccctg	aatggcaaac	ggtagcgaat	aaagagcaac	agggaacagt	Cactatoon	
gaagaaaaag	gtgtccgcta	caaccaacta	tcctcaactg	Ctcaaaataa	taacacacac	420
aaaccagccc	tgtttgaaaa	gaagggcttg	accottoato	CCaatogaaa	tacaactatt	480
gatttaacct	tcaaagatga	ttctgaaaag	ggcaaatcac	Octitantat	cttttta	540
tttaaagata	ccaagaataa	tatttttatc	ggttatgaca	addatageta	ctttttgaaa	600
tataaatctc	caacaactad	cacttagtat	nga mata at a	aggatggctg	gttctgggag	660
gattana	caacaactag	cactitygtat	agaggtagtc	gtgttgctgc	tcctgaaaca	720
gyaccaacaa	accgtctctc	tatcactctc	aagtcagacg	gtcagctaaa	tgccagcaat	780
aatgatgtca	atctctttga	cacagtgact	ctaccagctg	cggtcaatga	ccatcttaaa	840
aatgagaaga	agattcttct	caaggcgggc	tcttatgacg	atgagcgaac	agttgttagc	900
gttaaaacgg	ataaccaaga	gggggtaaaa	acagaggata	cccctgctga	aaaagaaaca	960
ggtcctgaag	ttgatgatag	caaggtgact	tatgacacga	ttcagtctaa	ggtcctcaaa	1020
gcagtgattg	accaagcctt	ccctcgtgtc	aaggaataca	gcttgaacgg	gcatacttta	
ccaggacagg	tgcaacagtt	caaccaagtc	tttatcaa+=	20020000	second -	1080
	-		Page 15	uccaccyaat	cacccctgaa	1140

-			~=====================================	en elemente de la medicale.	*	and the second of the second o	
		ayaaaattaa	tyayacaaca	gcagagtact	tgatgaagct	tcgcgatgat	1200
				cgcttgcaag			1260
				caagtcactc			1320
				ctcggcaatg			1380
-						tgtcagcgga	_1440
				aaggatttgg			1500
	tttgtttcta	cagataagct	tgctgctggt	gtttggagta	actctcaaaa	cagctatggt	1560
	ggtggttcga	atgactggac	tcgtttgaca	gcttataaag	aaacagtcgg	aaatgccaac	1620
				tgggaaaaag			1680
				aaggttgtta			1740
				attgcttatc			1800
				gcttaccgta			1860
	caagcacaaa	acccattcct	tatgaccttg	gatggtatca	agaaaatcaa	tctccataca	1920
				ggatatggta			1980
	cacttgaact	atgctgatat	tggtaagcgt	atcggtggtg	tcgaagactt	caagacccta	2040
				ctaggtatcc			2100
				attctccgta			2160
				atcaacattg			2220
				aagaaaaaac			2280
	atctatgtgg	acgtttgggg	taatggtcaa	tcaggtgata	acggtgcctg	ggctacccac	2340
	gttcttgcta	aagaaattaa	caaacaaggc	tggcgctttg	cgatcgagtg	gggccatggt	2400
				gcagctgact			2460
	aataaaggta	tcaacagtgc	catcacccgc	tttatccgta	accaccaaaa	agatgcttgg	2520
	gtaggggact	acagaagtta	tggtggtgca	gccaactatc	cactgctagg	tggctacagc	2580
	atgaaagact	ttgaaggctg	gcagggaaga	agtgactaca	atggctatgt	aaccaactta	2640
	tttgcccatg	acgtcatgac	taagtacttc	caacacttca	ctgtaagtaa	atgggaaaat	2700
	ggtacaccgg	tgactatgac	cgataacggt	agcacctata	aatggactcc	agaaatgcga	2760
	gtggaattgg	tagatgctga	caataataaa	gtagttgtaa	ctcgtaagtc	aaatgatgtc	2820
	aatagtccac	aatatcgcga	acgtacagta	acgctcaacg	gacgtgtcat	ccaagatggt	2880
	tcagcttact	tgactccttg	gaactgggat	gcaaatggta	agaaactttc	tactgataag	2940
	gaaaagatgt	actacttcaa	tacgcaggcc	ggtgcaacaa	cttggaccct	tccaagcgat	3000
	tgggcaaaga	gcaaggttta	cctttacaag	ctaactgacc	aaggtaagac	agaagagcaa	3060
	gaactaactg	taaaagatgg	taaaattacc	ctagatcttc	tagcaaatca	accatacgtt	3120
				atgtcatgga Page 16	gtgaaggcat	_	3180

geagaaattg tcaagtctca aggggcaaac gatatgcttc gtattcaagg aaacaaagaa 330 aaagttagtc tcactcagaa attaactggc ttgaaaccaa ataccaagta tgccgtttat 336 gttggtgtag ataaccgtag taatgccaag gcaagtatca ctgtgaatac tggtgaaaaa 342 gaagtgacta cttataccaa taagtctctc gcgctcaact atgttaaggc ctacgcccac 348 aatacacgtc gtgacaatgc tacagttgac gatacaaggt acttccaaaa catgtacgcc 354 ttcttacaa ctggagcgga cgtctcaaat gttactctga cattgagtcg tgaagctggt gatacaagcaa cttactttga tgaaattcg acctttgaaa acaattcaag catgtacgga 366 gacaagcaag atacaaggtaa aggcaccttc aagcaaggact ttgaaaatgt tgctcagggt 372 atcttcccat ttgtagtggg tggtgtcgaa ggtgttgaag ataaccgcac tcacttgtct 378 gaaaaacaca atccatatac acaacgtggt tggaatggta agaaagtcga tgatgttatc 384 gaaggaaatt ggtcactcaa gacaatggac taggtaggac gtcgtaactt ggttaccaa 390 aagagaagaat ggtcactcaa gacaatggac tggaaggcc gcgtaactt ggtttaccaa 390 aagagaagat cagacaatac ctatgctttt gtagtgggg ggtaggacaat ccagtgagac ctaggggagaatt ccagacgaga cacattccga aacttggaa atgatggac ggtaggagaatt ccagtcaggt 402 cgtcgtggtga ctcaagaagg caacttggaa atgactggat aggagaaatac cttggacagga accttcctt gtgacaggag atctcaagaag caacttggaa atgacaggac gagaaacag cgatacttgg 402 accatccac aagaaggc aacttctctt gtagacaggg cagaaacag cgatacttgg 420 acatacacca agaagga aacttctctt gtacagggg gtgattcaga gtgaagacag cgatacttgg 420 aacttccgtg gttataacga cttcatgatg gataatcttc aaatcgaaga aattacccta 420 aacttccgtg gttataacga cttcatgatg gataatcttc aaatcgaaga aattaccca 420 aacttccgtg gttataacga agaaggcgg gcagaatact tgccaacggt tgccaagact 420 aactacacca aagagtctat ggatgttg gaagaactact tgccaacggt tgccatgact 432 aactacacca agagtctat ggatgttg gaagacatact tgccaacggt tgccatgac 420 actgaagaa tgttgacaga aastgctcg gaagaactac tgccaacggt tgccatgac 432 aactacacca agaggtcta ggatgtggg agaagacca ctagtggcg ttcaagaaga actgcagaa actgcagga aactgcaga actgcagaa acaacacaa acaacaaca aaaagaatt gacaaagga aacaac	•						
aaagttagtc tcactcagaa attaactggc ttgaaaccaa ataccaagta tgccgtttat gttggtgtag ataaccgtag taatgccaag gcaagtatca ctgtgaatac tggtgaaaaa 342 gaagtgacta cttataccaa taagtctctc gcgctcaact atgttaaggc ctacgccac 348 aatacacgtc gtgacaatgc tacagttgac gatacaagtt acttccaaaa catgtacgcc 354 ttctttacaa ctggagcgga cgtctcaaat gttactctga cattgagtcg tgaagctggt 360 gaccaagcaag cttactttga tgaaattcgt acctttgaaa acaattcaag catgtacgga 366 gacaagcatg atacaggtaa aggcaccttc aagcaagact ttgaaaatgt tgctcaggga 372 atcttcccat ttgtagtggg tggtgtcgaa ggtgttgaag ataaccgcac tcacttgtct 378 gaaaacacaa atccataca acaacgtggt tggaatggta agaaagtcga tgatgttatc 384 gaaggaaatt ggtcactcaa gacaaatgga ctagtgagc gtcgtaactt ggtttaccaa 390 accatcccac aaacttccg ttttgaagca ggtaagacct accgtgtaac ctttgaatac 390 gaaggaagat cagacaatac ctatgctttt gtagtggga atgacggaagt ccagtcaggt 402 cgtcgtggta ccaagcaag caacttcgg ttggaatgcga agggagaatt ccagtcaggt 402 cgtcgtggta ccaagcaag caacttcgg tggaatgcga atgacggaagcga cagacatgga accettccg gtgaacggaa tgccaagaag cagacagaag accettccg gtgaacggaa atgcaagaag accettcgg aaatgcaag atgacagaa tgccaagaag cagacaatctgga aatgcacga aacttccgg gtaaacaacga caagaagga accettcaagaag accettccgg gtaaacacga caacaaggaagaagaagacgaaagacgaagaagaagaaga							3240
getoggetage ataaccgtag taatgccaag geaagtatea etggtgaatae tggtgaaaaa 342 gaagtgacta ettataccaa taagtetee gegeteaact atgttaagge etacgeccae 348 aatacacgte gfgacaatge tacagttgae gatacaagtt acttecaaaa catgtacgee 354 ttetttacaa etggagegga egetetaaat gttactega cattgagteg tgaagetggt 360 gatcaagcaa ettactttga tgaaattegt acetttgaaa acaatteaag catgtacgga 366 gacaagcatg atacaggtaa aggeacette aagcaagaet ttgaaaatgt tgeteagggt 372 atetteccat ttgtagtggg tggtgtegaa ggtgttgaag ataaccgcae teaettget 378 gaaaaacaca atecatatae acaacgtggt tggaatggta agaaagtega tgatgttate 384 gaaggaaatt ggteactcaa gacaaatgg etaggagee gtegtaacet ggttaccaa 390 accateccae aaaactteeg ttttgaagea ggtaagaeet agggagaatt eeagtaagge gaaggagaat eggeacatae etagettt gaagacgee gtegtaace ettgaatae 396 gaaggaggaa etagaaatae etagetttt gtagteggaa aggagagaatt eeagtaagge 402 egtegtggta etcaageaag caactteggaa atgecatgaat tgecaaatae ttggacaggat 402 egtegtggta etcaageag caacttegga atgecatgeta aggagaatt eeagtaagget 402 egtegtggta etcaageag caacttegga atgecatgat tgecaaatae ttggacaggat 408 etcaagaaag ceaagaagge aactteett gtgacaggtg eagaacaagg egatacttgg 414 etagaagaa tgttgacaga aatgecagt gataactete aactcagaga aattacecta 426 acaggtaaga tgttgacaga aaatgectg gaaaactaet tgccaaatae tggaaatgee 420 aacttecetg gttataacga etteatgaga gaaageegg gataacteet aactcagaga aattacecta 426 acaggtaaga tgttgacaga aaatgectg gaagaactaet tgccaacggt tgccatgaet 432 aactacacca aagagtetat ggatgettig aagageggg tecttaacet cagtcaggee 432 aatgettigg tteagaaga gaeggettig gaagactae ttgccaaagg tectacagee 432 aatgettigg tecagaaga gaeggettig gaagactae ettigcaag tetttacaget 432 aatgettigg tecagaaga gaeggettig gaagagatga actttegaag tettacaget 432 aatgettigg tecagaaga gaeggettig gaagagatg actttgeaag tettaagge 442 aatgettigg tecagaaga gaeggettig gaagagaea ettigeaag tettacaget 432 aatgetaact eaggaaga gagageegg gaagagaea ettigeag agtttgaaga aatgetgea 642 actgaaatae eaggaactee etagtteeg 62 actgaaatae etaggaaga gaagaeggegg  aagaegaea etagggaa aactettegga 442 aatgetaagaa etaggaaga egaggatgaga  gaagaegae aaccttee tggaagaaa							3300
gaagtgactacttataccaataagtctctcgegctcaactatgttaaggcctacgccac348aatacacgtcgtgacaatgctacagttgacgatacaagttacttccaaaacattgacgc354ttctttacaactggagcggacgtctcaaatgttactctgacattgagtcgtgaagctggt366gacaagcatgatacaggtaaaggacacttcaagacagactttgaaaatgttgctcagggt372atcttcccatttgtagtgggtgggtgtcgaaggtgttgaagataaccgcactcacttgtct378gaaaaacacaatccattaccacaacgtggttggaatggtaagaaagtcgatgatgttatc384gaaggaaattggcactcaaggcaatggaaataaccgcactcacttgtct378gaagagaattggcactcaagacaaatggactagtgagccgtcgtaactggtttaccaa390accatcccacaaaacttccgttttgaagcaggtaagacctaccgtgtaaccctttgaatac390aaccatcccacaaaacttccgttttgaagcaggtaagacctaccgtgaacctttgaatac390cgtcgtggtaccaagaaggccaacttggaaatgcaggaatccaagcagg402cgtcgtgggtaccaagaaggccaacttggaaatgcaaggaatggaagaagattcaggaagat402gaaggtatctactcaactggaacttccttgtgaacaggtcagaaacaggcgaaacagg420aacttccgtggttataacgaaatgcaagtaatactcggagaatactcttggaaatgat420aactacacacaaggtctatggatgtttggaagaactacttgccaagggtctttaacct420aactacacacaaggtctatggatgttg<							3360
aatacacgtc grgacaatgc tacagtrgac gatacaagtt acttccaaaa catgtacgcc 354 ttctttacaa ctggagcgga cgctctaaat gtactctga cattgagtcg tgaagctggt 360 gatcaagcaa cttactttga tgaaattcgt acctttgaaa acaattcaag catgtacgga 366 gacaagcatg atacaggtaa aggcaccttc aagcaagact ttgaaaatgt tgctcagggt 372 atcttcccat ttgtagtggg tggtgtcgaa ggtgttgaag ataaccgcac tcacttgtct 378 gaaaaacaca atccatatac acaacgtggt tggaatggta agaaagtcga tggtttacca 390 accatcccac aaaacttccg ttttgaagca ggtagtgac gtcgtaactt ggtttaccaa 390 accatcccac aaaacttccg ttttgaagca ggtaggacct accgtgtaac ctttgaatac 396 gaagcaggat ccaagcaaga caacttggaa atgcatgaat tgccaagata ccagtcaggt 402 cgtcgtggta ctcaagcaag caacttggaa atgcatgaat tgccaaatac ttggacagat 408 tctaagaaag ccaagaagg aaccttcctt gtgacaggt cagaaacagg cgatacttgg 414 gtaggtatct actcaactgg aaatgcaagt aatactcgg gtgattctgg tggaaatgcc 420 aacttccgtg gttataacga ctcatgatg gataatcttc aaatcgaaga aattacccta 426 acaggtaaga tgttgacaga aaatgctcg aagaactact tgccaacagg tgccatgact 420 aacttccgtg gttataacga ctcatgatg gataatcttc aaatcgaaga aattacccta 426 acaggtaaga tgttgacaga agaagcgcg gcagaactac tgccaacggt tgccatgact 432 aactacacca aagagtctat ggatgctttg aagaactact tgccaacggt tgccatgact 432 aatggttata tcagtgtgga agaagcgcgt gcagagattg ccaagagttg agctttgaag 444 aatgctttgg ttcagaaga gacggcttg gtagcagatg acctttgaag tcttacagct 450 cctgctcagg ctcaagaagg tcttgcaaat gcctttgatg gcaatgtgc tagtctatgg 456 cctgctcagg ctcaagaagg tcttgcaaat gcctttgatg gcaatgtgc tagtctatgg 468 actgaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taacttgga 468 actgaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taacttgga 468 actgaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taacttgga 468 actgaatca caggacttcg caagagac aaaagacca ctatggtgt agacgacca 462 actgaatca caggacttcg caagagac agacgacca ctatggtga agacgacca 462 actgaatca caggacttcg caagagac agacgacaca ctatggac agacgacaca 462 actgaatca caggacttcg gaatacaca gacatacag agacgacaca accgacacacacacacacacacac							3420
tetettacaa ctggagegga cgtetcaaat gttactetga cattgagteg tgaagetggt 360 gatcaagcaa cttactttga tgaaattegt acctttgaaa acaatteaag catgtacgga 366 gacaagcatg atacaggtaa aggcacette aagcaagact ttgaaaatgt tgetcagggt 372 atetteccat ttgtagtggg tggtgtcgaa ggtgttgaag ataacegcae teacttgtet 378 gaaaaacaca atecatataa acaactgggt tggaatggta agaaagtega tgatgttate 384 gaaggaaatt ggtcactcaa gacaaatgga ctagtgagee gtegtaactt ggtttaceaa 390 accateccae aaactteeg ttttgaagea ggtaagacet acegtgtaac ctttgaatac 396 gaagcaggat cagacaatac ctatgettt gtagteggta aggagagatt ceagteaggt 402 cgtegtggta cteaagcaag caacttegga atgeatggat tgeaaaacag cgatacttgg tetaagaaag ccaagaagge aacetteett gtgacaggt aggagaaat teggacaggat tetaagaag caagaagge aacetteett gtgacaggt cagaaacagg cgatacttgg tetaagaaag ccaagaagge aacetteett gtgacaggt cagaaacagg cgatacttgg tetaagaaag caactace aaatgeaga aatacteetg gtgacaggta tgeaaaacagg cgatacttgg tetaagaaag cttcaagaagg aatacteetg gtgacaggta tgeaaaacagg cgatacttgg tetaagaaga tgttgacaga aaatgeetg gataatette aaaategaaga aattaceeta 426 aactgagtaaga tgttgacaga aaatgeetg gataacteet tgecaacggt teecaagaet 420 aactacacca aagagtetat ggatgetttg aaagaageegg teettaaceet cagteaggee 432 aactacacca aagagtetat ggatgetttg aaagaageegg teettaaceet cagteaggee 432 aactgaagaa teagtgagga agaageegg geagagatg ccaagaattga agetttgaag 444 aatgetttgg teeagaaga gacggeettg gtageagatg ccaagattga agetttgaag 446 aatgetttgg teeagaaga gacggeettg gtageagatg ccaagattga agetttgaag 446 aatgetttgg teeagaaga gacggeettg gtageagatg geaatggteet tagetcaaget 450 cetgetcaagg cteagaagg teettgeaaa geettgaag geaatgteet tagetcaage 462 catacateet ggaatggtgg agatgagge atacetteet tgacaatgga 462 catacateet ggaatggtgg agatgagge atacetteet tgacaatgaa 462 aactgaaatca caggactee agaatgacg agatgagga atacetteet tgacaatgaa 460 aactgaaatca caggactee agaagacta ggeagaggac atacetteet tgacaatgaa 474 tggecaaata acacaaace aaaagatat ggeettggga ataaaceca atetggagga 474 tggecaaata acacaaace aaaagatat ggeagaggac atacetteet tgacaggaa aggeetage 474 tggecaaata acacaaace aaaagatat ggacaaagaca ateaagagga aga							3480
gatcaagcaacttactttgatgaaattcgtacctttgaaaacaattcaagcatgtacgga366gacaagcatgatacaggtaaaggcaccttcaagcaagactttgaaaatgttgctcagggt372atcttcccatttgtagtgggtggtgtcgaaggtgttgaagataaccgcactcacttgtct378gaaaaacacaatccatatacaccactgggttggaatggtaagaaagtcgatgatgttacc384gaaggaaattggtcactcaagacaaatggactagtgagccgtcgtaacttggttaccaa390accatcccccaaaacttccgttttgaagcaggtaagacctaccgtgtaacctttgaatac396gaagcaggatcagacaatacctatgcttttgtagtcggtaagggagaattccagtcaggt402cgtcgtggtgactcaagcaagcaacttggaaatgcatgaattgccaaatacttggacaggtcgtcgtggtactcaagcaagcaacttggaaatgcatgatttgccaaatacttggacaggttttaagaaagccaagaaggcaacttccttggtgaattctggtggaattctggtggaattctgggaagtgatactactcaactgggataatctcgggtgattctggtggaattctggtggaattgccaactacaccaaagagtctaccttcatgatggataatctcttgccaacggt420aactacaccaaagagtctacgatagcttggataatctcttgccaacggt420aactacaccaaagagtctacgatagacttcgtttaccaccggtgccatgacc432aactacaccaaagagtcttggatagcagttccaacaggttcttacacc432aatgetttggttcaagaagagcctagaagatgccttgacagagttttacacc450cctgct	aatacacgtc	gťgacaatgc	tacagttgac	gatacaagtt	acttccaaaa	catgtacgcc	3540
gacaagcatg         atacaggtaa         aggcaccttc         aagcaagact         ttgaaaatgt         tgctcagggg         372           atcttcccat         ttgtagtggg         tggtgtcgaa         ggtgttgaag         ataaccgcac         tcacttgtct         378           gaaaaacaca         atccatatac         acaacgtggt         tggaatggta         agaaagtcga         tgatgttatc         384           gaaggaaatt         ggtcactcaa         gacaaatgga         ctagtgagcc         gtcgtaact         ggtttaacaa         396           aacatcccac         aaaacttccg         ttttgaagca         ggtaagacct         accgtgtaac         ctttgaatac         396           gaagcaggat         cagacaatac         ctatgcttt         gtagtcggt         agggagaatt         ccagtcaggt         402           cgtcgtggga         ctcaagcaag         caacttggaa         atgcatgaag         tggaacagga         ttggacagat         402           catagaagag         caacttgcaag         aacttcaagaag         caacttgcaag         aacttcagaag         caacttcgg         420           aacttcaggaag         tcttcatgatg         gataatctc         gtgaaaatacc         420           aactgaagag         tttcatagatg         gataatctcg         tgccaagagt         tgccatgaactg         420           aactgatgaag	ttctttacaa	ctggagcgga	cgtctcaaat	gttactctga	cattgagtcg	tgaagctggt	3600
atcttcccat ttgtagtggg tggtgtcgaa ggtgttgaag ataaccgcac tcacttgtct 378 gaaaaacaca atccatatac acaacgtggt tggaatggta agaaagtcga tggatgttatc 384 gaaggaaatt ggtcactcaa gacaaatgga ctagtgagcc gtcgtaactt ggtttaccaa 390 accatcccac aaaacttccg ttttgaagca ggtaagacct accgtgtaac ctttgaatac 396 gaagcaggat cagacaatac ctatgctttt gtagtcggta agggagaatt ccagtcaggt 402 cgtcgtggta ctcaagcaag caacttggaa atgcatgaat tgccaaatac ttggacaggt 414 gtaggtactt accaactgg aaacgcatct gtgacaggt cagaaacagg cgatacttgg 414 gtaggtactt accaactgg aaatgcaagt aatactcgg gtgattctgg tggaaatgcc 420 accttccgtg gttataacga cttcatgatg gataatcttc aaaatcgaaga aattacccta 426 acaaggtaaga tgttgacaga aaatgcctg aggaactact tgccaacggt tgccatgact 432 acactacacca agagtctat ggatgcttg aaagaactact tgccaacggt tgccatgact 432 aatgctttgg ttcagaagaa gacggcgt gcagaagtgg ccaagatga agctttgaag 444 aatgctttgg ttcagaagaa gacggcgt gtagcaggatg ccaagatga agctttgaag 444 aatgctttgg ttcagaagaa gacggcgt gtagcaggatg ccaagatga accttcacagct 450 cctgctcagg ctcaagaagg tcttgcaaat gcctttgatg gcaatgtgtc tagtctatgg 456 catacactct ggaatggtg agatgtaggc agacctgcaa ctatggtct ggaagaacca 462 actgaaatca caggacttcg ctatgtccg cgtggatcag gttcaaatgg taacttgga 468 gatgtgaaac ttgttgtga agatgagct ggcaaggagc atacctttac tgcaactgat 474 tggccaaata acaacaacc aaaagatatt gactttggta agacaatcaa ggctaagaaa 480 attgtcctta ctggtaccaa gacatacaga gatggtgga ataacatcaa acctgcaacg 486 gaatgtcaatct ttaccgcc acaggtagc gaaggtggag ataacatcaa acctgcaacg 486 gaacttactct ttaccgcc acaggtagc gaagtgggag ataacatcaa acctgcaacg 486 gaacttactct ttaccgcc acaggtagc gaacacaccc ttgacttgc aggctaagaa 480 acttgccaaca gcaacaacc acaagataac gaacacacc ttgacatgaa agcgcaagaa 480 acttgccaaca gcaacacac gaacatacaa gacaacacca accaggcaagaa 480 acttgccaaca gacacacac gaacacacac accaggaaa agaagacaa 480 acttgccaaca gacacacac gacacacaca accacacac accaggaaa agaagacaa 480 acttgccaaca accacacac accaggaaa agaagacaca accacacac accaggaaa agaacacacac	gatcaagcaa	cttactttga	tgaaattcgt	acctttgaaa	acaattcaag	catgtacgga	3660
gaaaaacacaatccatatacacaacgtggttggaatggtaagaaagtcgatggatgttatc384gaaggaaattggtcactcaagacaaatggactagtgagccgtcgtaacttggtttaccaa390accatcccacaaaacttccgttttgaagcaggtaagacctaccgtgtaacctttgaatac396gaagcaggatcagacaatacctatgcttttgtagtcggtaagggagaattccagtcaggt402cgtcgtgggtactcaagcaagcaacttcggaaatgcatgaattggcaaatacttggacaggt414gtaggtatctaccaagcaagaaccttccttgtgacaggtcagaaacaggcgatacttgg420acttccgtggttataacgacttcatgatggataatcttcaaatcgaagaaattacccta426acaggtaagatgttgacagaaaatgcttgaagaactacttgccaacggttgccatgact432acatacaccaaagagtctatggatgctttgaaagaggcggtctttaacctcagtcaggcc438gatgatgatatcaggagaagatgctttggtagcagatgccaagattgaagctttgaagaatgctttggttcagaagaagacggctttggtagcagatgccaagattga426catacatctggaatggtgggtagcagatgcctttaacct432catacatcttggaatggtgggtagcagatgcctttaacct450catacatcttggaatggtgggcatttgaag4cttacagct450catacatcttggaatggtgggaatggtctgaaagaacca462aatggaaaccaggattggagatcctttactggcaactaga468gatggcaactctggttggagatacctttactggcaactaga480<	gacaagcatg	atacaggtaa	aggcaccttc	aagcaagact	ttgaaaatgt	tgctcagggt	3720
gaaaggaaattggtcactcaagacaaatggactagtgagccgtcgtaacttggtttaccaa390accatcccacaaaacttccgttttgaagcaggtaagacctaccgtgtaacctttgaatac396gaagcaggatcagacaatacctatgcttttgtagtcggtaagggagaattccagtcaggt402cgtcgtggtactcaagcaagcaacttggaaatgcatgaatttggacaagtattggacaggt408tctaagaaagccaagaaggcaaccttccttgtgacaggtgcagaaacaggcgatacttgg414gtaggtatctactcaactggaaatgcaagtaatactcgtggtgattctggtggaaatgcc420aacttccgtggttataacgacttcatgatggataatcttcaaatcgaagaaattacccta426acaggtaagatgttgacagaaaatgctctgaagaactacttgccaacggttgccatgact432aactacaccaaagagtctatggatgctttgaaagaggcggtctttaacctcagtcaggcc438gatgatgatatcagtgtggaagaagcgcgtgcaagagattgccaagattgaagctttgaag444aatgctttggttcagaagaagactggtgtggaagcagatgtcttacagct450cctgctcaggttcaagaagatcttgcaaatgcctttgatggcaatgtgtctagtctatggcatacatcttggaatggtggaagcttgaattcttacagct450catacatcttggaatggtggaagcttgaatgggttcaaatggtaacttgcga462aatggaaaccaggacttcgctagttcagagttcaaatggtaacttgcga462gatggcaaacttgttgtgaatacctttactgcaactgat474tggccaaata </td <td>atcttcccat</td> <td>ttgtagtggg</td> <td>tggtgtcgaa</td> <td>ggtgttgaag</td> <td>ataaccgcac</td> <td>tcacttgtct</td> <td>3780</td>	atcttcccat	ttgtagtggg	tggtgtcgaa	ggtgttgaag	ataaccgcac	tcacttgtct	3780
accateccae aaaactteeg tittgaagea ggtaagacet accgitgtaae cittgaatae gaageaggat cagacaatae citatgetitt gtagteggta agggagaatt ceagteaggt 402 cgtegtggta cicaageagg caactteggaa atgeatgaat tgeeaaatae titggacagat 408 tetaagaaag ceaagaagge aaccitectt gtgacaggtg cagaaacagg cgatacttgg 414 gtaggtatet acceaactgg aaatgeaagt aatacteeg gtgatitetgg tggaaatgee 420 aactiecgtg gitataacga citeatgatg gataateet acagggaaga aattaceeta 426 acaggstaaga tgitgacaga aaatgeeteg aagaactaet tgeeaacggt tgeeatgaet 432 aactacacea aagagtetat ggatgetitg aaagaageegg teettaaceet cagteaggee 438 gatgatgata teagtgigga agaageegg geaagaggg teettaaceet 426 aagagtagata teagaggaa agaageegg geaagaggg teettaaceet 426 aagagteeggatgata teagaggag agaageegg geaagaggg teettaaceet 432 aagagteeggg teetaagaegg 444 aaatgeettigg ticaagaaga gaeggeettig gtageagatg accitigaag 444 aatgeettigg ticaagaaga gaeggeettig gtageagatg accitigaag 426 ceatacacet ggaatgggg agatgtagg agactgeaga geaatggeet tageetaagg 456 catacactet ggaatgggg agatgtagge aageettegg geaaggate tageetagg 456 catacactet ggaatgggg agatgtagge agactgeaa ctatggeet ggaaagaacca 462 accgaaatea caggacteeg etatgteeg eggaaggae ataceettae tgeaactgaa 468 gaatggaaac 462 accgaaatea accacaace aaaagaatat ggeetaggaag ataacacea accettaac tgeaactgaa 480 aattgeetta etggacaaa accacacac acaggaagae gaacacacee ttgacetaga ageetagga 492 geageettigg taaagaaca accacaggagaa gaacacee 492 gaacettaet ttaceegee gaaattaaca gaacaaceee ttgaceggaa agtageetage 498 geageettigg taaagaaata tgeegacggat aaccaceee ttgaceggaa agtageetage 498 geageettigg taaagaaaa tgeegaaataa gaacaceee ttgaceggaa agtageetage 498 geageettigg attacegaa accacacac accacacaca accacacaca accacacaca accacacacacacacacacacacacacacacacacacaca	gaaaaacaca	atccatatac	acaacgtggt	tggaatggta	agaaagtcga	tgatgttatc	3840
gaagcaggatcagacaatacctatgcttttgtagtcggtaagggagaattccagtcaggt402cgtcgtggtactcaagcaagcaacttggaaatgcatgaattgccaaatacttggacagat408tctaagaaagccaagaaggcaaccttccttgtgacaggtgcagaaacaggcgatacttgg414gtaggtatctactcaactggaaatgcaagtaatactcgggtgattctggtggaaatgcc420aacttccgtggttataacgacttcatgatggataatcttcaaatcgaagaaattacccta426acaggtaagatgttgacagaaaatgctctgaagaactacttgccaacggttgccatgact432aactacaccaaagagtctatggatgctttgaaagaggcggtctttaacctcagtcaggcc438gatgatgatatcagtgtggaagaaggcgggtctttaacctcagtcaggcc436aatgctttggttcagaagaagacggctttggtagcagattgccaagattgatcttacagct450cctgctcaggctcaagaaggtcttgcaaatgccattgatgtcattgcaag462catacatcttggaatggtggaagccttgaactatggtcttgaaagaacca462actgaaatcacaggacttcgctatgttccgcgtggatcaggttcaaatggtaacttgcga468gatggaaacttgttgtgacagatgagtctggcaaggagcatacctttactgcaactgat474tggccaaataacaacaaaccaaaaggatatgactttggtaagaccatcaaggctaagaa480gaacttactttactcgtcacaggtagcagaacacacctttgacttgtcaggctatgaa492gcagctttggttaaggctagaaattacaagacaacacac	gaaggaaatt	ggtcactcaa	gacaaatgga	ctagtgagcc	gtcgtaactt	ggtttaccaa	3900
cestegara ctcaagcaag caacttegaa atgcatgaat tgccaaatac ttggacagat 408 tctaagaaag ccaagaaggc aaccttcctt gtgacaggtg cagaaacagg cgatacttgg 414 gtaggtatct actcaactgg aaatgcaagt aatactcgtg gtgattctgg tggaaatgcc 420 aacttccgtg gttataacga cttcatgatg gataactttc aaatcgaaga aattacccta 426 acaggtaaga tgttgacaga aaatgctctg aagaactact tgccaacggt tgccatgact 432 aactacacca aagagtctat ggatgcttg aaagaggcgg tctttaacct cagtcaggcc 438 gatgatgata tcagtgtgga agaagcgcgt gcagagattg ccaagattga agctttgaagg 444 aatgctttgg ttcagaaga gacggctttg gtagcagatg actttgcaag tcttacagct 450 cctgctcagg ctcaagaagg tcttgcaaat gcctttgatg gcaatgtgtc tagtctatgg 456 catacatctt ggaatggtg agatgtaggc aagctgcaa ctatggtctt gaaagaacca 462 actgaaatca caggacttcg ctatgtccg cgtggatcag gttcaaatgg taacttgcga 468 actgaaatca acaacaacc agaatgatc ggcaaggagc atacctttac tgcaactgat 474 tggccaaata acaacaaacc aaaagatat gactttggta agacaatcaa ggctaagaaa 480 aattgcctta ctggtaccaa gacatacaga gacaatacag gacagcactc ttgactgtc aggctatgaa 492 gcagctttgg ttaaggctca gaaataaca gacaacacct ttgacggaa agtagctagc 498 ggcagctttgg ttaaggctca gaaataaca gacaaagaca accacctc ttgacggaa aatggtggaa 504 cactttgcag attatctca ccaattaaaa gattctgcta cgaaaccaga tgctccaact 510 cacttgcagaaaaa ctaagagaaa ccaagacaa ctaagagaaa ccaaccaga tgctccaact 510 cacttgcagaaaaa ctaagagaaaa ccaacacaga ttaaccttaa ccaattaaaa gattctgcca agcaaggtaa gacgccagat 5160 cacttgcagaaaaa ccaacacac ctaagagaaa ccaaccaga ttaaccttaaccaacca ccaattaaaa gattctgcca agcaaggtaa gacgccagat 5160 cacttgcagaaaaa ccaacacac ctaagagaaaa ccaacacac 5160 cacttgcagaaaaa ccaacacacaccacaccacacaccacac	accatcccac	aaaacttccg	ttttgaagca	ggtaagacct	accgtgtaac	ctttgaatac	3960
tctaagaaag ccaagaaggc aaccttcctt gtgacaggtg cagaaacagg cgatacttgg 414 gtaggtatct actcaactgg aaatgcaagt aatactcgtg gtgattctgg tggaaatgcc 420 aacttccgtg gttataacga cttcatgatg gataacttc aaatcgaaga aattacccta 426 acaggtaaga tgttgacaga aaatgctctg aagaactact tgccaacggt tgccatgact 432 aactacacca aagagtctat ggatgctttg aaagaggcgg tctttaacct cagtcaggcc 438 gatgatgata tcagtgtgga agaaggcggt gcagagattg ccaagattga agctttgaagg 444 aatgctttgg ttcagaaga gacggctttg gtagcagatg actttgcaag tcttacagct 450 cctgctcagg ctcaagaagg tcttgcaaat gcctttgatg gcaatgtgtc tagtctatgg 456 catacatctt ggaatggtg agatgtaggc aagcctgcaa ctatggtctt gaaagaacca 462 actgaaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taacttgcga 466 gatgtgaaac ttgttgtgac agatgagtc ggcaaggagc atacctttac tgcaactgat 474 tggccaaata acaacaacc aaaagatat gactttggta agacaatcaa ggctaagaaa 480 attgtcctta ctggtaccaa gacatacgga gatggtggag ataaatacca atctgcagcg 486 gaacttact ttactcgtc acaggtagca gaaacacct ttgacttgtc aggctatgaa 492 gcagctttgg ttaaggctca gaaattaaca gacaacacct ttgacttgtc aggctatgaa 492 gcagctttgg ttaaggctca gaaattaaca gacaacacct ttgacttgtc aggctatgaa 5040 gttcaggcaa gcatgaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5040 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgagttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160	gaagcaggat	cagacaatac	ctatgctttt	gtagtcggta	agggagaatt	ccagtcaggt	4020
graggtatet acteaactgg aaatgcaagt aatactegtg gragatettgg tggaaatgce 4200 aactteegtg graatacga ceteatgatg gataatette aaategaaga aattaceeta 4260 acaggtaaga tgtegacaga aaatgeetetg aagaactace tgeeaacgget tgeeatgaeet 4320 aactacacca aagageetat ggatgeettg aaagaggegg teettaacet eageeaggee 4380 gatgatgata teeaggaga agaageegg geaggaattg eeaagattga ageettggaag 4440 aatgeettegg tteaagaaga gaeggeettg geaggagattg eeaaggattga ageettgaagg 4460 eetgeeteggee eetgeeteggeeggeeteggeegggeegggggggg	cgtcgtggta	ctcaagcaag	caacttggaa	atgcatgaat	tgccaaatac	ttggacagat	4080
aacttccgtg gttataacga cttcatgatg gataatcttc aaatcgaaga dattacccta 4266 acaggtaaga tgttgacaga aaatgctctg aagaactact tgccaacggt tgccatgact 4326 aactacacca aagagtctat ggatgctttg aaagaggcgg tctttaaccc cagtcaggcc 4388 gatgatgata tcagtgtgga agaagcgcgt gcagagattg ccaagattga agctttgaagg 4446 aatgctttgg ttcagaaga gacggctttg gtagcagatg actttgcaag tcttacagct 4506 cctgctcagg ctcaagaagg tcttgcaaat gcctttgatg gcaatgtgtc tagtctatgg 4566 catacatctt ggaatggtgg agatgtaggc aagcctgcaa ctatggtctt gaaagaacca 4626 actgaaatca caggacttcg ctatgtccg cgtggatcag gttcaaatgg taacttgcga 4566 gaatgtgaaac ttgttgtgac agatgagct ggcaaggagc atacctttac tgcaactgat 4746 tggccaaata acaacaacc aaaagatatt gactttggta agacaatcaa ggctaagaa 4806 gaacttatct ttactcgtcc acaggtagca gaacacccc ttgactgtc aggctatgaa 4926 gaacttatct ttactcgtcc acaggtagca gaacacccc ttgactgtc aggctatgaa 4926 gtcaggcaa gcatgaaata tgcgacggat aaccacctc ttgacggaaa gatggtggaa 5046 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5106 gtaggaaaaa ctgaggtaaa cctaggtttaa accttaggaaa ccaaggtagaa ccaaggtaagaa ccaaggtaagaa ccaaggtaagaa ccaaggtagaaa ccaaggtagaaa ccaaggtagaaa ccaaggaaaa ccaaggtagaa ccaaggtaagaa ccaaggtaagaa ccaaggaaaa ccaagaggaa attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtaggaaaaa ccaaggtaaaa ccaaggtagaa ccaaggtaagaa ccaaggtaagaaa ccaagagaaaa ccaagagaaaa ccaagaggaaaccaagacaaccaagagaaaccaagacaaccacc	tctaagaaag	ccaagaaggc	aaccttcctt	gtgacaggtg	cagaaacagg	cgatacttgg	4140
acaggtaaga tgttgacaga aaatgctctg aagaactact tgccaacggt tgccatgact 4320 aactacacca aagagtctat ggatgctttg aaagaggcgg tctttaacct cagtcaggcc 4380 gatgatgata tcagtgtgga agaaggcggt gcagagattg ccaaagattga agctttgaag 4440 aatgctttgg ttcagaaga gacggctttg gtagcagatg actttgcaag tcttacagct 4500 cctgctcagg ctcaagaagg tcttgcaaat gcctttgatg gcaatgtgtc tagtctatgg 4560 catacatctt ggaatggtgg agatgtaggc aagcctgcaa ctatggtct ggaaagaacca 4620 actgaaatca caggacttcg ctatgtccg cgtggatcag gttcaaatgg taacttgcga 4680 gatgtgaaac ttgttgtgac agatgagct ggcaaggagc atacctttac tgcaactgat 4740 tggccaaata acaacaacc aaaagatatt gactttggta agacaatcaa ggctaagaaa 4800 gaacttact ttactcgtcc acaggtagca gaacaccct ttgacttgtc aggctatgaa 4920 gaacttatct ttactcgtcc acaggtagca gaacacacct ttgacttgtc aggctatgaa 4920 gttcaggcaa gcatgaaata tgcgacggat aaccactct tgacggaaag aatggtggaa 5040 tacttgcag attactcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgaggttaa accttagatc ttaggttaa acttagatct ttagcttcaa ccaattaaaa gattctgcta cgaaaggtaa gacgccagat 5160 gtagagaaac ctgaggttaa accttagatct ttaggttaa accttagatct ttagcttgca gacaaggtaa gacgccagat 5160 gtagagaaac ctgaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatca gacaaggtaa gacgccagat 5160 gtagagaaac ctgaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttaa accttagatct ttaggttagaa gacgacaaggtaa gacgccagat 5160 gtagagaaaac ctgaggttaa accttagatct ttaggttagaa accttagatct ttaggttagaa accttagatct ttaggttagaa gacgacaaggtaa gacgccagat 5160 gtagagaaaacca ctgaggttaa accttagatct ttaggttagaa accttagagaaaacca acctagaggtaa gacgagaaaacca accaaaccaa							4200
aactacacca aagagtctat ggatgctttg aaagaggcgg tctttaacct cagtcaggcc 4386 gatgatgata tcagtgga agaagcgcgt gcagagattg ccaagattga agctttgaag 4446 aatgctttgg ttcagaagaa gacggctttg gtagcagatg actttgcaag tcttacagct 4506 cctgctcagg ctcaagaagg tcttgcaaat gcctttgatg gcaatgtgtc tagtctatgg 4566 catacatctt ggaatggtg agatgtaggc aagcctgcaa ctatggtctt gaaagaacca 4626 actgaaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taacttgcga 4686 gatgtgaaac ttgttgtgac agatgagct ggcaaggagc atacctttac tgcaactgat 4746 tggccaaata acaacaaacc aaaagatatt gactttggta agacaatcaa ggctaagaaa 4806 gaacttatct ttactcgcc acaggtagca gaacacccc ttgactgtc aggctatgaa 4926 gaacttatct ttactcgcc acaggtagca gaaacacccc ttgactgtc aggctatgaa 4926 gtcaggcaa gcatgaaata tgcgacggat aaccatctc tgacggaaag aatggtggaa 5046 tactttgcag attactcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5106 gtagagaaac ctgaggttaa acctaggtaa gacgacaggtaa gacgccagat 5166							4260
gatgatgata tcagtgtgga agaagcgcgt gcagagattg ccaagattga agctttgaag 4444 aatgctttgg ttcagaagaa gacggctttg gtagcagatg actttgcaag tcttacagct 4506 cctgctcagg ctcaagaagg tcttgcaaat gcctttgatg gcaatgtgtc tagtctatgg 4566 catacatctt ggaatggtgg agatgtaggc aagcctgcaa ctatggtctt gaaagaacca 4626 actgaaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taaccttgcga 4686 gatgtgaaac ttgttgtgac agatgagtct ggcaaggagc atacctttac tgcaactgat 4746 tggccaaata acaacaaacc aaaagatatt gactttggta agacaatcaa ggctaagaaa 4800 gaacttatct ttactcgtcc acaggtagca gaaacacctc ttgacttgtc aggctatgaa 4920 gcagctttgg ttaaggctca gaaattaaca gacaacacct ttgacttgtc aggctatgaa 4980 gtcaggcaa gcagcttgg ttaaggctca gaaattaaca gacaacacct ttgacttgtc aggctatgaa 4980 gtcaggcaa gcagcttgg ttaaggctca gaaattaaca gacaacacct ttgactgtc aggctatgaa 4980 gtcaggcaa gcagcttgg ttaaggctca gaaattaaca gacaacagaca atcaagagga agtagctagc 4980 gtcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5040 tacttgcag attactcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgagttaa accttagatct ttagcttccg agcaaggtaa gacgccagat 5160							4320
aatgetttgg tteagaagaa gaeggetttg gtageagatg actttgeaag tettacaget 4500 cetgeteagg eteaagaagg tettgeaaat geetttgatg geaatgtgee tagtetatgg 4560 catacatett ggaatggtgg agatgtagge aageetgeaa etatggetet gaaagaacea 4620 actgaaatea eaggaetteg etatgteeg egtggateag gtteaaatgg taacettgega 4680 gatgtgaaac ttgttgtgae agatgaget ggeaaggage atacetttae tgeaactgat 4740 tggeeaaata acaacaace aaaagatatt gaetttggta agacaateaa ggetaagaaa 4800 gaacttate teageegaa gaeaateagg gatggtggag ataaatacea acetgeageg 4860 gaacttatet ttaetegte acaggtagea gaaacacete ttgaettgte aggetatgaa 4920 geagetttgg ttaaggetea gaaattaaca gaeaaagaca ateaagagga agtagetage 4980 gtteaggeaa geatgaaata tgeegaeggat aaceateete tgaeggaaag aatggtggaa 5040 taetttgeag attaeteea eeaattaaaa gattetgeta egaaaceaga tgeeteeaact 5100 gtagagaaac etgaggttaa acetagaget ttaagetea gaegeeagat 5160 gtagagaaac etgaggttaa acetagaget ttaagetee gaeaaggtaa gaegeeagat 5160 gtagagaaac etgaggttaa acetagaget ttaagetee gaeaaggtaa gaegeeagat 5160 gtagagaaac etgaggtaa acetagagete ttageegaaag acetagagea gaegeeagat 5160 gtagagaaac etgaggtaa acetagagete ttageeteegaaceteegageagaa gaegeeagat 5160 gtagagaaac etgaggtaa acetagageteegaa acetagagaaaceteegaa							4380
catacatctt ggaatggtgg agatgtaggc aagcctgcaa ctatggtctt gaaagaacca 4620 actgaaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taacttgcga 4680 gatgtggaac ttgttgtgac agatgagtct ggcaaggagc atacctttac tgcaactgat 4740 tggccaaata acaacaacc aaaagatatt gactttggta agacaatcaa ggctaagaaa 4800 attgtcctta ctggtaccaa gacatacgga gatggtggag ataaatacca atctgcagcg 4860 gaacttatct ttactcgtcc acaggtagca gaaacacctc ttgacttgtc aggctatgaa 4920 gcagctttgg ttaaggcta gaaattaaca gacaaagaca atcaagagga agtagctagc 4980 gttcaggcaa gcatgaaata tgcggacggat aaccatctct tgacggaaag agtagctagc 4980 gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5040 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagaagaaac ctgagtttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160							4440
catacatctt ggaatggtgg agatgtaggc aagcctgcaa ctatggtctt gaaagaacca 4620 actgaaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taacttgcga 4680 gatgtgaaac ttgttgtgac agatgagtct ggcaaggagc atacctttac tgcaactgat 4740 tggccaaata acaacaacc aaaagatatt gactttggta agacaatcaa ggctaagaaa 4800 gaacttatct ctggtaccaa gacatacgga gatggtggag ataaatacca atctgcagcg 4860 gaacttatct ttactcgtcc acaggtagca gaaacacctc ttgacttgtc aggctatgaa 4920 gcagctttgg ttaaggctca gaaattaaca gacaaagaca atcaagagga agtagctagc 4980 gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5040 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgagttaa acctagatct ttagcttccg agcaaggtaa gacgccagat 5160							4500
actgaaatca caggacttcg ctatgttccg cgtggatcag gttcaaatgg taacttgcga 4686 gatgtgaaac ttgttgtgac agatgagtct ggcaaggagc atacctttac tgcaactgat 4746 tggccaaata acaacaacc aaaagatatt gactttggta agacaatcaa ggctaagaaa 4806 gaacttatct ctggtaccaa gacatacgga gatggtggag ataaatacca atctgcagcg 4866 gaacttatct ttactcgtcc acaggtagca gaaacacctc ttgacttgtc aggctatgaa 4926 gcagctttgg ttaaggctca gaaattaaca gacaaagaca atcaagagga agtagctagc 4986 gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5046 tactttgcag attatctaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5106 gtagagaaac ctgagttaa acctagatct ttagcttccg agcaaggtaa gacgccagat 5166							4560
gatgtgaaac ttgttgtgac agatgagtct ggcaaggagc atacctttac tgcaactgat 4746 tggccaaata acaacaacc aaaagatatt gactttggta agacaatcaa ggctaagaaa 4806 attgtcctta ctggtaccaa gacatacgga gatggtggag ataaatacca atctgcagcg 4866 gaacttatct ttactcgtcc acaggtagca gaaacacctc ttgacttgtc aggctatgaa 4926 gtcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag agtagctagc 4986 gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5046 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5106 gtagagaaac ctgagttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5166							4620
tggccaaata acaacaacc aaaagatatt gactttggta agacaatcaa ggctaagaaa 4800 attgtcctta ctggtaccaa gacatacgga gatggtggag ataaatacca atctgcagcg 4860 gaacttatct ttactcgtcc acaggtagca gaaacacctc ttgacttgtc aggctatgaa 4920 gcagctttgg ttaaggctca gaaattaaca gacaaagaca atcaagagga agtagctagc 4980 gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5040 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgagttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160							4680
attgtcctta ctggtaccaa gacatacgga gatggtggag ataaatacca atctgcagcg 4860 gaacttatct ttactcgtcc acaggtagca gaaacacctc ttgacttgtc aggctatgaa 4920 gcagctttgg ttaaggctca gaaattaaca gacaaagaca atcaagagga agtagctagc 4980 gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5040 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgagttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160							4740
gaacttatct ttactcgtcc acaggtagca gaaacacctc ttgacttgtc aggctatgaa 4920 gcagctttgg ttaaggctca gaaattaaca gacaaagaca atcaagagga agtagctagc 4980 gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5040 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgagttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160							4800
gcagctttgg ttaaggctca gaaattaaca gacaaagaca atcaagagga agtagctagc 4980 gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5040 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgagttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160							4860
gttcaggcaa gcatgaaata tgcgacggat aaccatctct tgacggaaag aatggtggaa 5040 tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgagttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160							4920
tactttgcag attatctcaa ccaattaaaa gattctgcta cgaaaccaga tgctccaact 5100 gtagagaaac ctgagtttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160	gcagctttgg	ttaaggctca	gaaattaaca	gacaaagaca	atcaagagga	agtagctagc	4980
gtagagaaac ctgagtttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160	gttcaggcaa	gcatgaaata	tgcgacggat	aaccatctct	tgacggaaag	aatggtggaa	5040
gtagagaaac ctgagtttaa acttagatct ttagcttccg agcaaggtaa gacgccagat 5160	tactttgcag	attatctcaa	ccaattaaaa	gattctgcta	cgaaaccaga	tgctccaact	5100
							5160
Page 17				cctgaacaaa			5220

Page 17

			catcctagca			tgctctcttt	
		cgaagaaaga			angece care	egetetetet	5280
		_					530:
	.7		•	•	_	•	
<211> 2	157	) 		tatione en est	والمتدام والمارة		
	NA						
<213> S	tre	ptococcus p	oneumoniae				
	.7 .ac	caacgattct	gcgcctaatc	aagtatctga	Ocattagett	cttoocatto	•
				gttttttct			60
				acttctagta			120
				cgcgtcaatg			180
				gaagaccatc			24
				ttgcgcaatc			30
							36
				aagttgactt			42
				gcttggttag			48
				ataaataagg			54
				tatggtaaag			60
				caggcaccaa			66
				ttggtcttat			72
				gtcaatacac			78
				tacatggata			840
				ctactcacaa			900
				tgggatattt			960
				tctaccattg			1020
				tcaagtaatg			1080
				actatgaaac			1140
				gctactatcg			1200
				tgggataggg			1260
				gtcccagccg			1320
				ggtctaggaa			1380
tactcaaa	tg (	ccatttcaag	taacacaacc	gaatcagaca	aaaaatatgg	agcaagtagt	1440
gaaaagat	gg (	ctgctgctta	cgctgccttt	gcaaatggtg	gaacttacta	taaaccaatg	1500
tatatcca	ta a	aagtcgtctt	tagtgatggg	agtgaaaaag Page 18	agttctctaa	tgtcggaact	1560

cgtgccatga	aggaaacgac	agcctatatg	atgaccgaca	tgatgaaaac	agtcttgact	1620
tatggaactg	gacgaaatgc	ctatcttgct	tggctccctc	aggctggtaa	aacaggaacc	1680
tctaactata	cagacgagga	aattgaaaac	cacatcaaga	cctctcaatt	tgtagcacct	1740
gatgaactat	ttgctggcta	tacgcgtaaa	tattcaatgg	ctgtatggac	aggctattct	1800
aaccgtctga	caccacttgt	aggcaatggc	cttacggtcg	ctgccaaagt	ttaccgctct	1860
atgatgacct	acctgtctga	aggaagcaat	ccagaagatt	ggaatatacc	agaggggctc	1920
tacagaaatg	gagaattcgt	atttaaaaaat	ggtgctcgtt	ctacgtggaa	ctcacctgct	1980
ccacaacaac	ccccatcaac	tgaaagttca	agctcatcat	cagatagttc	aacttcacag	2040
tctagctcaa	ccactccaag	cacaaataat	agtacgacta	ccaatcctaa	caataatacg	2100
caacaatcaa	atacaacccc	tgatcaacaa	aatcagaatc	ctcaaccagc	acaacca	2157

<210> 18

<211> 1392

<212> DNA

<213> Streptococcus pneumoniae

<400≻ 18 atgagtaaaa	aaagacgaaa	tcgtcataaa	aaagaaggtc	aagaaccgca	atttgatttt	60
				aaaatgaaga		120
				agcaacacag		180
				agttcgttga		240
				agtcagaagc		300
•				tggacgatga		360
				tgactgaaga		420
gagcaaaacc	tttctcgtct	ggatcaagag	gactcagaaa	agaaaagtaa	aaaaggcttt	480
attttgaccg	ttttggcgct	tgtatcagta	attatttgtg	tcagtgctta	ttatgtctac	540
cgtcaagtgg	ctcgttcgac	taaggaaatt	gaaacttctc	aatcaactac	agccaatcaa	600
tcggatgtgg	atgattttaa	tacactttat	gacgcctttt	acacagatag	caataaaacg	660
gctttgaaaa	atagccagtt	tgataaactg	agtcaactca	agactttact	tgataagctg	720
gaaggtagtc	gtgaacatac	gcttgccaaa	tctaaatatg	atagtctagc	aacgcaaatc	780
aaggctattc	aagatgtcaa	tgctcaattt	gagaaaccag	ctattgtgga	tggtgtgttg	840
gataccaatg	ccaaagccaa	atcggatgct	aaatttacgg	atattaaaac	tggaaatacg	900
gagcttgata	aagtgctaga	taaggctatc	agtcttggta	agagccagca	aacaagtact	960
tctagctcaa	gttcaagtca	aactagcagc	tcaagttcaa	gtcaagcaag	ttcaaatacg	1020
actagtgagc	caaaaccaag	tagttcaaat	gagactagaa Page 19	gtagtcgcag )	tgaagtcaat	1080

str pneumoniae patentin.ST25	
atgggtctct cgagtgcagg ggttgctgtt caaagaagtg ccagtcgtgt tgcct	ataat 1140
cagtctgcta ttgatgatag taataactct gcctgggatt ttgcggatgg tgtct	tggaa 1200
caaattctag cgacttcacg ttcacgtggc tatatcactg gagaccaata tatcc	ttgaa 1260
cgtgtcaata tcgttaacgg caatggttat tacaacctct acaagccaga tggaa	cctat 1320
ctctttaccc ttaactgtaa-gacaggetac tttgtcggaa-atggcgctgg-teatg	cggat 1380
gacttagatt ac	1392
<210> 19	
<211> 1020	
<212> DNA	
<213> Streptococcus pneumoniae	
	•
<400> 19	
atgaagettt tgaaaaaaat gatgeaagte geattageag tettttett tggtt	
gctacaaata cggtatttgc gaataccaca ggtggccgat ttgttgataa ggata	
aaatattatg taaaagatga tcataaagca atctattggc ataaaataga cggta	
tactattttg gtgatattgg agagatggtt gtcggttggc aatacttaga aattc	
acaggttatc gtgataattt attcgataac caaccagtta atgaaattgg ccttc	
aagtggtact attttggaca agatggtgct ttgctagaac aaacagataa acaag	
gaggcaaaaa cgtctgaaaa tacaggaaaa gtatacggtg aacaatatcc tctat	
gaaaagagaa cttattattt tgataataat tatgctgtaa agacaggctg gattt	
gagggtcatt ggtattattt aaataagcta ggaaattttg gcgatgattc ttaca	
ctaccaattg gtgaagttgc taagggttgg actcaagatt ttcatgttac tattg	acatt 600
gatagaagca aacctgctcc atggtactac ctagatgctt caggtaagat gctta	
tggcaaaaag taaacggaaa atggtattat tttggctcct ctggttctat ggcaa	
tggaaatatg tacgaggcaa atggtattac ttagataata aaaatggtga tatga	aaaca 780

ataggttgga caaaagtaaa tggaaaatgg tattatctca attcaaatgg agcaatggtt acaggtagcc aaactatcga tggtaaagtt tataatttcg cctcatctgg tgagtggatt

ggatggcaat accttggtaa caagtggtac tacctccgtt catcaggagc tatggtaact

ggctggtatc aagatggttc aacttggtac tatttagatc cttctaatgg agatatgaaa

<210> 20

<211> 996

<212> DNA

<213> Streptococcus pneumoniae

840

900

960

<400> atgaaa	20 attt	†02222222	tatocaaott	GG2 64 40 44 -	***		
			tatgcaagtt				60
gggacc	agta	cagtatttgc	agatgattct	gaaggatggc	agtttgtcca	agaaaacgga	120
agaacc	tact	acaaaaaggg	ggacctcaaa	gaaacctact	ggcgagtgat	tgatggtaag	180
tactat	tatt	ttgattctct	atctggagag	atggttgtcg	gctggcaata	tatcccgttt	240
ccatct	aaag	gtagtacaat	tggtccttac	ccaaatggta	tcagattaga	aggttttcca	300
aagtca	gagt	ggtactactt	cgataaaaat	ggagtgctac	aagagtttgt	tggttggaaa	360
acatta	gaga	ttaaaactaa	agacagtgtt	ggaagaaagt	acggggaaaa	acgtgaagat	420
			gcgttattat				480
ttagag	acag	gttggcttta	tgatcagtct	aactggtatt	atctagctaa	gacggaaatt	540
aatgga	gaaa	actaccttgg	tggtgaaaga	cgtgcggggt	ggataaacga	tgattcgact	600
tggtac	tacc	tagatccaac	aactggtatt	atgcaaacag	gttggcaata	tctaggtaat	660
aagtgg	tact	acctccgttc	ctcaggagca	atggccactg	gctggtatca	ggaaggtacc	720
			cccaaatggc				780
			ttcatcagga				840
tcaact	tggt	actacctaaa	tgcaggtaat	ggagacatga	agacaggttg	gttccaggtc	900
aatggc	aact	ggtactatgc	ttatagctca	ggtgctttgg	cagtgaatac	gaccgtagat	960
ggctat	tctg	tcaactataa	tggcgaatgg	gttcgg			996
<210>	21						
<211>	855						
<212>	DNA						

<212> DNA
<213> Streptococcus pneumoniae

<400> 21 atggttttat ctaagtatta tggagtagcc gatggaatga atgtagaagg gaggggaagt 60 gcgaatttta ttaaagataa tgtgttaatt acagcggctc acaactacta cagacatgac 120 tatgggaaag aagcggatga tatttatgtt cttccggctg ttagtccaag tcaagaacca 180 tttggaaaga tcaaagtaaa ggaagttcgt tatttgaagg aatttagaaa tttaaattct 240 aaggatgcaa gggaatatga cttggcttta ttaattctag aagagcccat tggtgcaaaa 300 ttagggactt tgggtcttcc tactagtcaa aaaaatttga caggaataac tgtgactatc 360 acaggctatc catcatataa ttttaaaatt catcaaatgt atacagataa aaaacaagtt 420 ttaagtgatg atggcatgtt cttggattac caagttgata ctttagaggg gtctagtgga 480 tctacagttt atgatgctag tcaccgtgta gtaggagtgc atactttagg agatggagct 540 aatcaaatta acagtgcagt taaattaaat gaacgaaatt tgccatttat ttattcggtt 600 Page 21

 enen 1.142	/ <del>***</del>	str pn	eumon <u>i</u> ae pa	tentin. <u>ST25</u>	1989 - Brandstander
cttaaaggtt	actctcttga	aggatggaag	aaaataaatg	gtagttggta	ccattataga
caacatgata	aacaaacaaa	ttaacaaaaa	ataaatnata	Cttaatatta	****

855----

660

1260

1320

1380

caacatgata aacaaacggg ttggcaggag ataaatgata cttggtatta tttagacagt 720
tccggtaaga tgcttacaga ttggcaaaaa gtaaatggaa aatggtatta tctcaattca 780
aatggagcaa tggttacagg tagccaaact atcgatggta aagtttataa cttcgcttca 840
tctggtgagt ggatt 855-

<210> 22

<211> 1890

<212> DNA

<213> Streptococcus pneumoniae

<400> 22						
	aaacttttt	cttactggtg	ttaggcttgt	tttgccttct	tccactctct	60
gtttttgcca	ttgatttcaa	gataaactct	tatcaagggg	atttgtatat	tcatgcagac	120
aatacggcag	agtttagaca	gaagatagtt	taccagtttg	aggaggactt	taagggccaa	180
atcgtgggac	ttggacgtgc	tggtaagatg	cctagcgggt	ttgacattga	ccctcatcca	240
aagattcagg	ccgcgaaaaa	cggtgcagaa	ctagcagatg	tgactagcga	agtaacagaa	300
gaagcggatg	gttatactgt	gagagtctat	aatccaggtc	aggagggcga	catagttgaa	360
gttgacctcg	tctggaactt	aaaaaattta	cttttccttt	atgatgatat	cgctgaatta	420
aattggcaac	ctctgacaga	tagttcagag	tctattgaaa	agtttgaatt	tcatgtaagg	480
ggagacaagg	gggctgaaaa	actctttttc	catacaggga	aactttttag	agagggaacg	540
attgaaaaga	gtaaccttga	ttatactatc	cgtttagaca	atcttccggc	taagcgtgga	600
gttgagttgc	atgcctattg	gcctcggacc	gattttgcta	gcgctaggga	tcagggattg	660
aaagggaatc	gtttagaaga	gtttaataag	atagaagact	cgattgttag	agaaaaagat	720
cagagtaaac	aactcgttac	ttgggtcctc	ccttcgatcc	tttccatctc	cttgttattg	780
agtgtctgct	tctattttat	ttatagaaga	aagaccactc	cttcagtcaa	atatgccaaa	840
aatcatcgtc	tctatgaacc	accaatggaa	ttagagccta	tggttttatc	agaagcagtc	900
tactcgacct	ccttggagga	agtgagtccc	ttggtcaagg	gagctggaaa	attcaccttt	960
gatcaactta	ttcaagctac	cttgctagat	gtgatagacc	gtgggaatgt	ctctatcatt	1020
tcagaaggag	atgcagttgg	tttgaggcta	gtaaaagaag	atggtttgtc	aagctttgag	1080
aaagactgcc	taaatctagc	tttttcaggt	aaaaaagaag	aaactctttc	caatttgttt	1140
gcggattaca	aggtatctga	tagtctttat	cgtagagcca	aagtttctga	tgaaaaacgg	1200

attcaagcaa gagggcttca actcaaatct tcttttgaag aggtattgaa ccagatgcaa

gaaggagtga gaaaacgagt ttccttctgg gggctcccag attattatcg tcctttaact

ggatttggtt	tgttcttgta	cagtttagac	gttcatggct	atctttacct	ccctttgcca	1440
atacttggtt	ttctagggtt	agttttgtct	gttttctatt	attggaagct	tcgactagat	1500
aatcgtgatg	gtgttctaaa	tgaagcggga	gctgaggtct	actatctctg	gaccagtttt	1560
gaaaatatgt	tgcgtgagat	tgcacgattg	gatcaggctg	aactggaaag	tattgtggtc	1620
tggaatcgcc	tcttggtcta	tgcgacctta	tttggctatg	cggacaaggt	tagtcatttg	1680
atgaaggttc	atcagattca	agtggaaaat	ccagatatca	atctctatgt	agcttatggc	1740
tggcacagta	cgttttatca	ttcaacagca	caaatgagcc	attatgctag	tgtcgcaaat	1800
acagcaagca	cctactctgt	atcttctgga	agtggaagtt	ctggtggtgg	cttctctgga	1860
ggcggaggtg	gcggcagtat	cggtgccttt				1890

<210> 23

<211> 1995

<212> DNA

<213> Streptococcus pneumoniae

### <400> 23 atgaaatcaa tcaacaaatt tttaacaatg cttgctgcct tattactgac agcgagtagc 60 ctgttttcag ctgcaacagt ttttgcggct gggacgacaa caacatctgt taccgttcat 120 aaactattgg caacagatgg ggatatggat aaaattgcaa atgagttaga aacaggtaac 180 tatgctggta ataaagtggg tgttctacct gcaaatgcaa aagaaattgc cggtgttatg 240 ttcgtttgga caaatactaa taatgaaatt attgatgaaa atggccaaac tctaggagtg 300 aatattgatc cacaaacatt taaactctca ggggcaatgc cggcaactgc aatgaaaaaa 360 ttaacagaag ctgaaggagc taaatttaac acggcaaatt taccagctgc taagtataaa 420 atttatgaaa ttcacagttt atcaacttat gtcggtgaag atggagcaac cttaacaggt 480 tctaaagcag ttccaattga aattgaatta ccattgaacg atgttgtgga tgcgcatgtg 540 tatccaaaaa atacagaagc aaagccaaaa attgataaag atttcaaagg taaagcaaat 600 ccagatacac cacgtgtaga taaagataca cctgtgaacc accaagttgg agatgttgta 660 gagtacgaaa ttgttacaaa aattccagca cttgctaatt atgcaacagc aaactggagc 720 gatagaatga ctgaaggttt ggcattcaac aaaggtacag tgaaagtaac tgttgatgat 780 gttgcacttg aagcaggtga ttatgctcta acagaagtag caactggttt tgatttgaaa 840 ttaacagatg ctggtttagc taaagtgaat gaccaaaacg ctgaaaaaac tgtgaaaatc 900 acttattcgg caacattgaa tgacaaagca attgtagaag taccagaatc taatgatgta 960 acatttaact atggtaataa tccagatcac gggaatactc caaagccgaa taagccaaat 1020 gaaaacggcg atttgacatt gaccaagaca tgggttgatg ctacaggtgc accaattccg 1080 gctggagctg aagcaacgtt cgatttggtt aatgctcaga ctggtaaagt tgtacaaact 1140 Page 23

٠٠.	Tamar and talking a con-		str.pn	eumoniae -pa	tentin st25			
	gtaactttga	caacagacaa	aaatacagtt	actgttaacq	gattggataa	aaatacagaa	1200	
						aatcactaca	1260	
		ttgctgtcaa					1320	
		ttgttacata					1380	
<b>-</b>	ttagctgggg	cagaatttgt	aattgcaaat	gctgataatg	Ctootcaata	tttagcacgt		·
	aaagcagata	aagtgagtca	agaagagaag	cagttggttg	ttacaacaaa	ggatgcttta	1500	
	gatagagcag	ttgctgctta	taacgctctt	actgcacaac	aacaaactca	gcaagaaaaa	1560	
						caacaatgca	1620	
	tttgaatggg	tggcagataa	ggacaatgaa	aatgttgtga	aattagtttc	tgatgcacaa	1680	
		aaattacagg <sup>.</sup>					1740	
	cctgctggtt	atgcattact	aactagccgt	cagaaatttg	aagtcactgc	aacttcttat	1800	
		gacaaggcat					1860	
	gtagtcaaca	aaaaaatcac	tatcccacaa	acgggtggta	ttggtacaat	tatctttqct	1920	
		ctgcgattat					1980	
	gaggatcaac					_	1995	
	<210> 24							
	<211> 837							
	<212> DNA							
		ptococcus p	neumoniae					
						•		
	<400> 24							
		tggcgtatcc					60	_
		actttgataa					120	
		cacaagcctt					180	
		tgaagaaaaa					240	
		atgtggaaat					300	
		tattgcagca					360	
		cccatgcggt					420	
		ccaaacttaa					480	
		aagtggatca					540	
		gtcatgatta					600	
		tggttcgggg					660	
		acaaactcag					720	•
	attgtgattc	ttttatggat	tattcgacgc	ttgcgcaaga	agaaaaaaca	accggaaaag	780	
				Page 24				

str preumontae patentin.s	ST25
gctttgaagg cgctgaaagc agcaaggaag gaagtgaagg tggagga	atgg acaacag 837
<210> 25	
<211> 849	
<212> DNA	
<213> Streptococcus pneumoniae	
<400> 25 atotcaagga ctaaactacg agcettattg ggatactact to the control of the contro	
atgtcaagga ctaaactacg agccttattg ggatacttgt tgatgtt	
attectattt attgttttgg acagatggtg ttgcagtctc ttggaca	
gctacatttg tgaaatccat gacaactgaa atgtaccaag aacaaca	
gcctacaatc aacgcttggc ttcgcaaaat cgcattgtag atccttt	
tatgaggtca attaccaagt gtctgacgac cctgatgcag tctatgg	
ccaagtttgg aaatcatgga gccggtttat ttgggagcag attatca	
ggcttggctc atgtggatgg tacaccgctg cctctggatg gtacagg	
attgctgggc accgtgcaga gccaagccat gtcttttcc gccattt	
gttggagatg ctctttatta tgataatggc caggaaattg tagaata	
acagagatta ttttaccgtc ggaatgggaa aaattagaat cggttag	
atgaccttga taacctgcga tccgattcct acctttaata aacgctt	
gaacgagtcg ctgtttatca aaaatcagat ccacaaacag ctgcagt	
tttacgaaag aaggacaatc tgtatcgcgt gttgcaacct ctcaatg	
ctagtggtac tggcatttct gggaatcctg tttgttttgt	agc acgtttacta 840
Cgagggaaa	849
<210> 26	
<211> 4977	
<212> DNA	
<213> Streptococcus pneumoniae	
<400> 26 atgaagaatc cattttttga aagacgttgt cgttacagta ttcgtaag	Tit atcagtagga co
gcctgctcgc tgatgattgg tgctgtttta tttgctggtc cagccttg	
gcagttcctg aaaatagcgg agctaataca gagcttgttt caggagag	
accaatgaag ctgataagca gaatgaaggg gaacatgcta gagaaaag	
gcagaaggag tagcgatagc atctgaaact gcttcgccag caagcaat	
actgaaactg cagaagcagc tagcgcagct aaaccagagg aaaaagca Page 25	ag tgaggtggtt 360
	•

· · · · · · · · · · · · · · · · · · ·		· str p	neumoniae p	atentin cro	E .		
		a agcaaaacc	t aagtetgae	300222	a agcaaagccc		er - Amazarra (m. 1921).
gaagcaacta	a accaagggg	a tgagtctaa:	. ccancancan	ayyaaacag	a agcaaagccc a gactgaaaaa	420	
gaagtccag	c cagatgtcc	c taaaaataca	. caaaaaacat	tanana	a gactgaaaaa a ggaaatcaaa	480	
tttaattct	t gggaagaati	gttaaaatg	. gaaccannto	. ctcatas	a ggaaatcaaa a tgatgctatt	540	
aaccgcgga1	t. etgttgtcci	cgcttcacgi	:-Caascaaato	: atttagtgaag	a tgatgctatt a tgaaaaagct	600	
agcaaggaag	g caaaagttca	agccttatca	l aacaccaatt	Ctanage	a agaccatgct		The same of the same
tctgttggtg	gagaagagtt	: caaggcctat	gcttttgact	attoncasts	a daccatgct a tctagattca	720	
atggtcttct	gggaaggtct	cgtaccaact	: CCtgacgtta	ttaatacaa	tcaccgtaac	780	
ggggttcctg	j tatacggtac	actcttcttc	aactggtcta	atagtattag	agatcaagaa	840	
agatttgctg	, aagctttgaa	gcaagacgca	gatggtagct	tcccaattac	ccgtaaattg	900	
gtagacatgg	ccaagtatta	tggctatgat	ggctatttca	tcaaccaaga	aacaactgga	960	
gatttggtta	ı aacctcttgg	agaaaagatg	cgccagttta	tgctctatao	caaggaatat	1020	
gctgctaagg	taaaccatcc	aatcaagtat	tcttggtacg	atgccatgac	: ctataactat	1080 1140	
ggacgttato	atcaagatgg	tttgggagaa	tacaactacc	aattcatgca	accagaagga	1200	
gataaggttc	cggcagataa	cttctttgct	aactttaact	gggataaggc	taaaaatgat	1260	
tacactattg	caactgccaa	ctggattggt	cgtaatcctt	atgatgtatt	tgcaggtttg	1320	
gaattgcaac	agggtggttc	ctacaagaca	aaggttaagt	ggaatgacat	tttagacgaa	1380	
aatgggaaat	tgcgcctttc	tcttggttta	tttgccccag	ataccattac	aagtttagga	1440	
aaaactggtg	aagattatca	taaaaatgaa	gatatcttct	ttacaggtta	tcaaggagac	1500	
cctactggcc	aaaaaccagg	tgacaaagat	tggtatggta	ttgctaacct	agttgcggac	1560	
cgtacgccag	cggtaggtaa	tacttttact	acttctttta	atacaggtca	tggtaaaaaa	1620	
tggttcgtag	atggtaaggt	ttctaaggat	tctgagtgga	attatcgttc	agtatcaggt	1680	
gttcttccaa	catggcgctg	gtggcagact	tcaacagggg	aaaaacttcg	tgcagaatat	1740	
gattttacag	atgcctataa	tggcggaaat	tcccttaaat	tctctggtga	tgtagccggt	1800	
aagacagatc	aggatgtgag	actttattct	actaagttag	aagtaactga	gaagaccaaa	1860	
CCCCGtGttg	cccacaaggg	aggaaaaggt	tctaaagttt	atatggcatt	ctctacaact	1920	
CCagactaca	aattcgatga	tgcagatgca	tggaaagagc	taaccctttc	tgacaactgg	1980	
* acadacydag	aatttgatct	tagctcacta	gcgggtaaaa	ccatctatgc	agtcaaacta	2040	
teggagete	atgaaggtgc	tgtaaaagat	tatcagttta	acctaggaca	attaactatc	2100	
ccygacaatc	accaagagcc	acaatcgccg	acaagctttt	ctgtagtgaa	acaatctctt	2160	
tatassatt	aagaagcgga	agcagttgtg.	caatttaaag	gcaacaagga	tgcagatttc	2220	
actatttata	atgaaaaaga	tggagacagc	tggaaattac	taactggctc	atcttctaca	2280	
actatttatc	caccaaaagt	tagccgctca	gcaagtgctc	agggtacaac	tcaagaactg	2340	
uayyıtytag	caytcggtaa	aaatggagtt	cgttcagaag Page 26	ctgcaaccac	aacctttgat	2400	

tggggtatga	ctgtaaaaga	taccagccta	ccaaaaccac	tagctgaaaa	tatcgttcca	2460
ggtgcaacag	ttattgatag	tactttccct	aagactgaag	gtggagaagg	tattgaaggt	2520
atgttgaacg	gtaccattac	tagcttgtca	gataaatggt	cttcagctca	gttgagtggt	2580
agtgtggata	ttcgtttgac	caagccacgt	accgttgtta	gatgggtcat	ggatcatgca	2640
ggagctggtg	gtgagtctgt	taacgatggc	ttgatgaaca	ctaaagactt	tgacctttat	2700
tataaagatg	cagatggtga	gtggaagcta	gctaaggaag	tccgtggtaa	caaagcacac	2760
gtgacagata	tcactcttga	taaaccaatc	actgctcaag	actggcgctt	gaatgttgtc	2820
acttctgaca	atggaactcc	atggaaggct	attcgtatct	ataactggaa	aatgtatgaa	2880
aagcttgata	ctgagagtgt	caatattccg	atggccaagg	ctgcagcccg	ttctctaggc	2940
aataacaagg	tacaagttgg	ctttgcagat	gtaccggctg	gagcaactat	taccgtttat	3000
gataatccaa	attctcaaac	tccgctcgca	accttgaaga	gcgaagttgg	aggagaccta	3060
gcaagtgcac	cattggattt	gacaaatcaa	tctggtcttc	tttattatcg	tacccagttg	3120
ccaggcaagg	aaattagtaa	tgtcctagca	gtttccgttc	caaaagatga	cagaagaatc	3180
aagtcagtca	gcctagaaac	aggacctaag	aaaacaagct	acgccgaagg	ggaggatttg	3240
gaccttagag	gtggtgttct	tcgagttcag	tatgaaggag	gaactgagga	cgaactcatt	3300
cgcctaactc	acgcaggtgt	atcagtatca	ggttttgata	cgcatcataa	gggagaacag	3360
aatcttactc	tccaatattt	gggacaaccg	gtaaatgcta	atttgtcagt	gactgtcact	3420
ggccaagacg	aagcaagtcc	gaaaactatt	ttgggaattg	aagtaagtca	ggaaccgaaa	3480
aaagattacc	tagttggtga	tagcttagac	ttgtctgaag	gacgctttgc	agtggcttat	3540
agcaatgaca	ccatggaaga	acattccttt	actgatgagg	gagttgaaat	ttctggttac	3600
			acgcttcatt			3660
			ttgaacgatg			3720
			gtctataact			3780
			gaacaagtgt			3840
			aaattgacag			3900
			gagcttgatc			3960
gaactcttgg	ctgccaaacc	aaaccatcct	tcaggttctg	ccctagctcc	gcttcttgag	4020
aaaaacaagg	ccttggttga	aaaagtagat	ttgagtccag	aagagcttac	aacagcgaaa	4080
cagagtctaa	aagatctggt	tgctttattg	aaagaagaca	agccagcagt	cttttctgat	4140
agtaaaacag	gtgttgaagt	acacttctca	aataaagaga	agactgtcat	caagggtttg	4200
aaagtagagc	gtgttcaagc	aagtgctgaa	gagaagaaat	actttgctgg	agaagatgct	4260
			aaaggtcaag			4320
			aagaaagtta			4380
gaaggcaaag	aggcagtaga	attggctttt	gaacaaacgg Page 27	atagtcatgt	tatctttaca	4440

						•		
. u.		versa essente e e	str.pn	eumoniae pa	tentin.ST25	······································	The fact of the limit	en en en en en en en en en en en en en e
	gcacctcact	ttactcatta	tgcctttgtt	tatgaatctg	ctgaaaaacc	acaacctgct	4500	
						ttctgatcaa	4560	
						tcaagagcat	4620	
	gaaaatactg	agatgctagt	.tggggaacaa	cgagtcatca	tacagggacg	agatggactg	4680	
•	ttaagacatg	fctttgaagt	tgatgaaaac	<sup>a</sup> ggtcagcgtc	gtcttcgttc	aacagaagtc	· · · 4740 · ·	
	atccaagaag	cgattccaga	aattgttgaa	attggaacaa	aagtaaaaac	agtaccagca	4800	
	gtagtagcta	cacaggaaaa	accagctcaa	aatacagcag	ttaaatcaga	agaagcaagc	4860	
	aaacaattgc	caaatacagg	aacagctgat	gctaatgaag	ccctaatagc	aggcttagcc	4920	
	agccttggtc	ttgctagttt	agccttgacc	ttgagacgga	aaagagaaga	taaagat	4977	
	<210> 27							
	<211> 146	1						
	<212> DNA							
	<213> Str	eptococcus ¡	oneumoniae					
	<400> 27							
		catcatttgt					60	
		ctcaacgtat					120	
		tggtttggga					180	
		gaaattgggc					240	
		ttgtcaataa					300	
		ttcgaaaaac					360	
		tcttgttacg					420	
		gtcattcgtt					480	
		caggagaatt					540	
		aacttggaga					600	
		tgaaccgttt					660	
		tttttggtat					720	
		acgaaattga					780	
		atacggatga					840	
	gggtcagaat	tagaaacaat	aaaaaataac	tttccagcag	aattacggag	ttctgaaaca	900	
	gctgatttat	ttatggctgt	cattatgtat	cgtttgaaag	aaaatggtcg	tgttggagtt	960	
	attttacctg	atggttttct	atttggtgaa	ggtgtaaaaa	ctcgcttgaa	acaaaaactg	1020	
	gtagatgagt	tcaacttgca	tacgattatt	aggttgcctc	atagtgtctt	tgcaccgtat	1080	
		atacgaacat		gataaaacaa			1140	
				Page 28				

ttttatcgtt	tagatatgcc	agatggttat	aaaaatttct	cgaaaactaa	gccgatgaag	1200
tcagaacact	tcaatcctgt	tcgtgactgg	tgggaaaatc	gtgaagagat	tctggaaggt	1260
aagttctaca	aatctaaatc	atttacacct	agtgaattgg	ctgagttgaa	ttataattta	1320
gaccagtgtg	actttccaaa	agaggaagag	gaaatcttaa	atccctttga	gttgattcag	1380
aattatcaag	cggaaagagc	aactttaaat	cataagattg	ataatgtatt	agctgatatt	1440
ttgcagttgt	tggaggacaa	a				1461

<210> 28

<211> 1134

<212> DNA

<213> Streptococcus pneumoniae

<400> 28						
atgaacaata	ctgaatttta	tgatcgtctg	ggggtatcca	aaaacgcttc	ggcagacgaa	60
atcaaaaagg	cttatcgtaa	gctttccaaa	aaatatcacc	cagatatcaa	caaggagcct	120
ggtgctgagg	acaagtacaa	ggaagttcaa	gaagcctatg	agactttgag	tgacgaccaa	180
aaacgtgctg	cctatgacca	gtatggtgct	gcaggcgcca	atggtggttt	tggtggagct	240
ggtggtttcg	gcggtttcaa	tggggcaggt	ggcttcggtg	gttttgagga	tattttctca	300
agtttcttcg	gcggaggcgg	ttcttcgcgc	aatccaaacg	ctcctcgcca	aggagatgat	360
ctccagtatc	gtgtcaattt	gacctttgaa	gaagctatct	tcggaactga	gaaggaagtt	420
aagtatcatc	gtgaagctgg	ctgtcgtaca	tgtaatggat	ctggtgctaa	gccagggaca	480
agtccagtca	cttgtggacg	ctgtcatggc	gctggtgtca	ttaacgtcga	tacgcagact	540
cctcttggta	tgatgcgtcg	ccaagtaacc	tgtgatgtct	gtcacggtcg	aggaaaagaa	600
atcaaatatc	catgtacaac	ctgtcatgga	acaggtcatg	agaaacaagc	tcatagcgta	660
catgtgaaaa	tccctgctgg	tgtggaaaca	ggtcaacaaa	ttcgcctcgc	tggtcaaggt	720
gaagcaggct	ttaacggtgg	accttatggt	gacttgtatg	tagtagtttc	tgtggaagct	780
agcgacaagt	ttgaacgtga	aggaacgact	atcttctaca	atctcaacct	caactttgtc	840
caagcggctc	ttggtgatac	agtagatatt	ccaactgttc	acggtgatgt	tgaattggtt	900
attccagagg	gaactcagac	tggtaagaag	ttccgcctac	gtagtaaggg	ggcaccgagc	960
cttcgtggcg	gtgcagttgg	tgaccaatac	gttactgtta	atgtcgtaac	accgacaggc	1020
ttgaacgacc	gccaaaaagt	agccttgaaa	gaattcgcgg	ctgctggtga	cttgaaagta	1080
aatccaaaga	aaaaaggctt	ctttgaccat	attaaagatg	cctttgatgg	agaa	1134

<210> 29

<211> 1359

## <213> Streptococcus pneumoniae

<400>, 29 atgaatccta atcttttag aagcgtcgag ttttatcaga gacgttacca taactatgcg	
	60
-acagtgttaa ttatacctct-ttcattacta-tttacttca tcttgatttt.etecettgtt	120
gccacaaaag aaattactgt tacttcccaa ggagaaatcg cccctacaag tgtcattgcc	180
tccattcagt caaccagtga taatcctatc ctagctaatc atttagtggc aaatcaagta	240
gttgaaaaag gggacttact catcaaatac tctgaaacaa tggaagaaag tcagaaaact	300
gccttagcaa ctcaattaca aagacttgag aagcaaaaag aaggacttgg aattttgaaa	360
caaagcttag aaaaagcgac tgatcttttt tctggcgagg atgaatttgg ctaccataat	420
acctttatga attttactaa acaatcccat gatattgaac tgggtatcac aaagactaac	480
accgaagttt caaatcaagc taatctttcc aatagcagtt catcagctat tgaacaagaa	540
attacaaaag ttcaacaaca aattggagaa tatcaagagt tgagagatgc tatcataaat	600
aacagagcac gcttaccaac tggcaatccg caccagtcaa ttttgaatcg ttatcttgta	660
gcctcacaag gacaaacaca aggaactgca gaggagccat ttttatctca aattaatcaa	720
agtattgcag gtcttgaatc atctatcgca agcctcaaaa ttcagcaagc tggtatcgga	780
agtgtagcaa cttatgataa cagtttagca accaaaattg aagtactccg cactcagttt	840
ttacagacag cctcacagca acaactaact gtggagaatc aattaacaga attaaaagta	900
caactagatc aagccacaca gcgtttggaa aacaatacct taacctcccc aagtaaaggt	960
atcgttcatc tgaacagcga atttgaaggt aaaaatagaa ttccaactgg tacagaaatt	1020
gctcaaatat tccctgtcat cacagataca agagaagtac taatcactta ctacgtatct	
tctgactatc tacctctact agataaagga caaactgtaa gattaaaact ggagaagatt	1080
ggaaatcacg gcaccaccat catcggccaa cttcagacaa ttgatcaaac tcctaccaga	1140
acagagcaag gaaatctctt taaattaacc gctcttgcaa aactatctaa cgaggatagt	1200
	1260
aaactcatcc aatatggctt acaaggtcgc gtcactagtg taactacaaa gaaaacatat	1320
tttgattatt tcaaagataa aattttaaca cattctgat	1359
<210> 30	•
<211> 393	
<212> DNA	
<213> Streptococcus pneumoniae	
· ·	

<400> 30 atgtcaaaga aactcaatcg taaaaaacaa ttacgaaatg gcctccgtcg cgcaggtgcc 60 ttttcaagta cggtgactaa ggttgtagat gagacaaaaa aagtcgtgaa gcgtgcagaa 120 Page 30

		5 t. pii(	cumorriae pa	CC11C 11113123		
cagtcagcaa	gcgcagctgg	taaggctgtt	tctaaaaaag	ttgaacaagc	agtagaagct	180
accaaagagc	aagctcaaaa	agtagctaat	tctgtagaag	attttgcagc	aaatttgggt	240
ggacttccac	ttgatcgtgc	caagactttc	tatgatgaag	gaatcaagtc	tgcttcagat	300
ttcaaaaact	ggactgaaaa	agaactcctt	gccttgaaag	gaatcggccc	agctaccatc	360
aagaaattga	aagaaaatgg	catcaagttc	aag			393
<210> 31		,				
<211> 762						
<212> DNA						
	eptococcus ¡	oneumoniae	•			
1225	op co co a cao	pricamorriae				
<400> 31						
ttgattagcc	ttttcggcct	tgctgctgcc	aaaccagtcc	aggctgatac	aagtatcgca	60
gacattcaaa	aaagaggcga	actggttgtc	ggtgtcaaac	aagacgttcc	caattttggt	120
tacaaagatc	ccaagaccgg	tacttattct	ggtatcgaaa	ccgacttggc	caagatggta	180
gctgatgaac	tcaaggtcaa	gattcgctat	gtgccggtta	cagcacaaac	ccgcggcccc	240
cttctagaca	atgaacaggt	cgatatggat	atcgcgacct	ttaccatcac	ggacgaacgc	300
aaaaaactct	acaactttac	cagtccctac	tacacagacg	cttctggatt	tttggtcaat	360
aaatctgcca	aaatcaaaaa	gattgaggac	ctaaacggca	aaaccatcgg	agtcgcccaa	420
ggttctatca	cccaacgcct	gattactgaa	ctgggtaaaa	agaaaggtct	gaagtttaaa	480
ttcgtcgaac	ttggttccta	cccagaattg	attacttccc	tgcacgctca	tcgtatcgat	540
accttttccg	ttgaccgctc	tattctatct	ggctacacta	gtaaacggac	agcactacta	600
gatgatagtt	tcaagccatc	tgactacggt	attgttacca	agaaatcaaa	tacagagctc	660
aacgactato	ttgataactt	ggttactaaa	tggagcaagg	atggtagttt	gcagaaactt	. 720
tatgaccgtt	: acaagctcaa	accatctage	catactgcag	at		762
<210> 32						
<211> 165	59					
<212> DNA	•					
<213> Str	reptococcus	pneumoniae				
<400> 32						
	_				aaatatgtac	60
					tcctgaaaat	120
					aaatagcgac	180
cgtattgct	gggttttct1	gacccacggg	catgcggatg Page 3		tctaccgtat	240

	-				·	
٠		str pneumoniae	patentin.s <u>r</u> 2		ANN AND ALLES OF THE SECOND STATES	
	ctcttggcag aggctaaagt to	cctgtattt gggtctga	gt tgaccattga	gttggcaaag	300	
	ctctttgtca aaggaaatga to	gccgttaag aaatttaa	tg atttccatgt	cattgatgag	360	
	aatacggaga ttgattttgg tg	gggacagtg gtttcctt	ct tccctacgac	ttactccgtt	420	
	ccagagagtc tgggaattgt ct	ttgaagaca tcggaagg	aa gcatcgttta	tacaggtgac	480	
~	-ttcaaatttg-accaaacgge-ta	agtgaatct tatgcaac	tg-attttgctcg	tttggcagag	-540	.m
	attggtcgtg acggcgtcct gg	ctctcctc agtgattc	gg ccaatgcaga	cagcaatatt	600	
	caggtggcta gtgaaagtga ag	gttagggat gaaattac	cc aaactattgc	tgactgggaa	660	
	ggtcgtatca tcgttgcagc tg	tttccagt aatctttc	c gtattcagca	gatttttgac	720	
	gctgcggata aaacaggtcg ac	gtatcgtc ttgacagg	at ttgatattga	aaatatcgtc	780	
	cgcacagcga ttcgtcttaa ga	agttgtct ttagccaa	g aaattcttt	gattaagcct	840	
	aaagatatgt ctcgctttga ag	accatgag ttgattat	c ttgagacagg	tcgtatgggt	900	
	gagcctatca atggacttcg ta	agatgtcg attggtcg	c atcgttatgt	agaaatcaag	960	
	gatggggacc tagtctatat tg	ctacggct ccgtctat	g ctaaagaagc	ctttgttgcg	1020	
	cgtgtggaaa atatgattta tc	aggcaggt ggggttgt	a aattgattac	ccaaagttta	1080	
	catgtatcag ggcacggaaa tg	tgcgtgat ttgcagct	ga tgatcaatct	tttgcaacct	1140	
	aagtacctct tccctgtcca ag	gggagtat cgtgagtt	Ig atgctcacgc	taaggctgcc	1200	
	atggcagttg ggatgttgcc ag	aacgcatc ttcattcc	a aaaaggggac	gaccatggct	1260	
	tacgagaatg gagactttgt tc	cagctgga tcggtttca	g caggagatat	cttgattgat	1320	
	gggaatgcca ttggtgatgt tg	gaaatgtt gttcttcg	g accgtaaggt	cttgtcagag	1380	
	gatggaattt tcatcgtggc ta	ttacagtc aaccgtcg	g agaagaaaat	tgtggctagg	1440	
	gctcgtgttc acacgcgtgg at	ttgtttat ctcaagaag	a gtcgcgatat	tctccgtgaa	1500	
	agttcagaat tgattaacca aa				1560	
	gcagatctca aaggtaaggt to			tcaaaccaag	1620	
	cgtcgcccag ccattttacc ag	tagtcatg gaagcaaaa			1659	
	<210> 33					
	<211> 6420					
	<212> DNA					•
	<213> Streptococcus pne	umoniae				
	, as some pine.					
	<400> 33					
	atgaaaaaaa gtacagtatt gto				60	
	cctaatgagg tagtcttagc aga				120	
	aaagaaaaag tagcagaaaa taa	aagagaaa catgaaaat	a tccatagtgc	tatggaaact	180	•

tcacaggatt ttaaagagaa gaaaacagca gtcattaagg aaaaagaagt tgttagtaaa Page 32

aatcctgtga	tagacaataa	cactagcaat	gaagaagcaa	aattcaaaga	agaaaattcc	300
aataaatccc	aaggagatta	tacggactca	tttgtgaata	aaaacacaga	aaatcccaaa	360
aaagaagata	aagttgtcta	tattgctgaa	tttaaagata	aagaatctgg	agaaaaagca	420
atcaaggaac	tatccagtct	taagaataca	aaagttttat	atacttatga	tagaatttt	480
aacggtagtg	ccatagaaac	aactccagat	aacttggaca	aaattaaaca	aatagaaggt	· 540
atttcatcgg	ttgaaagggc	acaaaaagtc	caacccatga	tgaatcatgc	cagaaaggaa	600
attggagttg	aggaagctat	tgattaccta	aagtctatca	atgctccgtt	tgggaaaaat	660
tttgatggta	gaggtatggt	catttcaaat	atcgatactg	gaacagatta	tagacataag	720
gctatgagaa	tcgatgatga	tgccaaagcc	tcaatgagat	ttaaaaaaaga	agacttaaaa	780
ggcactgata	aaaattattg	gttgagtgat	aaaatccctc	atgcgttcaa	ttattataat	840
ggtggcaaaa	tcactgtaga	aaaatatgat	gatggaaggg	attattttga	cccacatggg	900
atgcatattg	cagggattct	tgctggaaat	gatactgaac	aagacatcaa	aaactttaac	960
ggcatagatg	gaattgcacc	taatgcacaa	attttctctt	acaaaatgta	ttctgacgca	1020
ggatctgggt	ttgcgggtga	tgaaacaatg	tttcatgcta	ttgaagattc	tatcaaacac	1080
aacgttgatg	ttgtttcggt	atcatctggt	tttacaggaa	caggtcttgt	aggtgagaaa	1140
tattggcaag	ctattcgggc	attaagaaaa	gcaggcattc	caatggttgt	cgctacgggt	1200
aactatgcga	cttctgcttc	aagttcttca	tgggatttag	tagcaaataa	tcatctgaaa	1260
atgaccgaca	ctggaaatgt	aacacgaact	gcagcacatg	aagatgcgat	agcggtcgct	1320
tctgctaaaa	atcaaacagt	tgagtttgat	aaagttaaca	taggtggaga	aagttttaaa	1380
tacagaaata	taggggcctt	tttcgataag	agtaaaatca	caacaaatga	agatggaaca	1440
aaagctccta	gtaaattaaa	atttgtatat	ataggcaagg	ggcaagacca	agatttgata	1500
ggtttggatc	ttaggggcaa	aattgcagta	atggatagaa	tttatacaaa	ggatttaaaa	1560
aatgctttta	aaaaagctat	ggataagggt	gcacgcgcca	ttatggttgt	aaatactgta	1620
aattactaca	atagagataa	ttggacagag	cttccagcta	tgggatatga	agcggatgaa	1680
ggtactaaaa	gtcaagtgtt	ttcaatttca	ggagatgatg	gtgtaaagct	atggaacatg	1740
attaatcctg	ataaaaaaac	tgaagtcaaa	agaaataata	aagaagattt	taaagataaa	1800
ttggagcaat	actatccaat	tgatatggaa	agttttaatt	ccaacaaacc	gaatgtaggt	1860
gacgaaaaag	agattgactt	taagtttgca	cctgacacag	acaaagaact	ctataaagaa	1920
gatatcatcg	ttccagcagg	atctacatct	tgggggccaa	gaatagattt	acttttaaaa	1980
cccgatgttt	cagcacctgg	taaaaatatt	aaatccacgc	ttaatgttat	taatggcaaa	2040
tcaacttatg	gctatatgtc	aggaactagt	atggcgactc	caatcgtggc	agcttctact	2100
gttttgatta	gaccgaaatt	aaaggaaatg	cttgaaagac	ctgtattgaa	aaatcttaag	2160
ggagatgaca	aaatagatct	tacaagtctt	acaaaaattg	ccctacaaaa	tactgcgcga	2220.
cctatgatgg	atgcaacttc	ttggaaagaa	aaaagtcaat		acctagacaa	2280
			Page 33			

str pneumoniae patentin.ST25	
cagggagcag gcctaattaa tgtggccaat gctttgagaa atgaagttgt agcaactttc	2340
aaaaacactg attctaaagg tttggtaaac tcatatggtt ccatttctct taaagaaata	2400
aaaggtgata aaaaatactt tacaatcaag cttcacaata catcaaacag acctttgact	2460
tttaaagttt cagcatcagc gataactaca gattctctaa ctgacagatt aaaacttgat	2520
gaaacatata aagatgaaaa atctccagat ggtaagcaaa ttgttccaga aattcaceca	
gaaaaagtca aaggagcaaa tatcacattt gagcatgata ctttcactat aggcgcaaat	2640
tctagctttg atttgaatgc ggttataaat gttggagagg ccaaaaacaa aaataaattt	2700
gtagaatcat ttattcattt tgagtcagtg gaagaaatgg aagctctaaa ctccaacggg	2760
aagaaaataa acttccaacc ttctttgtcg atgcctctaa tgggatttgc tgggaattgg	2820
aaccacgaac caatccttga taaatgggct tgggaagaag ggtcaagatc aaaaacactg	2880
ggaggttatg atgatgatgg taaaccgaaa attccaggaa ccttaaataa gggaattggt	2940
ggagaacatg gtatagataa atttaatcca gcaggagtta tacaaaatag aaaagataaa	3000
aatacaacat ccctggatca aaatccagaa ttatttgctt tcaataacga agggatcaac	3060
gctccatcat caagtggttc taagattgct aacatttatc ctttagattc aaatggaaat	3120
cctcaagatg ctcaacttga aagaggatta acaccttctc cacttgtatt aagaagtgca	3180
gaagaaggat tgatttcaat agtaaataca aataaagagg gagaaaatca aagagactta	3240
aaagtcattt cgagagaaca ctttattaga ggaattttaa attctaaaag caatgatgca	3300
aagggaatca aatcatctaa actaaaagtt tggggtgact tgaagtggga tggactcatc	3360
tataateeta gaggtagaga agaaaatgea eeagaaagta aggataatea agateetget	3420
actaagataa gaggtcaatt tgaaccgatt gcggaaggtc aatatttcta taaatttaaa	3480
tatagattaa ctaaagatta cccatggcag gtttcctata ttcctgtaaa aattgataac	3540
accgccccta agattgtttc ggttgatttt tcaaatcctg aaaaaattaa gttgattaca	3600
aaggatactt atcataaggt aaaagatcag tataagaatg aaacgctatt tgcgagagat	3660
caaaaagaac atcctgaaaa atttgacgag attgcgaacg aagtttggta tgctggcgcc	3720
gctcttgtta atgaagatgg agaggttgaa aaaaatcttg aagtaactta cgcaggtgag	3780
ggtcaaggaa gaaatagaaa acttgataaa gacggaaata ccatttatga aattaaaggt	3840
gcgggagatt taaggggaaa aatcattgaa gtcattgcat tagatggttc tagcaatttc	3900
acaaagattc atagaattaa atttgctaat caggctgatg aaaaggggat gatttcctat	3960
tatctagtag atcctgatca agattcatct aaatatcaaa agcttggcga gattgcagaa	4020
tctaaattta aaaatttagg aaatggaaaa gagggtagtc taaaaaaaga tacaactggg	4080
gtagaacatc atcatcaaga aaatgaagag tctattaaag aaaaatctag ttttactatt	4140
gatagaaata tttcaacaat tagagacttt gaaaataaag acttaaagaa actcattaaa	4200
aagaaattta gagaagttga tgattttaca agtgaaactg gtaagagaat ggaggaatac	4260
gattataaat acgatgataa aggaaatata atagcctacg atgatgggac tgatctagaa Page 34	4320

+2+0222c+0	0.000		•			
latyadacty	agaaacttga	cgaaatcaaa	tcaaaaattt	atggtgttct	aagtccgtct	4380
aaayatggac	actttgaaat	tcttggaaag	ataagtaatg	tttctaaaaa	tgccaaggta	4440
tattatggga	ataactataa	atctatagaa	atcaaagcga	ccaagtatga	tttccactca	4500
aaaacgatga	catttgatct	atacgctaat	attaatgata	ttgtggatgg	attagctttt	4560
gcaggagata	tgagattatt	tgttaaagat	aatgatcaga	aaaaagctga	aattaaaatt	4620
agaatgcctg	aaaaaattaa	ggaaactaaa	tcagaatatc	cctatgtato	: aagttatggg	4680
aatgtcatag	aattagggga	aggagatctt	tcaaaaaaca	aaccagacaa	tttaactaaa	4740
atggaatctg	gtaaaatcta	ttctgattca	gaaaaacaac	aatatctgtt	aaaggataat	4800
atcattctaa	gaaaaggcta	tgcactaaaa	gtgactacct	ataatcctgg	aaaaacggat	4860
atgttagaag	gaaatggagt	ctatagcaag	gaagatatag	caaaaataca	aaaggccaat	4920
cctaatctaa	gagccctttc	agaaacaaca	atttatgctg	atagtagaaa	tgttgaagat	4980
ggaagaagta	cccaatctgt	attaatgtcg	gctttggacg	gctttaacat	tataaggtat	5040
caagtgttta	catttaaaat	gaacgataaa	ggggaagcta	tcgataaaga	cggaaatctt	5100
gtgacagatt	cttctaaact	tgtattattt	ggtaaggatg	ataaagaata	cactggagag	5160
gataagttca	atgtagaagc	tataaaagaa	gatggctcca	tgttatttat	tgataccaaa	5220
ccagtaaacc	tttcaatgga	taagaactac	tttaatccat	ctaaatctaa	taaaatttat	5280
gtacgaaatc	cagaatttta	tttaagaggt	aagatttctg	ataagggtgg	ttttaactgg	5340
gaattgagag	ttaatgaatc	ggttgtagat	aattatttaa	tctacggaga	tttacacatt	5400
gataacacta	gagattttaa	tattaagctg	aatgttaaag	acggtgacat	catggactgg	5460
ggaatgaaag	actataaagc	aaacggattt	ccagataagg	taacagatat	ggatggaaat	5520
gtttatcttc	aaactggcta	tagcgatttg	aatgctaaag.	cagttggagt	ccactatcag	5580
tttttatatg	ataatgttaa	acccgaagta	aacattgatc.	ctaagggaaa	tactagtatc	5640
gaatatgctg	atggaaaatc <sup>.</sup>	tgtagtcttt	aacatcaatg	ataaaagaaa	taatggattc	5700°
gatggtgaga	ttcaagaaca	acatatttat	ataaatggaa	aagaatatac	atcatttaat	5760
gatattaaac	aaataataga	caagacacta	aacattaaga	ttgttgtaaa	agattttgca	5820
agaaatacaa	ccgtaaaaga	attcatttta	aataaagata	cgggagaggt	aagtgaatta	5880
aaacctcata	gggtaactgt	gaccattcaa	aatggaaaag	aaatgagttc	aacgatagtg	5940
tcggaagaag	attttattt	acctgtttat	aagggtgaat	tagaaaaagg	ataccaattt	6000
gatggttggg	aaatttctgg	tttcgaaggt	aaaaaagacg	ctggctatgt	tattaatcta	6060
tcaaaagata	cctttataaa	acctgtattc	aagaaaatag	aggagaaaaa	ggaggaagaa	6120
aataaaccta	cttttgatgt	atcgaaaaag	aaagataacc	cacaagtaaa	ccatagtcaa	6180
ttaaatgaaa	gtcacagaaa	agaggattta	caaagagaag	agcattcaca	aaaatctgat	6240
tcaactaagg	atgttacagc	tacagttctt	gataaaaaca	atatcagtag	taaatcaact	6300
actaacaatc	ctaataagtt	gccaaaaact	ggaacagcaa	gcggagccca	gacactatta	6360
			Page 35			~>00

st	r pneumoniae p	atentin.ST25			
 gctgccggaa taatgtttat agtagg	The state of the s			6420	Series of the series
<210> 34					
<211> 6699		•			
<212> DNA					
<213> Streptococcus pneumon	iae	· • • · · · · · · · · · · · · · · · · ·		م استعاد الماسيد	ينهاها الماليا
<400> 34 atggggaaag gccattggaa tcggaaa	aaga gtttatagca	ttcgtaagtt	tgctgtggga	60	
gcttgctcag taatgattgg gacttg				120	
tctgtagttt atgcggatga aacact				180	
aaaatgatag tagaagaaaa ggctga	taaa gctttggaaa	ı ctaaaaatat	agttgaaagg	240	
acagaacaaa gtgaacctag ttcaac	gag gctattgca	ctgagaagaa	agaagatgaa	300	
gccgtaactc caaaagagga aaaagtg	tct gctaaaccg	g aagaaaaagc	tccaaggata	360	
gaatcacaag cttcaaatca agaaaaa	accg ctcaaggaaq	g atgctaaagc	tgtaacaaat	420	
gaagaagtga atcaaatgat tgaaga	tagg aaagtggati	ttaatcaaaa	ttggtacttt	480	
aaactcaatg caaattctaa ggaagc				540	
aaattagatt taccgtatga ctggag				600	
caaaatgaag gtggacagct caacgg				660	
gatgaaaaag acctcaagaa aaatgt				720	
caagtttatg tcaatggtca gttagt				780	
tatgatatca ccaaatacct tcaaaaa				840	
gtcaacaaac agccaagtag ccgttgg				900	
ttacaagtga cagataaggt gcatgt				960	
cttgaagaac aacaacatgg caaggtt	gaa actcatgtga	ccagcaaaaţ	cgtcaatacg	1020	

gtaacaggct tagttcgtac agcgagtcgt accttaaaag cacatgaatc aacaagccta 1140 gatgcgattt tagaagttga aagaccaaaa ctctggactg ttttaaatga caaacctgcc 1200 ttgtacgaat tgattacgcg tgtttaccgt gacggtcaat tggttgatgc taagaaggat 1260 ttgtttggtt accgttacta tcactggact ccaaatgaag gtttctcttt gaatggtgaa 1320 cgtattaaat tccatggagt atccttgcac cacgaccatg gggcgcttgg agcagaagaa 1380 aactataaag cagaatatcg ccgtctcaaa caaatgaagg agatgggagt taactccatc 1440 cgtacaaccc acaaccctgc tagtgagcaa accttgcaaa tcgcagcaga actaggttta 1500

1080

gacgacaaag accatgaact tgtagccgaa tatcaaatcg ttgaacgagg tggtcatgct

ctcgttcagg aagaggcctt tgatacgtgg tatggtggca agaaacctta tgactatgga 1560

cgtttctttg aaaaagatgc cactcaccca gaagctcgaa aaggtgaaaa atggtctgat 1620 Page 36

tttaacctac	* *********				•	
attact	gtaccatggt	cgaaagaggo	aaaaacaaco	ctgctatctt	: catgtggtca	1680
ttante	aaataggtga	agctaatggt	gatgcccact	ctttagcaac	: tġttaaacgt	1740
teggeraagg	ttatcaagga	tgttgataag	actcgctatg	ttaccatggg	agcagataaa	1800
ttccgtttcg	gtaatggtag	cggagggcat	gagaaaattg	ctgatgaact	cgatgctgtt	1860
ggatttaact	attctgaaga	taattacaaa	gcccttagag	ctaagcatcc	aaaatggttg	1920
atttatggat	cagaaacatc	ttcagctacc	cgtacacgtg	gaagttacta	tcgccctgaa	1980
cgtgaattga	aacatagcaa	tggacctgag	cgtaattatg	aacagtcaga	ttatggaaat	2040
gatcgtgtgg	gttgggggaa	aacagcaacc	gcttcatgga	cttttgaccg	tgacaacgct	2100
ggctatgctg	gacagtttat	ctggacaggt	acggactata	ttggtgaacc	tacaccatgg	2160
cacaaccaaa	atcaaactcc	tgttaagagc	tcttactttg	gtatcgtaga	tacagccggc	2220
attccaaaac	atgacttcta	tctctaccaa	agccaatggg	tttctgttaa	gaagaaaccg	2280
atggtacacc	ttcttcctca	ctggaactgg	gaaaacaaag	aattagcatc	caaagtagct	2340
gactcagaag	gtaagattcc	agttcgtgct	tattcgaatg	cttctagtgt	agaattgttc	2400
ttgaatggaa	aatctcttgg	tcttaagact	ttcaataaaa	aacaaaccág	cgatgggcgg.	2460
acttaccaag	äaggtgcaaa	tgctaatgaa	ctttatcttg	aatggaaagt	tgcctatcaa	2520
ccaggtacct	tggaagcaat	tgctcgtgat	gaatctggca	aggaaattgc	tcgagataag	2580
attacgactg	ctggtaagcc	agcggcagtt	cgtcttatta	aggaagacca	tgcgattgca	2640
gcagatggaa	aagacttgac	ttacatctac	tatgaaattg	ttgacagcca	ggggaatgtg	2700
gttccaactg	ctaataatct	ggttcgcttc	caattgcatg	gccaaggtca	actggtcggt	2760
gtagataacg	gagaacaagc	cagccgtgaa	cgctataagg	cgcaagcaga	tggttcttgg	2820
attcgtaaag	catttaatgg	taaaggtgtt	gccattgtca	aatcaactga	acaagcaggg	2880
aaattcaccc	tgactgccca	ctctgatctc	ttgaaatcga	accaagtcac	tgtctttact	2940
ggtaagaaag	aaggacaaga	gaagactgtt	ttggggacag	aagtgccaaa	agtacagacc	3000
attattggag	aggcacctga	aatgcctacc	actgttccgt	ttgtatacag	tgatggtagc	3060
cgtgcagaac	gtcctgtaac	ctggtcttca	gtagatgtga	gcaagcctgg	tattgtaacg	3120
gtgaaaggta	tggctgacgg	acgagaagta	gaagctcgtg	tagaagtgat	tgctcttaaa	3180
tcagagctac	cagttgtgaa	acgtattgct	ccaaatactg	acttgaattc	tgtagacaaa	3240
tctgtttcct	atgttttgat	tgatggaagt	gttgaagagt	atgaagtgga	caagtgggag	3300
attgccgaag	aagataaagc	taagttagca	attccaggtt	ctcgtattca	agcgaccggt	3360
tatttagaag	gtcaaccaat	tcatgcaacc	cttgtggtag	aagaaggcaa	tcctgcggca	3420
cctgcagtac	caactgtaac	ggttggtggt	gaggcagtaa	caggtcttac	tagtcaaaaa	3480
ccaatgcaat	accgcactct	tgcttatgga	gctaagttgc	cagaagtcac	agcaagtgct	3540
aaaaatgcag	ctgttacagt	tcttcaagca	agcgcagcaa	acggcatgcg	tgcgagcatc	3600
tttattcagc	ctaaagatgg	tggccctctt	caaacctatg Page 37	caattcaatt	ccttgaagaa	3660
			_			

		a		e emple contraction e en		Transaction of the transaction of	
	-gcyceaaaa	90000000	- gagettycaa	r-grggaaaaag	-ctgacagtc1	- caaagaagac -	3720
	CadaCtgtCa	aattgtcggt	tcgagctcad	: tatcaagatg	gaacgcaago	tgtattacca	3780
	gctgataaaq	] taaccttctc	tacaagtggt	gaaggggaag	; tcgcaattcg	taaaggaatg	3840
	cttgagttg	: ataagccagg	agcagtcact	ctgaacgctg	g aatatgaggg	agctaaagac	3900
<b>~</b> .	caagttgaac	tcactatcca	agccaatact	gagaagaaga	ttgcgcaatc	catccgtcct	3960
	gtaaatgtag	, tgacagattt	gcatcaggaa	ccaagtcttc	: cagcaacagt	aacagttgag	4020
	tatgacaaag	, gtttccctaa	aactcataaa	gtcacttggc	aagctattco	gaaagaaaaa	4080
	ctagactcct	: atcaaacatt	tgaagtacta	ggtaaagttg	aaggaattga	ccttgaagcg	4140
	cgtgcaaaag	; tctctgtaga	aggtatcgtt	: tcagttgaag	aagtcagtgt	gacaactcca	4200
	atcgcagaag	caccacaatt	accagaaagt	gttcggacat	atgattcaaa	tggtcacgtt	4260
	tcatcagcta	aggttgcatg	ggatgcgatt	cgtccagagc	aatacgctaa	ggaaggtgtc	4320
	tttacagtta	atggtcgctt	agaaggtacg	caattaacaa	ctaaacttca	tgttcgcgta	4380
	tctgctcaaa	ctgagcaagg	tgcaaacatt	tctgaccaat	ggaccggttc	agaattgcca	4440
	cttgcctttg	cttcagactc	aaatccaagc	gacccagttt	caaatgttaa	tgacaagctc	4500
	atttcctaca	ataaccaacc	agccaatcgt	tggacaaact	ggaatcgtac	taatccagaa	4560
	gcttcagtcg	gtgttctgtt	tggagattca	ggtatcttga	gcaaacgctc	cgttgataat	4620
	ctaagtgtcg	gattccatga	agaccatgga	gttggtgtac	cgaagtctta	tgtgattgag	4680
	tattatgttg	gtaagactgt	cccaacagct	cctaaaaacc	ctagttttgt	tggtaatgag	4740
	gaccatgtct	ttaatgattc	tgccaactgg	aaaccagtta	ctaatctaaa	agcccctgct	4800
	caactcaagg	ctggagaaat	gaaccacttt	agctttgata	aagttgaaac	ctatgctgtt	4860
	cgtattcgca	tggttaaagc	agataacaag	cgtggaacgt	ctatcacaga	ggtacaaatc	4920
	tttgcgaaac	aagttgcggc	agccaagcaa	ggacaaacaa	gaatccaagt	tgacggcaaa	4980
	gacttagcaa	acttcaaccc	tgatttgaca	gactactacc	ttgagtctgt	agatggaaaa	5040
	gttccggcag	tcacagcaag	tgttagcaac	aatggtctcg	ctaccgtcgt	tccaagcott	5100
	cgtgaaggtg	agccagttcg	tgtcatcgcg	aaagctgaaa	atggcgacat	Cttaggagaa	5160
	taccgtctgc	acttcactaa	ggataagagc	ttactttctc	ataaaccagt	tactacaatt	5220
	aaacaagctc	gcttgctaca	agtaggtcaa	gcacttgaat	tgccgactaa	qqttccaqtt	5280
	tacttcacag	gtaaagacgg	ctacgaaaca	aaagacctga	cagttgaatg	qqaaqaaqtt	5340
	ccagcggaaa	atctgacaaa	agcaggtcaa	tttactgttc	gaggccqtqt	CCttggtagt	5400
	aaccttgttg	ctgagatcac	tgtacgagtg	acagacaaac	ttggtgagac	tctttcagat	5460
i	aaccctaact	atgatgaaaa	cagtaaccag	gcctttgctt	cagcaaccaa	toatattoac	5520
	aaaaactctc	atgaccgcgt	tgactatctc	aatgacggag	atcattcana	aaatcotcot	5580
-	tggacaaact	ggtcaccaac	accatcttct	aatccagaag	tatcagenna	totoat+++c	
(	cgtgaaaatg	gtaagattgt	agaacggact	gttacacaaa	gaaaan+ra	attetttaes	5640
		_		Page 38	Januagetta	yeccityca	5700


gatagtggta	cggatgcacc	atctaaactc	gttttagaac	gctatgtcgg	tccagagttt	5760
gaagtgccaa	cctactattc	aaactaccaa	gcctacgacg	cagaccatcc	attcaacaat	5820
ccagaaaatt	gggaagctgt	tccttatcgt	gcggataaag	acattgcagc	tggtgatgaa	5880
atcaacgtaa	catttaaagc	tatcaaagcc	aaagctatga	gatggcgtat	ggagcgtaaa	5940
gcagataaga	gcggtgttgc	gatgattgag	atgaccttcc	ttgcaccaag	tgaattgcct	6000
caagaaagca	ctcaatcaaa	gattcttgta	gatggaaaag	aacttgctga	tttcqctqaa	6060
aatcgtcaag	actatcaaat	tacctataaa	ggtcaacggc	caaaagtctc	agttgaagaa	6120
aacaatcaag	tagcttcaac	tgtggtagat	agtggagaag	atagctttcc	agtacttgtt	6180
cgcctcgttt	cagaaagtgg	aaaacaagtc	aaggaatacc	gtatccactt	gactaaggaa	6240
aaaccagttt	ctgagaagac	agttgctgct	gtacaagaag	atcttccaaa	aatcgaattt	6300
gttgaaaaag	atttggcata	caagacagtt	gagaaaaaag	attcaacact	gtatctaggt	6360
				gtatctttac		6420
				aagttccgac		6480
				aaccacaagt		6540
				ctaataaagc		
						6600
				gtttaactct	tctaggtttg	6660
aytycaggat	tagtagttac	taaaggtaaa	aaagaagac			6699

<210> 35

<211> 5643

<212> DNA

<213> Streptococcus pneumoniae



str pneumoniae patentin.ST25	
gaagaagtag-gtggagaagt tgagtcaaaa ccagaggaaa aagtagcagt taagccagaa	
agtcaaccat cagacaaacc agctgaggaa tcaaaagttg aacaagcagg tgaaccagtc	720
gcgccaagag aagacgaaaa ggcaccagtc gagccagaaa agcaaccaga agctcctgaa	780
gaagagaagg ctgtagagga aacaccgaaa caagaagagt caactccaga taccaaggct	840
gaagaaactg tagaaccaaa agaggagact gttaatcaat ctattgaaca accaaaagtt	900
gaaacgcctg ctgtagaaaa acaaacagaa ccaacagagg aaccaaaagt tgaacaagca	960
ggtgaaccag tcgcgccaag agaagacgaa caggcaccaa cggcaccagt tgagccagaa	1020
aagcaaccag aagttcctga agaagagaag gctgtagagg aaacaccgaa accagaagat	1080
aaaataaagg gtattggtac taaagaacca gttgataaaa gtgagttaaa taatcaaatt	1140
gataaagcta gttcagtttc tcctactgat tattctacag caagttacaa tgctcttgga	1200 1260
cctgttttag aaactgcaaa aggtgtctat gcttcagagc ctgtaaaaca gcctgaggta	1320
aatagcgaga caaataaact taaaacggct attgacgctc taaacgttga taaaactgaa	1380
ttaaacaata cgattgcaga tgcaaaaaca aaggtaaaag aacattacag tgatagaagt	1440
tggcaaaacc tccaaactga agttacaaag gctgaaaaag ttgcagctaa tacagatgct	1500
aaacaaagtg aagttaacga agctgttgaa aaattaactg caactattga aaaattggtt	1560
gaattatctg aaaagccaat attaacattg actagtaccg ataagaaaat attggaacgt	1620
gaagctgttg ctaagtatac tctagaaaat caaaacaaaa	1680
gctgaattga aaaaaggaga agaagttatt aatactgtag tccttacaga tgacaaggta	1740
acaacagaaa ctataagcgc tgcatttaag aacctagagt actacaaaga atacacccta	1800
tctacaacta tgatttacga cagaggtaac ggtgaagaaa ctgaaactct agaaaatcaa	1860
aatattcaat tagatcttaa aaaagttgag cttaaaaata ttaaacgtac agatttaatc	1920
aaatacgaaa atggaaaaga aactaatgaa tcactgataa caactattcc tgatgataag	1980
agcaattatt atttaaaaat aacttcaaat aatcagaaaa ctacattact agctgttaaa	2040
aatatagaag aaactacggt taacggaaca cctgtatata aagttacagc aatcgcagac	2100
aatttagtct ctagaactgc tgataataaa tttgaagaag aatacgttca ctatattgaa	2160
aaacctaaag tccacgaaga taatgtatat tataatttca aagaattagt ggaagctatt	2220
caaaacgatc cttcaaaaga atatcgtctg ggacaatcaa tgagcgctag aaatgttgtt	2280
cctaatggaa aatcatatat cactaaagaa ttcacaggaa aacttttaag ttctgaagga	2340
aaacaatttg ctattactga attggaacat ccattattta atgtgataac aaacgcaacg	2400
ataaataatg tgaattttga aaatgtagag atagaacgtt ctggtcaaga taatattgca	2460
tcattagcca atactatgaa aggttcttca gttattacaa atgtcaaaat tacaggcaca	2520
ctttcaggtc gtaataatgt tgctggattt gtaaataata tgaatgatgg aactcgtatt	2580
gaaaatgttg ctttctttgg caaactacac tctacaagtg gaaatggctc tcatacaggg	2640
ggaattgcag gtacaaacta tagaggaatt gttagaaaag catatgttga tgctactatt Page 40	2700

acaggaaaca	aaacacgcgc	cagcttgtta	gttcctaaag	tagattatgg	attaactcta	2760
gaccatctta	ttggtacaaa	agctctccta	actgagtcgg	ttgtaaaagg	taaaatagat	2820
gtttcaaatc	cagtagaagt	tggagcaata	gcaagtaaga	cttggcctgt	aggtacggta	2880
agtaattctg	tcagctatgc	taagattatc	cgtggagagg	agttattcgg	ctctaacgac	2940
gttgatgatt	ctgattatgc	tagtgctcat	ataaaagatt	tatatgcggt	agagggatat	3000
tcgtcaggta	atagatcatt	taggaaatct	aaaacattta	ctaaattaac	taaagaacaa	3060
gctgatgcta	aagttactac	tttcaatatt	actgctgata	aattagaaag	tgatctatct	3120
cctcttgcaa	aacttaatga	agaaaaagcc	tattctagta	ttcaagatta	taacgctgaa	3180
tataaccaag	cctataaaaa	tcttgaaaaa	ttaataccat	tctacaataa	agattatatt	3240
gtatatcaag	gtaataaatt	aaataaagaa	caccatctaa	atactaaaga	agttctttct	3300
gttaccgcga	tgaacaacaa	tgagtttatc	acaaacctag	atgaagctaa	taaaattatt	3360
gttcactatg	cggacggtac	aaaagattac	tttaacttgt	cttctagcag	tgaaggttta	3420
agtaatgtaa	aagaatatac	tataactgac	ttaggaatta	aatatacacc	taatatcgtt	3480
caaaaagata	acactactct	tgttaatgat	ataaaatcta	ttttagaatc	agtagagctt	3540
		gcatctaaat				3600
		aagcttcaca				3660
acaaaattag	ttcaaaacga	agaacatcaa	ctaaatgatt	ctccagctgc	tcgtcaaatg	3720
		aaacaaagca				3780
		tggtgatgtt				3840
		tagcgtatta				3900
		tacattcgac				3960
		atttttaaat				4020
		tgatgctaca				4080
		aaattctaaa				4140
		cccactactg				4200
		ctttggtagt				4260
gatattaaag	atatcgttaa	caaagctgca	gatggttata	gaaactatta	tgatttctgg	4320
tatcgtctag	cgtctgataa	cgttaaacaa	cgactactaa	gagatgctgt	tattcctatt	4380
tgggaaggtt	ataacgctcc	tggtggatgg	gttgaaaaat	atggccgcta	taataccgac	4440
aaagtatata	ctcctcttag	agaattcttt	ggtcctatgg	ataagtatta	taattataat	4500
ggaacaggag	cttatgctgc	tatatatcct	aactctgatg	atattagaac	tgatgtaaaa	4560
tatgttcatt	tagaaatggt	tggtgaatac	ggtatttcag	tttacacaca	tgaaacaaca	4620
cacgtcaacg	accgtgcgat	ttacttaggt	ggctttggac	accgtgaagg	tactgatgct	4680
gaagcatatg	ctcagggtat	gctacaaact	cctgttactg Page 41		tgatgagttt	4740

	•						
		str pn	eumoniae pa	tentin.sT25			
	ggttctttag gtattaatat					4800	- 11112 22 (2 )
	acagatccaa aaactctaaa					4860	
	gacactttaa ctcttcttga						
	gatttaaata gtgcatggtt	caaaaaaata	gatagagaat	accotoataa		4920	
• ~	aatcaatggg_ataaaattcg.	.aaatctaagt.	. caagaagaga		- 222121102	4980	
	tctgttaatg atttagttga	tcaacaatta	atgactaatc	acaatccaaa	taatatttaa		e eministrati annon mesanesse. L
	tataaacccg aagcaattag	Ctataacgat	caatcacctt	atataaatat	taatggtatc	5100	
	accggtatct acggaggtaa					5160	
						5220	
	aatgctttta gattatgggg	taaaacaaat	catgadaatg	ggttcttagg	ttatgcttca	5280	
	aataaatata aacaacaatc	tacatttant	ggtgagtctg	ttctaagtga	tgaatatatt	5340	
	atcaagaaaa tatctaacaa					5400	
	aaagaagtta aagataaagc					5460 <sub>.</sub>	
	gtttcatcat acgatgattt					5520	
	actcttaaac aagaagcaaa					5580	
	aaagaagctg tttataagaa	acttcttcaa	caaacaaata	gctttaaaac	ttcaatcttt	5640	
	aaa					5643	
	<210> 36						
	<211> 996						
	<212> DNA						
	<213> Streptococcus p	neumoniae					
	p op op oo oo oo o	Treumon rae					
	<400> 36	•					
	atgaataaac gtctattttc	aaaaatgagt	ctggtgacgt	tgccaatttt	agccttgttt	60	
	tcacaatcag ttttggcgga					120	
	aatggctatt cggatattca					180	
	catgatggtg tggcttgcga					240	
	tcaacggcta ttcaaatcaa					300	
	aggasttagt astastttag			_ 32 333		300	

aatggctatt cggatattca cgaggagaa cctggttatt ctgccaagtt agaccgtgat 180 catgatggtg tggcttgcga attgaaaaat gctcctaagg gtgctttaa agcaaaacag 240 tcaacggcta ttcaaatcaa cacaagttca gcaacaacaa gtggttgggt taagcaggac 300 ggcgcttggt actactttga tggaaatgga aatctagtga aaaatgcatg gcagggaagc 360 tattacctga aagctgatgg taaaatggca cagagtgaat ggatttatga ctcttcttat 420 caagcttggt attatttgaa atcagatggt tcttatgcaa aaaatgcatg gcaaggagct 480 tattacctta aatcaaacgg taaaatggca caaggtgagt gggtttatga ttcttcttac 540 caagcatggt attacttgaa atcagatggt tcatatgctc gcaatgcatg gcaaggaaac 600 tactatttga aatcagatgg taaaatggct aaaggtgaat gggtttatga tgccacctat 660 caagcttggt attattgac atcagatggt tcttatgctt acagtacatg gcaaggaaat 720 Page 42

tactat	ctaa	aatcggatgg	taaaatggct	gtcaatgaat	gggttgatgg	tggacgttat	780
tatgtt	ggcg	ctgacggagt	ttggaaggaa	gttcaagcaa	gtacagcttc	ttctagtaat	840
gatago	aata	gtgaatattc	tgctgcttta	ggaaaggcaa	aaagttataa	ttcgttattc	900
cacatg	tcaa	aaaaacgtat	gtatagacaa	ttaacttctg	attttgataa	attttcaaat	960
		aatatgccat					996

<210> 37

<211> 1350

<212> DNA

				taaaataa	tanatraatt	<400> 37
60	ggccaagtct	ttttaggttt	aaagtccttg	taaaaataag	cagaccaacc	a cycludy cad
120			ctaggtgcca			
180	caaggtcatt	aagaagggat	agtttgctgg	agctgcccaa	aggacaatcc	aaacctttcg
240	gaaaaatcca	cccttatggt	gaagagtttg	actcttggat	atcctttgga	acaggtggcc
300	tccagtcttg	ccaagggaat	aaggctttgg	catgattgaa	acaacaatcc	ggtatcccct
360			gaagcaccga			
420	tggccaacat	tgactgctgc	ggggaagttt	gactatgatt	caaccacaac	aacggtaaga
480	agcatcagat	ttgctcaaat	gctagtcagg	cggctatcca	cagggaatat	ggtcttttat
540	agaattccat	tgggtgttca	ttccaactca	actttcttct	ttgttatgga	aaggacacgc
600	tgggtcattt	tcgactacca	ccaactcata	caacctcatg	cggttattac	ccagagattg
660			cagaacaaga			
720			gacttgactt			
780			ggagcttatc			
840			gaaatcggtg			
900			aagcttcgtg			
960			aaacaccgtc			
1020			tcaactaata			
1080			ttgattgcag			
1140			ggactcaaga			
1200			aaggctggtg			
1260			gagcttgcga			
			tatgctaact			
1320	rygcyaccic	yaay tacy			cagtagcgga	
1350			Dago 43	3		, J

str	pneumoniae	patentin.	ST25
-----	------------	-----------	------

str pneumoniae patentin.ST25	:
<210> 38	
<211> 1158	
<212> DNA	
<213> Streptococcus pneumoniae	· · · · · · · · · · · · · · · · · · ·
The state of the s	مين منه المرادية والمرادية الم
<400> 38 atgaagaaa aatttgcct atcgtttata aaatt	
atgaagaaaa aatttgccct atcgtttgtg gcgcttgcaa gtgtagcact tcttgca	agcc 60
tgtggagaag tgaagtctgg agcagtcaac actgctggta actcagtaga ggaaaag	gaca 120
attaaaatcg ggtttaactt tgaagaatca ggttctttag ctgcatacgg aacagct	gaa 180
caaaaaggtg cccaattggc tgttgatgaa atcaatgccg caggtggtat cgatgga	aaaa 240
caaatcgaag tagtcgataa agataataag tctgaaacag ctgaggctgc ttcagtt	aca 300
actaaccttg taacccaatc taaagtatca gcagtcgtag gacctgcgac atctggt	:gcg 360
actgcagctg cggtagcgaa cgctacaaaa gcaggtgttc cattgatctc accaagt	gcg 420
actcaagatg gattgactaa aggtcaagat tacctcttta ttggaacttt ccaagat	agc 480
ttccaaggaa aaattatctc aaactatgtt tctgaaaaat taaatgctaa gaaagtt	gtt 540
ctttacactg acaatgccag tgactatgct aaagggattg caaaatcttt ccgcgag	tca 600
tacaagggtg aaatcgttgc agatgaaact ttcgtagcag gtgacacaga cttccaa	gca 660
gcccttacaa aaatgaaagg gaaagacttt gatgctatcg ttgttcctgg ttactat	aat 720
gaggctggta aaattgtaaa ccaagcgcgt ggcatgggaa ttgacaaacc aatcgtt	ggt . 780
ggtgatggat tcaacggtga ggagtttgta caacaagcaa ctgctgaaaa agcatca	aac 840
atctacttta tctcaggctt ctcaactact gtagaagttt cagctaaagc taaagcc	ttc 900
cttgacgctt accgtgctaa gtacaatgaa gagccttcaa catttgcagc cttggct	tat 960
gattcagttc accttgtagc aaacgcagca aaaggtgcta aaaattcagg tgaaatca	aag 1020
aataaccttg ctaaaacaaa agattttgaa ggtgtaactg gtcaaacaag cttcgat	gca <b>1080</b>
gaccacaaca cagtcaaaac tgcttacatg atgaccatga acaatggtaa agttgaa	gca 1140
gcagaagttg taaaacca	1158
<210> 39	
<211> 1539	
<212> DNA	•
<213> Streptococcus pneumoniae	
· · · · · · · · · · · · · · · · · · ·	
<400> <u>.</u> 39	
atgagtattt tagaagttaa aaatctgagt cacggttttg gtgaccgtgc aatttttg	aa 60
gatgtgtcct tccgtctcct caagggagaa catatcggcc tggtcggtgc caatggtg	aa 120
Page 44	

ggaaaatcaa	cctttatgag	tatcgtgact	ggtaaaatgc	tgccagatga	aggaaaggtt	180
gagtggtcca	aatatgtgac	ggctggttac	ttggatcagc	actctgtcct	tgctgaaaga	240
cagtcggtgc	gtgatgttct	ccgtacggct	tttgatgagc	ttttcaaagc	tgaagctcgt	300
atcaatgacc	tctatatgaa	aatggctgaa	gacggcgcgg	atgttgatgc	tctcatggaa	360
gaagtaggag	aacttcaaga	ccgtctggag	agtcgtgatt	tctatacctt	ggatgctaag	420
attgacgaag	tagcgcgtgc	tcttggtgtt	atggactttg	gcatggatac	ggatgtaact	480
tctttgtcag	gtgggcaaag	aaccaaggtg	cttttggcaa	aacttctcct	tgaaaagcct	540
gatatcttgc	tgttggacga	gccgaccaac	tacttggatg	ctgagcatat	tgattggctc	600
aagcgctatc	tccaaaacta	tgagaatgcc	tttgttctca	tttcgcacga	tattccattc	660.
ctcaatgacg	ttattaatat	tgtctatcat	gtggaaaatc	aacagctgac	gcgttactct	720
ggtgactact	accagttcca	agaagtttat	gctatgaaga	aatctcagct	agaggcagcc	780
tacgaacgcc	agcagaaaga	gattgcagac	ctcaaggact	ttgtggctcg	taataaagcc	840
cgtgttgcaa	ctcgtaatat	ggctatgtct	cgtcaaaaga	aattggataa	gatggatatt	900
atcgaactcc	aaagtgagaa	accaaaacca	tcctttgatt	tcaaaccagc	tcgtacacca	960
gggcgcttta	tcttccaagc	caagaacttg	caaattggtt	acgaccgtcc	tcttactaag	1020
cctttaaatc	ttaccttcga	acgcaatcaa	aaggttgcga	ttattggtgc	taatggtatt	1080
ggaaaaacaa	ctctcttgaa	gagtctcttg	ggcattatct	cgccaatcgc	tggggaagtg	1140
gagcgtggag	attatttaga	acttggttat	tttgagcagg	aagtagaagg	cggtaatcgc	1200
caaactcctc	ttgaagctgt	ctggaatgcc	tttcctgccc	ttaatcaagc	agaagtccgt	1260
gcagcccttg	cccgttgtgg	tttgacaacc	aaacatattg	aaagccagat	tcaagtatta	1320
tcagggggag	agcaagccaa	ggttcgtttc	tgtctcttga	tgaatcgtga	aaacaacgtt	1380
ttagtgctgg	acgagccgac	caaccatttg	gatgtggatg	caaaggatga	gctcaaacgc	1440
gctctcaaag	aatatagggg	atctatcctt	atggtctgcc	acgagccaga	cttttatgaa	1500
ggctggatag	accaaatatg	ggattttaat	aatttaact			1539
-210- 40						

<210> 40

<211> 1197

<212> DNA

<400> 40					
atgaagaaaa agaatggtaa	agctaaaaag	tggcaactgt	atgcagcaat	cggtgctgcg	60
agtgtagttg tattgggtgc	tggggggatt	ttactcttta	gacaaccttc	tcagactgct	120
ctaaaagatg agcctactca	tcttgttgtt	gccaaggaag	gaagcgtggc	ctcctctgtt	180
ttattgtcag ggacagtaac			tttattttga		240

٠. يو		na i i nama i mina	str. pn	eumoniae pa	tentin.sT25			
	ggtgatttag	atgaaatcct	tgtttctgtg	ggcgataagg	tcagcgaagg	gcaggcttta	300	
	gtcaagtaca	gtagttcaga	agcgcaggcg	gcctatgatt	cagctagtcg	agcagtagct	360	
	agggcagatc	gtcatatcaa	tgaactcaat	caagcacgaa	atgaagccgc	ttcagctccg	420	
	gctccacagt	taccagcgcc	agtaggagga	gaagatgcaa	cggtgcaaag	cccaactcca	480	
-	gtggctggaa	attctgttgc	ttctattgac	gctcaattgg	gtgatgcccg	-tgatgcgcgt	5:40···	<del></del>
	gcagatgctg	cggcgcaatt	aagcaaggct	caaagtcaat	tggatgcaac	aactgttctc	600	
						tccaacaggg	660	
	gcgagtcaag	ttatggttca	tattgtcagc	aatgaaaatt	tacaagtcaa	gggagaattg	720	
						ttctaaagtg	780	
						taaaaacaat	840	
	ggtgaagcag	ctagtccagc	agccgggaat	aatacaggtt	ctaaataccc	ttatactatt	900	
	gatgtgacag	gcgaggttgg	tgatttgaaa	caaggttttt	ctgtcaacat	tgaggttaaa	960	
						tagtaaaaat	1020	
	tatgtctgga	ttgtggatga	acaacaaaag	gctaaaaaag	ttgaggtttc	attgggaaat	1080	
						ggtcatcagt	1140	
				gaggtgaagg			1197	
	<210> 41							•
	<211> 690							
	<212> DNA							
	<213> Stre	ptococcus p	neumoniae					
	<400> 41							
				tttgcaggtc			60	
				tccattgctg			120	
				ttatcaggtt			180	
•	gccttttcaa	tggctggtgg	agaatatgta	tccgtttcaa	ctccaaaaga	taccgaggaa	240	
	gctgccgttt	cgcgagaaaa	actcttgcta	gaccaagata	gggaactagc	caaaaaatcc	300	
	ctctatgctg	cttatatcca	aaatggagaa	ttcaaaactt	ctgcccaact	cttgaccaat	360	
	aagatctttc	ttaaaaatcc	actcaaggct	ctggtagagg	aaaaatatgg	gattgagtat	420	
	gaagaattta	ccaatccttg	gcacgctgcc	atttctagct	tcgttgcctt	tttccttaga	480	
				tttccaagtg			540	
				actggttaca			600	
				cttgctattg			660	
	accttcctgc							

accttcctgc tcggacaact tttcagcatt

690

<210> 42
<211> 1881
<212> DNA
<213> Streptococcus pneumoniae

<400> 42atgaaaaagaaattaactagtittagcacttgtaggcgctttitttaggtttgtcatggtatgggaatgttcaggccaaagaaagttcaagaaataaaatccactttatcaatgttcaagaaggggaatgttatcttgaaaagaatggacatttttgccatgggyatacaggagaagattatgattcccaaatcttgaaagcattggaagaaaggaattgaaacgtcttataagcatgttctaacagaccgtgtctttcgtcgtttgaaggaattgggtgtccaaaaacttgattttattttgygacccatacccacagtgatctatattggaatgttgatgaattactgtctacctatccagttgaccgagtctatcttaagaaatatagtgatagtcgtattactaattctgaacgtctatgggataatctgtatggctatgataaggttttacagactgctgcagaaaaaggtttcagttattcaaaatatcacacaaggggatgcctatttcaggctgcagaaaaaggtttcagttattcaaaatatcacacaaggggagggagcattcaggtgatttgggggacatggatattcagctctataattatgaaaaggctatttcagtttggggacatggatattcagctctataattatgaaaaggcaactaatgctttggggacattggatagtctatttcaagfcoaagaaaatttaccttggggagcaattcaatgcaactaaggcctctcattggaaaagttgatttgatgaagtttgttcaaacttcggatagtcctctcattggaaaagtggattagtgaagtttggatgagacagagagatcatcattggaaaattggaaccaagactagttttgataatttcgaaagacggattggaataacgagtgattactttaacggttttaacagttgttcatgagggttggaataacagaatgga <t< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th></t<>							
ggggaatgttc aggctcaaga aagttcagga aataaaatcc actttatcaa tgttcaagaa 180 gggggaggg atgcgattat tcttgaaagc aatgggacatt ttgccatggt gggatacagga 180 gaagattatg atttccaaga tgggaatgat tctcgctatc catgggagga agggaattgaa 240 acgtcttata agcatgttct aacagaccgt gtctttcgtc gtttgaagga attggggttc 300 gaattactgt ctacctatcc agttgaccga gtcatctta agaaatatag tgatagtcgt 420 attactaatt ctgaacgtct atgggataat ctgatggct atgaataatg tgatagtcgt 420 attactaatt ctgaacgtct atgggataat ctgatggct atgaataatg tgatagtcgt 420 attactaatt ctgaacgtct agggataat ctgatggct atgaaaggt tttacagact 480 gctgcagaaa aaggtgttc agttatcaa aatatcacac aaggggatgc tcatttcag 540 tttggggaca tgggatat accttagat atggggaat accttataga aactggggaa attgggggaa 600 aagaaaattt accttggggg cgatttagat aatgtcatg ggcggggaa agcaataggg 720 cctctcattg gaaaagttga tttgatgaag tttaatcac accatgatac caacaaatca 780 aataccaagg atttcattaa aaatttgagt ccgagttga ttggtcaaag acgaggaatt 900 gagaggaatca acgcagccag caaagactat gatgcaacag ttttgataa acgagggaatt ccacttgga aaaatgggg tgataggga taggtaata acgagggaat atggttaat gggtcaaaga aacgagggaat 1020 aagagtgcat atgggaacgg gtggatcaa gcgactgat ctacaggag ggtttggaa aaccaggg gggtttggaa aaccagggg tgatggaa acaaggggaat 1020 aaaaaattggaa aaccagagg tgaatggat tactttaac accacgaggaa caaggggaatgggtggaagggtggaaggaggaacagg gggggaaggaacag gtggatggaa acaaggaggaat 1020 aaaaaattggaa aaaatggaa ggaatggat tactttaacc aaccacaagg ggttggaacagg gtaggaatggaa tacaaggaggaat cttggtaaga 1140 aaaaaaatggaa agaaaatcgg tggaatcgg tactatttg acaaagaaaa ccagaggaa 1260 attggtgga tacaaagaa agaaacctgg tactatttg ctccacagg ggaaatggaa 1380 atgggctgg taaaaagataa agaaacctgg tactatattg atccacaagaacgg ttcaataga 1380 atgggctggg taaaaagataa agaaacctgg tactatattg aagaatcaag agcatgaga 1440 acagggagga taaaaagaca aggacaagg tactctctga aagaaccagg ttcacaaga 1500 caaggctggc ataaaaagac aggacaaatgg tactctctga aagaacacgg ttcacatactt 1620 gtggatcgga agaaccaag aggttaact gtggatacaa ggataaatgg tactctctga aagaacacgg tcaatacct 1620 gtggatcgga agaaccaaga aggttaaccgg ggaataacagg tcacttcttg aagaaaaccgg tcaattacct 1620 gtggatcgga agaacca		aattaactag	tttagcactt	gtaggcgctt	ttttagg <del>tt</del>	: Otcatootat	60
gatygatatg attcccaga tggaagtgat tctcgctatc catggagaga aggaattgaa 240 acgtcttata agcatgtct acacgaccgt gtcttcgtc gtttgaagga attgggggtc 300 caaaaacttg atttatttt ggtgacccat acccacagtg atcatattgg aaatgtgat 420 gaattactgt ctacctatcc agttgaccga gtctatctta agaaatatag tgatagtcgt 420 attactaatt ctgaacgtct atgggataat ctgtatggct atgataaggt tttacagact 480 gctgcagaaa aaggtgttc agttatcaa aatatcacac aaggggatgc tcattttcag 540 tttggggaca tggatattca gctctataat tatgaaaatg aaactgattc atcgggtgaa 6600 ttaaagaaaa tttgggatga caattccaat tccttgatta gcgtggtgaa agtcaatggc 660 aagaaaattt accttggggg cgatttagat aatgtcatg gagcagaaga caagtatggt 720 cctctcattg gaaaagtga tttgatgaag tttaatcac accatgatac cacacaatca 780 aataccaagg atttcattaa aaatttgag ccgagttga ttgtcacaag accatgatac 420 cctctctattg gaaaagtgg ttgatagaa attgtcatg gagcagaaga caagtatggt 720 cctctctatgg aaaatgggt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt 9900 gagagaatca acgcagccag caaagactat gatgtcaatg ggctcaaaga acgaggaatt 9900 gagagagaatca acgcagccag caaagactat gatgtcaacag tttttgatat tcggaaagac 960 ggtttgtca atattcaac atcctacaag ccgattcaa gttttcaag ttggtagaag 2960 ggttggaatg aaacgaagg tggtatcaa gcgcctgatt ctacaggaga gtatgtgtc 1020 aaagatggat atggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgtgtc 1020 aaaaattgga aaaacagag tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga agaaaatcg tggaatctgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcg tggaatctgg tattatttg acaaagaaaa ccagatggaa 1320 atgggttgga ttcaatatat ggggcaatgg tattatttg atcatatgg ggaaatgaaa 1380 atgggctggg taaaagataa agaacctgg tactatatgg atgttgatgg ttcatagaag 1500 caaggctgg taaaaagaca aggataaatgg tatttctaca agacagacg ttcactgag 1500 caaggctgg ataaaaaggc aaatgatgg tatttctaca agacagacgg ttcacagacc 1560 gtgggttgga agacaccag aggttatacc gtgggatcaa aggaaaatgg tcaatacct 1620 gtggattgga agacaccag aggttatacc gtgggattcaa gtgggtcctg gttagtggat 1680							
gaagattata atttcccaga tggaagtgat tctcgctatc catggagaga aggaattgaa 240 acgtcttata agcatgttct aacagaccgt gtctttcgtc gtttgaagga attgggtgtc 300 caaaaacttg attttatttt ggtgacccat acccacagtg atcatattgg aaattgtgat 360 gaattactgt ctacctatcc agttgaccga gtctatctta agaaaatatag tgatagtcgt 420 attactaatt ctgaacgtct atgggataat ctgtatggct atgataaggt tttacagact 480 gctgcagaaa aaggtgttc agttattcaa aatatcacac aaggggatgc tcattttcag 540 tttggggaca tggatattca gctctataat tatgaaaatg aaactgattc atcgggtgaa 6600 ttaaagaaaa tttgggatga caattccaat tccttgatta gcgtggtgaa agtcaatggc 660 aagaaaattt accttggggg cgatttagat aatgttcatg gagcagaaga caagtatggt 720 cctctcattg gaaaagtgg tttgatgaag tttaatcac accatgatac caacaaatca 780 aataccaagg atttcattaa aaatttgagt ccgagttga ttgtcaaaag acgaggaatt 900 gagagaatca acgcagccag caaagactat gatgcaacag tttttgata tcggaatggt 960 ggtttgtca atatttcaac atcctacaag ccgattcaa gttttgata tcggaaaga acgaggaatt 900 ggtttggaat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgt 1020 aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgt 1080 ggttggaatg aaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaaattgga agaaaatcgc tggaatcgg tattatttg acaagagaaa ccagatggaa 1320 acaggatgg ttcaataat ggggcaatgg tattatttg atcttatgg ggaaatgaaa 1380 atgggttgga ttcaagataa agaacctgg tattatttg atctatctgg tgctcatgaag 1320 acaggatgg ttcaatatat ggggcaatgg tattatttg agaagaacag ggaaatgaa 1380 atgggctgg taaaagataa agaacctgg tactatattgg agattcatgg tgctatagaag 1500 caaggctgg ataaaaaggc aaatgatgg tatttctaca agacagacgg ttcacagagc 1560 gtgggttgga tcaaggaca aggataatgg tattctcta agaaaaatgg tcaatactt 1620 gtggatgga agaacccag aggttatacc gtggattcaa gtgggtcctg gttagtgga tcaatactt 1620 gtggatggat agaacccag aggttatacc gtgggattcaa gtgggtcctg gttagtggat 1680							
acagtettata agcatgttet aacagaccgt gtetttegte gtttgaagga attgggtgte 300 caaaaacttg attttattt ggtgacccat acceacagtg atcatattgg aaatgttgat 360 gaattactgt ctacctatee agttgaccga gtetatetta agaaatatag tgatagtegt 420 attactaatt etgaacgtet atgggataat etgatgget atgataaggt tttacagact 480 getgeagaaa aaggtgtte agttateaa aatateaac aagggggatge teattteag 540 tttggggaca tggatatea getetaaat tatgaaaatg aaactgatte ategggtgaa 600 ttaaagaaaa tttggggatga caatteeaat teettgatta gegtggtgaa agteaatgge 660 aagaaaattt acettggggg egatttagat aatgteeatg gagcagaaga caagtatggt 720 ceteteattg gaaaagttga tttgatgaag tttaateat accatgatae eaacaaatea 780 aataceaagg atteeattaa aaatttgagt eegagttga ttggteaaag acgaggaatt 900 gagagaatea acgeagecag caaagactat gatgeaacag tttttgatat teggaaagae 960 ggttttgea atatteeaa ateeetaaga eegagteea gatgeaacag tttttgatat teggaaagae 960 ggttttgea atatteeaa ateeetaag eegateeaa gegeetaaa gegeetaaga ggttggaat atgggaactg gtggateaa gegeetaaga gttteeaaga ggtttgaa agaagtgaa tatgetgee 1020 aagagtgaat aagggaactg gtggateaa gegeetgat eetaaggag tatgetgee 1020 aaaaaattgga aaaaatggaa caatcattgg teetattaac aacaaggaaa eeaacagggaa 1260 aattggttgga teaaagataa agagcagtgg tatatatttg aacaagaaaa eeaagggaaa 1260 aattggttgga teaaagataa agagcagtgg tatatatttg ateetaagag ggaaatgaaa 1380 aatgggtgg taaaaagataa agaaacetgg taetaattgg atteetaegg ggaaatgaaa 1380 aatgggetgg taaaaagataa agaaacetgg taetaattgg atteetaegg ggaaatgaag 1500 caaggetgga taaaaaagge aaatgggt tatteetaea agaaaaatgg teetaataet 1560 gtgggttgga teaaaaggea aggataaatgg taeteetaa agaaaaatgg teaataactgg taeteetaa agaaaaatgg teaataactg 1560 gtgggttgga teaaaaggaa aggataaagg taeteetaga 1500 caaggetgga aaaaaatgg agaaaatgg taeteetaa agaaaaatgg teaataactg 1560 gtgggttgga teaaaaagga aggataaatgg taeteetaa agaaaaatgg teaataactg 1560 gtgggttgga aagaacaaa aggataaagg taeteetaa agaaaaatgg teaataactg 1560 gtgggttgga aaaaaaagga aaggataaagg taeteetaa agaaaaatgg teaataactgg 1560 gtgggttgga aaaaaaagga aaggataaaggaaaaatgg taeteetaa agaaaaatgg teaataactgg 1560 gtgggataaaaggaa aagaaaaaaagga aaaaaatgg taaaaaaa	gaagattatg	atttcccaga	tggaagtgat	tctcgctatc	catggagaga	aggaattgaa	
caaaaacttg atttattt ggtgacccat acccacagtg atcatatgg aaatgttgat 420 gaattactgt ctacctatcc agttgaccga gtctatctta agaaatatag tgatagtcgt 420 attactaatt ctgaacgtct atgggataat ctgtatggct atgataaggt tttacagact 480 gctgcagaaa aaggtgtttc agttattcaa aatatcacac aaggggatgc tcattttcag 540 tttggggaca tggatatca gctctataat tatgaaaatg aaactgattc atcgggtgaa 600 ttaaagaaaa tttggggatg caattccaat tccttgatta gcgtggtgaa agtcaatggc 660 aagaaaattt accttggggg cgatttagat aatgttcatg gagcagaaga caagtatggt 720 cctctcattg gaaaagttga tttgatgaag tttaatcatc accatgatac caacaaatca 780 aataccaagg atttcattaa aaatttgagt ccgagtttga ttgttcaaac ttcggatagt 840 ctaccttgga aaaatggtgt tgataggag tatgttaatt ggctcaaaga acgaggaatt 900 gagagaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggttttgtca atatttcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aagagtgcat atgggaactg gtggatacaa gcgcctgatt ctacaggaga gtatgctgtc 1080 ggttggaatg aaaatcgaag tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaaattgga agaaaatcgc tggaatctgg tattatttta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattattttg attgtatgg ttctatgaag 1320 acaggatggc taaaagataa agaacctgg tactatattg attctactgg tgctactagag 1380 attggctgg taaaagataa agaacctgg tactatattg attctactgg tgctatgaag 1400 acaggtgga tagaagttgc tggtcaacat tattactgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tattctcaca agacagacgg ttcactgct 1560 gtgggttgga tcaaggacaa ggataaatgg tactctttga aagaaaatgg tcaattactt 1620 gtggaacggta agacaccag aggttaacc	acgtcttata	agcatgttct	aacagaccgt	gtctttcgtc	gtttgaagga	attaggtatc	
gaattactgt ctacctatcc agttgaccga gtctatctta agaaatatag tgatagtcgt 480 attactaatt ctgaacgtct atgggataat ctgtatggct atgataaggt tttacagact 480 gctgcagaaa aaggtgttc agttatcaa aatatcacca aaggggatgc tcattttcag 540 tttgggggaca tgggatatca gctctataat tatgaaaatg aaactgattc atcgggtgaa 600 ttaaagaaaat tttgggatga caattccaat tccttgatta gcgtggtgaa agtcaatggc 660 aagaaaattt accttggggg cgatttagaa aatgttcatg gagcagaaga caagtatggt 720 cctctcattg gaaaagttga tttgatgaag tttaatcatc accatgatac caacaaatca 780 aataccaagg atttcattaa aaatttgagt ccgagtttga ttgttcaaac ttcggatagt 840 ctaccttgga aaaatgggt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt 900 gagagaaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggtttgtca atatttcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aaaggtgcat atggggaactg gtgggtatcaa gcgcctgatt ctacaggaga gtatgctgc 1080 ggttggaatg aaaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga agaaaatcgc tggaatctgg tattattta acaaagaaaa ccagatggaa 1260 attggttgga ttcaataat ggggcaatgg tattatttg atggttgatgg ttctatgaag 1320 acaggatggc ttcaataat ggggcaatgg tattatttg atcatcagg ggaaatgaaa 1380 atggggtggg taaaaaggta caatggtg tattatttg atcatcatgg tgctatgaag 1500 caaggctgg taaaaaggc aaatgatgg tattatcttg aagaatcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgatgg tatttcaca agacaagacgg ttcactgagct 1560 gtgggttgga tcaaggacaa gggataaatgg tatttctaca agacaagacgg ttcaatgag 1500 gtgggttgga tcaaggacaa gggataaatgg tatttctaca agacaagacgg ttcaatgag 1500 gtgggttgga tcaaggacaa gggataaatgg tatttctaca agacaagacgg ttcaatgag 1500 gtgggttgga tcaaggacaa gggataaatgg tatttctaca agacaagacgg ttcaatgag 1560 gtgggttgga tcaaggacaa gggataatgg tatttctaca agacaagacgg ttcaatgag 1500 gtgggttgga tcaaggacaa gggataaatgg tatttctaca agacaagacgg ttcaatgag 1500 gtgggttgga tcaaggacaa gggataatagg tatttctaca agacaaaatgg tcaattactt 1620 gtggatcgga agacaccaga aggttatacc gtgggtgcctg gttagtggat 1680	caaaaacttg	attttattt	ggtgacccat	acccacagtg	atcatattgg	aaatottoat	
attactaatt ctgaacgtct atgggataat ctgtatggct atgataaggt tttacagact 480 gctgcagaaa aaggtgtttc agttattcaa aatatcacac aaggggatgc tcattttcag 540 tttgggggaca tggatattca gctctataat tatgaaaatg aaactgattc atcgggtgaa 600 ttaaaggaaaa tttggggtga caattccaat tccttgatta gcgtggtgaa agtcaatggc 660 aagaaaattt accttggggg cgatttagat aatgttcatg gagcagaaga caagtatggt 720 cctctcattg gaaaagttga tttgatgaag tttaatcatc accatgatac caacaaatca 780 aataccaagg atttcattaa aaatttgagt ccgagttga ttgtcaaac ttcggatagt 840 ctaccttgga aaaatggtgt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt 900 gagagaaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggttttgtca atatttcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aaaggtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaag gtatgctgtc 1080 ggttggaatg aaaactggag tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga agaaaatcgc tgggaatctgg tattattta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttta acaaagaaaa ccagatggaa 1380 acaggatggc ttcaatatat ggggcaatgg tattatttgg atgttgatgg ttctatgaag 1320 acaggatggc taaaagataa agaaacctgg tactatatgg attctactgg tggtcatgaag 1500 caaggctggc ataaaaggca aaatgattg tattattcaa agaacagacgg ttcacagag 1560 gtgggttgga tcaaggaca agaaaatgg tagtatgtg tattattcaa agaacagacgg ttcacagag 1560 gtgggttgga tcaagagaca aggataaatgg tattctcaca agacagacgg ttcacagaag 1560 gtgggttgga tcaagagaca aggataaaagg tattctcaca agacagacgg ttcacagagc 1560 gtgggttgga tcaagagaca aggataaatgg tattctctaca agacagacgg ttcacagagct 1560 gtgggttgga tcaagagaca aggataaatgg tattctctaca agacagacgg ttcacagagct 1560 gtgggttgga tcaagagaca aggataaatgg tattctctaca agacagacgg ttcacagagct 1560 gtgggttgga tcaaggaca aggataaatgg tattctctaca agacagacgg ttcactgagct 1560 gtgggttgga tcaaggacaa aggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaaacggta agacaccaga aggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaaacggta agaacccaga aggataacccag aggataacccag aggataacccag aggataacccag aggataacccag aggataacccag aggataacccag aggataacccag aggataacccag aggataacccag aggataacccag aggataacccag aggat	gaattactgt	ctacctatcc	agttgaccga	gtctatctta	agaaatatag	tgatagtcgt	
tttggggaca tggatattca gctctataat tatgaaaatg aaactgattc atcgggtgaa 600 ttaaagaaaa tttgggatga caattccaat tccttgatta gcgtggtgaa agtcaatggc 660 aagaaaattt accttggggg cgatttagat aatgtcatg gagcagaaga caagtatggt 720 cctctcattg gaaaagttga tttgatgaag tttaatcatc accatgatac caacaaatca 780 aataccaagg atttcattaa aaatttgagt ccgagtttga ttgttcaaac ttcggatagt 840 ctaccttgga aaaatggtgt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt 900 gagagaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggttttgtca atattcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgt 1080 ggttggaatg aaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcgc tggaatctgg tattatttta acaaagaaaa ccagatggaa 1320 acaggatggc ttcaatatat ggggcaatgg tattattttg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tattattttg atgttgatgg ttctatgaag 1340 acaggttgga taaaagataa agaacctgg tactatattg atgttgatgg ttctatgaag 1320 acaggctggg taaaaagataa agaacctgg tactatattg atgttgatgg ttctatgaag 1320 acaggttgga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tattctaca agacagacgg ttcacagacg 1560 gtgggttgga tcaagacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgggatcgg taaaagacaa aggataaatgg tacttcttga aggaaaatgg tcaattactt 1620 gtggaacggta agaacccaga aggttatact gtggatcaa gtgggtcctg gttagtggat 1680	attactaatt	ctgaacgtct	atgggataat	ctgtatggct	atgataaggt	tttacagact	
tttggggaca tgggatattca gctctataat tatgaaaatg aaactgattc atcgggtgaa 660 ttaaagaaaa tttgggatga caattccaat tccttgatta gcgtggtgaa agtcaatggc 660 aagaaaattt accttggggg cgatttagat aatgttcatg gagcagaaga caagtatggt 720 cctctcattg gaaaagttga tttgatgaag tttaatcatc accatgatac caacaaatca 780 aataccaagg atttcattaa aaatttgagt ccgagtttga ttgttcaaac ttcggatagt 840 ctaccttgga aaaatggtgt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt 900 gagagaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggtttgtca atatttcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgc 1080 ggttggaatg aaaactggag tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga agaaaatcgc tggaatcgg tattattta acaaagaaaa ccagatggaa 1320 acaggatggc ttcaatata ggggcaatgg tattatttg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaaagataa agaaacctgg tactatatgg atgtcacgg agctatgaag 1500 caaggctggc ataaaaaggc aaatgatgg tattactttga aagactagg ttccacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttctctaa agacaagacg ttcacgagct 1560 gtgggttgga tcaaggacaa aggataacc gtgggatcaa gtgggttcaa ggataaccaga aggttaacct gtgggatcaa gtggtgcctg gttagtggat 1680 gtggaacggta agacaccaga aggttaacct gtgggatcaa gtgggtcctg gttagtggat 1680	gctgcagaaa	aaggtgtttc	agttattcaa	aatatcacac	aaggggatgc	tcattttcag	
aagaaaaattt accttggggg cgatttagat aatgtcaatg gggcagaaga caagtatggt 720 cctctcattg gaaaagttga tttgatgaag tttaatcatc accatgatac caacaaatca 780 aataccaagg atttcattaa aaatttgagt ccgagtttga ttgttcaaac ttcggatagt 840 ctaccttgga aaaatggtgt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt 900 gagagaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggttttgtca atattcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgtc 1080 ggttggaatg aaaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcgc tggaatctgg tattattta acaaagaaaa ccagatggaa 1260 attggttgga ttcaatatat ggggcaatgg tattatttgg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaagataa agaaacctgg tactatatgg atctactgg tgctcatgaag 1440 acaggtgga taaaagataa agaaacctgg tactatatgg atctactgg tgctcatgaag 1500 caaggctggc ataaaagaca ggataaatgg tattacttga aagacaggg ttcacagagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttctga aagacaaggg tcaattactt 1620 gtggaacggta agacacaga aggttatact gtggatcaa gtgggtcctg gttagtggat 1680	tttggggaca	tggatattca	gctctataat	tatgaaaatg	aaactgattc	atcgggtgaa	
cctctcattg gaaaagttga tttgatgaag tttaatcatc accatgatac caacaaatca 780 aataccaagg atttcattaa aaatttgagt ccgagtttga ttgttcaaac ttcggatagt 840 ctaccttgga aaaatggtgt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt 900 gagagaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggttttgtca atattcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgtc 1080 ggttggaatg aaaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcgc tggaatctgg tattattta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttgg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tactatattgg atgttgatgg ttctatgaag 1380 atgggctggg taaaagataa agaaacctgg tactatattgg atgtcactgg ggcaatggaa 1500 caaggctggc ataaaaaggc aaatgattgg tatttctaca agacagacgg ttcacagagct 1560 gtgggttgga tcaaggacaa gggtaaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtggaacggta agacaccaga aggttatact gtggaatcaa gtggtgcctg gttagtggat 1680	ttaaagaaaa	tttgggatga	caattccaat	tccttgatta	gcgtggtgaa	agtcaatggc	
aataccaagg atttcattaa aaatttgagt ccgagtttga ttgttcaaac ttcggatagt 840 ctaccttgga aaaatggtgt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt 900 gagagaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggtttgca atatttcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgtc 1080 ggttggaatg aaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga agaaaatcgc tggaatctgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcgc tggaatctgg tattattta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttga atgttgatgg ttctatgaag 1320 acaggatggc ttcaatata ggggcaatgg tattatttg ctccatcagg ggaaatgaa 1380 atgggctggg taaaaagataa agaacctgg tactatatgg attctactgg tgctatgaag 1440 acaggtgga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgatgg tattctctga aagacaggg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtggaacggta agaacgga aggttatacc gtggatcaa gtgggtcccg gttagtggat 1680	aagaaaattt	accttggggg	cgatttagat	aatgttcatg	gagcagaaga	caagtatggt	
ctaccttgga aaaatggtgt tgatagtgag tatgttaatt ggctcaaaga acgaggaatt 900 gagagaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggttttgtca atatttcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgtc 1080 ggttggaatg aaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcgc tggaatctgg tattattta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttgg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaaagataa agaaacctgg tactatatgg attctactgg tgctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tatttctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680	cctctcattg	gaaaagttga	tttgatgaag	tttaatcatc	accatgatac	caacaaatca	780
gagagaatca acgcagccag caaagactat gatgcaacag tttttgatat tcgaaaagac 960 ggtttgtca atattcaac atcctacaag ccgattccaa gttttcaagc tggttggcat 1020 aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgtc 1080 ggttggaatg aaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcgc tggaatctgg tattattta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaagataa agaaacctgg tactatatgg attctactgg tgtcatgaag 1440 acaggtgaga tagaagttgc tggtcaacat tattactgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tattctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttctga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtgggattcaa gtggtgcctg gttagtggat 1680							840
aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgtc 1080 ggttggaatg aaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcgc tggaatctgg tattattta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatata ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaaagataa agaaacctgg tactatatgg atgttgatgg tgctatgaag 1440 acaggtggg tagaagtgc tggtcaacat tattactgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tattctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttctga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtgggattcaa gtggtgcctg gttagtggat 1680	ctaccttgga	aaaatggtgt	tgatagtgag	tatgttaatt	ggctcaaaga	acgaggaatt	900
aagagtgcat atgggaactg gtggtatcaa gcgcctgatt ctacaggaga gtatgctgtc 1080 ggttggaatg aaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaaattgga agaaaatcgc tggaatctgg tattatttta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttgg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaaagataa agaaacctgg tactatatgg attctactgg tgtcatgaag 1440 acaggtgaga tagaagttgc tggtcaacat tattactgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tattctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680							960
ggttggaatg aaatcgaagg tgaatggtat tactttaacc aaacgggtat cttgttacag 1140 aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcgc tggaatctgg tattattta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttgg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaagataa agaaacctgg tactatatgg attctactgg tgtcatgaag 1440 acaggtgaga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tattctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680							1020
aatcaatgga aaaaatggaa caatcattgg ttctatttga cagactctgg tgcttctgct 1200 aaaaattgga agaaaatcgc tggaatctgg tattatttta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttgg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat gggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaagataa agaaacctgg tactatatgg attctactgg tgtcatgaag 1440 acaggtgaga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tattctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680							1080
aaaaattgga agaaaatcgc tggaatctgg tattatttta acaaagaaaa ccagatggaa 1260 attggttgga ttcaagataa agagcagtgg tattatttgg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaagataa agaaacctgg tactatatgg attctactgg tgtcatgaag 1440 acaggtgaga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tattctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680							1140
attggttgga ttcaagataa agagcagtgg tattatttgg atgttgatgg ttctatgaag 1320 acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaagataa agaaacctgg tactatatgg attctactgg tgtcatgaag 1440 acaggtgaga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tatttctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680							1200
acaggatggc ttcaatatat ggggcaatgg tattactttg ctccatcagg ggaaatgaaa 1380 atgggctggg taaaagataa agaaacctgg tactatatgg attctactgg tgtcatgaag 1440 acaggtgaga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tattctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680							1260
atgggctggg taaaagataa agaaacctgg tactatatgg attctactgg tgtcatgaag 1440 acaggtgaga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tatttctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680							1320
acaggtgaga tagaagttgc tggtcaacat tattatctgg aagattcagg agctatgaag 1500 caaggctggc ataaaaaggc aaatgattgg tatttctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680							1380
caaggctggc ataaaaaggc aaatgattgg tatttctaca agacagacgg ttcacgagct 1560 gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680	atgggctggg	taaaagataa	agaaacctgg	tactatatgg	attctactgg	tgtcatgaag	1440
gtgggttgga tcaaggacaa ggataaatgg tacttcttga aagaaaatgg tcaattactt 1620 gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680							1500
gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680	caaggctggc	ataaaaaggc	aaatgattgg	tatttctaca	agacagacgg	ttcacgagct	1560
gtgaacggta agacaccaga aggttatact gtggattcaa gtggtgcctg gttagtggat 1680 Page 47	gtgggttgga	tcaaggacaa	ggataaatgg	tacttcttga	aagaaaatgg	tcaattactt	1620
	gtgaacggta	agacaccaga	aggttatact	gtggattcaa Page 47	gtggtgcctg	gttagtggat	1680

	str pneumo	oniae patentin. <u>ST25</u>
	gtttcgatcg agaaatctgc tacaattaaa act	acaagtc attcagaaat aaaagaatcc 1740
	aaagaagtag tgaaaaagga tcttgaaaat aaa	
	aatttttcaa ctagtcaaga tttgacatcc tca	
	aacaaatcgg aatcagaaca g	1881
	<210> 43	A CONTRACTOR OF THE CONTRACTOR
	<211> 1368	
	<212> DNA	
	<213> Streptococcus pneumoniae	
	programment and	
	<400> 43	
	atggacttag gtcccaccca aagaggtatt agt	
ì	atcggtgctg gtttggcagg ttctgaagca gct	
	gttaaactat atgaaatgcg tggtgtcaag tct	
	gctgagttgg tttgttccaa ttctttgcgt ggg	
	ctcaaggaag aaatgcgtcg cttgggttct gtt	
	gttcctgcag gtggtgccct tgcagtggac cgt	
	aaagttgcca accaccctt gattgaagtg gtt	
	gatgttatta cggttatcgc tactggtcct ttg	
	catgctctta atgacggtgc tggtttttat ttc	
	gtcaacacta tcgatatgag caaggtctac ctc	
	gcctacctca atgcccctat gaccaagcaa gaa	
	aatgcagaag aagcaccgct tagttctttt gaa	
)	cctatcgaag tcatggccaa acgtggcatt aaa	
	gtcggtcttg agtacccaga cgactataca gga	
	tatgcggttg tgcaacttcg tcaggataat gca	
	ttccagaccc acctcaaatg gggagaacaa aag	
	gaaaatgcgg agtttgtccg ttatggtgtg atg	•
	aatcttcttg agcagactta ccgttctaag aaa	
	atgacgggtg tggaaggcta tgttgagtcg gcg	
•	gcagctcgtc tcttcaagga agaaagcgag gct	
	agcttagctc attacattac ccatgccgac agc	
	tttgggatca tcaaggagtt ggaaggcgag cgt	atccgtg ataagaaggc tcgttatgaa 1320
	annakanii -	

1368

aaaattgcag agcgtgccct tgccgactta gaggaatttt tgactgtc

<210> 44	
<211> 1097	
<212> DNA	
<213> Streptococcus pneumoniae	
<400> 44	
atgttaatcg gaatcccaaa agaaattaaa aataacgaaa accgtgtcgc cctcacacct	. 60
gcaggtgttc atagcttagt tagtcgtggt catcgtgtcc ttatcgaaac aaatgctggt	120
ctcggttctg gctttactga tgctgactat caaaagcaag gagctgagat tgtcgctact	180
gctggtgaag cttgggcagc agagttggtt gtgaaagtaa aagaatcttt aagttctgaa	240
tacggttact tgcgcgacga tcttcttctc ttcacctact tgcacatggc cgctgctcca	300
gaattagcag atgctatgtt aacagcaaaa acaactgaaa ctgttcgtga caatcaagga	360
caactaccgc tcctcgttcc tatgagtgag gttgcaggtc gtatggctgt tcaaatcgga	420
gctcacttcc ttactaagca agctggtggc tctggtgttc tacttggtgg tgtaccaggt	480
gttccaaaag gaaaagtaac tatcatcggt ggtggtgtcg tcggtacaca tgctgcccgc	540
atcgcccttg gtcttggtgc tcaagtgact attttagata ttagttccaa gcgtctctca	600
gttctagaag aagtctttgg aagtcaaatt caaactctta tgtctaattc attcaacatt	660
gaagcaagtg tgagagatgc tgatgtggtg attggagcca ttctcatccc tggtgcaaaa	720
gcaccggaat tggtgacaga tgagatggtc aaacaaatgc gtccaggctc tgtatcgttg	780
acgttgctgt tgaccaaggt ggcgttatcg aaacagctga ccgtgtgaca acgcacgatg	840
aacccgtcta tgaaaaacac ggtgttctcc actatgccgt tgccaatatc cctggtgcgg	900
ttgctcgcac ttcaaccatc gccctaacca atgtcactct tccttatatc gaagctttgg	960
ctggcaaagg attcgcacaa gcaatctctg aagatgaagg cttgcgtcaa ggtgtgacta	1020
cttatcaagg ttacttgact aacctaccag ttgctcaagg acttaatcgt gactacactg	1080
atatcaatga tttagta	1097
<210> 45	
<211> 2517	
'	
<213> Streptococcus pneumoniae	
<400> 45	
<400> 45 atgaaaatta ataaaaaata tctagcaggt tcagtggcag tccttgccct aagtgtttgt	60
tcctatgaac ttggtcgtca ccaagctggt caggttaaga aagagtctaa tcgagtttct	120
tatatagatg gtgatcaggc tggtcaaaag gcagaaaact tgacaccaga tgaagtcagt	180
aagagggagg ggatcaacgc cgaacaaatc gtcatcaaga ttacggatca aggttatgtg	
Page 49	240


: -		·	<u>str pn</u>	eumoniae pa	tentin ST25		** *	
	acctctcatg	gagaccatta	tcattactat	aatggcaagg	tcccttatga	tgccatcatc	300	
	agtgaagagc	tcctcatgaa	agatccgaat	tatcagttga	aggattcaga	cattgtcaat	360	
					actatgttta		420	
						gcaggaacac	480	
						ragcccaagga	540	
					atatcattga		600	
						tgagttatca	660	
					agcagggatc		720	
					tgtcagagaa		780	
					tttcaagcct		840	
					atggccttat		900	
					ctcatggtaa		960	
	tttatccctt	atgaacaaat	gtctgaattg	gaaaaacgaa	ttgctcgtat	tattcccctt	1020	
	cgttatcgtt	caaaccattg	ggtaccagat	tcaagaccag	aacaaccaag	tccacaatcg	1080	
	actccggaac	ctagtccaag	tccgcaacct	gcaccaaatc	ctcaaccagc	tccaagcaat	1140	
					taggcgatgg		1200	
					tttcagcaga		1260	
					ataagctagg		1320	
	actgacctcc	catctagtga	tcgagaattt	tacaataagg	cttatgactt	actagcaaga	1380	
					attttgaggc		1440	
					agttagtgga		1500	
					aaccaaatgc		1560	
					agtacacaac		1620	
	tatatctttg	atcctcgtga	tataaccagt	gatgaggggg	atgcctatgt	aactccacat	1680	
					aagctgagag		1740	
					cagaccatca		1800	•
					tgaaagcagc		1860	
					aagtcaaaaa		1920	
					agtggtttga		1980	
					cgactgtcaa		2040	
					gtaacgctag		2100	
					ataaggaaca		2160	
					acgctggttt		2220	
	gcagataatc	tttataaacc	aagcactgat	acggaagaga Page 50	cagaggaaga	agctgaagat	2280	

accacagatg	aggctgaaat	tcctcaagta	gagaattctg	ttattaacac	taagatagca	2240
gatocopano	CCTTactaga	22222		· · · · · · · · · · · · · · · · · · ·	caagacagca	2340
2 -2-35 <del>-3</del> 5	cccgctaga	aaaagtaaca	gatcctagta	ttagacaaaa	tgctatggag	2400
acattgactg	gtctaaaaag	tagtcttctt	Ctcaaaacaa	22224	cactatttca	- 100
0626222####		3	cceggaacga	aayataataa	cactatttca	2460
gcagaagtag	atagtctctt	ggctttgtta	aaagaaagtc	aaccggctcc	tatacad	2517
			<del>-</del>	33,000	cacacag	Z2T/

<210> 46

<211> 3117

<212> DNA



				neumoniae pa	tentin.ST25		
	gcgcaaaaac	atttagagga	_agttaaaact	_agtcataatg	gattagatte	-tttgtcatct -	<b>-1</b> 500
	catgaacagg	attatccaag	taatgccaaa	gaaatgaaag	atttagataa	aaaaatcgaa	1560
	gaaaaaattg	ctggcattat	gaaacaatat	ggtgtcaaac	gtgaaagtat	tgtcgtgaat	1620
	aaagaaaaaa	atgcgattat	ttatccgcat	ggagatcacc	atcatgcaga	tccgattgat	1680
•	gaacataaac	cggttggaat	tggtcattct	cacagtaact	atgaactgtt	taaacccgaa	1740
	gaaggagttg	ctaaaaaaga	agggaataaa	gtttatactg	gagaagaatt	aacgaatgtt	1800
	gttaatttgt	taaaaaatag	tacgtttaat	aatcaaaact	ttactctagc	caatggtcaa	1860
	aaacgcgttt	cttttagttt	tccgcctgaa	ttggagaaaa	aattaggtat	caatatgcta	1920
						agtatttgga	1980
	gaaggagtag	ggaatattgc	aaactttgaa	ttagatcaac	cttatttacc	aggacaaaca	2040
	tttaagtata	ctatcgcttc	aaaagattat	ccagaagtaa	gttatgatgg	tacatttaca	2100
	gttccaacct	ctttagctta	caaaatggcc	agtcaaacga	ttttctatcc	tttccatgca	2160
	ggggatactt	atttaagagt	gaaccctcaa	tttgcagtgc	ctaaaggaac	tgatgcttta	2220
	gtcagagtgt	ttgatgaatt	tcatggaaat	gcttatttag	aaaataacta	taaagttggt	2280
	gaaatcaaat	taccgattcc	gaaattaaac	caaggaacaa	ccagaacggc	cggaaataaa	2340
	attcctgtaa	ccttcatggc	aaatgcttat	ttggacaatc	aatcgactta	tattgtggaa	2400
				gataaaccaa			2460
				gatgaaaagg			2520
				actgggaata			2580
				gaaaaagtag			2640
				atggacggaa			2700
				gattttacag			2760
	ggtgaaaata	aaccatctga	aaatggaaaa	gtatctactg	gaacagttga	gaaccaacca	2820
	acagaaaata	aaccagcaga	ttctttacca	gaggcaccaa	acgaaaaacc	tgtaaaacca	2880
				ccagaaggga			2940
				gtagatcctg			3000
				agtgttatat			3060
	gaattaagat	tgccaagtgg	agaagtgata	aaaaagaatt	tatctgatct	catagcg	3117

<sup>&</sup>lt;210> 47

<sup>&</sup>lt;211> 1431

<sup>&</sup>lt;213> Streptococcus pneumoniae

<400> 47			eumoniae pa			
atgaaaattt	tatttgtagc	agcagagggt	gcaccctttt	caaaaacagg	tggtttggga	60
gacgtcattg	gcgctcttcc	aaaatcactg	gtaaaagctg	ggcacgaagt	tgcagtgatt	120
ttaccctact	atgatatggt	agaggctaaa	tttggaaatc	agattgaaga	tgtgcttcat	180
tttgaggtga	gcgttggttg	gcgcagacag	tattgtggaa	ttaagaaaac	agtattaaat	240
ggtgtaacct	tctactttat	tgacaatcaa	tattatttct	tccgtggtca	tgtttacggt	300
gattttgatg	acggagaacg	ctttgccttt	ttccaactgg	ctgccattga	ggctatggaa	360
aggattgact	ttattcctga	tcttctccat	gttcatgact	accatacagc	tatgattcct	420
ttcttgttga	aggaaaaata	ccgttggatt	caagcctatg	aggacattga	aacagtttta	480
accattcata	atttagaatt	ccaaggacaa	ttttcagaag	gaatgttggg	tgatttgttt	540
ggagttggct	ttgaacgtta	cgctgatggc	acccttcgat	ggaacaactg	tctgaactgg	600
atgaaggcag	gtattctcta	tgcgaaccgt	gtttcaaccg	tttcacctag	ctatgctcat	660
gaaattatga	ctagtcagtt	tggatgtaat	ttggatcaga	ttcttaaaat	ggagtctggt	720
aaagtatctg	gtatcgtgaa	tgggattgat	gctgatcttt	ataatcctca	gacggatgct	780
cttttagact	atcatttcaa	tcaggaagat	ttgtctggga	aagccaaaaa	taaggcaaaa	840
ttgcaagaaa	gagttggctt	gcctgttaga	gcagacgttc	cactggtggg	aattgtttct	900
cgtttgacac	gtcaaaaagg	ttttgatgtg	gtggtcgaaa	gtcttcacca	tatcttgcaa	960
gaagatgttc	agattgttct	tttgggaact	ggcgatccag	cctttgaagg	agctttctca	1020
tggtttgctc	agatttaccc	agacaagcta	tcaacaaata	tcacttttga	tgtcaaactt	1080
gctcaggaaa	tctacgctgc	ttgtgacctc	ttcctcatgc	caagtcgttt	tgaaccgtgt	1140
ggcttgtctc	aaatgatggc	tatgcgttat	ggaaccttgc	cattggtcca	tgaagttgga	1200
ggcttgcgag	atacagttcg	cgctttcaat	ccaatcgaag	gaagcggtac	tggctttagc	1260
citgacaatc	tatctcctta	ttggttaaat	tggactttcc	aaacagcatt	ggacttgtat	1320
	cagacatttg					1380
ryggatacag	cctgcaagtc	ataccttgac	ttgtaccata	gtttagttaa	t	1431

<210> 48

<211> 6012

<212> DNA

<213> Streptococcus pneumoniae

#### <400> 48 atggaaaagt attttggtga aaaacaagag cgtttttcat ttagaaaatt atcagtagga 60 cttgtatctg caacgatttc aagtttattt tttatgtctg tattagctag ttcatctgtg 120 gatgctcaag aaactgcggg agttcactat aaatatgtgg cagattcaga gctatcatca 180 gaagaaaaga agcagcttgt ctatgatatt ccgacatacg tggagaatga tgatgaaact 240 Page 53

or the property of the second		meumorrae p			
ta-rea-ceregt-t-a-ta	agtt-aaattctca	a aatcaactg	-cggaattgc	aaatactgga	300
agcaagaatg agaggc	aagc cctagttgc	t ggtgctagct	tagctgctat	gggaattta	360
attitigetg titcea	agaa aaaggttaa	g aataaaacgg	tattacatti	agtattoott	420
gcagggatag gaaatg	gtgt cttagtttc	a gtccatgctt	: tagaaaatca	tcttttgcta	480
aattacaata cggact	atga attgacctc	t ggagaaaaat	tacctcttcc	. taaagagatt.	- 540
tcaggttaca cttata	ttgg atatatcaaa	a gagggaaaaa	cgacttctga	gtctgaagta	600
agtaatcaaa agagtt	cagt tgccactcc	t acaaaacaac	aaaaggtgga	ttataatatt	660
acaccgaatt ttgtag	acca tccatcaaca	a gtacaagcta	ttcaggaaca	aacacctott	720 .
tcttcaacta agccga	caga agttcaagta	a gttgaaaaac	ctttctctac	tgaattaatc	780
aatccaagaa aagaag	agaa acaatcttca	a gattctcaag	aacaattago	cgaacataag	840
aatctagaaa cgaagaa	aaga ggagaagatt	tctccaaaag	aaaagactgg	ggtaaataca	900
ttaaatccac aggatga	agt tttatcaggt	caattgaaca	aacctgaact	cttatatcat	960
gaggaaacta tggagad	caaa aatagatttt	caagaagaaa	ttcaagaaaa	tcctgattta	1020
gctgaaggaa ctgtaag	gagt aaaacaagaa	ı ggtaaattag	gtaagaaagt	tgaaatcgtc	1080
agaatattct ctgtaaa	acaa ggaagaagtt	tcgcgagaaa	ttgtttcaac	ttcaacgact	1140
gcgcctagtc caagaat	tagt cgaaaaaggt	: actaaaaaaa	ctcaagttat	aaaggaacaa	1200
cctgagactg gtgtaga	aaca taaggacgta	cagtctggag	ctattgttga	acccgcaatt	1260 -
cagcctgagt tgcccga	agc tgtagtaagt	gacaaaggcg	aaccagaagt	tcaacctaca	1320
ttacccgaag cagttgt	gac cgacaaaggt	gagactgagg	ttcaaccaga	gtcgccaqat	1380
actgtggtaa gtgataa	lagg tgaaccagag	caggtagcac	cgcttccaga	atataagggt	1440
aatattgagc aagtaaa	acc tgaaactccg	gttgagaaga	ccaaagaaca	aggtccagaa	1500
aaaactgaag aagttco	agt aaaaccaaca	gaagaaacac	cagtaaatcc	aaatgaaggt	1560
actacagaag gaaccto	aat tcaagaagca	gaaaatccag	ttcaacctgc	agaagaatca	1620
acaacgaatt cagagaa	agt atcaccagat	acatctagca	aaaatactgg	ggaagtgtcc	1680
agtaatccta gtgattc	gac aacctcagtt	ggagaatcaa	ataaaccaga	acataatgac	1740
tctaaaaatg aaaattc	aga aaaaactgta	gaagaagttc	cagtaaatcc	aaatgaaggc	1800
acagtagaag gtacctc	aaa tcaagaaaca	gaaaaaccag	ttcaacctgc	agaagaaaca	1860
caaacaaact ctgggaa	aat agctaacgaa	aatactggag	aagtatccaa	taaacctagt	1920
gattcaaaac caccagt	tga agaatcaaat	caaccagaaa	aaaacggaac	tgcaacaaaa	1980
ccagaaaatt caggtaa	tac aacatcagag	aatggacaaa	cagaaccaga	accatcaaac	2040
ggaaattcaa ctgagga	tgt ttcaaccgaa	tcaaacacat	ccaattcaaa	tggaaacgaa	2100
gaaattaaac aagaaaa	tga actagaccct	gataaaaagg	tagaagaacc	agagaaaaca	2160
cttgaattaa gaaatgt	ttc cgacctagag	ttatacagtt	tgtcaaatgg	tacttataaa	2220
caacacattt cgttaga	gca agttccaagc	aatccaaata	gctactttat	taaantnaaa	2280
		Page 54		y - yaaa	4200

Page 54

	+-++-+						
	tcttcttcat	tcaaagatgt	atacctacca	gtagcatcaa	tatcagagga	aagaaaaaat	2340
	gataaaatcc	tttataaaat	cacagcaaaa	gtagagaagc	ttcagcagga	gatagaaagc	2400
	agatataaag	ataattttac	cttctatcta	gctaagaagg	gaacagaaga	aacaacaaac	2460
	tttacttcct	ttagtaatct	ggtcaaagct	ataaaccaaa	atccctctgg	aacctatcat	2520
	ttagcggcca	gcctgaatgc	taacgaagtg	gagcttggtc	ctgatgaaag	atcctatatc	2580
	aaggacacct	ttactggtcg	tttaatcggt	gaaaaagatg	gcaagaatta	tgctatctat	2640
	aatttgaaaa	aacctctgtt	tgaaaacttg	agtggtgcta	cagtagaaaa	actgagtcta	2700
	aaaaatgttg	ctatttcagg	gaaagatgat	atcggttcac	tggcaaatga	agctcagaat	2760
	aacacaaaaa	ttaagcaagt	tcacgtcgat	ggtgttctgg	ctggtgaacg	tggtatcggt	2820
	ggtttgctgg	ctaaggctga	gcaatcaagc	atcacagaga	gcagtttcaa	gggaagaatt	2880
	atcaacactt	atgaaacgac	tgctgcctac	aatatcggtg	gtatggtcgg	tcatttgaca	2940
	ggtgacaagg	ctttacttac	taagtcaaaa	gcgacagtag	ccatttcatc	taacacaaat	3000
	acttcagatc	agactgtggg	tggacttgca	ggcctagtag	accgagatgc	acagatccaa	3060
	gatagctatg	ctgaaggtga	tatcaacaat	gtcaagcact	ttggtagagt	cgctggagtg	3120
	gcaggcaatt	tgtgggatcg	aacttctggt	gatgttaggc	atgctggaag	tttgaccaat	3180
	gttctcagcg	atgttaatgt	aaccaacgga	aatgccatca	ctggttacca	ctataacgaa	3240
	atgaaggtaa	aggacacatt	cagcagcaag	gccaacagag	tctacaatgt	caccttggtc	3300
	aaggatgagg	tcgtcagcaa	ggaatccttt	gaagaaagag	gaacaatgct	agatgcttct	3360
	caaattgcaa	gcaaaaaagc	agaaatcaat	cctctcattt	taccaacagt	ggagccactt	3420
	tcaacaagtg	gcaaaaaaga	cagtgatttt	tctaaggtgg	cctattatca	agctaagcgc	3480
	aacttgactt	ataaaaacat	tgaaaaattg	ctacctttct	acaacaaggc	aaccatcgtc	3540
	aaatacggaa	acctggtcaa	tgagaacagt	cttttatatc	aaaaagaact	cttgtcagca	3600
	gtcatgatga	aggacaacca	agtcatcaca	gacattgttt	ctaacaaaca	gactgcaaac	3660
					tggatctcaa		3720
					gacttctcta		3780
	caattcctgt	atgaccaaac	ctctatcatc	aagcaagtct	tacctgactt	acaaaaggtt	3840
	gactatcatt	cagaagccat	cagaaagacg	ctgggtattt	ctccaaacgt	caagcaaact	3900
					aactggaaga		3960
					ccgtcactga		4020
					gcttgaccta		4080
					tagttctgta		4140
٠	ttctttggta	aggggaatgc	ttcaccatta	gatactctga	ttgagttggg	taaatctggc	4200
	tttaacaatc	ttctagctaa	gaataatgtc	gatacttatg	gtatcagtct	tgccaqtcaa	4260
•	catggaacga	cagatttgtt	tagcacgctg	gaacattacc Page 55	gaaaagtctt	tttaccaaat	4320

Page 55.

ensperante de la companya de la comp	November in eastern	str pn	eumoniae pa	tentin.sT25		
acaagcaata a	tgactggtt	taaatcagag	actaaggctt	acattgtcga	agaaaaatcc	4380
actatcgaag ag						4440
tatgatcgta to						4500
ttgccagaga ga						4560
						~4620 <del>~~</del> -
aatgcgcgtg aa	aacagccaa	acgtcagcga	gatcactacg	attattggta	tcgtatttta	4680
gacgacaatg ca						4740
ggcgatgata at						4800
gcaatgcaac at						4860
tatgctacag gt						4920
attacttata co						4980
ggtcgaagaa gt						5040
catccagatg at	tgcgaccat	taccatcaac	tccatcttga	aacattcaaa	atctgatagt	5100
acagaaagtc ga	acgattaca	agtacttgat	ccaactacaa	gatttaataa	tgcagatgat	5160
ttgaagcaat at	gtccacaa	catgtttgac	gttgtttata	tgttggaata	tctcgaagga	5220
aattcaattc tt	taaattgga	tacgaatcaa	aaacaacaac	ttcttagaaa	agttacaaat	5280
gagtaccatc ct	gatcctga	tggaaataag	gtctatgcaa	caaatgttgt	cagaaatcta	5340
acagtagaag aa	gttgaaag	actacgttca	ttcaatgatt	tgattgataa	taatattctt	5400
tcgtctaggg aa	tatgcctc	aggtaaatac	gaaagaaatg	gctacttcac	tattaagtta	5460
tttgcaccga tt						5520
cgtcgtatag co						5580
atctcaaacc aa	itacgaaga	agaagccaaa	caaaagggca	agacaatcaa	tctctacggt	5640
aaaacaagag gt						5700
catacttgga gt						5760
ttgaacaaag tt						5820
acaagcagtg ta						5880
cacaattact ac						5940
aagagagcaa to	tttaaagc	ctatcttgac	caaacaaatg	attttagaag	ttcaattttt	6000
gagaataaaa aa	l					6012
<210> 49						
<211> 2457						
<212> DNA						
		•				

<400> 49 atgaaaatta	ataaaaaata	tctagcaggt	tcagtggcag	tccttgccct	aagtgtttgt	60
		ccaagctggt				120
		tggtcaaaag				180
		cgaacaaatt				240
		tcattactat				300
		agatccgaat				360
gaaatcaagg	gtggttatgt	cattaaggta	aacggtaaat	actatgttta	ccttaaggat	420
		tcggacaaaa				480
		agcagataat				540
tatacaacgg	atgatgggta	tatcttcaat	gcatctgata	tcattgagga	cacgggtgat	600
gcttatatcg	ttcctcacgg	cgaccattac	cattacattc	ctaagaatga	gttatcagct	660
agcgagttag	ctgctgcaga	agcctattgg	aatgggaagc	agggatctcg	tccttcttca	720
agttctagtt	ataatgcaaa	tccagctcaa	ccaagattgt	cagagaacca	caatctgact	780
gtcactccaa	cttatcatca	aaatcaaggg	gaaaacattt	caagcctttt	acgtgaattg	840
tatgctaaac	ccttatcaga	acgccatgtg	gaatctgatg	gccttatttt	cgacccagcg	900
caaatcacaa	gtcgaaccgc	cagaggtgta	gctgtccctc	atggtaacca	ttaccacttt	960
atcccttatg	aacaaatgtc	tgaattggaa	aaacgaattg	ctcgtattat	tccccttcgt	1020
tatcgttcaa	accattgggt	accagattca	agaccagaag	aaccaagtcc	acaaccgact	1080
ccagaaccta	gtccaagtcc	gcaaccagct	ccaagcaatc	caattgatga	gaaattggtc	1140
aaagaagctg	ttcgaaaagt	aggcgatggt	tatgtctttg	aggagaatgg	agtttctcgt	1200
tatatcccag	ccaaggatct	ttcagcagaa	acagcagcag	gcattgatag.	caaactggcc	1260
aagcaggaaa	gtttatctca	taagctagga	actaagaaaa	ctgacctccc	atctagtgat	1320
cgagaatttt	acaataaggc	ttatgactta	ctagcaagaa	ttcaccaaga	tttacttgat	1380
aataaaggtc	gacaagttga	ttttgaggct	ttggataacc	tgttggaacg	actcaaggat	1440
gtctcaagtg	ataaagtcaa	gttagtggaa <sup>.</sup>	gatattcttg	ccttcttagc	tccgattcgt	1500
catccagaac	gtttaggaaa	accaaatgcg	caaattacct	acactgatga	tgagattcaa	1560
gtagccaagt	tggcaggcaa	gtacacaaca	gaagacggtt	atatctttga	tcctcgtgat	1620
ataaccagtg	atgaggggga	tgcctatgta	actccacata	tgacccatag	ccactggatt	1680
aaaaaagata	gtttgtctga	agctgagaga	gcggcagccc.	aggcttatgc	taaagagaaa	1740
ggtttgaccc	ctccttcgac	agaccatcag	gattcaggaa	atactgaggc	aaaaggagca	1800
gaagctatct	acaaccgcgt	gaaagcagct	aagaaggtgc	cacttgatcg	tatgccttac	1860
		agtcaaaaac				1920
		gtggtttgac		atgaggcacc		1980

Page 57

#### str pneumoniae patentin.sT25 actcttgagg atcttttggc gactgtcaag tactatgtcg aacatccaaa cgaacgtccg 2040 cattcagata atggttttgg taacgctagc gaccatgttc aaagaaacaa aaatggtcaa 2100 gctgatacca atcaaacgga aaaaccaagc gaggagaaac ctcagacaga aaaacctgag 2160 gaagaaaccc ctcgagaaga gaaaccgcaa agcgagaaac cagagtctcc aaaaccaaca 2220 ----gaggaaccag-aagaatcacc-agaggaatca-gaagaacctc aggtcgagac tgaaaaggtt^-′2280 · · · · gaagaaaaac tgagagaggc tgaagattta cttggaaaaa tccaggatcc aattatcaag 2340 tccaatgcca aagagactct cacaggatta aaaaataatt tactatttgg cacccaggac 2400 aacaatacta ttatggcaga agctgaaaaa ctattggctt tattaaagga gagtaag 2457 <210> 50 <211> 2406 <212> DNA <213> Streptococcus pneumoniae <400> 50 ttgattttaa gtgtttgttc ttacgagttg ggactgtatc aagctagaac ggttaaggaa 60 aataatcgtg tttcctatat agatggaaaa caagcgacgc aaaaaacgga gaatttgact 120 cctgatgagg ttagcaagcg tgaaggaatc aatgctgagc aaatcgtcat caagataaca 180 gaccaaggct atgtcacttc acatggcgac cactatcatt attacaatgg taaggttcct 240 tatgacgcta tcatcagtga agaattactc atgaaagatc caaactataa gctaaaagat 300 gaggatattg ttaatgaggt caagggtgga tatgttatca aggtagatgg aaaatactat 360 gtttacctta aggatgctgc ccacgcggat aacgtccgta caaaagagga aatcaatcga 420 caaaaacaag agcatagtca acatcgtgaa ggtggaactc caagaaacga tggtgctgtt 480 gccttggcac gttcgcaagg acgctatact acagatgatg gttatatctt taatgcttct 540 gatatcatag aggatactgg tgatgcttat atcgttcctc atggagatca ttaccattac 600 attcctaaga atgagttatc agctagcgag ttggctgctg cagaagcctt cctatctggt 660 cgaggaaatc tgtcaaattc aagaacctat cgccgacaaa atagcgataa cacttcaaga 720 acaaactggg taccttctgt aagcaatcca ggaactacaa atactaacac aagcaacaac 780 agcaacacta acagtcaagc aagtcaaagt aatgacattg atagtctctt gaaacagctc 840 tacaaactgc ctttgagtca acgacatgta gaatctgatg gccttgtctt tgatccagca 900 caaatcacaa gtcgaacagc tagaggtgtt gcagtgccac acggagatca ttaccacttc 960

ttggttagtc agctggtacg aaaagttggg gaaggatatg tattcgaaga aaagggcatc Page 58 1020

1080

1140

1200

atcccttact ctcaaatgtc tgaattggaa gaacgaatcg ctcgtattat tccccttcgt

tatcgttcaa accattgggt accagattca aggccagaac aaccaagtcc acaaccgact

ccggaaccta gtccaggccc gcaacctgca ccaaatctta aaatagactc aaattcttct

tctcgttatg	tctttgcgaa	agatttacca	tctgaaactg	ttaaaaatct	tgaaagcaag	1260
ttatcaaaac	aagagagtgt	ttcacacact	ttaactgcta	aaaaagaaaa	tgttgctcct	1320
cgtgaccaag	aattttatga	taaagcatat	aatctgttaa	ctgaggctca	taaagccttg	1380
tttgaaaata	agggtcgtaa	ttctgatttc	caagccttag	acaaattatt	agaacgcttg	1440
aatgatgaat	cgactaataa	agaaaaattg	gtagatgatt	tattggcatt	cctagcacca	1500
attacccatc	cagagcgact	tggcaaacca	aattctcaaa	ttgagtatac	tgaagacgaa	1560
gttcgtattg	ctcaattagc	tgataagtat	acaacgtcag	atggttacat	ttttgatgaa	1620
catgatataa	tcagtgatga	aggagatgca	tatgtaacgc	ctcatatggg	ccatagtcac	1680
tggattggaa	aagatagcct	ttctgataag	gaaaaagttg	cagctcaagc	ctatactaaa	1740
gaaaaaggta	tcctacctcc	atctccagac	gcagatgtta	aagcaaatcc	aactggagat	1800
agtgcagcag	ctatttacaa	tcgtgtgaaa	ggggaaaaac	gaattccact	cgttcgactt	1860
ccatatatgg	ttgagcatac	agttgaggtt	aaaaacggta	atttgattat	tcctcataag	1920
gatcattacc	ataatattaa	atttgcttgg	tttgatġatc	acacatacaa	agctccaaat	1980
ggctatacct	tggaagattt	gtttgcgacg	attaagtact	acgtagaaca	ccctgacgaa	2040
cgtccacatt	ctaatgatgg	atggggcaat	gccagtgagc	atgtgttagg	caagaaagac	2100
cacagtgaag	atccaaataa	gaacttcaaa	gcggatgaag	agccagtaga	ggaaacacct	2160
gctgagccag	aagtccctca	agtagagact	gaaaaagtag	aagcccaact	caaagaagca	2220
gaagttttgc	ttgcgaaagt	aacggattct	agtctgaaag	ccaatgcaac	agaaactcta	2280
gctggtttac	gaaataattt	gactcttcaa	attatggata	acaatagtat	catggcagaa	2340
gcagaaaaat	tacttgcgtt	gttaaaagga	agtaatcctt	catctgtaag	taaggaaaaa	2400
ataaac						2406

<210> 51 <211> 3252 <212> DNA

Streptococcus pneumoniae

<213>

<400> 51
atgccagtag aaattaaaac cactaaagaa attcatccta aaatctatgc ctacaccaca 60
ccgacagtaa ccagtaatga aggctggatt aagattgggt atacagaacg tgatgtcaca 120
caacgtatca aggagcaaac gcatacagct catatagcta cagatgtctt atggactggt 180
gatgcagctt atacagaaga gcctgataag gggaaaactt tcaaggacca tgatttccac 240
catttccttt ctttccatga tgtagaacgt cgtcccaaga cggaatggtt ctatttaat 300

ggaactcctg aaaaatcaaa aaatcttttt gataagtttg ttcagcatga tttgtctggt 360 tatcagcctg gaaaaggaca ggactatact ctgcgacaag agcaagaaga agcagttgct 420

Page 59

••=	er aan oo oo oo oo oo oo oo oo oo oo oo oo oo		strpn	eumoniae-pa	tentin.sT25	Lessan randera ( ) Le	الم في الدورة من المراكبية المستورة ( 17 مولود المستورة المستورة المستورة المستورة المستورة المستورة المستورة الم مستورة المراكبة المستورة المستورة المستورة المستورة المستورة المستورة المستورة المستورة المستورة المستورة الم
	aagacattag	cttatttcca	agaacatgct	ggaggcaagt	ttctctggaa	tgccaagcca	480
	cgctttggta	aaaccttgtc	tacctatgac	ctagctcgac	ggatggaagc	tgtcaatgtc	540
	ctaattgtaa	caaaccgccc	tgccattgct	aactcatggt	atgatgattt	tgaaacattc	600
	atagcaggtc	aaacgactta	caagtttgtt	tctgaatcag	atagccttaa	gagtcgtcca	660
	atcttgtcac	gacaagaat <del>t</del>	tcttggtatt	ttagctgacg	-atgtaagaca	acttgctttt	720
	atcagtctcc	aagacttgaa	aggatctgtt	tatttaggtg	gagagcacga	taaactcaaa	780
	tgggtaactg	atctgcattg	ggacttgttg	gttattgacg	aggctcatga	aggagttgat	840
	accttcaaga	ctgaccaagc	ctttaataag	attcgacgaa	attttactct	gcatttgtca	900
	ggtacatcat	ttaaagcatt	ggctaaagga	gattttacag	aggaacaaat	ctacaactgg	960
	tcttatgctg	atgagcaggc	tgctaagtat	tcgtggtctc	ttgagcaaga	agaggaaaat	1020
	ccttatgaaa	gcttgcctca	gttgaatctc	tttacctatc	aaatgtctca	gatgattggc	1080
	gaaaagttag	aaaaaggcgc	tcagatcgat	ggtgaaaata	ttgactatgt	ttttgactta	1140
	agtgaatttt	tcgctacaga	tgataaaggg	aaatttattc	atgagcatga	tgtcagaaat	1200
	tggttagata	ctctatcaag	caatgaaaaa	tatccatttt	caaccaaaga	actccgtaat	1260
	gaactcaagc	atactttttg	gcttttagaa	cgtgtcgctt	cggccaaagc	attaaaagcc	1320
	ctactagaag	aacacccaat	ctatgaaaac	tatgagatcg	ttctagctgc	tggtgacgga	1380
	cgtatgtccg	aagaagacga	taaagtcaaa	ctcaaatcct	tggacttggt	tagaaaagcg	1440
	atagcagaga	atgacaaaac	cattacccta	tccgttggtc	agctgacgac	aggtgtcact	1500
	atccctgaat	ggacaggtgt	attgatgtta	tcaaatttga	aatcaccagc	tctttatatg	1560
	caggccgcct	tccgtgctca	aaatccttac	tcatggagcg	ataacaaagg	aaatcacttt	1620
	Cgcaaagaaa	gagcctatgt	atttgacttt	gcgccggaaa	gaaccttgat	tctctttgat	1680
	gagtttgcca	acaacttatt	gcttgtaact	gcagctggta	gaggaacttc	agctacacgc	1740
	gaagaaaata	ttagagaatt	attaaacttc	tttccaatta	ttgccgaaga	ccgtgctggt	1800
	aagatggttg	aaattgatgc	aaaggcagtt	ctaaccactc	ctcgccagat	aaaagctaga	1860
		aacgaggttt					1920
	caagcaagtc	aaacagtttt	agatatttta	aatgagctgc	cagttgaaaa	ggaagggaag.	1980
		gttctgattt					2040
		accatgaaat					2100
		gtgaatctgt					2160
		atgacttgag					2220
		taaaaacaag					2280
	gagaatgaaa ·						2340
	gagttgcaac	agcagctcaa	agaagcaaat	gataaagcgc	aaaaagataa	gattcaagaa	2400
	gatttggaaa a	aacgtttaga :	agaaaataaa	ctcattcata Page 60	aagaaaaact	agaacaaaca	2460

ctcaaaaaag	aagtggaaaa	aatgcctgag	aaatttatcg	aacaggttga	gataaaacgt	2520
gtggaacagt	tgaaacaatc	agctcaagat	gaaattcgtg	accatttacg	agggtttgca	2580
agaacaattc	caagttttat	tatggcttac	ggtgatcaaa	ctctaacact	tgataatttt	2640
gatgcctttg	ttcctgaaca	tgtttttat	gaagtaacag	ggattacgat	tgatcagttt	2700
agatatttgc	gagatggtgg	gcaggatttt	gcagggcatc	tctttgataa	agcaacattt	2760
gacgaagcta	ttcaagaatt	tcttcgcaag	aaaaaggagt	tggcggatta	ttttaaagat	2820
caaaaagaag	acatttttga	ctatattcca	ccgcagaaga	ccaaccaaat	tttcactcct	2880
aaacgagtgg	tgaaaaggat	ggtagatgat	ttggaaaagg	aaaatccagg	gatttttgat	2940
gatccatcta	agacttttat	tgatttatat	atgaagtcag	gcctctatat	tgcagaactt	3000
gtgaagcggt	tatataatag	caatggcttg	aaagaggcct	ttccaaatcc	tgaagaacgc	3060
ttaaaacata	ttttggaaaa	gcaagtttat	ggatttgctc	cgtctgagat	tatctataac	3120
atttccacta	attttatatt	tggcaatctt	tctaaagata	tcagtaggaa	gaattttgtt	3180
ttagcagata	ccattccagc	ggctaaagaa	gggagcattc	aaaagttggt	tgattcctat	3240
tttgaaaata	at					3252

<210> 52

<211> 702

<212> DNA

<213> Streptococcus pneumoniae

<400> 52 atgaaaaaaa tactaattgt agatgatgag aaaccaatct cggatattat caagtttaat 60 atgaccaagg aaggttacga agttgtaact gcttttaatg gtcgtgaagc gctagagcaa 120 tttgaagcag agcaaccaga tattattatt ctggatttga tgcttccaga aattgatggt 180 ttagaagttg ctaagaccat tcgtaagaca agcagtgtgc ccattcttat gctttcagcc 240 aaagatagtg aatttgataa ggttatcggt ttggaacttg gggcagatga ctatgtaaca 300 aaacccttct ccaatcgtga gttgcaggcg cgtgttaaag ctcttctgcg tcgttctcaa 360 cctatgccag tagatggtca ggaagcagat agtaaacctc aacctatcca aattggggat 420 ttagaaattg ttccagacgc ctacgtggct aaaaaatatg gcgaagaact agacttaacc 480 catcgtgaat ttgagctttt gtatcattta gcatcgcata caggtcaagt catcacgcgc 540 gaacacttgc ttgagactgt ctggggttat gactattttg gtgatgtccg tacagttgat 600 gtgactgtac gacgtctgcg tgagaagatt gaagatacgc ccagccgacc agagtatatc 660 ttgacgcgcc gtggtgtagg gtattacatg agaaataatg ct 702

# <2115 2163 str pneumoniae patentin.ST25

<212> DNA

<213> Streptococcus pneumoniae

<400> 53 atgaagaaaa-aatttetagc-atttttgcta attttattcc caattttctc-attaggtatt --- 60 gccaaagcag aaacgattaa gattgtttct gataccgcct atgcaccttt tgagtttaaa 120 gattcagatc aaacttataa aggaattgat gttgacatta ttaacaaagt cgctgagatt 180 aaaggctgga acattcagat gtcctatcct ggatttgacg cagcagtcaa tgcggttcaa 240 gctgggcaag ccgacgctat catggcaggg atgacaaaga ctaaagaacg tgaaaaagtc 300 ttcaccatgt ctgatactta ctatgataca aaagttgtca ttgctactac aaagtcacac 360 aaaattagca agtacgacca attaactggc aaaaccgttg gtgttaaaaa cggaactgcc 420 gctcaacgtt tccttgaaac aatcaaagat aaatacggct ttactattaa aacatttgac 480 actggtgatt taatgaacaa cagcttgagt gctggtgcca tcgatgccat gatggatgac 540 aaacctgtta tcgaatatgc cattaaccaa ggtcaagacc tccatattga aatggatggt 600 gaagctgtag gaagttttgc tttcggtgtg aaaaaaggaa gtaaatacga gcacctggtt 660 actgaattta accaagcctt gtctgaaatg aaaaaagatg gtagtcttga taaaattatc 720 aagaaatgga ctgcttcatc atcttcagca gtgccaacta caactactct cgcaggatta 780 aaagctattc ctgttaaggc taaatatatc attgccagcg attcttcttt tgcccctttt 840 gttttccaaa attcaagcaa ccaatacact ggtattgata tggaattgat taaggcaatc 900 gctaaagacc aaggttttga aattgaaatc accaaccctg gttttgatgc tgctatcagt 960 gctgtccaag ctggtcaagc cgatggtatc atcgctggta tgtctgtcac agatgctcgt 1020 aaggcaactt ttgacttctc agaatcatac tacactgcta ataccattct tggtgtcaaa 1080 gaatcaagca atattgcttc ttatgaagat ctaaaaggaa agacagtcgg tgttaaaaac 1140 ggaactgctt ctcaaacctt cctaacagaa aatcaaagca aatacggcta caaaatcaaa 1200 acctttgctg atggttcttc aatgtatgac agtttaaaca ctggtgccat tgatgccgtt 1260 atggatgatg aacctgttct caaatattct atcagccaag gtcaaaaatt gaaaactcca 1320 atctctggaa ctccaatcgg tgaaacagcc tttgccgtta aaaaaggagc aaatccagaa 1380 ctgattgaaa tgttcaacaa cggacttgca aaccttaaag caaacggtga attccaaaag 1440 attcttgaca aatacctagc tagcgaatct tcaactgctt caacaagtac tgttgacgaa 1500 acaacgctct ggggcttgct tcaaaacaac tacaaacaac tccttagcgg tcttggtatc 1560 actcttgctc tagctcttat ctcatttgct attgccattg tcatcggaat tatcttcggt 1620 atgtttagcg ttagcccata caaatctctt cgcgtcatct ctgagatttt cgttgacgtt 1680 attcgtggta ttccattgat gattcttgca gccttcatct tctggggaat tccaaacttc 1740 atcgagtcta tcacaggcca acaaagccca attaacgact ttgtagctgg aaccattgcc 1800 Page 62

ctctcactca	atgcggctgc	ttatatcgct	gaaatcgttc	gtggtggtat	tcaggccgtt	1860
ccagttggcc						1920
aagattatcț	tgccacaagc	aactaaattg	atgttgccaa	actttgtcaa	ccaattcgtt	1980
atcgctctta						2040
ggtaagatta						2100
ttctatcttg						2160
cġt '						2163

<210> 54

<211> 1569

<212> DNA

<400> 54						
	aaagtttaac					60
	ctgaatctga					120
gaggccgacg	ttgccttgcc	tgttgtaaag	gactttatca	agaaagttcg	tgagcgtgca	180
gtcgggcatg	aggtcattga	tacacttaat	cctgcgcaac	agattattaa	aatcgttgat	240
gaggaattga	cagccgtttt	aggttctgat	acggcagaaa	ttatcaagtc	acctaagatt	300
	tcatgatggt					360
	aactcaagaa					420
tatcgtccag	ctgccattga	ccagcttaag	accttgggac	aacagattga	tgtgcctgtc	480
tttgcacttg	gaacagaagt	accagctgtt	gagattgtac	gtcaaggttt	ggagcaagcc	540
caaactaatc	ataacgacta	tgtcttgatt	gatactgcgg	gtcgtttgca	gattgatgag	600
ctcctcatga	atgagcttcg	tgatgtgaaa	gcattggctc	aaccaaatga	aatcttgctt	660
gtcgttgatg	ctatgattgg	tcaggaagca	gccaatgttg	cgcgtgagtt	taatgctcag	720
ttggaagtga	ctggggtcat	ccttaccaag	attgatggcg	atactcgtgg	tggtgctgct	780·
ctgtctgttc	gtcacattac	tggaaaacca	atcaagttca	ctggtacagg	tgaaaagatt	840
acggacattg	aaaccttcca	cccagaccgc	atgtctagcc	gtatccttgg	tatgggggat	900
atgctcactt	tgattgagaa	agcttctcag	gaatacgatg	aacaaaaagc	ccttgaaatg	960
gctgagaaga	tgcgcgaaaa	cacctttgat	tttaatgatt	tcatcgatca	attagatcag	1020
	tggggccgat					1080
	aaaacatgaa					1140
_	cacctgaaga					1200
	ctggttctgg			ataaattcat		1260


	str pneumoniae patentin.ST25	
	aaccaggcta_aacagetcat_gcagggtgtt_atgtctgggg_atatgaataa_aatgatgaag	ENSINE CIPCUI FAN A VESS.
	Caaatgggga ttaatccaaa taaccttcct aaaaatatgc caaatatggg aggaatggat	1320
	atgtctgccc ttgaaggaat gatggacaa ggcggtatga at a said	1380
	atgtctgccc ttgaaggaat gatgggacaa ggcggtatgc ctgacttatc agctctcgga	1440
	ggagcaggaa tgccagatat gagccagatg tttggtggcg gtttgaaagg taaaattggt	1500
	gaatttgcca tgaaacagtc catgaaacgt atggctaaca aaatgaagaa agcgaagaag - aaacgcaag	1560
	unicycuty	1569
	<210> 55	
	<211> 699	
	<212> DNA	
	<213> Streptococcus pneumoniae	
,	<400> 55	
	atgagccaaa tttggactaa agaaaaattt ataagccaag ttcaaggtgg agtcattgtt	60
	tcttgtcaag ctttacctgg tgaagccctt tataatgaag aatttagctt gatgcctttt	120
	atggctaaag cagctttaga ggcaggagca gtgggcattc gcgcaaattc tgtgcgtgat	180
	attaaagcaa ttcagaaagt agtagattta ccaataattg gaattatcaa aagggattat	240
	ccacctcaag aaccatatat tactgctacg atgaaagaag tagatgaact tgtagaatgc	300
	ggaacaacag tcattgcatt tgatgcaact ttaagaccaa gatatgatgg cttagttgtc	360
	agtgaattta tcaaaaaaat aaaagaaaaa tatccgaatc aattgctgat ggcggatgta	420
	agtaatttag atgaaggtct ctatgcattt aaatcaggcg ttgattttgt tggtacaaca	480
	ttatcaggtt acacaagtac aagtgtacaa tcagatgagc ctgattttga actaatgaaa	540
	aaattggctg attttaatat tccggtaatt gccgaaggaa aaattcatta tccagaacaa	600
)	ttaaaaaaag cttatagttt aggtgttacc agtgtagtca ttggtggagc gattacacgt	660
,	ccaaaagaaa ttgctcagcg atttattaat gtcatcaaa	699
	<210> 56	
	<211> 1164	
	<212> DNA	
	<213> Streptococcus pneumoniae	
	<400> 56	
	atgagatatt taactgcagg agaatcacac ggcccccgtc taacagctat tattgaggga	60

cacac ggcccccgtc taacagctat tattgaggga 60 attccagctg gacttccatt gacagctgag gatatcaatg aggaccttag acgccgtcag 120 ggtggctacg gtcgtggtgg tcgtatgaag attgagaatg accaggttgt ctttacttcg 180 ggcgttcgcc acgggaagac gacaggggcg cctattacta tggatgtcat caataaggac 240 Page 64

caccagaaat	ggctggacat	catgtctgcg	gaggacattg	aagaccgcct	taaaagcaag	300
cggaaaatta	ctcatcctcg	cccaggtcat	gccgatttgg	ttggggggat	taagtaccgt	360
tttgatgatt	tgcgaaattc	tttggagcgt	tcatcagctc	gtgaaaccac	catgcgggtg	420
	cagtagccaa					480
	ttggtggcaa					540
	ctgcccagtc					600
	ttgaccaaat					660
	gcgttccagt					720
	ctcaagctgt					780
	ctggttatcg					840
	atactcgccg					900
	tcgttgttcg					960
	atatcgaaac					1020
	cagctgcagg					1080
	aaaaattctc					1140
	atacaaagaa		, <b>5 5</b>	uuuguuge	ggtagctaaa	
						1164
<210> 57						

<211> 1170

<212> DNA



•	
str pneumoniae patentin.ST25	
_acaacttctg_ttgatctagc_eaaaegttea_egagaattgt_ctcaagcgca_ttttcaggca_	780
aatgggctca gcacagacga gcatcgtttt atagtcatgg atgtctttga gtatttcaaa	840
tatgccaaac gcaaagactt gacctacgat gtgattgtcc tagatccgcc tagctttgct	900
cggaataaaa aacaaacttt ctctgtggcc aaggattatc acaagttgat ttcccagagt	960
cttgagattt taaatccggg agggattatc attgccagta ccaatgctgc caatgtttcc	_ 1020
cgtcagaaat ttacagaaca aattgataaa ggttttgcag gaagaagtta ccagatttta	1080
aacaaatatg gtcttccagc agattttgcc tataataaaa aagatgaaag tagtaattac	1140
ctcaaggtga ttagtatgaa ggttagtaaa	1170
<210> 58	
<211> 1284	
<212> DNA	
<213> Streptococcus pneumoniae	_
<400> 58	
atgacaaaaa cattaaaacg tcctgaggtt ttatcacctg cagggacttt agagaagcta	60
aaggtagctg ttcagtatgg agcagatgct gtctttatcg gtggtcaggc ctatggtctt	120
cgtagccgtg cgggaaactt tactttcgaa cagatggaag aaggcgtgca gtttgcggcc	180

	<b>540U&gt;</b>	ספ						
č	atgacaa	aaa	cattaaaacg	tcctgaggtt	ttatcacctg	cagggacttt	agagaagcta	60
ć	aaggtag	ctg	ttcagtatgg	agcagatgct	gtctttatcg	gtggtcaggc	ctatggtctt	120
(	gtagco	gtg	cgggaaactt	tactttcgaa	cagatggaag	aaggcgtgca	gtttgcggcc	180
ē	agtatg	gtg	ccaaggtcta	tgtagcggct	aatatggtta	tgcacgaagg	aaatgaagct	240
ç	gtgctg	gtg	agtggttccg	taaactgcgt	gatatcggga	ttgcagcagt	tatcgtatct	300
g	jacccag	cct	tgattatgat	tgcagtgact	gaagcaccag	gccttgaaat	ccacctttct	360
a	eccaag	cca	gtgccactaa	ctatgaaacc	cttgagttct	ggaaagagct	aggcttgact	420
C	gtgtcg	ttt	tagcgcgtga	ggtttcaatg	gaagaattag	ctgagatccg	caaacgtaca	480
Ğ	atgttg	aaa	ttgaagcctt	tgtccatgga	gctatgtgta	tttcatactc	tggacgttgt	540
а	ctcttt	caa	accacatgag	tatgcgtgat	gccaaccgtg	gtggatgttc	tcagtcatgc	600
.C	gttgga	aat	acgaccttta	cgatatgcca	tttgggaaag	aacgtaagag	tttgcagggt	660
g	agattc	cag	aagaattttc	aatgtcagcc	gttgacatgt	ctatgattga	ccacattcca	720
g	atatga	ttg	aaaatggtgt	ggacagtcta	aaaatcgaag	gacgtatgaa	gtctattcac	780
				ctgctacaag				840
g	aaaagt <sup>.</sup>	ttg	aagctatcaa	acaagacttg	gtggacgaga	tgtggaaggt	tgcccaacgt	900
g	aactgg	cta	caggatttta	ctatggtaca	ccatctgaaa	atgagcagtt	gtttggtgct	960
C	gccgta	aaa	ttcctgagta	caagtttgtc	gctgaagtgg	tttcttatga	tgatgcggca	1020
C	aaacag	caa	caattcgtca	acgaaatgtc	attaacgaag	gggaccaagt	tgagttttat	1080
g	gtccag	gtt	tccgtcattt	tgaaacctat	attgaagatt	tgcatgatgc	caaaggcaat	1140
a	aaatcga	acc i	gcgctccaaa	tccaatggaa	ctattgacta	ttaaggtgcc	tcaacccatt	1200
				•	Page 66	25 5		1200

				1 cent 111.512;		
caatcaggag	atatggttcg	tgcattaaaa	a gaaggactca	tcaatcttta	ı taaggaagat	1260
ggaaccagcg	tcacagttcg	agct				1284
<210> 59						
<211> 840						
<212> DNA						
	ptococcus	nneumoniae		•		
	,	pricumonrae				
<400> 59					•	
	atcaattaaa	taatggagta	gaaattccag	tattgggatt	tggaactttt	60
aaggctaagg	atggagaaga	agcctatcgt	gcagtgttag	aagccttgaa	ggctggttat	120
cgtcatattg	atacggcggc	gatttatcag	aatgaagaaa	gtgttggtca	agcaatcaaa	180
gatagcggag	ttccacgtga	agaaatgtto	gtaactacca	agctttggaa	tagtcagcaa	240
acctatgagc	aaactcgtca	agctttggaa	aaatctatag	aaaaactggg	cttggattat .	300
ttggatttgt	atttgattca	ttggccgaac	ccaaaaccgc	tcagagaaaa	tgacgcatgg	360
aaaactcgca	atgcggaagt	ttggagagcg	atggaagacc	tctatcaaga	agggaaaatc	420
cgtgctatcg	gcgttagcaa	ttttcttccc	catcatttgg	atgccttgct	tgaaactgca	480
actatcgttc	ctgcggtcaa	tcaagttcgc	ttggcgccag	gtgtgtatca	agatcaagtc	540
gtagcttact	gtcgtgaaaa	gggaatttta	ttggaagctt	gggggccttt	tggacaagga	600
gaactgtttg	atagcaagca	agtccaagaa	atagcagcaa	atcacggaaa	atcggttgct	660
cagatagcct	tggcctggag	cttggcagaa	ggatttttac	cacttccaaa	atctgtcaca	720
acctctcgta	ttcaagctaa	tcttgattgc	tttggaattg	aactgagtca	tgaggagaga	780
gaaaccttaa	aaacgattgc	tgttcaatcg	ggtgctccac	gagttgatga	tgtggatttc	840
<210> 60						
<211> 1653						
<212> DNA						
<213> Stre	otococcus n	neumoniae				
•		······································				
<400> 60						
ttgagtgaaa a	agtcaagaga	agaagagaaa	ttaagcttta	aagagcagat	tctgagagat	60
ttagaaaaag 1	taaaaggcta	tgatgaagtt	ctgaaagaag	atgaggcagt	agttcgcact	120
cctgcaaatg a	accttcaac	tgaagaactc	atggctgatt	ccttgtcaac	ggtagaggag	180
attatgagaa a	agctcctac	cgtgcctact	cacccaagtc	aaggtgtacc	agcttctcca	240
gcagatgaga t	tcaaagaga	aactcctggt	gttccaagtc	atccaagtca	agatgtacct	300
tcttctccag o	:ggaagaaag	tggatcaaga	ccaggtccag	gtcctgttag	acctaagaaa	360
			Page 67		<b>-</b>	

Str pneumoniae patentin.ST25						
cttgaaagag aatacaatga aaccccaaca agggtagctg tttcctatac gacggcagag	420					
aaaaaagcag aacaagcagg tccagaaaca cctacgcctg ctacagaaac agtggatatc	480					
atcagagata catcacgtcg tagccgtaga gaaggagcaa aacccgttaa gcctaagaaa	540					
gagaagaagt cacatgtgaa agcttttgtg atttcattcc ttgtattcct tgccttgctc	600					
tcagcaggtg gttactttgg.ttaccagtac gtgctagatt ccttattacc tatcgatgct	660					
aattctaaga aatatgtgac ggttggaatt ccagaaggtt caaacgttca agaaatcggt	<b>720</b>					
acgacgcttg aaaaagctgg tttggtaaag catggtctga tttttagttt ttatgccaag	780					
tataaaaatt ataccgactt gaaagcaggt tactacaatt tgcaaaagag tatgagtaca	840					
gaagacttac tcaaagagtt gcaaaaaggt ggaacagatg aaccgcaaga acctgtactt	900					
gcgactttga caattccaga aggttatacc ttggatcaga ttgctcaagc tgtgggtcaa	960					
ttgcaaggtg acttcaaaga gtctttgaca gcggaggctt tcttggctaa agttcaagat	1020					
gagacgttta tcagtcaagc agtagcgaaa tatcctactt tactggaaag tttgcctgta	1080					
aaagacagcg gtgcgcgtta tcgtttggaa ggataccttt tcccagctac atactctatc	1140					
aaggaaagca caactattga gagcttgatt gatgagatgt tagctgctat ggataagaac	1200					
ctatctcctt actatagtac tatcaaatct aaaaacttga ctgtcaatga gttgttgacc	1260					
attgcttcct tggtcgaaaa agaaggtgcc aagacagaag atcgtaagct cattgcaggt	1320					
gtattctaca atcgtttgaa tcgtgatatg ccacttcaaa gtaatattgc aatcttgtat	1380					
gcccaaggaa aactggggca aaatatcagt ctagctgagg atgttgcgat tgataccaac	1440					
attgattcac cttataatgt ttataaaaat gtaggtctca tgcctggtcc agtcgatagt	1500					
ccaagtctgg atgcgattga gtcaagcatc aatcaaacta agagcgataa cctctacttt	1560					
gtagcagatg tcacagaagg caaggtctac tatgctaaca atcaagaaga cċacgaccgc	1620					
aatgtcgctg aacatgtcaa cagcaaatta aac	1653					
<210> 61						
<211> 615						
<212> DNA						
<213> Streptococcus pneumoniae						
TELES SCIENCOCCUS PREGMOTTAE						
<400> 61						

atgaaacaag aacgatttcc attggtgtca gatgacgagg tcatgttgac tgaaatgcca 60 gtcatgaatc tctatgatga gtctgatctg atcagtaata tcaagggtga gtatcgagat 120 aaaaattatt tagaatgggc tcctattgct gaagaaaaac cagtaaaacc gattgaaaag 180 caagtcgaaa aacctaaaaa ggctccttta ggggttaaaa aagaaggaaa gagctatgcg 240 gaggtggcgc gtgaagaagc gcgtgcggac ttgaaaaaga aacgctctgc taactaccta 300 actcaggatt tcagccttgc gagacgtcat tctcagccca gtctagttag acagggcaat 360

Page 68

caaccgacag	ctcctttcca	aaaggaaaat	cctggtgaat	ttgtcaaata	tagccaaaaa	420
ttgacccagt	ctcattatat	cttggcggaa	gaagttcatt	ctatccctac	caagaatgaa	480
					gagccaaatc	540
tacaataaaa	aaagtaaaca	aacagaacaa	gaacgtcggg	ttgcccaaga	gttgaatctg	600
accagaatga	cagaa					615

<210> 62

<211> 1956

<212> DNA

<213> Streptococcus pneumoniae

<400> atgaaaaagt ctaagagcaa atatctaacc ttggcaggtc ttgtcctggg tacaggagtt 60 ttattgagcg cgtgtggaaa ttctagcacg gcgtcaaaaa cctacaacta tgtttattca 120 agtgatccat ctagcttgaa ctatctagca gaaaaccgcg cagcaacatc cgatattgtt 180 gcaaatttgg tagacgggtt attagaaaat gaccaatatg ggaatattat tccatcatta 240 gcagaggatt ggactgtttc tcaggacggt ttgacctata cctacaaact tcgtaaggat 300 gccaagtggt ttacttctga gggagaagaa tatgcgcctg taactgccca ggattttgtg 360 acaggtttgc aatatgcagc tgataaaaaa tcagaagcct tgtatctagt gcaggactct 420 gttgctggtt tggatgacta tatcactggt aaaacaagcg acttttcaac tgtcggtgtc 480 aaggcacttg atgaccaaac ggttcaatat actttggtta aaccagaact ttactggaat 540 tcaaaaacac ttgcaacgat acttttcct gttaatgcag atttcctgaa atcaaaaggg 600 gatgattttg ggaaggcgga tccatctagt attttgtaca atggaccttt cttgatgaaa 660 gcacttgtct caaaatctgc tattgaatat aagaaaaacc ctaattactg ggatgctaag 720 aatgtctttg tagacgatgt gaaattgacc tactatgatg gtagcgacca agaatcactg 780 gaacgtaatt ttacagctgg tgcttatact acggctcgtc tttttcctaa cagctccagc 840 tatgaaggga ttaaagaaaa atacaaaaac aatatcatct atagtatgca aaattcaact 900 tcatatttct ttaattttaa cctagatagg aagtcttaca attatacttc taaaacaagt 960 gacattgaaa agaaatcgac tcaggaagca gttctcaata aaaacttccg tcaggctatc 1020 aattttgctt ttgacagaac atcttatggg gctcagtctg aagggaaaga aggtgcaaca 1080 aagattttgc gtaacctagt ggttcctcca aactttgtca gtatcaaggg aaaagacttt 1140 ggtgaagttg tagcctctaa gatggtcaac tatggtaagg aatggcaagg tatcaacttt 1200 gcggatggtc aagaccctta ctacaatcct gagaaagcca aggctaagtt tgcggaagct 1260 aagaaagaac tcgaagcaaa gggtgttcaa ttcccaatcc acttggataa gactgtggaa 1320 gtaacagata aagtaggcat acaaggagtt agttctatca aacaatcaat tgaatctgtt 1380

		· · ·
str pneum	moniae patentin.ST25	
_ttaggttctg_ataatgtagt_gattgacatt_ca	gcaattaa catcagatga gtttgacast	1440
tcaggctact ttgctcaaac agctgctcag aa	lagattatg atttatatca togcogttag	1440
ggacctgatt atcaagaccc gtcaacctat ct	Cgatattt ttaatactaa tagtggagg	1500
tttctgcaaa atcttggact agagcctggt ga	ggccaatg acaaggctaa ggcagttaga	1560
Ctggatgtct atactcaaat gttggaagaa gc	taataaaq.aqcaagatcc	
tatgagaaat atgctgatat tcaagcttgg tt	gattgata qttctttagt tcttccaae	1680
gtttcgcgtg ggggaacacc atcattgaga ag	aaccetac catttectec tecttage	1740
ttaaccggta caaaaggggt tgaatcatat aa	atacctca aagtacaaga taagattata	1800
acaacagacg aatatgcaaa agccagagaa aa	atggttga aagaaaaaga agaatcaat	1860
aaaaaagccc aagaagaatt ggcaaaacat gt	Caaa	1920
<210> 63		1956
<211> 1518		
<212> DNA		
<213> Streptococcus pneumoniae		
<400> 63		
gtggaacagc attcagatgt ctgttacatt ttt	ttatagga gagaaagatt gaaaacaaa	
attggattag caagtatctg tttactaggc ttg	gcaacta gtcatgtcgc tgcaaatgaa	60
actgaagtag caaaaacttc gcaggataca acg	Jacagett caagtagtte agageasas+	120 180
cagtetteta ataaaaegea aaegagegea gaa	Igtacaga Ctaatgctgc tgccactag	100

g cagtcttcta ataaaacgca aacgagcgca gaagtacaga ctaatgctgc tgcccactgg 240 gatgggggatt attatgtaaa ggatgatggt tctaaagctc aaagtgaatg gatttttgac 300 aactactata aggcttggtt ttatattaat tcagatggtc gttactcgca gaatgaatgg 360 catggaaatt actacctgaa atcaggtgga tatatggccc aaaacgagtg gatctatgac 420 agtaattaca agagttggtt ttatctcaag tcagatgggg cttatgctca tcaagaatgg 480 caattgattg gaaataagtg gtactacttc aagaagtggg gttacatggc taaaagccaa 540 tggcaaggaa gttatttctt gaatggtcaa ggagctatga tgcaaaatga atggctctat 600 gatccagcct attctgctta tttttatcta aaatccgatg gaacttatgc taaccaagag 660 tggcaaaaag tgggcggcaa atggtactat ttcaagaagt ggggctatat ggctcggaat 720 gagtggcaag gcaactacta tttgactgga agtggtgcca tggcgactga cgaagtgatt 780 atggatggta ctcgctatat ctttgcggcc tctggtgagc tcaaagaaaa aaaagatttg 840 aatgtcggct gggttcacag agatggtaag cgctatttct ttaataatag agaagaacaa 900 gtgggaaccg aacatgctaa gaaagtcatt gatattagtg agcacaatgg tcgtatcaat 960 gattggaaaa aggttattga tgagaacgaa gtggatggtg tcattgttcg tctaggttat 1020 agcggtaaag aagacaagga attggcgcat aacattaagg agttaaaccg tctgggaatt 1080

Page 70

	-			
ccttatggtg tctatctcta tacctatgct	gaaaatgaga	ccgatgctga	gagtgacgct	1140
aaacagacca ttgaacttat aaagaaatac	aatatgaacc	tgtcttaccc	tatctattat	1200
gatgttgaga attgggaata tgtaaataag	agcaagagag	ctccaagtga	tacaggcact	1260
tgggttaaaa tcatcaacaa gtacatggac	acgatgaagc	aggcgggtta	tcaaaatgtg	1320
tatgtctata gctatcgtag tttattacag	acgcgtttaa	aacacccaga	tattttaaaa	1380
catgtaaact gggtagcggc ctatacgaat	gctttagaat	gggaaaaccc	tcattattca	1440
ggaaaaaaag gttggcaata tacctcttct	gaatacatga	aaggaatcca	agggcgcgta	1500
gatgtcagcg tttggtat				1518
<210> 64				
<211> 474		•		
<212> DNA				
<213> Streptococcus pneumoniae				
•				
<400> 64				
atggcaaaag aaccgtggca agaagatatc				60
Cggcatcgaa accacggagg ggctgatagg				120
agtattttct ttgtaattgt ggtggtgatg				180
gggagtaatc gcacagcagc cttaaaaggc				240
atctcatctt caagtagttc tcagcctgag				300
agttcagaag aagctgctaa tcctgaagga				360
gcagctattg ccgctcgtgc aggaatctcc				420
cacatggcta caggatettg gtttgctaat	ccaggtgatg	ttataaaaat	aaaa	474
<210> 65				
<211> 786				
<212> DNA				
<213> Streptococcus pneumoniae				
<400> 65				
atgccaatta catcattaga aataaaggac				60
gatccagaag aagtcgatga atttttagat				120
cgtgcgaatc atgataaaaa tttgcgtatt				180
gatgaaataa aagattcatt gagccagtct				240
gtgaaacagg cggcgcatga acgttcaaac				300
caacgcttgt tggaagaagc taaatataag	gcaaacgaga	ttcttcgtca	agcaactgat	360

Page 71

	str pneumoniae patentin.sT25	
	aatgctaaga aagtcgctgt tgaaacagaa gaattgaaga acaagagccg tgtcttccac	420
	caacgtctca aatctacaat tgagagtcag ttggctattg ttgaatcttc agattgggaa	480
	gatattctcc gtccaacagc tacttatctt caaaccagtg atgaagcctt taaagaagtg	540
	gttagcgaag tacttggaga accgattcca gctccaattg aagaagaacc aattgatatg	600
•.•	acacgtcagt tctctcaagc agaaatggca-gaattacaag ctcgtattga-ggtagccgat	660-
	aaagaattgt ctgaatttga agctcagatt aaacaggaag tggaagctcc aactcctgta	720
	gtgagtcctc aagttgaaga agagcctctg ctcatccagt tggcccaatg tatgaagaac	780
	Cagaag	786
	<210> 66	
	<211> 537	
•	<212> DNA	
	<213> Streptococcus pneumoniae	
	<400> 66	
	atgtctttaa aagatagatt cgatagattt atagattatt ttacggagga tgaggattca	60
	agtctccctt atgaaaaaag agatgagcct gtgtttactt cagtaaattc ttcacaggaa	120
	ccggctctcc caatgaatca accttcacag tcggctggca caaaagagaa caatatcacc	180
	agacttcatg caagacaaca ggaattggca aatcagagtc agcgtgcaac ggataaggtc	240
	atťatagatg ttcgttatcc tagaaaatat gaggatgcaa cagaaattgt tgatttattg	300
	gcaggaaacg aaagtatctt gattgatttt cagtatatga cagaggtgca ggctcgtcgt	360
	tgtttggact atttggatgg agcttgtcat gttttagctg gaaatttgaa aaaggtagct	420
	tctaccatgt atttgttgac accagtgaac gttattgtaa atgttgaaga tatccgttta	480
	ccagatgaag atcaacaggg tgagttcggt tttgatatga agcgaaatag agtacga	537
	<210> 67	
	<211> 915	
	<212> DNA	
	<213> Streptococcus pneumoniae	
	·	
	<400> 67	
	atgtcagatt tgaaaaaata cgaaggtgtc attccagcct tctacgcatg ttatgatgat	60
	caaggagaag taagcccaga acgtacgcgt gccttggttc aatacttcat tgataaaggt	120
,	gttcaaggtc tttatgtcaa tggttcttct ggtgaatgta tctaccaaag cgttgaagat	180
	cgcaagttga ttttggaaga agtcatggcg gtagccaaag gtaaattgac cattattgcc	240
	catgttgctt gcaataatac taaagatagt atggaacttg ctcgccatgc tgaaagcttg	300
	Page 72	

~~~~~~~~~~						
ggagtagatg	ctattgcaac	gattccacca	atttatttcc	gcttgccaga	atactcagtt	360
gccaaatact	ggaacgatat	cagttctgca	gctccaaaca	cagactacgt	gatttacaac	420
attcctcaat	tggcaggggt	tgctttgact	CCaageettt	acacacaa+	Stance	
		5 15 11 1		ucacagaaat	grigaaaaat	480
cctcgtgtta	tcggtgtgaa	gaactcttct	atgccagttc	aagatatcca	aacctttgtc	540
agccttggtg	gagaagacca	tatcgtcttt	aatggtcctg	atgagcagtt	cctaggagga	600
cacctcataa	agactagaac	tantatonat	00to otto.		50 55	
-5	gggctagggc	rggtattggt	gytacttatg	gtgctatgcc	agaactcttc	660
ttgaaactca	atcagttgat	tacaaataaa	###		- • •	
_		-9-99acaag	gacciayaaa	cagegegega	attgcagtat	720
gctatcaacg	caatcattgg	taaactcact	tctactcata	naaatatata		700
			gercacy	gaaatatyta	Cygrateate	780
aaagaagtct	tgaaaatcaa	tgaaggcttg	aatattooat	ctattcattc	accattanca	940
				90009000	accartyaca	840
ccagtgactg	aagaagatcg	tccagttgta	gaagcggctg.	ctgccttgat	tcqtqaaacc	900
			_	- •	. 5 -5	500
aaggagcgct						915

<210> 68

<211> 2091

<212> DNA

	<400> 68							
	atgaataaa	aa	gaggtcttta	ttcaaaacta	ggaatttccg	ttgtaggcat	tagtctttta	60
					gaattaaact			120
	cctattttt	tc	aaggaggttc	atatcaactg	aacaataaga	gtatagatat	cagctctttg	180
	ttattagat	ta	aattgtctgg	agagagtcag	acagtagtaa	tgaaatttaa	agcagataaa	240
					tctaatagta			300
	tacttttca	aa	ttttcatgag	agattctggt	gagataggtg	tagaaataag	agacgcccaa	360
	aagggaata	aa	attatttatt	ttccagacca	gcttcattat	ggggaaaaca	taaaggacag	420
	gcagttgaa	aa	atacactagt	atttgtatct	gattctaaag	ataaaacata	cacaatgtat	480
	gttaatgga	aa	tagaagtgtt	ctctgaaaca	gttgatacat	ttttgccaat	ttcaaatata	540
	aatggtata	ŧg	ataaggcaac	àctaggagct	gttaatcgtg	aaggtaagga	acattacctc	600
	gcaaaagga	ıa	gtattgatga	aatcagtcta	tttaacaaag	caattagtga	tcaggaagtt	660
٠	tcaactatt	:c	ccttgtcaaa	tccatttcag	ttaattttcc	aatcaggaga	ttctactcaa	720
					acattaagta			780
					tctaaaagta			840
					gagccaattt			900
					gataataaat			960
					gttgaagata Page 73			1020
								_

			oe. pii	cumonitae pa	rentin.51/25	-		
	_ttactac	octg_atgttatgcc	-tgegggtatt	ggaaataata	-atgcaaataa	agccgactca	1080	F.a 22.2
	ggtttta	aaag aaataaatgg	tcattattat	ttaaaactaa	agaagaatgg	agataacgat	1140	
	ttccgtt	tata cagttagaga	aaatggtgtc	gtttataatg	aaacaactaa	taaacctaca	1200	
	aattata	acta taaatgataa	gtatgaagtt	ttggagggag	gaaagtcttt	aacagtcgaa	1260	
	caatatt	cgg ttgattttga	tagtggctct	ttaagagaaa	ggcataatgg	aaaacaggtt	1320	<b></b>
	cctatga	atg ttttctacaa	agattcgtta	tttaaagtga	ctcctactaa	ttatatagca	1380	an employee a com-
	atgacaa	cta gtcagaatag	aggagagagt	tgggaacaat	ttaagttgtt	gcctccattc	1440	
•	ttaggag	aaa aacataatgg	aacttactta	tgtcccggac	aaggtttagc	attaaaatca	1500	
	agtaaca	gat tgatttttgc	aacatatact	agtggagaac	taacctatct	catttctgat	1560	
	gatagtg	gtc aaacatggaa	gaaatcctca	gcttcaattc	cgtttaaaaa	tqcaacagca	1620	
	gaagcac	aaa tggttgaact	gagagatggt	gtgattagaa	cattctttag	aaccactaca	1680	
	ggtaaga	tag cttatatgac	tagtagagat	tctggagaaa	catggtcgaa	agtttcgtat	1740	
	attgatg	gaa tccaacaaac	ttcatatggc	acacaagtat	ctgcaattaa	atactctcaa	1800	
	ttaattg	atg gaaaagaagc	agtcattttg	agtacaccaa	attctagaag	tggccgcaag	1860	
	ggaggcc	aat tagttgtcgg	tttagtcaat	aaagaagatg	atagtattga	ttggaaatac	1920	
	cactatg	ata ttgatttgcc	ttcgtatggt	tatgcctatt	ctgcgattac	agaattqcca	1980	
	aatcatca	aca taggtgtact	gtttgaaaaa	tatgattcgt	ggtcgagaaa	tgaattqcat	2040	
	ttaagca	atg tagttcagta	tatagatttg	gaaattaatg	atttaacaaa	a	2091	
		69						
		2884						
		DNA						
			noumori					
_		Streptococcus p	neumon rae					

atgaatcgga gtgttcaaga acgtaagtgt cgttatagca ttaggaaact atcggtagga 60 gcggtttcta tgattgtagg agcagtggta tttggaacgt ctcctgtttt agctcaagaa 120 ggggcaagtg agcaacctct ggcaaatgaa actcaacttt cgggggagag ctcaacccta 180 actgatacag aaaagagcca gccttcttca gagactgaac tttctggcaa taagcaagaa 240 caagaaagga aagataagca agaagaaaaa attccaagag attactatgc acgagatttg 300 gaaaatgtcg aaacagtgat agaaaaagaa gatgttgaaa ccaatgcttc aaatggtcag 360 agagttgatt tatcaagtga actagataaa ctaaagaaac ttgaaaacgc aacagttcac 420 atggagttta agccagatgc caaggcccca gcattctata atctctttc tgtgtcaagt 480 gctactaaaa aagatgagta cttcactatg gcagtttaca ataatactgc tactctagag 540 gggcgtggtt cggatgggaa acagttttac aataattaca acgatgcacc cttaaaagtt

600

	333CC2001C 201000000	
	aaaccaggtc agtggaattc tgtgactttc acagttgaaa aaccgacagc agaactacct	660
	aaaggccgag tgcgcctcta cgtaaacggg gtattatctc gaacaagtct gagatctggc	720
	aatttcatta aagatatgcc agatgtaacg catgtgcaaa tcggagcaac caagcgtgcc	780
	adcadiacgg trigggggtc aaatctacag attcggaatc tcactgtgta taatcgtoct	840
	ttaacaccay aagaggtaca aaaacgtagt caacttttta aacgctcaga tttagaaaaa	900
	additacetg aaggagegge tttaacagag aaaaeggaca tattegaaag egggegtaac	960
	gytaacceaa ataaagatgg aatcaagagt tatcgtattc cagcacttct caagacagat	1020
	addygaacii tgatcgcagg tgcagatgaa cgccgtctcc attcgagtga ctggggtgat	1080
	acceptated teatcagacg tagtgaagat aatggtaaaa ettggggtga ecgagtaace	1140
	attaccaact tacgtgacaa tccaaaagct tctgacccat cgatcggttc accagtgaat	1200
	accgatatgg tgttggttca agatectgaa accaaacgaa tetttetat etatgacatg	1260
1	treccagaag ggaagggaat ctttggaatg tcttcacaaa aagaagaagc ctacaaaaaa	1320
	accyatggaa aaacctatca aatcctctac cgtgaaggag aaaagggagc ttataccatt	1380
	cyayadaatg gtactgtcta tacaccagat ggtaaggcga cagactatcg cgttgttgta	1440
	galletgita aaccageeta tagegacaag ggtgatetat acaagggtga ccaattacta	1500
	gyadatatet aetteacaae aaacaaaaet tetecattta gaattgeeaa ggatagetat	1560
	ctatggatgt cctacagtga tgacgacggg aagacatggt cagctcctca agatattact	1620
	ccyalggtca aagccgattg gatgaaattc ttgggtgtag gtcctggaac aggaattgta	1680
	citeggaarg ggcctcacaa gggacggatt ttgataccgg tttatacgac taataatgta	1740
	teleactrag atggetegea atettetegt gteatetatt cagatgatea tggaaaaact	1800
	tyycatgctg gagaagcggt caacgataac cgtcaggtag acggtcaaaa gatccactct	1860
	tetacgatga acaatagacg tgcgcaaaat acagaatcaa cggtggtaca actaaacaat	1920
	gyagatgtta aactetttat gegtggtttg aetggagate tteaggttge tacaagtaaa	1980
	gacggaggag tgacttggga gaaggatatc aaacgttatc cacaggttaa agatgtctat	2040
	gricaaatgt ctgctatcca tacgatgcac gaaggaaaag aatacatcat cctcagtaat	2100
	gcaggtggac cgaaacgtga aaatgggatg gtccacttgg cacgtgtcga agaaaatggt	2160 <sup>-</sup>
	gagttgactt ggctcaaaca caatccaatt caaaaaggag agtttgccta taattcgctc	2220
	caagaattag gaaatgggga gtatggcatc ttgtatgaac atactgaaaa aggacaaaat	
	gcctataccc tatcatttag aaaatttaat tgggaatttt tgagcaaaaa tctgatttct	2280
	cctaccgaag cgaactagag agatgggcaa aggagagatg ggcaaaggag ttattggctt	2340
	ggagttcgac tcagaagtat tggtcaacaa ggctccaacc cttcaattgg caaatggtaa	2400
	aacagcgact ttcctaaccc agtatgatag caagaccttg ttgtttgcag tagataagga	2460
	agatatcgga caggaaatta ttggtatagc taaaggaagc atcgaaagta tgcataatct	2520
	tcctgtaaat ctagcaggtg ccagagttcc tggcggagta aatggtagca aagcagcggt	2580
	Page 75	2640

#### str pneumoniae patentin.ST25 gcatgaagtt ccagaattta cagggggagt taatggtaca gagccagctg ttcatgaaat 2700 cgcagagtat aagggatctg attcgcttgt aactcttact acaaaaaaag attatactta 2760 caaagctcct cttgctcagc aggcacttcc tgaaacagga aacaaggaga gtgacctcct 2820 agcttcacta ggactaacag ctttcttcct tggtctgttt acgctaggga aaaagagaga 2880 والراب المحكمين والمستواطع المراجع المستوانية والمراجع المراجع والمستواع والمستواع والمستواع والمستوانية 2884 <210> 70 <211> 1977 <212> DNA <213> Streptococcus pneumoniae

<400> 70 atgatccaaa tcggcaagat ttttgccgga cgctatcgga ttgtcaaaca gattggtcga 60 ggaggtatgg cggatgtcta cctagccaaa gacttaatct tagatgggga agaagtggca 120 gtgaaggttc tgaggaccaa ctaccagacg gacccgatag ctgtagctcg ttttcagcgt 180 gaagcgagag ctatggcaga tctagaccat cctcatatcg ttcggataac agatattggc 240 300 tatatcaagg aacattatcc tctttctaat gaagaagcag tccgtatcat gggacaaatt 360 ctcttggcta tgcgcttggc ccatactcga ggaattgttc acagggactt gaaacctcaa 420 aatatcctct tgacaccaga tgggactgcc aaggtcacag actttgggat tgctgtagcc 480 tttgcagaga caagtctgac ccagactaac tcgatgttgg gctcagttca ttacttgtca 540 ccagagcagg cgcgtggttc gaaggcgact gtgcagagtg atatctatgc catggggatt 600 attttctatg agatgctgac aggccatatc ccttatgacg gggatagcgc ggtgaccatt 660 gccctccagc atttccagaa acccctgccg tccgttattg cagaaaatcc atctgtacct 720 caggetttag aaaatgttat tateaaggea aetgetaaaa agttgaeeaa tegetaeege 780 tcggtttcag agatgtatgt ggacttgtct agtagcttgt cctacaatcg tagaaatgaa 840 agtaagttaa tetttgatga aacgagcaag gcagatacca agacettgee gaaggtttet 900 cagagtacct tgacatctat tcctaaggtt caagcgcaaa cagaacacaa atcaatcaaa 960 aacccaagcc aggctgtgac agaggaaact taccaaccac aagcaccgaa aaaacataga 1020 tttaagatgc gttacctgat tttgttggcc agccttgtat tggtggcagc ttctcttatt 1080 tggatactat ccagaactcc tgcaaccatt gccattccag atgtggcagg tcagacagtt 1140 gcagaggcca aggcaacgct caaaaaagcc aattttgaga ttggtgagga gaagacagag 1200 gctagtgaaa aggtggaaga agggcggatt atccgtacag atcctggcgc tggaactggt 1260 cgaaaagaag gaacgaaaat caatttggtt gtctcatcag gcaagcaatc tttccaaatt 1320 agtaattatg tcggtcggaa atcctctgat gtcattgcgg aattaaaaga gaaaaaagtt 1380 Page 76

ccagataatt	tgattaaaat	tgaggaagaa	gagtcgaatg	agagtgaggc	tggaacggtc	1440
		aggtacgacc				1500
ttgacagtag	ctaaaaaagc	tacgacgatt	caattaggga	actatattgg	acggaactct	1560
acagaagtaa	tctcagaact	caagcagaag	aaggttcctg	agaatttgat	taagatagag	1620
gaagaagagt	ccagcgaaag	cgaaccagga	acgattatga	aacaaagtcc	aggtgccgga	1680
acgacttatg	atgtgagtaa	acctactcaa	attgtcttga	cagtagctaa	aaaagttaca	1740
agtgttgcca	tgccgagtta	cattggttct	agcttggagt	ttactaagaa	caatttgatt	1800
caaattgttg	ggattaagga	agctaatata	gaagttgtag	aagtgacgac	agcgcctgca	1860
		tgttgaacaa				1920
aataagacta	gagtcaagat	ttcaatctac	aaacctaaaa	caacttcagc	tactcct	1977

<210> 71

<211> 933

<212> DNA

<400> 71						
atgacaaaac	taatctttat	ggggaccccc	gacttttcag	caacagtctt	aaaaggactt	60
ttgacagatg	accgttacga	aattctagcc	gttgtgaccc	agccagaccg	tgctgttggt	120
cgtaaaaaag	ttatccaaga	aaccccagtc	aagcaggctg	ccaaggaagc	aggactatct	180
atctaccaac	ctgaaaaatt	atctggaagt	ccagagatgg	aagatcttat	gaagctagga	240
gcagatggaa	ttgtgactgc	tgcttttggg	cagtttctcc	caagcaaact	ccttgatagc	300
atggactttg	ctgtcaacgt	tcatgcctcc	ctccttccta	gacaccgtgg	tggtgcgcct	360
atccattatg	ccttgattca	aggggatgag	gaagctggtg	tgaccatcat	ggaaatggtt	420
aaggaaatgg	atgcaggaga	tatgatttct	cgtcgcagca	ttccgatcac	agatgaggac	480
aatgttggca	ccttgtttga	aaaattggcg	ctagttggtc	gtgatttgct	tttggacact	540
ctgcctgcct	atattgctgg	tgatatcaaa	cctgaaccgc	aggatacgag	tcaggttacc	600
ttctctccaa	atataaagcc	agaggaagaa	aaactggact	ggaacaaaac	caatcgtcaa	660
ctctttaacc	aaattcgtgg	aatgaacccc	tggcctgttg	cccatacttt	ccttaagggc	720
gaccgcttta	agatttatga	agccctacca	gtagaaggtc	agggaaatcc	aggtgagatt	780
ctctctatcg	gcaagaaaga	attgattgtc	gcaacggctg	aaggggctct	atccctcaaa	840
		gcctaagatg				900
		acgatttggt				933.
						= -

### str pneumoniae patentin.ST25 .\_\_ <211> 2370 \_\_\_\_\_ 2370

rosenia ili. Nel ililaros i el la liminezarizari, elegerizado lesta electros

<b>₹</b> Ζ.	112	ے۔	4-3	/	Ų

<212>

Streptococcus pneumoniae <213>

<400> 72 gtgtttagac gtttaggtca agatttccag cttaggaaag tgaaaaagat tttaaagcag - - 60 - - - 60 attaatgccc tgaaaggcaa gatgtcctct ctttcggatc aagaattagt agctaaaaca 120 gtagagtttc gtcagcgtct ttccgaggga gaaagtctag acgatatttt ggttgaagct 180 tttgctgtgg tgcgtgaagc agataagcgg attttaggga tgtttcctta tgatgttcaa 240 gtcatgggag ctattgtcat gcactatgga aatgttgctg agatgaatac gggggaaggt 300 aagaccttga cagctaccat gcctgtctat ttgaacgctt tttcaggaga aggagtgatg 360 gttgtgactc ctaatgagta tttatcaaag cgtgatgccg aggaaatggg tcaagtttat 420 cgttttctag gattgaccat tggtgtacca tttacggaag atccaaagaa ggagatgaaa 480 gctgaagaaa agaagcttat ctatgcttcg gatatcatct acacaaccaa tagtaattta 540 ggttttgatt atctaaatga taacctagcc tcgaatgaag aaggtaagtt tttacgaccg 600 tttaactatg tgattattga tgaaattgat gatatcttgc ttgatagtgc acaaactcct 660 ctgattattg cgggttctcc tcgtgttcag tctaattact atgcgatcat tgatacactt 720 gtaacaacct tggtcgaagg agaggattat atctttaaag aggagaaaga ggaggtttgg 780 ctcactacta agggggccaa gtctgctgag aatttcctag ggattgataa tttatacaag 840 gaagagcatg cgtcttttgc tcgtcatttg gtttatgcga ttcgagctca taagctcttt 900 actaaagata aggactatat cattcgtgga aatgagatgg tactggttga taagggaaca 960 gggcgtctaa tggaaatgac taaacttcaa ggaggtctcc atcaggctat tgaagccaag 1020 gaacatgtca aattatctcc tgagacgcgg gctatggcct cgatcaccta tcagagtctt 1080 tttaagatgt ttaataagat atctggtatg acagggacag gtaaggtcgc ggaaaaagag 1140 tttattgaaa cttacaatat gtctgtagta cgcattccaa ccaatcgtcc gagacaacgg 1200 attgactatc cagataatct atatatcact ttacctgaaa aagtgtatgc atccttggag 1260 tacatcaagc aataccatgc taagggaaat cctttactcg tttttgtagg ctcagttgaa 1320 atgtctcaac tctattcgtc tctcttgttt cgtgaaggga ttgcccataa tgtcctaaat 1380 gctaataatg cggcgcgtga ggctcagatt atctccgagt caggtcagat gggggctgtg 1440 acagtggcta cctctatggc aggacgtggt acggatatca agcttggtaa aggagtcgca 1500 gagcttgggg gcttgattgt tattgggact gagcggatgg aaagtcagcg gatcgaccta 1560 caaattcgtg gccgttctgg tcgtcaggga gatcctggta tgagtaaatt ttttgtatcc 1620 ttagaggatg atgttatcaa gaaatttggt ccatcttggg tgcataaaaa gtacaaagac 1680 tatcaggttc aagatatgac tcaaccggaa gtattgaaag gtcgtaaata ccggaaacta 1740 gtcgaaaagg ctcagcatgc cagtgatagt gctggacgtt cagcacgtcg tcagactctg 1800

1	gagtatgctg	aaagtatgaa	tatacaacaa	datatagece	2422222	_	
	<b></b>			gatatagett	acaaagagag	aaatcgtcta	1860
•	acagatggtt	ctcgtgactt	agaggatgtt	gttgtggata	tcattgagag	atatacagaa	1020
4	gaggtagcgg	Ctdatcacta	tactaateat			·	1920
,		- vya ceaeta	tyctayttyt	gaattattgt	ttcactttat	tgtgaccaat	1980
i	attagttttc,	atgttaaaga	ggttccagat	tatatagatg	taactgacaa	aactgcagtt	
	Cutaucttta	torraches		35	cauctyacaa	aactgcagtt	2040
	-yeagetta	cyaaycaygt	gattgataaa	gaactttctg	aaaagaaaga	attacttaat	2100
•	caacatgact	tatatgaaca	gtttttacga	Ctttcactac	******		-=-0
	<b>.</b>		J = = = = = = = = = = = = = = = = = = =	Ceccaccyc	LLaaagccat	tgatgacaac	2160
•	Lyggragage	aggtagacta	tctacaacag	ctatccatgg	ctatcaataa	tcaatctact	2220
ä	agtcagaaaa	atccaatcot	agagtactat		33-33		2220
	•		agagtactat	caagaagcct	acgcgggctt	tgaagctatg	2280
ē	ıaagaacaga	ttcatgcgga	tatggtgcgt	aatctcctoa	tagaactaat	tanaatan	22.45
c	Caaaannto	222100100			-aaaacradt	LydyytCact	2340
•	·-uuuuuggeg	aaatcgtgac	tcattttcca				2370

<210> 73

<211> 14328

<212> DNA

<400> 73	•					
atgaccgaaa	cggtagaaga	taaagtaagt	cattcaatta	ctgggcttga	tatcctcaag	60
gggatagttg	ctgcgggagc	tgtcataagt	ggaaccgttg	caactcaaac	gaaggtattt	120
acaaatgagt	cagcagtact	tgaaaaaact	gtagagaaaa	cggatgcttt	ggcaacaaat	180
gatacagtag	ttctaggtac	gatatctaca	agtaattcag	cgagttcaac	tagtttgtca	240
gcttcagagt	cggcaagtac	atctgcatct	gagtcagcct	caaccagcgc	ttcgacctca	300
gcaagtacaa	gtgcatcaga	atcagcaagt	acatcggctt	cgacaagtat	ttctgcatca	360
tctactgtgg	taggttcaca	aacagctgcc	gctacagaag	caactgctaa	gaaggtcgaa	420
gaagatcgta	agaaaccagc	tagtgattat	gtagcatcag	ttacaaatgt	caatctccaa	480
tcttatgcta	agcgacgcaa	gcgttcagtg	gattccatcg	agcaattqct	ggcttctata	540
aaaaatgctg	ctgtttttc	tggcaatacg	attgtaaatg	gcgcccctac	aattaatoca	600
agtctaaaca	ttgctaaaag	tgagacaaaa	gtttatacag	gtgaaggtgt	agattcggta	
tatcgtgttc	caatttacta	taaattgaaa	gtgacaaatg	atggttcaaa	attracettt	660
acctatacgg	ttacgtatgt	gaatcctaaa	acaaatgatc	ttagtaatat	atcaggette	720
cgtcctggat	attctatcta	taattcaggt	acttcaacac	aaacaatatt	acceptacy	780
agtgatcttg	gtaaaccttc	aggtgtaaag	aactacatta	ctuacaaaaa	tastastas	840
gttctatcct	ataatacatc	tacaatgaca	acacacacta	ataaatata	tggtagacag	900
ggtgcccaaa	tgaatggttt	ctttactaaa	222002+2+0	grygyratac	rtggggaaat	960
gtaccaatta	ctagaacaga	tacatcc++	acattte	yattaacatc	atcttggact.	1020
gtaccaatta	JJ JJ		Page 79	cttacgctgc	tagaacagat	1080

	str pneumoniae patentin.ST25	•
agaattggaa ttaactactt	and the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second o	1140
	gtcactctca gtaagtgcta gtcaaagcgc ctcagcttca	
		1200
	ttcagcatca accagtgcct cggcttcagc gtcaaccagt	1260
	cagtgcttca gtctcagcat caacaagtgc ttcagcctca ttcagcaagc acatcagcat ctgaatcagc gtcaaccagt	1320
		1380
	cagtgcttca gcttcagcat caaccagcgc ctcggcctca atcggcctca accagcgcct cggcctcagc aagcacctca	1440
		1500
	cagcgcctca gcctcagcat caacgagtgc ttcggcttca	1560
	ttcagcatca acgagtacgt cagcttcagc gtcaaccagt	1620
	aagtgcgtca gcctcagcaa gtatctcagc gtctgaatcg	1680
	gtcagcatca acgagtacgt cagcctcagc aagcacctca	1740
	cagtgcgtca gcctcagcat cgacaagcgc ctcagcttca	1800
	ctcagcgtcg acaagtgcgt cggcctcaac cagtgcatct	1860
	gtcagcctca gcaagtacta gtgcatcggc ttcagcatca	1920
	gtcaaccagt gcgtcagctt cagcaagtac cagtgcttca	1980
	ttcagcctca gcatcgacaa gtgcctcggc ttcagcaagc gtcgacaagc gcctcagctt cagcaagtac cagtgcgtca	2040
	gtcagcctca gcaagtacta gtgcatcagc ttcagcatca	2100
•	gtcaaccagt gcatcagagt cagcaagtac cagtgcgtca	2160
	ctcggcttca gcaagcacca gtgcgtcggc ttcagcaagt	2220 2280
	ctcaaccagt gcgtcagcct cagcaagtat ctcagcgtct	2340
	gtccgcttca gcaagtacta gcgcctcagc ctcagcgtca	2400
	gtcaacgagt gcgtctgaat cggcatcaac gagtgcgtcc	2460
	ctcagcctca gcgtcaacaa gtgcatcggc ttcagcatca	2520
	aagtactagc gcctcagcct cagcgtcaac aagtgcatcg	2580
	gtctgagtca gcatcaacga gtgcgtcagc ctcagcaagc	2640
•	atcaaccagt gcgtcagcct cagcatcgac aagcgcctca	2700
•	gtcagcctca gcgtcgacaa gtgcgtcggc ttcagcaagt	2760
	aagtaccagt gcgtcagcct cagcgtcgac aagtgcgtcg	2820
	atcggcatca accagtgcgt cagcctcagc aagtactagt	2880
	gagtgcatcg gcttcagcat caaccagtgc atcagagtca	2940
	ttccgcatca acaagtgcct cggcttcagc aagtactagc	3000
	aagtgcttca gcttccgcgt caaccagcgc ctcggcctca	3060
	atcggcatca acaagtgcct cggcttcagc atcaacgagt	3120
2 2 mars 3 3 5 5 5 5 5	Page 80	3120

acateaatet	CD C C C C C C C C C C C C C C C C C C					
gcatcagtct	cagcaagcac	cagtgcgtcg	gcctcagcaa	gcaccagcgo	gtctgaatcc	3180
gcatcaacca	gtgcctcagc	ttcagcaagt	acctcagcat	ctgaatcago	: atcaacaagt	3240
gcctcggctt	cagcaagcac	aagtgcttca	gcctcagcaa	gtatctcago	gtctgaatcg	3300
gcatcaacga	gtgcgtccgc	ttcagcaagt	actagcgcct	cagcatcago	gtcaacaagt	3360
gcttcggctt	cagcgtcaac	gagtgcgtct	gagtcagcat	caacgagtac	gtcagcctca	3420
gcaagcacat	cagcttctga	atctgcatca	accagtgcgt	cagcctcagc	atcgacaagc	3480
gcctcagctt	cagcaagtac	cagtgcgtca	gcctcagcaa	gtaccagtgc	ttcagcctca	3540
gcgtcgacaa	gtgcgtcggc	ctcaaccagt	gcatctgaat	cggcatcaac	cagtgcgtca	3600
gcctcagcaa	gtactagcgc	ctcagcctca	gcatcaacga	gtgcgtccgc	ttcagcaagt	3660
actagtgcat	cagcttcagc	aagtactagc	gcctcagcct	cagcgtcgac	aagcgcctca	3720
gcttcagcaa	gtaccagtgc	gtcagcctca	gcgtcgacaa	gtgcgtcggc	ttcagcaagt	3780
acctcagcgt	ctgaatcagc	atcaacaagt	gcgtcggctt	cagcatcaac	gagtgcatca	3840
gcttcagcat	caacaagtgc	ttcagcttca	gcaagtacca	gtgcgtcggc	ttcagcatca	3900
acgagtgctt	cagtctcagc	gtcaaccagt	gcctctgaat	ccgcatcaac	aagtgcctcg	3960
gcttcagcaa	gcaccagtgc	ttcggcttca	gcgtcaacga	gtgcgtctga	gtcagcatca	4020
acgagtgcgt	cagcctcagc	aagcacatca	gcttctgaat	ctgcatcaac	cagtgcgtca	4080 .
gcttccgcat	caacaagcgc	ctcggcctca	gcaagtacaa	gtgcttcagc	ctcagcatca	4140
accagtgcat	cagcttcagc	ctcaacaagt	gcttcagcct	cagcgtcaac	cagtgcctcg	4200
gcttcagcaa	gtaccagtgc	gtcagcttca	gcaagcacaa	gtgcgtcagc	ttcagcatca	4260
accagtgctt	cggcttcggc	atcaacaagt	gcctcagcat	cagcatcaac	gagtgcgtca	4320
gcctcagcaa	gtactagtgc	atcagcatca	gcatcaacca	gtgcatcagc	ctcagcaagt	4380
atctcagcgt	ctgaatcggc	atcaacgagt	gcatcagcat	cagcatcaac	gagtgcatcg	4440
gcttcagcgt	caaccagtgc	atcagtctca	gcaagcacca	gtgcgtcggc	ttcagcatca	4500
acgagtgcct	cagcctcagc	aagtatctca	gcgtctgaat	cggcatcaac	gagtgcgtca	4560
gcctcagcaa	gtactagtgc	atcggcttca	gcaagcacca	gtgcgtcggc	ttcagcatca	4620
accagtgcct	cagcctcagc	aagtatctca	gcgtctgaat	cggcatcaac	gagtgcgtca	4680
gcctcagcaa						4740
accagcgcct						4800
gcctcagcaa						4860
acaagtgcgt						4920
gcttcagcat.	caacaagtgc	ttcagcttca	gcaagtacca	gtgcgtcggc	ttcagcatca	4980
acgagtgctt	cagtctcagc	gtcaaccagt	gcctctgaat	cagcatcaac	aagtgcctcg	5040
gcttcagcaa						5100
acaagtgcgt	ctgaatcggc	atcaacgagt	gcttcggctt Page 81	cagcatcaac	gagtgcgtca	5160

		str pr	neumoniae n	atentin.ST2	5	
gcctcagcaa-g	geaeatcage	-t-tetgaatet	gcatcaacc	2	ttcagcgtca	
accagtgcgt (	ggcttcagc	gtcgacaagt	gcttcaact	t carcatean	- ttcagcgtca	
gcctcagcaa g	gcgcaagtac	ctcagcgtca	acttone	t cascasta	gagtgcgtcg	5280
gcaagcacaa g	tgcgtcagc	ctcagcaagt	atctcanco	t ctantagry	gtcggcttca	5340
gcgtctgagt c	agcatcaac	gagtacgtca	Occtcanca	acacatan	atcaacgagt ttctgaatct	5400
gcatcaacca g	tgcgtcagc	ctcagcatcg	acaagegee	t caacttaa	Ltctgaatct_	
gcttcagcct c	agcgtcgac	aagtgcgtcg	Occtroace:	atacatata	aagtaccagt	5520
accagtgcgt c	agcctcagc	aagtactagt	gcatcagcts	cagsatore	atcggcatca	5580
gcttcagcat c	aaccagtgc	ctcggcttca	acatcaacca	atacataa	gagtgcatcg	5640
accagtgctt c	agtctcagc	atcaacaagt	acttcaacct	· grycytcago	ttcagcaagt	5700
gcttcagcaa g	cacatcagc :	atctgaatca	OCOTCORCE	. caycatcgac	aagtgcctcg	5760
accagtgcgt c	agcctcagc	gtcgacaágt	gcgtcagcc+	· cageaneta -	ttcagcaagt	5820
gcttcagcat c	aacgagtgc	atcoocttco	acatcaacca	. caycaagtac	tagtgcatca	5880
accagtgcgt c	agcttccgc a	atcaacaaat	acctcaactt	: grgcarcaga	gtcagcaagt	5940
gcttcagcaa g	tactagcgc (	ctcagcctca	acctcaacca	. caycaagcac	cagtgcgtcg	6000
atctcagcgt c	tgaatcggc a	atcaacgagt	acat coact+	grycytcagc	ctcagcaagt	6060
gcctcagcgt ca	aacaagtgc a	atcaacttca	acatesses.	cagcaagtac	tagcgcctca	6120
acgagtgcgt co	cgcttcagc a	agtactage	Occtonace	grgcgtctga	atcggcatca	6180
gcttcagcat ca	aacgagtgc d	itccacttca	OC22Gtacta	cagcgtcaac	aagtgcatcg	6240
acaagtgcat co	getteage o	tcaacgagt	Ocatetanat	gcgcctcagc	ctcagcgtca	6300
gcctcagcaa go	acatcage t	tctgaatct	acateaacea	caycatcaac	gagtgcgtca	6360
acaagcgcct ca	agcttcagc a	antaccant	gcatcaacca	gtgcgtcagc	ctcagcatcg	6420
gcttcagcaa qt	accaptor o	tcaacctca	gcgccagcct	cagcgtcgac	aagtgcgtcg	6480
gcttcagcaa gt	gcctcaac c	antheatet	gcaaytacca	gtgcgtcagc	ctcagcgtcg	6540
acaagtgcgt cg	ocatcado t	tcancatos	gaarcygcat	caaccagtgc	gtcagcctca	6600
gcaagtacta gt gcatcagagt ca	acaaatac c	antocotca	acyayıycat	cggcttcagc	atcaaccagt	6660
gcatcagagt ca	acctcaac c	tcagcatea	gcttccgcat	caacaagtgc	ctcggcttca	6720
gcaagtacta gc	ncaantat c	teagegreat	acaagtgctt	cagcttccgc	gtcaaccagc	6780
gcctcggcct ca	acatcaat c	teagegree	gaatcggcat	caacaagtgc	ctcggcttca	6840
gcatcaacga gt	gratians s	ccaycaagc :	accagtgcgt	cggcctcagc	aagcaccagc	6900
gcgtctgaat cc	gcatcaac c	ayiycctca (	gcttcagcaa	gtacctcagc	atctgaatca	6960
gcatcaacaa gt	gcallyge T	ccaycaagc ;	acaagtgctt	cagcctcagc	aagtatctca	7020
gcgtctgaat cg	ycarcaac g	agtgcgtcc (	Jcttcagcaa	gtactagcgc	ctcagcatca	7080
gcgtcaacaa gt	gettegge ti	ccagcgtca a	acgagtgcgt	ctgagtcagc a	atcaacgagt	7140
acgtcagcct cag	ycaagcac at	tcagcttct <u>c</u>	Jaatctgcat Page 82	caaccagtgc (	gtcagcctca	7200

gcatcgacaa	Ococctcane	******				
acttonacet	gegeeteage	ttcagcaagt	accagtgcgt	cagcctcago	aagtaccagt	7260
2000 staget	cagegregae	aagtgcgtcg	gcctcaacca	gtgcatctga	atcggcatca	7320
accagtgcgt	cagcctcagc	aagtactago	gcctcagcct	cagcatcaac	gagtgcgtcc	7380
gcttcagcaa	gtactagtgc	atcagcatca	gcatcaacga	gtgcatcggc	ttcagcaagt	7440
accagcgcct	cagcttcagc	aagcaccagt	gcgtcagcct	cagcaagtac	cagcgcctca	7500
gcctcagcaa	gcaccagtgc	ctcagcttca	gcaagtacca	gtgcgtcagc	ctcagcgtcg	7560
acaagtgcgt	cggcttcagc	aagtacctca	gcgtctgaat	cagcatcaac	gagtgcatca	7620
gcttcagcat	caacaagtgc	ttcagcttca	gcaagtacca	gtgcgtcggc	ttcagcatca	7680
acgagtgctt	cagtctcagc	gtcaaccagt	gcctctgaat	cagcatcaac	aagtgcctcg	7740
gcttcagcaa	gcaccagtgc	gtcggcttca	gcaagtacta	gtgcatcggc	ttcagcatcg	7800
acaagtgcgt	ctgaatcggc	atcaacgagt	gcttcggctt	cagcatcaac	gagtgcgtca	7860
gcctcagcaa	gcacatcagc	ttctgaatct	gcatcaacca	gtgcgtccgc	ttcagcgtca	7920
accagtgcgt	cggcttcagc	gtcgacaagt	gcttcggctt	cagcatcaac	gagtgcgtcg	7980
gcctcagcaa	gcgcaagtac	ctcagcgtca	gcttccgcct	caaccagtgc	gtccgcttca	8040
gcaagcacaa	gtgcgtcagc	ctcagcaagt	atctcagcgt	ctgaatcggc	atcaacgagt	8100
gcgtcggcct	cagcaagcgc	aagtacctca	gcgtcagctt	ccgcctcaac	cagtgcgtcg	8160
gcttcagcaa	gcacaagtgc	gtcagcctca	gcaagtatct	cagcgtctga	atcggcatca	8220
acgagtgcgt	ctgagtcagc	atcaacgagt	acgtcagcct	cagcaagcac	atcagcttct	8280
gaatcggcat	caaccagtgc	gtcagcctca	gcatcgacaa	gcgcctcagc	ttcagcaagt	8340
accagtgctt	cagcctcagc	gtcgacaagt	gcgtcggcct	caaccagtgc	atctgaatcg	8400
gcatcaacca	gtgcgtcagc	ctcagcaagt	actagtgcat	cagcttcagc	atcaacgagt	8460
gcatcggctt	cagcatcaac	cagtgcctcg	gcttcagcgt	caaccagtgc	gtcagcttca	8520
gcaagtacca	gtgcttcagt	ctcagcatca	acaagtgctt	cagcctcagc	atcgacaagt	8580
			gaatcagcgt			8640
accagtgcat	ctgaatcggc	atcaaccagt	gcgtcagcct	cagcaagtac	tagtgcatca	8700
gcttcagcat	caacgagtgc	atcggcttcg	gcgtcaacca	gtgcatcaga	gtcagcaagt	8760
accagtgcgt	cagcttccgc	atcaacaagt	gcctcggctt.	cagcaagcac	atcagcatct	8820
gaatcagcgt	caaccagtgc	ttcggcttca	gcaagtacca	gtgcttcagc	ttcagcatca	8880
accagcgcct	cggcctcagc	aagcacctca	gcttctgaat	cggcctcaac	cagcgcctcg	8940
gcctcagcaa	gcacctcagc	ttctgaatcg	gcctcaacca	gcgcctcagc	ctcagcatca	9000
acgagtgctt	cggcttcagc	aagcacaagc	gcctcgggtt	cagcatcaac	gagtacgtca	9060
gcttcagcgt	caaccagtgc	ttcagcctca	gcatcaacaa	gtgcgtcagc	ctcagcaagt	9120
atctcagcgt	ctgaatcggc	atcaacgagt	gcgtctgagt	cagcatcaac	gagtacgtca	9180
gcctcagcaa	gcacctcagc	ttctgaatcg	gcctcaacca Page 83	gtgcgtcagc	ctcagcatcg	9240
			• •••• •• •• •• •• •• •• •• •• •• •• ••			

Str proumoning naturals and	
str pneumoniae patentin.sT25	en entare alle alternations in the second of the second
acaagcgcct cagcttcagc aagtaccagt gcttcagcct cagcgtcgac aagtgcgtcg	9300
gcctcaacca gtgcatctga atcggcatca accagtgcgt cagcctcagc aagtactagt	9360
gcatcggctt cagcatcaac cagtgcctcg gcttcagcgt caaccagtgc gtcagcttca	9420
gcaagtacca gtgcttcagt ctcagcatca acaagtgctt cagcctcagc atcgacaagt	9480
gcctcggctt cagcaagcac atcagcatct gaatcagcgt cgacaagcgc ctcagcttca	.9540
gcaagtacca gtgcgtcagc ctcagcgtcg acaagtgcgt cagcctcagc aagtactagt	9600
gcatcagctt cagcatcaac gagtgcatcg gcttcggcgt caaccagtgc atcagagtca	9660
gcaagtacca gtgcgtcagc ttccgcatca acaagtgcct cggcttcagc aagcaccagt	9720
gcgtcggctt cagcaagtac tagcgcctca gcctcagcct caaccagtgc gtcagcctca	9780
gcaagtatct cagcgtctga atcggcatca acgagtgcgt ccgcttcagc aagtactagc	9840
gcctcagcct cagcgtcaac aagtgcatcg gcttcagcgt caacgagtgc gtctgaatcg	9900
gcatcaacga gtgcgtccgc ttcagcaagt actagcgcct cagcctcagc gtcaacaagt	9960
gcatcggctt cagcatcaac gagtgcgtcc gcttcagcaa gtactagcgc ctcagcctca	10020
gcgtcaacaa gtgcatcggc ttcagcgtca acgagtgcgt ctgagtcagc atcaacgagt	10080
gcgtcagcct cagcaagcac atcagcttct gaatctgcat caaccagtgc gtcagcctca	10140
gcatcgacaa gcgcctcagc ttcagcaagt accagtgcgt cagcctcagc gtcgacaagt	10200
gcgtcggctt cagcaagtac cagtgcgtca gcctcagcaa gtaccagtgc gtcagcctca	10260
gcgtcgacaa gtgcgtcggc ctcaaccagt gcatctgaat cggcatcaac cagtgcgtca	10320
gcctcagcaa gtactagtgc atcagcttca gcatcaacga gtgcatcggc ttcagcatca	10380
accagtgcat cagagtcagc aagtaccagt gcgtcagctt ccgcatcaac aagtgcctcg	10440
gcttcagcaa gtactagcgc ctcagcctca gcgtcaacaa gtgcttcagc ttccgcgtca	10500
accagcgcct cggcctcagc aagtatctca gcgtctgaat cggcatcaac aagtgcctcg	10560
gcttcagcat caacgagtgc atcagtctca gcaagcacca gtgcgtcggc ctcagcaagc	10620
accagegegt etgaateege atcaaccagt geeteagett cageaagtae etcageatet	10680
gaatcagcat caacaagtgc ctcggcttca gcaagcacaa gtgcttcagc ctcagcaagt	10740
atctcagcgt ctgaatcggc atcaacgagt gcgtccgctt cagcaagtac tagcgcctca	10800
gcatcagcgt caacaagtgc ttcggcttca gcgtcaacga gtgcgtctga gtcagcatca	10860
acgagtacgt cagcctcagc aagcacatca gcttctgaat ctgcatcaac cagtgcgtca	10920
gcctcagcat cgacaagcgc ctcagcttca gcaagtacca gtgcgtcagc ctcagcaagt	10980
accagtgctt cagcctcagc gtcgacaagt gcgtcggcct caaccagtgc atctgaatcg	11040
gcatcaacca gtgcgtcagc ctcagcaagt actagcgcct cagcctcagc atcaacgagt	11100
gcgtccgctt cagcaagtac tagtgcatca gcttcagcaa gtactagcgc ctcagcctca	11160
gcgtcgacaa gcgcctcagc ttcagcaagt accagtgcgt cagcctcagc gtcgacaagt	11220
gcgtcggctt cagcaagtac ctcagcgtct gaatcagcat caacaagtgc gtcggcttca	11280
Page 84	

	gtgcatcagc					11340
	cagcatcaac					11400
	gtgcctcggc					11460
	cagcatcaac					11520
	gtgcgtcagc					11580
	cagcatcaac					11640
	gtgcctcggc					11700
gcgtcagctt	cagcatcaac	cagtgcttcg	gcttcggcat	caacaagtgc	ctcagcatca	11760
	gtgcgtcagc					11820
gcatcagcct	cagcaagtat	ctcagcgtct	gaatcggcat	caacgagtgc	atcagcatca	11880
gcatcaacga	gtgcatcggc	ttcagcgtca	accagtgcat	cagtctcagc	aagcaccagt	11940
	cagcatcaac					12000
	gtgcgtcagc					12060
	cagcatcaac					12120
	gtgcgtcagc					12180
	cagcaagtac					12240
	gcgcctcagc					12300
gcgtcagcct	cagcgtcgac	aagtgcgtcg	gcttcagcaa	gtacctcagc	gtctgaatca	12360
	gtgcatcagc					12420
	cggcatcaac					12480
	gtgcttcggc					12540
	cagcaagcac					12600
	gcgcctcagc					12660
	cagcgtcgac					12720
	cagcctcagc					12780
	gtactagtgc					12840
	cagcttcagc					12900
	gtacctcagc					12960
	cagcttcagc					13020
gcttcagcat	caacgagtgc	ttcagtctca	gcgtcaacca	gtgcctctga	atccgcatca	13080
	cggcttcagc					13140
	caacgagtgc					13200
	cagcttccgc					13260
gcctcagcat	caaccagtgc	atcagcttca	gcctcaacaa Page 85	gtgcttcagc	ctcagcgtca	13320

_			22		er erementer er og god	- components 2.20	. er mann blammingilm b	
	accagtgcct	-cggcttcagc	aagtaccagt	gcgtcagctt	cagcaagcac	aagtgcgtca	13380	
	gcttcagcat	caaccagtgc	ttcggcttcg	gcatcaacaa	gtgcctcagc	atcagcatca	13440	
	acgagtgcgt	cagcctcagc	aagtactagt	gcatcagcat	cagcatcaac	cagtgcatca	13500	
	gcctcagcaa	gtatctcagc	gtctgaatcg	gcatcaacga	gtgcatcagc	atcagcatca	13560	
	acgagtgcat	_cggcttcagc.	_gtcaaccagt	gcatcagtct	cagcaagcac.	_cagtgcgtcg	13620	
	gcttcagcat	caacgagtgc	ctcagcctca	gcaagtatct	cagcgtctga	atcggcatca	13680	
	acgagtgcgt	cagcctcagc	aagtactagt	gcatcggctt	cagcaagcac	cagtocotco	13740	
	gcttcagcat	caaccagtgc	ctcagcctca	gcaagtatct	cagcgtctga	atcoocatca	13800	
	acgagtgcgt	cagcctcagc	aagtactagt	gcatcagcct	cagcatcaac	gagtgcatcg	13860	
	gcttcagcaa	gtaccagcgc	ctcagcttca	gcaagcacca	qtqcatcaac	ctcaccaagt	13920	
	accagcgcct	cagcctcagc	aagcaccagt	gcctcagctt	cagcaagtac	Cantacates	13980	
	gcctcagcat	caacaagtgc	ttcagcttcg	gcctcaacaa	atacatcaac	ttcagcatca	14040	1
			aagcaccagt					
			gtcagcttca				14100	
	cattcgaact	cacaaattaa	aaatacttct	quatcuacad	atanateen	ccagcaaac	14160	
			gtcaattgga				14220	
			gaaacgccgt			agcagctgtt	14280	
		3466996696	guaacyccyc	adacytyaty	aagaagag		14328	
	<210> 74							
	<211> 606							
	<212> DNA							
	<213> Stre	ptococcus p	neumoniae					

	74					•	
atgtcaa	acg	aaaaaacac	aaacactaac	gtagaaaaga	aagatgctac	tgttgtagct	60
cacgaaa	tca	aaggggaact	tacttacgaa	gataaagtta	tccaaaaaat	cattggtctt	120
tcactag	aaa	acgtttcagg	tcttttggga	atcgatggtg	gtttcttctc	aaatcttaaa	180
gaaaaaa	tcg	ttaacagcga	tgacgtaaca	agtggtgtta	acgtagaagt	tggtaaaaca	240
caagttg	cag	ttgacttaaa	cgttattgtt	gagtaccaaa	aaaatgttcc	agctttatat	300
tcagaaa	tca	gagaaatcgt	atcttcagaa	gttgctaaaa	tgactgactt	ggaaattgtt	360
gaaatca	acg	taaacgttgt	cgacatcaaa	actaaagaac	agcatgaagc	agactcagta	420
			tgacgttgct				480
			tcttggatct				540
			aggtgcagca				600
gtaaac					_	J	
•							606

<210>	75						
<211>	106	5					
<212>	DNA						
<213>	Str	eptococcus ,	oneumoniae				
<400>	75						
			aattttgact				60
			cattcgcggc				120
			aggatcaggt				180
			tattgcccaa				240
			ggattgggaa				300
			tttggacccc				360
			aaaaacagct				420
atgaata	aagg	ttggcattcc	agacgcagat	agacgtttta	atgaataccc	attccaatat	480
tctggag	ggaa	tgcgtcaacg	tatcgttatt	gctattgccc	ttgcctgccg	acctgatgtc	540
ttgatct	tgtg	atgagccaac	aactgccttg	gatgtaacta	ttcaagctca	gattattgat	600
ttgctaa	aaat	ctttacaaaa	cgagtatcat	ttcacaacaa	tctttattac	ccacgacctt	660
ggtgtgg	gtgg	caagtattgc	ggataaggta	gcggttatgt	atgcaggaga	aatcgttgag	720
tatggaa	acgg	ttgaggaagt	cttctatgac	cctcgccatc	catatacatg	gagtctcttg	780
tctagct	ttgc	ctcagcttgc	tgatgataaa	ggggatcttt	actcaatccc	aggaacacct	840
ccgtcad	ttt	atactgacct	gaaaggggat	gcttttgcct	tgcgttctga	ctacgcaatg	900
cagatto	gact	tcgaacaaaa	agctcctcaa	ttctcagtat	cagagacaca	ttgggctaaa	960
acttggd	cttc	ttcatgagga	tgctccgaaa	gtagaaaaac	cagctgtgat	tgcaaatctc	1020
catgata	aaga	tccgtgaaaa	aatgggattt	gcccatctgg	ctgac		1065
<210>	76						
<211>	1977	7					
<212>	DNA						
<213>		eptococcus p	meumonise				
		speadocens t	, reamon rae				
<400>	76						
		atcgtgtatt	tgctacagca	ggtcttgttt	tattagcagc	aggtgtactt	60
gcagcat	gca	gttcttcaaa	atcatctgat	tcatcagccc	ctaaagctta	tggctatgtt	120
tatacag	gcag	acccagaaac	cttggactac	ctgatttcaa	gtaaaaatag	tacaacagta	180
			tggtttattc		attacggtaa		240

. " ": ===	taan oo aanson oo					-	
	,	. ugiciciaai	yarygtttg	a cctacactt	a taagattcgt	300	
aaaggggtta	a aatggtttac	: ctctgatgga	gaagaatat	g cagaggtga	C ggctaaagat	360	
ttcgtgaac	g gtttaaaaca	cgcagcagat	aaaaaatca	g aagctatgta	a tttagctgaa	420	
aattcggtta	a aaggcttggc	agattatcta	tcaggaact	t caacagatt	t ttcaacam++	480	
ggtgtcaagg	, cggttgatga	_ttatacgtta	caatacact	t_tgaaccagc	c. tgaaccattc.	540	• - <del>-</del>
egguactee	agetyaceta	ttctattttc	tggcctctga	a atgaagaati	t cgaaacatca	600	
aaaggaagcg	ı attttgctaa	accaacagat	ccgacatcct	t tgctttataa	a tggtccattc	660	
ttgttgaaag	ggttgactgc	aaaatcttct	gtagagtttg	) taaaaaatga	a gcaatattgg	720	
gataaagaaa	atgtccacct	agatactatc	aatctagctt	actatgatge	atcagatcag	780	
gagtcgctag	agcgtaactt	cactagtgga	gcttatagtt	atgcccgtct	ttaccctacc	840	
agctccaact	attctaaggt	tgcagaagaa	tacaaggaca	atatctatta	l cacacaatca	900	
ggctctggga	ttgctggtct	gggtgtgaat	attgatcgcc	aaagttacaa	ctatacttct	960	
aaaactacag	attcagagaa	agtagctact	aagaaggcat	: tgcttaacaa	agatttccgt	1020	
caagccttga	attttgctct	tgatcgctca	gcttactcag	ctcaaatcaa	tggtaaagat	1080	
ggagcagctt	tagcagttcg	taatttattt	gtaaaaccag	actttgtttc	agctqqtqaq	1140	
aagacctttg	gtgatttagt	cgctgctcaa	cttcctgctt	atggtgatga	gtggaaaggt	1200	
gtgaatttag	ctgatgggca	ggatggttta	ttcaatgctg	acaaggccaa	ggcagagttt	1260	
gcgaaagcta	agaaagcttt	agaagcagac	ggcgttcagt	ttcctattca	tctggacgtt	1320	
ccagtagacc	aagcatcaaa	aaactacata	tctcgtattc	agtcctttaa	acaatctgta	1380	
gaaacagttc	ttggtgttga	aaatgtcgtt	gttgatattc	aacaaatgac	aagtgatgaa	1440	
ttccttaata	ttacttacta	tgctgccaat	gcttcatctg	aggattggga	tgtatcagga	1500	
ggagtttcat	gggggccaga	ctatcaagac	ccatctactt	acctggatat	tttaaaaaca	1560	
actagcagtg	aaactacaaa	aacatattta	ggatttgata	atccaaatag	cccttcagta	1620	
gttcaagttg	gtttgaaaga	atacgataaa	ttagttgatg	aagctgccag	agagacaagc	1680	
gacttgaatg	tccgttatga	aaaatatgca	gcggctcaag	catggttgac	agatagttca	1740	
ctctttattc	ctgctatggc	ttcttctggt	gcagcaccag	tgctttcacg	aattgttcca	1800	
tttactggag	cttctgcgca	aacaggctct	aaggggtcag	atgtttactt	caaatatttg	1860	
aaatcacaag	ataaagtggt	gactaaggaa	gagtatgaaa	aagctcgtga	aaaatggttg	1920	
aaagaaaaag	ctgaatcaaa	tgagaaagct	caaaaagaat	tggcaagtca	tgtgaag	1977	
<210> 77					-		
<211> 954							
-212 pu			•				

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Streptococcus pneumoniae

<400>	77						
atggaa	ıatta	atgtgagtaa	attaagaaca	gatttgcctc	aagtcggcgt	gcaaccatat	60
aggcaa	igtac	acgcacactc	aactgggaat	ccgcattcaa	ccgtacagaa	tgaagcggat	120
tatcac	tggc	ggaaagaccc	agaattaggt	tttttctcgc	acattgttgg	gaacggttgc	180
atcatg	cagg	taggacctgt	tgataatggt	gcctgggacg	ttgggggcgg	ttggaatgct	240
gagaco	tatg	cagcggttga	actgattgaa	agccattcaa	ccaaagaaga	gttcatgacg	300
gactac	cgcc	tttatatcga	actcttacgc	aatctagcag	atgaagcagg	tttgccgaaa	360
acgctt	gata	cagggagttt	agctggaatt	aaaacgcacg	agtattgcac	gaataaccaa	420
ccaaac	aacc	actcagacca	cgttgaccct	tatccatatc	ttgctaaatg	gggcattagc	480
cgtgag	cagt	ttaagcatga	tattgagaac	ggcttgacga	ttgaaacagg	ctggcagaag	540
aatgac	actg	gctactggta	cgtacattca	gacggctctt	atccaaaaga	caagtttgag	6.00
aaaatc	aatg	gcacttggta	ctactttgac	agttcaggct	atatgcttgc	agaccgctgg	660
aggaag	caca	cagacggcaa	ctggtactgg	ttcgacaact	caggcgaaat	ggctacaggc	720
tggaag	aaaa	tcgctgataa	gtggtactat	ttcaacgaag	aaggtgccat	gaagacaggc	780
tgggtc	aagt	acaaggacac	ttggtactac	ttagacgcta	aagaaggcgc	catggtatca	840
aatgcc	ttta	tccagtcagc	ggacggaaca	ggctggtact	acctcaaacc	agacggaaca	900
ctggca	gaca	agccagaatt	cacagtagag	ccagatggct	tgattacagt	aaaa	954
<210>	78		·				
<211>	1401						
<212>	DNA						
<213>	Stre	ptococcus p	neumoniae				

<400> 78 atgaaaaaaa aatattggac tttagcgata ttattctttt gtttgttcaa taattctgtt 60 actgctcaag aaatacctaa aaatcttgat ggcaatataa ctcacactca gactagcgaa 120 agtttttctg aatctgatga aaaacaggtt gactattcta ataaaaatca agaagaagta 180 gaccaaaata aatttcgtat tcaaatcgat aagacagaat tatttgtaac aacagataaa 240 catttagaaa aaaactgttg taaattggaa cttgaaccac aaataaataa cgatattgtt 300 aactctgaaa gtaataattt actaggcgaa gataatttag ataataaaat taaggaaaat 360 gtttctcatc tagataatag aggaggaaat atagagcatg acaaagataa cttagaatcg 420 tcgattgtaa gaaaatatga atgggatata gataaagtta ctggtggagg cgaaagttat 480 aaattatatt ctaaaagtaa ttctaaagtt tcaattgcta ttttagattc aggagtcgat 540 ttacaaaata ctggattact gaaaaatctt tcaaatcact caaaaaacta tgtccccaat 600 aaaggatatt taggaaaaga ggagggagag gaaggaataa tatcagatat tcaagataga 660 Page 89

			•				
	entendent			atentin.sT2			
-ttaggtca	g-gtacggctgt	tgtagctcaa	attgtaggg	atgacaatat	taatggagta	720	
aatcctcad	g ttaatattaa	ı cgtctataga	atatttggta	agtcgtcago	tagtccagat	780	
tggattgta	a aagcaattt	tgatgctgta	gatgatggca	atgatattat	caatcttagt	840	
actggacaa	it atttaatgat	: tgatggagaa	tatgaggacg	gaacaaatga	ttttgaaaca	900	
_tttttgaac	ıt ataaaaaggo	tattgattac	_gcgaatcaaa	<u>.aaggagtaat</u>	tatagtagct		
gcattaggg	a atgactccct	aaatgtatca	aatcagtcag	atttattgaa	acttattagt	1020	
tcacgcaaa	a aagtaagaaa	accaggatta	gtagttgatg	ttccaagtta	tttctcatct	1080	
acaatttcg	g tcggaggcat	agatcgctta	ggtaatttat	cagattttag	Caataaaggg	1140	
gattctgat	g caatatatgo	gcctgcaggc	tcaacattat	CtCtttcaga	attagaac++		
aataacttt	a ttaatgcaga	aaaatataaa	gaagattgga	ttttttcaac	accaggaccc	1200	
ggatatacg	t atctttatgg	aaactcattt	gctgctccta	aaatttctaa	tacactagga	1260	
atgattatt	g ataaatacaa	attaaaagat	Cagccctata	attatatatat	tgtgattgca	1320	
ttctggaag	a aacattacca	g	3	accacacyc	LyLadaaaaa	1380	
		J				1401	
<210> 79							
<211> 92	4						
<212> DN	4						
<213> St	reptococcus	pneumoniae					
						•	
<400> 79	7 atmamttatt	†####	*****				
actroact	g atgagttatt	cataggettt	tacctaatca	aatcagctga	cctgaggcaa	60	
aacegaget	g ggaaaaacta	cctagccttt	accttccaag	atgatagtgg	cgagattgat	120	
C2C2ta222	gggatgccca	acctcataac	attgaggcct	ttaccgcagg	taaggttgtc	180	
cacatyaaa	g gacgccgaga	agtttataac	aatacccctc	aagtcaatca	aattactctc	240	
	aagctggtga	acccaatgac	ccagctgatt	tcaaggtcaa	gtcaccagtt	300	
yatgtcaagg	g aaattcgtga	ctacatgtcg	caaatgattt	tcaaaattga	aaatcctgtc	360	
_	ttgtccgaaa			aggaattcta	ctcctatcca	420	
OCTOCCAROR	CCAACCACCA	tacctttaaa	20000000				

gctgccaaga ccaaccacca tgcctttgaa acgggcttgg cctatcatac ggcgaccatg 480 gtgcgtttgg cagacgctat tagcgaagtt tatcctcagc tcaataagag cctgctctat 540 gcggggatta tgttgcatga cttagctaag gtcatcgagt tgacggggcc agaccagaca 600 gagtacacag tgcgaggtaa tcttcttgga catatcgctc tcattgatag cgaaattacc 660 aagacagtta tggaactcgg catcgatgat accaaggaag aagtcgtttt gcttcgtcat 720 gtcatcctca gtcaccacgg cttgcttgag tatggaagcc cagtccgtcc acgcattatg 780 gaagcagaga ttatccatat gattgacaat ctggatgcaa gcatgatgat gatgtcaaca 840 gctcttgctt tggtggataa aggagagatg accaataaaa tcttcgctat ggataatcgt 900 Page 90

	tccttctata aaccagattt agat	924
		924
	<210> 80	
	<211> 663	
	<212> DNA	
	<213> Streptococcus pneumoniae	
	<400> 80	
	gtgacgattc taggaaaaga tacagttcaa caatctgcga aaggtgaatc tgtaactcaa	60
	gaagctacac cagagtataa gctagaaaat acaccaggtg gagataaggg aggcaatact	120
	ggaagctcag atgctaatgc gaatgaaggc ggtggtagcc aggcgggtgg atcagctcac	180
	acaggitcac aaaactcagc tcaatcacaa gcttctaagc aattagctac tgaaaaagaa	240
	tcagctaaaa atgccattga aaaagcagcc aaggacaagc aggatgaaat caaaggcgca	300
	ccgctttctg ataaagaaaa agcagaactt ttagcaagag tggaagcaga aaaacaagca	360
	gctctcaaag agattgaaaa tgcgaaaact atggaagatg tgaaggaagc agaaacgatt	420
	ggagtgcaag ccattgccat ggttacagtt cctaagagac cagtggctcc taatgctgct	480
	cctaagacaa caagtgcacc gcaagcaact gcaggaacaa tgcaagatgt tacctaccag	540
	tcacctgctg gcaaacaatt acctaacaca ggttcagcat caagtgcagc acttgctagt	600
	cttggtctag tggtggcaac aagtggtttt gctttgctag gaagaaagac tagacgtaga	660
	aaa	663
	<210> 81	
	<211> 1008	
	<212> DNA	
	<213> Streptococcus pneumoniae	
•		
	<400> 81	
	atgaatgcag atgatacagt aaccatttat gatgtcgctc gtgaagcagg tgtttccatg	60
	gcgacggtca gccgtgtggt caatggcaat aaaaatgtaa aagagaatac ccgtaaaaaa	120
	gtgctagagg taattgatcg tttggattat cgtccaaatg cagttgcgcg tggtcttgca	180
	agtaaaaaga caaccactgt cggtgtcgtg attccaaata ttaccaatgg ttatttttcg	240
	agtttggcta aggggattga tgatattgca gaaatgtaca agtacaatat tgtcctagct	300
	aatagcgatg aagataacga gaaagaagtt tctgttgtca ataccctctt ttcaaagcag	360
	gtagatggca ttatctatat ggggtatcac ttgacagata aaattcgctc agaattttcg	420
	cgttcacgta ctccgattgt tctcgcagga actgtcgatg ttgagcacca gttgccaagt	480
	gtcaatattg actataagca agcaacaatt gatgcagtga gttaccttgc taaagaaaat	540
	Page 91	240

-	Na mandritanta nota de t <del>emp</del> onio esperio.		eumoniae pa	a er a makamananan a	FETSLANDET DE 121 . F ;	مد و مجوور دود	
	gagcgtattg ctttcgt	tag cggtccgcta	gtggatgaca	tcaatggtaa	ggttcgttta	600	
	gttggctaca aggaaac	ctt gaaaaaagca	ggaatcactt	atagtgaggg	tttggtattt	660	
	gaatctaaat atagcta	tga tgatggttac	gccttagcag	agcgtttgat	ttcatcaaat	720	
	gcaactgcag cagttgt	gac aggtgatgag	ttggcagcag	gagtcttgaa	cggtttggct	780	•
	gataagggtg_tttctgt	gcc agaagatttt	_gaaattatta	.ctagtgatga.	ttcacaaatc.	8.40	
	tcacgcttta cccgtcc	aaa cttgacaacg	attgcccaac	ctctttatga	ccttggtgcc	900	
	attagtatgc gtatgtt	gac caagattatg	cataaggaag	agttggaaga	acgtgaagtt	960	
	ctcttacctc atggttt	gac agaacgtagc	tcaacacgaa	aacgtaaa		1008	
	<210> 82						
	<211> 1407						
	<212> DNA						
		us pneumoniae					
	•						
	<400> 82						
	atgaaaaaaa agttagt					60	
	cagacagaag gtcaata	tgg aaaagtacat	gaaaatgtga	tggactactg	gttcaaaacg	120	
	catccagaag attttt	cga taatgtcgga	cctcttgtag	ccagtaactt	ttttcatact	180	
	tacaccgaag atttcca	ctt gatgaaggaa	attggagtta	attctttccg	cacttccatc	240	
	caatggagtc gactcat	caa gaatttagag	acaggtgagc	ctgatccaaa	aggtattgct	300	
	ttctacaatg ccatcat	tga agaagctaaa	aagaaccaga	tggatcttgt	gatgaattta	360	
	catcattttg atttacc	agt ggaacttctt	caaaaatacg	gtggttggga	aagcaaacat	420	
	gtagtggagt tattcgt	gaa gtttgccaag	actgctttca	catgctttgg	agataaggtt	480	
	cattactgga caacttt	caa tgagccaatg	gtcattccag	aagcaggata	cttatatgct	540	
	ttccattatc caaatct	aaa aggaaaggga	aaagaggccg	tacaagtcat	ctataatcta	600	
	aaccttgcta gtgcaaa	agt gattcaacta	tatcgctcat	tagaacttga	tggaaagatt	660	
	gggattattt taaactt	gac acctgcttat	ccaagaagta	attctccaga	agacttagaa	720	
	gcaagtcgat ttacaga	tga cttctttaac	aaagtcttct	tgaatccagc	tgttaaagga	780	
	actttcccag aaagatt	ggt aaaacagcta	gagagagatg	gcgtgttatg	gagtcatacc	840	
	gaaaaagagc ttcaact	gat gaaatcaaat	acggttgatt	ttcttggagt	aaactactac	900	

gaaaatggag ttatcgatga cgtgtatcgt attgaatttt atgaagaaca tttaagatgg Page 92

960

1020

1080

1140

1200

catccaaaac gtgttcaagc acaagcaaat cctgaggaat atcagacgcc ctggatgcca

gaccaatact tcaaagagta tgaatggctg gagcgtcgca tgaatccata tcgtggttgg

gaaatttttc cgaaagccat ttatgatatt gctatgattg tgaaggaaga atatggtaat

atcccatggt ttatcagtga aaacggaatg ggtgttgaaa acgaagcacg gtttatcgat

ctacataaa	ccattgaaga	gggaagtcac	tgttttggat	accacgcttg	gaccgcattt	1260
gattgctgg1	cttggaataa	tgcatataag	aatcgttacg	gatttatctc	cgttgattta	1320
gaaacgcaaa	agagaaccat	caagagctca	ggaagatggt	atcgcaaagt	aagtgacaat	1380
aacggttttc	aagtagaaat	tgaggag				1407
<210> 83						
<211> 408						
<212> DNA						
<213> Str	eptococcus pi	neumoniae				
	·					
<400> 83						
grggaaaarc	ttacgaattt 1	ttacgaaaag	tatcgtgtct	atctgactcg	tccacgttta	60
gagcttttgg	cagtagttac (	cattgttttc	tgtgctgtac	tcgtctttt	tctaaatatt	120
ccaggaaaag	gtgtcttaaa a	actcgataat	ggaacgattg	tttatgatgg	cagtcttgtc	180
	tgaatggcca a					240
ggcttcaaca	atggagcctt d	caacggaaaa	ggtacctttc	aatctaaaga	aggctggacc	300
tacgaaggtg	attttgtaaa t	ggtcaggct	gaaggaaaag	ggaaactaac	aacagaacaa	360
gaagtcgttt	atgaaggaac t	tttaaacaa	ggcgtttttc	aacaaaaa		408
<210> 84						
<211> 621						
<212> DNA						
<213> Str	eptococcus pn	eumoniae				
<400> 84						
	agataagaga c					60
aaagcgggag	cagagcgaga g	aagatgctg	gcattccgcc	acaaaggaca	agaggcccga	120
	cagaactggc c					180
cagactagcc	agtggatgaa t	caggcccag	cgtttgagac	cacatttttg	ggtttatcta	240
cagagagacg	gacaagtgac a	gaacctatg a	atggccttac	gtttgtatgg	gacatctact	300
gactttggaa	tttctttgga a	gtcagtttc a	atcgaacgta	agaaggatga	gcaaacactg	360
	ccaaagtttt a					420
tctaatggtc	aaagtcaacg g	tgggaggcg a	aatgaagaaa	agcgtcgtac	tttacgcgag	480
aaggtgagaa	gtcaagaagt t	cgaaaagtt 1	ttagtgaagg	tagatgttcc	tatgacagaa	540
aattcgtctg	aagaagaaat c	gtagaaggc. 1	ttattgaagt	cttattctaa	aattcttccc	600

621

tattatctag ctacgagaaa a

str pneumoniae patentin.ST25
------------------------------

.

.

.

	str pneumoniae pate	entin.ST25
<210>	85	
<211>	459	
<212>	DNA	
<213>	Streptococcus pneumoniae	
	and the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second s	- Discourse to the second second second
<400>		
gaate	caga acagttgttg gcaatcaaag agccataagg t	caaggcttt taccttgtta
cancti	ctgc ttgccctcat tgtcatcagt gggggattac to	cctttttca agctatgagt
tttate	ctca tttcagaagt tcgctaccag caacaaagcg a	gcaaaagga gtggctcttg
caccts	gacc aacttgaggt agaattagac cgttcgcagt to	cgaaaaagt agaaggcaat
ttccat	taca tgaagcaaga tggcaaggac atcgccatcg g	taagtcaaa gtcagatgat
	aaaa cgaatgctcg tggtcgaggt tatcagccta t	
	atta cagaggacaa tcaactggtt cgctttcatt to	ccagttcca aaaaggctta
gadage	gagt tcatctatcg tgtggaaaaa gaaaaaagt	
<210>	86	
<211>	324	
<212>	DNA	
<213>	Streptococcus pneumoniae	
<400>	86 aaaa tgatgacatt cttgaaaaaa gctaaggtta aa	
	gtgg tcttgctgat tatcagcgtg cttttcttgc to	
	aaag aagcagtcaa tgacaaagga aaagcagctg tt	
	gaac tttatagctt agaaaagaat gaagatgcta go	
	cgca tcacggaaga acaggctaaa gcttataaag aa	
	aatc gtaaagtcaa tgat	racaatya Taaaaatgga
J. J.	J <b></b>	
<210>	87	
<211>	897	
<212>	DNA	•
<213>	Streptococcus pneumoniae	
<b>&lt;400&gt;</b> .	87	
		*******
	caa aagttagaaa ggcagtcatc cctgctgctg ga	ctaggaac tcgattttta

tttatcgtgg	aagaagctct	caaatcaggt	attgaagata	ttctagttgt	cactggtaaa	180
tcaaaacgtt	ctattgagga	ccactttgat	tcaaacttcg	aattggaata	taacctcaaa	240
gaaaaaggga	aaacagatct	tttgaagcta	gttgataaaa	caactgacat	gcgtctgcat	300
tttatccgcc	aaactcatcc	acgcggtctc	ggagatgctg	ttttgcaagc	caaggctttc	360
gtcggaaatg	aaccttttgt	cgttatgctt	ggtgatgact	tgatggatat	cacagacgaa	420
aaggctgttc	cacttacċaa	acaactcatg	gatgactacg	agcgtaccca	cgcgtctact	480
atcgctgtca	tgccagtccc	tcatgacgaa	gtatctgctt	acggggttat	tgctccgcaa	540
ggcgaaggaa	aagatggtct	ttacagtgtt	gaaacctttg	ttgaaaaacc	agctccagag	600
gacgctccta	gcgaccttgc	tattatcgga	cgctacctcc	tcacgcctga	aatttttgag	660
attctcgaaa	agcaagctcc	aggtgcagga	aatgaaattc	agctgacaga	tgcaatcgac	720
accctcaata	aaacacaacg	tgtatttgct	cgtgagttca	aaggggctcg	ttacgatgtc	780
ggagacaagt	ttggcttcat	gaaaacatcc	atcgactacg	ccctcaaaca	cccacaagtc	840
aaagatgatt	tgaagaatta	cctcatccaa	cttggaaaag	aattgactga	gaaggaa	897

<210> 88

<211> 2463

<212> DNA

<400>	88						
atgcaaa	atc	aattaaatga	attaaaacga	aaaatgctgg	aatttttcca	gcaaaaacaa	60
aaaaata	aaaa	aatcagctag	acctggcaaġ	aaaggttcaa	gtaccaaaaa	atctaaaacc	120
ttagata	agt	cagtcatttt	cccagctatt	ttactgagta	taaaagcctt	atttaactta	180
ctctttg	jtac	tcggttttct	aggaggaatg	ttgggagctg	ggattgcttt	gggatacgga	240
gtggcct	tat	ttgacaaggt	tcgggtgcct	cagacagaag	aattggtgaa	tcaggtcaag	300
gacatct	ctt	ctatttcaga	gattacctat	tcggacggga	cggtgattgc	ttccatagag	360
agtgatt	tgt	tgcgcacttc	tatctcatct	gagcaaattt	cggaaaatct	gaagaaggct	420
atcatto	gcga	cagaagatga	acactttaaa	gaacataagg	gtgtagtacc	caaggcggtg	480
attcgtg	jcga	ccttggggaa	atttgtaggt	ttgggttcct	ctagtggggg	ttcaaccttg	540
acccago	caac	taattaaaca	gcaggtggtt	ggggatgcgc	cgaccttggc	tcgtaaggcg	600
gcagaga	ittg	tggatgctct	tgccttggaa	cgcgccatga	ataaagatga	gattttaacg	660
		atgtggctcc					720
cggcaag	gcag	ctgagggaat	tttcggtgta	gatgccagtc	agttgactgt	tcctcaagca	780
gcatttt	tag	caggacttcc	acagagtccc	attacttact	ctccttatga	aaatactggg	840
gagttga	aga	gtgatgaaga	cctagaaatt	ggcttaagac Page 95		agttctttac	900

·	Por transfer and the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of t		icamonitae pe			
	-agtatgtate-gtacaggtg	-attaagcaaa	gacgagtatt	ctcagtacaa	ggattatgac	960
	cttaaacagg acttttac	atcgggcacg	gttacaggaa	tttcacgaga	ctatttatac	1020
	tttacaactt tggcagaag	tcaagaacgt	atgtatgact	atctagctca	gagagacaat	1080
	gtctccgcta aggagttgaa	a aaatgaggca	actcagaagt	tttatcgaga	tttggcagcc	1140
	aaggaaattg aaaatggtg	<u>ttataagatt</u>	actactacca	tagatcagaa	aattcattct	. 1200
	gccatgcaaa gtgcggttg	tgattatggc	tatcttttag	acgatggaac	aggtcgtgta	1260
	gaagtaggga atgtcttgat	ggataaccaa	acaggtgcta	ttctaggctt	tgtaggtggt	1320
	cgtaattatc aagaaaatca	aaataatcat	gcctttgata	ccaaacgttc	gccagcttct	1380
	actaccaagc ccttgctggc	ctacggtatt	gctattgacc	agggcttgat	gggaagtgaa	1440
	acgattctat ctaactatco	: aacaaacttt	gctaatggca	atccgattat	gtatgctaat	1500
	agcaagggaa caggaatgat					1560
l	gcttactgga cctatcgtat	gctccgtgaa	aagggtgttg	atgtcaaggg	ttatatggaa	1620
	aagatgggtt acgagattco	tgagtacggt	attgagagct	tgccaatggg	tggtggtatt	1680
	gaagtcacag ttgcccagca	taccaatggc	tatcagacct	tagctaataa	tggagtttat	1740
	catcagaagc atgtgatttc	aaagattgaa	gcagcagatg	gtagagtggt	gtatgagtat	1800
	caggataaac cggttcaagt	ctattcaaaa	gctactgcga	cgattatgca	gggattgcta	1860
	cgagaagttc tatcctctcg	tgtgacaaca	accttcaagt	ctaacctgac	ttctttaaat	1920
	cctactctgg ctaatgcaga	ttggattggg	aagactggta	caaccaacca	agacgaaaat	1980
	atgtggctca tgctttcgac	acctagatta	accctaggtg	gctggattgg	gcatgatgat	2040
	aatcattcat tgtcacgtag					2100
	gtaaatgcga ttcagcaagc	ttccccaagc	atttggggga	acgagcgctt	tgctttagat	2160
	cctagtgtag tgaaatcgga					2220
	gttgaaggaa aagaagtaga	ggtcacaggt	tcgactgtta	ccagctattg	ggctaataag	2280
	tcaggagcgc cagcgacaag	ttatcgcttt	gctattggcg	gaagtgatgc	ggattatcag	2340
	aatgcttggt ctagtattgt					2400 .
	agtägttcta gcgatagcag	taactcaagt	actacacgac	cttcttcttc	aagggcgaga	2460
	cga					2463
	<210> 89					
	<211> 1269					
						•

<212> DNA

		-				
		caaaactgct				120
gtcaaagaac	tcactgtata	tgtagacgag	ggatataaga	gctatattga	agaggttgct	180
		tggagtaaaa				240
		tgacaaccaa				300
		ccttggttct				360
		cacaactaaa				420
		cgagtcactt				480
		tgacttggaa				540
		tactgccttc				600
		cggtgcttac				660
		cggttctatc				720
		gcaagataca				780
		tgctatcatc				840
		agttgcaact				900
		agcttgggtc				960
		ccttgttgca				1020
		tactgaggct				1080
		acagttcaag				1140
		agcgaaaaat				1200
		cgatgctgta				1260
tttggtgaa						1269
<210> 90			•			
~~TU> 30						

<210> 90

<211> 465

<212> DNA

<400> 90		
atgatagata aagtggtcag gaacctactc ctgacctttt tcttttgcaa	a aatgacaaaa	60
atcataattt ttttgacaac tatacttgtc aaaaagaaaa agatatgtta	a caatgaattc	120
aagttaagaa ataggaagca gaaaggagtt ataatgtggg tactaggat	tatactattt	180
atgattttct tttattctaa taattctaaa aaaatcaaga aactagagaa	taaaatcaaa	240
agacttgagc gaaaagagaa aggaaacgca gaaatgtcga gattattaca		300
ggaaaggaac caattataac gggagtgtat attgggccag ataactggga		360
gttgatgagg aatgggtaaa gctacgacgt gtagataata cgggaaaagg		420

		•				
	- Maria di Paparana di Parana		neumoniae pa		5 	
ttgcaacgt	a ttgaggatat	ccaaaccgtt	gaatttgacg	gagag		465
<210> 91						
<211> 85	5 .	-				
<212> DN/	٠ .					
<213> St	reptococcus	pneumoniae	• • • • • • • • • •	**************************************	<del>-</del>	
<400> 91						
					catccgatta	60
					tctgtctatc	120
					aatatttgca	180
					tctatacagt	240
					tacaaatgga	300
					gacaacgggc	360
	aaggaattag					420
					acaatgttgg	480
	agtttgcttc					540
					tttcgtagaa	600
	catttggatt					660
	ttgtccaatt					720
	aaggtcaagg					780
	tagaggagaa	acaaatgtta	acttcagttg	tagaaagatt	aagtcaggaa	840
ttggaggaaa	Cagaa					855
<210> 92						
<211> 186	3					
<212> DNA	•	•				
<213> Str	eptococcus p	oneumoniae			•	
<400> 92	cto coetate	*********				
	ctacaatatt					60
	caatcctagc					120
	ttcaacaaaa					180
	aagtgggtaa					240
	cgattcctac					300
ycagctagtc	aagcttttag	ttattatcca	gatgaaacag Page 98	gtagaattgt	ctactatcct	360
			5- 50			

agctctatta	ctatcccatc	aagcataaaa	aaaatacaaa	aaaaaggctt	ccatggaagt	420
aaagctaaaa	ctattatttt	tgacaaaggc	agtcagctgg	agaaaattga	agatagagct	480
tttgattttt	ctgaattaga	agagattgaa	ttgcctgcat	ctctagaata	tattggaaca	540
agtgcatttt	cttttagtca	aaaattgaaa	aagctaacct	tttcctcaag	ttcaaaatta	600
gaattaatat	cacatgaggc	ttttgctaat	ttatcaaatt	tagagaaact	aacattacca	660
aaatcggtta	aaacattagg	aagtaatcta	tttagactca	ctactagctt	aaaacatgtt	720
gatgttgaag	aaggaaatga	atcgtttgcc	tcagttgatg	gtgttttgtt	ttcaaaagat	780
aaaacccaat	taatttatta	tccaagtcaa	aaaaatgacg	aaagttataa	aacgcctaag	840
gagacaaaag	aacttgcatc	atattcgttt	aataaaaatt	cttacttgaa	aaaactcgaa	900
ttgaatgaag	gtttagaaaa	aatcggtact	tttgcatttg	cagatgcgat	taaacttgaa	960
gaaattagct	taccaaatag	tttagaaact	attgaacgtt	tagcctttta	cggtaattta	1020
gaattaaaag	aacttatatt	accagataat	gttaaaaatt	ttggtaaaca	cgttatgaac	1080
ggtttaccaa	aattaaaaag	tttaacaatt	ggtaataata	tcaactcatt	gccgtccttc	1140
ttcctaagtg	gcgtcttaga	ttcattaaag	gaaattcata	ttaagaataa	aagtacagag	1200
ttttctgtga	aaaaagatac	atttgcaatt	cctgaaactg	ttaagttcta	tgtaacatca	1260
gaacatataa	aagatgttct	taaatcaaat	ttatctacta	gtaatgatat	cattgttgaa	1320
aaagtagata	atataaaaca	agaaactgat	gtagctaaac	ctaaaaagaa	ttctaatcag	1380
ggagtagttg	gttgggttaa	agacaaaggt	ttatggtatt	acttaaacga	atcaggttca	1440
atggctactg	gttgggttaa	agacaaaggt	ttatggtatt	acttaaacga	atcaggttca	1500
atggctactg	gttgggttaa	agacaaaggc	ttatggtact	acttaaatga	atcaggttca	1560
atggctactg	gttgggttaa	agacaaaggc	ttatggtatt	acttaaacga	atcaggttca	1620
atggctactg	gttgggttaa	agacaaaggc	ttatggtact	acttaaatga	atcaggttca	1680
atggctactg	gttgggttaa	agacaaaggc	ttatggtatt	acttaaatga	atcaggttca	1740
		agtttctggt				1800
ttattagtaa	acacgactac	acccgatggc	tatcgagtca	atgctaacgg	tgagtgggta	1860
gga						1863
-210- 02		•				

<210> 93

<211> 1878

<212> DNA

<213> Streptococcus pneumoniae

٠.	- Truncas as the state of	· · = · · · · · · · · · · · · · · · · ·	<u> </u>	**************************************	TO TAKE TO AN INC. TO LANGE			
	-arcgagggtg	aggaaggcca	craccaacty	acctaccgca	aacctcacca	actttatcgt	180	
	gccttgtcct	tgttggtaac	agttctagca	gaagctgata	aagtagagat	tgaggaacaa	240	
	gcagcttacg	aagatttggc	ttacatggtt	gactgttctc	gaaatgcggt	gctgaatgtg	300	
	gcttctgcca	agcagatgat	tgagatattg	gctctcatgg	gctactcaac	ctttgagctt	360	
	<u>tacatggaag</u>	acacttacca	gattgaaggg	_cagccttact	ttggctattt	ccgtggagct_	420	
	tattcagcag	aggagttgca	ggaaatcgaa	gcctatgccc	aacagtttga	cgtgaccttt	480	
	gtaccatgca	tccagacctt	ggcccacttg	tcggcctttg	tcaaatgggg	tgtcaaggaa	540	
	gtgcaggagc	tccgtgatgt	agaggacatt	cttctcattg	gcgaagaaaa	ggtttatgac	600	
	ttgattgatg	gcatgtttgc	cacgttgtct	aaactgaaga	ctcgcaaggt	caatatcggg	660	
	atggacgaag	cccacttggt	tggtttggga	cgctacctga	ttctgaacgg	tgttgtggat	720	
	cgtagtctcc	tcatgtgcca	acacttggag	cgcgtgctgg	atattgctga	caaatatggt	780	
	ttccactgcc	agatgtggag	tgatatgttc	ttcaaactca	tgtcagcgga	tggccagtac	840	`
	gaccgtgatg	tggaaattcc	agaggaaact	cgtgtctacc	tagaccgtct	caaagaccgt	900	
	gtgactctgg	tttactggga	ttattatcag	gatagcgagg	aaaaatacaa	ccgtaatttc	960	
	cgcaatcatc	acaagattag	ccatgacctt	gcatttgcag	ggggagcttg	gaagtggatt	1020	
	ggctttacac	ctcacaacca	ttttagccgt	ctagtggcta	tcgaggctaa	taaagcctgc	1080	
	cgtgccaatc	agattaaaga	agtcatcgta	acgggttggg	gagacaatgg	tggtgaaact	1140	
	gcccagttct	ctatcctacc	aagcttgcaa	atctgggcag	aactcagcta	tcgcaatgac	1200	
	ctagatggtt	tgtctgcgca	cttcaagacc	aatactggtc	taacggttga	ggattttatg	1260	
	cagattgacc	ttgccaacct	cttaccagac	ctaccaggca	atctcagcgg	tatcaatccc	1320	
	aaccgctatg	ttttttatca	ggatattctt	tgtccgattc	ttgatcaaca	catgacacct	1380	
	gaacaggaca	aaccgcactt	cgctcaggct	gctgagacgc	ttgctaacat	taaagaaaaa	1440	
	gctggaaact	atgcctatct	ctttgaaact	caggcccagt	tgaatgctat	tttaagtagc	1500	
	aaagtagatg	tgggacgacg	cattcgtcag	gcctaccaag	cggatgataa	agaaagttta	1560	
	caacaaatcg	ccagacaaga	attaccagaa	cttagaagcc	aaattgaaga	cttccatgcc	1620	
	ctctttagcc a	accaatggct	gaaagaaaac	aaggtctttg	gtttggatac	agttgacatc	1680	
	cgtatgggcg (	gactcttgca	acgcatcaaa	cgagcagaaa	gccgtatcga	ggtttatctg	1740	
	gctggtcagc 1	ttgaccgcat	cgacgagctg	gaagttgaaa	tcctaccatt	tactgacttc	1800	
	tacgcagaca a	aggatttcgc	agcaactaca	gccaaccagt	ggcataccat	tgcgacagcg	1860	
	tcgacgattt a					-	1878	
	<210> 94							
	=- <b></b> -							

<sup>&</sup>lt;211> 831

<sup>&</sup>lt;212> DNA

### 

<400> 94
atgtctaatt catttgtcaa gttgttagtc tctcaattat ttgcaaattt agcagatatt 60
ttctttagag taacaatcat tgctaacata tacattattt caaaatcagt aattgccaca 120
tcactagttc ctatcttaat aggaatatcc tcttttgttg cgagtctttt agttccgttg 180
gttactaaaa ggttagcgct aaatagggtt ttatctttat ctcaatttgg aaagactata 240
ttattggcga tactggtagg aatgtttacc gtaatgcaat ccgtagcgcc tttggtgacc 300
tatctatttg ttgttgcaat ttccatacta gatggttttg cagcacccgt ttcctatgct 360
attgtgccac gctatgcgac cgatttgggt aaggctaatt cagccttatc aatgactggt 420
gaagctgttc aattgatagg ttggggatta ggtggactct tgtttgcaac aattggtctg 480
ttacctacca cgtgtatcaa tttagtcttg tatatcattt ctagctttct gatgttattt 540
cttcctaacg ctgaagtgga ggtgttagag tcagaaacta atcttgaaat tttgctcaaa 600
ggttggaagt tagttgctag aaatcctaga ttaagacttt ttgtatcagc aaatttattg 660
gaaatttttt caaatacgat ttgggtttct tccattatac ttgtttttgt aacggagtta 720
ttaaataaaa cggaaagtta ctggggatat tctaatacag catactctat tggtattata 780
attagtggct taattgcttt taggctatct gaaaagttcc ttgctgctaa a 831
<210> 95
<211> 2079
<212> DNA
<213> Streptococcus pneumoniae
•
<400> 95

atgtttgcat caaaaagcga aagaaaagta cattattcaa ttcgtaaatt tagtgttgga 60 gtagctagtg tagttgttgc cagtcttgtt atgggaagtg tggttcatgc gacagagaac 120 gagggagcta cccaagtacc cacttcttct aatagggcaa atgaaagtca ggcagaacaa 180 ggagaacaac ctaaaaaact cgattcagaa cgagataagg caaggaaaga ggtcgaggaa 240 tatgtaaaaa aaatagtggg tgagagctat gcaaaatcaa ctaaaaagcg acatacaatt 300 actgtagctc tagttaacga gttgaacaac attaagaacg agtatttgaa taaaatagtt 360 gaatcaacct cagaaagcca actacagata ctgatgatgg agagtcgatc aaaagtagat 420 gaagctgtgt ctaagtttga aaaggactca tcttcttcgt caagttcaga ctcttccact 480 aaaccggaag cttcagatac agcgaagcca aacaagccga cagaaccagg agaaaaggta 540 gcagaagcta agaagaaggt tgaagaagct gagaaaaaag ccaaggatca aaaagaagaa 600 gatcgtcgta actacccaac cattacttac aaaacgcttg aacttgaaat tgctgagtcc 660 gatgtggaag ttaaaaaagc ggagcttgaa ctagtaaaag tgaaagctaa cgaacctcga 720 Page 101

	i alah 1998 di kecampan menganjan 1992 di kecampan menganjan berbangan berbangan berbangan berbangan berbangan	str pn	eumoniae pa	tentin.sT25			
;	-gacgagcaaa-aaattaagca-	agcagaagcg	gaagttgaga	gtaaacaagc	tgaggctaca	780	
	aggttaaaaa aaatcaagac	agatcgtgaa	gaagcagaag	aagaagctaa	acgaagagca	840	
	gatgctaaag agcaaggtaa	accaaagggg	cgggcaaaac	gaggagttcc	tggagagcta	900	
	gcaacacctg ataaaaaaga	aaatgatgcg	aagtcttcag	attctagcgt	aggtgaagaa	960	
	actcttccaa gcccatccct	gaaaccagaa.	aaaaaggtag	cagaagctga	-gaagaaggtt		- 
	gaagaagcta agaaaaaagc	cgaggatcaa	aaagaagaag	atcgccgtaa	ctacccaacc	1080	
	aatacttaca aaacgcttga					1140	
•	gagcttgaac tagtaaaaga	ggaagctaag	gaacctcgaa	acgaggaaaa	agttaagcaa	1200	
	gcaaaagcgg aagttgagag					1260	
	gatcgtaaaa aagcagaaga					1320	
	gaaaaaccag ctgaacaacc	acaaccagcg	ccggctccaa	aagcagaaaa	accagctcca	1380	
	gctccaaaac cagagaatcc	agctgaacaa	ccaaaagcag	aaaaaccagc	tgatcaacaa	1440	
	gctgaagaag actatgctcg	tagatcagaa	gaagaatata	atcgcttgac	tcaacagcaa	1500	
	ccgccaaaaa ctgaaaaacc					1560	
	aacggtatgt ggtacttcta	caatactgat	ggttcaatgg	cgacaggatg	gctccaaaac	1620	
	aatggctcat ggtactacct	caacagcaat	ggcgctatgg	cgacaggatg	gctccaaaac	1680	
	aatggttcat ggtactatct	aaacgctaat	ggttcaatgg	caacaggatg	gctccaaaac	1740	
	aatggttcat ggtactacct	aaacgctaat	ggttcaatgg	cgacaggatg	gctccaatac	1800	
	aatggctcat ggtactacct	aaacgctaat	ggttcaatgg	cgacaggatg	gctccaatac	1860	
	aatggctcat ggtactacct					1920	
	ggagatacct ggtactatct					1980	
	gtatcagata aatggtacta					2040	
	gatggctatg gagtcaatgc					2079	
_	<210> 96					,	
	<211> 2430						
	<212> DNA						
	<213> Streptococcus p	neumonico					
	bei epeococcus p	umon rae					
	4400- 00						

<400> 96 atgaactatt caaaagcatt gaatgaatgt atcgaaagtg cctacatggt tgctggacat 60 tttggagctc gttatctaga gtcgtggcac ttgttgattg ccatgtctaa tcacagttat 120 agtgtagcag gggcaacttt aaatgattat ccgtatgaga tggaccgttt agaagaggtg 180 gctttggaac tgactgaaac ggactatagc caggatgaaa cctttacgga attgccgttc 240 tcccgtcgtt tgcaggttct ttttgatgaa gcagagtatg tagcgtcagt ggtccatgct 300 Page 102

2200120120	2222222					
				atgatagcaa		360
				agaaagatca		420
				ctcgtgaaga		480
				ctatggccaa		540
				atgatttgac		600
cgttctggca	agttagaacc	agtcatcggt	cgggacaagg	aaatctcacg	tatgattcaa	660
atcttgagcc	ggaagactaa	gaacaaccct	gtcttggttg	gggatgctgg	tgtcgggaaa	720
acagctctgg	cgcttggtct	tgcccagcgt	attgctagtg	gtgacgtgcc	tgcggaaatg	780
gctaagatgc	gcgtgttaga	acttgatttg	atgaatgtcg	ttgcagggac	acgcttccgt	840
				ttgaagaaga		900
				gtagcgggat		960
				gaactttgag		1020
				atgcggcact		1080
				gtatgactat		1140
ttgaaggcga	cttatgagaa	acatcaccgt	gtacaaatca	cagatgaagc	ggttgaaaca	1200
				tgccagactc		1260
				agcatgtaaa		1320
				agtggaaaca		1380
				tggtgacaga		1440
				aactgactca		1500
				ttatcggtca		1560
gtttcaagca	ttagccgtgc	cattcgccgc	aaccagtcag	ggattcgcag	tcataagcgt	1620
				ggaaaactga		1680
gctctggcag	aagttctttt	tgacgacgaa	tcagccctta	tccgctttga	tatgagtgag	1740
tatatggaga	aatttgcagc	tagtcgtctc	aacggagctc	ctccaggcta	tgtaggatat	1800
				cctattccgt		1860
gatgaggtag	agaaggccca	cccagatatc	tttaatgttc	tcttgcaggt	tctggatgac	1920
				caaataccat		1980
				ctgttggttt		2040
				ttgaagaact		2100
				tcttccatag		2160
				tagtggcaag		2220
				tgttagcaaa		2280
				aaacagaagt		2340

: ·			Str pn	eumoniae pa				•
				gtggcaggca	gcacacttaa	gattggtgtc	2400	
			tgatattgca				2430	
	<210> 97							•
	<211> 37	1						
. a. lawe.	<212> DNA	-	والمستحددة المستحددة	٠	· •-•			
	\Z13> 3(i	eptococcus	pheumontae			•		
	<400> 97							
		taccgtttat	agcaagagga	acaagttatt	acttgaagat	gtcagttaaa	60	
			agtaggattg				120	
_			gattgcgcgt				180	
			gtggcgcatg				240	
	tttcgtttga	gtaatgtcaa	tggttttgaa	attccggcag	cttatggaaa	tgcgaatgaa	300	
	tggggacatc	gtgctcgtcg	ggaaggttat	cgtgtagata	atacaccgac	gattggttcc	360	
	attacttggt	ctactgcagg	aacttatggt	catgttgcct	gggtgtcaaa	tgtaatggga	420	•
	gatcagattg	agattgagga	atataactat	ggttatacag	aatcctataa	taaacgagtt	480	
	ataaaagcaa	acacgatgac	aggatttatt	cattttaaag	atttggatgg	tggcagtgtt	540	
	gggaatagtc	aatcctcaac	ttcaacaggc	ggaactcatt	attttaagac	caagtctgct	600	
	attaaaactg	aacctctagc	tagcggaact	gtgattgatt	actattatcc	tggggagaag	660	•
	gttcattatg	atcagatact	tgaaaaagac	ggctataagt	ggttgagtta	tactgcctat	720	
	aatggaagct	atcgttatgt	tcaattggag	gctgtgaata	aaaatcctct	aggtaattct	780	
	gttctttctt	caacaggtgg	aactcattat	tttaagacca	agtctgctat	caaaactgaa	840	
	cccctagtta	gtgcaactgt	gattgattac	tattatcctg	gagagaaggt	tcattatgat	900	
	caaattctcg	aaaaagacgg	ctacaagtgg	ttgagttata	cggcttataa	cggaagtcgt	960	
	cgctatatac	agctagaggg	agtgacttct	tcacaaaatt	atcagaatca	atcaggaaac	1020	
	atctctagct	atggatccca	tagtagttca	actgtcggtt	ggaagaaaat	aaatggtagt	1080	
	tggtatcatt	tcaaatcaaa	tggttctaaa	tcaacaggat	ggctgaaaga	cggttctagc	1140	
	tggtattatt	tgaaattatc	tggtgaaatg	cagacaggat	ggttaaagga	aaatggtttg	1200	
	tggtattatc	tgggtagttc	aggggcaatg	aaaacaggct	ggtaccaggt	ctctggtaag	1260	
	tggtattatt	cttactcttc	aggcgcctta	gctgttaata	cgacggtgga	tggctacaga	1320	
	gtaaacagtg	atggagaacg	agta				1344	
	≥210> 08							

<210> 98

<211> 450

<212> DNA

## <213> Streptococcus pneumoniae

<400> 98 atgaaagtaa tetttttag	r anatnttaaa	00222200+2	22222222		
atgaaagtaa tctttttag					60
gtaccaacag ggtatgcgc					120
gctcaagctg taggtgaac					180
atgattgcag aaggaaaag					240
tttgttgaaa aagttggtc					300
gcagaagaat tgcaaaagc					360
gctccgattc gagcggttg		gtgccagtga	aaatctatca	agatatcaca	420
agtgtaatca atcttcgtg	t gaaagaagga				450
<210> 99		•			
<211> 1176					
<212> DNA					

<212> DNA

<400> 99						
	aaatcttagc	gtcactttta	ttaagtacag	taatggtttc	tcaagtagct	. 60
gttttaacaa	ctgcgcatgc	agaaacgact	gatgacaaaa	ttgctgctca	agataataaa	120
attagtaact	taacagcaca	acaacaagaa	gcccaaaaac	aagttgacca	aattcaggag	180
caagtatcag	ctattcaagc	tgagcagtct	aacttgcaag	ctgaaaatga	tagattacaa	240
gcagaatcta	agaaactcga	gggtgagatt	acagaacttt	ctaaaaacat	tgtttctcgt	300
aaccaatcgt	tggaaaaaca	agctcgtagt	gctcaaacaa	atggagccgt	aactagctat	360
atcaatacca	ttgtaaactc	aaaatcaatt	acagaagcta	tttcacgtgt	tgctgcaatg	420
agtgaaatcg	tatctgcaaa	caacaaaatg	ttagaacaac	aaaaggcaga	taaaaaagct	480
atttctgaaa	aacaagtagc	aaataatgat	gctatcaata	ctgtaattgc	taatcaacaa	540
aaattggctg	atgatgctca	agcattgact	acgaaacagg	cagaactaaa	agctgctgaa	600
ttaagtcttg	ctgctgagaa	agcgacagct	gaaggggaaa	aagcaagtct	attagagcaa	660
aaagcagcag	ctgaggcaga	ggctcgtgca	gctgcggtag	cagaagcagc	ttataaagaa	720
aaacgagcta	gccaacaaca	atcagtactt	gcttcagcaa	acactaactt	aacagctcaa	780
gtgcaagcag	tatctgaatc	tgcagcagca	cctgtccgtg	caaaagttcg	tccaacatac	840
agtacaaacg	cttcaagtta	tccaattgga	gaatgtacat	ggggagtaaa	aacattggca	900
ccttgggctg	gagactactg	gggtaatgga	gcacagtggg	ctacaagtgc	agcagcagca	960
ggtttccgta	caggttcaac	acctcaagtt	ggagcaattg Page 10		tgatggtgga	1020.

#### str pneumoniae patentin.ST25 in the constitution of the second continues of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control of the second control and the major of same over the end of an tatggtcacg tagcggttgt tacagctgtt gaatcaacaa cacgtatcca agtatcagaa 1080 tcaaattatg caggtaatcg tacaattgga aatcaccgtg gatggttcaa tccaacaaca 1140 acttctgaag gttttgttac atatatttat gcagat 1176 <210> 100 387 <212> DNA <213> Streptococcus pneumoniae <400> 100 atggtaaaaa gacgtataag gagagggacg agagaacctg aaaaagttgt tgttcctgag 60 caatcatcta ttccttcgta tcctgtatct gttacatcta accaaggaac agatgtagca 120 gtagaaccag ctaaagcagt tgctccaaca acagactgga aacaagaaaa tggtatgtgg 180 tatttttata atactgatgg ttccatggca acaggttggg tacaagttaa tagttcatgg 240 tactacctca acagcaacgg ttctatgaaa gtcaatcaat ggttccaagt tggtggtaaa 300 tggtattatg taaatacatc gggtgagtta gcggtcaata caagtataga tggctataga 360 gtcaatgata atggtgaatg ggtgcgt 387 <210> 101 <211> 138 <212> DNA <213> Streptococcus pneumoniae <400> 101 gagttgcgac ggctatcaag gttggtggac caggagctct attttggatg tggatggcgg 60 ctttctttgg aatggctacc aagtatgcgg aaggactctt ggccatcaaa taccgcacca 120 aggacgacca tggtgcag 138 <210> 102 <211> 93 <212> DNA

60

93

gactgtatca ggaaacaacc gttcacacgc gatgaaccaa acaaaacgtg ccgtaaaacc

<213>

<400> 102

Streptococcus pneumoniae

aaaccttcaa aaagttactg ttcttatcga tgg

### str pneumoniae patentin.ST25 <210> 103 <211> 78 <212> DNA <213> Streptococcus pneumoniae <400> 103 60 ggacaaagaa accctcgaag aattgaaaga gttatcagaa tggcagaaac gaaaccaaga 78 atatctaaaa aagaaggc <210> 104 <211> 249 <212> DNA <213> Streptococcus pneumoniae 104 <400> cagaggaagc tgttcaaaat cttccaccta ttccagaaga aaagtgggtg gaaccagaaa 60 tcatcctgcc tcaagctgaa cttaaattcc ctgaacagga agatgactca gatgacgaag 120 180 atgttcaggt cgatttttca gccaaagaag cccttgaata caaacttcca agcttacaac 240 tctttgcacc agataaacca aaagatcagt ctaaagagaa gaaaattgtc agagaaaata 249 tcaaaatct <210> 105 <211> 312 <212> DNA <213> Streptococcus pneumoniae <400> 105 ttggtgatta tagttttgaa aatccagtcc aaatcggaga cagactttat tttcaagaca 60 tggccattta ttcttttgtc aaaaataata cctttaatgg tattggattg ccaagtctct 120 atctcatgga cgaacaggga gactgtagct tactcaaagc ttttggctat caagacttta 180 aagggagatt atcatgatgg acagtccaaa aaaattaggc tatcacatgc cagcagagta 240 cgaaccccat catggtaccc tcatgatatg gccgactcga ccaggatcat ggccttttca 300 312 aggaaaggct gc <210> 106 <211> 90

<212>

DNA

st <213>Streptococcus:-pneumor	tŗ	pneumon	iae	pat	entir	1.ST25	
<413> STFEDTOCOCCUS nneumor	าาส	A		·			

			•						<del></del>
	.400	105							
		106 ctac	cagcttttcc	tagaagtctt	tcagggagga	agttggacca	aggcggaacc	60	
			gctcggatgg				33-33	90	
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	7. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.						•	
	<210> <211>								metroma ett mustaan milii milii sett
		DNA	nto	· · · · · · · · · · · · · · · · · · ·					
	<213>	Stre	eptococcus p	oneumoniae					
	<400>	107							
			tctctacttg	gaaaagctcc	tcaaactatc	acactgaaat	caagcgtggg	60	
						tttattctgc		120	
						aatcaagctt		180	
	ctaaagg	aaa	agattctcca	ctatcataac	caaaaatttt	cgcctgaaat	gatggttatg	240	
	gctaaag	1999	ttaacgtggg	aatttcaacc	atttactatt	ggattcatca	tggaaaattg	300	
	gggttaa	gca	agcaggattt	gctttaccct	agaaaaggaa	aagcgcttaa	gaaacaggct	360	
	agcacca	act	ttaaacctgc	tggtcaatcc	atcgaacagc	ggcctgaagc	tatcaatctt	420	
	cgcttgg	aga	atgggcatta	tgagattgat	acggttctac	ttacgagatc	gaaaaactac	480	
	tgcttga	ttg	tcttgacgga	tcgaaagagt	agacatcaga	tcatccgatt	gattccaaat	540	
	aaaagtg	ctg	aggtggtcaa	tcaggctcta	aaactcatct	taaaacaaca	caagattctt	600	
	tccatca	cgg	cagataatgg	aacggaattc	aatcgcttgt	ttgatatatt	ttctgaggag	660	
	cacatct	att	atgcgcaccc	ctatgcctct	tgggaaaggg	gaactaatga	gaatcacaac	720	
}	aggctca	ttc	gtagatagtt	acctaaggga	accaagaaaa	tgactcccaa	agaagtcgca	780	
						tggactacaa		840	
	gaagact	tct	ggatggctaa	cttgaacttg	aaatttagca	aaatggaaat	aatttttatt	900	
	aaacgct	tcc	aa			•		912	•
	<210>	108							
	<211>	108							
	<212>	DNA							
	<213>	Stre	ptococcus p	neumoniae					
			, <b>,</b>						
	<400>			•					
						atttgtcaac	gaaggccagt	60	•
	cccagtc	aac	ctttgcaggg <sub>.</sub>	gaaacatggt				108	
					Page 108	•			

<210>	109	
<211>	84	
<212>	DNA	
<213>	Streptococcus pneumoniae	
<400> acatcat	109 tcaa taaggataca cacaaggaaa tcatcgccaa actggactac gacgccccat	60
cttgcc	ctga gtgcggaaac caat	84
<210>	110	
<211>	81	
<212>	DNA	
<213>	Streptococcus pneumoniae	
	·	
<400> tacttce	110 cttc cacacaagta tgccagagaa agcttatcgc taccctctac caacaaaata	60
ttacaca	agaa aacaaggttc g	81
<210>	111	
<211>	159	
<212>	DNA	
<213>	Streptococcus pneumoniae	
<400>	111	
	ttca aaaaagatca aattaatgag cgtgtcgaga aattaggtaa gttaaaacct	60
	ataa attacaacgg aaaatcagaa gtaattgata gtaaagaaaa attacaagag	120
cccacga	aata aagccgttaa agacgaagtg gctcaaata	159
<210>	112	
<211>	99	
<212>	DNA	
<213>	Streptococcus pneumoniae	
<400>	112 GCGC attctaaaag aagcgctgga agtggcaggg caggaggcag acaatgtctt	60
	tgtc aaaataaatg taggagagat tttaagtat	60 99
	-2	- uu

		•
<del>-</del>	str pneumoniae patentin.ST25	
	<211> 108	
	<212> DNA	
	<213> Streptococcus pneumoniae	
	<400> 113	
	cacggccgac cttatcataa gcctcaccaa ccgcatcatc acgggtttcc ccaacaatct	60
	tataatctcc tgcctccgaa acataaacca actctgtgtg tccgccgc	108
	<210> 114	
	<211> 390	
	<212> DNA	
	<213> Streptococcus pneumoniae	
	<400> 114	
	aaaggaaaaa tcctcctgct accaaggcta accactcaaa gatggcaaag aaaaatccgc	60
	cctgactcac gtaagtcagc aaataataaa gcaaaccttg acttccataa tagtcgctgt	120
	aaatcttccc tgtctgatga agcgcccaac ctgcataaaa atcctgcact tcttgtgcac	180
	tcattaagtc gagtaatagc ggtactccta gagttatccc cgttacaagc gtactccata	240
	gtaaaatttt caccaaagga agacgacttg attcacgatg atgcgattct tgttcgattt	300
	ggtattctag aggttcacga ttctccttat gaacttcttc tactctacca tacacactca	360
	tatcgtttct cctgttcaat ttatctgtct	390
	<210> 115	
	<211> 432	
,	<212> DNA	
	<213> Streptococcus pneumoniae	
	<400> 115	
	tttacggtaa gccatgtatt cctcctttat ttatctttta atccaagacc caaatcaatg	60
	agtitgagit tractictic caaactcitg cgtccaagat ticgtactit catcatcit	120
	gcttcagatt tttctgtcaa atcatgcaca gtattgatac cggcacgttt taaacagttg	180
	tatgaacgca cagacaagtc cagttcctca atcgtacgat ctaaaatacg gtcgtcagat	240
	tcagtatcag cttctttcat cacttcagtt gacttagcaa tctcagtaag atttgtaaac	300
	aaatcaagat gttctgtcaa aatacgtgct gaaagcccta aagcatcttc tggaataatt	360
	gttccatttg tcaagatttc aagggttaat ttgtcgaaac catcattgct acctacacga	420
	gcaggttcca ct Page 110	432

<210>	116	
<211>	54	
<212>	DNA	
<213>	Streptococcus pneumoniae	
<400> cttgtc	116 tgca tgaagaataa gggctgctac aaggaaagaa acaactgctg ccac	54
<210>	117	
<211>	174	
<212>	DNA	
<213>	Streptococcus pneumoniae	
	· .	
<400>		
	tatt tgtcaaaata ctttttagtt tcagcaataa cgactggcga caagaccaag	60
	atca agtttggcag agccatcaag gcgttaacga tatctgcgat aatccagacc	120
atatec	aact cgataaatcc tcctaacaag accatgagca caaaaaccac acgg	174
<210>	118	
<211>	141	
<212>	DNA	
<213>	Streptococcus pneumoniae	
<400>	118 paagg tattcataaa ataccctcta tcaagagtct cctcaaaaac aggaccgatg	60
	aggca ggacaaaaga taagatagtc gataaaaagg ttggttgtcc atttgaaaaa	120
_	ggtaa aatactcatc a	141
<210>		
<211>		
<212>		
<213>	Streptococcus pneumoniae	
<400> tcttca	119 accag tttttcctaa acttgtaatg gtatctgggg caaataaacc aagagaaagg	60
	tttcc cattttcgtc taaaatgtca ttccacttaa cctttgtctt g	111

	-		
≼210>	str pneumoniae patentin.ST25		
<211>	231		_
<212>	DNA		
<213>	Streptococcus pneumoniae		
<400>	120		د: د
	aactt ccttctcagt tccgaagata gcttcttcaa aggtcaaatt gacacg		
	atcat ctccttggcg aggagcgttt ggattgcgcg aagaaccgcc tccgcc		
	tgaga aaatatcctc aaaaccaccg aagccacctg ccccattgaa accgcc	gaaa 180	
ccacca	agctc caccaaaacc accattggcg cctgcagcac catactggtc a	231	
<210>	121		
<211>	267		
<212>	DNA		
<213>	Streptococcus pneumoniae		
<400>	121		
	atggc gtcctattcc agattcaaaa tgctatacac aagaaaaact cactate		
	aagaa gaaaagacat caaggacttc taccacaatt ccatccaaag acacaaa		
agccat	taaga gtcacctcct tgattcctat aggctgatta taacaagact ggctgaa	aatt 180	
gtacat	tgaaa ataaaatcct aatagtactc attttgtatg tgactaatat tccgtc1	tcgc 240	
tccaga	aaggt acgaagtaaa tagagtt	267	
<210>	122		
<211>	180		
<212>	DNA		1
<213>			
	productive.		
<400>	122		
ctgttt	control territorial control territorial contro	att 60	
	gaatt tgcagtacgt tcaaaacgtt ttccgaaagg atcgattcct tgttcgc		
	ccat tttttcacgg cgaacgatct gctggtcatt tagttcttcc atatgtt		
<210>	123		
<211>	180		
<212>	DNA		
<213>		•	
<5T2>	Streptococcus pneumoniae		

## str pneumoniae patentin.ST25

<400> 123 ataactcacc ctccactaaa ccctgagcat tttgtttcaa gagtcttttc atctcttggt	60												
ttgaagtctt atcagccaaa agatgataga tttctgagaa agccttcaga tagtaggcat	120												
cctgaatcag gtaatagcgg aaaatggcag gttctaaatt cccctcttgt aattgtaaaa	180												
<210> 124													
<211> 90													
<212> DNA													
<213> Streptococcus pneumoniae													
<pre>&lt;400&gt; 124 acattggcta aagcagtcgg tttgatgtat tctccaccaa ttccaccaaa accattctta</pre>	60												
ggccgaataa cgacagattc gtcttctata	90												
	30												
<210> 125													
<21 <b>1</b> > 249													
<212> DNA													
<213> Streptococcus pneumoniae													
<400> 125 cctggttctc cattttcaga gatttccggt gcaggatttt ttggtgtcgc gaaacgaata	60												
tttccacgtc caccacgacc accgtgggca acgataaatt cttgcccatg ttcaatcaaa	120												
tctgttaaaa ccttgccagt ctccgcatca cgaacagtcg taccttgtgg tactcgaact	180												
ctaaggtcct cagcaccacg accatgcatc cctttggtca tccctttttc accagaatca	240												
gccttgaaa	249												
<210> 126													
<211> 333													
<212> DNA													
<213> Streptococcus pneumoniae													
2237 Scroptossos pricamon rac													
<400> 126													
ataaattcct tgaccttggc cacatcctta tccaaaagaa gggcaccaag aaaggcttca	60												
aaggcatcac caagaatggt gtcacgattg cgaccacctg atttttcttc ccctttaccc	120												
aacttgataa actggtcaaa ctggcaatca cgcgcaaaac cagctaaact ctcctcacgg	180												
acaatcatag cacggagttt tgataggtca ccttcaggct ttttaggata ttttttatat	240												
agatattctg aaatcaataa ctgtagaaca gcgtctccta aaaattccaa gcgttcattg Page 113	. 300												

# str pneumoniae patentin.ST25

Totogaatti ttaagaggg atgeteatha geografia	
tgtgaaattt ttaagaggcg gtgctcattg gca	333
· <210> 127	
<211> 147	
<212> DNA	•
<213> Streptococcus pneumoniae	
•	
<400> 127	
ccaataggaa aaaggaattg taaagctgaa tgccaatccc accacctgct tgaaaagcag	60
aagaccttcc agtcaagaaa gaccaagaga tatggggcaa gccccgaacc aagatataga	120
gaatcaagga agccaagatt gtcacaa	147
<210> 128	
<211> 174	_
<212> DNA	
<213> Streptococcus pneumoniae	
<400> 128	
cagccattgg gacactcgaa agccgaagaa catgagacta tctgttcgca taccttcgat	60
aaccatacga ccgaaaccat accaaatcaa gtaaaaggcc gtgatatgac ctcgtctgag	120
actcttccat ttccgtctaa aaatcagaat caaggcaaag ccaagcagat tcca	174
<210> 129	
<211> 375	
<212> DNA	
<213> Streptococcus pneumoniae	
<400> 129	
ccttgctctt tacctgatta tgggctggtt ggttctggct atcattcctg ccattatcag	60
tcaaacgaca cccgttttct ggagtctcat ggtaactggc ggactctgtt atacagttgg	120
agctggattt tatgccaaga aaaaacctta tttccacatg atttggcatc tctttatcct	180
agctgcgtcc gcacttcaat acatcgctat tgtttattac atgtaaaaaa gttgagaaat	240
tcaatctcaa cttttttctt tacacatatt gataaagtac tggtgcaagc gcacatcatc	300
agtcaattct ggatgaaaag aacttaccaa catattttt tcttgggctg caacaatttg	360
attgttcact gttgc	375
<210> 130	

## str pneumoniae patentin.sT25 <211> 207 <212> DNA <213> Streptococcus pneumoniae <400> 130 cgagtaaaag ataatcatct ggataagctt gtgaaagctc ttctaaaaag gcgttcatcc 60 actcagtatt acatccacca gctattaaga aaaatgattc gcctgtatgg gcatcaacag 120 ctccataaca atagcgaaat tctcgtatat agtgactatg gacatgtgga cctactccta 180 ttggagacca acaagatccc agtttac 207 <210> 131 <211> 120 <212> DNA <213> Streptococcus pneumoniae <400> 131 caagtcatca aaatagacat agcaactaca aataaaacgg aatctgtaaa gagccaaagt 60 gagagagaaa agaaaagatt gacaagcagt aatatactaa aggttagagg gcgaccgata 120 <210> 132 <211> 96 <212> DNA <213> Streptococcus pneumoniae <400> 132 gcctttaaga gttccaaggt cccatcactt gatccatcat cgacaaagac atactcgatt 60 tctgtttcca aatctggaag taaagcttcc agagcc 96 <210> 133 <211> 207 <212> DNA <213> Streptococcus pneumoniae <400> 133 gataaaactg acccactggc taggaaactt cctgacaaaa gtaagccgtc aacttccttt 60 tgcaccaaat cactttctcc cgttaacatg gcttcattga cttccgcaaa gccttccaaa 120 accaaggcat cactaggaat ctgctctcct gcagacaaac gaatgacatc tcctagcact 180 aattcttcag gattaagagc aacttcc 207

·		str pneumoniae patentin.ST25	
	<210> 134		
	<211> 114	4	
	<212> DN/	4	
	<213> St	reptococcus pneumoniae	
		the state of the s	e – e u umuneteruidas siden sum num
	<400> 134	1	
	aataaaatat	t tacaaacaca agcaaggcca cgagggtctg tgaccaatct aacgaagcaa	60
	uu cuagg ca (	t atagatacct aaattatctc cgccagacgc aattgtcagc aatg	114
	<210> 135	5	
	<211> 330		
_	<212> DNA	A.	
,	<213> Str	reptococcus pneumoniae	
	<400> 135	; gcattggcaa tgagggacag tgcaaaggca atagttgtta cgtaggcaag	60
	gagattcatc	ttgcccccat atccgatata gttggtcaca aaggcaaaga ggaaggcgat	60 120
	gatggaaatg	atgatggccg ccaattttac ctgtttttgg ctcatttggt tgggtctgcc	180
	ttcttgcgaa	gcttcccact tctttatagc aaaggtataa atgaggaagg tgacgggata	240
	ggtaatgatg	gccgccttat ttccaaggat ataatcaata gcaccggaca aaatggtatt	300
		aagtaatttc cccatttgct	330
	<210> 136		330
	<210> 136 <211> 363		
	7213> 2ft/	eptococcus pneumoniae	
	<400> 136	•	•
		agctggttat cgatacgacg actttcatga cgttctgtac caataacaca	60
		agttcacgaa caccttcacc aagcttgatg tcggtaccac gacccgccat	120
		atggtaacgg caccacgttg accagcattc atgatgattt gggcttctct	180
		ttggcattca agacttcgtg aggaacacca gctgcaacca atttcttaga	240
		ctagtttcaa ccgctactgt accaaccaag acaggttgac ccttttggta	300
		acgtcttcga caaccgcttt aaacttagat tcgatacttg cataaagaag	360
	gtc		363
			303

		str pneumoniae patentin.ST25	
<210>		pacements pacements	
<211>			
<212>			
<213>	Str	eptococcus pneumoniae	
<400> atctct		gtgtaccgac ctgttcgatg tatccattgt taaagactgc aattctatca	60
		aggcttcctc t	8:
<210>	138		
<211>			
<212>			
<b>&lt;213&gt;</b>	Str	eptococcus pneumoniae	
<400> ttaagt		tatcaacat aaaatcaatc ttataataat ta	
		tgtccagcat aaagtcaatc ttgtgctctt taccgacaca caccattttc ccatatcacc aaaaagagga tccactgcca ta	60
	Tug	contactace and agagga tecatigeta ta	102
<210>	139		
<211>	333		
<212>	DNA		
<213>	Str	eptococcus pneumoniae	
<400>	139 tcat	actications caacticaan genteetees to the contraction of the contractio	
		actcatctac caactccaag gcatgctcaa tcgtcggttt atcaaaacca	60
		tctgtgtcac acccatctca gcagccaagg caatttcttc tgcctcacga	120
		cttctacatt caagtgtgta tgtgtatcaa aaatcatctc ttctaacctc	180
		ttctattata ccaaaaaaga ggaggggcac ctaatttttc ggtttcccct	240
		atagagaget attetgetat etttetate egatattgee eateteetat gagacagaag agattggeta eat	300
TOULCU;	geta	sugacagaag agattggcta tat	333
<210>	140		
<211>	330		
<212>	DNA		
<213>	Stre	ptococcus pneumoniae	
<400>	140		
ycaacat	CTT	gcattgttcc tgcagttgct tgcggtgcac ttgttgtctt aggagcagca Page 117	60

,	Sur pneumoniae patentin.st25	
	ttaggagcca ctggtctctt aggaactgta accatggcaa tggcttgcac tccaatcgtt	120
	tctgcttcct tcacatcttc catagttttc gcattttcaa tctctttgag agctgcttgt	180
	ttttctgctt ccactcttgc taaaagttct gctttttctt tatcagaaag cggtgcgcct	240
	ttgatttcat cctgcttgtc cttggctgct ttttcaatgg catttttagc tgattcttt	300
۹.,	tcagtagcta_attgcttaga_agcttgtgat	330-
	<210> 141	
	<211> 159	
	<212> DNA	
	<213> Streptococcus pneumoniae	
	•	
	<400> 141	
	tattctcctt tcaaccactc cattctcata aggaaaacga cgaaaatcat aaatccaaac	60
	cccaaagcac cacgaatgaa ttggcgaagc aaggtttggt caaaccaacc tgtaaacatt	120
	tccactaacc ataccaagag tgacaggccg ataaagaaa	159
	<210> 142	
	<211> 144	•
	<212> DNA	•
	<213> Streptococcus pneumoniae	
	<400> 142 Gattattica agriticaac aactittaca agattitata companya	
	gattatttca agtttcgaac aacttttaca agattttcta cagtaaagcc atattctgcc	60
	aatacttttg gtgctggggc agaggctccg aaggtatcaa tacctagaac ggcaccatcg agaccaacat atttgtacca gttt	120
	The state of the s	144
	<210> 143	
	<211> 222	
	<212> DNA	
	<213> Streptococcus pneumoniae	
	<400> 143 agaggcagac gtggattatg cgttgcacga atcaaggctc ctagactagt cattaaacct	60
	aagagaacaa tcgatccgcc taccaaagat agatacagtc caccactctc agctacatcc	120
	ctctccgtcc ccaaaagtcc tatcatctct ttcccagcga agatggacaa aaatcctaaa	180
•	aggaaactta atagtaaggt aatcttcaac gcctcagtca ca	222
		444

<210> 144 str pneumoniae patentin.ST25													
<211> 90													
<212> DNA													
<213> Streptococcus pneumoniae													
proceduc pricumontac													
<400> 144 actcctccat ataccaaaat tcctgccaaa acagctataa taccatttat ttcagctcaa													
gatttcaacc aagcccaacg gctctctgga													
<210> 145													
<210> 145 <211> 122													
<212> PRT													
<213> Streptococcus pneumoniae													
,													
<400> 145													
Met Ser Lys Asn Ile Val Gln Leu Asn Asn Ser Phe Ile Gln Asn Glu 10 15													
Tyr Gln Arg Arg Arg Tyr Leu Met Lys Glu Arg Gln Lys Arg Asn Arg 20 25 30													
Phe Met Gly Gly Val Leu Ile Leu Ile Met Leu Leu Phe Ile Leu Pro 35 40 45													
Thr Phe Asn Leu Ala Gln Ser Tyr Gln Gln Leu Leu Gln Arg Arg Gln 50 60													
Gln Leu Ala Asp Leu Gln Thr Gln Tyr Gln Thr Leu Ser Asp Glu Lys 65 70 75 80													
Asp Lys Glu Thr Ala Phe Ala Thr Lys Leu Lys Asp Glu Asp Tyr Ala 85 90 95													
Ala Lys Tyr Thr Arg Ala Lys Tyr Tyr Tyr Ser Lys Ser Arg Glu Lys 100 105 110													
Val Tyr Thr Ile Pro Asp Leu Leu Gln Arg 115													
<210> 146													
<211> 877													
<212> PRT													

60

90

<213> Streptococcus pneumoniae

<400> 146

Met Asp Lys Lys Leu Leu Leu Ile Asp Gly Ser Ser Val Ala Phe 1 10 15

Arg Ala Phe Phe Ala Leu Tyr Gln Gln Leu Asp Arg Phe Lys Asn Val

Ala Gly Leu His Thr Asn Ala Ile Tyr Gly Phe Gln Leu Met Leu Ser

His Leu Leu Glu Arg Val Glu Pro Ser His Ile Leu Val Ala Phe Asp  $50 \hspace{1.5cm} 60$ 

Ala Gly Lys Thr Thr Phe Arg Thr Glu Met Tyr Ala Asp Tyr Lys Gly 65 70 75 80

Gly Arg Ala Lys Thr Pro Asp Glu Phe Arg Glu Gln Phe Pro Phe Ile 85 90 95

Arg Glu Leu Leu Asp His Met Gly Ile Arg His Tyr Asp Leu Ala Gln 100 110

Tyr Glu Ala Asp Asp Ile Ile Gly Thr Leu Asp Lys Leu Ala Glu Gln 115 120 125

Asp Gly Phe Asp Ile Thr Ile Val Ser Gly Asp Lys Asp Leu Ile Gln 130 140

Leu Thr Asp Glu His Thr Val Val Glu Ile Ser Lys Lys Gly Val Ala 145 150 155 160

Glu Phe Glu Ala Phe Thr Pro Asp Tyr Leu Met Glu Glu Met Gly Leu 165 170 175

Thr Pro Ala Gln Phe Ile Asp Leu Lys Ala Leu Met Gly Asp Lys Ser 180 185 190

Asp Asn Ile Pro Gly Val Thr Lys Val Gly Glu Lys Thr Gly Ile Lys
195 200 205

Leu Leu Glu His Gly Ser Leu Glu Gly Ile Tyr Glu Asn Ile Asp 210 220

Gly Met Lys Thr Ser Lys Met Lys Glu Asn Leu Ile Asn Asp Lys Glu 235 230 240

Gln Ala Phe Leu Ser Lys Thr Leu Ala Thr Ile Asp Thr Lys Ala Pro 245 250 255 str pneumoniae patentin.ST25
Ile Ala Ile Gly Leu Glu Asp Leu Val Tyr Ser Gly Pro Asp Val Glu
260 265 270 Asn Leu Gly Lys Phe Tyr Asp Glu Met Gly Phe Lys Gln Leu Lys Gln 275 285 Ala Leu Asn Val Ser Ser Ala Asp Val Ser Glu Ser Leu Asp Phe Thr 290 295 300 Ile Val Asp Gln Ile Ser Gln Asp Met Leu Ser Glu Glu Ser Ile Phe 305 310 315 320 His Phe Glu Leu Phe Gly Glu Asn Tyr His Thr Asp Asn Leu Val Gly 325 330 335 Phe Val Trp Ser Cys Gly Asp Lys Leu Tyr Ala Thr Asp Lys Leu Glu 340 345 350 Leu Leu Gln Asp Pro Ile Phe Lys Asp Phe Leu Glu Lys Thr Ser Leu 355 360 365 Arg Val Tyr Asp Phe Lys Lys Val Leu Leu Gln Arg Phe Gly 370 375 380 Val Asp Leu Gln Ala Pro Ala Phe Asp Ile Arg Leu Ala Lys Tyr Leu 385 390 395 400 Leu Ser Thr Val Glu Asp Asn Glu Ile Ala Thr Ile Ala Ser Leu Tyr 405 410 415 Gly Gln Thr Tyr Leu Val Asp Asp Glu Thr Phe Tyr Gly Lys Gly Val 420 425 430 Lys Lys Ala Ile Pro Glu Arg Glu Lys Phe Leu Glu His Leu Ala Cys 435 440 445 Lys Leu Ala Val Leu Val Glu Thr Glu Pro Ile Leu Leu Glu Lys Leu 450 460 Ser Glu Asn Gly Gln Leu Glu Leu Leu Tyr Asp Met Glu Gln Pro Leu 465 470 475 480 Ala Phe Val Leu Ala Lys Met Glu Ile Ala Gly Ile Met Val Lys Lys 485 490 495 Glu Thr Leu Leu Glu Met Gln Ala Glu Asn Glu Leu Val Ile Glu Lys 500 510 Leu Thr Gln Glu Ile Tyr Glu Leu Ala Gly Glu Glu Phe Asn Val Asn 515 520 525

Leu Glu Tyr Thr Lys Lys Thr Lys Thr Gly Tyr Ser Thr Ala Val Asp 545 550 555 Val Leu Glu Arg Leu Ala Pro Ile Ala Pro Ile Val Lys Lys Ile Leu
565 570 575 Asp Tyr Arg Gln Ile Ala Lys Ile Gln Ser Thr Tyr Val Ile Gly Leu 580 590 Gln Asp Trp Ile Leu Ala Asp Gly Lys Ile His Thr Arg Tyr Val Gln 595 600 Asp Leu Thr Gln Thr Gly Arg Leu Ser Ser Val Asp Pro Asn Leu Gln 610 620 Asn Ile Pro Ala Arg Leu Glu Gln Gly Arg Leu Ile Arg Lys Ala Phe 625 630 635 640 Val Pro Glu Trp Glu Asp Ser Val Leu Ser Ser Asp Tyr Ser Gln 645 655 Ile Glu Leu Arg Val Leu Ala His Ile Ser Lys Asp Glu His Leu Ile 660 665 670 Lys Ala Phe Gln Glu Gly Ala Asp Ile His Thr Ser Thr Ala Met Arg 675 685 Val Phe Gly Ile Glu Arg Pro Asp Asp Val Thr Ala Asn Asp Arg Arg 690 700 Asn Ala Lys Ala Val Asn Phe Gly Val Val Tyr Gly Ile Ser Asp Phe 705 710 715 720 Gly Leu Ser Asn Asn Leu Gly Ile Ser Arg Lys Glu Ala Lys Ala Tyr 725 735 735 Ile Asp Thr Tyr Phe Glu Arg Phe Pro Gly Ile Lys Asn Tyr Met Asp 740 745 Glu Val Val Arg Glu Ala Arg Asp Lys Gly Tyr Val Glu Thr Leu Phe 755 760 765 Lys Arg Arg Glu Leu Pro Asp Ile Asn Ser Arg Asn Phe Asn Ile 770 780 Arg Gly Phe Ala Glu Arg Thr Ala Ile Asn Ser Pro Ile Gln Gly Ser 785 790 795 800

Ala Ala Asp Ile Leu Lys Ile Ala Met Ile Gln Leu Asp Lys Ala Leu 805 810 815

Val Ala Gly Gly Tyr Gln Thr Lys Met Leu Leu Gln Val His Asp Glu 820 830

Ile Val Leu Glu Val Pro Lys Ser Glu Leu Val Glu Met Lys Lys Leu 835 840 845

Val Lys Gln Thr Met Glu Glu Ala Ile Gln Leu Ser Val Pro Leu Ile 850 860

Ala Asp Glu Asn Glu Gly Ala Thr Trp Tyr Glu Ala Lys 865 870 875

<210> 147

<211> 211

<212> PRT

<213> Streptococcus pneumoniae

<400> 147

Met Gly Met Ala Ala Phe Lys Asn Pro Asn Asn Gln Tyr Lys Ala Ile 10 15

Thr Ile Ala Gln Thr Leu Gly Asp Asp Ala Ser Ser Glu Glu Leu Ala 20 25 30

Gly Arg Tyr Gly Ser Ala Val Gln Cys Thr Glu Val Thr Ala Ser Asn 35 40 45

Leu Ser Thr Val Lys Thr Lys Ala Thr Val Val Glu Lys Pro Leu Lys 50 60

Asp Phe Arg Ala Ser Thr Ser Asp Gln Ser Gly Trp Val Glu Ser Asn 65 70 75 80

Gly Lys Trp Tyr Phe Tyr Glu Ser Gly Asp Val Lys Thr Gly Trp Val 85 90 95

Lys Thr Asp Gly Lys Trp Tyr Tyr Leu Asn Asp Leu Gly Val Met Gln 100 105 110

Thr Gly Phe Val Lys Phe Ser Gly Ser Trp Tyr Tyr Leu Ser Asn Ser 115 120 125

Gly Ala Met Phe Thr Gly Trp Gly Thr Asp Gly Ser Arg Trp Phe Tyr 130 140

str pneumoniae patentin.ST25

Phe Asp-Gly-Ser-Gly-Ala-Met-Lys-Thr-Gly Trp Tyr Lys-Glu Asn Gly

145

150

155

160

Thr Trp Tyr Tyr Leu Asp Glu Ala Gly Ile Met Lys Thr Gly Trp Phe 165 170 175

Lys Val Gly Pro His Trp Tyr Tyr Ala Tyr Gly Ser Gly Ala Leu Ala

Val Ser Thr Thr Pro Asp Gly Tyr Arg Val Asn Gly Asn Gly Glu 195 200 205

Trp Val Asn 210

<210> 148

<211> 1856

<212> PRT

<213> Streptococcus pneumoniae

<400> 148

Met Ser Arg Lys Ser Ile Gly Glu Lys Arg His Ser Phe Ser Met Arg 10 15

Lys Leu Ser Val Gly Leu Val Ser Val Thr Val Ser Ser Phe Phe Leu 20 25 30

Met Ser Gln Gly Ile Gln Ser Val Ser Ala Asp Asn Met Glu Ser Pro 35 40 45

Ile His Tyr Lys Tyr Met Thr Glu Gly Lys Leu Thr Asp Glu Glu Lys 50 60

Ser Leu Leu Val Glu Ala Leu Pro Gln Leu Ala Glu Glu Ser Asp Asp 65 70 75 80

Thr Tyr Tyr Leu Val Tyr Arg Ser Gln Gln Phe Leu Pro Asn Thr Gly 85 90 95

Phe Asn Pro Thr Val Gly Thr Phe Leu Phe Thr Ala Gly Leu Ser Leu 100 110

Leu Val Leu Leu Val Ser Lys Arg Glu Asn Gly Lys Lys Arg Leu Val 115 120 125

His Phe Leu Leu Chr Ser Met Gly Val Gln Leu Leu Pro Ala Ser 130 140 str pneumoniae patentin.ST25
Ala Phe Gly Leu Thr Ser Gln Ile Leu Ser Ala Tyr Asn Ser Gln Leu
145 150 155 160 Ser Ile Gly Val Gly Glu His Leu Pro Glu Pro Leu Lys Ile Glu Gly 165 170 175 Tyr Gln Tyr Ile Gly Tyr Ile Lys Thr Lys Lys Gln Asp Asn Thr Glu 180 185 190 Leu Ser Arg Thr Val Asp Gly Lys Tyr Ser Ala Gln Arg Asp Ser Gln
195 200 205 Pro Asn Ser Thr Lys Thr Ser Asp Val Val His Ser Ala Asp Leu Glu 210 220 Trp Asn Gln Gly Gln Gly Lys Val Ser Leu Gln Gly Glu Ala Ser Gly 225 230 235 240 Asp Asp Gly Leu Ser Glu Lys Ser Ser Ile Ala Ala Asp Asn Leu Ser 245 250 255 Ser Asn Asp Ser Phe Ala Ser Gln Val Glu Gln Asn Pro Asp His Lys 260 270 Gly Glu Ser Val Val Arg Pro Thr Val Pro Glu Gln Gly Asn Pro Val 275 280 285 Ser Ala Thr Thr Val Gln Ser Ala Glu Glu Glu Val Leu Ala Thr Thr 290 295 300 Asn Asp Arg Pro Glu Tyr Lys Leu Pro Leu Glu Thr Lys Gly Thr Gln 305 310 315 Glu Pro Gly His Glu Gly Glu Ala Ala Val Arg Glu Asp Leu Pro Val 325 330 335 Tyr Thr Lys Pro Leu Glu Thr Lys Gly Thr Gln Gly Pro Gly His Glu 340 345 Gly Glu Ala Ala Val Arg Glu Glu Glu Pro Ala Tyr Thr Glu Pro Leu 355 . 360 . 365 Ala Thr Lys Gly Thr Gln Glu Pro Gly His Glu Gly Lys Ala Thr Val Arg Glu Glu Thr Leu Glu Tyr Thr Glu Pro Val Ala Thr Lys Gly Thr 385 390 395 Gln Glu Pro Glu His Glu Gly Glu Ala Ala Val Glu Glu Glu Leu Pro 405 410 415

\_\_\_\_\_Ala\_Leu\_Glu\_Val\_Thr\_Thr\_Arg\_Asn\_Arg\_Thr\_Glu\_Ile\_Gln\_Asn\_Ile\_Pro\_\_\_\_\_\_ 420 425 430 Tyr Thr Thr Glu Glu Ile Gln Asp Pro Thr Leu Leu Lys Asn Arg Arg 445 Lys Ile Glu Arg Gln Gly Gln Ala Gly Thr Arg Thr Ile Gln Tyr Glu
450 460 Asp Tyr Ile Val Asn Gly Asn Val Val Glu Thr Lys Glu Val Ser Arg 465 470 475 480 Thr Glu Val Ala Pro Val Asn Glu Val Val Lys Val Gly Thr Leu Val 485 490 495 Lys Val Lys Pro Thr Val Glu Ile Thr Asn Leu Thr Lys Val Glu Asn 500 510 Lys Lys Ser Ile Thr Val Ser Tyr Asn Leu Ile Asp Thr Thr Ser Ala 515 Tyr Val Ser Ala Lys Thr Gln Val Phe His Gly Asp Lys Leu Val Lys 530 540 Glu Val Asp Ile Glu Asn Pro Ala Lys Glu Gln Val Ile Ser Gly Leu 545 550 560 Asp Tyr Tyr Thr Pro Tyr Thr Val Lys Thr His Leu Thr Tyr Asn Leu 565 575 Gly Glu Asn Asn Glu Glu Asn Thr Glu Thr Ser Thr Gln Asp Phe Gln 580 590 Leu Glu Tyr Lys Lys Ile Glu Ile Lys Asp Ile Asp Ser Val Glu Leu 595 600 Tyr Gly Lys Glu Asn Asp Arg Tyr Arg Arg Tyr Leu Ser Leu Ser Glu 610 620 Ala Pro Thr Asp Thr Ala Lys Tyr Phe Val Lys Val Lys Ser Asp Arg 625 630 635 Phe Lys Glu Met Tyr Leu Pro Val Lys Ser Ile Thr Glu Asn Thr Asp  $645 \hspace{1.5cm} 650 \hspace{1.5cm} 655$ Gly Thr Tyr Lys Val Thr Val Ala Val Asp Gln Leu Val Glu Glu Gly 660 665 Thr Asp Gly Tyr Lys Asp Asp Tyr Thr Phe Thr Val Ala Lys Ser Lys 675 680

str pneumoniae patentin.ST25 Ala Glu Gln Pro Gly Val Tyr Thr Ser Phe Lys Gln Leu Val Thr Ala 690 695 700 Met Gln Ser Asn Leu Ser Gly Val Tyr Thr Leu Ala Ser Asp Met Thr 705 710 715 720 Ala Asp Glu Val Ser Leu Gly Asp Lys Gln Thr Ser Tyr Leu Thr Gly
725 730 735 Ala Phe Thr Gly Ser Leu Ile Gly Ser Asp Gly Thr Lys Ser Tyr Ala 740 745 750 Ile Tyr Asp Leu Lys Lys Pro Leu Phe Asp Thr Leu Asn Gly Ala Thr 755 760 765 Val Arg Asp Leu Asp Ile Lys Thr Val Ser Ala Asp Ser Lys Glu Asn 770 780 Val Ala Ala Leu Ala Lys Ala Ala Asn Ser Ala Asn Ile Asn Asn Val 785 790 795 800 Ala Val Glu Gly Lys Ile Ser Gly Ala Lys Ser Val Ala Gly Leu Val 805 810 815 Ala Ser Ala Thr Asn Thr Val Ile Glu Asn Ser Ser Phe Thr Gly Lys 820 830 Leu Ile Ala Asn His Gln Asp Ser Asn Lys Asn Asp Thr Gly Gly Ile 835 840 845 Val Gly Asn Ile Thr Gly Asn Ser Ser Arg Val Asn Lys Val Arg Val 850 860 Asp Ala Leu Ile Ser Thr Asn Ala Arg Asn Asn Asn Gln Thr Ala Gly 865 870 880 Gly Ile Val Gly Arg Leu Glu Asn Gly Ala Leu Ile Ser Asn Ser Val 885 890 Ala Thr Gly Glu Ile Arg Asn Gly Gln Gly Tyr Ser Arg Val Gly Gly 900 905 910 Ile Val Gly Ser Thr Trp Gln Asn Gly Arg Val Asn Asn Val Val Ser 915 920 925 Asn Val Asp Val Gly Asp Gly Tyr Val Ile Thr Gly Asp Gln Tyr Ala 930 940 Ala Ala Asp Val Lys Asn Ala Ser Thr Ser Val Asp Asn Arg Lys Ala 945 950 955 960

						-				•					
·***	AS	p Arg	Phe	Ala	Thr 965	Lys	st <u>Leu-</u>	r pn Ser	Lys"/	niae Asp 970	pat Gln	entin Ile A	.ST2 Sp A	5 <u>l</u> ā <u> </u>	/\$_Va] /5
	Ala	a Asp	Tyr	Gly 980	Ile	Thr	Val '	Thr !	Leu / 985	Asp /	Asp <sup>-</sup>	Thr G	ly Gl 99	in As 90	p Leu
	Lys	Arg	Asn 995	Leu	Arg	Glu	Va] ,	Asp 1000	Tyr	Thr	Arg	Leu /	Asn 1005-	Lys	Ala Glu
	Ala	Glu 1010						Sei					Leu		
	Phe	Tyr 1025	Asn	Lys	Asp	Leu	Va] 1030	Val	His	Tyr	· G7y	' Asn 103	Lys	Val	Ala
	Thr	Thr 1040	Asp	Lys	Leu	Tyr	Thr 1045	Thr	· Glu	Leu	l Leu	1 Asp 1050	Val	٧a٦	Pro
	Met	Lys 1055	Asp	Asp	Glu	va1	Va] 1060	Thr	` Asp	Ile	. Asn	Asn 1065	Lys	Lys	Asn
	Ser	Ile 1070	Asn	Lys	Val	Met	Leu 1075	His	Phe	Lys	Asp	Asn 1080	Thr	٧a٦	Glu
	Tyr	Leu 1085	Asp	٧a٦	Thr	Phe	Lys 1090	G]u	Asn	Phe	Ile	Asn 1095	Ser	Gln	Val
	Ile	.Glu 1100	Tyr	Asn	Val	Thr	Gly 1105	Lys	Glu	Tyr	Ile	Phe 1110	Thr	Pro	Glu
	Ala	Phe 1115	Va1	Ser	Asp	Tyr	Thr 1120	ΑΊа	Ile	Thr	Asn	Asn 1125	۷a٦	Leu	Ser
	Asp	Leu 1130	Gln	Asn	val	Thr	Leu 1135	Asn	Ser	Glu	Ala	Thr 1140	Lys	Lys	Val
	Leu	Gly 1145	Ala	Ala	Asn	Asp	Ala 1150	Аlа	Leu	Asp	Asn	Leu 1155	Tyr	Leu	Asp
	Arg	G]n 1160	Phe	Glu	Glu	Val	Lys 1165	Аla	Asn	Ile	Ala	G]u 1170	His	Leu	Arg
	Lys	va] 1175	Leu	Ala	Met	Asp	Lys 1180	Ser	Ile	Asn	Thr	Thr 1185	Gly	Asp	Gly
	Val	va] 1190	Glu	Tyr	Val	Ser	G]u 1195	Lys	Ile	Lys	Asn	Asn 1200	Lys	Glu ,	41a
. •	Phe	Met 1205	Leu	Gly	Leu	Thr	Tyr 1210	Met	Asn-	Arg	Trp	Tyr 1215	Asp	Ile /	Asn
		1203					1210				•	1215		_,,	1011

str pneumoniae patentin.ST25
Tyr Gly Lys Met Asn Thr Lys Asp Leu Ser Thr Tyr Lys Phe Asp
1220 1230 Phe Asn Gly Asn Asn Glu Thr Ser Thr Leu Asp Thr Ile Val Ala 1235 1240 1245 Leu Gly Asn Ser Gly Leu Asp Asn Leu Arg Ala Ser Asn Thr Val 1250 1260 Gly Leu Tyr Ala Asn Lys Leu Ala Ser Val Lys Gly Glu Asp Ser 1265 1270 . 1275 Val Phe Asp Phe Val Glu Ala Tyr Arg Lys Leu Phe Leu Pro Asn 1280 1285 1290 Lys Thr Asn Asn Glu Trp Phe Lys Glu Asn Thr Lys Ala Tyr Ile 1295 1300 Val Glu Met Lys Ser Asp Ile Ala Glu Val Arg Glu Lys Gln Glu 1310 1320 Ser Pro Thr Ala Asp Arg Lys Tyr Ser Leu Gly Val Tyr Asp Arg 1325 1330 1335 Ile Ser Ala Pro Ser Trp Gly His Lys Ser Met Leu Leu Pro Leu 1340 1345 Leu Thr Leu Pro Glu Glu Ser Val Tyr Ile Ser Ser Asn Met Ser 1355 1360 1365 Thr Leu Ala Phe Gly Ser Tyr Glu Arg Tyr Arg Asp Ser Val Asp 1370 1380 Gly Val Ile Leu Ser Gly Asp Ala Leu Arg Thr Tyr Val Arg Asn 1385 1390 1395 Arg Val Asp Ile Ala Ala Lys Arg His Arg Asp His Tyr Asp Ile 1400 1410 Trp Tyr Asn Leu Leu Asp Ser Ala Ser Lys Glu Lys Leu Phe Arg 1415 1420 1425 Ser Val Ile Val Tyr Asp Gly Phe Asn Val Lys Asp Glu Thr Gly 1430 1440 Arg Thr Tyr Trp Ala Arg Leu Thr Asp Lys Asn Ile Gly Ser Ile 1445 1455 Lys Glu Phe Phe Gly Pro Val Gly Lys Trp Tyr Glu Tyr Asn Ser 1460 1465 1470 str pneumoniae patentin.ST25
Ser Ala Gly Ala Tyr Ala Asn Gly Ser Leu Thr His Phe Val Leu

1475
1485 Asp Arg Leu Leu Asp Ala Tyr Gly Thr Ser Val Tyr Thr His Glu 1490 1500 Met Val His Asn Ser Asp Ser Ala Ile Tyr Phe Glu Gly Asn Gly Arg Arg Glu Gly Leu Gly Ala Glu Leu Tyr Ala Leu Gly Leu Leu 1520 1530 Gln Ser Val Asp Ser Val Asn Ser His Ile Leu Ala Leu Asn Thr 1535 1540 1545 Leu Tyr Lys Ala Glu Lys Asp Asp Leu Asn Arg Leu His Thr Tyr 1550 1560 Asn Pro Val Glu Arg Phe Asp Ser Asp Glu Ala Leu Gln Ser Tyr 1565 1570 1575 Met His Gly Ser Tyr Asp Val Met Tyr Thr Leu Asp Ala Met Glu 1580 1590 Ala Lys Ala Ile Leu Ala Gln Asn Asn Asp Val Lys Lys Lys Trp 1595 1600 1605 Phe Arg Lys Ile Glu Asn Tyr Tyr Val Arg Asp Thr Arg His Asn 1610 1620 Lys Asp Thr His Ala Gly Asn Lys Val Arg Pro Leu Thr Asp Glu 1625 1630 1635 Glu Val Ala Asn Leu Thr Ser Leu Asn Ser Leu Ile Asp Asn Asp 1640 1650 Ile Ile Asn Arg Arg Ser Tyr Asp Asp Ser Arg Glu Tyr Lys Arg 1655 1665 Asn Gly Tyr Tyr Thr Ile Ser Met Phe Ser Pro Val Tyr Ala Ala 1670 1680 Leu Ser Asn Ser Lys Gly Ala Pro Gly Asp Ile Met Phe Arg Lys 1685 1690 1695 Ile Ala Tyr Glu Leu Leu Ala Glu Lys Gly Tyr His Lys Gly Phe 1700 1710 Leu Pro Tyr Val Ser Asn Gln Tyr Gly Ala Glu Ala Phe Ala Ser 1715 1720 1725

Gly Ser Lys Thr Phe Ser Ser Trp His Gly Arg Asp Val Ala Leu 1730 1740

Val Thr Asp Asp Leu Val Phe Lys Lys Val Phe Asn Gly Glu Tyr 1745 1755

Ser Ser Trp Ala Asp Phe Lys Lys Ala Met Phe Lys Gln Arg Ile 1760 1765

Asp Lys Gln Asp Asn Leu Lys Pro Ile Thr Ile Gln Tyr Glu Leu 1775 1785

Gly Asn Pro Asn Ser Thr Lys Glu Val Thr Ile Thr Thr Ala Ala 1790 1800

Gln Met Gln Gln Leu Ile Asn Glu Ala Ala Ala Lys Asp Ile Thr . 1805 1815

Asn Ile Asp Arg Ala Thr Ser His Thr Pro Ala Ser Trp Val His 1820 1830

Leu Leu Lys Gln Lys Ile Tyr Asn Ala Tyr Leu Arg Thr Thr Asp 1835 1840 1845

Asp Phe Arg Asn Ser Ile Tyr Lys 1850 1855

<210> 149

<211> 857

<212> PRT

<213> Streptococcus pneumoniae

<400> 149

Met Lys Phe Asn Pro Asn Gln Arg Tyr Thr Arg Trp Ser Ile Arg Arg 1 10 15

Leu Ser Val Gly Val Ala Ser Val Val Ala Ser Gly Phe Phe Val 20 25 30

Leu Val Gly Gln Pro Ser Ser Val Arg Ala Asp Gly Leu Asn Pro Thr 35 40 45

Pro Gly Gln Val Leu Pro Glu Glu Thr Ser Gly Thr Lys Glu Gly Asp 50 60

Leu Ser Glu Lys Pro Gly Asp Thr Val Leu Thr Glm Ala Lys Pro Glu 65 70 75 80 str pneumoniae patentin.ST25

Gly Val Thr Gly Asn Thr Asn Ser Leu Pro Thr Pro Thr Glu Arg Thr

85

90

95 Glu Val Ser Glu Glu Thr Ser Pro Ser Ser Leu Asp Thr Leu Phe Glu 100 105 110 . Lys Asp Glu Glu Ala Gln Lys Asn Pro Glu Leu Thr Asp Val Leu Lys Glu Thr Val Asp Thr Ala Asp Val Asp Gly Thr Gln Ala Ser Pro Ala 130 140 Glu Thr Thr Pro Glu Gln Val Lys Gly Gly Val Lys Glu Asn Thr Lys 155 160 Asp Ser Ile Asp Val Pro Ala Ala Tyr Leu Glu Lys Ala Glu Gly Lys 165 170 175 Gly Pro Phe Thr Ala Gly Val Asn Gln Val Ile Pro Tyr Glu Leu Phe 180 190 Ala Gly Asp Gly Met Leu Thr Arg Leu Leu Leu Lys Ala Ser Asp Asn 195 200 205 Ala Pro Trp Ser Asp Asn Gly Thr Ala Lys Asn Pro Ala Leu Pro Pro 210 215 220 Leu Glu Gly Leu Thr Lys Gly Lys Tyr Phe Tyr Glu Val Asp Leu Asn 225 230 240 Gly Asn Thr Val Gly Lys Gln Gly Gln Ala Leu Ile Asp Gln Leu Arg 245 250 255 Ala Asn Gly Thr Gln Thr Tyr Lys Ala Thr Val Lys Val Tyr Gly Asn 260 270 Lys Asp Gly Lys Ala Asp Leu Thr Asn Leu Val Ala Thr Lys Asn Val 275 280 285 Asp Ile Asn Ile Asn Gly Leu Val Ala Lys Glu Thr Val Gln Lys Ala 290 295 300 Val Ala Asp Asn Val Lys Asp Ser Ile Asp Val Pro Ala Ala Tyr Leu 305 310 315 320 Glu Lys Ala Lys Gly Glu Gly Pro Phe Thr Ala Gly Val Asn His Val 325 Ile Pro Tyr Glu Leu Phe Ala Gly Asp Gly Met Leu Thr Arg Leu Leu 340 350

str pneumoniae patentin.5T25 Leu Lys Ala Ser Asp Lys Ala Pro Trp Ser Asp Asn Gly Asp Ala Lys 355 360 365 Asn Pro Ala Leu Ser Pro Leu Gly Glu Asn Val Lys Thr Lys Gly Gln 370 380 Tyr Phe Tyr Gln Val Ala Leu Asp Gly Asn Val Ala Gly Lys Glu Lys 385 390 395 400 Gln Ala Leu Ile Asp Gln Phe Arg Ala Asn Gly Thr Gln Thr Tyr Ser 405 410 415 Ala Thr Val Asn Val Tyr Gly Asn Lys Asp Gly Lys Pro Asp Leu Asp 420 430 Asn Ile Val Ala Thr Lys Lys Val Thr Ile Asn Ile Asn Gly Leu Ile 435 440 445 Ser Lys Glu Thr Val Gln Lys Ala Val Ala Asp Asn Val Lys Asp Ser 450 460 Ile Asp Val Pro Ala Ala Tyr Leu Glu Lys Ala Lys Gly Glu Gly Pro 465 470 480 Phe Thr Ala Gly Val Asn His Val Ile Pro Tyr Glu Leu Phe Ala Gly 485 490 495 Asp Gly Met Leu Thr Arg Leu Leu Leu Lys Ala Ser Asp Lys Ala Pro 500 510 Trp Ser Asp Asn Gly Asp Ala Lys Asn Pro Ala Leu Ser Pro Leu Gly 515 Glu Asn Val Lys Thr Lys Gly Gln Tyr Phe Tyr Gln Leu Ala Leu Asp 530 540 Gly Asn Val Ala Gly Lys Glu Lys Gln Ala Leu Ile Asp Gln Phe Arg 545 550 555 Ala Asn Gly Thr Gln Thr Tyr Ser Ala Thr Val Asn Val Tyr Gly Asn 565 . 570 Lys Asp Gly Lys Pro Asp Leu Asp Asn Ile Val Ala Thr Lys Lys Val 580 590 Thr Ile Asn Ile Asn Gly Leu Ile Ser Lys Glu Thr Val Gln Lys Ala 595 600 605 Val Ala Asp Asn Val Lys Asp Ser Ile Asp Val Pro Ala Ala Tyr Leu 610 620

Ile Pro Tyr Glu Leu Phe Ala Gly Asp Gly Met Leu Thr Arg Leu Leu 645 655. Leu Lys Ala Ser Asp Lys Ala Pro Trp Ser Asp Asn Gly Asp Ala Lys
660 660 670 Asn Pro Ala Leu Ser Pro Leu Gly Glu Asn Val Lys Thr Lys Gly Gln 675 685 Tyr Phe Tyr Gln Val Ala Leu Asp Gly Asn Val Ala Gly Lys Glu Lys 690 700 Gln Ala Leu Ile Asp Gln Phe Arg Ala Asn Gly Thr Gln Thr Tyr Ser 705 710 715 720 Ala Thr Val Asn Val Tyr Gly Asn Lys Asp Gly Lys Pro Asp Leu Asp 725 730 735 Asn Ile Val Ala Thr Lys Lys Val Thr Ile Lys Ile Asn Val Lys Glu 740 745 750 Thr Ser Asp Thr Ala Asn Gly Ser Leu Ser Pro Ser Asn Ser Gly Ser 755 760 765 Gly Val Thr Pro Met Asn His Asn His Ala Thr Gly Thr Thr Asp Ser 770 780 Met Pro Ala Asp Thr Met Thr Ser Ser Thr Asn Thr Met Ala Gly Glu 785 790 795 800 Asn Met Ala Ala Ser Ala Asn Lys Met Ser Asp Thr Met Met Ser Glu 805 810 815 Asp Lys Ala Met Leu Pro Asn Thr Gly Glu Thr Gln Thr Ser Met Ala 820 825 830 Ser Ile Gly Phe Leu Gly Leu Ala Leu Ala Gly Leu Leu Gly Gly Leu 835 840 845 Gly Leu Lys Asn Lys Lys Glu Glu Asn 850 855 <210> 150 <211> 195 <212>

Streptococcus pneumoniae

### str pneumoniae patentin.ST25

<400> 150

Met Lys Ser Ile Thr Lys Lys Ile Lys Ala Thr Leu Ala Gly Val Ala
10 15

Ala Leu Phe Ala Val Phe Ala Pro Ser Phe Val Ser Ala Gln Glu Ser 20 25 30

Ser Thr Tyr Thr Val Lys Glu Gly Asp Thr Leu Ser Glu Ile Ala Glu 35 40 45

Thr His Asn Thr Thr Val Glu Lys Leu Ala Glu Asn Asn His Ile Asp 50 60

Asn Ile His Leu Ile Tyr Val Asp Gln Glu Leu Val Ile Asp Gly Pro 65 70 75 80

Val Ala Pro Val Ala Thr Pro Ala Pro Ala Thr Tyr Ala Ala Pro Ala 85 90 95

Ala Gln Asp Glu Thr Val Ser Ala Pro Val Ala Glu Thr Pro Val Val 100 105 110

Ser Glu Thr Val Val Ser Thr Val Ser Gly Ser Glu Ala Glu Ala Lys 115 120 125

Glu Trp Ile Ala Gln Lys Glu Ser Gly Gly Ser Tyr Thr Ala Thr Asn 130 140

Gly Arg Tyr Ile Gly Arg Tyr Gln Leu Thr Asp Ser Tyr Leu Asn Gly 155 160

Asp Tyr Ser Ala Glu Asn Gln Glu Arg Val Ala Asp Ala Tyr Val Ala 165 170 175

Gly Arg Tyr Gly Ser Trp Thr Ala Ala Lys Asn Phe Trp Leu Asn Asn 180

Gly Trp Tyr 195

<210> 151

<211> 744

<212> PRT

<213> Streptococcus pneumoniae

<400> 151

str pneumoniae patentin.ST25

Met-Asn Lys-Lys-Met I le Leu Thr Ser-Leu Ala Ser Val Ala I le

1 15 Leu Gly Ala Gly Phe Val Thr Ser Gln Pro Thr Phe Val Arg Ala Glu 20 30 Glu Ser Pro Gln Val Val Glu Lys Ser Ser Leu Glu Lys Lys Tyr Glu Glu Ala Lys Ala Lys Ala Asp Thr Ala Lys Lys Asp Tyr Glu Thr Ala 50 60 Lys Lys Lys Ala Glu Asp Ala Gln Lys Lys Tyr Glu Asp Asp Gln Lys 65 70 75 80 Arg Thr Glu Glu Lys Ala Arg Lys Glu Ala Glu Ala Ser Gln Lys Leu 85 90 95 Asn Asp Val Ala Leu Val Val Gln Asn Ala Tyr Lys Glu Tyr Arg Glu 100 105 110 Val Gln Asn Gln Arg Ser Lys Tyr Lys Ser Asp Ala Glu Tyr Gln Lys 115 120 125 Lys Leu Thr Glu Val Asp Ser Lys Ile Glu Lys Ala Arg Lys Glu Gln 130 Gln Asp Leu Gln Asn Lys Phe Asn Glu Val Arg Ala Val Val Pro 145 150 160 Glu Pro Asn Ala Leu Ala Glu Thr Lys Lys Ala Glu Glu Ala Lys 165 170 175 Ala Glu Glu Lys Val Ala Lys Arg Lys Tyr Asp Tyr Ala Thr Leu Lys 180 185 Val Ala Leu Ala Lys Lys Glu Val Glu Ala Lys Glu Leu Glu Ile Glu 195 200 205 Lys Leu Gln Tyr Glu Ile Ser Thr Leu Glu Gln Glu Val Ala Thr Ala 210 215 220 Gln His Gln Val Asp Asn Leu Lys Lys Leu Leu Ala Gly Ala Asp Pro 230 235 240 Asp Asp Gly Thr Glu Val Ile Glu Ala Lys Leu Lys Lys Gly Glu Ala 245 250 255

Glu Leu Asn Ala Lys Gln Ala Glu Leu Ala Lys Lys Gln Thr Glu Leu 260 265 270

Glu Lys Leu Leu Asp Ser Leu Asp Pro Glu Gly Lys Thr Gln Asp Glu 275 280 285 Leu Asp Lys Glu Ala Glu Glu Ala Glu Leu Asp Lys Lys Ala Asp Glu 290 295 300 Leu Gln Asn Lys Val Ala Asp Leu Glu Lys Glu Ile Ser Asn Leu Glu 305 310 315 320 Ile Leu Leu Gly Gly Ala Asp Pro Glu Asp Asp Thr Ala Ala Leu Gln 325 330 335 Asn Lys Leu Ala Ala Lys Lys Ala Glu Leu Ala Lys Lys Gln Thr Glu 340 350 Leu Glu Lys Leu Leu Asp Ser Leu Asp Pro Glu Gly Lys Thr Gln Asp 355 360 365 Glu Leu Asp Lys Glu Ala Glu Glu Ala Glu Leu Asp Lys Lys Ala Asp 370 380 Glu Leu Gln Asn Lys Val Ala Asp Leu Glu Lys Glu Ile Ser Asn Leu 385 390 395 400 Glu Ile Leu Leu Gly Gly Ala Asp Ser Glu Asp Asp Thr Ala Ala Leu 405 410 415 Gln Asn Lys Leu Ala Thr Lys Lys Ala Glu Leu Glu Lys Thr Gln Lys 420 430 Glu Leu Asp Ala Ala Leu Asn Glu Leu Gly Pro Asp Gly Asp Glu Glu 435 Glu Thr Pro Ala Pro Ala Pro Glu Glu Glu Pro Ala Pro Ala Pro 450 455 Lys Pro Glu Gln Pro Ala Pro Ala Pro Lys Pro Glu Gln Pro Ala Pro 465 470 475 480 Ala Pro Lys Pro Glu Gln Pro Ala Pro Ala Pro Lys Pro Glu Gln Pro 485 490 495 Ala Pro Ala Pro Lys Pro Glu Gln Pro Ala Lys Pro Glu Lys Pro Ala 500 510 Glu Glu Pro Thr Gln Pro Glu Lys Pro Ala Thr Pro Lys Thr Gly Trp 515 525 Lys Gln Glu Asn Gly Met Trp Tyr Phe Tyr Asn Thr Asp Gly Ser Met 530 540

Asn Gly Ala Met Ala Thr Gly Trp Val Lys Asp Gly Asp Thr Trp Tyr 565 575 Tyr Leu Glu Ala Ser Gly Ala Met Lys Ala Ser Gln Trp Phe Lys Val Ser Asp Lys Trp Tyr Tyr Val Asn Ser Asn Gly Ala Met Ala Thr Gly 595 600 Trp Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Asp 610 620 Met Ala Thr Gly Trp Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn 625 630 640 Ala Asn Gly Asp Met Ala Thr Gly Trp Ala Lys Val Asn Gly Ser Trp 645 655 Tyr Tyr Leu Asn Ala Asn Gly Ala Met Ala Thr Gly Trp Ala Lys Val 660 665 670 Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ser Met Ala Thr Gly 675 680 Trp Val Lys Asp Gly Asp Thr Trp Tyr Tyr Leu Glu Ala Ser Gly Ala 690 695 Met Lys Ala Ser Gln Trp Phe Lys Val Ser Asp Lys Trp Tyr Tyr Val 705 710 715 720 Asn Gly Leu Gly Ala Leu Ala Val Asn Thr Thr Val Asp Gly Tyr Lys
725 730 735 Val Asn Ala Asn Gly Glu Trp Val 740 <210> 152 <211> 189 <212> PRT Streptococcus pneumoniae <400> 152 Met Lys Lys Ile Val Leu Val Ser Leu Ala Phe Leu Phe Val Leu Val . 10 15

str pneumoniae patentin.ST25 Gly Cys Gly Gln Lys Lys Glu Thr Gly Pro Ala Thr Lys Thr Glu Lys 20 25 30 Asp Thr Leu Gln Ser Ala Leu Pro Val Ile Glu Asn Ala Glu Lys Asn 40 45Thr Val Val Thr Lys Thr Leu Val Leu Pro Lys Ser Asp Asp Gly Ser 50Gln Gln Thr Gln Thr Ile Thr Tyr Lys Asp Lys Thr Phe Leu Ser Leu 65 70 75 80 Ala Ile Gln Gln Lys Arg Pro Val Ser Asp Glu Leu Lys Thr Tyr Ile 85 90 95 Asp Gln His Gly Val Glu Glu Thr Gln Lys Ala Leu Leu Glu Ala Glu 100 105 110 Glu Lys Asp Lys Ser Ile Ile Glu Ala Arg Lys Leu Ala Gly Phe Lys 115 120 125 Leu Glu Thr Lys Leu Leu Ser Ala Thr Glu Leu Gln Thr Thr Thr Ser 130 140 Phe Asp Phe Gln Val Leu Asp Val Lys Lys Ala Ser Gln Leu Glu His 145 150 155 160 Leu Lys Asn Ile Gly Leu Glu Asn Leu Leu Lys Asn Glu Pro Ser Lys 165 170 175 Tyr Ile Ser Asp Arg Leu Ala Asn Gly Ala Thr Glu Gln 180

<210> 153

<211> 416

<212> PRT

<213> Streptococcus pneumoniae

<400> 153

Met Phe Glu Val Glu Glu Trp Leu His Ser Arg Ile Gly Leu Asn Phe  $10^{\circ}$  .  $15^{\circ}$ 

Arg Ser Gly Leu Gly Arg Met Gln Gln Ala Val Asp Leu Leu Gly Asn 20 25 30

Pro Glu Gln Ser Tyr Pro Ile Ile His Val Thr Gly Thr Asn Gly Lys 35 40 45

Lys Val Ala Thr Phe Thr Ser Pro His Ile Val Ser Ile Asn Asp Arg 65 70 75 80 Ile Cys Ile Asn Gly Gln Pro Ile Ala Asp Ala Asp Phe Ile Arg Leu 85 90 95 Thr Asp Gln Val Lys Glu Met Glu Lys Thr Leu Leu Gln Thr Pro Ala 100 105 110 Gln Leu Ser Phe Phe Glu Leu Leu Thr Leu Val Ala Phe Leu Tyr Phe 115 120 125 Arg Glu Gln Glu Val Asp Leu Val Leu Leu Glu Val Gly Ile Gly Gly 130 140 Leu Leu Asp Thr Thr Asn Val Val Thr Gly Glu Phe Ala Val Ile Thr 145 150 160 Ser Ile Gly Leu Asp His Gln Glu Thr Leu Gly Asp Ser Leu Glu Ala 165 170 175 Ile Ala Glu Gln Lys Ala Gly Ile Phe Lys Ala Gly Lys Lys Ala Val 180 185 190 Ile Ala Lys Leu Pro Pro Glu Ala Arg Leu Ala Cys Gln Lys Lys Ala 195 200 205 Glu Ser Leu Ala Val Asn Leu Tyr Gln Ala Gly Gln Asp Phe Leu Met 210 215 220 Leu Asn Gly Asp Phe Ser Ser Ser Leu Leu Asn Leu Ser Gln Leu Asn 225 230 240 Ile Gly Leu Glu Gly Val Tyr Gln Gln Glu Asn Ala Ala Leu Ala Leu 245 250 255 Gln Thr Phe Leu Leu Phe Met Arg Glu Arg Lys Glu Ala Val Asp Glu 260 265 270 Gln Ala Val Arg Lys Ala Leu Glu Gln Thr His Trp Ala Gly Arg Leu 275 285 Glu Arg Ile Arg Pro Gln Ile Tyr Leu Asp Gly Ala His Asn Leu Pro 290 295 300 Ala Leu Thr Arg Leu Ala Glu Phe Ile Lys Glu Lys Glu Gln Glu Gly 305 310 315 320

Tyr Arg Pro Gln Ile Leu Phe Gly Ser Leu Lys Arg Lys Asp Tyr Gln 325 Leu Phe Gly Ser Leu Lys Arg Lys Asp Tyr Gln Gly Met Leu Gly Tyr Leu Thr Glu Lys Leu Pro Gln Val Glu Leu Lys Val Thr Gly Phe Asp Tyr Gln Gly Ala Leu Asp Glu Arg Asp Val Thr Gly Tyr Asp Ile Val Ser Ser Tyr Arg Glu Phe Ile Ser Asp Phe Glu Glu Arg Ala Asp Ala Gln Asp Leu Leu Phe Val Thr Gly Ser Leu Tyr 400

Phe Ile Ser Glu Val Arg Gly Tyr Leu Leu Asp Arg Glu Gln Ile Asn 405 410 415

<210> 154

<211> 277

<212> PRT

<213> Streptococcus pneumoniae

<400> 154

Val Gly Ile Arg Val Tyr Lys Pro Thr Thr Asn Gly Arg Arg Asn Met
1 10 15

Thr Ser Leu Asp Phe Ala Glu Ile Thr Thr Ser Thr Pro Glu Lys Ser 20 25 30

Leu Leu Val Ala Leu Lys Ser Lys Ala Gly Arg Asn Asn Gly Arg 35 40 45

Ile Thr Val Arg His Gln Gly Gly Gly His Lys Arg Phe Tyr Arg Leu 50 60

Val Asp Phe Lys Arg Asn Lys Asp Asn Val Glu Ala Val Val Lys Thr 65 70 75 80

Ile Glu Tyr Asp Pro Asn Arg Ser Ala Asn Ile Ala Leu Val His Tyr 85 90 95

Thr Asp Gly Val Lys Ala Tyr Ile Ile Ala Pro Lys Gly Leu Glu Val 100 105 110

Gly Gln Arg Ile Val Ser Gly Pro Glu Ala Asp Ile Lys Val Gly Asn 115 120 125

Glu Leu Lys Pro Gly Arg Gly Gly Glu Leu Val Arg Ala Ala Gly Ala 150 155 160 Ser Ala Gln Val Leu Gly Ser Glu Gly Lys Tyr Val Leu Val Arg Leu
175 Gln Ser Gly Glu Val Arg Met Ile Leu Gly Thr Cys Arg Ala Thr Val 180 185 190 Gly Val Val Gly Asn Glu Gln His Gly Leu Val Asn Leu Gly Lys Ala 195 200 205 Gly Arg Ser Arg Trp Lys Gly Ile Arg Pro Thr Val Arg Gly Ser Val 210 220 Met Asn Pro Asn Asp His Pro His Gly Gly Gly Glu Gly Lys Ala Pro 235 235 240 Val Gly Arg Lys Ala Pro Ser Thr Pro Trp Gly Lys Pro Ala Leu Gly 250 255 Leu Lys Thr Arg Asn Lys Lys Ala Lys Ser Asp Lys Leu Ile Val Arg 260 265 270 Arg Arg Asn Glu Lys 275 <210> 155 <211> 89 <212> PRT Streptococcus pneumoniae <400> 155 Met Ala Lys Lys Ser Met Val Ala Arg Glu Ala Lys Arg Gln Lys Ile 10 15 Val Asp Arg Tyr Ala Glu Lys Arg Ala Ala Leu Lys Ala Ala Gly Asp 20 25 30 Tyr Glu Gly Leu Ser Lys Leu Pro Arg Asn Ala Ser Pro Thr Arg Leu 35 40 45

His Asn Arg Cys Arg Val Thr Gly Arg Pro His Ser Val Tyr Arg Lys 50 60

Str pneumoniae patentin.ST25
Phe Gly Leu Ser Arg Ile Ala Phe Arg Glu Leu Ala His Lys Gly Gln
65 70 75 80

Ile Pro Gly Val Thr Lys Ala Ser Trp 85

<210> 156

<211> 445

<212> PRT

<213> Streptococcus pneumoniae

<400> 156

Met Asp Ile Arg Gln Val Thr Glu Thr Ile Ala Met Ile Glu Glu Gln 10 15

Asn Phe Asp Ile Arg Thr Ile Thr Met Gly Ile Ser Leu Leu Asp Cys 20 25 30

Ile Asp Pro Asp Ile Asn Arg Ala Ala Glu Lys Ile Tyr Gln Lys Ile 45

Thr Thr Lys Ala Ala Asn Leu Val Ala Val Gly Asp Glu Ile Ala Ala 50 55 60

Glu Leu Gly Ile Pro Ile Val Asn Lys Arg Val Ser Val Thr Pro Ile 65 70 75 80

Ser Leu Ile Gly Ala Ala Thr Asp Ala Thr Asp Tyr Val Val Leu Ala 85 90 95

Lys Ala Leu Asp Lys Ala Ala Lys Glu Ile Gly Val Asp Phe Ile Gly 100 105 110

Gly Phe Ser Ala Leu Val Gln Lys Gly Tyr Gln Lys Gly Asp Glu Ile 115 120 125

Leu Ile Asn Ser Ile Pro Arg Ala Leu Ala Glu Thr Asp Lys Val Cys 130 140

Ser Ser Val Asn Ile Gly Ser Thr Lys Ser Gly Ile Asn Met Thr Ala 145 150 155 160

Val Ala Asp Met Gly Arg Ile Ile Lys Glu Thr Ala Asn Leu Ser Asp 165 170 175

Met Gly Val Ala Lys Leu Val Val Phe Ala Asn Ala Val Glu Asp Asn 180 185 190

							S.	tr n	naum	onia	e na	tant	in c	T75		a garag
	Pro	_Phe	_Met 195	Alā	_G.l y.	Ala	Phe	_His 200	-Gly	_va l	_Gly	-Glu-	-Ala- 205	-Asp	-Va-1-	Ile-
	Ile	Asn 210	۷a٦	Gly	Val	Ser	Gly 215	Pro	Gly	Val.	Val	Lys 220	Arg	Ala	Leu	Glu
<b>-</b>	Lys -225-	Val	Arg	G]y	Gln	Ser -230-	Phe	Asp	Val	val	A1a 235	GJu	Thr	Val		Lys 240~
	Thr	Ala	Phe	Lys	11e 245	Thr	Arg	Ile	Glу	G]n 250	Leu	٧a٦	Gly	Gln	Met 255	Alа
	Ser	Glu	Arg	Leu 260	Gly	Val	Glu	Phe	Gly 265	Ile	va]	Asp	Leu	Ser 270	Leu	Ala
	Pro	Thr	Pro 275	Ala	٧a٦	G1y	Asp	Ser 280	٧a٦	Ala	Arg	٧a٦	Leu 285	Glu	Gไน	Met
	Gly	Leu 290	Glu	Thr	Va1	Gly	Thr 295	His	Gly	Thr	Thr	Ala 300	Ala	Leu	Ala	Leu
	Leu 305	Asn	Asp	Gln	٧a٦	Lys 310	Lys	Gly	GЛу	Val	Met 315	Ala	Cys	Asn	Gln	Va1 320
	Gly	Gly	Leu	.ser	Gly 325	Ala	Phe	Ile	Pro	Va1 330	Ser	Glu	Asp	Glu	G]y 335	Met
	Ile	Аla	Ala	Va7 340	Gln	Asn	Gly	Ser	Leu 345	Asn	Leu	Glu	Lys	Leu 350	Glu	Ala
	Met	Thr	A]a 355	Ile	Cys	Ser	Val	Gly 360	Leu	Asp	Met	Ile	A1a 365	Ile	Pro	Glu
	Asp	Thr 370	Pro	Ala	Glu	Thr	Ile 375	Ala	Ala	Met	Ile	Ala 380	Asp	Glu	Ala	Ala
	11e 385	Glу	val	Ile	Asn	Met 390	Lys	Thr	Thr	Ala	va1 395	Arg	Ile	Ile	Pro	Lys 400
	Gly	Lys	Glu	Gly	Asp 405	Met	Ile	Glu	Phe	Gly 410	G1y	Leu	Leu	Gly	Thr 415	Ala
	Pro	Val	Met	Lys 420	Val	Asn	Gly	Ala	Ser 425	Ser	٧a٦	Asp	Phe	Ile 430	Ser	Arg
	Glу	GТу	Gln 435	Ile	Pro	ΑΊа	Pro	Ile 440	His	Ser	Phe	Lys	Asn 445			
	<210	)> 1	L57													
	<211	> 8	312													

#### str pneumoniae patentin.ST25

<212> PRT

<213> Streptococcus pneumoniae

<400> 157

Met Val Asn Thr Glu Val Ala Arg Thr Thr Ile Lys Thr Glu Tyr Phe 10 15 15 Gly Ser Leu Thr Glu Arg Met Asn Lys Tyr Arg Glu Asp Val Leu Asn 20 25

Lys Lys Pro Tyr Ile Asp Ala Glu Arg Ala Val Leu Ala Thr Arg Ala 35 40 45

Tyr Glu Arg Tyr Lys Glu Gln Pro Asn Val Leu Lys Arg Ala Tyr Met 50 55 60

Leu Lys Glu Ile Leu Glu Asn Met Thr Ile Tyr Ile Glu Glu Glu Ser 65 70 75

Met Ile Ala Gly Asn Gln Ala Ser Ser Asn Lys Asp Ala Pro Ile Phe 85 90 95

Pro Glu Tyr Thr Leu Glu Phe Val Leu Asn Glu Leu Asp Leu Phe Glu 100 105 110

Lys Arg Asp Gly Asp Val Phe Tyr Ile Thr Glu Glu Thr Lys Glu Gln 115 120 125

Leu Arg Ser Ile Ala Pro Phe Trp Glu Asn Asn Leu Arg Ala Arg 130 140

Ala Gly Ala Leu Leu Pro Glu Glu Val Ser Val Tyr Met Glu Thr Gly 145 150 150

Phe Phe Gly Met Glu Gly Lys Met Asn Ser Gly Asp Ala His Leu Ala . 165 170 175

Val Asn Tyr Gln Lys Leu Leu Gln Phe Gly Leu Arg Gly Phe Glu Glu 180 185 190

Arg Ala Arg Lys Ala Lys Val Ala Leu Asp Leu Thr Asp Pro Ala Ser 195 200 205

Ile Asp Lys Tyr His Phe Tyr Asp Ser Ile Phe Ile Val Ile Asp Ala 210 215 220

Ile Lys Val Tyr Ala Lys Arg Phe Val Ala Leu Ala Lys Ser Leu Ala 225 230 235 240

	- 657	·	erika Li	5.1° <u>5</u>	,.	٠	S	tr p	neum	onia	epa	tent	in.s	T25.		
	G.I.U	∴AS⊓	A.I.a	ASN	P.P.O 245	-Lys	Arg	-Lys	-Lys	–G∄ս 250	–Leu	Leu	G∃u	I-Ì∙e	-Ala 255	-Asp-
	Ile	Cys	Ser	Arg 260	Val	Pro	Tyr	Glu	Pro 265	Ala	Thr	Thr	Phe	Ala 270		Аlа
4 CE, ferbusies,	Ile	Gln	Ser 275	Val	Trp	Phe	Ile	G]n ∵280	Cys	Ile	Leu	Gln	Ile 285	Glu	Ser	Asn
	G1y	His 290	Ser	Leu	Ser	Tyr	Gly 295	Arg	Phe	Asp	Gln	Tyr 300	Met	Tyr	Pro	Tyr
	Met 305	Lys	Ala	Asp	Leu	G]u 310	Ser	Gly	Lys	Glu	Thr 315	Glu	Asp	Ser	Ile	Va1 320
_	Glu	Arg	Leu	Thr	Asn 325	Leu	Trp	Ile	Lys	Thr 330	Ile	Thr	Ile	Asn	Lys 335	Val
	Arg	Ser	Gln	Ser 340	His	Thr	Phe	Ser	Ser 345	Ala	Gly	ser	Pro	Leu 350	Tyr	Gln
	Asn	val	Thr 355	Ile	Gly	GТу	Gln	Thr 360	Arg	Asp	Lys	Lys	Asp 365	Ala	Val	Asn
	Pro	Leu 370	Ser	Туг	Leu	val	Leu 375	Lys	Ser	Va1	Аlа	G]n 380	Thr	ніѕ	Leu	Pro
	G1n 385	Pro	Asn	Leu	Thr	va1 390	Arg	Tyr	His	Ala	G1y 395	Leu	Asp	Ala	Arg	Phe 400
	Met	As <b>n</b>	Glu	Cys	17e 405	Glu	val	Met	Lys	Leu 410	Gly	Phe	Gly	Met	Pro 415	Ala
•	Phe	Asn	Asn	Asp 420	Glu	Ile	Ile	Ile	Pro 425	Ser	Phe	Ile	Ala	Lys 430	Gly	Val
	Leu	Glu	Asp 435	Asp	ΑΊа	Tyr	Asp	Tyr 440	Ser	Ala	Ile	Gly	Cys 445	Val	Glu	Thr
	Аla	Va 1 450	Pro	Glу	Lys	Trp	G]y 455	Tyr	Arg	Cys	Thr	G]y 460	Met	Ser	Tyr	Met
	Asn 465	Phe	Pro	Lys	Va1	Leu 470	Leu	Ile	Thr	Met	Asn 475	Asp	GТу	Ile	Asp	Pro '
	Ala	Ser	GJy	Lys	Arg 485	Phe	Ala	Pro	ser	Phe 490	Gly	Arg	Phe	Lys	Asp 495	Met
	Lys	Asn .	Phe	ser 500	Glu	Leu	Glu	Asn	Ala 505	Trp	Asp	Lys	Thr	Leu 510	Arg	Tyr

str pneumoniae patentin.ST25 Leu Thr Arg Met Ser Val Ile Val Glu Asn Ser Ile Asp Leu Ser Leu 515 520 525 Glu Arg Glu Val Pro Asp Ile Leu Cys Ser Ala Leu Thr Asp Asp Cys 530 540 Ile Gly Arg Gly Lys His Leu Lys Glu Gly Gly Ala Val Tyr Asp Tyr 545 550 555 560 Ile Ser Gly Leu Gln Val Gly Ile Ala Asn Leu Ser Asp Ser Leu Ala 565 570 575 Ala Ile Lys Lys Leu Val Phe Glu Glu Glu Arg Ile Ser Pro Ser Gln 580 590 Leu Trp His Ala Leu Glu Thr Asp Tyr Ala Gly Glu Gly Lys Val 595 600 605 Ile Gln Glu Met Leu Ile His Asp Ala Pro Lys Tyr Gly Asn Asp Asp 610 620 Asp Tyr Ala Asp Lys Leu Val Thr Ala Ala Tyr Asp Ile Tyr Val Asp 625 630 635 Glu Ile Ala Lys Tyr Pro Asn Thr Arg Tyr Gly Arg Gly Pro Ile Gly 645 650 655 Gly Ile Arg Tyr Ser Gly Thr Ser Ser Ile Ser Ala Asn Val Gly Gln 660 665 Gly Arg Gly Thr Leu Ala Thr Pro Asp Gly Arg Asn Ala Gly Thr Pro 675 680 685 Leu Ala Glu Gly Cys Ser Pro Ser His Asn Met Asp Gln His Gly Pro 690 700 Thr Ser Val Leu Lys Ser Val Ser Lys Leu Pro Thr Asp Glu Ile Val 705 710 715 720 Gly Gly Val Leu Leu Asn Gln Lys Val Asn Pro Gln Thr Leu Ala Lys 725 730 735 Glu Glu Asp Lys Leu Lys Leu Ile Ala Leu Leu Arg Thr Phe Phe Asn 740 745 750 Arg Leu His Gly Tyr His Ile Gln Tyr Asn Val Val Ser Arg Glu Thr 755 760 765 Leu Ile Asp Ala Gln Lys His Pro Glu Lys His Arg Asp Leu Ile Val 770 780

str pneumoniae patentin.sT25
Arg Val Ala Gly Tyr Ser Ala Phe Phe Asn Val Leu Ser Lys Ala Thr
785
790
795
800

Gln Asp Asp Ile Ile Gly Arg Thr Glu His Thr Leu 805

<210> 158

<211> 130

<212> PRT

<213> Streptococcus pneumoniae

<400> 158

Met Ser Gln Ala Gln Tyr Ala Gly Thr Gly Arg Arg Lys Asn Ala Val 1 15

Ala Arg Val Arg Leu Val Pro Gly Thr Gly Lys Ile Thr Val Asn Lys 20 25 30

Lys Asp Val Glu Glu Tyr Ile Pro His Ala Asp Leu Arg Leu Val Ile 35 40 45

Asn Gln Pro Phe Ala Val Thr Ser Thr Val Gly Ser Tyr Asp Val Phe 50 60

Val Asn Val Ile Gly Gly Gly Tyr Ala Gly Gln Ser Gly Ala Ile Arg 65 70 75 80

His Gly Ile Ala Arg Ala Leu Leu Gln Val Asp Pro Asp Phe Arg Asp 90 95

Ser Leu Lys Arg Ala Gly Leu Leu Thr Arg Asp Ser Arg Lys Val Glu 100 100 110

Arg Lys Lys Pro Gly Leu Lys Lys Ala Arg Lys Ala Ser Gln Phe Ser 115

Lys Arg 130

<210> 159

<211> 333

<212> PRT

<213> Streptococcus pneumoniae

<400> 159

str pneumoniae patentin.ST25 Leu Glu Lys Lys Leu Thr Ile Lys Asp Ile Ala Glu Met Ala Gln Thr 1 5 10 15 Ser Lys Thr Thr Val Ser Phe Tyr Leu Asn Gly Lys Tyr Glu Lys Met 20 25 30 Ser Gln Glu Thr Arg Glu Lys Ile Glu Lys Val Ile His Glu Thr Asn
45 Tyr Lys Pro Ser Ile Val Ala Arg Ser Leu Asn Ser Lys Arg Thr Lys 50 60Leu Ile Gly Val Leu Ile Gly Asp Ile Thr Asn Ser Phe Ser Asn Gln 75 75 80 Ile Val Lys Gly Ile Glu Asp Ile Ala Ser Gln Asn Gly Tyr Gln Val 85 90 95 Met Ile Gly Asn Ser Asn Tyr Ser Gln Glu Ser Glu Asp Arg Tyr Ile 100 105 110 Glu Ser Met Leu Leu Gly Val Asp Gly Phe Ile Ile Gln Pro Thr 115 120 Ser Asn Phe Arg Lys Tyr Ser Arg Ile Ile Asp Glu Lys Lys Lys 130 140 Met Val Phe Phe Asp Ser Gln Leu Tyr Glu His Arg Thr Ser Trp Val 145 150 160 Lys Thr Asn Asn Tyr Asp Ala Val Tyr Asp Met Thr Gln Ser Cys Ile 165 170 Glu Lys Gly Tyr Glu His Phe Leu Leu Ile Thr Ala Asp Thr Ser Arg 180 185 190 Leu Ser Thr Arg Ile Glu Arg Ala Ser Gly Phe Val Asp Ala Leu Thr 195 200 205 Asp Ala Asn Met Arg His Ala Ser Leu Thr Ile Glu Asp Lys His Thr 210 220 Asn Leu Glu Gln Ile Lys Glu Phe Leu Gln Lys Glu Ile Asp Pro Asp 225 230 235 Glu Lys Thr Leu Val Phe Ile Pro Asn Cys Trp Ala Leu Pro Leu Val 245 250 255 Phe Thr Val Ile Lys Glu Leu Asn Tyr Asn Leu Pro Gln Val Gly Leu 260 265 270

str pneumoniae patentin.sT25

Tle-Gly Phe Asp Asm-Thr Glu Trp Thr Cys Phe Ser Ser Pro Ser Val

275

280

285

Ser Thr Leu Val Gln Pro Ser Phe Glu Glu Glu Gln Gln Ala Thr Lys 290 300

Ile Leu Ile Asp Gln Ile Glu Gly Arg Asn Gln Glu Glu Arg Gln Gln 305\_\_\_\_\_310 .\_\_\_\_320

Val Leu Asp Cys Ser Val Asn Trp Lys Glu Ser Thr Phe 325

<210> 160

<211> 1767

<212> PRT

<213> Streptococcus pneumoniae

<400> 160

Met Asn Lys Gly Leu Phe Glu Lys Arg Cys Lys Tyr Ser Ile Arg Lys 10 15

Phe Ser Leu Gly Val Ala Ser Val Met Ile Gly Ala Ala Phe Phe Gly 20 25 30

Thr Ser Pro Val Leu Ala Asp Ser Val Gln Ser Gly Ser Thr Ala Asn 35 40 45

Leu Pro Ala Asp Leu Ala Thr Ala Leu Ala Thr Ala Lys Glu Asn Asp 50 60

Gly Arg Asp Phe Glu Ala Pro Lys Val Gly Glu Asp Gln Gly Ser Pro 65 70 75 80

Glu Val Thr Asp Gly Pro Lys Thr Glu Glu Glu Leu Leu Ala Leu Glu 85 90 95

Lys Glu Lys Pro Ala Glu Glu Lys Pro Lys Glu Asp Lys Pro Ala Ala 100 105 110

Ala Lys Pro Glu Thr Pro Lys Thr Val Thr Pro Glu Trp Gln Thr Val 115 120 125

Ala Asn Lys Glu Gln Gln Gly Thr Val Thr Ile Arg Glu Glu Lys Gly 130

Val Arg Tyr Asn Gln Leu Ser Ser Thr Ala Gln Asn Asp Asn Ala Gly 150 155 160

str pneumoniae patentin.ST25 Lys Pro Ala Leu Phe Glu Lys Lys Gly Leu Thr Val Asp Ala Asn Gly 165 170 175 Asn Ala Thr Val Asp Leu Thr Phe Lys Asp Asp Ser Glu Lys Gly Lys
180
185 Ser Arg Phe Gly Val Phe Leu Lys Phe Lys Asp Thr Lys Asn Asn Val Phe Val Gly Tyr Asp Lys Asp Gly Trp Phe Trp Glu Tyr Lys Ser Pro 210 220 Thr Thr Ser Thr Trp Tyr Arg Gly Ser Arg Val Ala Ala Pro Glu Thr 225 230 . 235 Gly Ser Thr Asn Arg Leu Ser Ile Thr Leu Lys Ser Asp Gly Gln Leu 245 250 255 Asn Ala Ser Asn Asn Asp Val Asn Leu Phe Asp Thr Val Thr Leu Pro 260 265 270 Ala Ala Val Asn Asp His Leu Lys Asn Glu Lys Lys Ile Leu Leu Lys 275 280 285 Ala Gly Ser Tyr Asp Asp Glu Arg Thr Val Val Ser Val Lys Thr Asp 290 295 Asn Gln Glu Gly Val Lys Thr Glu Asp Thr Pro Ala Glu Lys Glu Thr 305 310 315 320 Gly Pro Glu Val Asp Asp Ser Lys Val Thr Tyr Asp Thr Ile Gln Ser 325 330 335 Lys Val Leu Lys Ala Val Ile Asp Gln Ala Phe Pro Arg Val Lys Glu 340 345 350 Tyr Ser Leu Asn Gly His Thr Leu Pro Gly Gln Val Gln Gln Phe Asn 355 360 Gln Val Phe Ile Asn Asn His Arg Ile Thr Pro Glu Val Thr Tyr Lys 370 380 Lys Ile Asn Glu Thr Thr Ala Glu Tyr Leu Met Lys Leu Arg Asp Asp 385 400 Ala His Leu Ile Asn Ala Glu Met Thr Val Arg Leu Gln Val Val Asp 405 410 415 Asn Gln Leu His Phe Asp Val Thr Lys Ile Val Asn His Asn Gln Val 420 430

Ser Phe Leu Gly Asn Ala Leu Val Ser Val Ser Ser Asn Gln Thr Gly 450 460 Asp Asp His Ile Asp Val Thr Asn Pro Met Lys Asp Leu Ala Lys Gly
485 490 495 Tyr Met Tyr Gly Phe Val Ser Thr Asp Lys Leu Ala Ala Gly Val Trp 500 510 Ser Asn Ser Gln Asn Ser Tyr Gly Gly Gly Ser Asn Asp Trp Thr Arg 515 Leu Thr Ala Tyr Lys Glu Thr Val Gly Asn Ala Asn Tyr Val Gly Ile 530 540 His Ser Ser Glu Trp Gln Trp Glu Lys Ala Tyr Lys Gly Ile Val Phe 545 550 560 Pro Glu Tyr Thr Lys Glu Leu Pro Ser Ala Lys Val Val Ile Thr Glu 565 570 575 Asp Ala Asn Ala Asp Lys Asn Val Asp Trp Gln Asp Gly Ala Ile Ala 580 . 585 . 590 Tyr Arg Ser Ile Met Asn Asn Pro Gln Gly Trp Glu Lys Val Lys Asp 595 600 Ile Thr Ala Tyr Arg Ile Ala Met Asn Phe Gly Ser Gln Ala Gln Asn 610 620 Pro Phe Leu Met Thr Leu Asp Gly Ile Lys Lys Ile Asn Leu His Thr 625 630 640 Asp Gly Leu Gly Gln Gly Val Leu Leu Lys Gly Tyr Gly Ser Glu Gly 645 655 His Asp Ser Gly His Leu Asn Tyr Ala Asp Ile Gly Lys Arg Ile Gly 660 665 Gly Val Glu Asp Phe Lys Thr Leu Ile Glu Lys Ala Lys Lys Tyr Gly 675 685 Ala His Leu Gly Ile His Val Asn Ala Ser Glu Thr Tyr Pro Glu Ser 690 700

str pneumoniae patentin.ST25
Lys Tyr Phe Asn Glu Lys Ile Leu Arg Lys Asn Pro Asp Gly Ser Tyr
705 710 715 720 Ser Tyr Gly Trp Asn Trp Leu Asp Gln Gly Ile Asn Ile Asp Ala Ala 725 730 735 Tyr Asp Leu Ala His Gly Arg Leu Ala Arg Trp Glu Asp Leu Lys Lys 740 745 750 Lys Leu Gly Asp Gly Leu Asp Phe Ile Tyr Val Asp Val Trp Gly Asn 755 760 765 Gly Gln Ser Gly Asp Asn Gly Ala Trp Ala Thr His Val Leu Ala Lys 770 780 Glu Ile Asn Lys Gln Gly Trp Arg Phe Ala Ile Glu Trp Gly His Gly 785 790 795 800 Gly Glu Tyr Asp Ser Thr Phe His His Trp Ala Ala Asp Leu Thr Tyr 805 810 815 Gly Gly Tyr Thr Asn Lys Gly Ile Asn Ser Ala Ile Thr Arg Phe Ile 820 825 Arg Asn His Gln Lys Asp Ala Trp Val Gly Asp Tyr Arg Ser Tyr Gly 835 840 845 Gly Ala Ala Asn Tyr Pro Leu Leu Gly Gly Tyr Ser Met Lys Asp Phe 850 860 Glu Gly Trp Gln Gly Arg Ser Asp Tyr Asn Gly Tyr Val Thr Asn Leu 865 870 875 Phe Ala His Asp Val Met Thr Lys Tyr Phe Gln His Phe Thr Val Ser 885 890 895 Lys Trp Glu Asn Gly Thr Pro Val Thr Met Thr Asp Asn Gly Ser Thr  $900 \hspace{1.5cm} 905 \hspace{1.5cm} 910$ Tyr Lys Trp Thr Pro Glu Met Arg Val Glu Leu Val Asp Ala Asp Asn 915 920 925 Asn Lys Val Val Val Thr Arg Lys Ser Asn Asp Val Asn Ser Pro Gln 930 940 Tyr Arg Glu Arg Thr Val Thr Leu Asn Gly Arg Val Ile Gln Asp Gly 945 955 960 Ser Ala Tyr Leu Thr Pro Trp Asn Trp Asp Ala Asn Gly Lys Lys Leu 965 970 975

## 

Thr Thr Trp Thr Leu Pro Ser Asp Trp Ala Lys Ser Lys Val Tyr Leu 995 1000

Tyr Lys Leu Thr Asp Gln Gly Lys Thr Glu Glu Gln Glu Leu Thr
1010 1020

Val Lys Asp Gly Lys Ile Thr Leu Asp Leu Leu Ala Asn Gln Pro 1025 1035

Tyr Val Leu Tyr Arg Ser Lys Gln Thr Asn Pro Glu Met Ser Trp 1040 1045

Ser Glu Gly Met His Ile Tyr Asp Gln Gly Phe Asn Ser Gly Thr 1055 1060

Leu Lys His Trp Thr Ile Ser Gly Asp Ala Ser Lys Ala Glu Ile 1070 1080

Val Lys Ser Gln Gly Ala Asn Asp Met Leu Arg Ile Gln Gly Asn 1085 1095

Lys Glu Lys Val Ser Leu Thr Gln Lys Leu Thr Gly Leu Lys Pro 1100 1110

Asn Thr Lys Tyr Ala Val Tyr Val Gly Val Asp Asn Arg Ser Asn 1115 1125

Ala Lys Ala Ser Ile Thr Val Asn Thr Gly Glu Lys Glu Val Thr 1130 1140

Thr Tyr Thr Asn Lys Ser Leu Ala Leu Asn Tyr Val Lys Ala Tyr 1145 1155

Ala His Asn Thr Arg Arg Asp Asn Ala Thr Val Asp Asp Thr Ser 1160 1165 1170

Tyr Phe Gln Asn Met Tyr Ala Phe Phe Thr Thr Gly Ala Asp Val 1175 1180 1185

Ser Asn Val Thr Leu Thr Leu Ser Arg Glu Ala Gly Asp Gln Ala 1190 1200

Thr Tyr Phe Asp Glu Ile Arg Thr Phe Glu Asn Asn Ser Ser Met 1205 1215

Tyr Gly Asp Lys His Asp Thr Gly Lys Gly Thr Phe Lys Gln Asp 1220 1230 str pneumoniae patentin.ST25
Phe Glu Asn Val Ala Gln Gly Ile Phe Pro Phe Val Val Gly Gly
1235 1240 1245 Val Glu Gly Val Glu Asp Asn Arg Thr His Leu Ser Glu Lys His 1250 . 1260 Asn Pro Tyr Thr Gln Arg Gly Trp Asn Gly Lys Lys Val Asp Asp 1265 1270 Val Ile Glu Gly Asn Trp Ser Leu Lys Thr Asn Gly Leu Val Ser 1280 1290 Arg Arg Asn Leu Val Tyr Gln Thr Ile Pro Gln Asn Phe Arg Phe 1295 1300 1305 Glu Ala Gly Lys Thr Tyr Arg Val Thr Phe Glu Tyr Glu Ala Gly 1310 1320 Ser Asp Asn Thr Tyr Ala Phe Val Val Gly Lys Gly Glu Phe Gln 1325 1330 1335 Ser Gly Arg Arg Gly Thr Gln Ala Ser Asn Leu Glu Met His Glu 1340 1350 Leu Pro Asn Thr Trp Thr Asp Ser Lys Lys Ala Lys Lys Ala Thr 1355 1360 1365 Phe Leu Val Thr Gly Ala Glu Thr Gly Asp Thr Trp Val Gly Ile 1370 1380 Tyr Ser Thr Gly Asn Ala Ser Asn Thr Arg Gly Asp Ser Gly Gly 1385 Asn Ala Asn Phe Arg Gly Tyr Asn Asp Phe Met Met Asp Asn Leu 1400 1405 1410 Gln Ile Glu Glu Ile Thr Leu Thr Gly Lys Met Leu Thr Glu Asn 1420 1425 Ala Leu Lys Asn Tyr Leu Pro Thr Val Ala Met Thr Asn Tyr Thr 1430 1440 Lys Glu Ser Met Asp Ala Leu Lys Glu Ala Val Phe Asn Leu Ser 1445 1455 Gln Ala Asp Asp Asp Ile Ser Val Glu Glu Ala Arg Ala Glu Ile 1460 1465 1470 Ala Lys Ile Glu Ala Leu Lys Asn Ala Leu Val Gln Lys Lys Thr 1475 1480 1485

Page 155

							•							-	
4.	Ala	Leu.	Va	l. Ala	⊾Asp	·Asp				niae '∵Leu	pato ⊩∸Thi	entin ~~∆la-	ST2	5 5~ A-3	a⁻ Gl'n
		1490	9				-1495	;				<del>-1</del> 500	)	Ale	3_GIII_
	Ala	150	G]ı S	ı Gly	' Leu	Аlа	Asn 1510	Ala )	Phe	: Asp	(FD o	/ Asn 1515	∨a⊺	Sei	Ser
	Leu	152(	His	Thr	ser	Trp	Asn 1525	Gly	Gly	Asp	Val	Gly 1530	Lys	.Pro	Ala
	Thr	Met 1535	Val	Leu	Lys	Glu	Pro 1540	Thr	Glu	Ile	Thr	Gly 1545	Leu	ı Arg	ı Tyr
	٧a٦	Pro 1550	Arg	Gly	Ser	Gly	Ser 1555	Asn	Gly	Asn	Leu	Arg 1560	Asp	Va]	Lys
	Leu	val 1565	Val	Thr	Asp	Glu	Ser 1570	Gly	Lys	Glu	His	Thr 1575	Phe	Thr	Ala
	Thr	Asp 1580	Trp	Pro	Asn	Asn	Asn 1585	Lys	Pro	Lys	Asp	11e 1590	Asp	Phe	Gly
	Lys	Thr 1595	Ile	Lys	Ala	Lys	Lys 1600	Ile	Val	Leu	Thr	Gly 1605	Thr	Lys	Thr
	Tyr	Gly 1610	Asp	Gly	Gly	Asp	Lys 1615	Tyr	G]n	Ser	Αla	Ala 1620	Glu	Leu	Ile
	Phe	Thr 1625	Arg	Pro	Gln	٧a٦	Ala 1630	Glu	Thr	Pro	Leu	Asp 1635	Leu	Ser	Gly
	Tyr	Glu 1640	Ala	Ala	Leu	Val	Lys 1645	Ala	Gln	Lys	Leu	Thr 1650	Asp	Lys	Asp
	Asn	G]n 1655	Glu	Glu	Val	Ala	Ser 1660	va1	Gln	Ala	Ser	Met 1665	Lys	Tyr	Ala
	Thr	Asp 1670	Asn	His	Leu	Leu	Thr 1675	Glu	Arg	Met	۷a٦	G7u 1680	Tyr	Phe	Ala
	Asp	Tyr 1685	Leu	Asn	Gln	Leu	Lys 1690	Asp	ser	Ala	Thr	Lys 1695	Pro	Asp	Ala
	Pro	Thr 1700	Val <sub>.</sub>	Glu	Lys	Pro	Glu 1705	Phe	Lys	Leu	Arg	Ser 1710	Leu	Ala	Ser
	Glu	G]n 1715	Gly	Lys	Thr	Pro	Asp 1720	Tyr	Lys	Gln	Glu	Ile 1725	Ala	Arg	Pro
	Glu	Thr 1730	Pro	Glu.	G]n	Ile.	Leu 1735	Pro .	Ala	Thr	Gly	Glu 1740	Ser <sub>.</sub>	Gln	Ser

Asp Thr Ala Leu Ile Leu Ala Ser Val Ser Leu Ala Leu Ser Ala 1745 1750 1755

Leu Phe Val Val Lys Thr Lys Lys Asp 1760 1765

<210> 161

<211> 719

<212> PRT

<213> Streptococcus pneumoniae

<400> 161

Met Asn Lys Pro Thr Ile Leu Arg Leu Ile Lys Tyr Leu Ser Ile Ser 10 15

Phe Leu Ser Leu Val Ile Ala Ala Ile Val Leu Gly Gly Val Phe  $20 \ 25 \ 30$ 

Phe Tyr Tyr Val Ser Lys Ala Pro Ser Leu Ser Glu Ser Lys Leu Val

Ala Thr Thr Ser Ser Lys Ile Tyr Asp Asn Lys Asn Gln Leu Ile Ala 50 60

Asp Leu Gly Ser Glu Arg Arg Val Asn Ala Gln Ala Asn Asp Ile Pro 65 75 80

Thr Asp Leu Val Lys Ala Ile Val Ser Ile Glu Asp His Arg Phe Phe 85 90 95

Asp His Arg Gly Ile Asp Thr Ile Arg Ile Leu Gly Ala Phe Leu Arg 100 105 110

Asn Leu Gln Ser Asn Ser Leu Gln Gly Gly Ser Thr Leu Thr Gln Gln 115 125

Leu Ile Lys Leu Thr Tyr Phe Ser Thr Ser Thr Ser Asp Gln Thr Ile 130 140

Ser Arg Lys Ala Gln Glu Ala Trp Leu Ala Ile Gln Leu Glu Gln Lys 150 155 160

Ala Thr Lys Gln Glu Ile Leu Thr Tyr Tyr Ile Asn Lys Val Tyr Met 165 170 175

Ser Asn Gly Asn Tyr Gly Met Gln Thr Ala Ala Gln Asn Tyr Tyr Gly 180 180

						_									
 -Lys	Asp	)₌.Leu	l.₌Asn	Asn	Leu	s ∙Ser	tr p	neun -Pro	non 1 a ) - G ] r	ae pa i~l-eu	itent L Ala	in.S	ST25	::.Λ-7. <b>-</b> .π	-Gly-
 		195	; <del></del>				-200					205	Lea	Ala	-Gry
Met	210	G]n	. А]а	Pro	Asn	G]n 215	Tyr	Asp	Pro	Tyr	Ser 220	His	Pro	Glu	Ala
 Ala 225	Gln	Asp	Arg	Arg	Asn 230	Leu	va1	Leu	Ser	Glu 235	Met	Lys	Asn	Gln	G]y _240
Tyr	Ile	. Ser	Ala				Glu			. Val			Pro	Ile 255	Thr
Asp	Gly	Leu	G]n 260	Ser	Leu	Lys	Ser	Ala 265	Ser	Asn	Tyr	Pro	A]a 270	Tyr	Met
Asp	Asn	Tyr 275	Leu	Lys	Glu	۷a٦	Ile 280	Asn	Gln	Val	Glu	G1u 285	Glu	Thr	Gly
Tyr	Asn 290	Leu	Leu	Thr	Thr	G7y 295	Met	Asp	val	Tyr	Thr 300	Asn	Val	Asp	Gln
Glu 305	ΑΊа	Gln	Lys	His	Leu 310	Тгр	Asp	Ile	Tyr	Asn 315	Thr	Asp	Glu	Tyr	Va1 320
Ala	Туг	Pro	Asp	Asp 325	Glu	Leu	Gln	٧a٦	A7a 330	Ser	Thr	Ile	Val	Asp 335	val
Ser	Asn	GТу	Lys 340	Val	Ile	Ala	Gln	Leu 345	Gly	Ala	Arg	His	G]n 350	Ser	Ser
Asn	Val	Ser 355	Phe	Gly	Ile	Asn	G]n 360	Ala	Val	Glu	Thr	Asn 365	Arg	Asp	Trp
Gly	Ser 370	Thr	Met	Lys	Pro	11e 375	Thr	Asp	Туг	Ala	Pro 380	Ala	Leu	Glu	Tyr
G]y 385	val ·	Tyr	Asp	Ser	Thr 390	Ala	Thr	Ile	Va]	His 395	Asp	Glu	Pro	Tyr	Asn 400
Tyr	Pro	Gly	Thr	Asn 405	Thr	Pro	۷a٦	Tyr	Asn 410	Trp	Asp	Arg	Gly	Tyr 415	Phe
Gly	Asn	Ile	Thr 420	Leu	Gln	Tyr	Ala	Leu 425	Gln	Gln	Ser	Arg	Asn 430	Val	Pro
Αla	Val	G]u 435	Thr	Leu	Asn	Lys	Va1 440	Gไу	Leu	Asn	Arg	Ala 445	Lys	Thr	Phe
Leu	Asn 450	Gly	Leu	G.Ì y	Ile	Asp 455	Tyr	Pro	Ser.	Ile	ніs 460	Tyr	Ser	Asn	Ala

str pneumoniae patentin.ST25 Ile Ser Ser Asn Thr Thr Glu Ser Asp Lys Lys Tyr Gly Ala Ser Ser 465 470 475 480 Glu Lys Met Ala Ala Ala Tyr Ala Ala Phe Ala Asn Gly Gly Thr Tyr 485 490 495 Tyr Lys Pro Met Tyr Ile His Lys Val Val Phe Ser Asp Gly Ser Glu 500 505 510 Lys Glu Phe Ser Asn Val Gly Thr Arg Ala Met Lys Glu Thr Thr Ala 515 520 525 Tyr Met Met Thr Asp Met Met Lys Thr Val Leu Thr Tyr Gly Thr Gly 530 540 Arg Asn Ala Tyr Leu Ala Trp Leu Pro Gln Ala Gly Lys Thr Gly Thr 545 550 560 Ser Asn Tyr Thr Asp Glu Glu Ile Glu Asn His Ile Lys Thr Ser Gln 565 570 575 Phe Val Ala Pro Asp Glu Leu Phe Ala Gly Tyr Thr Arg Lys Tyr Ser 580 590 Met Ala Val Trp Thr Gly Tyr Ser Asn Arg Leu Thr Pro Leu Val Gly 595 600 605 Asn Gly Leu Thr Val Ala Ala Lys Val Tyr Arg Ser Met Met Thr Tyr 610 620 Leu Ser Glu Gly Ser Asn Pro Glu Asp Trp Asn Ile Pro Glu Gly Leu 625 630 640 Tyr Arg Asn Gly Glu Phe Val Phe Lys Asn Gly Ala Arg Ser Thr Trp 645 650 655 Asn Ser Pro Ala Pro Gln Gln Pro Pro Ser Thr Glu Ser Ser Ser Ser 660 665 670 Ser Ser Asp Ser Ser Thr Ser Gln Ser Ser Ser Thr Thr Pro Ser Thr 675 680 685 Asn Asn Ser Thr Thr Asn Pro Asn Asn Asn Thr Gln Gln Ser Asn 690 700 Thr Thr Pro Asp Gln Gln Asn Gln Asn Pro Gln Pro Ala Gln Pro 705 715 <210> 162 <211> 464

Page 159

## <213> Streptococcus pneumoniae

<400> 162

Met Ser Lys Lys Arg Arg Asn Arg His Lys Lys Glu Gly Gln Glu Pro

Gln Phe Asp Phe Asp Glu Ala Lys Glu Leu Thr Val Gly Gln Ala Ile 20 25 30

Arg Lys Asn Glu Glu Val Glu Ser Gly Val Leu Pro Glu Asp Ser Ile 35 40 45

Leu Asp Lys Tyr Val Lys Gln His Arg Asp Glu Ile Glu Ala Asp Lys 50 60

Phe Ala Thr Arg Gln Tyr Lys Lys Glu Glu Phe Val Glu Thr Gln Ser 75

Leu Asp Asp Leu Ile Gln Glu Met Arg Glu Ala Val Glu Lys Ser Glu 85 90 95

Ala Ser Ser Glu Glu Val Pro Ser Ser Glu Asp Ile Leu Leu Pro Leu 100 105 110

Pro Leu Asp Asp Glu Glu Gln Gly Leu Asp Pro Leu Leu Leu Asp Asp 115 120 125

Glu Asn Pro Thr Glu Met Thr Glu Glu Val Glu Glu Glu Gln Asn Leu 130 140

Ser Arg Leu Asp Gln Glu Asp Ser Glu Lys Lys Ser Lys Lys Gly Phe 150

Ile Leu Thr Val Leu Ala Leu Val Ser Val Ile Ile Cys Val Ser Ala 165 170 175

Tyr Tyr Val Tyr Arg Gln Val Ala Arg Ser Thr Lys Glu Ile Glu Thr 180 185 190

Ser Gln Ser Thr Thr Ala Asn Gln Ser Asp Val Asp Asp Phe Asn Thr 195 200 205

Leu Tyr Asp Ala Phe Tyr Thr Asp Ser Asn Lys Thr Ala Leu Lys Asn 210 220

Ser Gln Phe Asp Lys Leu Ser Gln Leu Lys Thr Leu Leu Asp Lys Leu 225 230 235 240 Glu Gly Ser Arg Glu His Thr Leu Ala Lys Ser Lys Tyr Asp Ser Leu 245 250 255 Ala Thr Gln Ile Lys Ala Ile Gln Asp Val Asn Ala Gln Phe Glu Lys 260 265 270 Pro Ala Ile Val Asp Gly Val Leu Asp Thr Asn Ala Lys Ala Lys Ser 275 280 285 Asp Ala Lys Phe Thr Asp Ile Lys Thr Gly Asn Thr Glu Leu Asp Lys 290 300 Val Leu Asp Lys Ala Ile Ser Leu Gly Lys Ser Gln Gln Thr Ser Thr 305 310 315 320 Ser Ser Ser Ser Ser Gln Thr Ser Ser Ser Ser Ser Gln Ala 325 330 335 Ser Ser Asn Thr Thr Ser Glu Pro Lys Pro Ser Ser Ser Asn Glu Thr 340 345 350 Arg Ser Ser Arg Ser Glu Val Asn Met Gly Leu Ser Ser Ala Gly Val 355 360 Ala Val Gln Arg Ser Ala Ser Arg Val Ala Tyr Asn Gln Ser Ala Ile 370 380 Asp Asp Ser Asn Asn Ser Ala Trp Asp Phe Ala Asp Gly Val Leu Glu 385 390 395 400 Gln Ile Leu Ala Thr Ser Arg Ser Arg Gly Tyr Ile Thr Gly Asp Gln 405 410 415 Tyr Ile Leu Glu Arg Val Asn Ile Val Asn Gly Asn Gly Tyr Tyr Asn 420 425 430 Leu Tyr Lys Pro Asp Gly Thr Tyr Leu Phe Thr Leu Asn Cys Lys Thr 435 440 Gly Tyr Phe Val Gly Asn Gly Ala Gly His Ala Asp Asp Leu Asp Tyr 450 460 <210> 163 <211> 340 <212> PRT

Page 161

<213>

<400>

163

Streptococcus pneumoniae

Arg Phe Val Asp Lys Asp Asn Arg Lys Tyr Tyr Val Lys Asp Asp His

Asp Ile Gly Glu Met Val Val Gly Trp Gln Tyr Leu Glu Ile Pro Gly 65 70 75 80

Lys Ala Ile Tyr Trp His Lys Ile Asp Gly Lys Thr Tyr Tyr Phe Gly 50 60

Thr Gly Tyr Arg Asp Asn Leu Phe Asp Asn Gln Pro Val Asn Glu Ile 85 90 95

Gly Leu Gln Glu Lys Trp Tyr Tyr Phe Gly Gln Asp Gly Ala Leu Leu 100 105 110

Glu Gln Thr Asp Lys Gln Val Leu Glu Ala Lys Thr Ser Glu Asn Thr 115 120 125

Gly Lys Val Tyr Gly Glu Gln Tyr Pro Leu Ser Ala Glu Lys Arg Thr 130 140

Tyr Tyr Phe Asp Asn Asn Tyr Ala Val Lys Thr Gly Trp Ile Tyr Glu 145 150 155

Glu Gly His Trp Tyr Tyr Leu Asn Lys Leu Gly Asn Phe Gly Asp Asp 165 170 175

Ser Tyr Asn Pro Leu Pro Ile Gly Glu Val Ala Lys Gly Trp Thr Gln 180 190

Asp Phe His Val Thr Ile Asp Ile Asp Arg Ser Lys Pro Ala Pro Trp 195 200 205

Tyr Tyr Leu Asp Ala Ser Gly Lys Met Leu Thr Asp Trp Gln Lys Val 210 220

Asn Gly Lys Trp Tyr Tyr Phe Gly Ser Ser Gly Ser Met Ala Thr Gly 225 230 235

Trp Lys Tyr Val Arg Gly Lys Trp Tyr Tyr Leu Asp Asn Lys Asn Gly 250 255

Asp Met Lys Thr Gly Trp Gln Tyr Leu Gly Asn Lys Trp Tyr Tyr Leu 260 265 270 str pneumoniae patentin.ST25

Arg Ser Ser Gly Ala Met Val Thr Gly Trp Tyr Gln Asp Gly Ser Thr
275

280

285

Trp Tyr Tyr Leu Asp Pro Ser Asn Gly Asp Met Lys Ile Gly Trp Thr 290 295 300

Lys Val Asn Gly Lys Trp Tyr Tyr Leu Asn Ser Asn Gly Ala Met Val 305 310 315

Thr Gly Ser Gln Thr Ile Asp Gly Lys Val Tyr Asn Phe Ala Ser Ser 325 330 335

Gly Glu Trp Ile 340

<210> 164

<211> 332

<212> PRT

<213> Streptococcus pneumoniae

<400> 164

Met Lys Ile Leu Lys Lys Thr Met Gln Val Gly Leu Thr Val Phe Phe 1 10 15

Phe Gly Leu Leu Gly Thr Ser Thr Val Phe Ala Asp Asp Ser Glu Gly 20 25 30

Trp Gln Phe Val Gln Glu Asn Gly Arg Thr Tyr Tyr Lys Lys Gly Asp 35 40 45

Leu Lys Glu Thr Tyr Trp Arg Val Ile Asp Gly Lys Tyr Tyr Phe  $50 ext{ } 60$ 

Asp Ser Leu Ser Gly Glu Met Val Val Gly Trp Gln Tyr Ile Pro Phe 65 70 75 80

Pro Ser Lys Gly Ser Thr Ile Gly Pro Tyr Pro Asn Gly Ile Arg Leu 85 90 95

Glu Gly Phe Pro Lys Ser Glu Trp Tyr Tyr Phe Asp Lys Asn Gly Val 100 105 110

Leu Glu Glu Phe Val Gly Trp Lys Thr Leu Glu Ile Lys Thr Lys Asp 115 120 125

Ser Val Gly Arg Lys Tyr Gly Glu Lys Arg Glu Asp Ser Glu Asp Lys

									•						•	
	~ഭിന്	· clo	Lve	· · A- Ñ a-	~~.i.i	1.1223	S	tr p	neum	onia	e pa	tent	in.s	T25	~	
	145	Giu		AI 9	<u>iyr</u>	150	TUL	ASI	<u> </u>	_i <u>yr</u>	155	_Asn	<u> </u>	Asn	His	ser_ 160
	Leu	Glu	Thr	Gly	Trp 165	Leu	Tyr	Asp	GÌn	Ser 170	Asn	Trp	Tyr	Туг	Leu 175	Ala
	Lys	Thr	Glu	17e 180	Asn	.Gly 	Glu	Asn	Tyr -185	Leu	Gly	Gly	Glu · ·	Arg -190		Ala
	Gly	Тгр	Ile 195	Asn	Asp	Asp	Ser	Thr 200	Trp	Туг	Tyr	Leu	Asp 205	Pro	Thr	Thr
	Gly	Ile 210	Met	Gln	Thr	Gly	Trp 215	Gln	Туг	Leu	Gly	Asn 220	Lys	Тгр	туг	Tyr
	Leu 225	Arg	Ser	ser	Gly	Ala 230	Met	Ala	Thr	Gly	Trp 235	Tyr	Gln	Glu	Gไу	Thr 240
	Thr	Trp	туг	Tyr	Leu 245	Asp	His	Pro	Asn	Gly 250	Asp	Met	Lys	Thr	Gly 255	Тгр
	Gln	Asn	Leu	Gly 260	Asn	Lys	Trp	Туг	Tyr 265	Leu	Arg	ser	ser	Gไy 270	Ala	Met
	Ala	Thr	Gly 275	Trp	Tyr	Gln	Asp	Gly 280	Ser	Thr	Trp	Tyr	Tyr 285	Leu	Asn	Ala
	Gly	Asn 290	GТу	Asp	Met	Lys	Thr 295	Gly	Trp	Phe	Gln	Val 300	Asn	Gly	Asn	Trp
	Tyr 305	Туг	Аlа	Tyr	Ser	Ser 310	Gly	Ala	Leu	Ala	Val 315	Asn	Thr	Thr	۷a٦	Asp 320
	Gly	Tyr	ser	٧a٦	Asn 325	Tyr	Asn	GТу	Glu	Trp 330	٧a٦	Arg				
_	<210	)> :	<b>L</b> 65													
	<211	ر د حا	285													
	<212	2> i	PRT													
	<213	3> 5	Strep	toco	occus	pne	eumor	niae								
	<400	)> :	165													
	Met 1	٧a٦	Leu	Ser	Lys 5	Tyr	Tyr	Glу	val	Ala 10	Asp	G]y	Met	Asn	val 15	Glu
	Gly	Arg	Gly	5er 20	Ala.	Asn	Phe	Ile	Lys 25	Asp	Asņ	val	Leu	Ile 30	Thr	Ala

str pneumoniae patentin.ST25
Ala His Asn Tyr Tyr Arg His Asp Tyr Gly Lys Glu Ala Asp Asp Ile
35 40 45 Tyr Val Leu Pro Ala Val Ser Pro Ser Gln Glu Pro Phe Gly Lys Ile 50 60 Lys Val Lys Glu Val Arg Tyr Leu Lys Glu Phe Arg Asn Leu Asn Ser 65 70 75 80 Lys Asp Ala Arg Glu Tyr Asp Leu Ala Leu Leu Ile Leu Glu Glu Pro 85 90 95 Ile Gly Ala Lys Leu Gly Thr Leu Gly Leu Pro Thr Ser Gln Lys Asn 100 105 110 Leu Thr Gly Ile Thr Val Thr Ile Thr Gly Tyr Pro Ser Tyr Asn Phe 115 120 125 Lys Ile His Gln Met Tyr Thr Asp Lys Lys Gln Val Leu Ser Asp Asp 130 Gly Met Phe Leu Asp Tyr Gln Val Asp Thr Leu Glu Gly Ser Ser Gly 155 150 Ser Thr Val Tyr Asp Ala Ser His Arg Val Val Gly Val His Thr Leu 165 170 175 Gly Asp Gly Ala Asn Gln Ile Asn Ser Ala Val Lys Leu Asn Glu Arg 180 185 190 Asn Leu Pro Phe Ile Tyr Ser Val Leu Lys Gly Tyr Ser Leu Glu Gly 195 205 Trp Lys Lys Ile Asn Gly Ser Trp Tyr His Tyr Arg Gln His Asp Lys 210 220 Gln Thr Gly Trp Gln Glu Ile Asn Asp Thr Trp Tyr Tyr Leu Asp Ser 235 240 Ser Gly Lys Met Leu Thr Asp Trp Gln Lys Val Asn Gly Lys Trp Tyr 245 250 255 Tyr Leu Asn Ser Asn Gly Ala Met Val Thr Gly Ser Gln Thr Ile Asp 260 270 Gly Lys Val Tyr Asn Phe Ala Ser Ser Gly Glu Trp Ile 275 280 285 <210> 166 <211> 630

<213> Streptococcus pneumoniae

<400>

Leu Pro Leu Ser Val Phe Ala Ile Asp Phe Lys Ile Asn Ser Tyr Gln 20 25 30

Ile Vál Tyr Gln Phe Glu Glu Asp Phe Lys Gly Gln Ile Val Gly Leu 50 60

Gly Arg Ala Gly Lys Met Pro Ser Gly Phe Asp Ile Asp Pro His Pro 65 70 75 80

Lys Ile Gln Ala Ala Lys Asn Gly Ala Glu Leu Ala Asp Val Thr Ser 85 90 95

Glu Val Thr Glu Glu Ala Asp Gly Tyr Thr Val Arg Val Tyr Asn Pro 100 105 110

Gly Gln Glu Gly Asp Ile Val Glu Val Asp Leu Val Trp Asn Leu Lys 115 125

Asn Leu Leu Phe Leu Tyr Asp Asp Ile Ala Glu Leu Asn Trp Gln Pro 130 140

Leu Thr Asp Ser Ser Glu Ser Ile Glu Lys Phe Glu Phe His Val Arg 155 150 160

Gly Asp Lys Gly Ala Glu Lys Leu Phe Phe His Thr Gly Lys Leu Phe 165 170 175

Arg Glu Gly Thr Ile Glu Lys Ser Asn Leu Asp Tyr Thr Ile Arg Leu 180 185 190

Asp Asn Leu Pro Ala Lys Arg Gly Val Glu Leu His Ala Tyr Trp Pro 195 200 205

Arg Thr Asp Phe Ala Ser Ala Arg Asp Gln Gly Leu Lys Gly Asn Arg 210 220

Leu Glu Glu Phe Asn Lys Ile Glu Asp Ser Ile Val Arg Glu Lys Asp 225 230 240

str pneumoniae patentin.ST25
Gln Ser Lys Gln Leu Val Thr Trp Val Leu Pro Ser Ile Leu Ser Ile
245
250
255 Ser Leu Leu Ser Val Cys Phe Tyr Phe Ile Tyr Arg Arg Lys Thr 260 265 270 Thr Pro Ser Val Lys Tyr Ala Lys Asn His Arg Leu Tyr Glu Pro Pro 275 280 285 Met Glu Leu Glu Pro Met Val Leu Ser Glu Ala Val Tyr Ser Thr Ser 290 295 300 Leu Glu Glu Val Ser Pro Leu Val Lys Gly Ala Gly Lys Phe Thr Phe 305 310 315 320 Asp Gln Leu Ile Gln Ala Thr Leu Leu Asp Val Ile Asp Arg Gly Asn 325 330 335 Val Ser Ile Ile Ser Glu Gly Asp Ala Val Gly Leu Arg Leu Val Lys 340 345 350 Glu Asp Gly Leu Ser Ser Phe Glu Lys Asp Cys Leu Asn Leu Ala Phe 355 360 365 Ser Gly Lys Lys Glu Glu Thr Leu Ser Asn Leu Phe Ala Asp Tyr Lys 370 380 Val Ser Asp Ser Leu Tyr Arg Arg Ala Lys Val Ser Asp Glu Lys Arg 385 390 395 Ile Gln Ala Arg Gly Leu Gln Leu Lys Ser Ser Phe Glu Glu Val Leu 405 410 415 Asn Gln Met Gln Glu Gly Val Arg Lys Arg Val Ser Phe Trp Gly Leu 420 425 430 Pro Asp Tyr Tyr Arg Pro Leu Thr Gly Gly Glu Lys Ala Leu Gln Val Gly Met Gly Ala Leu Thr Ile Leu Pro Leu Phe Ile Gly Phe Gly Leu 450 460 Phe Leu Tyr Ser Leu Asp Val His Gly Tyr Leu Tyr Leu Pro Leu Pro 465 470 480 Ile Leu Gly Phe Leu Gly Leu Val Leu Ser Val Phe Tyr Tyr Trp Lys
485 490 495 Leu Arg Leu Asp Asn Arg Asp Gly Val Leu Asn Glu Ala Gly Ala Glu 500 505 510

str pneumoniae patentin.ST25 Val Tyr Tyr Leu Trp Thr Ser Phe Glu Asn Met Leu Arg Glu Tle Ala 515 520 525

Arg Leu Asp Gln Ala Glu Leu Glu Ser Ile Val Val Trp Asn Arg Leu 530 540

Met Lys Val His Gln Ile Gln Val Glu Asn Pro Asp Ile Asn Leu Tyr 565 570

Val Ala Tyr Gly Trp His Ser Thr Phe Tyr His Ser Thr Ala Gln Met 580 590

Ser His Tyr Ala Ser Val Ala Asn Thr Ala Ser Thr Tyr Ser Val Ser 595 600 605

Gly Ser Ile Gly Ala Phe 625 630

<210> 167

<211> 665

<212> PRT

<213> Streptococcus pneumoniae

<400> 167

Met Lys Ser Ile Asn Lys Phe Leu Thr Met Leu Ala Ala Leu Leu 10 15

Thr Ala Ser Ser Leu Phe Ser Ala Ala Thr Val Phe Ala Ala Gly Thr 20 25 30

Thr Thr Ser Val Thr Val His Lys Leu Leu Ala Thr Asp Gly Asp 35 40 45

Met Asp Lys Ile Ala Asn Glu Leu Glu Thr Gly Asn Tyr Ala Gly Asn 50 60

Lys Val Gly Val Leu Pro Ala Asn Ala Lys Glu Ile Ala Gly Val Met 65 70 75 80

Phe Val Trp Thr Asn Thr Asn Asn Glu Ile Ile Asp Glu Asn Gly Gln 85 90 95

Thr Leu Gly Val Asn Ile Asp Pro Gln Thr Phe Lys Leu Ser Gly Ala
100 105 110 Met Pro Ala Thr Ala Met Lys Lys Leu Thr Glu Ala Glu Gly Ala Lys 115 120 125 Phe Asn Thr Ala Asn Leu Pro Ala Ala Lys Tyr Lys Ile Tyr Glu Ile 130 140 His Ser Leu Ser Thr Tyr Val Gly Glu Asp Gly Ala Thr Leu Thr Gly 145 150 155 Ser Lys Ala Val Pro Ile Glu Ile Glu Leu Pro Leu Asn Asp Val Val 165 170 175 Asp Ala His Val Tyr Pro Lys Asm Thr Glu Ala Lys Pro Lys Ile Asp 180 185 190 Lys Asp Phe Lys Gly Lys Ala Asn Pro Asp Thr Pro Arg Val Asp Lys
195 200 205 Asp Thr Pro Val Asn His Gln Val Gly Asp Val Val Glu Tyr Glu Ile 210 220 Val Thr Lys Ile Pro Ala Leu Ala Asn Tyr Ala Thr Ala Asn Trp Ser 225 230 235 240 Asp Arg Met Thr Glu Gly Leu Ala Phe Asn Lys Gly Thr Val Lys Val 245 250 255 Thr Val Asp Asp Val Ala Leu Glu Ala Gly Asp Tyr Ala Leu Thr Glu 260 265 270 Val Ala Thr Gly Phe Asp Leu Lys Leu Thr Asp Ala Gly Leu Ala Lys 275 280 285 Val Asn Asp Gln Asn Ala Glu Lys Thr Val Lys Ile Thr Tyr Ser Ala 290 295 300 Thr Leu Asn Asp Lys Ala Ile Val Glu Val Pro Glu Ser Asn Asp Val 305 310 315 Thr Phe Asn Tyr Gly Asn Asn Pro Asp His Gly Asn Thr Pro Lys Pro 325 330 335 Asn Lys Pro Asn Glu Asn Gly Asp Leu Thr Leu Thr Lys Thr Trp Val 340 Asp Ala Thr Gly Ala Pro Ile Pro Ala Gly Ala Glu Ala Thr Phe Asp 355 360 365

str pneumoniae patentin.ST25 Val Ala Gly Ala Ala Ile Met Gly Ile Ala Val Tyr Ala Tyr Val Lys 645 650 655

Asn Asn Lys Asp Glu Asp Gln Leu Ala 660 665

<210> 168

<211> 279

<212> PRT

<213> Streptococcus pneumoniae

<400> 168

Met Ala Val Met Ala Tyr Pro Leu Val Ser Arg Leu Tyr Tyr Arg Val 10 15

Glu Ser Asn Gln Gln Ile Ala Asp Phe Asp Lys Glu Lys Ala Thr Leu 20 25 30

Asp Glu Ala Asp Ile Asp Glu Arg Met Lys Leu Ala Gln Ala Phe Asn . 35 40 45

Asp Ser Leu Asn Asn Val Val Ser Gly Asp Pro Trp Ser Glu Glu Met 50 60

Lys Lys Gly Arg Ala Glu Tyr Ala Arg Met Leu Glu Ile His Glu 65 70 75 80

Arg Met Gly His Val Glu Ile Pro Val Ile Asp Val Asp Leu Pro Val 85 90 95

Tyr Ala Gly Thr Ala Glu Glu Val Leu Gln Gln Gly Ala Gly His Leu 100 110

Glu Gly Thr Ser Leu Pro Ile Gly Gly Asn Ser Thr His Ala Val Ile 115 120 125

Thr Ala His Thr Gly Leu Pro Thr Ala Lys Met Phe Thr Asp Leu Thr 130 140

Lys Leu Lys Val Gly Asp Lys Phe Tyr Val His Asn Ile Lys Glu Val 145 150 160

Met Ala Tyr Gln Val Asp Gln Val Lys Val Ile Glu Pro Thr Asn Phe 165 170 175

Asp Asp Leu Leu Ile Val Pro Gly His Asp Tyr Val Thr Leu Leu Thr 180 185 190 -Cys-Thr-Pro-Tyr-Met-Ile Asn Thr His Arg Leu Leu Val Arg Gly His 200 205

Arg Ile Pro Tyr Val Ala Glu Val Glu Glu Glu Phe Ile Ala Ala Asn 210 220 ...

Lys Leu Ser His Leu Tyr Arg Tyr Leu Phe Tyr Val Ala Val Gly Leu 225 230 240

Ile Val Ile Leu Leu Trp Ile Ile Arg Arg Leu Arg Lys Lys Lys 245 250 255

Gln Pro Glu Lys Ala Leu Lys Ala Leu Lys Ala Ala Arg Lys Glu Val 260 270

Lys Val Glu Asp Gly Gln Gln 275

<210> 169

<211> 283

<212> PRT

<213> Streptococcus pneumoniae

<400> 169

Met Ser Arg Thr Lys Leu Arg Ala Leu Leu Gly Tyr Leu Leu Met Leu 10 15

Val Ala Cys Leu Ile Pro Ile Tyr Cys Phe Gly Gln Met Val Leu Gln 20 25 30

Ser Leu Gly Gln Val Lys Gly His Ala Thr Phe Val Lys Ser Met Thr 35 40 45

Thr Glu Met Tyr Gln Glu Gln Gln Asn His Ser Leu Ala Tyr Asn Gln 50 60

Arg Leu Ala Ser Gln Asn Arg Ile Val Asp Pro Phe Leu Ala Glu Gly 65 70 75 80

Tyr Glu Val Asn Tyr Gln Val Ser Asp Asp Pro Asp Ala Val Tyr Gly
85 90 95

Tyr Leu Ser Ile Pro Ser Leu Glu Ile Met Glu Pro Val Tyr Leu Gly

Ala Asp Tyr His His Leu Gly Met Gly Leu Ala His Val Asp Gly Thr 115 120 125 
 Pro
 Leu
 Asp
 Gly
 Thr Gly
 Preumoniae patentin. ST25 ser Val ile Ala
 Gly
 His

 Arg
 Ala
 Glu
 Pro
 Ser
 His
 Val
 Phe
 Phe
 Arg
 His
 Leu
 Asp
 Gln
 Leu
 Lys

 Arg
 Ala
 Glu
 Pro
 Ser
 His
 Val
 Phe
 Arg
 His
 Leu
 Asp
 Glu
 Ile Val
 Glu
 Tyr
 Tyr
 Asp
 Asn
 Gly
 Glu
 Ile Val
 Glu
 Tyr
 Lys
 Leu
 Leu
 Pro
 Ser
 Glu
 Tyr
 Hys
 Leu
 Leu
 Pro
 Ser
 Glu
 Tyr
 Leu
 Leu
 Val
 Asn
 Pro
 Pro
 Asn
 Pro
 Asn
 Pro
 Asn
 Pro
 Asn
 Pro
 Ala
 Pro
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala
 Ala

<210> 170

<211> 1659

<212> PRT

<213> Streptococcus pneumoniae

<400> 170

Met Lys Asn Pro Phe Phe Glu Arg Arg Cys Arg Tyr Ser Ile Arg Lys Leu Ser Val Gly Ala Cys Ser Leu Met Ile Gly Ala Val Leu Phe Ala Gly Pro Ala Leu Ala Glu Glu Thr Ala Val Pro Glu Asn Ser Gly Ala Asn Thr Glu Leu Val Ser Gly Glu Ser Glu His Ser Thr Asn Glu Ala

str pneumoniae patentin.ST25

Asp Lys Gln Asn Glu Gly Glu His Ala Arg Glu Asn Lys Leu Glu Lys

70

75

80 Ala Glu Gly Val Ala Ile Ala Ser Glu Thr Ala Ser Pro Ala Ser Asn 85 90 95 Glu Ala Ala Thr Thr Glu Thr Ala Glu Ala Ala Ser Ala Ala Lys Pro Glu Glu Lys Ala Ser Glu Val Val Ala Glu Thr Pro Ser Ala Glu Ala 115 120 125 Lys Pro Lys Ser Asp Lys Glu Thr Glu Ala Lys Pro Glu Ala Thr Asn 130 140 Gln Gly Asp Glu Ser Lys Pro Ala Ala Glu Ala Asn Lys Thr Glu Lys 145 150 160 Glu Val Gln Pro Asp Val Pro Lys Asn Thr Glu Lys Thr Leu Lys Pro 165 170 175 Lys Glu Ile Lys Phe Asn Ser Trp Glu Glu Leu Leu Lys Trp Glu Pro 180 185 190 Gly Ala Arg Glu Asp Asp Ala Ile Asn Arg Gly Ser Val Val Leu Ala 195 200 205 Ser Arg Arg Thr Gly His Leù Val Asn Glu Lys Ala Ser Lys Glu Ala 210 220 Lys Val Gln Ala Leu Ser Asn Thr Asn Ser Lys Ala Lys Asp His Ala 225 235 240 Ser Val Gly Glu Glu Phe Lys Ala Tyr Ala Phe Asp Tyr Trp Gln 245 250 255 Tyr Leu Asp Ser Met Val Phe Trp Glu Gly Leu Val Pro Thr Pro Asp 260 270 Val Ile Asp Ala Gly His Arg Asn Gly Val Pro Val Tyr Gly Thr Leu 275 280 285 Phe Phe Asn Trp Ser Asn Ser Ile Ala Asp Gln Glu Arg Phe Ala Glu 290 300 Ala Leu Lys Gln Asp Ala Asp Gly Ser Phe Pro Ile Ala Arg Lys Leu 305 310 315 Val Asp Met Ala Lys Tyr Tyr Gly Tyr Asp Gly Tyr Phe Ile Asn Gln 325 330 335

str pneumoniae patentin.ST25
Glu Thr Thr Gly Asp Leu Val Lys Pro Leu Gly Glu Lys Met Arg Gln
340
345
350 Phe Met Leu Tyr Ser Lys Glu Tyr Ala Ala Lys Val Asn His Pro Ile 355 360 365 Lys Tyr Ser Trp Tyr Asp Ala Met Thr Tyr Asn Tyr Gly Arg Tyr His 370 380 Gln Asp Gly Leu Gly Glu Tyr Asn Tyr Gln Phe Met Gln Pro Glu Gly 385 390 395 Asp Lys Val Pro Ala Asp Asn Phe Phe Ala Asn Phe Asn Trp Asp Lys 405 Ala Lys Asn Asp Tyr Thr Ile Ala Thr Ala Asn Trp Ile Gly Arg Asn 420 425 430 Pro Tyr Asp Val Phe Ala Gly Leu Glu Leu Gln Gln Gly Gly Ser Tyr 435 440 445 Lys Thr Lys Val Lys Trp Asn Asp Ile Leu Asp Glu Asn Gly Lys Leu 450 460 Arg Leu Ser Leu Gly Leu Phe Ala Pro Asp Thr Ile Thr Ser Leu Gly 465 470 480 Lys Thr Gly Glu Asp Tyr His Lys Asn Glu Asp Ile Phe Phe Thr Gly 485 490 495 Tyr Gln Gly Asp Pro Thr Gly Gln Lys Pro Gly Asp Lys Asp Trp Tyr 500 505 Gly Ile Ala Asn Leu Val Ala Asp Arg Thr Pro Ala Val Gly Asn Thr 515 520 525 Phe Thr Thr Ser Phe Asn Thr Gly His Gly Lys Lys Trp Phe Val Asp 530 540 Gly Lys Val Ser Lys Asp Ser Glu Trp Asn Tyr Arg Ser Val Ser Gly 545 555 555 Val Leu Pro Thr Trp Arg Trp Trp Gln Thr Ser Thr Gly Glu Lys Leu 565 570 575 Arg Ala Glu Tyr Asp Phe Thr Asp Ala Tyr Asn Gly Gly Asn Ser Leu 580 590 Lys Phe Ser Gly Asp Val Ala Gly Lys Thr Asp Gln Asp Val Arg Leu 595

	.Tyı	. Sei	Thr	Lys	<u>.</u> Lei	ıGTu	Va∫	str (	pneur Glu	noni:	ae pa	aten <sup>.</sup>	tin.	ST25		Ala
		61(	)				-61-5	j				-620	)	u Arg	va-i	Ala
	His 625	Lys	G Ty	∕ Gly	' Lys	630	' Ser	Lys	val	Туг	Met 635	Ala	≀ Phe	e Ser	Thr	Thr 640
. •	Pro	Asp	Tyr	Lys	Phe 645	Asp	Asp	Ala	Asp	Ala 650	Trp	Lys	6]ເ 	ı Leu	Thr _ 655	Leu
	Ser	Asp	) Asn	Trp 660	Thr	Asn	Glu	Glu	Phe 665	Asp	) Leu	ı Ser	' Ser	Leu 670	Ala	Gly
	Lys	Thr	1]e 675	Tyr	Ala	Val	Lys	Leu 680	Phe	Phe	G Tu	His	G]u 685	Gly	Ala	٧a٦
_	Lys	Asp 690	Tyr	Gln	Phe	Asn	Leu 695	Gly	Gln	Leu	Thr	700	Ser	` Asp	Asn	His
	G]n 705	Glu	Pro	Gln	Ser	Pro 710	Thr	Ser	Phe	Ser	Val 715	Val	Lys	G]n	Ser	Leu 720
	Lys	Asn	Ala	Gln	G1u 725	Ala	Glu	Ala	٧a٦	Va 1 730	Gln	Phe	Lys	Gly	Asn 735	Lys
	Asp	ΑΊа	Asp	Phe 740	Tyr	Glu	Val	Tyr	G]u 745	Lys	Asp	Gly	Asp	Ser 750	Trp	Lys
	Leu	Leu	Thr 755	Gly	Ser	Ser	Ser	Thr 760	Thr	Ile	Tyr	Leu	Pro 765	Lys	Val	Ser
	Arg	Ser 770	Ala	Ser	Аla	Gln	Gly 775	Thr	Thr	Gln	Glu	Leu 780	Lys	۷a٦	Va1	Ala
	Va1 785	Gly	Lys	Asn	GТу	Va1 790	Arg	Ser	Glu	Ala	A]a 795	Thr	Thr	Thr	Phe	Asp 800
	Trp	Gly	Met	Thr	Va1 805	Lys	Asp	Thr	Ser	Leu 810	Pro	Lys	Pro	Leu	Ala 815	Glu
	Asn	Ile	٧al	Pro 820	Glу	Ala	Thr	Val	11e 825	Asp	Ser	Thr	Phe	Pro 830	Lys	Thr
	Glu	GТу	G]y 835	Glu	GТу	Ile	Glu	G]y 840	Met	Leu	Asn	Gly	Thr 845	Ile	Thr	Ser
	Leu	Ser 850	Asp	Lys	Trp	Ser	Ser 855	Аlа	Gln	Leu	Ser	G]y 860	Ser	Val	Asp	Ile
	Arg 865	Leu	Thr	Lys	Pro	Arg 870	Thr	Val	٧a٦	Arg	Trp 875	Va1	Met	Asp		Ala 880

Gly Ala Gly Gly Glu Ser Val Asn Asp Gly Leu Met Asn Thr Lys Asp 885 890 895 Phe Asp Leu Tyr Tyr Lys Asp Ala Asp Gly Glu Trp Lys Leu Ala Lys 900 905 Glu Val Arg Gly Asn Lys Ala His Val Thr Asp Ile Thr Leu Asp Lys 915 920 925 Pro Ile Thr Ala Gln Asp Trp Arg Leu Asn Val Val Thr Ser Asp Asn 930 940 Gly Thr Pro Trp Lys Ala Ile Arg Ile Tyr Asn Trp Lys Met Tyr Glu 945 950 960 Lys Leu Asp Thr Glu Ser Val Asn Ile Pro Met Ala Lys Ala Ala 965 970 975 Arg Ser Leu Gly Asn Asn Lys Val Gln Val Gly Phe Ala Asp Val Pro 980 985 990 Ala Gly Ala Thr Ile Thr Val Tyr Asp Asn Pro Asn Ser Gln Thr Pro 995 1000 1005 Leu Ala Thr Leu Lys Ser Glu Val Gly Gly Asp Leu Ala Ser Ala 1010 1020 Pro Leu Asp Leu Thr Asn Gln Ser Gly Leu Leu Tyr Tyr Arg Thr 1025 Gln Leu Pro Gly Lys Glu Ile Ser Asn Val Leu Ala Val Ser Val 1040 1050 Pro Lys Asp Asp Arg Arg Ile Lys Ser Val Ser Leu Glu Thr Gly 1055 Pro Lys Lys Thr Ser Tyr Ala Glu Gly Glu Asp Leu Asp Leu Arg 1070 1080 Gly Gly Val Leu Arg Val Gln Tyr Glu Gly Gly Thr Glu Asp Glu 1085 1095 Leu Ile Arg Leu Thr His Ala Gly Val Ser Val Ser Gly Phe Asp 1100 1105 Thr His His Lys Gly Glu Gln Asn Leu Thr Leu Gln Tyr Leu Gly 1115 1125 Gln Pro Val Asn Ala Asn Leu Ser Val Thr Val Thr Gly Gln Asp 1130 1140

Pro Lys Lys Asp Tyr Leu Val Gly Asp Ser Leu Asp Leu Ser Glu 1160 1170 Gly Arg Phe Ala Val Ala Tyr Ser Asn Asp Thr Met Glu Glu His Ser Phe Thr Asp Glu Gly Val Glu Ile Ser Gly Tyr Asp Ala Gln 1190 1200 Lys Thr Gly Arg Gln Thr Leu Thr Leu His Tyr Gln Gly His Glu 1205 1215 Val Ser Phe Asp Val Leu Val Ser Pro Lys Ala Ala Leu Asn Asp 1220 1230 Glu Tyr Leu Lys Gln Lys Leu Ala Glu Val Glu Ala Ala Lys Asn 1235 1240 1245 Lys Val Val Tyr Asn Phe Ala Ser Ser Glu Val Lys Glu Ala Phe 1250 Leu Lys Ala Ile Glu Ala Ala Glu Gln Val Leu Lys Asp His Glu 1270 1275 Thr Ser Thr Gln Asp Gln Val Asn Asp Arg Leu Asn Lys Leu Thr 1280 1290 Glu Ala His Lys Ala Leu Asn Gly Gln Glu Lys Phe Thr Glu Glu 1295 1300 1305 Lys Thr Glu Leu Asp Arg Leu Thr Gly Glu Val Gln Glu Leu Leu 1310 1320 Ala Ala Lys Pro Asn His Pro Ser Gly Ser Ala Leu Ala Pro Leu 1330 1335 Leu Glu Lys Asn Lys Ala Leu Val Glu Lys Val Asp Leu Ser Pro 1340 1350 Glu Glu Leu Thr Thr Ala Lys Gln Ser Leu Lys Asp Leu Val Ala 1355 1360 1365 Leu Leu Lys Glu Asp Lys Pro Ala Val Phe Ser Asp Ser Lys Thr 1370 1380 Gly Val Glu Val His Phe Ser Asn Lys Glu Lys Thr Val Ile Lys ... 1385 1390 1395

str pneumoniae patentin.ST25
Gly Leu Lys Val Glu Arg Val Gln Ala Ser Ala Glu Glu Lys Lys
1400 1410 Tyr Phe Ala Gly Glu Asp Ala His Val Phe Glu Ile Glu Gly Leu 1415 1420 1425 Asp Glu Lys Gly Gln Asp Val Asp Leu Ser Tyr Ala Ser Ile Val 1430 1440 Lys Ile Pro Ile Glu Lys Asp Lys Lys Val Lys Lys Val Phe Phe 1445 1450 Leu Pro Glu Gly Lys Glu Ala Val Glu Leu Ala Phe Glu Gln Thr 1460 1465 1470 Asp Ser His Val Ile Phe Thr Ala Pro His Phe Thr His Tyr Ala 1475 1480 1485 Phe Val Tyr Glu Ser Ala Glu Lys Pro Gln Pro Ala Lys Pro Ala 1490 1500 Pro Gln Asn Thr Val Leu Pro Lys Pro Thr Tyr Gln Pro Thr Ser 1505 1510 Asp Gln Gln Lys Ala Pro Lys Leu Glu Val Gln Glu Glu Lys Val 1520 1530 Ala Phe His Arg Gln Glu His Glu Asn Thr Glu Met Leu Val Gly 1535 1540 1545 Glu Gln Arg Val Ile Ile Gln Gly Arg Asp Gly Leu Leu Arg His 1550 1560 Val Phe Glu Val Asp Glu Asn Gly Gln Arg Arg Leu Arg Ser Thr 1575 1570 Glu Val Ile Gln Glu Ala Ile Pro Glu Ile Val Glu Ile Gly Thr 1580 1590 Lys Val Lys Thr Val Pro Ala Val Val Ala Thr Gln Glu Lys Pro 1595 1600 1605 Ala Gln Asn Thr Ala Val Lys Ser Glu Glu Ala Ser Lys Gln Leu 1610 1620 Pro Asn Thr Gly Thr Ala Asp Ala Asn Glu Ala Leu Ile Ala Gly 1625 1630 Leu Ala Ser Leu Gly Leu Ala Ser Leu Ala Leu Thr Leu Arg Arg 1640 1650

Page 179

	ærræ.	. :	. ·			kr a	5	tr n	naum	onia	0. no	tont	in c	T25-		
	Lys	-Arg 165	1-0-1	·u-As	p-Ly	s-As	p				.е ра			123		
	<21	0>	171													
	<21	1>	487													
	<21	2>	PRT			·			. <b></b> .							
	<21	3>	Stre	ptoc	occu	s pn	eumo	niae								
	<b>&lt;40</b>	0>	171													
	Met 1	Ser	Ile	Thr	ser 5	Phe	٧a٦	Lys	Arg	Ile 10	Gln	Asp	Ile	Thr	Arg 15	Asn
	Asp	Ala	Gly	Val 20	Asn	σΊу	Asp	Аlа	G]n 25	Arg	Ile	Glu	GÌn	Met 30	ser	Trp
•	Leu	Leu	Phe 35	Leu	Lys	Ile	Туг	Asp 40	Ser	Arg	Glu	Met	Va1 45	Trp	Glu	Leu
	Glu	Glu 50	Asp	Glu	Tyr	Glu	Ser 55	Ile	Ile	Pro	Glu	G]u 60	Leu	Lys	Trp	Arg
	Asn 65	Тгр	Аlа	His	ΑΊа	G]n 70	Asn	Gly	Glu	Arg	Va 1 75	Leu	Thr	Gly	Asp	Glu 80
	Leu	Leu	Asp	Phe	Va 1 85	Asn	Asn	Lys	Leu	Phe 90	Lys	Glu	Leu	Lys	Glu 95	Leu
	Glu	Ile	Thr	Ser 100	Asn	Met	Pro	Ile	Arg 105	Lys	Thr	Ile	Val	Lys 110	ser	Ala
	Phe	Glu	Asp 115	Ala	Asn	Asn	Tyr	Met 120	Lys	Asn	GÌy	٧a٦	Leu 125	Leu	Arg	Gln
	val	Ile 130	Asn	va1	Ile	Asp	Glu 135	٧a٦	Asp	Phe	Asn	Ser 140	Pro	Glu	Asp	Arg
	His 145	Ser	Phe	Asn	Asp	Ile 150	Tyr	Glu	Lys	Ile	Leu 155	Lys	Asp	Ile	Gln	Asn 160
	Ala	Gly	Asn	Ser	G]y 165	Glu	Phe	Tyr	Thr	Pro 170	Arg	Ala	Аlа	Thr	Asp 175	Phe
	Ile	ΑΊa	Glu	va7 180	Leu	Asp	Pro	Lys	Leu 185	G1y	Glu	Ser	Met	A7a 190	Asp	Leu

Ala Cys Gly Thr Gly Gly Phe Leu Thr Ser Thr Leu Asn Arg Leu Ser

Ser Gln Arg Lys Thr Ser Glu Asp Thr Lys Lys Tyr Asn Thr Ala Val 210 215 220 Phe Gly Ile Glu Lys Lys Ala Phe Pro His Leu Leu Ala Val Thr Asn 225 230 235 240 Leu Phe Leu His Glu Ile Asp Asp Pro Lys Ile Val His Gly Asn Thr 245 250 255 Leu Glu Lys Asn Val Arg Glu Tyr Thr Asp Asp Glu Lys Phe Asp Ile 260 265 270 Ile Met Met Asn Pro Pro Phe Gly Gly Ser Glu Leu Glu Thr Ile Lys 275 280 285 Asn Asn Phe Pro Ala Glu Leu Arg Ser Ser Glu Thr Ala Asp Leu Phe 290 295 300 Met Ala Val Ile Met Tyr Arg Leu Lys Glu Asn Gly Arg Val Gly Val 305 310 315 Ile Leu Pro Asp Gly Phe Leu Phe Gly Glu Gly Val Lys Thr Arg Leu 325 330 335 Lys Gln Lys Leu Val Asp Glu Phe Asn Leu His Thr Ile Ile Arg Leu 340 345 350 Pro His Ser Val Phe Ala Pro Tyr Thr Gly Ile His Thr Asn Ile Leu 355 360 365 Phe Phe Asp Lys Thr Lys Lys Thr Glu Glu Thr Trp Phe Tyr Arg Leu 370 380 Asp Met Pro Asp Gly Tyr Lys Asn Phe Ser Lys Thr Lys Pro Met Lys 385 390 395 Ser Glu His Phe Asn Pro Val Arg Asp Trp Trp Glu Asn Arg Glu Glu 405 410 415 Ile Leu Glu Gly Lys Phe Tyr Lys Ser Lys Ser Phe Thr Pro Ser Glu 420 425 430Leu Ala Glu Leu Asn Tyr Asn Leu Asp Gln Cys Asp Phe Pro Lys Glu
435 440 445 Glu Glu Glu Ile Leu Asn Pro Phe Glu Leu Ile Gln Asn Tyr Gln Ala 450 455 460 Glu Arg Ala Thr Leu Asn His Lys Ile Asp Asn Val Leu Ala Asp Ile 465 470 475 480

## str pneumoniae patentin.ST25

Leu-Glu-Leu-Leu-Glu-Asp-Lys

<210> 172

<211> 378

<212> PRT

<213> Streptococcus pneumoniae

<400> 172

Met Asn Asn Thr Glu Phe Tyr Asp Arg Leu Gly Val Ser Lys Asn Ala
1 10 15

Ser Ala Asp Glu Ile Lys Lys Ala Tyr Arg Lys Leu Ser Lys Lys Tyr 20 25 30

His Pro Asp Ile Asn Lys Glu Pro Gly Ala Glu Asp Lys Tyr Lys Glu

Val Gln Glu Ala Tyr Glu Thr Leu Ser Asp Asp Gln Lys Arg Ala Ala 50 60

Tyr Asp Gln Tyr Gly Ala Ala Gly Ala Asn Gly Gly Phe Gly Gly Ala 65 70 75 80

Gly Gly Phe Gly Gly Phe Asn Gly Ala Gly Gly Phe Gly Phe Glu 85 90 95

Asp Ile Phe Ser Ser Phe Phe Gly Gly Gly Ser Ser Arg Asn Pro 100 105 110

Asn Ala Pro Arg Gln Gly Asp Asp Leu Gln Tyr Arg Val Asn Leu Thr 115 120 125

Phe Glu Glu Ala Ile Phe Gly Thr Glu Lys Glu Val Lys Tyr His Arg 130 140

Glu Ala Gly Cys Arg Thr Cys Asn Gly Ser Gly Ala Lys Pro Gly Thr 150 155 160

Ser Pro Val Thr Cys Gly Arg Cys His Gly Ala Gly Val Ile Asn Val 165 170 175

Asp Thr Gln Thr Pro Leu Gly Met Met Arg Arg Gln Val Thr Cys Asp 180 185 190

Val Cys His Gly Arg Gly Lys Glu Ile Lys Tyr Pro Cys Thr Thr Cys 195 200 205

str pneumoniae patentin.ST25
His Gly Thr Gly His Glu Lys Gln Ala His Ser Val His Val Lys Ile
210 215 220 Pro Ala Gly Val Glu Thr Gly Gln Gln Ile Arg Leu Ala Gly Gln Gly 225 235 240 Glu Ala Gly Phe Asn Gly Gly Pro Tyr Gly Asp Leu Tyr Val Val Val 245 255 Ser Val Glu Ala Ser Asp Lys Phe Glu Arg Glu Gly Thr Thr Ile Phe 260 265 270 Tyr Asn Leu Asn Leu Asn Phe Val Gln Ala Ala Leu Gly Asp Thr Val 275 280 285 Asp Ile Pro Thr Val His Gly Asp Val Glu Leu Val Ile Pro Glu Gly 290 295 300 Thr Gln Thr Gly Lys Lys Phe Arg Leu Arg Ser Lys Gly Ala Pro Ser 305 310 315 320 Leu Arg Gly Gly Ala Val Gly Asp Gln Tyr Val Thr Val Asn Val Val 325 Thr Pro Thr Gly Leu Asn Asp Arg Gln Lys Val Ala Leu Lys Glu Phe 340 350 Ala Ala Gly Asp Leu Lys Val Asn Pro Lys Lys Gly Phe Phe 355 360 Asp His Ile Lys Asp Ala Phe Asp Gly Glu 370

<210> 173

<211> 453

<212> PRT

<213> Streptococcus pneumoniae

<400> 173

Met Asn Pro Asn Leu Phe Arg Ser Val Glu Phe Tyr Gln Arg Arg Tyr 1 15

His Asn Tyr Ala Thr Val Leu Ile Ile Pro Leu Ser Leu Leu Phe Thr 20 25 30

Phe Ile Leu Ile Phe Ser Leu Val Ala Thr Lys Glu Ile Thr Val Thr  $\frac{35}{40}$ 

Thr Ser Asp Asn Pro Ile Leu Ala Asn His Leu Val Ala Asn Gln Val 65 75 80 Val Glu Lys Gly Asp Leu Leu Ile Lys Tyr Ser Glu Thr Met Glu Glu 85 90 95 Ser Gln Lys Thr Ala Leu Ala Thr Gln Leu Gln Arg Leu Glu Lys Gln 105 110Lys Glu Gly Leu Gly Ile Leu Lys Gln Ser Leu Glu Lys Ala Thr Asp 115 120 125 Leu Phe Ser Gly Glu Asp Glu Phe Gly Tyr His Asn Thr Phe Met Asn 130 140 Phe Thr Lys Gln Ser His Asp Ile Glu Leu Gly Ile Thr Lys Thr Asn 150 155 160 Thr Glu Val Ser Asn Gln Ala Asn Leu Ser Asn Ser Ser Ser Ala 165 170 175 Ile Glu Gln Glu Ile Thr Lys Val Gln Gln Gln Ile Gly Glu Tyr Gln 180 185 190 Glu Leu Arg Asp Ala Ile Ile Asn Asn Arg Ala Arg Leu Pro Thr Gly Asn Pro His Gln Ser Ile Leu Asn Arg Tyr Leu Val Ala Ser Gln Gly 210 Gln Thr Gln Gly Thr Ala Glu Glu Pro Phe Leu Ser Gln Ile Asn Gln 225 230 235 240 Ser Ile Ala Gly Leu Glu Ser Ser Ile Ala Ser Leu Lys Ile Gln Gln 245 255 Ala Gly Ile Gly Ser Val Ala Thr Tyr Asp Asn Ser Leu Ala Thr Lys 260 265 270 Ile Glu Val Leu Arg Thr Gln Phe Leu Gln Thr Ala Ser Gln Gln Gln 275 280 285 Leu Thr Val Glu Asn Gln Leu Thr Glu Leu Lys Val Gln Leu Asp Gln 290 295 300 Ala Thr Gln Arg Leu Glu Asn Asn Thr Leu Thr Ser Pro Ser Lys Gly 315 310 315

Ile Val His Leu Asn Ser Glu Phe Glu Gly Lys Asn Arg Ile Pro Thr 335 Thr Gly Thr Glu Ile Ala Gln Ile Phe Pro Val Ile Thr Asp Thr Arg Glu Val Leu Ile Thr Tyr Tyr Val Ser Ser Asp Tyr Leu Pro Leu Leu Asp 355 Thr Tyr Val Arg Leu Glu Lys Ile Gly Asn His Gly 370 Gln Thr Val Arg Leu Gln Thr Ile Asp Gln Thr Pro Thr Arg 385 Thr Ile Ile Gly Gln Leu Gln Thr Ile Asp Gln Thr Pro Thr Arg 400 Thr Glu Gln Gly Asn Leu Phe Lys Leu Thr Ala Leu Ala Lys Leu Ser Asn Glu Asp Ser Lys Leu Ile Gln Tyr Gly Leu Gln Gly Arg Val Thr Ser Val Thr Thr Lys Lys Thr Tyr Phe Asp Tyr Phe Lys Asp Lys Ile Leu Thr His Ser Asp

<210> 174

<211> 131

<212> PRT

<213> Streptococcus pneumoniae

<400> 174

Met Ser Lys Lys Leu Asn Arg Lys Lys Gln Leu Arg Asn Gly Leu Arg 1 10 15

Arg Ala Gly Ala Phe Ser Ser Thr Val Thr Lys Val Val Asp Glu Thr 20 25 30

Lys Lys Val Val Lys Arg Ala Glu Gln Ser Ala Ser Ala Ala Gly Lys
35 40 45

Ala Val Ser Lys Lys Val Glu Gln Ala Val Glu Ala Thr Lys Glu Gln 50 60

Ala Gln Lys Val Ala Asn Ser Val Glu Asp Phe Ala Ala Asn Leu Gly 65 70 75 80

## 

Ser Ala Ser Asp Phe Lys Asn Trp Thr Glu Lys Glu Leu Leu Ala Leu 100 105 110

Lys Phe Lys 130

<210> 175

<211> 254

<212> PRT

<213> Streptococcus pneumoniae

<400> 175

Leu Ile Ser Leu Phe Gly Leu Ala Ala Lys Pro Val Gln Ala Asp 10 15

Thr Ser Ile Ala Asp Ile Gln Lys Arg Gly Glu Leu Val Val Gly Val 20 25 30

Lys Gln Asp Val Pro Asn Phe Gly Tyr Lys Asp Pro Lys Thr Gly Thr 35 40 45

Tyr Ser Gly Ile Glu Thr Asp Leu Ala Lys Met Val Ala Asp Glu Leu 50 60

Lys Val Lys Ile Arg Tyr Val Pro Val Thr Ala Gln Thr Arg Gly Pro 65 70 75 80

Leu Leu Asp Asn Glu Gln Val Asp Met Asp Ile Ala Thr Phe Thr Ile 85 90 95

Thr Asp Glu Arg Lys Lys Leu Tyr Asn Phe Thr Ser Pro Tyr Tyr Thr 100 110

Asp Ala Ser Gly Phe Leu Val Asn Lys Ser Ala Lys Ile Lys Lys Ile 115 120 125

Glu Asp Leu Asn Gly Lys Thr Ile Gly Val Ala Gln Gly Ser Ile Thr 130 140

Gln Arg Leu Ile Thr Glu Leu Gly Lys Lys Gly Leu Lys Phe Lys 145 150 155 160 Phe Val Glu Leu Gly Ser Tyr Pro Glu Leu Ile Thr Ser Leu His Ala His Arg Ile Asp Thr Phe Ser Val Asp Arg Ser Ile Leu Ser Gly Tyr Thr Ser Lys Arg Thr Ala Leu Leu Asp Asp Ser Phe Lys Pro Ser Asp Tyr Gly Ile Val Thr Lys Lys Ser Asn Thr Glu Leu Asn Asp Tyr Leu 200

Asp Asn Leu Val Thr Lys Trp Ser Lys Asp Gly Ser Leu Gln Lys Leu 225 230 235 240

Tyr Asp Arg Tyr Lys Leu Lys Pro Ser Ser His Thr Ala Asp 245 250

<210> 176

<211> 553

<212> PRT

<213> Streptococcus pneumoniae

<400> 176

Met Ser Asn Ile Ser Leu Thr Thr Leu Gly Gly Val Arg Glu Asn Gly 10 15

Lys Asn Met Tyr Ile Ala Glu Ile Gly Glu Ser Ile Phe Val Leu Asn 20 25 30

Val Gly Leu Lys Tyr Pro Glu Asn Glu Gln Leu Gly Val Asp Val Val 35 40 45

Ile Pro Asn Met Asp Tyr Leu Phe Glu Asn Ser Asp Arg Ile Ala Gly 50 60

Val Phe Leu Thr His Gly His Ala Asp Ala Ile Gly Ala Leu Pro Tyr 65 70 75 80

Leu Leu Ala Glu Ala Lys Val Pro Val Phe Gly Ser Glu Leu Thr Ile 85 90 95

Glu Leu Ala Lys Leu Phe Val Lys Gly Asn Asp Ala Val Lys Lys Phe

Asn Asp Phe His Val Ile Asp Glu Asn Thr Glu Ile Asp Phe Gly Gly 115

	Th	r Va	l-va	l ∵Se	r-Pho	ePhe	Pro	str Thi	oneu Thi	moni r Tyl	ae p	aten r Va	tin. I Pro	ST25	 I Ser	<u> Leu</u>		 	'a same		:
							13:	•				140	)		. <del>-</del>						
	G]: 14	y Ilo 5	e Va	l Lei	ı Lys	5 Thr 150	Ser	Glu	. G7y	/ Sei	r Ile 15	e Val	l туг	Thr	· Gly	/ Asp 160					
	Phe	e Lys	5 Phe	e Asi	Glr 165	Thr	· Ala	Ser	Glu	. Ser 170	Tyi	^ A]a	Thr	' Asp	Phe 175	Ala	<b>1</b>	·		 ــشحـــ ئـــــــــــــــــــــــــــــــ	<u></u>
	Arg	j Lei	ı Ala	4 G]ı 180	) Ile	e Gly	' Arg	Asp	Gly 185	/ Val	Leu	ı Ala	Leu	Leu 190	Ser	Asp					
	Ser	· Ala	195	Ala	Asp	Ser	Asn	Ile 200	Gln	Val	Ala	ser	Glu 205	Ser	Glu	Val					
-	Arg	210	Gไน	ılle	Thr	Gln	Thr 215	Ile	Ala	Asp	Trp	G]u 220	Gly	Arg	Ile	Ile					
	Va 1 225	Ala	. Ala	val	Ser	Ser 230	Asn	Leu	Ser	Arg	11e 235	G1n	Gln	Ile	Phe	Asp 240					
	Ala	Ala	Asp	Lys	Thr 245	Gly	Arg	Arg	Ile	Va1 250	Leu	Thr	Gly	Phe	Asp 255	Ile					
	Glu	Asn	Ile	Va 1 260	Arg	Thr	Αla	Ile	Arg 265	Leu	Lys	Lys	Leu	Ser 270	Leu	Ala					
	Asn	Glu	11e 275	Leu	Leu	Ile	Lys	Pro 280	Lys	Asp	Met	Ser	Arg 285	Phe	Glu	Asp					
	His	Glu 290	Leu	Ile	Ile	Leu	G]u 295	Thr	<b>G</b> ly	Arg	Met	Gly 300	Glu	Pro	Ile	Asn					
	Gly 305	Leu	Arg	Lys	Met	Ser 310	Ile	Gly	Arg	His	Arg 315	Tyr	۷a٦	Glu	Ile	Lys 320					)
	Asp	Gly	Asp	Leu	Va1 325	Tyr	Ile	Ala	Thr	Ala 330	Pro	Ser	Ile	Ala	Lys 335	Glu					
	Αla	Phe	val	Ala 340	Arg	Val	Glu	Asn	Met 345	Ile	Tyr	Gln	Ala	G]y 350	Gly	Val	•				
•	Val	Lys	Leu 355	Ile	Thr <sub>.</sub>	Gln	Ser	Leu 360	His	٧a٦	Ser	Gly	His 365	σΊу	Asn	Val					
	Arg	Asp 370	Leu	Gln	Leu	Met	I]e 375	Asn	Leu	Leu	GÌn	Pro 380	Lys	Туг	Leu	Phe					
	Pro 385	Val	GÌn	Gly	Glu	Tyr 390	Arg	Glu	Leu	Asp	A1a 395	His	Ala	Lys <sub>.</sub>		Ala 400					

Met Ala Val Gly Met Leu Pro Glu Arg Ile Phe Ile Pro Lys Lys Gly
Thr Thr Met Ala Tyr Glu Asn Gly Asp Phe Val Pro Ala Gly Asp Val
Ser Ala Gly Asp Ile Leu Ile Asp Gly Asn Ala Ile Gly Asp Val Gly
Asn Val Val Leu Arg Asp Arg Lys Val Leu Ser Glu Asp Gly Asp Gly Ile Phe
Ile Val Ala Ile Thr Val Asn Arg Arg Glu Lys Lys Ile Val Ala Arg
Asa Arg Val His Thr Arg Gly Phe Val Tyr Leu Lys Lys Ser Arg Asp
Ile Leu Arg Glu Ser Ser Glu Leu Ile Son Gln Thr Val Glu Tyr
Leu Gln Gly Asp Asp Phe Asp Trp Ala Asp Leu Lys Gly Lys Val Arg
Asp Asn Leu Thr Lys Tyr Leu Phe Asp Gln Thr Lys Arg Arg Pro Ala
Ile Leu Pro Val Val Met Glu Ala Lys

<210> 177

<211> 2140

<212> PRT

<213> Streptococcus pneumoniae

<400> 177

Met Lys Lys Ser Thr Val Leu Ser Leu Thr Thr Ala Ala Val Ile Leu Ala Ala Val Ile Leu Ala Ala Tyr Ala Pro Asn Glu Val Val Leu Ala Asp Thr Ser Ser Ser Glu Asp Ala Leu Asn Ile Ser Asp Lys Glu Lys Val Ala Glu Asn Lys Glu Lys His Glu Asn Ile His Ser Ala Met Glu Thr Ser Gln Asp Phe 50

	Ly	<b>5_G</b> ]	u Ly	/ <u>Ş</u> Ly	/s Th	r. Ali	a Va	str 1 тл	pneu	moni	ae p	aten	tin.	ST25		r- <del>L</del> ys-	
	65	<del>-</del>				70			<u> </u>	.5.2.6.1.	—-75	SG [ (	u va	1va	-ISe		-
	As	n Pr	o Va	וז דו	e As 85	P Ası	1 Ası	ר Th	r Se	r As. 90	n Gli	ı Glı	I A I	a Ly:	s Ile 95	-80 Lys	
•	G] i		u As	n Se 10	r Ası 0	n Lys	s sei	G]	n G]	y As <sub>i</sub>	p Tyr	Thr	Ası	Se:	r Phe )	val	
	ASI	ı Ly	s As 11	n Th 5	r Glu	ı Asn	) Pro	Lys 120	s Lys	s G]ı	u Asp	Lys	Va 125	l Va	l Tyr	·Ile	
	Ala	130	u Ph	e Ly:	s Asp	) Lys	Glu 135	Ser	r Gly	∕ Glu	ı Lyş	Ala 140	ΙΊε	e Lys	s Glu	Leu	
	Ser 145	Se	r Le	u Ly:	s Asr	Thr 150	Lys	Val	Leu	ı Tyr	Thr 155	Tyr	Asp	Arg	Ile	Phe 160	
										170	,				175	Lys	
	Gln	ΙΊ¢	e Glu	4 GTy 180	/ Ile	Ser	Ser	Val	Glu 185	Arg	ΑΊα	Gln	Lys	Va] 190	Gln	Pro	
	Met	Met	195	His	Ala	Arg	Lys	G]u 200	Ile	Gly	va1	Glu	G]u 205	Ala	Ile	Asp	
	Tyr	Leu 210	Lys	Ser	Ile	Asn	Ala 215	Pro	Phe	Gly	Lys	Asn 220	Phe	Asp	Gly	Arg	
	Gly 225	Met	Val	Ile	Ser	Asn 230	Ile	Asp	Thr	Gly	Thr 235	Asp	Tyr	Arg	His	Lys 240	
	Ala	Met	Arg	Ile	Asp 245	Asp	Asp	Ala	Lys	Ala 250	Ser	Met	Arg	Phe	Lys 255	Lys	
	Glu	Asp	Leu	Lys 260	Gly	Thr	Asp	Lys	Asn 265	Tyr	Trp	Leu	Ser	Asp 270	Lys	Ile	
	Pro	His	A7a 275	Phe	Asn	Tyr	Tyr	Asn 280	Gly	Gly	Lys	Ile	Thr 285	Val	Glu	Lys	
	Tyr	Asp 290	Asp	Gly	Arg	Asp	Tyr 295	Phe	Asp	Pro	His	Gly 300	Met	His	Ile	Ala	
	G] <i>y</i> 305	Ile	Leu	Ala	Gly	Asn 310	Asp	Thr	Glu	Gln	Asp : 315	Ile	Lys	Asn		Asn 320	
	Gly	Ile	Asp	Gly	17e 325	Ala :	Pro /	Asn	Ala	G]n 330	Ile i	Phe s	Ser '		Lys   335	Met ·	

Tyr Ser Asp Ala Gly Ser Gly Phe Ala Gly Asp Glu Thr Met Phe His 340 345 350 Ala Ile Glu Asp Ser Ile Lys His Asn Val Asp Val Val Ser Val Ser 355 Ser Gly Phe Thr Gly Thr Gly Leu Val Gly Glu Lys Tyr Trp Gln Ala 370 380 Ile Arg Ala Leu Arg Lys Ala Gly Ile Pro Met Val Val Ala Thr Gly 385 390 395 Asn Tyr Ala Thr Ser Ala Ser Ser Ser Ser Trp Asp Leu Val Ala Asn 405 410 415 Asn His Leu Lys Met Thr Asp Thr Gly Asn Val Thr Arg Thr Ala Ala 420 425 430 His Glu Asp Ala Ile Ala Val Ala Ser Ala Lys Asn Gln Thr Val Glu 435 440 445 Phe Asp Lys Val Asm Ile Gly Gly Glu Ser Phe Lys Tyr Arg Asm Ile 450 460 Gly Ala Phe Phe Asp Lys Ser Lys Ile Thr Thr Asn Glu Asp Gly Thr 465 470 480 Lys Ala Pro Ser Lys Leu Lys Phe Val Tyr Ile Gly Lys Gly Gln Asp 485 490 495 Gln Asp Leu Ile Gly Leu Asp Leu Arg Gly Lys Ile Ala Val Met Asp 500 510 Arg Ile Tyr Thr Lys Asp Leu Lys Asn Ala Phe Lys Lys Ala Met Asp 515 525 Lys Gly Ala Arg Ala Ile Met Val Val Asn Thr Val Asn Tyr Tyr Asn 530 540 Arg Asp Asn Trp Thr Glu Leu Pro Ala Met Gly Tyr Glu Ala Asp Glu 545 550 560 Gly Thr Lys Ser Gln Val Phe Ser Ile Ser Gly Asp Asp Gly Val Lys 565 570 575 Leu Trp Asn Met Ile Asn Pro Asp Lys Lys Thr Glu Val Lys Arg Asn 580 585 590 Asn Lys Glu Asp Phe Lys Asp Lys Leu Glu Gln Tyr Tyr Pro Ile Asp 595 600 605

Met\_Glu\_Ser\_Phe\_Asn-Ser\_Asn-Lys-Pro-Asn-Val-Gly-Asp-Glu-Lys-Glu 610 615 Ile Asp Phe Lys Phe Ala Pro Asp Thr Asp Lys Glu Leu Tyr Lys Glu 625 630 635 640 Asp Ile Ile Val Pro Ala Gly Ser Thr Ser Trp Gly Pro Arg Ile Asp
645
650
655 Leu Leu Lys Pro Asp Val Ser Ala Pro Gly Lys Asn Ile Lys Ser Thr Leu Asn Val Ile Asn Gly Lys Ser Thr Tyr Gly Tyr Met Ser Gly 685Thr Ser Met Ala Thr Pro Ile Val Ala Ala Ser Thr Val Leu Ile Arg 690 695 700 Pro Lys Leu Lys Glu Met Leu Glu Arg Pro Val Leu Lys Asn Leu Lys 705 710 715 720 Gly Asp Asp Lys Ile Asp Leu Thr Ser Leu Thr Lys Ile Ala Leu Gln 725 730 735 Asn Thr Ala Arg Pro Met Met Asp Ala Thr Ser Trp Lys Glu Lys Ser 745 750 Gln Tyr Phe Ala Ser Pro Arg Gln Gln Gly Ala Gly Leu Ile Asn Val 755 760 765 Ala Asn Ala Leu Arg Asn Glu Val Val Ala Thr Phe Lys Asn Thr Asp 770 780 Ser Lys Gly Leu Val Asn Ser Tyr Gly Ser Ile Ser Leu Lys Glu Ile 785 790 795 800 Lys Gly Asp Lys Lys Tyr Phe Thr Ile Lys Leu His Asn Thr Ser Asn 815 Arg Pro Leu Thr Phe Lys Val Ser Ala Ser Ala Ile Thr Thr Asp Ser 820 825 830 Leu Thr Asp Arg Leu Lys Leu Asp Glu Thr Tyr Lys Asp Glu Lys Ser 845 Pro Asp Gly Lys Gln Ile Val Pro Glu Ile His Pro Glu Lys Val Lys 850 Gly Ala Asn Ile Thr Phe Glu His Asp Thr Phe Thr Ile Gly Ala Asn 865 870 875

str pneumoniae patentin.ST25 Ser Ser Phe Asp Leu Asn Ala Val Ile Asn Val Gly Glu Ala Lys Asn 885 890 895 Lys Asn Lys Phe Val Glu Ser Phe Ile His Phe Glu Ser Val Glu Glu 900 905 910 Met Glu Ala Leu Asn Ser Asn Gly Lys Lys Ile Asn Phe Gln Pro Ser 915 925 Leu Ser Met Pro Leu Met Gly Phe Ala Gly Asn Trp Asn His Glu Pro 930 940 Ile Leu Asp Lys Trp Ala Trp Glu Glu Gly Ser Arg Ser Lys Thr Leu 945 950 955 960 Gly Gly Tyr Asp Asp Gly Lys Pro Lys Ile Pro Gly Thr Leu Asn 965 970 975 Lys Gly Ile Gly Glu His Gly Ile Asp Lys Phe Asn Pro Ala Gly 980 985 Val Ile Gln Asn Arg Lys Asp Lys Asn Thr Thr Ser Leu Asp Gln Asn 995 1000 Pro Glu Leu Phe Ala Phe Asn Asn Glu Gly Ile Asn Ala Pro Ser 1010 1020 Ser Ser Gly Ser Lys Ile Ala Asn Ile Tyr Pro Leu Asp Ser Asn 1025 1035 Gly Asn Pro Gln Asp Ala Gln Leu Glu Arg Gly Leu Thr Pro Ser 1040 1045 1050 Pro Leu Val Leu Arg Ser Ala Glu Glu Gly Leu Ile Ser Ile Val 1055 1060 Asn Thr Asn Lys Glu Gly Glu Asn Gln Arg Asp Leu Lys Val Ile 1070 1080 Ser Arg Glu His Phe Ile Arg Gly Ile Leu Asn Ser Lys Ser Asn 1085 1095 Asp Ala Lys Gly Ile Lys Ser Ser Lys Leu Lys Val Trp Gly Asp 1100 1110 Leu Lys Trp Asp Gly Leu Ile Tyr Asn Pro Arg Gly Arg Glu Glu 1115 1125 Asn Ala Pro Glu Ser Lys Asp Asn Gln Asp Pro Ala Thr Lys Ile 1130 1140

Phe Lys Tyr Arg Leu Thr Lys Asp Tyr Pro Trp Gln Val Ser Tyr 1160 1170 Ile Pro Val Lys Ile Asp Asn Thr Ala Pro Lys Ile Val Ser Val Asp Phe Ser Asn Pro Glu Lys Ile Lys Leu Ile Thr Lys Asp Thr 1190 1200 Tyr His Lys Val Lys Asp Gln Tyr Lys Asn Glu Thr Leu Phe Ala 1215 Arg Asp Gln Lys Glu His Pro Glu Lys Phe Asp Glu Ile Ala Asn 1220 1230 Glu Val Trp Tyr Ala Gly Ala Ala Leu Val Asn Glu Asp Gly Glu 1235 1240 1245 Val Glu Lys Asn Leu Glu Val Thr Tyr Ala Gly Glu Gly Gln Gly 1250 1260 Arg Asn Arg Lys Leu Asp Lys Asp Gly Asn Thr Ile Tyr Glu Ile 1275 Lys Gly Ala Gly Asp Leu Arg Gly Lys Ile Ile Glu Val Ile Ala 1280 1290 Leu Asp Gly Ser Ser Asn Phe Thr Lys Ile His Arg Ile Lys Phe 1295 1305 Ala Asn Gln Ala Asp Glu Lys Gly Met Ile Ser Tyr Tyr Leu Val 1310 1320 Asp Pro Asp Gln Asp Ser Ser Lys Tyr Gln Lys Leu Gly Glu Ile 1325 1335 Ala Glu Ser Lys Phe Lys Asn Leu Gly Asn Gly Lys Glu Gly Ser 1340 1350 Leu Lys Lys Asp Thr Thr Gly Val Glu His His His Gln Glu Asn 1355 1360 1365 Glu Glu Ser Ile Lys Glu Lys Ser Ser Phe Thr Ile Asp Arg Asn 1370 1380 Ile Ser Thr Ile Arg Asp Phe Glu Asn Lys Asp Leu Lys Lys Leu 1385 1390 1395

Ile Lys Lys Lys Phe Arg Glu Val Asp Asp Phe Thr Ser Glu Thr 1400 Gly Lys Arg Met Glu Glu Tyr Asp Tyr Lys Tyr Asp Asp Lys Gly 1425 Asn Ile Ile Ala Tyr Asp Asp Gly Thr Asp Leu Glu Tyr Glu Thr 1430 1440 Glu Lys Leu Asp Glu Ile Lys Ser Lys Ile Tyr Gly Val Leu Ser 1445 1455 Pro Ser Lys Asp Gly His Phe Glu Ile Leu Gly Lys Ile Ser Asn 1460 1465 Val Ser Lys Asn Ala Lys Val Tyr Tyr Gly Asn Asn Tyr Lys Ser 1475 1480 1485 Ile Glu Ile Lys Ala Thr Lys Tyr Asp Phe His Ser Lys Thr Met 1490 1500 Thr Phe Asp Leu Tyr Ala Asn Ile Asn Asp Ile Val Asp Gly Leu 1505 1510 1515 Ala Phe Ala Gly Asp Met Arg Leu Phe Val Lys Asp Asn Asp Gln 1520 1530 Lys Lys Ala Glu Ile Lys Ile Arg Met Pro Glu Lys Ile Lys Glu 1535 1545 Thr Lys Ser Glu Tyr Pro Tyr Val Ser Ser Tyr Gly Asn Val Ile 1550 1560 Glu Leu Gly Glu Gly Asp Leu Ser Lys Asn Lys Pro Asp Asn Leu 1565 1570 1575 Thr Lys Met Glu Ser Gly Lys Ile Tyr Ser Asp Ser Glu Lys Gln 1580 1590 Gln Tyr Leu Leu Lys Asp Asn Ile Ile Leu Arg Lys Gly Tyr Ala 1595 1600 1605 Leu Lys Val Thr Thr Tyr Asn Pro Gly Lys Thr Asp Met Leu Glu 1610 1620 Gly Asn Gly Val Tyr Ser Lys Glu Asp Ile Ala Lys Ile Gln Lys 1625 1635 Ala Asn Pro Asn Leu Arg Ala Leu Ser Glu Thr Thr Ile Tyr Ala 1640 1650

							str	nne	umon	iae	nato	ntin.	CT) E		
<u>. ·</u>	Asp	-ser-	-Arg	-Asn	~va-l	Glu	=Asp -	G V	Arg	·Ser	Thr	≕G]'n ⁻	Ser	'Val	Leu-
		1655					1660					1665			
	Met	Ser 1670	Ala	Leu	Asp	Gly	Phe 1675	Asn	Ile	Ile	Arg	Tyr 1680	Gln	٧a٦	Phe
· •.	Thr	Phe 1685	Lys	Met	Asn	Asp	Lys 1690	Gly	Glu	Ala	Ile	Asp 1695	Lys	Asp	Gly
	Asn	Leu 1700	Va1	Thr	Asp	Ser	Ser 1705	Lys	Leu	٧a٦	Leu	Phe 1710	Gly	Lys	Asp
	Asp	Lys 1715	Glu	Tyr	Thr	σΊу	Glu 1720	Asp	Lys	Phe	Asn	Val 1725	Glu	Ala	Ile
	Lys	Glu 1730	Asp	Gly	Ser	Met	Leu 1735	Phe	Ile	Asp	Thr	Lys 1740	Pro	val	Asn
	Leu	Ser 1745	Met	Asp	Lys	Asn	Tyr 1750	Phe	Asn	Pro	Ser	Lys 1755	Ser	Asn	Lys
	Ile	Tyr 1760	val	Arg	Asn	Pro	Glu 1765	Phe	Tyr	Leu	Arg	Gly 1770	Lys	Ile	Ser
	Asp	Lys 1775	Gly	Gly	Phe	Asn	Trp 1780	Glu	Leu	Arg	Val	Asn 1785	Glu	Ser	Val
	Val	Asp 1790	Asn	туг	Leu	Ile	Tyr 1795	Gly	Asp	Leu	His	Ile 1800	Asp	Asn	Thr
	Arg	Asp 1805	Phe	Asn	Ile	Lys	Leu 1810	Asn	۷al	Lys	Asp	Gly 1815	Asp	Ile	Met
	Asp	Trp 1820	Gly	Met	Lys	Asp	Tyr 1825	Lys	Ala	Asn	Gly	Phe 1830	Pro	Asp	Lys
	Val	Thr 1835	Asp	Met	Asp	Gly	Asn 1840	۷al	Tyr	Leu	Gln	Thr 1845	Gly	Tyr	Ser
	Asp	Leu 1850	Asn	Аlа	Lys	Ala	Val 1855	Gly	Val	His	Tyr	G]n 1860	Phe	Leu	Туг
	Asp	Asn 1865	Val	Lys	Pro	Glu	Val 1870	Asn	Ile	Asp	Pro	Lys 1875	Gly	Asn	Thr
	Ser	Ile 1880	Glu	Tyr	Ala	Asp	Gly 1885	Lys	Ser	Val	val	Phe 1890	Asn	Ile	Asn
	Asp	Lys 1895	Arg	Asn	Asn	Gly	Phe - 1900	Asp	GТу	Glu	Ile	G]n 1905	Glu	Gln	His

str pneumoniae patentin.ST25
Ile Tyr Ile Asn Gly Lys Glu Tyr Thr Ser Phe Asn Asp Ile Lys
1910 1920 Gln Ile Ile Asp Lys Thr Leu Asn Ile Lys Ile Val Val Lys Asp 1935 1935 Phe Ala Arg Asn Thr Thr Val Lys Glu Phe Ile Leu Asn Lys Asp 1940 1950 Thr Gly Glu Val Ser Glu Leu Lys Pro His Arg Val Thr 1955 1960 1965 Ile Gln Asn Gly Lys Glu Met Ser Ser Thr Ile Val Ser Glu Glu 1970 1980 Asp Phe Ile Leu Pro Val Tyr Lys Gly Glu Leu Glu Lys Gly Tyr 1985 1990 1995 Gln Phe Asp Gly Trp Glu Ile Ser Gly Phe Glu Gly Lys Lys Asp 2000 2010 Ala Gly Tyr Val Ile Asn Leu Ser Lys Asp Thr Phe Ile Lys Pro 2015 2025 Val Phe Lys Lys Ile Glu Glu Lys Lys Glu Glu Asn Lys Pro 2030 2040 Thr Phe Asp Val Ser Lys Lys Lys Asp Asn Pro Gln Val Asn His 2045 2050 Ser Gln Leu Asn Glu Ser His Arg Lys Glu Asp Leu Gln Arg Glu 2060 2070 Glu His Ser Gln Lys Ser Asp Ser Thr Lys Asp Val Thr Ala Thr 2075 2080 Val Leu Asp Lys Asn Asn Ile Ser Ser Lys Ser Thr Thr Asn Asn 2090 2100 Pro Asn Lys Leu Pro Lys Thr Gly Thr Ala Ser Gly Ala Gln Thr 2105 2110 2115 Leu Leu Ala Ala Gly Ile Met Phe Ile Val Gly Ile Phe Leu Gly 2120 2130 Leu Lys Lys Lys Asn Gln Asp 2135 2140

<210> 178 <211> 2233

Page 197

<213> Streptococcus pneumoniae

<400>

Met Gly Lys Gly His Trp Asn Arg Lys Arg Val Tyr Ser Ile Arg Lys 10 15

Phe Ala Val Gly Ala Cys Ser Val Met Ile Gly Thr Cys Ala Val Leu 20 25 30

Leu Gly Gly Asn Ile Ala Gly Glu Ser Val Val Tyr Ala Asp Glu Thr 35 40 45

Leu Ile Thr His Thr Ala Glu Lys Pro Lys Glu Glu Lys Met Ile Val

Glu Glu Lys Ala Asp Lys Ala Leu Glu Thr Lys Asm Ile Val Glu Arg
65 70 75 80

Thr Glu Gln Ser Glu Pro Ser Ser Thr Glu Ala Ile Ala Ser Glu Lys
85 90 95

Lys Glu Asp Glu Ala Val Thr Pro Lys Glu Glu Lys Val Ser Ala Lys 100 105 110

Pro Glu Glu Lys Ala Pro Arg Ile Glu Ser Gln Ala Ser Asn Gln Glu 115 120

Lys Pro Leu Lys Glu Asp Ala Lys Ala Val Thr Asn Glu Glu Val Asn 130 140

Gln Met Ile Glu Asp Arg Lys Val Asp Phe Asn Gln Asn Trp Tyr Phe 145 155 160

Lys Leu Asn Ala Asn Ser Lys Glu Ala Ile Lys Pro Asp Ala Asp Val 165 170 175

Ser Thr Trp Lys Lys Leu Asp Leu Pro Tyr Asp Trp Ser Ile Phe Asn 180 185 190

Asp Phe Asp His Glu Ser Pro Ala Gln Asn Glu Gly Gly Gln Leu Asn 195 200

Gly Gly Glu Ala Trp Tyr Arg Lys Thr Phe Lys Leu Asp Glu Lys Asp 210 220

Leu Lys Lys Asn Val Arg Leu Thr Phe Asp Gly Val Tyr Met Asp Ser 225 230 235 240

str pneumoniae patentin.ST25 Gln Val Tyr Val Asn Gly Gln Leu Val Gly His Tyr Pro Asn Gly Tyr 245 250 255 Asn Gln Phe Ser Tyr Asp Ile Thr Lys Tyr Leu Gln Lys Asp Gly Arg 260 265 270 Glu Asn Val Ile Ala Val His Ala Val Asn Lys Gln Pro Ser Ser Arg 275 280 285 Trp Tyr Ser Gly Ser Gly Ile Tyr Arg Asp Val Thr Leu Gln Val Thr 290 300 Asp Lys Val His Val Glu Lys Asn Gly Thr Thr Ilè Leu Thr Pro Lys 305 310 315 320 Leu Glu Glu Gln Gln His Gly Lys Val Glu Thr His Val Thr Ser Lys 325 330 335 Ile Val Asn Thr Asp Asp Lys Asp His Glu Leu Val Ala Glu Tyr Gln 340 350 Ile Val Glu Arg Gly Gly His Ala Val Thr Gly Leu Val Arg Thr Ala 355 360 365 Ser Arg Thr Leu Lys Ala His Glu Ser Thr Ser Leu Asp Ala Ile Leu 370 380 Glu Val Glu Arg Pro Lys Leu Trp Thr Val Leu Asn Asp Lys Pro Ala 385 390 395 400 Leu Tyr Glu Leu Ile Thr Arg Val Tyr Arg Asp Gly Gln Leu Val Asp 405 410 415 Ala Lys Lys Asp Leu Phe Gly Tyr Arg Tyr Tyr His Trp Thr Pro Asn 420 425 Glu Gly Phe Ser Leu Asn Gly Glu Arg Ile Lys Phe His Gly Val Ser 445 445 Leu His His Asp His Gly Ala Leu Gly Ala Glu Glu Asn Tyr Lys Ala 450 460 Glu Tyr Arg Arg Leu Lys Gln Met Lys Glu Met Gly Val Asn Ser Ile 465 470 480 Arg Thr Thr His Asn Pro Ala Ser Glu Gln Thr Leu Gln Ile Ala Ala 485 490 495 Glu Leu Gly Leu Leu Val Gln Glu Glu Ala Phe Asp Thr Trp Tyr Gly
500 505 510 His Pro Glu Ala Arg Lys Gly Glu Lys Trp Ser Asp Phe Asp Leu Arg 530 540 Thr Met Val Glu Arg Gly Lys Asn Asn Pro Ala Ile Phe Met Trp Ser 545 555 555 Ile Gly Asn Glu Ile Gly Glu Ala Asn Gly Asp Ala His Ser Leu Ala 565 570 575 Thr Val Lys Arg Leu Val Lys Val Ile Lys Asp Val Asp Lys Thr Arg 580 590 Tyr Val Thr Met Gly Ala Asp Lys Phe Arg Phe Gly Asn Gly Ser Gly 595 605 Gly His Glu Lys Ile Ala Asp Glu Leu Asp Ala Val Gly Phe Asn Tyr 610 620 Ser Glu Asp Asn Tyr Lys Ala Leu Arg Ala Lys His Pro Lys Trp Leu 625 630 640 Ile Tyr Gly Ser Glu Thr Ser Ser Ala Thr Arg Thr Arg Gly Ser Tyr 645 650 655 Tyr Arg Pro Glu Arg Glu Leu Lys His Ser Asn Gly Pro Glu Arġ Asn 660 665 670 Tyr Glu Gln Ser Asp Tyr Gly Asn Asp Arg Val Gly Trp Gly Lys Thr 675 685 Ala Thr Ala Ser Trp Thr Phe Asp Arg Asp Asn Ala Gly Tyr Ala Gly 690 700 Gln Phe Ile Trp Thr Gly Thr Asp Tyr Ile Gly Glu Pro Thr Pro Trp 705 710 715 720 His Asn Gln Asn Gln Thr Pro Val Lys Ser Ser Tyr Phe Gly Ile Val 725 730 735 Asp Thr Ala Gly Ile Pro Lys His Asp Phe Tyr Leu Tyr Gln Ser Gln 740 750 Trp Val Ser Val Lys Lys Lys Pro Met Val His Leu Leu Pro His Trp 755 760 765 Asn Trp Glu Asn Lys Glu Leu Ala Ser Lys Val Ala Asp Ser Glu Gly 770 780

str pneumoniae patentin.ST25 Lys Ile Pro Val Arg Ala Tyr Ser Asn Ala Ser Ser Val Glu Leu Phe 785 790 795 800 Leu Asn Gly Lys Ser Leu Gly Leu Lys Thr Phe Asn Lys Lys Gln Thr 805 810 815 Ser Asp Gly Arg Thr Tyr Glm Glu Gly Ala Asm Ala Asm Glu Leu Tyr 820 825 830 Leu Glu Trp Lys Val Ala Tyr Gln Pro Gly Thr Leu Glu Ala Ile Ala 845 Arg Asp Glu Ser Gly Lys Glu Ile Ala Arg Asp Lys Ile Thr Thr Ala 850 855 Gly Lys Pro Ala Ala Val Arg Leu Ile Lys Glu Asp His Ala Ile Ala 865 870 875 880 Ala Asp Gly Lys Asp Leu Thr Tyr Ile Tyr Tyr Glu Ile Val Asp Ser 885 890 895 Gln Gly Asn Val Val Pro Thr Ala Asn Asn Leu Val Arg Phe Gln Leu 900 905 His Gly Gln Gly Gln Leu Val Gly Val Asp Asn Gly Glu Gln Ala Ser 915 920 925 Arg Glu Arg Tyr Lys Ala Gln Ala Asp Gly Ser Trp Ile Arg Lys Ala 930 935 Phe Asn Gly Lys Gly Val Ala Ile Val Lys Ser Thr Glu Gln Ala Gly 945 950 955 960 Lys Phe Thr Leu Thr Ala His Ser Asp Leu Leu Lys Ser Asp Glm Val 965 970 975 Thr Val Phe Thr Gly Lys Lys Glu Gly Gln Glu Lys Thr Val Leu Gly 980 985 990 Thr Glu Val Pro Lys Val Gln Thr Ile Ile Gly Glu Ala Pro Glu Met 995 1000 1005 Pro Thr Thr Val Pro Phe Val Tyr Ser Asp Gly Ser Arg Ala Glu 1010 1020 Pro Val Thr Trp Ser Ser Val Asp Val Ser Lys Pro Gly Ile 1025 1030 1035 Val Thr Val Lys Gly Met Ala Asp Gly Arg Glu Val Glu Ala Arg 1040 1050

a	va	] <u>. G] u</u>	_ Va	l, IJ,	e Ala	ı.Lei						entin		5	
	<del></del>	105	5				-106	0				106	5	Lys	Arg
	110	e Ala 1070	Pro	) Asr	Thr	Ası	Leu 107	Ası 5	ı Sei	r Va	l Ası	D Lys 1080	Ser	' Val	Ser
	Туі	Val 108!	Lei	ı Ile	Asp	Gly	/ Ser _1090	Va <sup>-</sup>	G]ı	ı Glu	і Туі •	Glu _109	Va]	Asp	Lys
	Trp	Glu 1100	Ile )	e Ala	ı Glu	Glu	Asp 1105	Lys	a Ala	Lys	. Lei	A]a 1110	Ile	Pro	Gly
	Ser	Arg 1115	Ile	e Gln	Ala	Thr	Gly 1120	Tyr	. Len	ı Glu	ı Gly	' G]n 1125	Pro	Ile	His
	АÌа	Thr 1130	Leu )	∨a1	Val	Glu	Glu 1135	Gly	' Asn	) Pro	Ala	A]a 1140	Pro	Ala	۷al
	Pro	Thr 1145	va1	Thr	Val	GТу	Gly 1150	Glu	Ala	\Val	Thr	Gly 1155	Leu	Thr	Ser
	Gln	Lys 1160	Pro	Met	Gln	Tyr	Arg 1165	Thr	Leu	Ala	Tyr	Gly 1170	Ala	Lys	Leu
	Pro	Glu 1175	Val	Thr	Ala	Ser	Ala 1180	Lys	Asn	Ala	Ala	Val 1185	Thr	Val	Leu
	Gln	Ala 1190	Ser	ΑΊа	Аlа	Asn	Gly 1195	Met	Arg	Ala	Ser	Ile 1200	Phe	Ile	Gln
	Pro	Lys 1205	Asp	G1 <i>y</i>	Glу	Pro	Leu 1210	Gln	Thr	Tyr	Ala	Ile 1215	Gln	Phe	Leu
	Glu	Glu 1220	Ala	Pro	Lys	Ile	Ala 1225	His	Leu	Ser	Leu	Gln 1230	Val	Glu	Lys
	ΑΊα	Asp 1235	Ser	Leu	Lys	Glu	Asp 1240	Gln	Thr	val	Lys	Leu 1245	ser	۷a٦ .	Arg
•	Ala	His 1250	Tyr	Gln	Asp	Gly	Thr 1255	Gln	Ala	Val	Leu	Pro 1260	Ala .	Asp	Lys
	Val	Thr 1265	Phe	Ser	Thr	Ser	Gly 1270	Glu	Gly	Glu	Va1	Ala 1275	Ile .	Arg	Lys
	Gly	Met 1280	Leu	Glu	Leu	His	Lys 1285	Pro	Gly	Ala	Val	Thr 1290	Leu /	Asn /	Ala
	Glu	Tyr 1295	Glu	Gly .	Ala	Lys	Asp 1300	Gln	Val	Glu	Leu	Thr 1305	Ile	Gln A	A7a

str pneumoniae patentin.ST25
Asn Thr Glu Lys Lys Ile Ala Gln Ser Ile Arg Pro Val Asn Val
1310 . 1315 1320 Val Thr Asp Leu His Gln Glu Pro Ser Leu Pro Ala Thr Val Thr 1325 1330 1335 Val Glu Tyr Asp Lys Gly Phe Pro Lys Thr His Lys Val Thr Trp 1340 1350 Gln Ala Ile Pro Lys Glu Lys Leu Asp Ser Tyr Gln Thr Phe Glu 1355 1360 1365 Val Leu Gly Lys Val Glu Gly Ile Asp Leu Glu Ala Arg Ala Lys 1370 1380 Val Ser Val Glu Gly Ile Val Ser Val Glu Glu Val Ser Val Thr 1385 1390 1395 Thr Pro Ile Ala Glu Ala Pro Gln Leu Pro Glu Ser Val Arg Thr 1400 1405 Tyr Asp Ser Asn Gly His Val Ser Ser Ala Lys Val Ala Trp Asp 1425 1425 Ala Ile Arg Pro Glu Gln Tyr Ala Lys Glu Gly Val Phe Thr Val 1430 1440 Asn Gly Arg Leu Glu Gly Thr Gln Leu Thr Thr Lys Leu His Val 1445 1450 1455 Arg Val Ser Ala Gln Thr Glu Gln Gly Ala Asn Ile Ser Asp Gln 1460 1470 Trp Thr Gly Ser Glu Leu Pro Leu Ala Phe Ala Ser Asp Ser Asn 1475 1480 1485 Pro Ser Asp Pro Val Ser Asn Val Asn Asp Lys Leu Ile Ser Tyr 1490 1500 Asn Asn Gln Pro Ala Asn Arg Trp Thr Asn Trp Asn Arg Thr Asn 1505 1510 Pro Glu Ala Ser Val Gly Val Leu Phe Gly Asp Ser Gly Ile Leu 1520 1530 Ser Lys Arg Ser Val Asp Asn Leu Ser Val Gly Phe His Glu Asp 1535 1540 1545 His Gly Val Gly Val Pro Lys Ser Tyr Val Ile Glu Tyr Tyr Val 1550 1560 Asn Glu Asp His Val Phe Asn Asp Ser Ala Asn Trp Lys Pro Val 1580 1590 Thr Asn Leu Lys Ala Pro Ala Gln Leu Lys Ala Gly Glu Met Asn
1595 1600 1600 His Phe Ser Phe Asp Lys Val Glu Thr Tyr Ala Val Arg Ile Arg 1610 1620 Met Val Lys Ala Asp Asn Lys Arg Gly Thr Ser Ile Thr Glu Val 1625 Gln Ile Phe Ala Lys Gln Val Ala Ala Ala Lys Gln Gly Gln Thr 1640 1650 Arg Ile Gln Val Asp Gly Lys Asp Leu Ala Asn Phe Asn Pro Asp 1655 1660 1665 Leu Thr Asp Tyr Tyr Leu Glu Ser Val Asp Gly Lys Val Pro Ala 1670 1680 Val Thr Ala Ser Val Ser Asn Asn Gly Leu Ala Thr Val Val Pro 1685 1690 1695 Ser Val Arg Glu Gly Glu Pro Val Arg Val Ile Ala Lys Ala Glu 1700 1710 Asn Gly Asp Ile Leu Gly Glu Tyr Arg Leu His Phe Thr Lys Asp 1715 1720 1725 Lys Ser Leu Leu Ser His Lys Pro Val Ala Ala Val Lys Gln Ala 1730 1740 Arg Leu Leu Gln Val Gly Gln Ala Leu Glu Leu Pro Thr Lys Val 1745 1755 Pro Val Tyr Phe Thr Gly Lys Asp Gly Tyr Glu Thr Lys Asp Leu 1760 1765 Thr Val Glu Trp Glu Glu Val Pro Ala Glu Asn Leu Thr Lys Ala 1775 1780 1785 Gly Gln Phe Thr Val Arg Gly Arg Val Leu Gly Ser Asn Leu Val 1790 1800 Ala Glu Ile Thr Val Arg Val Thr Asp Lys Leu Gly Glu Thr Leu 1805 1815

str pneumoniae patentin.ST25 Ser Asp Asn Pro Asn Tyr Asp Glu Asn Ser Asn Gln Ala Phe Ala 1820 1825 1830 Ser Ala Thr Asn Asp Ile Asp Lys Asn Ser His Asp Arg Val Asp 1835 1840 Tyr Leu Asn Asp Gly Asp His Ser Glu Asn Arg Arg Trp Thr Asn 1850 1860 Trp Ser Pro Thr Pro Ser Ser Asn Pro Glu Val Ser Ala Glý Val 1865 1870 1875 Ile Phe Arg Glu Asn Gly Lys Ile Val Glu Arg Thr Val Thr Gln 1880 1890 Gly Lys Val Gln Phe Phe Ala Asp Ser Gly Thr Asp Ala Pro Ser 1895 1900 1905 Lys Leu Val Leu Glu Arg Tyr Val Gly Pro Glu Phe Glu Val Pro 1910 1920 Thr Tyr Tyr Ser Asn Tyr Gln Ala Tyr Asp Ala Asp His Pro Phe 1925 1930 Asn Asn Pro Glu Asn Trp Glu Ala Val Pro Tyr Arg Ala Asp Lys 1940 1950 Asp Ile Ala Ala Gly Asp Glu Ile Asn Val Thr Phe Lys Ala Ile 1955 1960 1965 Lys Ala Lys Ala Met Arg Trp Arg Met Glu Arg Lys Ala Asp Lys 1970 1980 Ser Gly Val Ala Met Ile Glu Met Thr Phe Leu Ala Pro Ser Glu 1985 1990 1995 Leu Pro Gln Glu Ser Thr Gln Ser Lys Ile Leu Val Asp Gly Lys 2000 2010 Glu Leu Ala Asp Phe Ala Glu Asn Arg Gln Asp Tyr Gln Ile Thr 2015 2025 Tyr Lys Gly Gln Arg Pro Lys Val Ser Val Glu Glu Asn Asn Gln 2030 2040 Val Ala Ser Thr Val Val Asp Ser Gly Glu Asp Ser Phe Pro Val 2045 2055 Leu Val Arg Leu Val Ser Glu Ser Gly Lys Gln Val Lys Glu Tyr 2060 2070

- 	Arg	-Ile	His	Leu	Thr	-Lys	str Glu-	pne Lys	umon Pro	iae   -Va]-	pate Ser	ntin.: -Glu	ST25 Lys=	=Thr∷	Val
		2075					2080					~2085			
	Ala	Ala 2090	Va1	Gln	Glu	Asp	Leu 2095	Pro	Lys 	Ile	Glu	Phe 2100	Va]	Glu	Lys
	Asp	Leu _2105_	Ala	Tyr	Lys	Thr	Val 2110	Glu	Lys	Lys	Asp	Ser 2115.	Thr	Leu 	Tyr
	Leu	Gly 2120	Glu	Thr	Arg	Val	Glu 2125	Gln	Glu	Gly	Lys	Val 2130	Gly	Lys	Glu
	Arg	Ile 2135	Phe	Thr	Аlа	Ile	Asn 2140	Pro	Asp	Gly	Ser	Lys 2145	Glu	Glu	Lys
	Leu	Arg 2150	Glu	٧a٦	۷a٦	Glu	Val 2155	Pro	Thr	Asp	Arg	Ile 2160	Val	Leu	۷a٦
•	Gly	Thr 2165	Lys	Pro	Val	Аlа	Gln 2170	Glu	Ala	Lys	Lys	Pro 2175	Gln	Val	ser
	Glu	Lys 2180	Ala	Asp	Thr	Lys	Pro 2185	Ile	Asp	ser	Ser	Glu 2190	Ala	Ser	Gln
	Thr	Asn 2195	Lys	ΑΊa	Gln	Leu	Pro 2200	Ser	Thr	Gly	Ser	Ala 2205	Ala	Ser	Gln
	Ala	Ala 2210	Val	Ala	ΑΊа	Gly	Leu 2215	Thr	Leu	Leu	Glу	Leu 2220	Ser	Ala	Gly
	Leu	va1 2225	val	Thr	Lys	GТу	Lys 2230	Lys	Glu	Asp					
	<210	0> 17	79												
	<21	1> 18	881												
	<21	2> PI	RT												
	<21	3> S1	trept	toco(	ccus	pne	umoni	ae							
	<400	0> . 17	79												
	Met 1	Ala I	Pro S		val ' 5	Val /	Asp A	la A	la Th 10		yr H	is Tyı	' ∨a]	Asr 15	ı Lys
	Glu	Ile:	Ile s	Ser ( 20	Gln (	Glu /	Ala L	ys A: 2:	sp Le	eu I`	le G	ln Thi	G]) 30	/ Lys	S Pro
	Asp	·Arg	Asn (	ilu v	√al '	Val 1	Гуr G 4	ly L 0	eu Va	al Ty	/r G	In Lys 45	s Asp	G]r	Leu

Pro Gln Thr Gly Thr Glu Ala Ser Val Leu Thr Ala Phe Gly Leu Leu
50 55 60 Thr Val Gly Ser Leu Leu Leu Ile Tyr Lys Arg Lys Lys Ile Ala Ser 65 70 75 80 Val Phe Leu Val Gly Ala Met Gly Leu Val Val Leu Pro Ser Ala Gly 85 90 95 Ala Val Asp Pro Val Ala Thr Leu Ala Leu Ala Ser Arg Glu Gly Val 100 105 110 Val Glu Met Glu Gly Tyr Arg Tyr Val Gly Tyr Leu Ser Gly Asp Ile 115 120 125 Leu Lys Thr Leu Gly Leu Asp Thr Val Leu Glu Glu Thr Ser Ala Lys 130 140 Pro Gly Glu Val Thr Val Val Glu Val Glu Thr Pro Gln Ser Ile Thr 145 150 155 160 Asn Gln Glu Gln Ala Arg Thr Glu Asn Gln Val Val Glu Thr Glu Glu 165 170 175 Ala Pro Lys Glu Glu Ala Pro Lys Thr Glu Glu Ser Pro Lys Glu Glu 180 185 190 Pro Lys Ser Glu Val Lys Pro Thr Asp Asp Thr Leu Pro Lys Val Glu 195 Glu Gly Lys Glu Asp Ser Ala Glu Pro Ala Pro Val Glu Glu Val Gly 210 220 Gly Glu Val Glu Ser Lys Pro Glu Glu Lys Val Ala Val Lys Pro Glu 225 230 235 240 Ser Gln Pro Ser Asp Lys Pro Ala Glu Glu Ser Lys Val Glu Gln Ala 245 250 255 Gly Glu Pro Val Ala Pro Arg Glu Asp Glu Lys Ala Pro Val Glu Pro 260 265 270 Glu Lys Gln Pro Glu Ala Pro Glu Glu Glu Lys Ala Val Glu Glu Thr 275 280 285 Pro Lys Gln Glu Glu Ser Thr Pro Asp Thr Lys Ala Glu Glu Thr Val 290 300 Glu Pro Lys Glu Glu Thr Val Asn Gln Ser Ile Glu Gln Pro Lys Val 305 310 320

Val Glu Gln Ala Gly Glu Pro Val Ala Pro Arg Glu Asp Glu Gln Ala 340 345 350 Pro Thr Ala Pro Val Glu Pro Glu Lys Gln Pro Glu Val Pro Glu Glu 365 Glu Lys Ala Val Glu Glu Thr Pro Lys Pro Glu Asp Lys Ile Lys Gly 370 380 Ile Gly Thr Lys Glu Pro Val Asp Lys Ser Glu Leu Asn Asn Gln Ile 385 390 395 400 Asp Lys Ala Ser Ser Val Ser Pro Thr Asp Tyr Ser Thr Ala Ser Tyr 405 415 Asn Ala Leu Gly Pro Val Leu Glu Thr Ala Lys Gly Val Tyr Ala Ser 420 425 430 Glu Pro Val Lys Gln Pro Glu Val Asn Ser Glu Thr Asn Lys Leu Lys 435 440 445 Thr Ala Ile Asp Ala Leu Asn Val Asp Lys Thr Glu Leu Asn Asn Thr 450 455 460 Ile Ala Asp Ala Lys Thr Lys Val Lys Glu His Tyr Ser Asp Arg Ser 470 475 480 Trp Gln Asn Leu Gln Thr Glu Val Thr Lys Ala Glu Lys Val Ala Ala 485 490 495 Asn Thr Asp Ala Lys Gln Ser Glu Val Asn Glu Ala Val Glu Lys Leu 500 510 Thr Ala Thr Ile Glu Lys Leu Val Glu Leu Ser Glu Lys Pro Ile Leu 515 525 Thr Leu Thr Ser Thr Asp Lys Lys Ile Leu Glu Arg Glu Ala Val Ala 530 540 Lys Tyr Thr Leu Glu Asn Gln Asn Lys Thr Lys Ile Lys Ser Ile Thr 545 550 555 560 Ala Glu Leu Lys Lys Gly Glu Glu Val Ile Asn Thr Val Val Leu Thr 565 575 Asp Asp Lys Val Thr Thr Glu Thr Ile Ser Ala Ala Phe Lys Asn Leu 580 590

str pneumoniae patentin.ST25 Glu Tyr Tyr Lys Glu Tyr Thr Leu Ser Thr Thr Met Ile Tyr Asp Arg 595 600 605 Gly Asn Gly Glu Glu Thr Glu Thr Leu Glu Asn Gln Asn Ile Gln Leu 610 620 Asp Leu Lys Lys Val Glu Leu Lys Asn Ile Lys Arg Thr Asp Leu Ile 625 630 635 Lys Tyr Glu Asn Gly Lys Glu Thr Asn Glu Ser Leu Ile Thr Thr Ile 645 655 Pro Asp Asp Lys Ser Asn Tyr Tyr Leu Lys Ile Thr Ser Asn Asn Gln 660 670 Lys Thr Thr Leu Leu Ala Val Lys Asn Ile Glu Glu Thr Thr Val Asn 675 685 Gly Thr Pro Val Tyr Lys Val Thr Ala Ile Ala Asp Asn Leu Val Ser 690 700 Arg Thr Ala Asp Asn Lys Phe Glu Glu Glu Tyr Val His Tyr Ile Glu 705 710 715 720 Lys Pro Lys Val His Glu Asp Asn Val Tyr Tyr Asn Phe Lys Glu Leu 725 730 735 Val Glu Ala Ile Gln Asn Asp Pro Ser Lys Glu Tyr Arg Leu Gly Gln 740 745 750 Ser Met Ser Ala Arg Asn Val Val Pro Asn Gly Lys Ser Tyr Ile Thr 755 765 Lys Glu Phe Thr Gly Lys Leu Leu Ser Ser Glu Gly Lys Gln Phe Ala 770 780 Ile Thr Glu Leu Glu His Pro Leu Phe Asn Val Ile Thr Asn Ala Thr 785 790 795 800 Ile Asn Asn Val Asn Phe Glu Asn Val Glu Ile Glu Arg Ser Gly Gln 805 810 815 Asp Asn Ile Ala Ser Leu Ala Asn Thr Met Lys Gly Ser Ser Val Ile 820 830 Thr Asn Val Lys Ile Thr Gly Thr Leu Ser Gly Arg Asn Asn Val Ala 835 840 845 Gly Phe Val Asn Asn Met Asn Asp Gly Thr Arg Ile Glu Asn Val Ala 850 860

\_\_\_\_\_Phe\_Phe\_Gly\_Lys\_Leu-His\_Ser\_Thr\_Ser\_Gly-Asn\_Gly-Ser\_His—Thr\_Gly-865 870 875 880 Gly Ile Ala Gly Thr Asn Tyr Arg Gly Ile Val Arg Lys Ala Tyr Val 885 890 895 Asp Ala Thr Ile Thr Gly Asn Lys Thr Arg Ala Ser Leu Leu Val Pro Lys Val Asp Tyr Gly Leu Thr Leu Asp His Leu Ile Gly Thr Lys Ala 915 925 Leu Leu Thr Glu Ser Val Val Lys Gly Lys Ile Asp Val Ser Asn Pro 930 940 Val Glu Val Gly Ala Ile Ala Ser Lys Thr Trp Pro Val Gly Thr Val 945 955 960 Ser Asn Ser Val Ser Tyr Ala Lys Ile Ile Arg Gly Glu Glu Leu Phe 965 970 975 Gly Ser Asn Asp Val Asp Asp Ser Asp Tyr Ala Ser Ala His Ile Lys 980 985 Asp Leu Tyr Ala Val Glu Gly Tyr Ser Ser Gly Asn Arg Ser Phe Arg 995 1000 1005 Lys Ser Lys Thr Phe Thr Lys Leu Thr Lys Glu Gln Ala Asp Ala 1010 1020 Lys Val Thr Thr Phe Asn Ile Thr Ala Asp Lys Leu Glu Ser Asp 1025 1030 1035 Leu Ser Pro Leu Ala Lys Leu Asn Glu Glu Lys Ala Tyr Ser Ser 1040 1045 Ile Gln Asp Tyr Asn Ala Glu Tyr Asn Gln Ala Tyr Lys Asn Leu 1055 1065 Glu Lys Leu Ile Pro Phe Tyr Asn Lys Asp Tyr Ile Val Tyr Gln 1070 1080 Gly Asn Lys Leu Asn Lys Glu His His Leu Asn Thr Lys Glu Val 1085 1090 1095 Leu Ser Val Thr Ala Met Asn Asn Asn Glu Phe Ile Thr Asn Leu 1100 1110Asp Glu Ala Asn Lys Ile Ile Val His Tyr Ala Asp Gly Thr Lys 1115 1120 1125

str pneumoniae patentin.ST25
Asp Tyr Phe Asn Leu Ser Ser Ser Glu Gly Leu Ser Asn Val
1130 1140 Lys Glu Tyr Thr Ile Thr Asp Leu Gly Ile Lys Tyr Thr Pro Asn 1145 1150 Ile Val Gln Lys Asp Asn Thr Thr Leu Val Asn Asp Ile Lys Ser 1160 1165 1170 Ile Leu Glu Ser Val Glu Leu Gln Ser Gln Thr Met Tyr Gln His 1175 1180 1185 Leu Asn Arg Leu Gly Asp Tyr Arg Val Asn Ala Ile Lys Asp Leu 1190 1200 Tyr Leu Glu Glu Ser Phe Thr Asp Val Lys Glu Asn Leu Thr Asn 1205 1210 1215 Leu Ile Thr Lys Leu Val Gln Asn Glu Glu His Gln Leu Asn Asp 1220 1225 1230 Ser Pro Ala Ala Arg Gln Met Ile Arg Asp Lys Val Glu Lys Asn 1235 1240 1245 Lys Ala Ala Leu Leu Gly Leu Thr Tyr Leu Asn Arg Tyr Tyr 1250 1260 Gly Val Lys Phe Gly Asp Val Asn Ile Lys Glu Leu Met Leu Phe 1265 1275 Lys Pro Asp Phe Tyr Gly Glu Lys Val Ser Val Leu Asp Arg Leu 1280 1290 Ile Glu Ile Gly Ser Lys Glu Asn Asn Ile Lys Gly Ser Arg Thr 1295 1300 Phe Asp Ala Phe Gly Gln Val Leu Ala Lys Tyr Thr Lys Ser Gly 1310 1320 Asn Leu Asp Ala Phe Leu Asn Tyr Asn Arg Gln Leu Phe Thr Asn 1325 1335 Ile Asp Asn Met Asn Asp Trp Phe Ile Asp Ala Thr Glu Asp His 1340 1345 Val Tyr Ile Ala Glu Arg Ala Ser Glu Val Glu Glu Ile Lys Asn 1355 Ser Lys His Arg Ala Phe Asp Asn Leu Lys Arg Ser His Leu Arg 1370 1380

*** .	Ası	n_Thr 138	I](	e Lei	u Pro	)_Leu	J I POID.	A C I	1		~ I \//	entin S-Ala 139		5 s÷⊹Lei	u∹Tyr≕
							255(	ΙΊε				1399 / Ser 1410	Ala		<del></del>
۰	Lei	J Gly 141	Lys 5	Lys	s Ser	Leu	Glu 1420	Asp	) Ile	. Lys	Asp	Ile 142		l Asr	ı Lys
												Trp			
	ΑÌa	Ser 1445	Asp	Asn	val	Lys	Gln 1450	Arg	Leu	Leu	Arg	Asp 1455	Ala	val	Ile
_	Pro	11e 1460	Trp )	Glu	Gly	Tyr	Asn 1465	Ala	Pro	Gly	Gly	Trp 1470	Val	Glu	Lys
	Tyr	Gly 1475	Arg	Tyr	Asn	Thr	Asp 1480	Lys	Val	Туг	Thr	Pro 1485	Leu	Arg	Glu
	Phe	Phe 1490	Gly	Pro	Met	Asp	Lys 1495	Tyr	Tyr	Asn	Tyr	Asn 1500	Gly	Thr	Gly
	Ala	Tyr 1505	Ala	Ala	Ile	Tyr	Pro 1510	Asn	Ser	Asp	Asp	Ile 1515	Arg	Thr	Asp
	Val	Lys 1520	Tyr	Val	His	Leu	Glu 1525	Met	Val	Gly	Glu	Tyr 1530	GТу	Ile	Ser
	Val	Tyr 1535	Thr	ніѕ	Glu	Thr	Thr 1540	His	Val	Asn	Asp	Arg 1545	Ala	Ile	Tyr
	Leu	G]y 1550	Gly	Phe	Gly	His	Arg 1555	Glu	Gly	Thr	Asp	Ala 1560	Glu	Ala	Tyr
	Ala	G]n 1565	Gly	Met	Leu	Gln	Thr 1570	Pro	Val	Thr	Gly	Ser 1575	Gly	Phe	Asp
	Glu	Phe 1580	Gly	Ser	Leu	Gly	Ile 1585	Asn	Met	Val	Phe	Lys 1590	Arg	Lys	Asn
	Asp	Gly 1595	Asn	Gln	Trp	Tyr	Ile 1600	Thr	Asp	Pro	Lys	Thr 1605	Leu	Lys	Thr
	Arg	G]u 1610	Asp	Ile	Asn	Arg	Tyr 1615	Met	Lys	Gly	Tyr	Asn 1620	Asp	Thr	Leu
	Thr.	Leu 1625	Leu	Asp	Glu	Ile	Glu 1630	Ala	G] u	Ser	Val	Ile 1635	Ser	Gln	Gln

str pneumoniae patentin.ST25
Asn Lys Asp Leu Asn Ser Ala Trp Phe Lys Lys Ile Asp Arg Glu
1640 1645 1650 Tyr Arg Asp Asn Asn Lys Leu Asn Gln Trp Asp Lys Ile Arg Asn 1655 1660 1665 Leu Ser Gln Glu Glu Lys Asn Glu Leu Asn Ile Gln Ser Val Asn 1670 1680 Asp Leu Val Asp Gln Gln Leu Met Thr Asn Arg Asn Pro Gly Asn 1685 1695 Gly Ile Tyr Lys Pro Glu Ala Ile Ser Tyr Asn Asp Gln Ser Pro 1700 1700 Tyr Val Gly Val Arg Met Met Thr Gly Ile Tyr Gly Gly Asn Thr 1715 1720 1725 Ser Lys Gly Ala Pro Gly Ala Val Ser Phe Lys His Asn Ala Phe 1730 1735 1740 Arg Leu Trp Gly Tyr Gly Tyr Glu Asn Gly Phe Leu Gly Tyr 1745 1755 Ala Ser Asn Lys Tyr Lys Gln Gln Ser Lys Thr Asp Gly Glu Ser 1760 1765 1770 Val Leu Ser Asp Glu Tyr Ile Ile Lys Lys Ile Ser Asn Asn Thr 1775 1780 Phe Asn Thr Ile Glu Glu Phe Lys Lys Ala Tyr Phe Lys Glu Val 1790 1800 Lys Asp Lys Ala Thr Lys Gly Leu Thr Thr Phe Glu Val Asn Gly 1805 1815 Ser Ser Val Ser Ser Tyr Asp Asp Leu Leu Thr Leu Phe Lys Glu 1820 1830 Ala Val Lys Lys Asp Ala Glu Thr Leu Lys Gln Glu Ala Asn Gly 1835 1840 Asn Lys Thr Val Ser Met Asn Asn Thr Val Lys Leu Lys Glu Ala 1850 1860 Val Tyr Lys Lys Leu Leu Gln Gln Thr Asn Ser Phe Lys Thr Ser 1865 1870 1875 Ile Phe Lys 1880

## str pneumoniae patentin.ST25

\_\_\_\_\_\_

<212> PRT

<213> Streptococcus pneumoniae

<400> 180

Met Asn Lys Arg Leu Phe Ser Lys Met Ser Leu Val Thr Leu Pro Ile  $10 ext{10}$ 

Leu Ala Leu Phe Ser Gln Ser Val Leu Ala Glu Glu Asn Ile His Phe 20 25 30

Ser Ser Cys Lys Glu Ala Trp Ala Asn Gly Tyr Ser Asp Ile His Glu 35 40 45

Gly Glu Pro Gly Tyr Ser Ala Lys Leu Asp Arg Asp His Asp Gly Val 50 60

Ala Cys Glu Leu Lys Asn Ala Pro Lys Gly Ala Phe Lys Ala Lys Gln 65 70 75 80

Ser Thr Ala Ile Gln Ile Asn Thr Ser Ser Ala Thr Thr Ser Gly Trp 85 90 95

Val Lys Gln Asp Gly Ala Trp Tyr Tyr Phe Asp Gly Asn Gly Asn Leu 100 110

val Lys Asn Ala Trp Gln Gly Ser Tyr Tyr Leu Lys Ala Asp Gly Lys
115 120 125

Met Ala Gln Ser Glu Trp Ile Tyr Asp Ser Ser Tyr Gln Ala Trp Tyr 130 140

Tyr Leu Lys Ser Asp Gly Ser Tyr Ala Lys Asn Ala Trp Gln Gly Ala 145 150 160

Tyr Tyr Leu Lys Ser Asn Gly Lys Met Ala Gln Gly Glu Trp Val Tyr 165 170 175

Asp Ser Ser Tyr Gln Ala Trp Tyr Tyr Leu Lys Ser Asp Gly Ser Tyr 180 185 190

Ala Arg Asn Ala Trp Gln Gly Asn Tyr Tyr Leu Lys Ser Asp Gly Lys 200 205

Met Ala Lys Gly Glu Trp Val Tyr Asp Ala Thr Tyr Gln Ala Trp Tyr 210 220

str pneumoniae patentin.ST25
Tyr Leu Thr Ser Asp Gly Ser Tyr Ala Tyr Ser Thr Trp Gln Gly Asn
225 230 235 240

Tyr Tyr Leu Lys Ser Asp Gly Lys Met Ala Val Asp Glu Trp Val Asp 245 250 255

Gly Gly Arg Tyr Tyr Val Gly Ala Asp Gly Val Trp Lys Glu Val Gln 260 265 270

Ala Ser Thr Ala Ser Ser Ser Asn Asp Ser Asn Ser Glu Tyr Ser Ala 275 280 285

Ala Leu Gly Lys Ala Lys Ser Tyr Asn Ser Leu Phe His Met Ser Lys 290 295 300

Lys Arg Met Tyr Arg Gln Leu Thr Ser Asp Phe Asp Lys Phe Ser Asn 315 320

Asp Ala Ala Gln Tyr Ala Ile Asp His Leu Asp Asp 325 330

<210> 181

<211> 450

<212> PRT

<213> Streptococcus pneumoniae

<400> 181

Met Lys Val Ile Asp Gln Phe Lys Asn Lys Lys Val Leu Val Leu Gly
10 15

Leu Ala Lys Ser Gly Glu Ser Ala Ala Arg Leu Leu Asp Lys Leu Gly 20 25 30

Ala Ile Val Thr Val Asn Asp Gly Lys Pro Phe Glu Asp Asn Pro Ala 35 40 45

Ala Gln Ser Leu Leu Glu Glu Gly Ile Lys Val Ile Thr Gly Gly His 50 60

Pro Leu Glu Leu Leu Asp Glu Glu Phe Ala Leu Met Val Lys Asn Pro 65 70 75 80

Gly Ile Pro Tyr Asn Asn Pro Met Ile Glu Lys Ala Leu Ala Lys Gly 85 90 95

Ile Pro Val Leu Thr Glu Val Glu Leu Ala Tyr Leu Ile Ser Glu Ala 100 105 110

Met Ile Gly Glu Val Leu Thr Ala Ala Gly Gln His Gly Leu Leu Ser 130 140 Gly Asn Ile Gly Tyr Pro Ala Ser Gln Val Ala Gln Ile Ala Ser Asp 145 150 160 Lys Asp Thr Leu Val Met Glu Leu Ser Ser Phe Gln Leu Met Gly Val Gln Glu Phe His Pro Glu Ile Ala Val Ile Thr Asn Leu Met Pro Thr 180 185 His Ile Asp Tyr His Gly Ser Phe Ser Glu Tyr Val Ala Ala Lys Trp 195 200 205 Asn Ile Gln Asn Lys Met Thr Ala Ala Asp Phe Leu Val Leu Asn Phe 210 220 Asn Gln Asp Leu Ala Lys Asp Leu Thr Ser Lys Thr Glu Ala Thr Val 225 230 235 240 Val Pro Phe Ser Thr Leu Glu Lys Val Asp Gly Ala Tyr Leu Glu Asp 245 250 255 Gly Gln Leu Tyr Phe Arg Gly Glu Val Val Met Ala Ala Asn Glu Ile 260 265 270 Gly Val Pro Gly Ser His Asn Val Glu Asn Ala Leu Ala Thr Ile Ala 275 280 285 Val Ala Lys Leu Arg Asp Val Asp Asn Gln Thr Ile Lys Glu Thr Leu 290 300 Ser Ala Phe Gly Gly Val Lys His Arg Leu Gln Phe Val Asp Asp Ile 305 310 315 320 Lys Gly Val Lys Phe Tyr Asn Asp Ser Lys Ser Thr Asn Ile Leu Ala 325 330 335 Thr Gln Lys Ala Leu Ser Gly Phe Asp Asn Ser Lys Val Val Leu Ile 340 345 Ala Gly Gly Leu Asp Arg Gly Asn Glu Phe Asp Glu Leu Val Pro Asp 355 360 365 Ile Thr Gly Leu Lys Lys Met Val Ile Leu Gly Gln Ser Ala Glu Arg 370 380

str pneumoniae patentin.ST25 Val Lys Arg Ala Ala Asp Lys Ala Gly Val Ala Tyr Val Glu Ala Thr 385 390 395 400

Asp Ile Ala Asp Ala Thr Arg Lys Ala Tyr Glu Leu Ala Thr Gln Gly 405 410 415

Asp Val Val Leu Leu Ser Pro Ala Asn Ala Ser Trp Asp Met Tyr Ala 420 425 430

Asn Phe Glu Val Arg Gly Asp Leu Phe Ile Asp Thr Val Ala Glu Leu 435 440 445

Lys Glu 450

<210> 182

<211> 386

<212> PRT

<213> Streptococcus pneumoniae

<400> 182

Met Lys Lys Lys Phe Ala Leu Ser Phe Val Ala Leu Ala Ser Val Ala 1 5 10 15

Leu Leu Ala Ala Cys Gly Glu Val Lys Ser Gly Ala Val Asn Thr Ala 20 25 30

Gly Asn Ser Val Glu Glu Lys Thr Ile Lys Ile Gly Phe Asn Phe Glu 45

Glu Ser Gly Ser Leu Ala Ala Tyr Gly Thr Ala Glu Gln Lys Gly Ala 50 60

Gln Leu Ala Val Asp Glu Ile Asn Ala Ala Gly Gly Ile Asp Gly Lys 70 75 80

Gln Ile Glu Val Val Asp Lys Asp Asn Lys Ser Glu Thr Ala Glu Ala 85 90 95

Ala Ser Val Thr Thr Asn Leu Val Thr Gln Ser Lys Val Ser Ala Val 100 105 110

Val Gly Pro Ala Thr Ser Gly Ala Thr Ala Ala Ala Val Ala Asn Ala 115 120 125

Thr Lys Ala Gly Val Pro Leu Ile Ser Pro Ser Ala Thr Gln Asp Gly 130 140

	•				_		5	str p	neun	nonia	ae pa	atent	in.s	T25		
:	Lei	i Tui	L Lys	5. G.J.)	/G1.n	)Asp	). · J.Y.	≟∴Leu	ıPne	$-II\epsilon$	:G-1 \	/ Thr	- Phe	-Glin	Acr	··Ser
	145	)——-				—15C	)				1-5-5	;				-160-
					•											
	Phe	Glr	, GIV	/ 1 1/5	: T]o	T 7			<b></b>	7	_					
			,	Lys	165	TIE	: Ser	ASn	ıyr	va i	Ser	' Glu	Lys	Leu	Asn	Ala
					103	, i				170	,				175	
															-	
	Lvs	LVS	: Val	Val	Leu	Tyr	Thr	Acn	Acn				_			Gly
	,			180	)			Tah	185	Ald	ser	ASP	ıyr	Ala	Lys	Gly
	٠. مــــــ ه		• ::	<u> </u>						<b>~</b> .•.		·		<u>. 190</u>		
	_	_														
	Ile	Ala	Lys	Ser	Phe	Arg	Glu	Ser	Tyr	LVS	GIV	Glu	Tle	Val	ΛĪα	Asp
			195		•	_		200	•	•	,		205	· u	714	ASh
	ch.	The	Dho	1/07	47.	67.					_					
	Giu	210	Pile	vai	Ala	GIY	ASP	Thr	Asp	Phe	Gln	Ala	Ala	Leu	Thr	Lys
		210	,				215					220				•
	Met	LVS	GIV	IVS	Δsn	Dha	Acn	475	T7.	1/-7	T		-7			
	225	-, -	٠.,	-, -		230	ASP	Aia	TIG	vai	vai	Pro	GIY	Tyr	Tyr	Asn
_						230					235					240
	Glu	Ala	Gly	Lys	Ile 245	Val	Asn	Gln	Ala	Ara	GIV	Met	GTV	TIO	A = ==	1
				-	245				٠	250	Giy	MEC	Giy	TIE		Lys
															255	
	D==	<b>~</b> 7 ~	4				_									
	Pro	Tie	vai	GIY	Gly	Asp	Gly	Phe	Asn	Gly	Glu	Glu	Phe	Val	Gln	Gln
				260					265					270	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •
	ΔТа	Thr	αTa	Glu	LVC	475	c		-7.	_						
	Aiu		275	Giu	Lys	Ald	ser	ASI	Tie	Tyr	Phe	Ile	Ser	Gly	Phe	Ser
			213					280					285	-		
	Thr	Thr	Val	Glu	Val	Ser	ΔТа	LVE	ΛТэ	1.46	۸٦.	<b>D</b> b =				
		290				J	295	Lys	Ala	Lys	Ala	200	Leu	ASP	Ala	Tyr
												300				
		_														
	Arg	Ala	Lys	Tyr	Asn	Glu	Glu	Pro	Ser	Thr	Phe	Ala	Ala	Leu	Δla	Tyr
	305					310					315		,		Alu	320
																320
	A = n		\-T						_							
	ASP	ser	vaı	HIS	Leu 325	va i	Ala	Asn	Ala	Ala	Lys	Gly	Ala	Lys	Asn	Ser
					325					330				•	335	
	Glv	Glu	aſT	LVE	۸cn	Acn	1 011	430		<b>Th</b>	•					
	٠.,	J.4	T16	340	Asn	ASII	Leu	Ala	145 345	ınr	Lys	Asp	Phe	G] u	Gly	٧a٦
				340					343					350		
	Thr	Glv	Gln	Thr	Ser	Phe	Δsn	Δla	Λcn	ui e	Acn	The	\/_ T		-1-	
		•	355				, .op	360	~⊃b	1113	A311	1111	365	Lys	ınr	Ala
													303			
	Tyr	Met	Met	Thr	Met	Asn	Asn	Glv	LVS	Val	Glu	Ala	Δla	G7 II	Val	Val
		370					375	-	_			380		J. u	vai	vai
	• • • •	<b>m</b>														
	Lys	PLO														
	385															
	<210	> 1	.83													
		- 1	ر.											•	•	
	<211	> 5	13													
		•														

## str pneumoniae patentin.sT25

<212> PRT

<213> Streptococcus pneumoniae

<400> 183

Met Ser Ile Leu Glu Val Lys Asn Leu Ser His Gly Phe Gly Asp Arg
1 10 15

Ala Ile Phe Glu Asp Val Ser Phe Arg Leu Leu Lys Gly Glu His Ile 20 25 30

Gly Leu Val Gly Ala Asn Gly Glu Gly Lys Ser Thr Phe Met Ser Ile 35 40 45

Val Thr Gly Lys Met Leu Pro Asp Glu Gly Lys Val Glu Trp Ser Lys 50 60

Tyr Val Thr Ala Gly Tyr Leu Asp Gln His Ser Val Leu Ala Glu Arg 65 70 75 80

Gln Ser Val Arg Asp Val Leu Arg Thr Ala Phe Asp Glu Leu Phe Lys 85 90 95

Ala Glu Ala Arg Ile Asn Asp Leu Tyr Met Lys Met Ala Glu Asp Gly 105 110

Ala Asp Val Asp Ala Leu Met Glu Glu Val Gly Glu Leu Gln Asp Arg 115 120 125

Leu Glu Ser Arg Asp Phe Tyr Thr Leu Asp Ala Lys Ile Asp Glu Val 130 135

Ala Arg Ala Leu Gly Val Met Asp Phe Gly Met Asp Thr Asp Val Thr 150 155 160

Ser Leu Ser Gly Gly Gln Arg Thr Lys Val Leu Leu Ala Lys Leu Leu 165 170 175

Leu Glu Lys Pro Asp Ile Leu Leu Leu Asp Glu Pro Thr Asn Tyr Leu 185 190

Asp Ala Glu His Ile Asp Trp Leu Lys Arg Tyr Leu Gln Asn Tyr Glu 195 200 205

Asn Ala Phe Val Leu Ile Ser His Asp Ile Pro Phe Leu Asn Asp Val 210 215 220

Ile Asn Ile Val Tyr His Val Glu Asn Gln Gln Leu Thr Arg Tyr Ser 230 235 240 str pneumoniae patentin.ST25
Gly Asp Tyr Tyr Gln Phe Gln Glu Val Tyr Ala Met Lys Lys Ser Gln
245
250
250 Leu Glu Ala Ala Tyr Glu Arg Gln Gln Lys Glu Ile Ala Asp Leu Lys 260 265 270 Asp Phe Val Ala Arg Asn Lys Ala Arg Val Ala Thr Arg Asn Met Ala Met Ser Arg Gln Lys Lys Leu Asp Lys Met Asp Ile Ile Glu Leu Gln 290 295 300 Ser Glu Lys Pro Lys Pro Ser Phe Asp Phe Lys Pro Ala Arg Thr Pro 305 310 315 320 Gly Arg Phe Ile Phe Gln Ala Lys Asn Leu Gln Ile Gly Tyr Asp Arg 325 330 335 Pro Leu Thr Lys Pro Leu Asn Leu Thr Phe Glu Arg Asn Gln Lys Val Ala Ile Ile Gly Ala Asn Gly Ile Gly Lys Thr Thr Leu Leu Lys Ser 355 360 365 Leu Leu Gly Ile Ile Ser Pro Ile Ala Gly Glu Val Glu Arg Gly Asp 370 380 Tyr Leu Glu Leu Gly Tyr Phe Glu Gln Glu Val Glu Gly Gly Asn Arg 385 390 395 Gln Thr Pro Leu Glu Ala Val Trp Asn Ala Phe Pro Ala Leu Asn Gln 405 410 415 Ala Glu Val Arg Ala Ala Leu Ala Arg Cys Gly Leu Thr Thr Lys His 420 425 430 Ile Glu Ser Gln Ile Gln Val Leu Ser Gly Gly Glu Gln Ala Lys Val 435 440 445 Arg Phe Cys Leu Leu Met Asn Arg Glu Asn Asn Val Leu Val Leu Asp 450 460 Glu Pro Thr Asn His Leu Asp Val Asp Ala Lys Asp Glu Leu Lys Arg 465 470 475 480 Ala Leu Lys Glu Tyr Arg Gly Ser Ile Leu Met Val Cys His Glu Pro 485 490 495 Asp Phe Tyr Glu Gly Trp Ile Asp Gln Ile Trp Asp Phe Asn Asn Leu 500 510

Thr

<210> 184

<211> 399

<212> PRT

<213> Streptococcus pneumoniae

<400> 184

Met Lys Lys Lys Asn Gly Lys Ala Lys Lys Trp Gln Leu Tyr Ala Ala 1 10 15

Ile Gly Ala Ala Ser Val Val Leu Gly Ala Gly Gly Ile Leu Leu 20 25 30

Phe Arg Gln Pro Ser Gln Thr Ala Leu Lys Asp Glu Pro Thr His Leu 35 40 45

Val Val Ala Lys Glu Gly Ser Val Ala Ser Ser Val Leu Leu Ser Gly 50 60

Thr Val Thr Ala Lys Asn Glu Gln Tyr Val Tyr Phe Asp Ala Ser Lys 70 75 80

Gly Asp Leu Asp Glu Ile Leu Val Ser Val Gly Asp Lys Val Ser Glu 85 90 95

Gly Gln Ala Leu Val Lys Tyr Ser Ser Glu Ala Gln Ala Ala Tyr 100 105 110

Asp Ser Ala Ser Arg Ala Val Ala Arg Ala Asp Arg His Ile Asn Glu 115 120 125

Leu Asn Gln Ala Arg Asn Glu Ala Ala Ser Ala Pro Ala Pro Gln Leu 130 140

Pro Ala Pro Val Gly Gly Glu Asp Ala Thr Val Gln Ser Pro Thr Pro 145 150 155 160

Val Ala Gly Asn Ser Val Ala Ser Ile Asp Ala Gln Leu Gly Asp Ala 165 170 175

Arg Asp Ala Arg Ala Asp Ala Ala Ala Gln Leu Ser Lys Ala Gln Ser 180 185 190

Gln Leu Asp Ala Thr Thr Val Leu Ser Thr Leu Glu Gly Thr Val Val 195 200 205

Glu\_Val\_Asn\_Ser\_Asn\_Val\_Ser\_Lys-Ser\_Pro\_Thr-Gly-Ala-Ser-Gln\_Val 210 215 220 Met Val His Ile Val Ser Asn Glu Asn Leu Gln Val Lys Gly Glu Leu 230 235 240 Ser Glu Tyr Asn Leu Ala Asn Leu Ser Val Gly Gln Glu Val Ser Phe 250 255 Thr Ser Lys Val Tyr Pro Asp Lys Lys Trp Thr Gly Lys Leu Ser Tyr 260 265 270 Ile Ser Asp Tyr Pro Lys Asn Asn Gly Glu Ala Ala Ser Pro Ala Ala 275 280 285 Gly Asn Asn Thr Gly Ser Lys Tyr Pro Tyr Thr Ile Asp Val Thr Gly 290 295 300 Glu Val Gly Asp Leu Lys Gln Gly Phe Ser Val Asn Ile Glu Val Lys 310 315 320 Ser Lys Thr Lys Ala Ile Leu Val Pro Val Ser Ser Leu Val Met Asp 325 330 335 Asp Ser Lys Asn Tyr Val Trp Ile Val Asp Glu Gln Gln Lys Ala Lys 340 345 350 Lys Val Glu Val Ser Leu Gly Asn Ala Asp Ala Glu Asn Gln Glu Ile 355 360 365 Thr Ser Gly Leu Thr Asn Gly Ala Lys Val Ile Ser Asn Pro Thr Ser 370 380 Ser Leu Glu Glu Gly Lys Glu Val Lys Ala Asp Glu Ala Thr Asn 385 <210> 185 <211> 230 <212> PRT <213> Streptococcus pneumoniae <400> 185 Ser Glu Thr Asn His Glu Ile Asp Ser Asn Phe Ala Gly Arg Leu Asn 1 10 15 Ile Leu Arg Ala Gly Val Leu Asp Ala Asn Asp Gly Ile Ile Ser Ile 20 25 30

str pneumoniae patentin.ST25
Ala Gly Val Val Ile Gly Val Ala Ser Ala Thr Thr Asn Ile Trp Ile
35 40 45 Ile Phe Leu Ser Gly Phe Thr Ala Ile Leu Ala Gly Ala Phe Ser Met 50 60 Ala Gly Gly Glu Tyr Val Ser Val Ser Thr Pro Lys Asp Thr Glu Glu 65 70 75 80 Ala Ala Val Ser Arg Glu Lys Leu Leu Leu Asp Gln Asp Arg Glu Leu 85 90 95 Ala Lys Lys Ser Leu Tyr Ala Ala Tyr Ile Gln Asn Gly Glu Phe Lys 100 105 Thr Ser Ala Gln Leu Leu Thr Asn Lys Ile Phe Leu Lys Asn Pro Leu 115 120 125 Lys Ala Leu Val Glu Glu Lys Tyr Gly Ile Glu Tyr Glu Glu Phe Thr 130 140 Asn Pro Trp His Ala Ala Ile Ser Ser Phe Val Ala Phe Phe Leu Arg 145 150 155 160 Ser Leu Pro Pro Met Leu Ser Val Thr Ile Phe Pro Ser Asp Tyr Arg 165 170 Ile Pro Ala Thr Val Leu Ile Val Gly Val Ala Leu Leu Leu Thr Gly 180 185 Tyr Thr Ser Ala Arg Leu Gly Lys Ala Pro Thr Lys Thr Ala Met Ile  $\frac{195}{200}$ Arg Asn Leu Ala Ile Gly Leu Leu Thr Met Gly Val Thr Phe Leu Leu 210 220

Gly Gln Leu Phe Ser Ile 225 230

<210> 186

<211> 627

<212> PRT

<213> Streptococcus pneumoniae

<400> 186

Met Lys Lys Leu Thr Ser Leu Ala Leu Val Gly Ala Phe Leu Gly 10 15

Glu Ser Asn Gly His Phe Ala Met Val Asp Thr Gly Glu Asp Tyr Asp

Phe Pro Asp Gly Ser Asp Ser Arg Tyr Pro Trp Arg Glu Gly Ile Glu 65 70 75 80

Thr Ser Tyr Lys His Val Leu Thr Asp Arg Val Phe Arg Arg Leu Lys

Glu Leu Gly Val Gln Lys Leu Asp Phe Ile Leu Val Thr His Thr His 100 105 110

Ser Asp His Ile Gly Asn Val Asp Glu Leu Leu Ser Thr Tyr Pro Val 115 120 125

Asp Arg Val Tyr Leu Lys Lys Tyr Ser Asp Ser Arg Ile Thr Asn Ser 130 140

Glu Arg Leu Trp Asp Asn Leu Tyr Gly Tyr Asp Lys Val Leu Gln Thr 145 150 160

Ala Ala Glu Lys Gly Val Ser Val Ile Gln Asn Ile Thr Gln Gly Asp 165 170 175

Ala His Phe Gln Phe Gly Asp Met Asp Ile Gln Leu Tyr Asn Tyr Glu 180 180 190

Asn Glu Thr Asp Ser Ser Gly Glu Leu Lys Lys Ile Trp Asp Asp Asn 195 200 205

Ser Asn Ser Leu Ile Ser Val Val Lys Val Asn Gly Lys Lys Ile Tyr 210 220

Leu Gly Gly Asp Leu Asp Asn Val His Gly Ala Glu Asp Lys Tyr Gly 235 240

Pro Leu Ile Gly Lys Val Asp Leu Met Lys Phe Asn His His Asp 245 250 255

Thr Asn Lys Ser Asn Thr Lys Asp Phe Ile Lys Asn Leu Ser Pro Ser 260 270

Leu Ile Val Gln Thr Ser Asp Ser Leu Pro Trp Lys Asn Gly Val Asp 275 280 285

str pneumoniae patentin.ST25
Ser Glu Tyr Val Asn Trp Leu Lys Glu Arg Gly Ile Glu Arg Ile Asn
290 295 300 Ala Ala Ser Lys Asp Tyr Asp Ala Thr Val Phe Asp Ile Arg Lys Asp 305 310 315 320 Gly Phe Val Asn Ile Ser Thr Ser Tyr Lys Pro Ile Pro Ser Phe Gln 325 330 335 Ala Gly Trp His Lys Ser Ala Tyr Gly Asn Trp Trp Tyr Gln Ala Pro 340 350 Asp Ser Thr Gly Glu Tyr Ala Val Gly Trp Asn Glu Ile Glu Gly Glu 355 Trp Tyr Tyr Phe Asn Gln Thr Gly Ile Leu Leu Gln Asn Gln Trp Lys 370 380 Lys Trp Asn Asn His Trp. Phe Tyr Leu Thr Asp Ser Gly Ala Ser Ala 385 390 395 Lys Asn Trp Lys Lys Ile Ala Gly Ile Trp Tyr Tyr Phe Asn Lys Glu 405 410 415 Asn Gln Met Glu Ile Gly Trp Ile Gln Asp Lys Glu Gln Trp Tyr Tyr 420 425 430 Leu Asp Val Asp Gly Ser Met Lys Thr Gly Trp Leu Gln Tyr Met Gly 435 Gln Trp Tyr Tyr Phe Ala Pro Ser Gly Glu Met Lys Met Gly Trp Val 450 460 Lys Asp Lys Glu Thr Trp Tyr Tyr Met Asp Ser Thr Gly Val Met Lys 465 470 475 Thr Gly Glu Ile Glu Val Ala Gly Gln His Tyr Tyr Leu Glu Asp Ser 485 490 495 Gly Ala Met Lys Gln Gly Trp His Lys Lys Ala Asn Asp Trp Tyr Phe 500 510Tyr Lys Thr Asp Gly Ser Arg Ala Val Gly Trp Ile Lys Asp Lys Asp 515 Lys Trp Tyr Phe Leu Lys Glu Asn Gly Gln Leu Leu Val Asn Gly Lys 530 540 Thr Pro Glu Gly Tyr Thr Val Asp Ser Ser Gly Ala Trp Leu Val Asp 545 550 560

Ile Lys Glu Ser Lys Glu Val Val Lys Lys Asp Leu Glu Asn Lys Glu 580 580

Thr Ser Gln His Glu Ser Val Thr Asn Phe Ser Thr Ser Gln Asp Leu 605

Thr Ser Ser Thr Ser Gln Ser Ser Glu Thr Ser Val Asn Lys Ser Glu 610 620

Ser Glu Gln 625

<210> 187

<211> 456

<212> PRT

<213> Streptococcus pneumoniae

<400> 187

Met Asp Leu Gly Pro Thr Gln Arg Gly Ile Ser Val Val Ser Gln Ser 1 15

Tyr Ile Asn Val Ile Gly Ala Gly Leu Ala Gly Ser Glu Ala Ala Tyr 20 25 30

Gln Ile Ala Glu Arg Gly Ile Pro Val Lys Leu Tyr Glu Met Arg Gly 35 40 45

Val Lys Ser Thr Pro Gln His Lys Thr Asp Asn Phe Ala Glu Leu Val 50 60

Cys Ser Asn Ser Leu Arg Gly Asp Ala Leu Thr Asn Ala Val Gly Leu 65 70 75 80

Leu Lys Glu Glu Met Arg Arg Leu Gly Ser Val Ile Leu Glu Ser Ala 85 90 95

Glu Ala Thr Arg Val Pro Ala Gly Gly Ala Leu Ala Val Asp Arg Asp 100 105 110

Gly Phe Ser Gln Met Val Thr Glu Lys Val Ala Asn His Pro Leu Ile 115 120 125

Glu Val Val Arg Asp Glu Ile Thr Glu Leu Pro Thr Asp Val Ile Thr 130 140

val Ile Ala Thr Gly Pro Leu Thr Ser Asp Ala Leu Ala Glu Lys Ile 145 150 155 160 His Ala Leu Asn Asp Gly Ala Gly Phe Tyr Phe Tyr Asp Ala Ala Ala 165 170 175 Pro Ile Ile Asp Val Asn Thr Ile Asp Met Ser Lys Val Tyr Leu Lys 180 185 190 Ser Arg Tyr Asp Lys Gly Glu Ala Ala Tyr Leu Asn Ala Pro Met Thr 195 200 205 Lys Gln Glu Phe Met Asp Phe His Glu Ala Leu Val Asn Ala Glu Glu 210 220 Ala Pro Leu Ser Ser Phe Glu Lys Glu Lys Tyr Phe Glu Gly Cys Met 225 230 235 240 Pro Ile Glu Val Met Ala Lys Arg Gly Ile Lys Thr Met Leu Tyr Gly 245 250 255 Pro Met Lys Pro Val Gly Leu Glu Tyr Pro Asp Asp Tyr Thr Gly Pro 260 265 270Arg Asp Gly Glu Phe Lys Thr Pro Tyr Ala Val Val Gln Leu Arg Gln 275 280 285 Asp Asn Ala Ala Gly Ser Leu Tyr Asn Ile Val Gly Phe Gln Thr His 290 300 Leu Lys Trp Gly Glu Gln Lys Arg Val Phe Gln Met Ile Pro Gly Leu 305 310 315 Glu Asn Ala Glu Phe Val Arg Tyr Gly Val Met His Arg Asn Ser Tyr 325 330 335 Met Asp Ser Pro Asn Leu Leu Glu Gln Thr Tyr Arg Ser Lys Lys Gln 340 350 Pro Asn Leu Phe Phe Ala Gly Gln Met Thr Gly Val Glu Gly Tyr Val 355 Glu Ser Ala Ala Ser Gly Leu Val Ala Gly Ile Asn Ala Ala Arg Leu 370 375 380 Phe Lys Glu Glu Ser Glu Ala Ile Phe Pro Glu Thr Thr Ala Ile Gly 385 390 395 Ser Leu Ala His Tyr Ile Thr His Ala Asp Ser Lys His Phe Gln Pro 405 410 415

## str pneumoniae patentin.ST25 Met Asn Val Asn\_Phe\_Gly\_Ile\_Ile\_Lys\_Glu\_Leu\_Glu\_Gly\_Glu\_Arg\_Ile 420 425 430

Arg Asp Lys Lys Ala Arg Tyr Glu Lys Ile Ala Glu Arg Ala Leu Ala 435 445

## Asp Leu Glu Glu Phe Leu Thr Val 450 455

<210> 188

<211> 360

<212> PRT

<213> Streptococcus pneumoniae

<400> 188

Met Leu Ile Gly Ile Pro Lys Glu Ile Lys Asn Asn Glu Asn Arg Val

Ala Leu Thr Pro Ala Gly Val His Ser Leu Val Ser Arg Gly His Arg 20 25 30

Val Leu Ile Glu Thr Asn Ala Gly Leu Gly Ser Gly Phe Thr Asp Ala 35 40 45

Asp Tyr Gln Lys Gln Gly Ala Glu Ile Val Ala Thr Ala Gly Glu Ala 50 60

Trp Ala Ala Glu Leu Val Val Lys Val Lys Glu Ser Leu Ser Ser Glu 65 70 75 80

Tyr Gly Tyr Leu Arg Asp Asp Leu Leu Leu Phe Thr Tyr Leu His Met 85 90 95

Ala Ala Ala Pro Glu Leu Ala Asp Ala Met Leu Thr Ala Lys Thr Thr 100 105 110

Glu Thr Val Arg Asp Asn Gln Gly Gln Leu Pro Leu Leu Val Pro Met 115 120 125

Ser Glu Val Ala Gly Arg Met Ala Val Gln Ile Gly Ala His Phe Leu 130 140

Thr Lys Gln Ala Gly Gly Ser Gly Val Leu Leu Gly Gly Val Pro Gly 145 150 150

Val Pro Lys Gly Lys Val Thr Ile Ile Gly Gly Gly Val Val Gly Thr 165 170 175 str pneumoniae patentin.ST25
His Ala Ala Arg Ile Ala Leu Gly Leu Gly Ala Gln Val Thr Ile Leu
180 185 190 Asp Ile Ser Ser Lys Arg Leu Ser Val Leu Glu Glu Val Phe Gly Ser 195 200 205 Gln Ile Gln Thr Leu Met Ser Asn Ser Phe Asn Ile Glu Ala Ser Val 210 215 220 Arg Asp Ala Asp Val Val Ile Gly Ala Ile Leu Ile Pro Gly Ala Lys 225 230 235 240 Ala Pro Glu Leu Val Thr Asp Glu Met Val Lys Gln Met Arg Pro Gly 245 250 255 Ser Val Ser Leu Thr Leu Leu Leu Thr Lys Val Ala Leu Ser Lys Gln 260 265 Leu Thr Val Gln Arg Thr Met Asn Pro Ser Met Lys Asn Thr Val Phe 275 280 285 Ser Thr Met Pro Leu Pro Ile Ser Leu Val Arg Leu Leu Ala Leu Gln 290 295 300 Pro Ser Pro Pro Met Ser Leu Phe Leu Ile Ser Lys Leu Trp Leu Ala 305 310 315 320 Lys Asp Ser His Lys Gln Ser Leu Lys Met Lys Ala Cys Val Lys Val 325 330 335 Leu Leu Ile Lys Val Thr Leu Thr Tyr Gln Leu Leu Lys Asp Leu Ile 340 345

Val Thr Thr Leu Ile Ser Met Ile 355 360

<210> 189

<211> 839

<212> PRT

<213> Streptococcus pneumoniae

<400> 189

Met Lys Ile Asn Lys Lys Tyr Leu Ala Gly Ser Val Ala Val Leu Ala 1 10 15

Leu Ser Val Cys Ser Tyr Glu Leu Gly Arg His Gln Ala Gly Gln Val 20 25 30 str pneumoniae patentin.ST25

Lys Lys Glu Ser Asn Arg Val Ser Tyr Ile Asp Gly Asp Gln Ala-Gly

35

40

45 Gln Lys Ala Glu Asn Leu Thr Pro Asp Glu Val Ser Lys Arg Glu Gly 50 60 Ile Asn Ala Glu Gln Ile Val Ile Lys Ile Thr Asp Gln Gly Tyr Val Thr Ser His Gly Asp His Tyr His Tyr Tyr Asn Gly Lys Val Pro Tyr 85 90 95 Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Lys Asp Pro Asn Tyr Gln
100 105 110 Leu Lys Asp Ser Asp Ile Val Asn Glu Ile Lys Gly Gly Tyr Val Ile 115 120 125 Lys Val Asp Gly Lys Tyr Tyr Val Tyr Leu Lys Asp Ala Ala His Ala 130 140 Asp Asn Ile Arg Thr Lys Glu Glu Ile Lys Arg Gln Lys Gln Glu His 145 150 160 Ser His Asn His Gly Gly Gly Ser Asn Asp Gln Ala Val Val Ala Ala 165 170 175 Arg Ala Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Asn Ala 180 180 Ser Asp Ile Ile Glu Asp Thr Gly Asp Ala Tyr Ile Val Pro His Gly 200 205 Asp His Tyr His Tyr Ile Pro Lys Asn Glu Leu Ser Ala Ser Glu Leu 210 220 Ala Ala Ala Glu Ala Tyr Trp Asn Gly Lys Gln Gly Ser Arg Pro Ser 225 230 235 240 Ser Ser Ser Tyr Asn Ala Asn Pro Ala Gln Pro Arg Leu Ser Glu 245 250 255 Asn His Asn Leu Thr Val Thr Pro Thr Tyr His Gln Asn Gln Gly Glu 265 270 Asn Ile Ser Ser Leu Leu Arg Glu Leu Tyr Ala Lys Pro Leu Ser Glu 275 280 285 Arg His Val Glu Ser Asp Gly Leu Ile Phe Asp Pro Ala Gln Ile Thr 290 295 300

str pneumoniae patentin.ST25 Ser Arg Thr Ala Arg Gly Val Ala Val Pro His Gly Asn His Tyr His 305 310 315 320 Phe Ile Pro Tyr Glu Gln Met Ser Glu Leu Glu Lys Arg Ile Ala Arg 325 330 335 Ile Ile Pro Leu Arg Tyr Arg Ser Asn His Trp Val Pro Asp Ser Arg 340 345 350 Pro Glu Gln Pro Ser Pro Gln Ser Thr Pro Glu Pro Ser Pro Ser Pro 355 360 365 Gln Pro Ala Pro Asn Pro Gln Pro Ala Pro Ser Asn Pro Ile Asp Glu 370 380 Lys Leu Val Lys Glu Ala Val Arg Lys Val Gly Asp Gly Tyr Val Phe 385 390 395 Glu Glu Asn Gly Val Ser Arg Tyr Ile Pro Ala Lys Asp Leu Ser Ala 405 410 415 Glu Thr Ala Ala Gly Ile Asp Ser Lys Leu Ala Lys Gln Glu Ser Leu 420 425 430 Ser His Lys Leu Gly Ala Lys Lys Thr Asp Leu Pro Ser Ser Asp Arg 445 GTu Phe Tyr Asn Lys Ala Tyr Asp Leu Leu Ala Arg Ile His Gln Asp 450 455 460 Leu Leu Asp Asn Lys Gly Arg Gln Val Asp Phe Glu Ala Leu Asp Asn 465 470 475 480 Leu Leu Glu Arg Leu Lys Asp Val Pro Ser Asp Lys Val Lys Leu Val 485 490 495 Asp Asp Ile Leu Ala Phe Leu Ala Pro Ile Arg His Pro Glu Arg Leu 500 510 Gly Lys Pro Asn Ala Gln Ile Thr Tyr Thr Asp Asp Glu Ile Gln Val 515 520 525 Ala Lys Leu Ala Gly Lys Tyr Thr Thr Glu Asp Gly Tyr Ile Phe Asp 530 540Pro Arg Asp Ile Thr Ser Asp Glu Gly Asp Ala Tyr Val Thr Pro His 545 550 560 Met Thr His Ser His Trp Ile Lys Lys Asp Ser Leu Ser Glu Ala Glu 565 570 575

Arg-Ala-Ala-Ala-Gln-Ala-Tyr Ala-Lys-Glu-Lys-Gly Leu Thr Pro Pro 580 585 590 Ser Thr Asp His Gln Asp Ser Gly Asn Thr Glu Ala Lys Gly Ala Glu 595 605Ala Ile Tyr Asn Arg Val Lys Ala Ala Lys Lys Val Pro Leu Asp Arg
610 620 Met Pro Tyr Asn Leu Gln Tyr Thr Val Glu Val Lys Asn Gly Ser Leu 625 630 635 640 Ile Ile Pro His Tyr Asp His Tyr His Asm Ile Lys Phe Glu Trp Phe 645 655 Asp Glu Gly Leu Tyr Glu Ala Pro Lys Gly Tyr Thr Leu Glu Asp Leu 660 665 670 Leu Ala Thr Val Lys Tyr Tyr Val Glu His Pro Asn Glu Arg Pro His 675 680 685 Ser Asp Asn Gly Phe Gly Asn Ala Ser Asp His Val Arg Lys Asn Lys 690 700 Val Asp Gln Asp Ser Lys Pro Asp Glu Asp Lys Glu His Asp Glu Val 705 710 715 720 Ser Glu Pro Thr His Pro Glu Ser Asp Glu Lys Glu Asn His Ala Gly 725 730 735 Leu Asn Pro Ser Ala Asp Asn Leu Tyr Lys Pro Ser Thr Asp Thr Glu 740 745 750 Glu Thr Glu Glu Glu Ala Glu Asp Thr Thr Asp Glu Ala Glu Ile Pro 755 760 765 Gln Val Glu Asn Ser Val Ile Asn Ala Lys Ile Ala Asp Ala Glu Ala 770 780 Leu Leu Glu Lys Val Thr Asp Pro Ser Ile Arg Gln Asn Ala Met Glu 785 790 795 800 Thr Leu Thr Gly Leu Lys Ser Ser Leu Leu Leu Gly Thr Lys Asp Asn 815 Asn Thr Ile Ser Ala Glu Val Asp Ser Leu Leu Ala Leu Leu Lys Glu 820 830 Ser Gln Pro Ala Pro Ile Gln 835

## str pneumoniae patentin.ST25

<210> 190

<211> 1039

<212> PRT

<213> Streptococcus pneumoniae

<400> 190

Met Lys Phe Ser Lys Lys Tyr Ile Ala Ala Gly Ser Ala Val Ile Val 10 15

Ser Leu Ser Leu Cys Ala Tyr Ala Leu Asn Gln His Arg Ser Gln Glu 20 25 30

Asn Lys Asp Asn Asn Arg Val Ser Tyr Val Asp Gly Ser Gln Ser Ser 35 40 45

Gln Lys Ser Glu Asn Leu Thr Pro Asp Gln Val Ser Gln Lys Glu Gly 50 60

Ile Gln Ala Glu Gln Ile Val Ile Lys Ile Thr Asp Gln Gly Tyr Val 65 70 75 80

Thr Ser His Gly Asp His Tyr His Tyr Tyr Asn Gly Lys Val Pro Tyr 85 90 95

Asp Ala Leu Phe Ser Glu Glu Leu Leu Met Lys Asp Pro Asn Tyr Gln
100 105 110

Leu Lys Asp Ala Asp Ile Val Asn Glu Val Lys Gly Gly Tyr Ile Ile 115 120 125

Lys Val Asp Gly Lys Tyr Tyr Val Tyr Leu Lys Asp Ala Ala His Ala 130 135 140

Asp Asn Val Arg Thr Lys Asp Glu Ile Asn Arg Gln Lys Gln Glu His 145 150 160

Val Lys Asp Asn Glu Lys Val Asn Ser Asn Val Ala Val Ala Arg Ser 165 170 175

Gln Gly Arg Tyr Thr Thr Asn Asp Gly Tyr Val Phe Asn Pro Ala Asp 180 185 190

Ile Ile Glu Asp Thr Gly Asn Ala Tyr Ile Val Pro His Gly Gly His
195 200 205

Tyr His Tyr Ile Pro Lys Ser Asp Leu Ser Ala Ser Glu Leu Ala Ala 210 225

Ala Lys Ala His Leu Ala Gly Lys Asn Met Gin Pro-Ser Glo Leu Ser 235 230 235 240 Tyr Ser Ser Thr Ala Ser Asp Asn Asn Thr Gln Ser Val Ala Lys Gly 245 255 Ser Thr Ser Lys Pro Ala Asn Lys Ser Glu Asn Leu Gln Ser Leu Leu 270 Lys Glu Leu Tyr Asp Ser Pro Ser Ala Gln Arg Tyr Ser Glu Ser Asp 275 280 285 Gly Leu Val Phe Asp Pro Ala Lys Ile Ile Ser Arg Thr Pro Asn Gly 290 295 Val Ala Ile Pro His Gly Asp His Tyr His Phe Ile Pro Tyr Ser Lys 305 310 315 320 Leu Ser Ala Leu Glu Glu Lys Ile Ala Arg Met Val Pro Ile Ser Gly 335 Thr Gly Ser Thr Val Ser Thr Asn Ala Lys Pro Asn Glu Val Val Ser . 340 345 350 Ser Leu Gly Ser Leu Ser Ser Asn Pro Ser Ser Leu Thr Thr Ser Lys 355 Glu Leu Ser Ser Ala Ser Asp Gly Tyr Ile Phe Asn Pro Lys Asp Ile 370 380 Val Glu Glu Thr Ala Thr Ala Tyr Ile Val Arg His Gly Asp His Phe 385 400 His Tyr Ile Pro Lys Ser Asn Gln Ile Gly Gln Pro Thr Leu Pro Asn 405 415 Asn Ser Leu Ala Thr Pro Ser Pro Ser Leu Pro Ile Asn Pro Gly Thr 420 425 430 Ser His Glu Lys His Glu Glu Asp Gly Tyr Gly Phe Asp Ala Asn Arg 435 440 445 Ile Ile Ala Glu Asp Glu Ser Gly Phe Val Met Ser His Gly Asp His 450 Asn His Tyr Phe Phe Lys Lys Asp Leu Thr Glu Glu Gln Ile Lys Ala 465 470 475 480 Ala Gln Lys His Leu Glu Glu Val Lys Thr Ser His Asn Gly Leu Asp 485 490 495

str pneumoniae patentin.ST25 Ser Leu Ser Ser His Glu Gln Asp Tyr Pro Ser Asn Ala Lys Glu Met 500 505 510 Lys Asp Leu Asp Lys Lys Ile Glu Glu Lys Ile Ala Gly Ile Met Lys 515 520 525 Gln Tyr Gly Val Lys Arg Glu Ser Ile Val Val Asn Lys Glu Lys Asn 530 540 Ala Ile Ile Tyr Pro His Gly Asp His His Ala Asp Pro Ile Asp 545 550 555 Glu His Lys Pro Val Gly Ile Gly His Ser His Ser Asn Tyr Glu Leu 565 570 575 Phe Lys Pro Glu Glu Gly Val Ala Lys Lys Glu Gly Asn Lys Val Tyr
580
585 Thr Gly Glu Glu Leu Thr Asn Val Val Asn Leu Leu Lys Asn Ser Thr 595 600 Phe Asn Asn Gln Asn Phe Thr Leu Ala Asn Gly Gln Lys Arg Val Ser 610 620 Phe Ser Phe Pro Pro Glu Leu Glu Lys Lys Leu Gly Ile Asn Met Leu 625 630 640 Val Lys Leu Ile Thr Pro Asp Gly Lys Val Leu Glu Lys Val Ser Gly 645 650 Lys Val Phe Gly Glu Gly Val Gly Asn Ile Ala Asn Phe Glu Leu Asp 660 670 Gln Pro Tyr Leu Pro Gly Gln Thr Phe Lys Tyr Thr Ile Ala Ser Lys 675 680 685 Asp Tyr Pro Glu Val Ser Tyr Asp Gly Thr Phe Thr Val Pro Thr Ser 690 695 700 Leu Ala Tyr Lys Met Ala Ser Gln Thr Ile Phe Tyr Pro Phe His Ala 705 710 ° 715 720 Gly Asp Thr Tyr Leu Arg Val Asn Pro Gln Phe Ala Val Pro Lys Gly 725 730 735 Thr Asp Ala Leu Val Arg Val Phe Asp Glu Phe His Gly Asn Ala Tyr 740 745 750 Leu Glu Asn Asn Tyr Lys Val Gly Glu Ile Lys Leu Pro Ile Pro Lys 755 760 765

·.	- Lei	u=Asr —7-7€	- G]r 	-G.].y	⁄Thr	The	s Arg 775	Inr	neun - Ala	nonja L-Gly	ae pa ⁄∸Asn	Lys	Ile	T25 Pro	Va]	Thr
							Leu					760 Thr				G] u 800
<del></del>	Val	Pro	Ile	Leu 	G]u 805	Lys	Glu	Asn	Gln	Thr .810	Asp	Lys	Pro	Ser	Ile -815	Leu
•	Pro	Gln	Phe	Lys 820	Arg			•								
	Lys	٧a٦	Glu 835	G1 u	Pro	Lys	Thr	Ser 840	Glu	Lys	۷a٦	Glu	Lys 845	Glu	Lys	Leu
	Ser	G]u 850	Thr	Glу	Asn	Ser	Thr 855	Ser	Asn	Ser	Thr	Leu 860	Glu	Glu	۷a٦	Pro
	Thr 865	۷a٦	Asp	Pro	Val	G]n 870	Glu	Lys	Val	Ala	Lys 875	Phe	Ala	Glu	Ser	Tyr 880
	Gly	Met	Lys	Leu	Glu 885	Asn	Val	Leu	Phe	Asn 890	Met	Asp	Gly	Thr	11e 895	Glu
	Leu	Tyr	Leu	Pro 900	Ser	Gly	G]u	Val	Ile 905	Lys	Lys	Asn	Met	A7a 910	Asp	Phe
	Thr	Gly	Glu 915	Ala	Pro	Gln	Gly	Asn 920	Gly	Glu	Asn	Lys	Pro 925	Ser	Glu	Asn
	Gly	Lys 930	٧a٦	Ser	Thr	Gly	Thr 935	Va1	Glu	Asn	Gln	Pro 940	Thr	Glu	Asn	Lys
	Pro 945	Ala	Asp	Ser	Leu	Pro 950	Glu	Ala	Pro	Asn	G]u 955	Lys	Prọ	Val		Pro 960
	Glu	Asn	Ser	Thr	Asp 965	Asn .	Gly	Met	Leu	Asn 970	Pro	Glu	Gly	Asn	Val 975	Gly
	Ser	Asp	Pro	Met 980	Leu .	Asp	Pro /	Ala	Leu 985	Glu	Glu /	Ala	Pro ,	Ala ' 990	val .	Asp
	Pro	Val (	G]n 995	Glu	Lys	Leu (	GTu !	Lys 1000	Phe	Thr	Ala	Ser	Tyr 100	Gl <sub>.</sub>	y Le	u Gly
	Leu	Asp 1010		Va1	Ile	Phe	Asn 101!	Ме <sup>.</sup> 5 .	t As	p Gl	y Thi	r Ile 102	e G 20	lu Le	eu Ai	rg
	Leu.	Pro 1025	Ser	Gly	Glu	٧a٦	Ile 1030	Ly:	s Lys	s Ası	n-Lei	ser 103	- As	SP Le	eu Il	le

<210> 191

<211> 477

<212> PRT

<213> Streptococcus pneumoniae

<400> 191

Met Lys Ile Leu Phe Val Ala Ala Glu Gly Ala Pro Phe Ser Lys Thr 1 10 15

Gly Gly Leu Gly Asp Val Ile Gly Ala Leu Pro Lys Ser Leu Val Lys
20 25 30

Ala Gly His Glu Val Ala Val Ile Leu Pro Tyr Tyr Asp Met Val Glu
35 40 45

Ala Lys Phe Gly Asn Gln Ile Glu Asp Val Leu His Phe Glu Val Ser 50 60

Val Gly Trp Arg Arg Gln Tyr Cys Gly Ile Lys Lys Thr Val Leu Asn 65 70 75 80

Gly Val Thr Phe Tyr Phe Ile Asp Asn Gln Tyr Tyr Phe Phe Arg Gly. 85 90 95

His Val Tyr Gly Asp Phe Asp Asp Gly Glu Arg Phe Ala Phe Phe Gln 100 105

Leu Ala Ala Ile Glu Ala Met Glu Arg Ile Asp Phe Ile Pro Asp Leu 115 120 125

Leu His Val His Asp Tyr His Thr Ala Met Ile Pro Phe Leu Leu Lys 130 140

Glu Lys Tyr Arg Trp Ile Gln Ala Tyr Glu Asp Ile Glu Thr Val Leu 150 155 160

Thr Ile His Asn Leu Glu Phe Gln Gly Gln Phe Ser Glu Gly Met Leu 165 170 175

Gly Asp Leu Phe Gly Val Gly Phe Glu Arg Tyr Ala Asp Gly Thr Leu 180 185 190

Arg Trp Asn Asn Cys Leu Asn Trp Met Lys Ala Gly Ile Leu Tyr Ala 195 200 205 str pneumoniae patentin.ST25

Asn Arg Val-Ser Thr Val Ser Pro Ser Tyr Ala His Glu Ile Met Thr
210
215
220 Ser Gln Phe Gly Cys Asn Leu Asp Gln Ile Leu Lys Met Glu Ser Gly 235 240 Lys Val Ser Gly Ile Val Asn Gly Ile Asp Ala Asp Leu Tyr Asn Pro Gln Thr Asp Ala Leu Leu Asp Tyr His Phe Asn Gln Glu Asp Leu Ser 260 265 270 Gly Lys Ala Lys Asn Lys Ala Lys Leu Gln Glu Arg Val Gly Leu Pro 275 280 285 Val Arg Ala Asp Val Pro Leu Val Gly Ile Val Ser Arg Leu Thr Arg 290 300 Gln Lys Gly Phe Asp Val Val Val Glu Ser Leu His His Ile Leu Gln 305 310 320 Glu Asp Val Gln Ile Val Leu Leu Gly Thr Gly Asp Pro Ala Phe Glu 325 330 335 . Gly Ala Phe Ser Trp Phe Ala Gln Ile Tyr Pro Asp Lys Leu Ser Thr 340 350 Asn Ile Thr Phe Asp Val Lys Leu Ala Gln Glu Ile Tyr Ala Ala Cys 355 360. Asp Leu Phe Leu Met Pro Ser Arg Phe Glu Pro Cys Gly Leu Ser Gln 370 Met Met Ala Met Arg Tyr Gly Thr Leu Pro Leu Val His Glu Val Gly 385 390 400 Gly Leu Arg Asp Thr Val Arg Ala Phe Asn Pro Ile Glu Gly Ser Gly 405 410 415 Thr Gly Phe Ser Phe Asp Asn Leu Ser Pro Tyr Trp Leu Asn Trp Thr 420 425 430 Phe Gln Thr Ala Leu Asp Leu Tyr Arg Asn His Pro Asp Ile Trp Arg 435 445 Asn Leu Gln Lys Gln Ala Met Glu Ser Asp Phe Ser Trp Asp Thr Ala 450 460 Cys Lys Ser Tyr Leu Asp Leu Tyr His Ser Leu Val Asn 475

## str pneumoniae patentin.ST25

<210> 192

<211> 2004

<212> PRT

<213> Streptococcus pneumoniae

<400> 192

Met Glu Lys Tyr Phe Gly Glu Lys Gln Glu Arg Phe Ser Phe Arg Lys 10 15

Leu Ser Val Gly Leu Val Ser Ala Thr Ile Ser Ser Leu Phe Phe Met 20 25 30

Ser Val Leu Ala Ser Ser Ser Val Asp Ala Gln Glu Thr Ala Gly Val 35 40 45

His Tyr Lys Tyr Val Ala Asp Ser Glu Leu Ser Ser Glu Glu Lys Lys 50 60

Gln Leu Val Tyr Asp Ile Pro Thr Tyr Val Glu Asn Asp Asp Glu Thr 65 70 75 80

Tyr Tyr Leu Val Tyr Lys Leu Asn Ser Gln Asn Gln Leu Ala Glu Leu 85 90 95

Pro Asn Thr Gly Ser Lys Asn Glu Arg Gln Ala Leu Val Ala Gly Ala 100 105 110

Ser Leu Ala Ala Met Gly Ile Leu Ile Phe Ala Val Ser Lys Lys 115 120 125

Val Lys Asn Lys Thr Val Leu His Leu Val Leu Val Ala Gly Ile Gly 130 140

Asn Gly Val Leu Val Ser Val His Ala Leu Glu Asn His Leu Leu Leu 145 150 160

Asn Tyr Asn Thr Asp Tyr Glu Leu Thr Ser Gly Glu Lys Leu Pro Leu 165 170 175

Pro Lys Glu Ile Ser Gly Tyr Thr Tyr Ile Gly Tyr Ile Lys Glu Gly 180 185 190

Lys Thr Thr Ser Glu Ser Glu Val Ser Asn Gln Lys Ser Ser Val Ala 195 200 205

Thr Pro Thr Lys Gln Gln Lys Val Asp Tyr Asn Val Thr Pro Asn Phe 210 220

	V	a] A	sp.₋H	is P	ro. s	er T	hr va	str al-G	pne In ∆	umon la∵r	iae	pat	enti	n.	ST2	5				 *		 	
		<b>45</b> -				2	30			<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	2	35	3.1.U_	.G.I.I	1 <u>T.</u> 1	ır_B	ro-	/a-1- 240		 		 	
	Se	er s	er T	hr L	ys P 2	ro Tl 45	hr Gl	u Va	al G	In V	al v 50	al d	il u	Lys	5 Pr	ю Р 2	he s 55	Ser					
	Th	r G	lu L	eu I 2	le A: 50	sn Pi	O Ar	g Ly	/s G1 26	lu G1 55	յս բ	ys G	ln:	ser	Se 27	г А: 0	sp s	er	•• .	 		 	مث بعدده
	G]	n G]	u G 27	In Le	eu Al	la Gl	u Hi	s Ly 28	's As 80	in Le	eu G	lu T	hr į	-ys 285	Ly	s G	lu G	lu					
	Ly	s I] 29	e Se 0	er Pr	O Ly	's Gl	u Ly 29	s Th 5	r G1	y Va	ıl As	sn T 30	իr լ	.eu	As	n Pr	ю G	lη					
	As <sub>i</sub> 30	o G1	u Va	l Le	u Se	r G] 31	y Gli 0	n Le	u As	п Ly	'5 Pr 31	o G	lu L	.eu	Lei	и Ту	r A 3:	rg 20					
	Glu	ı Gl	u Th	r Me	t G] 32	u Th 5	r Lys	וו	e As	P Ph 33	e G7 0	n G]	lu G	Тu	ΙΊe	e G1 33	n G <sup>*</sup>	lu					
	Asr	Pro	O As	9 Le 34	u Ala	a GÌ	i Gly	/ Thi	r Va 34!	l Arg	g Va	1 Ly	's G	1n	Gไม 350	GT:	y Ly	/S					
	Leu	G])	/ Ly:	S Lys	s Va	l Glu	ılle	Val 360	l Arg	] Ile	e Ph	e Se	r v:	a1 65	Asn	Lys	s G1	u		٠			
	Glu	Va1 370	Sei	arg	g Glu	ılle	Va] 375	Ser	Thr	` Ser	Th	r Th 38	r A <sup>-</sup>	la	Pro	Ser	' Pr	o			•		
	Arg 385	Ile	Val	Glu	Lys	G]y 390	Thr	Lys	Lys	Thr	G]r 395	va <sup>°</sup>	1 17	e i	Lys	Glu	GT 40						
•	Pro	Glu	Thr	Gly	Val 405	Glu	His	Lys	Asp	Va] 410	G]n	Sei	G]	уА	47a	Ile 415	· Va	7					
	Glu	Pro	Ala	Ile 420	Gln	Pro	Glu	Leu	Pro 425	Glu	Ala	Va]	Va	7 5	Ser 130	Asp	Lys	5					
	Gly	Glu	Pro 435	Glu	Val	Gln	Pro	Thr 440	Leu	Pro	Glu	Αla	Va 44	] v 5	al'	Thr	Asp	•					
	Lys	Gly 450	Glu	Thr	Glu	٧a٦	G]n 455	Pro	Glu	Ser	Pro	Asp 460	Th	r V	al	Val	Ser						
	Asp 465	Lys	Gly	Glu	Pro	G]u 470	G] ri	Val	Ala	Pro	Leu 475	Pro	G٦ι	ŧΤ	yr .	Lys	G7 <i>y</i> 480						
	Asn :	Ile	Glu	G1n	Va1 485	Lys	Pro (	sīu '	Thr	Pro 490	Val	Glu	Lys	: T	hr i	.ys 195	Glu						

str pneumoniae patentin.ST25 Gln Gly Pro Glu Lys Thr Glu Glu Val Pro Val Lys Pro Thr Glu Glu 500 505 510 Thr Pro Val Asn Pro Asn Glu Gly Thr Thr Glu Gly Thr Ser Ile Gln 515 520 Glu Ala Glu Asn Pro Val Gln Pro Ala Glu Glu Ser Thr Thr Asn Ser 530 540 Glu Lys Val Ser Pro Asp Thr Ser Ser Lys Asn Thr Gly Glu Val Ser 545 550 555 560 Ser Asn Pro Ser Asp Ser Thr Thr Ser Val Gly Glu Ser Asn Lys Pro 565 575 Glu His Asn Asp Ser Lys Asn Glu Asn Ser Glu Lys Thr Val Glu Glu 580 585 Val Pro Val Asn Pro Asn Glu Gly Thr Val Glu Gly Thr Ser Asn Gln 595 605 Glu Thr Glu Lys Pro Val Gln Pro Ala Glu Glu Thr Gln Thr Asn Ser 610 620 Gly Lys Ile Ala Asn Glu Asn Thr Gly Glu Val Ser Asn Lys Pro Ser 625 630 640 Asp Ser Lys Pro Pro Val Glu Glu Ser Asn Gln Pro Glu Lys Asn Gly 645 650 Thr Ala Thr Lys Pro Glu Asn Ser Gly Asn Thr Thr Ser Glu Asn Gly 660 670 Gln Thr Glu Pro Glu Pro Ser Asn Gly Asn Ser Thr Glu Asp Val Ser 675 680 Thr Glu Ser Asn Thr Ser Asn Ser Asn Gly Asn Glu Glu Ile Lys Gln 690 700 Glu Asn Glu Leu Asp Pro Asp Lys Lys Val Glu Glu Pro Glu Lys Thr 705 710 715 720 Leu Glu Leu Arg Asn Val Ser Asp Leu Glu Leu Tyr Ser Leu Ser Asn 725 730 735 Gly Thr Tyr Lys Gln His Ile Ser Leu Glu Gln Val Pro Ser Asn Pro 740 745 750 Asn Ser Tyr Phe Val Lys Val Lys Ser Ser Ser Phe Lys Asp Val Tyr 755 760 765

	Le	euP	<u>ro</u> 20	V.a.	1_A1	a. Se	r.IJ	e Sei	str p	oneu: IG]-L	moni J-Ar	ae p g-Ly:	aten s Ası	tin. n Ası	ST25	s Th	e Leu	·		:	 	uer ur russ	·
								/-/-:	)		·		78	0							 		
	Ту 78	r L	ys	IJę	≘ Th	r Ala	a Lys 790	s Val	l Glu	Lys	Lei	u Glr 795	g G]ı	n Glu	ı Ile	e Gli	ser 800						
	Ar	g T	yr 	Lys	Ası	9 Asr 805	Phe	Thr	Phe	Tyr	Lei 810	ı Ala	Lys	S Lys	Gly	/ Thr 815	G]u		<b>-</b>	•	 		
	G]	u Ti	ır	Thr	Asr 820	ı Phe	e Thr	' Ser	Phe		Asn					ıle	: Asn						
	G٦١	n As	n	Pro 835	Ser	· Gly	Thr	Tyr	His 840	Leu	Ala	Ala	. Ser	Leu 845	Asn	Ala	Asn						
	G]ı	4 Va 85	1 0	Glu	Leu	Gly	Pro	Asp 855	Glu	Arg	Ser	Туг	Ile 860	Lys	Asp	Thr	Phe						
	Thr 865	; G1	у .	Arg	Leu	Ile	Gly 870	Glu	Lys	Asp	GЛу	Lys 875	Asn	Tyr	Ala	Ile	Tyr 880						
	Asn	l Le	u i	Lys	Lys	Pro 885	Leu	Phe	Glu	Asn	Leu 890	Ser	Gly	Ala	Thr	Va7 895	Glu						
	Lys	Le	u s	Ser	Leu 900	Lys	Äsn	Val	Ala	Ile 905	Ser	Gly	Lys	Asp	Asp 910	Ile	Gly						
	Ser	Le	u 4	Ala 915	Asn	Glu	Ala	Gln	Asn 920	Asn	Thr	Lys ·	Ile	Lys 925	G]n	Val	His						
	Val	As <sub>1</sub> 930	)	Пу	Val	Leu	Αla	Gly 935	Glu Ü	Arg	Gly	Ile	Gly 940	Gly	Leu	Leu	Ala						
•	Lys 945	ΑTa	e G	ilu	Gln	Ser	Ser 950	Ile	Thr	Glu	Ser	Ser 955	Phe	Lys	Gly	Arg	Ile 960					•	)
	Ile	Asr	Т	hr '	Tyr	G]u 965	Thr	Thr ,	Ala /	Ala (	Tyr 970	Asn	Ile	Gly	Gly	Met 975	Val						
	Gly	His	L	eu :	Thr 980	Gly .	Asp	Lys /	Ala L	-eu 1 985	Leu '	Thr	Lys	Ser :	Lys /	Ala '	Thr						
	val	Аlа	9	le 5 95	Ser	Ser,	Asn '	Thr A	Asn LOOO	Thr	Ser	Asp	Gln	Thr 100	Va <sup>*</sup>	ָום ו	y Gly	٠					
	Leu	Ala 101	0	Gly	Leu	۷a٦	Asp	Arg 1015	Asp	Ala	e G]r	ılle	e G]r 102	n As 20	sp Se	er T)	/r						
	Ala	G] u 102:	5	ЗÌу	Asp	Ile	Asn	Asn 1030	Va]	Lys	His	Phe	Gly 103	/ Ar 35	g va	l Al	a -		•				

str pneumoniae patentin.ST25
Gly Val Ala Gly Asn Leu Trp Asp Arg Thr Ser Gly Asp Val Arg
1040 1045 1050 His Ala Gly Ser Leu Thr Asn Val Leu Ser Asp Val Asn Val Thr 1055 1060 1065 Asn Gly Asn Ala Ile Thr Gly Tyr His Tyr Asn Glu Met Lys Val 1070 1075 1080 Lys Asp Thr Phe Ser Ser Lys Ala Asn Arg Val Tyr Asn Val Thr 1085 1090 Leu Val Lys Asp Glu Val Val Ser Lys Glu Ser Phe Glu Glu Arg 1100 1110 Gly Thr Met Leu Asp Ala Ser Gln Ile Ala Ser Lys Lys Ala Glu 1115 1120 1125 Ile Asn Pro Leu Ile Leu Pro Thr Val Glu Pro Leu Ser Thr Ser 1130 1135 1140 Gly Lys Lys Asp Ser Asp Phe Ser Lys Val Ala Tyr Tyr Gln Ala 1145 1155 Lys Arg Asn Leu Thr Tyr Lys Asn Ile Glu Lys Leu Pro Phe 1160 1170 Tyr Asn Lys Ala Thr Ile Val Lys Tyr Gly Asn Leu Val Asn Glu 1175 1180 1185 Asn Ser Leu Leu Tyr Gln Lys Glu Leu Leu Ser Ala Val Met Met 1190 1200 Lys Asp Asn Gln Val Ile Thr Asp Ile Val Ser Asn Lys Gln Thr 1205 1210 1215 Ala Asn Lys Leu Leu Leu His Tyr Lys Asp Asp Leu Ser Glu Lys 1220 1230 Leu Asp Leu Lys Tyr Gln Asn Asp Phe Ala Lys Leu Ala Glu Tyr 1235 1240 1245 Ser Leu Gly Asn Thr Gly Leu Leu Tyr Thr Pro Asn Gln Phe Leu 1250 1260 Tyr Asp Gln Thr Ser Ile Ile Lys Gln Val Leu Pro Asp Leu Gln 1265 1270 1275 Lys Val Asp Tyr His Ser Glu Ala Ile Arg Lys Thr Leu Gly Ile 1280 1290

Str pneumoniae patenting
str pneumoniae patentin.sT25 Ser Pro Asn Val Lys Glu Thr Glu Leu Tyr Leu Glu Asp Glu Phe 1300 1305
Ala Lys Thr Lys Gln Gln Leu Glu Asp Ser Leu Lys Lys Leu Leu 1310 1315 1320
Ser Ala Asp Ala Gly Leu Ala Ser Ala Asn Pro Val Thr Glu Gly
Tyr Leu Val Asp Lys Ile Lys Arg Asn Lys Glu Ala Leu Leu Leu 1340 1345 1350
Gly Leu Thr Tyr Leu Glu Arg Trp Tyr Asn Phe Ser Tyr Gly Gln 1355 1360 1365
Val Asn Val Lys Asp Leu Val Leu Tyr His Leu Asp Phe Phe Gly 1370 1380
Lys Gly Asn Ala Ser Pro Leu Asp Thr Leu Ile Glu Leu Gly Lys 1385 1390
Ser Gly Phe Asn Asn Leu Leu Ala Lys Asn Asn Val Asp Thr Tyr 1400 1405 1410
Gly Ile Ser Leu Ala Ser Gln His Gly Thr Thr Asp Leu Phe Ser 1415 1420 1425
Thr Leu Glu His Tyr Arg Lys Val Phe Leu Pro Asn Thr Ser Asn 1430 1440
Asn Asp Trp Phe Lys Ser Glu Thr Lys Ala Tyr Ile Val Glu Glu 1445 1455
Lys Ser Thr Ile Glu Glu Val Lys Thr Lys Gln Gly Leu Ala Gly 1460 1465
Thr Lys Tyr Ser Ile Gly Val Tyr Asp Arg Ile Thr Ser Ala Thr 1475 1480 1485
Trp Lys Tyr Arg Asn Met Val Leu Pro Leu Leu Thr Leu Pro Glu 1490 1495
Arg Ser Val Phe Val Ile Ser Thr Met Ser Ser Leu Gly Phe Gly 1505 1510
Ala Tyr Asp Arg Tyr Arg Ser Ser Asp His Lys Ala Gly Lys Ala 1520 1525 1530
Leu Asn Asp Phe Val Glu Glu Asn Ala Arg Glu Thr Ala Lys Arg 1535 1540 1545

str pneumoniae patentin.ST25
Gln Arg Asp His Tyr Asp Tyr Trp Tyr Arg Ile Leu Asp Asp Asn
1550
1560 Ala Arg Glu Lys Leu Tyr Arg Asn Ile Leu Leu Tyr Asp Ala Tyr 1565 1570 Lys Phe Gly Asp Asp Asn Thr Val Gly Lys Ala Thr Glu Val Ala 1580 1590 Asp Phe Asp Asn Pro Asn Pro Ala Met Gln His Phe Phe Gly Pro 1595 1605 Val Gly Asn Lys Val Gly His Asn Gln His Gly Ala Tyr Ala Thr 1610 1620 Gly Asp Ala Val Tyr Tyr Met Gly Tyr Arg Met Leu Asp Lys Asp 1625 1635 Gly Ala Ile Thr Tyr Thr His Glu Met Thr His Asp Ser Asp Gln 1640 1650Asp Ile Tyr Leu Gly Gly Tyr Gly Arg Ser Gly Leu Gly Pro 1655 1660 Glu Phe Phe Ala Lys Gly Leu Leu Gln Ala Pro Asp His Pro Asp 1670 1680 Asp Ala Thr Ile Thr Ile Asn Ser Ile Leu Lys His Ser Lys Ser 1685 1690 1695 Asp Ser Thr Glu Ser Arg Arg Leu Gln Val Leu Asp Pro Thr Thr 1700 1710 Arg Phe Asn Asn Ala Asp Asp Leu Lys Gln Tyr Val His Asn Met 1715 1720 1725 Phe Asp Val Val Tyr Met Leu Glu Tyr Leu Glu Gly Asn Ser Ile 1730 1740 Leu Lys Leu Asp Thr Asn Gln Lys Gln Gln Leu Leu Arg Lys Val 1745 1750 Thr Asn Glu Tyr His Pro Asp Pro Asp Gly Asn Lys Val Tyr Ala 1760 1765 Thr Asn Val Val Arg Asn Leu Thr Val Glu Glu Val Glu Arg Leu 1775 1780 1785 Arg Ser Phe Asn Asp Leu Ile Asp Asn Asn Ile Leu Ser Ser Arg 1790 1800

str pneumoniae patentin.sT25 Glu Tyr Ala Ser Gly Lys Tyr Glu Arg Asn Gly Tyr Phe Thr Ile 1805 1810 1815 Lys Leu Phe Ala Pro Ile Tyr Ala Ala Leu Ser Asn Asp Ile Gly 1820 1830 Ala Ala Lys Gly Phe Lys Asp Gly Met Val Pro Tyr Ile Ser Asn 1850 1860 Gln Tyr Glu Glu Glu Ala Lys Gln Lys Gly Lys Thr Ile Asn Leu 1865 1870 1875 Tyr Gly Lys Thr Arg Gly Leu Val Thr Asp Asp Leu Val Leu Glu 1880 1890 Lys Val Phe Asn Asn Gln Tyr His Thr Trp Ser Glu Phe Lys Lys 1895 Ala Met Tyr Gln Glu Arg Gln Asp Gln Phe Asp Arg Leu Asn Lys 1910 1920 Val Thr Phe Asn Asp Thr Thr Gln Pro Trp Gln Thr Phe Ala Lys 1930 1935 Lys Thr Thr Ser Ser Val Asp Glu Leu Gln Lys Leu Met Asp Val 1940 1950 Ala Val Arg Lys Asp Ala Glu His Asn Tyr Tyr His Trp Asn Asn 1955 1960 1965 Tyr Asn Pro Asp Ile Asp Ser Glu Val His Lys Leu Lys Arg Ala 1970 1980 Ile Phe Lys Ala Tyr Leu Asp Gln Thr Asn Asp Phe Arg Ser Ser 1985 1990 1995 Ile Phe Glu Asn Lys Lys. <210> 193 <211> 819 <212> PRT <213> Streptococcus pneumoniae <400> 193

str pneumoniae patentin.ST25
Met Lys Ile Asn Lys Lys Tyr Leu Ala Gly Ser Val Ala Val Leu Ala
1 5 10 15 Leu Ser Val Cys Ser Tyr Glu Leu Gly Arg Tyr Gln Ala Gly Gln Asp Lys Lys Glu Ser Asn Arg Val Ala Tyr Ile Asp Gly Asp Gln Ala Gly 35 40 Gln Lys Ala Glu Asn Leu Thr Pro Asp Glu Val Ser Lys Arg Glu Gly 50 60 Ile Asn Ala Glu Gln Ile Val Ile Lys Ile Thr Asp Gln Gly Tyr Val Thr Ser His Gly Asp His Tyr His Tyr Tyr Asn Gly Lys Val Pro Tyr 85 90 95 Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Lys Asp Pro Asn Tyr Gln
100 105 110 Leu Lys Asp Ser Asp Ile Val Asn Glu Ile Lys Gly Gly Tyr Val Ile 115 120 125 Lys Val Asn Gly Lys Tyr Tyr Val Tyr Leu Lys Asp Ala Ala His Ala 130 140 Asp Asn Ile Arg Thr Lys Glu Glu Ile Lys Arg Gln Lys Gln Glu Arg 145 150 155 160 Ser His Asn His Asn Ser Arg Ala Asp Asn Ala Val Ala Ala Arg 165 170 175 Ala Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Asn Ala Ser 180 185 Asp Ile Ile Glu Asp Thr Gly Asp Ala Tyr Ile Val Pro His Gly Asp 195 200 205 His Tyr His Tyr Ile Pro Lys Asn Glu Leu Ser Ala Ser Glu Leu Ala 210 220 Ala Ala Glu Ala Tyr Trp Asn Gly Lys Gln Gly Ser Arg Pro Ser Ser 225 230 235 Ser Ser Ser Tyr Asn Ala Asn Pro Ala Gln Pro Arg Leu Ser Glu Asn 245 250 255 His Asn Leu Thr Val Thr Pro Thr Tyr His Gln Asn Gln Gly Glu Asn 260 265 270

						-						•	•		
I <u>.l.</u>	Ser	Ser 275	Le	i-Lei	JAr	g- G]	str u-Lei 280	pneui u-Tyi 0	moni Ala	ae pa	eteni Pro	Lei	ı≞Sei	r:≐G]	u Arg
												ZO. Glr	,		r Ser
Arg 305	Thr	Ala	Arg	Gly	/ Val	A1a	a Val	Pro	His	G]y 315	Asn	His	Tyr	His	S Phe 320
IJe	Pro	Tyr	Glu	G]n 325	Met	: Ser	Glu	Leu	G]u 330	Lys	Arg	Ile	Ala		l Ile
Ile	Pro	Leu	Arg 340	Tyr	Arg	Ser	` Asn	His 345	Trp	۷aΊ	Pro	Asp	Ser 350	Arg	Pro
Glu	Glu	Pro 355	Ser	Pro	Gln	Pro	Thr 360	Pro	Glu	Pro	Ser	Pro 365	Ser	Pro	Gln
Pro	Ala 370	Pro	Ser	Asn	Pro	11e 375	Asp	Glu	Lys	Leu	Va1 380	Lys	Glu	Ala	Val
Arg 385	Lys	Val	Gly	Asp	G]y 390	Tyr	Val	Phe	Glu	G]u 395	Asn	Gly	Val	Ser	Arg 400
Tyr	Ile	Pro .	Ala	Lys 405	Asp	Leu	Ser	ΑΊa	Glu. 410	Thr	Ala	Ala	Gly	Ile 415	Asp
Ser	Lys	Leu ,	41a 420	Lys	Gln	Glu	Ser	Leu 425	Ser	His	Lys	Leu	G]y 430	Thr	Lys
Lys	Thr A	Asp 1 135	Leu	Pro	Ser	Ser	Asp 440	Arg	Glu	Phe <sup>-</sup>	Tyr ,	Asn 445	Lys	Ala	Tyr
Asp t	.eu 1 150	₋eu ≉	Na A	Arg	Ile	His 455	Gln .	Asp	Leu (	Leu A	\sp / 160	Asn	Lys (	Gly	Arg
Gln V 465	/al A	.sp F	he o	Glu /	470	Leu	Asp ,	Asn (	Leu 1	Leu 6 175	Slu A	rg ۱	-eu i	Lys .	Asp 480
Val s	er s	er A	sp L	.ys \ 185	/alı	Lys	Leu \	√al d	31u A 190	\sp I	le L	.eu A	la p	Phe 1	Leu
Ala P	ro I	le A 5	rg н 00	lis F	ro (	a7u ,	Arg L	_eu	ily L	ys P	ro A	sn A 5	la 6 10	iln 1	(Te
Thr T	yr Ti 5:	hr A: 15	sp A	sp G	ilu I	:le (	31n V 520	al A	lа L	ys L	eu A 5	la G 25	lу L	ys 1	уr
Thr The 55	or G	lu As	sp G	]у т	yr I 5	le F 35	he A	sp P	ro A	rg As 54	sp I 40	le T	hr s	er A	sp

Str pneumoniae patentin.ST25
Glu Gly Asp Ala Tyr Val Thr Pro His Met Thr His Ser His Trp Ile
545
550
555
560 Lys Lys Asp Ser Leu Ser Glu Ala Glu Arg Ala Ala Ala Gln Ala Tyr
565 570 575 Ala Lys Glu Lys Gly Leu Thr Pro Pro Ser Thr Asp His Gln Asp Ser 580 585 590Gly Asn Thr Glu Ala Lys Gly Ala Glu Ala Ile Tyr Asn Arg Val Lys 595 600 Ala Ala Lys Lys Val Pro Leu Asp Arg Met Pro Tyr Asn Leu Gln Tyr 610 620 Thr Val Glu Val Lys Asn Gly Ser Leu Ile Ile Pro His Tyr Asp His 625 630 635 Tyr His Asn Ile Lys Phe Glu Trp Phe Asp Glu Gly Leu Tyr Glu Ala 645 655 Pro Lys Gly Tyr Thr Leu Glu Asp Leu Leu Ala Thr Val Lys Tyr Tyr 660 665 670 Val Glu His Pro Asn Glu Arg Pro His Ser Asp Asn Gly Phe Gly Asn 675 680 Ala Ser Asp His Val Gln Arg Asn Lys Asn Gly Gln Ala Asp Thr Asn 690 700 Gln Thr Glu Lys Pro Ser Glu Glu Lys Pro Gln Thr Glu Lys Pro Glu 705 710 715 720 Glu Glu Thr Pro Arg Glu Glu Lys Pro Gln Ser Glu Lys Pro Glu Ser 725 730 735 Pro Lys Pro Thr Glu Glu Pro Glu Glu Ser Pro Glu Glu Ser Glu Glu 740 745 750 Pro Gln Val Glu Thr Glu Lys Val Glu Glu Lys Leu Arg Glu Ala Glu 755 760 765 Asp Leu Leu Gly Lys Ile Gln Asp Pro Ile Ile Lys Ser Asn Ala Lys 770 780 Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp 785 790 795 800 Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys 805 810 815 <210> 194

<211> 802

<212>

Streptococcus pneumoniae

<400> 194

Leu Ile Leu Ser Val Cys Ser Tyr Glu Leu Gly Leu Tyr Gln Ala Arg 1 10 15

Thr Val Lys Glu Asn Asn Arg Val Ser Tyr Ile Asp Gly Lys Gln Ala 20 25 30

Thr Gln Lys Thr Glu Asn Leu Thr Pro Asp Glu Val Ser Lys Arg Glu 35 40 45

Gly Ile Asn Ala Glu Gln Ile Val Ile Lys Ile Thr Asp Gln Gly Tyr 50 60

Val Thr Ser His Gly Asp His Tyr His Tyr Tyr Asn Gly Lys Val Pro 75 80

Tyr Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Lys Asp Pro. Asn Tyr 85 90 95

Lys Leu Lys Asp Glu Asp Ile Val Asn Glu Val Lys Gly Gly Tyr Val 100 105 110

Ile Lys Val Asp Gly Lys Tyr Tyr Val Tyr Leu Lys Asp Ala Ala His 115 120 125

Ala Asp Asn Val Arg Thr Lys Glu Glu Ile Asn Arg Gln Lys Gln Glu 130

His Ser Gln His Arg Glu Gly Gly Thr Pro Arg Asn Asp Gly Ala Val 145 150 160

Ala Leu Ala Arg Ser Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile 165 170 175

Phe Asn Ala Ser Asp Ile Ile Glu Asp Thr Gly Asp Ala Tyr Ile Val 180 185 190

Pro His Gly Asp His Tyr His Tyr Ile Pro Lys Asn Glu Leu Ser Ala 195 200 205.

str pneumoniae patentin.ST25 Ser Glu Leu Ala Ala Glu Ala Phe Leu Ser Gly Arg Gly Asn Leu 210 215 220 Ser Asn Ser Arg Thr Tyr Arg Arg Gln Asn Ser Asp Asn Thr Ser Arg 225 230 235 Thr Asn Trp Val Pro Ser Val Ser Asn Pro Gly Thr Thr Asn Thr Asn 245 250 255 Thr Ser Asn Asn Ser Asn Thr Asn Ser Gln Ala Ser Gln Ser Asn Asp 260 270 Ile Asp Ser Leu Leu Lys Gln Leu Tyr Lys Leu Pro Leu Ser Gln Arg 275 280 285 His Val Glu Ser Asp Gly Leu Val Phe Asp Pro Ala Gln Ile Thr Ser 290 300 Arg Thr Ala Arg Gly Val Ala Val Pro His Gly Asp His Tyr His Phe 305 310 315 Ile Pro Tyr Ser Gln Met Ser Glu Leu Glu Glu Arg Ile Ala Arg Ile 325 330 335 Ile Pro Leu Arg Tyr Arg Ser Asn His Trp Val Pro Asp Ser Arg Pro 340 345 Glu Gln Pro Ser Pro Gln Pro Thr Pro Glu Pro Ser Pro Gly Pro Gln 355 360 365 Pro Ala Pro Asn Leu Lys Ile Asp Ser Asn Ser Ser Leu Val Ser Gln 370 380 Leu Val Arg Lys Val Gly Glu Gly Tyr Val Phe Glu Glu Lys Gly Ile 385 390 395 400 Ser Arg Tyr Val Phe Ala Lys Asp Leu Pro Ser Glu Thr Val Lys Asn 405 415 Leu Glu Ser Lys Leu Ser Lys Gln Glu Ser Val Ser His Thr Leu Thr 420 425 430 Ala Lys Lys Glu Asn Val Ala Pro Arg Asp Gln Glu Phe Tyr Asp Lys 445 445 Ala Tyr Asn Leu Leu Thr Glu Ala His Lys Ala Leu Phe Glu Asn Lys 450 460 Gly Arg Asn Ser Asp Phe Gln Ala Leu Asp Lys Leu Leu Glu Arg Leu 465 470 475 480 str pneumoniae patentin.sT25 Asn Asp Glu Ser Thr Asn Lys Glu Lys Leu Val Asp Asp Leu Leu Ala 485 490 495 Phe Leu Ala Pro Ile Thr His Pro Glu Arg Leu Gly Lys Pro Asn Ser 500 510 Gln Ile Glu Tyr Thr Glu Asp Glu Val Arg Ile Ala Gln Leu Ala Asp Lys Tyr Thr Thr Ser Asp Gly Tyr Ile Phe Asp Glu His Asp Ile Ile 530 540 Ser Asp Glu Gly Asp Ala Tyr Val Thr Pro His Met Gly His Ser His 545 555 560 Trp Ile Gly Lys Asp Ser Leu Ser Asp Lys Glu Lys Val Ala Gln 565 . 575 Ala Tyr Thr Lys Glu Lys Gly Ile Leu Pro Pro Ser Pro Asp Ala Asp 580 590 Val Lys Ala Asn Pro Thr Gly Asp Ser Ala Ala Ile Tyr Asn Arg 595 600 605 Val Lys Gly Glu Lys Arg Ile Pro Leu Val Arg Leu Pro Tyr Met Val 610 620 Glu His Thr Val Glu Val Lys Asn Gly Asn Leu Ile Ile Pro His Lys 625 630 640 Asp His Tyr His Asn Ile Lys Phe Ala Trp Phe Asp Asp His Thr Tyr 645 655 Lys Ala Pro Asn Gly Tyr Thr Leu Glu Asp Leu Phe Ala Thr Ile Lys 660 670 Tyr Tyr Val Glu His Pro Asp Glu Arg Pro His Ser Asn Asp Gly Trp 675 680 685 Gly Asn Ala Ser Glu His Val Leu Gly Lys Lys Asp His Ser Glu Asp 690 700 Pro Asn Lys Asn Phe Lys Ala Asp Glu Glu Pro Val Glu Glu Thr Pro 705 710 715 720 Ala Glu Pro Glu Val Pro Gln Val Glu Thr Glu Lys Val Glu Ala Gln 725 730 735 Leu Lys Glu Ala Glu Val Leu Leu Ala Lys Val Thr Asp Ser Ser Leu 740 745 750

str pneumoniae patentin.ST25 Lys Ala Asn Ala Thr Glu Thr Leu Ala Gly Leu Arg Asn Asn Leu Thr 755 760 765

Leu Gln Ile Met Asp Asn Asn Ser Ile Met Ala Glu Ala Glu Lys Leu 770 780

Leu Ala Leu Leu Lys Gly Ser Asn Pro Ser Ser Val Ser Lys Glu Lys 785 790 795 800

Ile Asn

<210> 195

<211> 1084

<212> PRT

<213> Streptococcus pneumoniae

<400> 195

Met Pro Val Glu Ile Lys Thr Thr Lys Glu Ile His Pro Lys Ile Tyr 10 15

Ala Tyr Thr Thr Pro Thr Val Thr Ser Asn Glu Gly Trp Ile Lys Ile 20 25 30

Gly Tyr Thr Glu Arg Asp Val Thr Gln Arg Ile Lys Glu Gln Thr His 35 40 45.

Thr Ala His Ile Ala Thr Asp Val Leu Trp Thr Gly Asp Ala Ala Tyr 50 55 60

Thr Glu Glu Pro Asp Lys Gly Lys Thr Phe Lys Asp His Asp Phe His 65 70 75 80

His Phe Leu Ser Phe His Asp Val Glu Arg Arg Pro Lys Thr Glu Trp 85 90 95

Phe Tyr Phe Asn Gly Thr Pro Glu Lys Ser Lys Asn Leu Phe Asp Lys 100 105

Phe Val Gln His Asp Leu Ser Gly Tyr Gln Pro Gly Lys Gly Gln Asp 115 120 125

Tyr Thr Leu Arg Gln Glu Glu Glu Ala Val Ala Lys Thr Leu Ala 130 140

Tyr Phe Gln Glu His Ala Gly Gly Lys Phe Leu Trp Asn Ala Lys Pro 145 150 155 160

	<b></b>	rg:-P	he o	57.yi	<u>.</u> .vs==	Thr	∵l er	I Sa	str	pne	umoi	nia	e pa	ten	tin.	ST25		
		<del>-</del>				165		1 36	1 11	11.	yr p	\sp .70	Leu	<u> </u>	a Ar	g_Arc	_Met	_G]u
	ΑĪ	ia v	al A	sn \	/a] ı l80	Leu	Ιlε	va	ገ ፐታ	ır A: 18		•	Pro	ΑÌa	ı Ile	e Ala 190	175 Asn	Ser
	Tr	р Т <u>у</u>	yr A 1	sp A 95	sp F.	he	Glu	Th	r Ph	e I 0	le A	la 	G]y	Glr	Thr 205			Lys
	Ph	e Va 21	al s lo	er G	lu s	er									Ile		Ser	Arg
	G1 22	n G1 5	u Pl	he L	eu G	Ίу	11e 230	Lei	ΓA ι	a As	p A:	sp	Va 1 235	Arg	G٦n	Leu	Ala	Phe 240
	IÌ	e Se	r L€	eu G	ln A 2	sp 45	Leu	Lys	G G T	y Se	r Va 25	al <sup>·</sup> 50	Tyr	Leu	Gly	Gly	Glu 255	His
	Ası	р Lу	s Le	eu Ly 20	ys T 50	rp '	۷a٦	Thr	AS	26	и Н1 5	is -	Ггр	Asp	Leu	Leu 270	۷a٦	Ile
	ASI	G]	u A] 27	а н <del>і</del> '5	is G	lu (	Gly	Val	Asp 280	Th:	r Ph	ie i	Lys	Thr	Asp 285	Gln	Ala	Phe
	Asr	1 Ly: 29(	s Il O	e Ar	'g Ai	rg A	Asn	Phe 295	Thr	. Tei	и Ні	s L	.eu	ser 300	Gly	Thr	Ser	Phe
	Lys 305	Ala	a Le	TA u	a Ly	/s G	ily 10	Asp	Phe	The	r Gl	u G 3	ilu 15	Gln	Ile	Tyr	Asn	Trp 320
	Ser	Tyr	TA:	a As	p G7 32	u G !5	iln .	Ala	Ala	Lys	33	r s O	er	Тгр	Ser	Leu	G]u ( 335	Gln
•	Glu	Glu	ı Glı	4 As	n Pr O	ОΤ	yr (	Glu	Ser	Leu 345	Pro	D G	In I	Leu .	Asn	Leu 350	Phe 7	Γhr
	Tyr	Gln	Me1 355	Se:	r Gl	n M	et :	Ile	Gly 360	Glu	Lys	5 <b>L</b>	eu (	alu i	Lys 365	Gly ,	4la d	S]n
	Ile	Asp 370	Gly	∕ G](	J AS	n I	le /	Asp 375	Tyr	Val	Phe	≥ A:	sp L	.eu :	ser (	G]u I	Phe P	he
	A7a 385	Thr	Asp	Asp	) Lys	s G 39	ly ι 90	-ys	Phe	Ile	His	G] 39	lu н 95	is A	ا sp	/al /	rg A 4	sn 00
	Trp	Leu	Asp	Thr	Let 405	ı S€	er s	er .	Asn	<b>G</b> lu	Lys 410	Ту	r P	ro F	he s	Ser T	hr L 15	ys
	Glu	Leu	Arg	Asn 420	Glu	I. Le	eu L	ys I	His	Thr 425	Phe	Tr	p Lo	eu L	eu G 4	ilu A 30	rg v	a]

str pneumoniae patentin.ST25
Ala Ser Ala Lys Ala Leu Lys Ala Leu Leu Glu Glu His Pro Ile Tyr
435
440
445 Glu Asn Tyr Glu Ile Val Leu Ala Ala Gly Asp Gly Arg Met Ser Glu 450 460 Glu Asp Asp Lys Val Lys Leu Lys Ser Leu Asp Leu Val Arg Lys Ala 465 470 480 Ile Ala Glu Asn Asp Lys Thr Ile Thr Leu Ser Val Gly Gln Leu Thr 485 490 495 Thr Gly Val Thr Ile Pro Glu Trp Thr Gly Val Leu Met Leu Ser Asn 500 510 Leu Lys Ser Pro Ala Leu Tyr Met Gln Ala Ala Phe Arg Ala Gln Asn 515 520 525 Pro Tyr Ser Trp Ser Asp Asn Lys Gly Asn His Phe Arg Lys Glu Arg 530 540 Ala Tyr Val Phe Asp Phe Ala Pro Glu Arg Thr Leu Ile Leu Phe Asp 545 550 555 Glu Phe Ala Asn Asn Leu Leu Leu Val Thr Ala Ala Gly Arg Gly Thr 565 570 575 Ser Ala Thr Arg Glu Glu Asn Ile Arg Glu Leu Leu Asn Phe Pro 580 585 590 Ile Ile Ala Glu Asp Arg Ala Gly Lys Met Val Glu Ile Asp Ala Lys 595 600 Ala Val Leu Thr Thr Pro Arg Gln Ile Lys Ala Arg Glu Val Leu Lys 610 620 Arg Gly Phe Met Ser Asn Leu Leu Phe Asp Asn Ile Ser Gly Ile Phe 625 635 640 Gln Ala Ser Gln Thr Val Leu Asp Ile Leu Asn Glu Leu Pro Val Glu 645 650 655 Lys Glu Gly Lys Val Gln Asp Ser Ser Asp Leu Leu Asp Phe Ser Asp 660 670 Val Thr Val Asp Asp Glu Gly Asn Ala Val Val Asp His Glu Ile Val 675 680 685 Val Asn Gln Gln Met Arg Leu Phe Gly Glu Lys Val Tyr Gly Leu Gly 690 700

. <u></u>	G1	<u>u</u> 9	er	' va	<u>] A</u> ]	a Gl	u Le	u Va	str ] Th	pneu rLy	S. AS	ip. G I	u GI	u-Ar	a Th	; rcl	n Lys
			··-					U				7-1	.5		9		720 ~
	G٦	n L	.eu	۷a	l As	n As 72	p Lei 5	u Se	г <b>L</b> y	s Th	r va 73	1 Se	r Se	r Va	ווו	e Va 73	] G]u 5
•	G1	u L	eu	Lys	740	A As	р Туі	se	r Le	u Ly 74	s Th	r Ar	g G1	u Th	r G1 75	u G]।	n Ile
	Ly	s L	ys	G]n 755	Ile	2 Th	r Ala	t The		u Gli					g Ly: 5	5 Ası	n Asp
	ΙÌ	e G 7	1u 70	Arg	Lys	: Ile	e Ser	G](	A]	a His	s IÌ	e Ly:	s G]; 780	ı Glı	u Lei	ı Glı	ı Gln
																	Glu 800
											0	•				815	
										023	•				830	)	Phe
	Ile	G]	u	G]n 835	Val	Glu	Ile	Lys	Arg 840	Val	Glu	ı Gln	Leu	Lys 845	Gln	Ser	Ala
	Gln	As 85	р 0	Glu	Ile	Arg	Asp	His 855	Leu	Arg	Gly	' Phe	Ala 860	Arg	Thr	Ile	Pro
	Ser 865	Ph	e :	Ile	Met	Ala	Tyr 870	Gly	Asp	Gln	Thr	Leu 875	Thr	Leu	Asp	Asn	Phe 880
	Asp	A7	a i	Phe	Val	Pro 885	Glu	His	Val	Phe	Tyr 890	Glu	Val	Thr	Gly	Ile 895	Thr
	Ile	Asį	р	5ln	Phe 900	Arg	Туг	Leu	Arg	Asp 905	GТу	Gly	Gln	Asp	Phe 910	Ala	Gly
	His	Lei	1	Phe . 915	Asp	Lys	Ala	Thr	Phe 920	Asp	Glu	Ala	Ile	G]n 925	Glu	Phe	Leu
	Arg	930	5 L	.ys	Lys	Glu	Leu	Ala 935	Asp	Tyr	Phe	Lys	Asp 940	Gln	Lys	Glu	Asp
	Ile 945	Phe	Α 6	sp -	Tyr	Ile	Pro 950	Pro	G1n	Lys	Thr	Asn 955	G1n	Ile	Phe		Pro 960
٠	Lys <sub>.</sub>	Arg	įV	al N	/al	Lys 965	Arg	Met.	Val	Asp	Asp 970	Leu	Glu	Lys		Asn <sup>-</sup> 975	Pro

str pneumoniae patentin.ST25
Gly Ile Phe Asp Asp Pro Ser Lys Thr Phe Ile Asp Leu Tyr Met Lys
980 985 990

Ser Gly Leu Tyr Ile Ala Glu Leu Val Lys Arg Leu Tyr Asn Ser Asn 995 1000 1005

Gly Leu Lys Glu Ala Phe Pro Asn Pro Glu Glu Arg Leu Lys His 1010 1015 1020

Ile Leu Glu Lys Gln Val Tyr Gly Phe Ala Pro Ser Glu Ile Ile 1025 1030 1035

Tyr Asn Ile Ser Thr Asn Phe Ile Phe Gly Asn Leu Ser Lys Asp 1040 1045 1050

Ile Ser Arg Lys Asn Phe Val Leu Ala Asp Thr Ile Pro Ala Ala 1055 1060 1065

Lys Glu Gly Ser Ile Gln Lys Leu Val Asp Ser Tyr Phe Glu Asn 1070 1080

Asn

<210> 196

<211> 234

<212> PRT

<213> Streptococcus pneumoniae

<400> 196

Met Lys Lys Ile Leu Ile Val Asp Asp Glu Lys Pro Ile Ser Asp Ile 1 5 10 15

Ile Lys Phe Asn Met Thr Lys Glu Gly Tyr Glu Val Val Thr Ala Phe 20 25 30

Asn Gly Arg Glu Ala Leu Glu Gln Phe Glu Ala Glu Gln Pro Asp Ile 35 40 45

Ile Ile Leu Asp Leu Met Leu Pro Glu Ile Asp Gly Leu Glu Val Ala 50 60

Lys Thr Ile Arg Lys Thr Ser Ser Val Pro Ile Leu Met Leu Ser Ala 65 70 75 80

Lys Asp Ser Glu Phe Asp Lys Val Ile Gly Leu Glu Leu Gly Ala Asp 85 90 95

str pneumoniae patentin.ST25

---- Asp Tyr Val Thr Lys-Pro Phe Ser Asn Arg Glu Leu Gln Ala Arg Val

100

105

110

Lys Ala Leu Leu Arg Arg Ser Gln Pro Met Pro Val Asp Gly Gln Glu 115 125

Ala Asp Ser Lys Pro Gln Pro Ile Gln Ile Gly Asp Leu Glu Ile Val

Pro Asp Ala Tyr Val Ala Lys Lys Tyr Gly Glu Glu Leu Asp Leu Thr 145 150 160

His Arg Glu Phe Glu Leu Leu Tyr His Leu Ala Ser His Thr Gly Gln 165 170 175

Val Ile Thr Arg Glu His Leu Leu Glu Thr Val Trp Gly Tyr Asp Tyr 180 185 190

Phe Gly Asp Val Arg Thr Val Asp Val Thr Val Arg Arg Leu Arg Glu 200 205

Lys Ile Glu Asp Thr Pro Ser Arg Pro Glu Tyr Ile Leu Thr Arg Arg 210 220

Gly Val Gly Tyr Tyr Met Arg Asn Asn Ala 225 230

<210> 197

<211> 721

<212> PRT

<213> Streptococcus pneumoniae

<400> 197

Met Lys Lys Lys Phe Leu Ala Phe Leu Leu Ile Leu Phe Pro Ile Phe 10 15

Ser Leu Gly Ile Ala Lys Ala Glu Thr Ile Lys Ile Val Ser Asp Thr 20 25 30

Ala Tyr Ala Pro Phe Glu Phe Lys Asp Ser Asp Gln Thr Tyr Lys Gly

Ile Asp Val Asp Ile Ile Asn Lys Val Ala Glu Ile Lys Gly Trp Asn 50 60

Ile Gln Met Ser Tyr Pro Gly Phe Asp Ala Ala Val Asn Ala Val Gln 65 70 75 80 str pneumoniae patentin.ST25 Ala Gly Gln Ala Asp Ala Ile Met Ala Gly Met Thr Lys Thr Lys Glu 85 90 95 Arg Glu Lys Val Phe Thr Met Ser Asp Thr Tyr Tyr Asp Thr Lys Val Val Ile Ala Thr Thr Lys Ser His Lys Ile Ser Lys Tyr Asp Gln Leu 115 120 125 Thr Gly Lys Thr Val Gly Val Lys Asn Gly Thr Ala Ala Gln Arg Phe 130 140 Leu Glu Thr Ile Lys Asp Lys Tyr Gly Phe Thr Ile Lys Thr Phe Asp 145 155 160 Thr Gly Asp Leu Met Asn Asn Ser Leu Ser Ala Gly Ala Ile Asp Ala 165 170 175 Met Met Asp Asp Lys Pro Val Ile Glu Tyr Ala Ile Asn Gln Gly Gln 180 185 190 Asp Leu His Ile Glu Met Asp Gly Glu Ala Val Gly Ser Phe Ala Phe 195 200 205 Gly Val Lys Lys Gly Ser Lys Tyr Glu His Leu Val Thr Glu Phe Asn 210 220 Gln Ala Leu Ser Glu Met Lys Lys Asp Gly Ser Leu Asp Lys Ile Ile 225 230 235 240 Lys Lys Trp Thr Ala Ser Ser Ser Ser Ala Val Pro Thr Thr Thr Thr 245 250 255 Leu Ala Gly Leu Lys Ala Ile Pro Val Lys Ala Lys Tyr Ile Ile Ala 260 265 270 Ser Asp Ser Ser Phe Ala Pro Phe Val Phe Gln Asn Ser Ser Asn Gln 275 280 285 Tyr Thr Gly Ile Asp Met Glu Leu Ile Lys Ala Ile Ala Lys Asp Gln 290 295 Gly Phe Glu Ile Glu Ile Thr Asn Pro Gly Phe Asp Ala Ala Ile Ser 305 310 315 Ala Val Gln Ala Gly Gln Ala Asp Gly Ile Ile Ala Gly Met Ser Val 325 330 335 Thr Asp Ala Arg Lys Ala Thr Phe Asp Phe Ser Glu Ser Tyr Tyr Thr 340 345 350

Ala Ash Thr Ile Leu Gly Val Lys Glu Ser Ser Ash Ile Ala Ser Tyr 355 360 365 Glu Asp Leu Lys Gly Lys Thr Val Gly Val Lys Asn Gly Thr Ala Ser 370 380 Gln Thr Phe Leu Thr Glu Asn Gln Ser Lys Tyr Gly Tyr Lys Ile Lys Thr Phe Ala Asp Gly Ser Ser Met Tyr Asp Ser Leu Asn Thr Gly Ala 405 410 415 Ile Asp Ala Val Met Asp Asp Glu Pro Val Leu Lys Tyr Ser Ile Ser 420 425 Gln Gly Gln Lys Leu Lys Thr Pro Ile Ser Gly Thr Pro Ile Gly Glu 435 440 445 Thr Ala Phe Ala Val Lys Lys Gly Ala Asn Pro Glu Leu Ile Glu Met 450 460 Phe Asn Asn Gly Leu Ala Asn Leu Lys Ala Asn Gly Glu Phe Gln Lys 475 480 Ile Leu Asp Lys Tyr Leu Ala Ser Glu Ser Ser Thr Ala Ser Thr Ser 485 490 495 Thr Val Asp Glu Thr Thr Leu Trp Gly Leu Leu Gln Asn Asn Tyr Lys 500 510 Gln Leu Leu Ser Gly Leu Gly Ile Thr Leu Ala Leu Ala Leu Ile Ser 515 520 525 Phe Ala Ile Ala Ile Val Ile Gly Ile Ile Phe Gly Met Phe Ser Val Ser Pro Tyr Lys Ser Leu Arg Val Ile Ser Glu Ile Phe Val Asp Val 545 550 560 Ile Arg Gly Ile Pro Leu Met Ile Leu Ala Ala Phe Ile Phe Trp Gly 565 570 Ile Pro Asn Phe Ile Glu Ser Ile Thr Gly Gln Gln Ser Pro Ile Asn 580 585 Asp Phe Val Ala Gly Thr Ile Ala Leu Ser Leu Asn Ala Ala Ala Tyr 595 600 605 Ile Ala Glu Ile Val Arg Gly Gly Ile Gln Ala Val Pro Val Gly Gln 610 620

Met Glu Ala Ser Arg Ser Leu Gly Ile Ser Tyr Gly Lys Thr Met Arg 640

Lys Ile Ile Leu Pro Gln Ala Thr Lys Leu Met Leu Pro Asn Phe Val

Asn Gln Phe Val Ile Ala Leu Lys Asp Thr Thr Ile Val Ser Ala Ile.

Gly Leu Val Glu Leu Phe Gln Thr Gly Lys Ile Ile Ile Ala Arg Asn

Tyr Gln Ser Phe Lys Met Tyr Ala Ile Leu Ala Ile Phe Tyr Leu Val

690

Ile Ile Thr Leu Leu Thr Arg Leu Ala Lys Arg Leu Glu Lys Arg Ile 705 710 715 720

Arg

<210> 198

<211> 523

<212> PRT

<213> Streptococcus pneumoniae

<400> 198

Met Ala Phe Glu Ser Leu Thr Glu Arg Leu Gln Asn Val Phe Lys Asn 1 10 15

Leu Arg Lys Lys Gly Lys Ile Ser Glu Ser Asp Val Gln Glu Ala Thr 20 25 30

Lys Glu Ile Arg Leu Ala Leu Leu Glu Ala Asp Val Ala Leu Pro Val 35 40 45

Val Lys Asp Phe Ile Lys Lys Val Arg Glu Arg Ala Val Gly His Glu 50 60

Val Ile Asp Thr Leu Asn Pro Ala Gln Gln Ile Ile Lys Ile Val Asp 65 70 75 80

Glu Glu Leu Thr Ala Val Leu Gly Ser Asp Thr Ala Glu Ile Ile Lys 85 90 95

Ser Pro Lys Ile Pro Thr Ile Ile Met Met Val Gly Leu Gln Gly Ala 100 105 110

	GÌ	<u>/</u> Ly	s Th	r Th	r Ph	e_ <u>A]</u>	a Gl	str <u>y Ly</u> 12	pneu s Lei 0	moni LAl	ae p a <u>.</u> Ası	aten 1 Ly:	tin. s_Le	ST25 uLy:	sLy:	sGlu.
	Glı	1 As 13	n Al: 0	a Ar	g Pro	) Lei	и Мет 135	t Ile	e Ala	a Ala	a Ası	0 I]( 14(	12 Э Ту	r Ar	g Pro	o Ala
	Ala 145	Il	e Ası	p Gli	n Lei	1 Lys	5 Thr	Let	. G]y	/ Glr	G]r 155	ı Ile	e Ası	o Va	l Pro	Val 160
	Phe	e Ala	a Lei	u Gly	/ Thr 165	G]ı	ı Val	Pro	a fa	Val 170	Glu )	ı Ile	⊵ Va	l Arg	G]r 175	Gly
	Leu	Gli	ı Glı	180	a Glr	Tḥr	' Asn	His	8 Asn 185	Asp	Tyr	' Val	Leu	17e 190	e Asp	Thr
_	Ala	Gly	/ Arg 195	Lei	₽ Glm	Ile	: Asp	G]u 200	Leu	Leu	Met	: Asn	G]u 205	. Leu	Arg	Asp
	۷a٦	Lys 210	Ala	. Leu	ı Ala	Gln	Pro 215	Asn	Glu	Ile	Leu	Leu 220	Val	۷a٦	Asp	Ala
	Met 225	Ile	e Gly	∕ Gln	Glu	Ala 230	Ala	Asn	Val	Ala	Arg 235	Glu	Phe	: Asn	Ala	G1n 240
	Leu	Glu	Val	Thr	Gly 245	۷a٦	Ile	Leu	Thr	Lys 250	Ile	Asp	Gly	Asp	Thr 255	Arg
	Glу	GТу	Ala	A1a 260	Leu	Ser	Val	Arg	His 265	Ile	Thr	Gly	Lys	Pro 270	Ile	Lys
	Phe	Thr	G]y 275	Thr	G]y	Glu	Lys	Ile 280	Thr	Asp	Ile	Glu	Thr 285	Phe	His	Pro
	Asp	Arg 290	Met	Ser	Ser	Arg	Ile 295	Leu	Gly	Met	Gly	Asp 300	Met	Leu	Thr	Leu
	Ile 305	Glu	Lys	Ala	Ser	G]n 310	Glu	Tyr	Asp	Glu	G]n 315	Lys	Ala	Leu	Glu	Met 320
	Ala	Glu	Lys	Met	Arg 325	Glu	Asn	Thr	Phe	Asp 330	Phe	Asn	Asp	Phe	Ile 335	Asp
	Gln	Leu	Asp	Gln 340	val	Gln	Asn	Met	G]y 345	Pro	Met	Glu	Asp	Leu 350	Leu	Lys
	Met	Ile	Pro 355	G]y	Met	Ala	Asn	Asn 360	Pro	Ala	Leu	Gln	Asn 365	Met	Lys	Val
	Asp	G]u 370	Arg	Gln	Ile	Ala	Arg 375	Lys	Arg	Ala	Ile	Va1 380	Ser	Ser	Met	Thr

str pneumoniae patentin.ST25
Pro Glu Glu Arg Glu Asn Pro Asp Leu Leu Asn Pro Ser Arg Arg 385
390
395
400

Arg Ile Ala Ala Gly Ser Gly Asn Thr Phe Val Glu Val Asn Lys Phe 405 410 415

Ile Lys Asp Phe Asn Gln Ala Lys Gln Leu Met Gln Gly Val Met Ser 420 425 430

Gly Asp Met Asn Lys Met Met Lys Gln Met Gly Ile Asn Pro Asn Asn 435 440

Leu Pro Lys Asn Met Pro Asn Met Gly Gly Met Asp Met Ser Ala Leu 450 460

Glu Gly Met Met Gly Gln Gly Gly Met Pro Asp Leu Ser Ala Leu Gly 465 470 475 480

Gly Ala Gly Met Pro Asp Met Ser Gln Met Phe Gly Gly Gly Leu Lys 485 490 495

Gly Lys Ile Gly Glu Phe Ala Met Lys Gln Ser Met Lys Arg Met Ala 500 510

Asn Lys Met Lys Lys Ala Lys Lys Lys Arg Lys 515 520

<210> 199

<211> 233

<212> PRT

<213> Streptococcus pneumoniae

<400> 199

Met Ser Gln Ile Trp Thr Lys Glu Lys Phe Ile Ser Gln Val Gln Gly 10 15

Gly Val Ile Val Ser Cys Gln Ala Leu Pro Gly Glu Ala Leu Tyr Asn 20 25 30

Glu Glu Phe Ser Leu Met Pro Phe Met Ala Lys Ala Ala Leu Glu Ala 35 40 45

Gly Ala Val Gly Ile Arg Ala Asn Ser Val Arg Asp Ile Lys Ala Ile 50 60

Gln Lys Val Val Asp Leu Pro Ile Ile Gly Ile Ile Lys Arg Asp Tyr 65 70 75 80 str pneumoniae patentin.ST25
Pro Pro Gln Glu Pro Tyr Ile Thr Ala Thr Met Lys Glu Val Asp Glu

85
90
95

Leu Val Glu Cys Gly Thr Thr Val Ile Ala Phe Asp Ala Thr Leu Arg 100 105 110

Pro Arg Tyr Asp Gly Leu Val Val Ser Glu Phe Ile Lys Lys Ile Lys 115 125

Glu Lys Tyr Pro Asn Gln Leu Leu Met Ala Asp Val Ser Asn Leu Asp 130 140

Glu Gly Leu Tyr Ala Phe Lys Ser Gly Val Asp Phe Val Gly Thr Thr 145 150 160

Leu Ser Gly Tyr Thr Ser Thr Ser Val Gln Ser Asp Glu Pro Asp Phe 165 170 175

Glu Leu Met Lys Lys Leu Ala Asp Phe Asn Ile Pro Val Ile Ala Glu 180 180 190

Gly Lys Ile His Tyr Pro Glu Gln Leu Lys Lys Ala Tyr Ser Leu Gly 195 200 205

Val Thr Ser Val Val Ile Gly Gly Ala Ile Thr Arg Pro Lys Glu Ile 210 220

Ala Gln Arg Phe Ile Asn Val Ile Lys 225 230

<210> 200

<211> 388

<212> PRT

<213> Streptococcus pneumoniae

<400> 200

Met Arg Tyr Leu Thr Ala Gly Glu Ser His Gly Pro Arg Leu Thr Ala 10 15

Ile Ile Glu Gly Ile Pro Ala Gly Leu Pro Leu Thr Ala Glu Asp Ile 20 25 30

Asn Glu Asp Leu Arg Arg Gln Gly Gly Tyr Gly Arg Gly Gly Arg
45

Met Lys Ile Glu Asn Asp Gln Val Val Phe Thr Ser Gly Val Arg His 50 60

str pneumoniae patentin.ST25
Gly Lys Thr Thr Gly Ala Pro Ile Thr Met Asp Val Ile Asn Lys Asp
65
70
75
80 His Gln Lys Trp Leu Asp Ile Met Ser Ala Glu Asp Ile Glu Asp Arg 85 90 95 Leu Lys Ser Lys Arg Lys Ile Thr His Pro Arg Pro Gly His Ala Asp 100 105 110 Leu Val Gly Gly Ile Lys Tyr Arg Phe Asp Asp Leu Arg Asn Ser Leu 115 125 Glu Arg Ser Ser Ala Arg Glu Thr Thr Met Arg Val Ala Val Gly Ala 130 140 Val Ala Lys Arg Leu Leu Ala Glu Leu Asp Met Glu Ile Ala Asn His 145 150 155 160 Val Val Phe Gly Gly Lys Glu Ile Asp Val Pro Glu Asn Leu Thr 165 170 175 Val Ala Glu Ile Lys Gln Arg Ala Ala Gln Ser Glu Val Ser Ile Val 180 185 190 Asn Gln Glu Arg Glu Gln Glu Ile Lys Asp Tyr Ile Asp Gln Ile Lys 195 200 205 Arg Asp Gly Asp Thr Ile Gly Gly Val Val Glu Thr Val Val Gly Gly 210 220 Val Pro Val Gly Leu Gly Ser Tyr Val Gln Trp Asp Arg Lys Leu Asp 225 230 235 240 Ala Arg Leu Ala Gln Ala Val Val Ser Ile Asn Ala Phe Lys Gly Val 245 250 255 Glu Phe Gly Leu Gly Phe Glu Ala Gly Tyr Arg Lys Gly Ser Gln Val 260 265 270 Met Asp Glu Ile Leu Trp Ser Lys Glu Asp Gly Tyr Thr Arg Arg Thr 275 280 285 Asn Asn Leu Gly Gly Phe Glu Gly Gly Met Thr Asn Gly Gln Pro Ile 290 295 300 Val Val Arg Gly Val Met Lys Pro Ile Pro Thr Leu Tyr Lys Pro Leu 305 310 315 320 Met Ser Val Asp Ile Glu Thr His Glu Pro Tyr Lys Ala Thr Val Glu 325 330 335

## str pneumoniae patentin.ST25 Arg Ser Asp Pro Thr Ala Leu Pro Ala Ala Gly Met Val Met Glu Ala 345 345 345

Val Val Ala Thr Val Leu Ala Gln Glu Ile Leu Glu Lys Phe Ser Ser 355 360 365

Asp Asn Leu Glu Glu Leu Lys Glu Ala Val Ala Lys His Arg Asp Tyr 370 380

Thr Lys Asn Tyr 385

<210> 201

<211> 390

<212> PRT

<213> Streptococcus pneumoniae

<400> 201

Met Val Val Met Asn Arg Ile Arg Val Ser Lys Arg Val Glu Lys Lys 10 15

Leu Ala Lys Gly Leu Val Leu Leu Glu Ala Ser Asp Leu Glu Asn Val 20 25 30

Asn Leu Lys Asp Gln Glu Val Glu Gln Gly Gln Glu Gly Asn Phe
35 40 45

Leu Gly Thr Ala Tyr Leu Ser Gln Gln Asn Lys Gly Leu Gly Trp Phe 50 60

Ile Ser Lys Asp Lys Val Ala Phe Asn Gln Ala Phe Phe Glu Thr Leu 65 70 75 80

Phe Arg Lys Ala Lys Glu Lys Arg Asn Ala Tyr Tyr Gln Asp Asp Leu 85 90 95

Thr Thr Ala Phe Arg Leu Phe Asn Gln Glu Gly Asp Gly Phe Gly Gly 100 100 110

Leu Thr Val Asp Leu Tyr Gly Asp Tyr Ala Val Phe Ser Trp Tyr Asn 115 125

Ser Tyr Val Tyr Gln Ile Arg Gln Thr Ile Ser Glu Ala Phe Arg Gln 130 140

Val Phe Pro Glu Val Leu Gly Ala Tyr Glu Lys Ile Arg Phe Lys Gly 145 150 155 str pneumoniae patentin.ST25 Leu Asp Tyr Glu Ser Ala His Val Tyr Gly Gln Glu Ala Pro Asp Phe 165 170 175 Phe Asn Val Leu Glu Asn Gly Val Leu Tyr Gln Val Phe Met Asn Asp 180 185 190 Gly Leu Met Thr Gly Ile Phe Leu Asp Gln His Glu Val Arg Gly Ser 195 200 205 Leu Val Asp Gly Leu Ala Met Gly Lys Ser Leu Leu Asn Met Phe Ser 210 220 Tyr Thr Ala Ala Phe Ser Val Ala Ala Ala Met Gly Gly Ala Ser His 225 230 235 240 Thr Thr Ser Val Asp Leu Ala Lys Arg Ser Arg Glu Leu Ser Gln Ala 245 250 255 His Phe Gln Ala Asn Gly Leu Ser Thr Asp Glu His Arg Phe Ile Val 260 265 270 Met Asp Val Phe Glu Tyr Phe Lys Tyr Ala Lys Arg Lys Asp Leu Thr 275 280 285 Tyr Asp Val Ile Val Leu Asp Pro Pro Ser Phe Ala Arg Asn Lys Lys 290 295 300 Gln Thr Phe Ser Val Ala Lys Asp Tyr His Lys Leu Ile Ser Gln Ser 305 310 315 Leu Glu Ile Leu Asn Pro Gly Gly Ile Ile Ile Ala Ser Thr Asn Ala 325 330 335 Ala Asn Val Ser Arg Gln Lys Phe Thr Glu Gln Ile Asp Lys Gly Phe 340 350 Ala Gly Arg Ser Tyr Gln Ile Leu Asn Lys Tyr Gly Leu Pro Ala Asp 355 360 365 Phe Ala Tyr Asn Lys Lys Asp Glu Ser Ser Asn Tyr Leu Lys Val Ile 370 375 Ser Met Lys Val Ser Lys 385 390

<210> 202

<211> 428

<212> PRT

<213> Streptococcus pneumoniae

### <400> 202

Met Thr Lys Thr Leu Lys Arg Pro Glu Val Leu Ser Pro Ala Gly Thr 10 15

Leu Glu Lys Leu Lys Val Ala Val Gln Tyr Gly Ala Asp Ala Val Phe
20
25
30

Ile Gly Gly Gln Ala Tyr Gly Leu Arg Ser Arg Ala Gly Asn Phe Thr 35 40 45

Phe Glu Gln Met Glu Glu Gly Val Gln Phe Ala Ala Lys Tyr Gly Ala 50 60

Lys Val Tyr Val Ala Ala Asn Met Val Met His Glu Gly Asn Glu Ala 65 70 75 80

Gly Ala Gly Glu Trp Phe Arg Lys Leu Arg Asp Ile Gly Ile Ala Ala 85 90 95

Val Ile Val Ser Asp Pro Ala Leu Ile Met Ile Ala Val Thr Glu Ala 100 105 110

Pro Gly Leu Glu Ile His Leu Ser Thr Gln Ala Ser Ala Thr Asn Tyr 115 120 125

Glu Thr Leu Glu Phe Trp Lys Glu Leu Gly Leu Thr Arg Val Val Leu 130 140

Ala Arg Glu Val Ser Met Glu Glu Leu Ala Glu Ile Arg Lys Arg Thr 145 150 160

Asp Val Glu Ile Glu Ala Phe Val His Gly Ala Met Cys Ile Ser Tyr 165 170 175

Ser Gly Arg Cys Thr Leu Ser Asn His Met Ser Met Arg Asp Ala Asn 180 190

Arg Gly Gly Cys Ser Gln Ser Cys Arg Trp Lys Tyr Asp Leu Tyr Asp 195 205

Met Pro Phe Gly Lys Glu Arg Lys Ser Leu Gln Gly Glu Ile Pro Glu 210 220

Glu Phe Ser Met Ser Ala Val Asp Met Ser Met Ile Asp His Ile Pro 235 230 235

Asp Met Ile Glu Asn Gly Val Asp Ser Leu Lys Ile Glu Gly Arg Met 245 250 255

Lys Ser Ile His Tyr Val ser Thr Val Thr Asn Cys Tyr Lys Ala Ala Ala Val Asp Ala Tyr Leu Glu Ser Pro Glu Lys Phe Glu Ala Ile Lys Gln Asp Leu Val Asp Glu Met Trp Lys Val Ala Gln Arg Glu Leu Ala Thr 290 Phe Tyr Tyr Gly Thr Pro Ser Glu Asn Glu Gln Leu Phe Gly Ala 305 Phe Tyr Tyr Gly Thr Pro Ser Glu Asn Glu Gln Leu Phe Gly Ala 320 Arg Arg Lys Ile Pro Glu Tyr Lys Phe Val Ala Glu Val Val Ser Tyr Asp Asp Ala Ala Gln Thr Ala Thr Ile Arg Gln Arg Asn Val Ile Asn Glu Gly Asp Gln Val Glu Phe Tyr Gly Pro Gly Phe Arg His Phe Glu Thr Tyr Ile Glu Asp Leu His Asp Ala Lys Gly Asn Lys Ile Asp Arg Ala Pro Asn Pro Met Glu Leu Leu Thr Ile Lys Val Pro Gln Pro Val 385

Gln Ser Gly Asp Met Val Arg Ala Leu Lys Glu Gly Leu Ile Asn Leu 405 410 415

Tyr Lys Glu Asp Gly Thr Ser Val Thr Val Arg Ala 420 425

<210> 203

<211> 280

<212> PRT

<213> Streptococcus pneumoniae

<400> 203

Met Asn Thr Tyr Gln Leu Asn Asn Gly Val Glu Ile Pro Val Leu Gly 10 15

Phe Gly Thr Phe Lys Ala Lys Asp Gly Glu Glu Ala Tyr Arg Ala Val 20 25 30

Leu Glu Ala Leu Lys Ala Gly Tyr Arg His Ile Asp Thr Ala Ala Ile 35 40 45

· ·	Ту	r Gli	n Aşı	ı Glu	ı Glu	Ser	Va] _55_	str p Gly	neun Gln	onia Ala	e pa	tent Lys	in.S Asp	T25 Ser	'=G1:y	⁄∨a-1-
	Pro 65	o Arg	g Glu	ı Glu	ı Met	Phe 70	Val	Thr	Thr	Lys	Leu 75	Trp	Asn	Ser	Gln	G]n 80
<del></del>	Thr	Tyı	Glu	ı Glr	Thr 85	Arg	Gln	Ala	Leu	Glu 90	Lys	Ser	Ile	Glu	Lys 95	Leu
	Gly	/ Lei	ı Asp	Tyr 100	Leu	Asp	Leu	Tyr	Leu 105	Ile	His	Trp	Pro	Asn 110	Pro	Lys
	Pro	Leu	115	Glu	Asn	Asp	Ala	Trp 120	Lys	Thr	Arg	Asn	Ala 125	Glu	Val	Trp
_	Arg	130	Met	Glu	Asp	Leu	Tyr 135	Gln	Glu	Glу	Lys	Ile 140	Arg	Ala	Ile	Gly
	Va7 145	Ser	' Asn	Phe	Leu	Pro 150	His	His	Leu	Asp	Ala 155	Leu	Leu	Glu	Thr	Ala 160
	Thr	Ile	val	Pro	А]а 165	Val	Asn	Gln	٧a٦	Arg 170	Leu	Ala	Pro	Gly	Val 175	Tyr
	Gln	Asp	Gln	Val 180	Val	Ala	Tyr	Cys	Arg 185	Glu	Lys	Gly	Ile	Leu 190	Leu	Glu
	Ala	Trp	Gly 195	Pro	Phe	Gly	Gln	Gly 200	Glu	Leu	Phe	Asp	Ser 205	Lys	Gln	Val
	Gln	G]u 210	Ile	Ala	Ala	Asn	нis 215	Gไу	Lys	Ser	Val	A]a 220	Gln	Ile	Ala	Leu
	A1a 225	Trp	Ser	Leu	Ala	Gไน 230	Gly	Phe	Leu	Pro	Leu 235	Pro	Lys	Ser	۷al	Thr 240
	Thr	Ser	Arg	Ile	G]n 245	Ala	Asn	Leu	Asp	Cys 250	Phe	Gly	Ile	Glu	Leu 255	Ser
	His	Glu	Glu	Arg 260	Glu	Thr	Leu	Lys	Thr 265	Ile	Ala	Val	Gln	Ser 270	Gly	Ala
	Pro	Arg	Va1 275	Asp	Asp	Val	Asp	Phe 280								
	<210	)> 2	204													
	<211	> 5	551													
	<212		PRT													
	<213	> S	trep	toco	ccus	pne	umon	iae								

### str pneumoniae patentin.ST25

<400> 204 Leu Ser Glu Lys Ser Arg Glu Glu Glu Lys Leu Ser Phe Lys Glu Gln 10 15 Ile Leu Arg Asp Leu Glu Lys Val Lys Gly Tyr Asp Glu Val Leu Lys Glu Asp Glu Ala Val Val Arg Thr Pro Ala Asn Glu Pro Ser Thr Glu
35 40 45 Glu Leu Met Ala Asp Ser Leu Ser Thr Val Glu Glu Ile Met Arg Lys 50 60 Ala Pro Thr Val Pro Thr His Pro Ser Gln Gly Val Pro Ala Ser Pro 65 70 75 80 Ala Asp Glu Ile Gln Arg Glu Thr Pro Gly Val Pro Ser His Pro Ser 85 90 95 Gln Asp Val Pro Ser Ser Pro Ala Glu Glu Ser Gly Ser Arg Pro Gly 100 105 Pro Gly Pro Val Arg Pro Lys Lys Leu Glu Arg Glu Tyr Asn Glu Thr 115 120 125 Pro Thr Arg Val Ala Val Ser Tyr Thr Thr Ala Glu Lys Lys Ala Glu 130 140 Gln Ala Gly Pro Glu Thr Pro Thr Pro Ala Thr Glu Thr Val Asp Ile 145 150 155 160 Ile Arg Asp Thr Ser Arg Arg Ser Arg Arg Glu Gly Ala Lys Pro Val 165 170 175 Lys Pro Lys Lys Glu Lys Lys Ser His Val Lys Ala Phe Val Ile Ser 180 185 190 Phe Leu Val Phe Leu Ala Leu Leu Ser Ala Gly Gly Tyr Phe Gly Tyr 195 205 Gln Tyr Val Leu Asp Ser Leu Leu Pro Ile Asp Ala Asn Ser Lys Lys 210 220 Tyr Val Thr Val Gly Ile Pro Glu Gly Ser Asn Val Gln Glu Ile Gly 225 230 240 Thr Thr Leu Glu Lys Ala Gly Leu Val Lys His Gly Leu Ile Phe Ser

	Dho	T) 48	. 47.	11.4-	<b>-</b>	•	5	t <u>r</u> p	neum	onia	e pa	tent	in.s	T25		
	Pile		Ald	_ <u>198</u> _260	. lyr	"Ly <u>s</u>	_Asn	Tyr	Thr _265.	_Asp	Leu	_ Ly.s	_A1.a	G]y 27∩	. Tyr.	Tyr
	Asn	Leu	G]n 275	Lys	Ser	Met	Ser	Thr 280	Glu	Asp	Leu	Leu	Lys 285	Glu	Leu	Gln
*	Lys	G]y 290	Gly	Thr	Asp	Glu	Pro 295	Gln	Glu	Pro	<b>v</b> al	Leu 300	Ala	Thr	Leu	Thr
	17e 305	Pro	Glu	Gly	туг	Thr 310	Leu	Asp	Gln	IJе	Ala 315	Gln	Ala	۷al	Gly	G]n 320
	Leu	Gln	Gly	Asp	Phe 325	Lys	Glu	Ser	Leu	Thr 330	Ala	Glu	Ala	Phe	Leu 335	Ala
	Lys	Val	Gln	Asp 340	Glu	Thr	Phe	Ile	Ser 345	Gln	Ala	۷a٦	Ala	Lys 350	Туг	Pro
•	Thr	Leu	Leu 355	Glu	Ser	Leu	Pro	Va1 360	Lys	Asp	Ser	Gly	Ala 365	Arg	Tyr	Arg
	Leu	G]u 370	Gly	Tyr	Leu	Phe	Pro 375	Аlа	Thr	Tyr	Ser	Ile 380	Lys	Glu	Ser	Thr
	Thr 385	Ile	Glu	Ser	Leu	Ile 390	Asp	Glu	Met	Leu	Ala 395	Ala	Met	Asp	Lys	Asn 400
	Leu	Ser	Pro	Tyr	Tyr 405	Ser	Thr	Ile	Lys	Ser 410	Lys	Asn	Leu	Thr	Val 415	Asn
	Glu	Leu	Leu	Thr 420	Ile	Ala	ser	Leu	Va7 425	Glu	Lys	Glu	Gly	Ala 430	Lys	Thr
•	Glu	Asp	Arg 435	Lys	Leu	Ile	Ala	G]y 440	Val	Phe	Tyr	Asn	Arg 445	Leu	Asn	Arg
	Asp	Met 450	Pro	Leu	Gln	Ser	Asn 455	Ile	Аlа	Ile	Leu	Tyr 460	Ala	Gln	Gly	Lys
	Leu 465	Gly	Gln	Asn	Пe	ser 470	Leu	Ala	Glu	Asp	Va1 475	Ala	Ile	Asp	Thr	Asn 480
	Ile.	Asp	Ser	Pro	Tyr 485	Asn	Va1	Tyr	Lys	Asn 490	Val	Gly	Leu	Met	Pro 495	Gly
	Pro	۷a٦	Asp	Ser 500	Pro	Ser	Leu	Asp	Ala 505	Ile	Glu	Ser	Ser	Ile 510	Asn	Gln
	Thr	Lys	Ser 515	Asp	Asn	Leu	Tyr	Phe 520	val	Alą	Asp	Val	Thr 525	Glu	Gly	Lys

str pneumoniae patentin.ST25 Val Tyr Tyr Ala Asn Asn Gln Glu Asp His Asp Arg Asn Val Ala Glu 530 535 540

His Val Asn Ser Lys Leu Asn 545 550

<210> 205

<211> 205

<212> PRT

<213> Streptococcus pneumoniae

<400> 205

Met Lys Gln Glu Arg Phe Pro Leu Val Ser Asp Asp Glu Val Met Leu  $1 \hspace{1cm} 15$ 

Thr Glu Met Pro Val Met Asn Leu Tyr Asp Glu Ser Asp Leu Ile Ser 20 25 30

Asn Ile Lys Gly Glu Tyr Arg Asp Lys Asn Tyr Leu Glu Trp Ala Pro 35 40 45

Ile Ala Glu Glu Lys Pro Val Lys Pro Ile Glu Lys Gln Val Glu Lys 50 60

Pro Lys Lys Ala Pro Leu Gly Val Lys Lys Glu Gly Lys Ser Tyr Ala 65 70 75 80

Glu Val Ala Arg Glu Glu Ala Arg Ala Asp Leu Lys Lys Lys Arg Ser 85 90 95

Ala Asn Tyr Leu Thr Gln Asp Phe Ser Leu Ala Arg Arg His Ser Gln 100 105 110

Pro Ser Leu Val Arg Gln Gly Asn Gln Pro Thr Ala Pro Phe Gln Lys 115 120 125

Glu Asn Pro Gly Glu Phe Val Lys Tyr Ser Gln Lys Leu Thr Gln Ser 130 135 140

His Tyr Ile Leu Ala Glu Glu Val His Ser Ile Pro Thr Lys Asn Glu 145 150 155 160

Glu Val Ser Ala Pro Ala Pro Lys Lys Asn Asn Tyr Asp Phe Leu Lys 165 170 175

Lys Ser Gln Ile Tyr Asn Lys Lys Ser Lys Gln Thr Glu Gln Glu Arg

Arg Val Ala Gln Glu Leu	str pneumoniae patentin.ST25
195	Asn Leu Thr Arg Met Thr Glu

en et alle anticone de la companie d

<210> 206

<211> 652

<212> PRT

-<213> -- Streptococcus pneumoniae --- --- ----

<400> 206

Met Lys Lys Ser Lys Ser Lys Tyr Leu Thr Leu Ala Gly Leu Val Leu 10 15

Gly Thr Gly Val Leu Leu Ser Ala Cys Gly Asn Ser Ser Thr Ala Ser 20 25 30

Lys Thr Tyr Asn Tyr Val Tyr Ser Ser Asp Pro Ser Ser Leu Asn Tyr 35 40 45

Leu Ala Glu Asn Arg Ala Ala Thr Ser Asp Ile Val Ala Asn Leu Val 50 60

Asp Gly Leu Leu Glu Asn Asp Gln Tyr Gly Asn Ile Ile Pro Ser Leu 75 75 80

Ala Glu Asp Trp Thr Val Ser Gln Asp Gly Leu Thr Tyr Thr Tyr Lys
85 90 95

Leu Arg Lys Asp Ala Lys Trp Phe Thr Ser Glu Gly Glu Glu Tyr Ala 100 105 110

Pro Val Thr Ala Gln Asp Phe Val Thr Gly Leu Gln Tyr Ala Ala Asp 115 120 125

Lys Lys Ser Glu Ala Leu Tyr Leu Val Gln Asp Ser Val Ala Gly Leu 130 140

Asp Asp Tyr Ile Thr Gly Lys Thr Ser Asp Phe Ser Thr Val Gly Val 145

Lys Ala Leu Asp Asp Gln Thr Val Gln Tyr Thr Leu Val Lys Pro Glu 165 170 175

Leu Tyr Trp Asn Ser Lys Thr Leu Ala Thr Ile Leu Phe Pro Val Asn 180 180

Ala Asp Phe Leu Lys Ser Lys Gly Asp Asp Phe Gly Lys Ala Asp Pro 195 200 205

str pneumoniae patentin.ST25 Ser Ser Ile Leu Tyr Asn Gly Pro Phe Leu Met Lys Ala Leu Val Ser 210 215 220 Lys Ser Ala Ile Glu Tyr Lys Lys Asn Pro Asn Tyr Trp Asp Ala Lys 235 240 Asn Val Phe Val Asp Asp Val Lys Leu Thr Tyr Tyr Asp Gly Ser Asp 245 250 255 Gln Glu Ser Leu Glu Arg Asn Phe Thr Ala Gly Ala Tyr Thr Thr Ala 260 265 270 Arg Leu Phe Pro Asn Ser Ser Ser Tyr Glu Gly Ile Lys Glu Lys Tyr 275 280 285 Lys Asn Asn Ile Ile Tyr Ser Met Gln Asn Ser Thr Ser Tyr Phe Phe 290 300 Asn Phe Asn Leu Asp Arg Lys Ser Tyr Asn Tyr Thr Ser Lys Thr Ser 305 310 315 320 Asp Ile Glu Lys Lys Ser Thr Gln Glu Ala Val Leu Asn Lys Asn Phe 325 330 335 Arg Gln Ala Ile Asn Phe Ala Phe Asp Arg Thr Ser Tyr Gly Ala Gln 340 345 Ser Glu Gly Lys Glu Gly Ala Thr Lys Ile Leu Arg Asn Leu Val Val 355 360 365 Pro Pro Asn Phe Val Ser Ile Lys Gly Lys Asp Phe Gly Glu Val Val 370 380 Ala Ser Lys Met Val Asn Tyr Gly Lys Glu Trp Gln Gly Ile Asn Phe 385 390 395 400 Ala Asp Gly Gln Asp Pro Tyr Tyr Asn Pro Glu Lys Ala Lys Ala Lys 405 410 415 Phe Ala Glu Ala Lys Lys Glu Leu Glu Ala Lys Gly Val Gln Phe Pro 420 425 430 Ile His Leu Asp Lys Thr Val Glu Val Thr Asp Lys Val Gly Ile Gln
435 440 445 Gly Val Ser Ser Ile Lys Gln Ser Ile Glu Ser Val Leu Gly Ser Asp 450 455 460 Asn Val Val Ile Asp Ile Gln Gln Leu Thr Ser Asp Glu Phe Asp Ser 465 470 475 480

# str pneumoniae patentin.ST25 Ser Gly Tyr Phe Ala Gln Thr Ala Ala Gln Lys Asp Tyr Asp Leu Tyr 485 His Gly Gly Trp Gly Pro Asp Tyr Gln Asp Pro Ser Thr Tyr Leu Asp 500 505

Ile Phe Asn Thr Asn Ser Gly Gly Phe Leu Gln Asn Leu Gly Leu Glu 515 520 525

Pro Gly Glu Ala Asn Asp Lys Ala Lys Ala Val Gly Leu Asp Val Tyr 530 540

Thr Gln Met Leu Glu Glu Ala Asn Lys Glu Gln Asp Pro Ala Lys Arg 545 550 560

Tyr Glu Lys Tyr Ala Asp Ile Gln Ala Trp Leu Ile Asp Ser Ser Leu 565 570 575

Val Leu Pro Ser Val Ser Arg Gly Gly Thr Pro Ser Leu Arg Arg Thr 580 585

Val Pro Phe Ala Ala Ala Tyr Gly Leu Thr Gly Thr Lys Gly Val Glu
595 600 605

Ser Tyr Lys Tyr Leu Lys Val Gln Asp Lys Ile Val Thr Thr Asp Glu 610 620

Tyr Ala Lys Ala Arg Glu Lys Trp Leu Lys Glu Lys Glu Glu Ser Asn 625 630 640

Lys Lys Ala Gln Glu Glu Leu Ala Lys His Val Lys 645 650

<210> 207

<211> 506

<212> PRT

<213> Streptococcus pneumoniae

<400> 207

Val Glu Gln His Ser Asp Val Cys Tyr Ile Phe Tyr Arg Arg Glu Arg 1 10 15

Leu Lys Thr Lys Ile Gly Leu Ala Ser Ile Cys Leu Leu Gly Leu Ala 20 25 30

Thr Ser His Val Ala Ala Asn Glu Thr Glu Val Ala Lys Thr Ser Gln
35 40 45

str pneumoniae patentin.ST25
Asp Thr Thr Thr Ala Ser Ser Ser Glu Gln Asn Gln Ser Ser Asn
50 55 60 Lys Thr Gln Thr Ser Ala Glu Val Gln Thr Asn Ala Ala Ala His Trp 65 70 75 80 Asp Gly Asp Tyr Tyr Val Lys Asp Asp Gly Ser Lys Ala Gln Ser Glu 85 90 95 Trp Ile Phe Asp Asn Tyr Tyr Lys Ala Trp Phe Tyr Ile Asn Ser Asp 100 105 110 Gly Arg Tyr Ser Gln Asn Glu Trp His Gly Asn Tyr Tyr Leu Lys Ser 115 120 125 Gly Gly Tyr Met Ala Gln Asn Glu Trp Ile Tyr Asp Ser Asn Tyr Lys 130 140 Ser Trp Phe Tyr Leu Lys Ser Asp Gly Ala Tyr Ala His Gln Glu Trp 145 150 155 160 Gln Leu Ile Gly Asn Lys Trp Tyr Tyr Phe Lys Lys Trp Gly Tyr Met
165 170 175 Ala Lys Ser Gln Trp Gln Gly Ser Tyr Phe Leu Asn Gly Gln Gly Ala 180 185 190 Met Met Gln Asn Glu Trp Leu Tyr Asp Pro Ala Tyr Ser Ala Tyr Phe 195 200 205 Tyr Leu Lys Ser Asp Gly Thr Tyr Ala Asn Gln Glu Trp Gln Lys Val 210 215 220 Gly Gly Lys Trp Tyr Tyr Phe Lys Lys Trp Gly Tyr Met Ala Arg Asn 225 230 235 240 Glu Trp Gln Gly Asn Tyr Tyr Leu Thr Gly Ser Gly Ala Met Ala Thr 245 250 255 Asp Glu Val Ile Met Asp Gly Thr Arg Tyr Ile Phe Ala Ala Ser Gly 260 265 270 Glu Leu Lys Glu Lys Lys Asp Leu Asn Val Gly Trp Val His Arg Asp 285 Gly Lys Arg Tyr Phe Phe Asn Asn Arg Glu Glu Gln Val Gly Thr Glu 290 295 300 His Ala Lys Lys Val Ile Asp Ile Ser Glu His Asn Gly Arg Ile Asn 305 310 315 str pneumoniae patentin.ST25
Asn Arg Ile Leu Thr Ile Leu Ala Ser Ile Phe Phe Val Ile Val Val
35 40 45

val Met Val Ile Val Leu Ile Tyr Leu Ser Ser Gly Gly Ser Asn Arg 50 60

Thr Ala Ala Leu Lys Gly Phe His Asp Ser Asp Ala Ser Val Val Gln 65 70 75 80

Ile Ser Ser Ser Ser Ser Gln Pro Glu Gln Ser Ser Glu Pro Glu 85 90 95

Ser Thr Ser Ser Ser Glu Glu Ala Ala Asn Pro Glu Gly Thr Ile 100 105 110

Lys Val Leu Ala Gly Glu Gly Glu Ala Ala Ile Ala Ala Arg Ala Gly 115 120 125

Ile Ser Ile Ala Gln Leu Glu Ala Leu Asn Pro Gly His Met Ala Thr 130 140

Gly Ser Trp Phe Ala Asn Pro Gly Asp Val Ile Lys Ile Lys 145 150

<210> 209

<211> 262

<212> PRT

<213> Streptococcus pneumoniae

<400> 209

Met Pro Ile Thr Ser Leu Glu Ile Lys Asp Lys Thr Phe Gly Thr Arg
1 10 15

Phe Arg Gly Phe Asp Pro Glu Glu Val Asp Glu Phe Leu Asp Ile Val 20 25 30

Val Arg Asp Tyr Glu Asp Leu Val Arg Ala Asn His Asp Lys Asn Leu 35 40 45

Arg Ile Lys Ser Leu Glu Glu Arg Leu Ser Tyr Phe Asp Glu Ile Lys 50 60

Asp Ser Leu Ser Gln Ser Val Leu Ile Ala Gln Asp Thr Ala Glu Arg 65 70 75

Val Lys Gln Ala Ala His Glu Arg Ser Asn Asn Ile Ile His Gln Ala 85 90 95

5-5	· <b>G</b> ]	u G1	n As	sp· A` -∵16	la (	Gln	Arg	l Lei	str   ! Le	oneu I Gli	moni u Gl	ae p	aten a Lys	tin.	ST25	s	a Acn	. Taur r.a. uraa :		-	
				<del>-</del> -				<del></del>		TO;	<b></b>				11	0		. 150 1 2. 1711			
	Glı	; I7	e Le 11	u Ar 5.	g (	รไก	Ala	Thr	Asp 120	) Asr	A]	a Lys	5 Lys	Va 125	l Ala	a Va	l Glu				
<del></del>	Thr	130	u G1	u Le	eu L	.ys	Asn	Lys 135	Ser	Arg	≀ Va⊺	Phe	His 140	G]n	Arg	) Lei	l Lys				
	Ser 145	Thi	יוו	e G7	u S	ier	G]n 150	Leu	Ala	Ile	Val	Glu 155	Ser	Ser	' Asp	Trp	G]u 160		••		
	Asp	ΙΊe	. Lei	u Ar	g P 1	ro 65	Thr	Ala	Thr	Tyr	Leu 170	Gln	Thr	Ser	Asp	Glu 175	ΑΊа				
	Phe	Lys	Glu	1 Va 18	7 V 0	<b>a</b> 7	Ser	Glu	Val	Leu 185	Gly	Glu	Pro	Ile	Pro 190	Ala	Pro				
	Ile	Glu	G]ı 195	i Gli	u P	ro :	Ile	Asp	Met 200	Thr	Arg	Gln	Phe	Ser 205	Gln	Ala	Glu			· ·	
	Met	Ala 210	Glu	Let	ı G.	ln /	47a	Arg 215	Ile	Glu	۷a٦	Ala	Asp 220	Lys	Glu	Leu	Ser				
												233	Ala				240				
	Val	Ser	Pro	Gln	24	17 G	alu (	Glu	Glu	Pro	Leu 250	Leu	Ile	Gln	Leu	A]a 255	Gln				
	Cys	Met	Lys	Asn 260	G٦	n L	.ys								•						
	<210	> 2	10																		
	<211:	> 1	79																		
	<212:	- P	RT																		_
	<213;	S S	trep	toc	OCCI	us	pneu	moni	ae												
	<400>	2:	10																		
	Met s 1	er ı	Leu	Lys	Asp 5	) Ai	rg P	he A	sp A	rg F	he 1 10	lle A	Asp 7	yr F	he 1	Thr o	ilu				
	Asp G	lu A	Asp	Ser 20	Ser	Le	eu P	ro T	yr G 2	]и L 5	ys A	.rg A	sp G	ilu p 3	ro v O	/al p	he				

Thr Ser Val Asn Ser Ser Gln Glu Pro Ala Leu Pro Met Asn Gln Pro

str pneumoniae patentin.ST25
Ser Gln Ser Ala Gly Thr Lys Glu Asn Asn Ile Thr Arg Leu His Ala
50 55 60

Arg Gln Gln Leu Ala Asn Gln Ser Gln Arg Ala Thr Asp Lys Val 65 70 75 80

Ile Ile Asp Val Arg Tyr Pro Arg Lys Tyr Glu Asp Ala Thr Glu Ile 85 90 95

Val Asp Leu Leu Ala Gly Asn Glu Ser Ile Leu Ile Asp Phe Gln Tyr 100 105 110

Met Thr Glu Val Gln Ala Arg Arg Cys Leu Asp Tyr Leu Asp Gly Ala 115 125

Cys His Val Leu Ala Gly Asn Leu Lys Lys Val Ala Ser Thr Met Tyr 130 140

Leu Leu Thr Pro Val Asn Val Ile Val Asn Val Glu Asp Ile Arg Leu 145 150 155 160

Pro Asp Glu Asp Gln Gln Gly Glu Phe Gly Phe Asp Met Lys Arg Asn 165 170 175

Arg Val Arg

<210> 211

<211> 305

<212> PRT

<213> Streptococcus pneumoniae

<400> 211

Met Ser Asp Leu Lys Lys Tyr Glu Gly Val Ile Pro Ala Phe Tyr Ala 1 5 10 15

Cys Tyr Asp Asp Gln Gly Glu Val Ser Pro Glu Arg Thr Arg Ala Leu 20 25 30

Val Gln Tyr Phe Ile Asp Lys Gly Val Gln Gly Leu Tyr Val Asn Gly

Ser Ser Gly Glu Cys Ile Tyr Gln Ser Val Glu Asp Arg Lys Leu Ile 50 60

Leu Glu Glu Val Met Ala Val Ala Lys Gly Lys Leu Thr Ile Ile Ala 65 70 75 80

·"·	His	<u>Val</u>	Ala	Cys	_ Asn _ 85_	.Asn	S Thr	tr p	neun Asp	onia Ser 90_	e pa	tent Glu	in.s Leu	5T25 I_A].a	. Arg	His
	Ala	. Glu	Ser	Leu 100	Gly	Val	Asp	Ala	Ile 105	Ala	Thr	Ile	Pro	Pro 110	Ile	Tyr
·	Phe	Arg	Leu 115	Pro	Glu	Tyr	Ser	Va1 120	Ala	Lys	Tyr	Trp	Asn 125	Asp	Ile	Ser.
	Ser	Ala 130	Ala	Pro	Asn	Thr	Asp 135	Tyr	۷al	Ile	Tyr	Asn 140	Ile	Pro	Gln	Leu
	Ala 145	Gly	Val	Аlа	Leu	Thr 150	Pro	Ser	Leu	Tyr	Thr 155	Glu	Met	Leu	Lys	Asn 160
	Pro	Arg	Val	Ile	Gly 165	Val	Lys	Asn	Ser	Ser 170	Met	Pro	Val	Gln	Asp 175	Ile
	Gln	Thr	Phe	Val 180	Ser	Leu	GÌу	Gly	G]u 185	Asp	His	Ile	Val	Phe 190	Asn	Gly
	Pro	Asp	G]u 195	Gln	Phe	Leu	GÌу	Gly 200	Arg	Leu	Met	Gly	Ala 205	Arg	Ala	Gly
	Ile	Gly 210	Gly	Thr	Tyr	Gly	Ala 215	Met	Pro	Glu	Leu	Phe 220	Leu	Lys	Leu	Asn
	G1n 225	Leu	Ile	Ala	Asp	Lys 230	Asp	Leu	Glu	Thr	Ala 235	Arg	Glu	Leu	Gln	Tyr 240
	ΑΊа	Ile	Asn	Ala	Ile 245	Ile	Gly	Lys	Leu	Thr 250	Ser	Ala	His	Gly	Asn 255	Met
	Tyr	Gly	Val	Ile 260	Lys	Glu	va1	Leu	Lys 265	Ile	Asn	Glu	Gly	Leu 270	Asn	Ile
	Gly	Ser	va1 275	Arg	Ser	Pro	Leu	Thr 280	Pro	Val	Thr	Glu	G]u 285	Asp	Arg	Pro
	Va1	Va1 290	Glu	Ala	Ala.	Ala	Ala 295	Leu	Ile	Arg	Glu	Thr 300	Lys	Glu	Arg	Phe
	Leu 305															
	<210	> 2	12								•					
	<211		 97													
	<212		RT													
	<213			toco	reue	nne		i a -			•					
			trep		ccus	hue	ullio <b>n</b>	ıae								

### str pneumoniae patentin.ST25

<400> 212 Met Asn Lys Arg Gly Leu Tyr Ser Lys Leu Gly Ile Ser Val Val Gly
1 10 15 Ile Ser Leu Leu Met Gly Val Pro Thr Leu Ile His Ala Asn Glu Leu 20 25 30 Asn Tyr Gly Gln Leu Ser Ile Ser Pro Ile Phe Gln Gly Gly Ser Tyr 35 40 45 Gln Leu Asn Asn Lys Ser Ile Asp Ile Ser Ser Leu Leu Leu Asp Lys 50 60 Leu Ser Gly Glu Ser Gln Thr Val Val Met Lys Phe Lys Ala Asp Lys 65 75 75 80 Pro Asn Ser Leu Gln Ala Leu Phe Gly Leu Ser Asn Ser Lys Ala Gly 85 90 95 Phe Lys Asn Asn Tyr Phe Ser Ile Phe Met Arg Asp Ser Gly Glu Ile 100 105 110 Gly Val Glu Ile Arg Asp Ala Gln Lys Gly Ile Asn Tyr Leu Phe Ser 115 120 125 Arg Pro Ala Ser Leu Trp Gly Lys His Lys Gly Gln Ala Val Glu Asn 130 140 Thr Leu Val Phe Val Ser Asp Ser Lys Asp Lys Thr Tyr Thr Met Tyr 145 150 155 160 Val Asn Gly Ile Glu Val Phe Ser Glu Thr Val Asp Thr Phe Leu Pro 165 170 175 Ile Ser Asn Ile Asn Gly Ile Asp Lys Ala Thr Leu Gly Ala Val Asn 180 185 190 Arg Glu Gly Lys Glu His Tyr Leu Ala Lys Gly Ser Ile Asp Glu Ile 195 200 205 Ser Leu Phe Asn Lys Ala Ile Ser Asp Gln Glu Val Ser Thr Ile Pro 210 215 220 Leu Ser Asn Pro Phe Gln Leu Ile Phe Gln Ser Gly Asp Ser Thr Gln 225 230 235 240 Ala Asn Tyr Phe Arg Ile Pro Thr Leu Tyr Thr Leu Ser Ser Gly Arg 245 250 255

:	. va	l Le	u. șe	r. Se 26	r. Il.	e_Asr	Ala	str   a_Arg	oneu J. Tyl – 26	[::::G:]:\	ae pa	aten /-Thi	tin. Hi:	ST25 S=Asi	S Se	r-Lys
	Sei	r Ly:	s Ile 27:	e Ası S	n Ile	e Ala	t Thi	r Ser 280	· Tyı	_	Asp	) Asp	Asi 28	270 Gly	/ Ly:	s Thr
🦡	Trp	Sei 290	Glu )	ı Pro	o Ile	Phe	A]a	. Met	Lys	5 Phe	Asn	Asp 300	Tyı	· Glu	 I G] I	i GJu
	Leu 305	val	l Tyr	Tr	) Pro	) Arg 310	ı Asp	) Asn	Lys	Leu	1 Lys 315	Asn	Ser	G]r	176	≘ Ser 320
	GТу	' Ser	· Ala	ı Ser	• Phe 325	Ile	Asp	) Ser	Ser	330	val	Glu	Asp	Lys	335	s ser
_	Gly	Lys	Thr	' Ile 340	Leu	Leu	Ala	Asp	Va 7 345	Met	Pro	Аlа	Gly	'Ile 350	G]	⁄ Asn
	Asn	Asn	A1a 355	Asn	Lys	Ala	Asp	Ser 360	Gly	' Phe	Lys	Glu	Ile 365	Asn	Gly	His
	Tyr	Tyr 370	Leu	Lys	Leu	Lys	Lys 375	Asn	Gly	Asp	Asn	Asp 380	Phe	Arg	Tyr	Thr
	Va1 385	Arg	Glu	Asn	Gly	Val 390	۷a٦	Tyr	Asn	Glu	Thr 395	Thr	Asn	Lys	Pro	Thr 400
	Asn	Tyr	Thr	Ile	Asn 405	Asp	Lys	Tyr	Glu	Va7 410	Leu	Glu	Gly	Gly	Lys 415	Ser
	Leu	Thr	Val	G]u 420	Gln	Tyr	Ser	۷a٦	Asp 425	Phe	Asp	Ser	Gly	Ser 430	Leu	Arg
	Glu	Arg	His 435	Asn	Gly	Lys	Gln	Va1 440	Pro	Met	Asn	val	Phe 445	Tyr	Lys	Asp
	Ser	Leu 450	Phe	Lys	Val	Thr	Pro 455	Thr	Asn	Tyr	Ile	Ala 460	Met	Thr	Thr	Ser
	G]n 465	Asn	Arg	σΊу	Glu	ser 470	Trp	Glu	Gln	Phe	Lys 475	Leu	Leu	Pro	Pro	Phe 480
	Leu	GТу	Glu	Lys	His 485	Asn	Glу	Thr	Tyr	Leu 490	Cys	Pro	Gly	Gln	G]y 495	Leu
	Ala	Leu	Lys	Ser 500	Ser	Asn	Arg	Leu	Ile 505	Phe	Ala	Thr	Tyr	Thr 510	Ser	Gly
	Glu	Leu	Thr 515	Tyr	Leu	Ile	Ser	Asp 520	Asp	Ser	Gly (	Gln	Thr 525	Trp	Lys	Lys

str pneumoniae patentin.ST25
Ser Ser Ala Ser Ile Pro Phe Lys Asn Ala Thr Ala Glu Ala Gln Met
530 540

Val Glu Leu Arg Asp Gly Val Ile Arg Thr Phe Phe Arg Thr Thr 545 550 560

Gly Lys Ile Ala Tyr Met Thr Ser Arg Asp Ser Gly Glu Thr Trp Ser 565 570 575

Lys Val Ser Tyr Ile Asp Gly Ile Gln Gln Thr Ser Tyr Gly Thr Gln 580 585 590

Val Ser Ala Ile Lys Tyr Ser Gln Leu Ile Asp Gly Lys Glu Ala Val 595 600 605

Ile Leu Ser Thr Pro Asn Ser Arg Ser Gly Arg Lys Gly Gln Leu
610 615 620

Val Val Gly Leu Val Asn Lys Glu Asp Asp Ser Ile Asp Trp Lys Tyr 625 630 635 640

His Tyr Asp Ile Asp Leu Pro Ser Tyr Gly Tyr Ala Tyr Ser Ala Ile 645 650 655

Thr Glu Leu Pro Asn His His Ile Gly Val Leu Phe Glu Lys Tyr Asp 660 665 670

Ser Trp Ser Arg Asn Glu Leu His Leu Ser Asn Val Val Gln Tyr Ile 675 680 685

Asp Leu Glu Ile Asn Asp Leu Thr Lys 690 695

<210> 213

<211> 946

<212> PRT

<213> Streptococcus pneumoniae

<400> 213

Met Asn Arg Ser Val Gln Glu Arg Lys Cys Arg Tyr Ser Ile Arg Lys 1 10 15

Leu Ser Val Gly Ala Val Ser Met Ile Val Gly Ala Val Val Phe Gly 20 25 30

Thr Ser Pro Val Leu Ala Gln Glu Gly Ala Ser Glu Gln Pro Leu Ala 35 40 45

str pneumoniae patentin.ST25 Gly Asn Pro Asn Lys Asp Gly Ile Lys Ser Tyr Arg Ile Pro Ala Leu 325 330 335 Leu Lys Thr Asp Lys Gly Thr Leu Ile Ala Gly Ala Asp Glu Arg Arg 340 345 Leu His Ser Ser Asp Trp Gly Asp Ile Gly Met Val Ile Arg Arg Ser 355 360 365Glu Asp Asn Gly Lys Thr Trp Gly Asp Arg Val Thr Ile Thr Asn Leu 370 375 380 Arg Asp Asn Pro Lys Ala Ser Asp Pro Ser Ile Gly Ser Pro Val Asn 385 390 400 Ile Asp Met Val Leu Val Gln Asp Pro Glu Thr Lys Arg Ile Phe Ser 405 410 415Ile Tyr Asp Met Phe Pro Glu Gly Lys Gly Ile Phe Gly Met Ser Ser 420 430 Gln Lys Glu Glu Ala Tyr Lys Lys Ile Asp Gly Lys Thr Tyr Gln Ile 445 Leu Tyr Arg Glu Gly Glu Lys Gly Ala Tyr Thr Ile Arg Glu Asn Gly 450 455 460 Thr Val Tyr Thr Pro Asp Gly Lys Ala Thr Asp Tyr Arg Val Val 465 470 480 Asp Pro Val Lys Pro Ala Tyr Ser Asp Lys Gly Asp Leu Tyr Lys Gly 485 490 495 Asp Gln Leu Leu Gly Asn Ile Tyr Phe Thr Thr Asn Lys Thr Ser Pro 500 510 Phe Arg Ile Ala Lys Asp Ser Tyr Leu Trp Met Ser Tyr Ser Asp Asp 515 520 525 Asp Gly Lys Thr Trp Ser Ala Pro Gln Asp Ile Thr Pro Met Val Lys 530 540 Ala Asp Trp Met Lys Phe Leu Gly Val Gly Pro Gly Thr Gly Ile Val 545 550 555 560 Leu Arg Asn Gly Pro His Lys Gly Arg Ile Leu Ile Pro Val Tyr Thr 565 570 575 Thr Asn Asn Val Ser His Leu Asp Gly Ser Gln Ser Ser Arg Val Ile 580 585 590

Arg Ser Lys Trp Gln Ser Ser Gly Ala Ser Ser Arg Ile Tyr Arg Gly 880

Ser Trp Tyr Arg Ala Ser Cys Ser Asn Arg Arg Val Gly Ile Phe Ala 885

Cys Asn Ser Tyr Tyr Lys Lys Arg Leu Tyr Leu Gln Ser Ser Ser Cys 910

Ser Ala Gly Thr Ser Asn Arg Lys Gln Gly Glu Pro Pro Ser Phe Thr 915 920 925

Arg Thr Asn Ser Phe Leu Pro Trp Ser Val Tyr Ala Arg Glu Lys Glu 930 940

Arg Thr 945

<210> 214

<211> 659

<212> PRT

<213> Streptococcus pneumoniae

<400> 214

Met Ile Gln Ile Gly Lys Ile Phe Ala Gly Arg Tyr Arg Ile Val Lys 1 10 15

Gln Ile Gly Arg Gly Gly Met Ala Asp Val Tyr Leu Ala Lys Asp Leu 20 25 30

Ile Leu Asp Gly Glu Glu Val Ala Val Lys Val Leu Arg Thr Asn Tyr 35 40 45

Gln Thr Asp Pro Ile Ala Val Ala Arg Phe Gln Arg Glu Ala Arg Ala 50 60

Met Ala Asp Leu Asp His Pro His Ile Val Arg Ile Thr Asp Ile Gly 65 70 75 80

Glu Glu Asp Gly Gln Gln Tyr Leu Ala Met Glu Tyr Val Ala Gly Leu 85 90 95

Asp Leu Lys Arg Tyr Ile Lys Glu His Tyr Pro Leu Ser Asn Glu Glu 105 110

Ala Val Arg Ile Met Gly Gln Ile Leu Leu Ala Met Arg Leu Ala His 115 125

	—-	_13(	0					-13	5	p-Le	mon-	//S: -P	1:0	140	AS	n-I	Te- (	.eu	Leu	 A	 	
1	hr 45	Pro	) A:	sp	Gly	/ Th	r Al: 150	a Ly O	s Va	7 Th	r As	p Pl	he 55	σΊу	17	e A	la v	⁄a]	Ala 160			
P	he	Ala	G	lu	Thr	Se:	r Lei	л Th	r Gli	1 Th	r As 17	n se	er 1	Иet	Lei	u Gi	ly s	er 75.	Va1			
H	is	Tyr	' Le	eu	Ser 180	Pro	G]ı	ı Glı	n Ala	18.	g G1;	y Se	er I	_ys	Αla	a Th	Ir V			 •	 	1,41
Se	er	Asp	17 19	e '	Tyr	Аlа	Met	c G I	/ Ile 200	e Ile	e Pho	е ту	r (	āTu	Met 205	Le	u T	hr	Gly			
Hi	is	Ile 210	Pr	o -	Гуr	Asp	G]y	Asp 215	Ser	' Ala	ı Va∃	l Th	r I	1e 20	Аlа	Le	u G	ln	His			4
Ph 22	e !5	Gln	Ly.	s F	Pro	Leu	Pro 230	Ser	Val	Ile	ala:	G] 23	u A 5	sn	Pro	Se	r Va		Pro 240			•
ĞΊ	n ,	41a	Lei	u G	i Tu	Asn 245	Val	Ile	Ile	Lys	Ala 250	Th.	r A	1a	Lys	Ly	5 Le 25	u '	Thr			
As	n A	Arg	Туі	^ A	rg 60	Ser	۷al	Ser	Glu	Met 265	Tyr	Va <sup>*</sup>	1 A	sp (	Leu	Sei 270	Se	r s	Ser			
Le	u S	Ser	Tyr 275	A	sn .	Arg	Arg	Asn	G1u 280	Ser	Lys	Lei	ı I.	le i	Phe 285	Asp	G 7	u 7	Thr			
Sei	r L 2	ys 90	Ala	ι Α.	sp ·	Thr	Lys	Thr 295	Leu	Pro	Lys	val	Se 30	er o	ā]n	Ser	Th	ր լ	.eu			
									Ala			313	1					3	20			•
									Glu		<b>J J J</b>						335	•				
Lys	L	ys F	lis	Ar 34	g P	he i	Lys I	Met .	Arg :	Tyr 345	Leu	Ile	Le	u L	eu ,	41a 350	Ser	· L	eu			
									11e <sup>-</sup> 360					31	05							
Thr	11 37	e A '0	la	IJ	еР	ro A	\sp \ 3	/a] / 875	Ala (	Пу (	sîn '	Thr	Va <sup>*</sup> 380	A   )	ia d	57u	Ala	Ly	/S			
A7a 385	Th	r L	eu	Ly:	s Ly	ys A	la A 90	sn F	he G	ilu J	le e	37 <i>y</i> 395	GΊι	ı - G7	u L	.ys	Thr	G7 40	u			

str pneumoniae patentin.ST25
Ala Ser Glu Lys Val Glu Glu Gly Arg Ile Ile Arg Thr Asp Pro Gly
405
410
415 Ala Gly Thr Gly Arg Lys Glu Gly Thr Lys Ile Asn Leu Val Val Ser 420 425 430 Ser Gly Lys Gln Ser Phe Gln Ile Ser Asn Tyr Val Gly Arg Lys Ser 435 440 445 Ser Asp Val Ile Ala Glu Leu Lys Glu Lys Lys Val Pro Asp Asn Leu 450 460 Ile Lys Ile Glu Glu Glu Ser Asn Glu Ser Glu Ala Gly Thr Val 465 470 475 480 Leu Lys Gln Ser Leu Pro Glu Gly Thr Thr Tyr Asp Leu Ser Lys Ala 485 490 495 Thr Gln Ile Val Leu Thr Val Ala Lys Lys Ala Thr Thr Ile Gln Leu 500 510 Gly Asn Tyr Ile Gly Arg Asn Ser Thr Glu Val Ile Ser Glu Leu Lys 515 520 525 Gln Lys Lys Val Pro Glu Asn Leu Ile Lys Ile Glu Glu Glu Glu Ser 530 540 Ser Glu Ser Glu Pro Gly Thr Ile Met Lys Gln Ser Pro Gly Ala Gly 545 550 555 560 Thr Thr Tyr Asp Val Ser Lys Pro Thr Gln Ile Val Leu Thr Val Ala 565 570 575 Lys Lys Val Thr Ser Val Ala Met Pro Ser Tyr Ile Gly Ser Ser Leu 580 590 Glu Phe Thr Lys Asn Asn Leu Ile Gln Ile Val Gly Ile Lys Glu Ala 595 600 605 Asn Ile Glu Val Val Glu Val Thr Thr Ala Pro Ala Gly Ser Ala Glu 610 615 620 Gly Met Val Val Glu Gln Ser Pro Arg Ala Gly Glu Lys Val Asp Leu 625 630 640 Asn Lys Thr Arg Val Lys Ile Ser Ile Tyr Lys Pro Lys Thr Thr Ser 645 655

Ala Thr Pro

<212> PRT

<213> Streptococcus pneumoniae

Met Thr Lys Leu Ile Phe Met Gly Thr Pro Asp Phe Ser Ala Thr Val 10 15

Leu Lys Gly Leu Leu Thr Asp Asp Arg Tyr Glu Ile Leu Ala Val Val 20 25 30

Thr Gln Pro Asp Arg Ala Val Gly Arg Lys Lys Val Ile Gln Glu Thr 35 40 45

Pro Val Lys Gln Ala Ala Lys Glu Ala Gly Leu Ser Ile Tyr Gln Pro 50 60

Glu Lys Leu Ser Gly Ser Pro Glu Met Glu Asp Leu Met Lys Leu Gly 65 75 80

Ala Asp Gly Ile Val Thr Ala Ala Phe Gly Gln Phe Leu Pro Ser Lys 85 90 95

Leu Leu Asp Ser Met Asp Phe Ala Val Asn Val His Ala Ser Leu Leu 105

Pro Arg His Arg Gly Gly Ala Pro Ile His Tyr Ala Leu Ile Gln Gly 115 125

Asp Glu Glu Ala Gly Val Thr Ile Met Glu Met Val Lys Glu Met Asp 130 135

Ala Gly Asp Met Ile Ser Arg Arg Ser Ile Pro Ile Thr Asp Glu Asp 145 150 155 160

Asn Val Gly Thr Leu Phe Glu Lys Leu Ala Leu Val Gly Arg Asp Leu 165 170 175

Leu Leu Asp Thr Leu Pro Ala Tyr Ile Ala Gly Asp Ile Lys Pro Glu 180 185

Pro Gln Asp Thr Ser Gln Val Thr Phe Ser Pro Asn Ile Lys Pro Glu 195 200 205

Glu Glu Lys Leu Asp Trp Asn Lys Thr Asn Arg Gln Leu Phe Asn Gln 210 220

str pneumoniae patentin.ST25
Ile Arg Gly Met Asn Pro Trp Pro Val Ala His Thr Phe Leu Lys Gly
225 230 235 240

Asp Arg Phe Lys Ile Tyr Glu Ala Leu Pro Val Glu Gly Gln Gly Asn 245 250 255

Pro Gly Glu Ile Leu Ser Ile Gly Lys Lys Glu Leu Ile Val Ala Thr 260 265 270

Ala Glu Gly Ala Leu Ser Leu Lys Gln Val Gln Pro Ala Gly Lys Pro 275 280 285

Lys Met Asp Ile Ala Ser Phe Leu Asn Gly Val Gly Arg Thr Leu Thr 290 295 300

Val Gly Glu Arg Phe Gly Asp 305 310

<210> 216

<211> 790

<212> PRT

<213> Streptococcus pneumoniae

<400> 216

Val Phe Arg Arg Leu Gly Gln Asp Phe Gln Leu Arg Lys Val Lys Lys 1 5 10 15

Ile Leu Lys Gl<br/>n Ile Asn Ala Leu Lys Gly Lys Met Ser Ser Leu Ser 20<br/> 25

Asp Gln Glu Leu Val Ala Lys Thr Val Glu Phe Arg Gln Arg Leu Ser 35 40 45

Glu Gly Glu Ser Leu Asp Asp Ile Leu Val Glu Ala Phe Ala Val Val 50 60

Arg Glu Ala Asp Lys Arg Ile Leu Gly Met Phe Pro Tyr Asp Val Gln 65 70 75 80

Val Met Gly Ala Ile Val Met His Tyr Gly Asn Val Ala Glu Met Asn 85 90 95

Thr Gly Glu Gly Lys Thr Leu Thr Ala Thr Met Pro Val Tyr Leu Asn 100 105 110

Ala Phe Ser Gly Glu Gly Val Met Val Val Thr Pro Asn Glu Tyr Leu 115 120 125 str pneumoniae patentin.ST25

Ser Lys Arg Asp Ala Glu Glu-Met-Gly-Gln Val Tyr Arg Phe Leu Gly 135

130

130 Leu Thr Ile Gly Val Pro Phe Thr Glu Asp Pro Lys Lys Glu Met Lys 150 155 160 Ala Glu Glu Lys Lys Leu Ile Tyr Ala Ser Asp Ile Ile Tyr Thr Thr Asn Ser Asn Leu Gly Phe Asp Tyr Leu Asn Asp Asn Leu Ala Ser Asn 180 Glu Glu Gly Lys Phe Leu Arg Pro Phe Asn Tyr Val Ile Ile Asp Glu 195 200 205 Ile Asp Asp Ile Leu Leu Asp Ser Ala Gln Thr Pro Leu Ile Ile Ala 210 220 Gly Ser Pro Arg Val Gln Ser Asn Tyr Tyr Ala Ile Ile Asp Thr Leu 235 240 Val Thr Thr Leu Val Glu Gly Glu Asp Tyr Ile Phe Lys Glu Glu Lys 245 250 255 Glu Glu Val Trp Leu Thr Thr Lys Gly Ala Lys Ser Ala Glu Asn Phe 260 265 270 Leu Gly Ile Asp Asn Leu Tyr Lys Glu Glu His Ala Ser Phe Ala Arg 275 280 285 His Leu Val Tyr Ala Ile Arg Ala His Lys Leu Phe Thr Lys Asp Lys 290 295 300 Asp Tyr Ile Ile Arg Gly Asn Glu Met Val Leu Val Asp Lys Gly Thr 305 310 315 320 Gly Arg Leu Met Glu Met Thr Lys Leu Gln Gly Gly Leu His Gln Ala 325 330 335 Ile Glu Ala Lys Glu His Val Lys Leu Ser Pro Glu Thr Arg Ala Met 340 345 Ala Ser Ile Thr Tyr Gln Ser Leu Phe Lys Met Phe Asn Lys Ile Ser 355 360 365 Gly Met Thr Gly Thr Gly Lys Val Ala Glu Lys Glu Phe Ile Glu Thr 370 380 Tyr Asn Met Ser Val Val Arg Ile Pro Thr Asn Arg Pro Arg Gln Arg 385 390 400

str pneumoniae patentin.ST25
Ile Asp Tyr Pro Asp Asn Leu Tyr Ile Thr Leu Pro Glu Lys Val Tyr
405
410
415 Ala Ser Leu Glu Tyr Ile Lys Gln Tyr His Ala Lys Gly Asn Pro Leu 420 425 430 Leu Val Phe Val Gly Ser Val Glu Met Ser Gln Leu Tyr Ser Ser Leu 435 440 445 Leu Phe Arg Glu Gly Ile Ala His Asn Val Leu Asn Ala Asn Asn Ala 450 455 460 Ala Arg Glu Ala Gln Ile Ile Ser Glu Ser Gly Gln Met Gly Ala Val 465 470 475 480 Thr Val Ala Thr Ser Met Ala Gly Arg Gly Thr Asp Ile Lys Leu Gly 485 490 495 Lys Gly Val Ala Glu Leu Gly Gly Leu Ile Val Ile Gly Thr Glu Arg 500 505 Met Glu Ser Gln Arg Ile Asp Leu Gln Ile Arg Gly Arg Ser Gly Arg 515 520 525 Gln Gly Asp Pro Gly Met Ser Lys Phe Phe Val Ser Leu Glu Asp Asp 530 540 Val Ile Lys Lys Phe Gly Pro Ser Trp Val His Lys Lys Tyr Lys Asp 545 550 555 560 Tyr Gln Val Gln Asp Met Thr Gln Pro Glu Val Leu Lys Gly Arg Lys 565 570 Tyr Arg Lys Leu Val Glu Lys Ala Gln His Ala Ser Asp Ser Ala Gly 580 585 590 Arg Ser Ala Arg Arg Gln Thr Leu Glu Tyr Ala Glu Ser Met Asn Ile 595 600 605 Gln Arg Asp Ile Val Tyr Lys Glu Arg Asn Arg Leu Ile Asp Gly Ser 610 620 Arg Asp Leu Glu Asp Val Val Asp Ile Ile Glu Arg Tyr Thr Glu 625 630 635 640 Glu Val Ala Ala Asp His Tyr Ala Ser Arg Glu Leu Leu Phe His Phe 645 650 655 Ile Val Thr Asn Ile Ser Phe His Val Lys Glu Val Pro Asp Tyr Ile 660 665 670

<u>··</u>	Asp	ov̯aʻ	l. <u>Th</u> i	ŗ,Ąsį	) Lys	5Thr	.Ala	t,v a i	LEALY	noni:	ae pa r∴Phe	aten	tin.	ST25	1∈Va	l I:le
			67.	)				<b>680</b>	)				68	5		. T.I.C
	Asp	690	s Glu	ı Lei	ı Ser	· Glu	695	Lys	G]ı	Lei	ı Lev	700	ı Glı (	ı His	S AS	) Leu
· ·	Tyr 705	Gli	ı Glr	Phe	Lei	710	Leu	ser	Leu	Lei	Lys 715	Ala	ı Ile	e Asp	) Asp	9 Asn 720
	Trp	∨a1	G]u	ı Glr	Va] 725	Asp	Tyr	Leu	Gln	G]r 730	Leu )	Ser	' Met	: Ala	1]e 735	Gly
	Gly	Gln	ser	` Ala 740	Ser	'G]n	Lys	Asn	Pro 745	Ile	val	Glu	Tyr	Tyr 750	Glr	ı Glu
	Ala	Tyr	^ Ala 755	Gly	Phe	Glu	Ala	Met 760	Lys	Glu	ı Gln	Ile	His 765	Ala	Asp	) Met
	Va]	Arg 770	Asn	Leu	Leu	Met	Gly 775	Leu	Va1	Glu	Val	Thr 780	Pro	Lys	Gly	g]u
	11e 785	٧a٦	Thr	His	Phe	Pro 790										
	<21	0>	217													
	<21	1>	4776													
	<21	2>	PRT													
	<21	3>	Stre	ptoc	occu	s pn	eumo	niae								
	<400	O> :	217													
	Met 1	Thr	Glu	Thr	val 5	Glu	Asp	Lys	٧a٦	Ser 10	His	Ser	Ile	Thr	G]y 15	Leu
	Asp	Ile	Leu	Lys 20	Glу	Ile	Va7	Ala	Ala 25	Gly	Ala	٧a٦	Ile	ser 30	Gly	Thr
	٧a٦	Ala	Thr 35	Gln	Thr	Lys	Val	Phe 40	Thr	Asn	Glu	Ser	Ala 45	Va]	Leu	Glu
	Lys	Thr 50	val	Glu	Lys	Thr	Asp 55	Ala	Leu	Ala	Thr	Asn 60	Asp	Thr	Val	۷al
	Leu 65	GТу	Thr	Ile	Ser	Thr 70	ser	Asn	Ser	Ala	Ser 75	Ser	Thr	Ser	Leu	Ser 80
	Ala	Ser	Glu	Ser	Ala 85	ser	Thr	Ser	Ala	Ser 90	Glu	Ser	ΑΊa	ser	Thr 95	Ser.

str pneumoniae patentin.ST25 Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser 100 105 110 Ala Ser Thr Ser Ile Ser Ala Ser Ser Thr Val Val Gly Ser Gln Thr 115 120 125 Ala Ala Ala Thr Glu Ala Thr Ala Lys Lys Val Glu Glu Asp Arg Lys 130 135 140 Lys Pro Ala Ser Asp Tyr Val Ala Ser Val Thr Asn Val Asn Leu Gln 145 150 160 Ser Tyr Ala Lys Arg Arg Lys Arg Ser Val Asp Ser Ile Glu Gln Leu 165 170 175 Leu Ala Ser Ile Lys Asn Ala Ala Val Phe Ser Gly Asn Thr Ile Val Asn Gly Ala Pro Ala Ile Asn Ala Ser Leu Asn Ile Ala Lys Ser Glu 195 200 205 Thr Lys Val Tyr Thr Gly Glu Gly Val Asp Ser Val Tyr Arg Val Pro 210 215 220 Ile Tyr Tyr Lys Leu Lys Val Thr Asn Asp Gly Ser Lys Leu Thr Phe 225 230 235 Thr Tyr Thr Val Thr Tyr Val Asn Pro Lys Thr Asn Asp Leu Gly Asn 245 250 255 Ile Ser Ser Met Arg Pro Gly Tyr Ser Ile Tyr Asn Ser Gly Thr Ser 260 265 270 Thr Gln Thr Met Leu Thr Leu Gly Ser Asp Leu Gly Lys Pro Ser Gly 275 285 Val Lys Asn Tyr Ile Thr Asp Lys Asn Gly Arg Gln Val Leu Ser Tyr 290 295 300 Asn Thr Ser Thr Met Thr Thr Gln Gly Ser Gly Tyr Thr Trp Gly Asn 305 310 315 Gly Ala Gln Met Asn Gly Phe Phe Ala Lys Lys Gly Tyr Gly Leu Thr 325 330 Ser Ser Trp Thr Val Pro Ile Thr Gly Thr Asp Thr Ser Phe Thr Phe 340 345 Thr Pro Tyr Ala Ala Arg Thr Asp Arg Ile Gly Ile Asn Tyr Phe Asn 355 360

		•														
_	. GIV	/ G] v	v 61v	v I v	έ Va⁻	l Val	. c1	str į	pneur	noni	ae p	aten	tin.	ST25		JSer
		3.7.0	0			1_m.v.Q	3.7-5	)	ser			r -Se 38	r GII 0	n- Sei	- Eet	ı-ser-
	Glr 385	Sei	r Lys	s Sei			· Val					ı Sei		a Sei	· Ala	s Ser 400
	Ala	Ser	Thr	Ser	A7a 405	Ser	Ala	Ser	^ Ala	Ser 410	Thr	Sei	^ Ala	a Ser	` Ala 415	Ser
	Ala	Ser	Thr	Ser 420	`Ala	. Ser	Ala	Ser	Ala 425	Ser	Thr	' Ser	· Ala	s Ser 430	Val	Ser
	Ala	. Ser	Thr 435	Ser	Ala	ser	Ala	Ser 440	Ala	Ser	Thr	' Ser	` Ala 445	ser	' Ala	Ser
	Ala	Ser 450	Thr	' Ser	' Ala	. ser	G]u 455	Ser	Ala	Ser	Thr	Ser 460	`Ala	ı Ser	Ala	Ser
	Ala 465	Ser	Thr	Ser	Ala	Ser 470	Ala	Ser	Ala	Ser	Thr 475	Ser	' Ala	Ser	Ala	Ser 480
	Ala	Ser	Thr	Ser	Ala 485	ser	Glu	Ser	Ala	Ser 490	Thr	Ser	Ala	Ser	Ala 495	Ser
	ΑΊa	Ser	Thr	Ser 500	Ala	Ser	Glu	Ser	Ala 505	Ser	Thr	Ser	Ala	Ser 510	Ala	Ser
	Аlа	Ser	Thr 515	Ser	Ala	Ser	ΑΊa	Ser 520	Ala	Ser	Thr	Ser	Ala 525	Ser	Gly	Ser
	Ala	Ser 530	Thr	Ser	Thr	Ser	Ala 535	Ser	Ala	Ser	Thr	Ser 540	Ala	Ser	Ala	Ser
•	Ala 545	Ser	Thr	Ser	Ala	Ser 550	Ala	Ser	Ala	Ser	Ile 555	Ser	ΑΊa	Ser	Glu	Ser 560
	Ala	Ser	Thr	Ser	Ala 565	Ser	Glu	Ser	Ala	Ser 570	Thr	Ser	Thr	Ser	Ala 575	Ser
	Ala	Ser	Thr	Ser 580	Ala	Ser	Glu	Ser	Ala 585	Ser	Thr	Ser	Ala	Ser 590	Ala	Ser
	Ala	Ser	Thr 595	ser	Ala	Ser	Ala	Ser 600	Ala	Ser	Thr	Ser	Ala 605	Ser	Ala	Ser
	ΑΊа	Ser 610	Thr	Ser	Ala	Ser	Ala 615	Ser	Thr	ser	Ala	Ser 620	Glu	Ser	Ala	Ser
	Thr 625	Ser	Ala	Ser	Ala	ser 630	Ala	Ser	Thr	Ser	Ala 635	Ser	Ala	Ser		Ser 640

str pneumoniae patentin.ST25
Thr Ser Ala Ser A Thr Ser Ala Ser Val Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 660 665 670 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser 675 680 685 Thr Ser Ala Se Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 705 710 715 720 Thr Ser Ala Ser Ala Ser Ala Ser Ala Ser Glu Ser Ala Ser 725 730 735 Thr Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser 740 745 750 Thr Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser 755 760 765 Thr Ser Ala Ser Ala Ser Ala Ser Ile Ser Ala Ser Glu Ser Ala Ser 770 780 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Se Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser 805 810 815 Thr Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser 820 825 830 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 835 840 845 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 850 860 Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 865 870 875 880 Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 890 895 Thr Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser 900 905 910

···	Thr	ser.	.Ala .915_	Ser.	Ala	.ser	Ala.	tr pi .Ser. .920-	neumo	oniae Ser	pat Ala-	entin Ser.A	.ST2!	S er-Al	a-Ser	
											Ala :				r Ser	
		Ser		Ser	Ala	Ser 950	Thr	Ser	Ala	Ser	Ala : 955	Ser Aï	la Se	er Th	r Ser 960	
	Ala	Ser	Ala	Ser	A1a 965				Ala	Ser 970	Ala s	Ser Al	la Se	r Th 97	r Ser 5	
	Ala	Ser	Glu	Ser 980	Ala	Ser	Thr	Ser	Ala 985	Ser	Ala s	Ser Al	a Se 99		r Ser	
	Ala	Ser	Ala 995	Ser	Ala	Ser	Thr	Ser 1000	Ala )	. Ser	Ala	Ser A	la 1005	Ser '	Thr Se	;
	Аlа	Ser 1010	Ala )	ser	Ala	Ser	Thr 101	. Se	r Al	a Se	r Ala	ser 1020	Ala	Ser	Ile	
	Ser	A7a 1025	Ser	Glu	Ser	Ala	Ser 103	тh	ır se	r Al	a Ser	Ala 1035	Ser	Ala	Ser	
	Thr	Ser 1040	Ala	Ser	Val	Ser	Ala 104	Se 5	r Th	r Se	r Ala	Ser 1050	Ala	Ser	Ala	
	Ser	Thr 1055	Ser	Ala	Ser	Glu	Ser 106	ΓΑ 0	a Se	r Th	r Ser	` Ala 1065	Ser	Ala	Ser	
	Ala	Ser 1070	Thr	Ser	Ala	Ser	Glu 107	Se 5	r Al	a Se	r Thr	Ser 1080	Ala	Ser	Ala	
	Ser	Ala 1085	Ser	Thr	Ser	Ala	Ser 109	ΓΑ 0	a se	r Ala	a Ser	lle 1095	Ser	ΑΊα	Ser	
	Glu	Ser 1100	Ala	Ser	Thr	Ser	Ala 110	Se 5	r Ala	a Se	r Ala	Ser 1110	Thr	Ser	Ala	
	Ser	Ala 1115	Ser	Аla	Ser	Thr	Ser 112	A].	a Se	r Ala	a Ser	Ala 1125	Ser	Thr	Ser	
	Ala	Ser 1130	Glu	Ser	ΑΊa	Ser	Thr 113	Se 5	r Thi	r Sei	r Ala	Ser 1140	Ala	Ser	Thr	
	Ser	Ala 1145	Ser	Glu	Ser	Аlа	Ser 115	Th	r Sei	r Ala	a Ser	Ala 1155	Ser	Ala	Ser	
	Thr	Ser 1160	Ala	Ser	Ala	Ser	Ala 116	Sei	r Thi	- Sei	· Ala	Ser 1170	Ala	Ser	Ala	

str pneumoniae patentin.ST25 Ser Thr Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser 1175 1180 1185 Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala 1190 1195 1200 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 1205 1215 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala 1220 1225 1230 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 1235 1240 1245 Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 1250 1255 1260 Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 1265 1270 1275 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 1280 1285 1290 Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Val Ser Ala Ser 1295 1300 1305 Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala 1310 1320 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser 1325 1330 1335 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu 1340 1345 1350 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 1355 1360 1365 Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 1370 1375 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 1385 1390 1395 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 1400 1405 1410 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 1415 1420 1425

str pneumoniae patentin.ST25 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Se Ser Thr Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 1445 1455 Ala Ser Ile Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala 1460 1465 1470 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 1475 1480 1485 Val Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 1490 1500 Ser Ala Ser Ala Ser Ile Ser Ala Ser Glu Ser Ala Ser Thr Ser 1505 1510 1515 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 1520 1530 Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 1535 Ile Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala 1550 1560 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 1565 1570 1575 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala 1580 1590 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 1595 1600 1605 Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 1610 1620 Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser 1625 1630 1635 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 1640 1650 Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Val Ser Ala Ser 1655 1660 1665 Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala 1670 1680

str pneumoniae patentin.ST25 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 1685 1690 1695 Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala 1700 1710 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 1715 1720 1725 Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 1730 1740 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 1745 1755 Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala 1760 1765 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 1775 1780 1785 Ala Ser Ile Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Glu 1790 1795 1800 Ser Ala Ser Thr Ser Thr Ser Ala Ser Ala Ser Thr Ser Ala Ser 1805 1810 1815 Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 1820 1830 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 1835 1840 1845 Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala 1850 1860 Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Thr Ser 1865 1870 Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Thr 1880 1885 1890 Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Val Ser Ala Ser 1895 1900 1905 Thr Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala 1910 1920 Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser 1925 1930 1935

<u> </u>	a _Ser 194(	Thi	r. Sei	Ala	ı,_Se	st r Ala 194					entin Ser			°=A·la·	
			-			3 Ser 1960	A٦a				<u>1950</u> • <u>Thr</u>	Sei			
						1960 Ala 1975		· Glu	Ser	Ala	196:	•			
a desta de la composição de la composição de la composição de la composição de la composição de la composição		<u></u>	4. <b>-</b>	4 A.M	<b></b>	19/5					1980	)		· · ·	
Ser	Ala 1985	Ser	` Ala	Ser	Thr	Ser 1990	Ala	Ser	Ala	Ser	' Ala 1995	Ser	Thr	Ser	
Ala	Ser 2000	Ala	Ser	Ala	Ser	Thr 2005	Ser	' Ala	Ser	Ala	Ser 2010	Ala	Ser	Thr	
Ser	Ala 2015	ser	Ala	Ser	Ala	Ser 2020	Ile	Ser	Ala	Ser	G]u 2025	Ser	Ala	Ser	
Thr	Ser 2030	Ala	Ser	Ala	Ser	Ala 2035	Ser	Thr	Ser	Ala	Ser 2040	Ala	Ser	Ala	
Ser	Thr 2045	Ser	Ala	Ser	Ala	Ser 2050	Ala	Ser	Thr	Ser	Ala 2055	Ser	Glu	Ser	
Ala	Ser 2060	Thr	Ser	Ala	Ser	Ala 2065	Ser	Ala	Ser	Thr	Ser 2070	Ala	Ser	Ala	
Ser	Ala 2075	Ser	Thr	Ser	Ala	Ser 2080	Ala	Ser	Ala	Ser	Thr 2085	Ser	Аlа	Ser	
Ala	Ser 2090	Ala	Ser	Thr	Ser	Ala 2095	Ser	Ala	Ser	Аlа	Ser 2100	Thr	Ser	Ala	
Ser	Ala 2105	Ser	Ala	Ser	Thr	Ser 2110	Ala	Ser	Glu	Ser	Ala 2115	Ser	Thr	Ser	
Ala	Ser 2120	Ala	Ser	Ala	Ser	Thr 2125	Ser	Ala	Ser	Glu	Ser 2130	Ala	Ser	Thr	
Ser	A7a 2135	ser	Ala	Ser	Ala	Ser 2140	Thr	Ser	Ala	Ser	Ala 2145	Ser	Ala	Ser	
Thr	Ser 2150	Ala	Ser	Ala	Ser	Ala 2155	Ser	Thr	Ser .	Ala	Ser 2160	Ala	Ser	Ala	
Ser	Thr 2165	Ser	Ala	Ser	Ala	Ser 2170	Ala	Ser	Thr	Ser	Ala 2175	Ser	Ala	Ser	
Ala	Ser 2180	Thr	Ser .	Ala :	Ser	Ala 2185	Ser	Thr :	Ser /	Ala	Ser 2190	Glu	Ser·,	Ala ·	

str pneumoniae patentin.ST25
Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 2195
2200
2205 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu 2210 2215 2220 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 2225 2235 Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 2240 2245 2250 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Ile Ser 2255 2260 2265 Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 2270 2280 Ser Ala Ser Val Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 2285 2295 Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala 2300 2305 2310 Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser 2315 2320 2325 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Ile Ser Ala Ser Glu 2330 2335 2340 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 2345 2350 2355 Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 2360 2365 2370 Ser Glu Ser Ala Ser Thr Ser Thr Ser Ala Ser Ala Ser Thr Ser 2375 2380 2385 Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 2390 2400 Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 2405 2415 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Thr 2420 2430 Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 2435

*	Th	rser 245	Ala	a Şei	r Ala	. Ser						entin Ser - 2460		; ∴Ser	Ala	
	Sei							A٦a				· Ala 2475	Ser	Ala	Ser	
	Ala	3 Ser 248	Thr 0	Ser	· Ala	Ser	Ala 2485	Ser	` Ala	Ser	Thr	Ser 2490	Ala	Ser	Ala	
								Αla				Thr 2505	Ser			
	Ala	ser 2510	Ala )	Ser	Thr	Ser	Ala 2515	Ser	Ala	Ser	Ala	Ser 2520	Thr	Ser	Ala	
	Ser	Ala 2525	Ser	Ala	. Ser	Thr	Ser 2530	Ala	Ser	Glu	Ser	Ala 2535	Ser	Thr	Ser	
	Αla	Ser 2540	Ala )	Ser	Ala	Ser	Thr 2545	Ser	Ala	Ser	Ala	Ser 2550	Ala	Ser	Thr	
	Ser	A7a 2555	Ser	Ala	Ser	Ala	Ser 2560	Thr	Ser	Ala	Ser	Val 2565	Ser	Ala	Ser	
	Thr	Ser 2570	Ala	Ser	Glu	Ser	Ala 2575	Ser	Thr	Ser	Ala	Ser 2580	Ala	Ser	Ala	
	Ser	Thr 2585	Ser	Ala	Ser	Ala	ser 2590	Аlа	Ser	Thr	Ser	Ala 2595	Ser	Ala	Ser	
	Ala	Ser 2600	Thr	ser	ΑΊα	Ser	G] u 2605	ser	Ala	Ser	Thr	Ser 2610	Ala	Ser	Ala	
	Ser	Ala 2615	Ser	Thr	Ser	Ala	ser 2620	Ala	Ser	Ala	Ser	Thr 2625	Ser	Ala	Ser	
	Glu	Ser 2630	Ala	Ser	Thr	Ser	Ala 2635	Ser	Ala	Ser	Ala	Ser 2640	Thr	Ser .	Ala	
	ser	A7a 2645	Ser	Ala	Ser	Thr	ser 2650	Ala	Ser	Ąla	Ser	Ala 2655	Ser '	Thr :	Ser	
	Ala	ser 2660	Ala	Ser	Ala	Ser	Ala 2665	Ser	Thr	Ser .	Ala	Ser 2670	Ala :	Ser /	Ala	
		Thr 2675	Ser	Ala	ser /	Ala	Ser 2680	Ala	Ser	Thr :	Ser	Ala 2685	Ser A	Ala s	Ser	
	Ala	Ser 2690	Ile	Ser	Ala s	Ser	Glu 2695	Ser	Ala	Ser	Thr	ser `/ 2700 `	Ala s	Ser A	Na	

str pneumoniae patentin.ST25
Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser
2705 2710 2715 Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ile 2720 2730 Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser 2735 2740 2745 Thr Ser Thr Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala 2750 2755 2760 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 2765 2770 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala 2780 2785 Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser 2795 2800 2805 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala 2810 2815 2820 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 2825 2830 2835 Ala Ser Ala Ser Thr Ser Ala Ser Val Ser Ala Ser Thr Ser Ala 2840 2845 2850 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 2855 2860 2865 Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Thr Ser Ala 2870 2875 2880 Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 2885 2895 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 2900 2905 2910 Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 2915 2925 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala 2930 2935 2940 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 2945 2955

·	A]a	Ser 2960	Thr	Ser	Ala	. Ser	str Ala _2965	pne Ser	umor Ala	iae Ser	pate Th <u>r</u>	entin Ser	ST25	s . sei	_G]u	
			Ser				Ser 2980	Αla					Ser			
	G]u	Ser 2990	Ala	Ser	Thr	Ser	Ala 2995	Ser	Ala	Ser	ΑΊa	Ser 3000	Thr	Ser		-
	Ser	Ala 3005	Ser	Ala	Ser	Thr	Ser 3010	Ala	Ser	Gly	Ser	Ala 3015	Ser	Thr	Ser	-Marie Arama
	Thr	Ser 3020	Ala	Ser	Ala	Ser	Thr 3025	Ser	Ala	Ser	Αla	Ser 3030	Ala	Ser	Thr	
_	Ser	Ala 3035	Ser	Ala	Ser	Ala	Ser 3040	Ile	Ser	ΑΊa	Ser	G]u 3045	Ser	Αla	Ser	
	Thr	Ser 3050	Ala	Ser	Glu	Ser	A1a 3055	Ser	Thr	Ser	Thr	Ser 3060	Ala	Ser	Ala	•
	Ser	Thr 3065	Ser	Ala	Ser	Glu	ser 3070	Ala	Ser	Thr	Ser	Ala 3075	Ser	Ala	Ser	
	Ala	ser 3080	Thr	Ser	Ala	Ser	Ala 3085	Ser	Ala	Ser	Thr	Ser 3090	Ala	Ser	Ala	
	Ser	Ala 3095	Ser	Thr	Ser	Ala	Ser 3100	Ala	Ser	Thr	Ser	Ala 3105	Ser	Glu	Ser	
	Аlа	ser 3110	Thr	Ser	Ala	Ser	Ala 3115	Ser	Ala	Ser	Thr	Ser 3120	Ala	Ser	Ala	
	ser	Ala 3125	ser	Thr	Ser	Ala	Ser 3130	Ala	Ser	Аlа	Ser	Thr 3135	Ser	Ala	Ser	
	Ala	Ser 3140	Ala	Ser	Thr	Ser	Ala 3145	Ser	Val	Ser	Ala	Ser 3150	Thr	Ser	Ala	•
	Ser	Ala 3155	Ser	Ala	Ser	Thr	ser 3160	Ala	Ser	Ala	Ser	Ala 3165	Ser	Thr	Ser	
	ΑΊα	ser 3170	Glu	Ser	Ala	Ser	Thr 3175	Ser	Ala	Ser	Ala	Ser 3180	Ala	Ser	Thr	
	Ser	Ala 3185	Ser	Ala	Ser	Ala	Ser 3190	Thr	Ser	Ala	Ser	Ala 3195	Ser	Ala	Ser	
٠	Thr	Ser 3200	Ala	Ser	Ala	Seŗ	A1a 3205	Ser	Thr	Ser	Ala	ser 3210	Ala	Ser	Ala	

str pneumoniae patentin.ST25
Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser
3215 3220 \_ 3225 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala 3230 3240 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 3245 3255 Ala Ser Ala Ser Ile Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala 3260 3265 3270 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 3275 3280 3285 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr 3290 3300 Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 3305 3315 Thr Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala 3320 3325 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 3335 3340 3345 Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala 3350 3360 Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser 3365 3370 3375 Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 3380 3385 3390 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 3395 3400 3405 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 3410 3415 3420 Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser 3425 3430 3435 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 3440 3445 3450 Ser Ala Ser Ala Ser Ala Ser Ala Ser Glu Ser Ala Ser 3455 3460 3465

						SŤ	r nn	ei imoi	niao				_	
 Th	r Ser 347	0 Al	a Se	r Ala	s Sei	r Ala 347	Sei	r Th	r Sei	pat Ala	entin Ser 348	.ST2 Al 0	5 a. Sei	-Ala.
	r Thr 348						Αla					se		
 A];	a ser 350	Thi O	r Ser	· Ala	Ser	Ala 3505	Ser	Ala	Ser	Ile	Ser 3510	A];	a Ser	· Glu
Sei	r Ala 351	Ser 5	Thr	` Ser	Ala	Ser 3520	A7a	. Ser	Ala	Ser	Thr 352	Sei	^ Ala	Ser
Val	l ser 3530	Ala )	. Ser	Thr	Ser	Ala 3535	Ser	' Ala	Ser	Ala	Ser 3540	Thr	· Ser	Ala
Ser	Glu 3545	Ser	' Ala	. Ser	Thr	Ser 3550	Ala	Ser	Ala	Ser	A]a 3555	Ser	Thr	Ser
ΑΊa	ser 3560	Glu )	Ser	Ala	Ser	Thr 3565	Ser	Ala	Ser	Ala	Ser 3570	Ala	Ser	Thr
Ser	Ala 3575	Ser	Аlа	Ser	Ala	ser 3580	Ile	Ser	Ala	Ser	G]u 3585	Ser	Ala	Ser
Thr	Ser 3590	Ala	Ser	Аlа	Ser	Ala 3595	Ser	Thr	Ser	Ala	Ser 3600	Ala	Ser	Ala
Ser	Thr 3605	Ser	Ala	Ser	Ala	Ser 3610	Ala	Ser	Thr	Ser	Ala 3615	Ser	Glu	Ser
Ala	Ser 3620	Thr	Ser	Thr	Ser	A7a 3625	Ser	Ala	Ser	Thr	Ser 3630	Ala	Ser	Glu
Ser	Ala 3635	Ser	Thr	Ser	Ala	Ser 3640	Ala	Ser	Ala	Ser	Thr 3645	Ser	Ala	Ser
Ala	Ser 3650	Ala	Ser	Thr	Ser	Ala 3655	ser	Ala	Ser	Ala	Ser 3660	Thr	Ser	Ala
Ser	Ala 3665	Ser	Ala	Ser	Thr	ser 3670	Ala	Ser	Ala	Ser	Thr 3675	Ser	Ala	Ser
Glu	Ser 3680	Ala	Ser	Thr	Ser	A1a 3685	Ser	Ala :	Ser ,	ΑΊа	Ser 3690	Thr	Ser /	Ala
	Ala 3695	Ser	Ala	Ser '	Thr	Ser 3700	Ala	Ser /	Ala :	Ser	Ala 3705	Ser	Thr :	Ser
Ala	Ser 3710	Ala	Ser /	Ala :	Ser :	Thr : 3715	Ser /	Ala s	Ser /	Ala :	Ser 3720	Ala	Ser 7	Γhr

str pneumoniae patentin.ST25 Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser 3725 3730 3735 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala 3740 3745 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 3765 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala 3770 3775 3780 Ser Ala Ser Thr Ser Ala Ser Val Ser Ala Ser Thr Ser Ala Ser 3785 3790 3795 Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 3800 3810 Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr Ser 3815 3820 3825 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala Ser Thr 3830 3840 Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser 3845 3850 3855 Thr Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala 3860 3865 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 3875 3880 3885 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala 3890 3895 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 3905 3915 Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 3920 3930 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Ile Ser 3935 3940 3945 Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr 3950 3955 3960 Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Val Ser Ala Ser 3965 3970 3975

	Τh	r ser 3980	Ala O	a Se	r Ala	a Ser	st: Ala 3985	r pne Ser	eumoi Thr	niae Ser	pate _Ala	entin LSer	. ST2: <u>A</u> ]a	5 a "Sej	r. Ala	2-
		r Ile 399						Αla					Ser			
4		a Ser 4010		Sei	^ Ala		Ala 4015				Thr	Ser 4020	Ala	sei	Ala	
	Sei	r Ala 4025	Ser	Thr	Ser	Ala	Ser 4030	Ala	Ser	Ala	Ser	Ile 4035	Ser	Αla	Ser	-
	Glu	ser 4040	Ala	Ser	Thr	Ser	Ala 4045	Ser	Ala	Ser	Ala	Ser 4050	Thr	Ser	Ala	
	Ser	Ala 4055	Ser	Ala	Ser	Thr	Ser 4060	Ala	Ser	Ala	Ser	Ala 4065	Ser	Thr	Ser	
	Ala	ser 4070	Ala	Ser	Ala	Ser	Thr 4075	Ser	ΑΊa	Ser	Ala	Ser 4080	Ala	Ser	Thr	
	Ser	Ala 4085	Ser	Ala	Ser	Ala	Ser 4090	Thr	Ser	Ala	Ser	Ala 4095	Ser	Αla	Ser	
	Thr	Ser 4100	Ala	Ser	Ala	Ser	Ala 4105	Ser	Thr	Ser	Ala	ser 4110	Ala	Ser	Ala	
	Ser	Thr 4115	Ser	ΑΊа	Ser	Glu	Ser 4120	ΑΊа	Ser	Thr	Ser	Ala 4125	Ser	Αla	Ser	
	Ala	Ser 4130	Thr	Ser	Ala	Ser	Ala 4135	Ser	Ala	Ser	Ile	Ser 4140	Ala	Ser	Glu	
•	ser	Ala 4145	Ser	Thr	Ser	Ala	Ser 4150	Ala	Ser	Ala	Ser	Thr 4155	Ser	Ala	Ser	
	Ala	Ser 4160	Ala	Ser	Thr	Ser	Ala 4165	Ser	Ala	Ser	Ala	Ser 4170	Thr	Ser	Ala	
	Ser	G]u 4175	Ser	Ala	Ser	Thr	Ser 4180	Thr	Ser	Ala	Ser	Ala 4185	Ser	Thr	Ser	
	Ala	Ser 4190	Glu	Ser	Ala	Ser	Thr 4195	ser	Ala	Ser	Ala	Ser 4200	Ala	Ser	Thr	
	Ser	Ala 4205	Ser	Ala	Ser	Ala	Ser 4210	Thr	Ser.	Ala	Ser	Ala 4215	Ser	Ala	Ser	
	Thr	Ser 4220	Ala	Ser	Ala	Ser .	Ala 4225	Ser '	Thr .	Ser /	Ala :	Ser 4230	Ala	Ser	Thr	

str pneumoniae patentin.ST25 Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser 4235 4240 4245 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala 4250 4255 4260 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser 4265 4270 4275 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala 4280 4285 4290 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 4300 4305 Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 4310 4315 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 4325 4330 Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Val Ser Ala Ser Thr 4340 4350 Ser Ala Ser Glu Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser 4365 Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser Ala 4370 4380 Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Glu Ser 4385 4390 4395 Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala 4400 4405 Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser 4415 4420 4425 Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala 4430 4440 Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser Thr Ser 4445 4455 Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Ala Ser Thr 4460 4465 4470 Ser Ala Ser Ala Ser Ala Ser Thr Ser Ala Ser Ala Ser Ala Ser

	Thir	ser 449(	A]a	. Ser	Ala	Ser	sti Ala 4495	Ser	' Thr	' Ser	· Al:	entin LSer	^7-		-Ala
	Ser	' Ile 4505	Ser	· Ala			Ser 4510	Аla					Ser		Ser
- # 100,000.	Ala	Ser 4520	Thr	Ser	Ala	Ser	Ala 4525	. Ser	Ala	Ser	Thr	Ser 4530	Ala	Ser	' Val
	Ser	Ala 4535	Ser	Thr	Ser	Ala	Ser 4540	Ala	Ser	Ala	Ser	Thr 4545	Ser	Ala	Ser
	Ala	ser 4550	Ala	Ser	Ile	Ser	Ala 4555	Ser	Glu	Ser	Αla	Ser 4560	Thr	Ser	Ala
	Ser	Ala 4565	Ser	Ala	Ser	Thr	Ser 4570	Ala	Ser	Αla	Ser	Ala 4575	Ser	Thr	Ser
	Ala	ser 4580	Ala	Ser	Ala	Ser	Thr 4585	Ser	Ala	Ser	Ala	Ser 4590	Ala	Ser	Ile
	Ser	A7a 4595	Ser	Glu	Ser	Ala	Ser 4600	Thr	Ser	Ala	Ser	Ala 4605	Ser	Ala	Ser
	Thr	Ser 4610	Ala	Ser	Ala	Ser	Ala 4615	Ser	Thr	Ser	Αla	Ser 4620	Αla	Ser	Ala
	Ser	Thr 4625	Ser	Ala	Ser	Ala	ser 4630	Ala	Ser	Thr	Ser	Ala 4635	Ser	Ala	Ser
	Ala	5er 4640	Thr	Ser	ΑΊa	Ser	A7a 4645	Ser	Ala	Ser	Thr	Ser 4650	Ala	Ser	Ala
	Ser	Ala 4655	Ser	Thr	Ser	Ala	Ser 4660	Ala	Ser	Ala	Ser	Thr 4665	Ser	Ala	Ser
	Ala	Ser 4670	Ala	Ser	Thr	Ser	Ala 4675	Ser	Ala	Ser	Ala	ser 4680	Thr	Ser	Ala
	Ser	Ala 4685	Ser	Ala	Ser	Thr	Ser 4690	Ala	Ser	Ala	Ser	Ala 4695	Ser	Thr	Ser
	Аlа	ser 4700	Ala	Ser	Ala	Ser	Thr 4705	Ser	Ala	Ser	ΑΊα	Ser 4710	Ala	Ser	Thr
		Va7 4715	Ser	Asn	Ser	Ala	Asn 4720	His	Ser	Asn	Ser	G1n 4725	Val	Gly	Asn
	Thr	Ser 4730	ĢÌy	Ser	Thr	Gly	Lys 4735	Ser	Gln	Lys	Glu	Leu 4740	Pro	Asn	Thr

str pneumoniae patentin.ST25 Gly Thr Glu Ser Ser Ile Gly Ser Val Leu Leu Gly Val Leu Ala 4745 4750 4755

Ala Val Thr Gly Ile Gly Leu Val Ala Lys Arg Arg Lys Arg Asp 4760 4765

Glu Glu Glu 4775

<210> 218

<211> 202

<212> **PRT** 

<213> Streptococcus pneumoniae

<400> 218 Met Ser Asn Glu Lys Asn Thr Asn Thr Asn Val Glu Lys Lys Asp Ala 1 10 15 Thr Val Val Ala His Glu Ile Lys Gly Glu Leu Thr Tyr Glu Asp Lys
20 25 30 Val Ile Gln Lys Ile Ile Gly Leu Ser Leu Glu Asn Val Ser Gly Leu 35 40 45 Leu Gly Ile Asp Gly Gly Phe Phe Ser Asn Leu Lys Glu Lys Ile Val Asn Ser Asp Asp Val Thr Ser Gly Val Asn Val Glu Val Gly Lys Thr 65 70 75 80 Gln Val Ala Val Asp Leu Asn Val Ile Val Glu Tyr Gln Lys Asn Val 85 90 95 Pro Ala Leu Tyr Ser Glu Ile Arg Glu Ile Val Ser Ser Glu Val Ala 100 105

Lys Met Thr Asp Leu Glu Ile Val Glu Ile Asn Val Asp 115 120 125

Ile Lys Thr Lys Glu Gln His Glu Ala Asp Ser Val Ser Leu Gln Asp 130 140

Arg Val Ser Asp Val Ala Glu Ser Thr Gly Glu Phe Thr Ser Glu Gln 145 150 155 160

Phe Glu Lys Ala Lys Ser Gly Leu Gly Ser Gly Phe Ser Thr Val Gln
165 170 175

## str pneumoniae patentin.ST25 Glu Lys Val Ser Glu Gly Val Glu Ala Val Lys Gly Ala Ala Asn Gly 180 180 185 190

Val Val Ser His Glu Asn Thr Arg Val Asn 195 200

<210> 219

<211> -355-

<212> PRT

<213> Streptococcus pneumoniae

<400> 219

Met Thr Lys Glu Lys Asn Val Ile Leu Thr Ala Arg Asp Ile Val Val 1 10 15

Glu Phe Asp Val Arg Asp Lys Val Leu Thr Ala Ile Arg Gly Val Ser

Leu Glu Leu Val Glu Gly Glu Val Leu Ala Leu Val Gly Glu Ser Gly 35 40 45

Ser Gly Lys Ser Val Leu Thr Lys Thr Phe Thr Gly Met Leu Glu Glu 50 60

Asn Gly Arg Ile Ala Gln Gly Ser Ile Asp Tyr Arg Gly Gln Asp Leu 70 75 75

Thr Ala Leu Ser Ser His Lys Asp Trp Glu Gln Ile Arg Gly Ala Lys 85 90 95

Ile Ala Thr Ile Phe Gln Asp Pro Met Thr Ser Leu Asp Pro Ile Lys
100 105 110

Thr Ile Gly Ser Gln Ile Thr Glu Val Ile Val Lys His Gln Gly Lys 115 120 125

Thr Ala Lys Glu Ala Lys Glu Leu Ala Ile Asp Tyr Met Asn Lys Val 130 135 140

Gly Ile Pro Asp Ala Asp Arg Arg Phe Asn Glu Tyr Pro Phe Gln Tyr 145 150 160

Ser Gly Gly Met Arg Gln Arg Ile Val Ile Ala Ile Ala Leu Ala Cys 165 170 175

Arg Pro Asp Val Leu Ile Cys Asp Glu Pro Thr Thr Ala Leu Asp Val 180 190 Thr Ile Gln Ala Gln Ile Ile Asp Leu Leu Lys Ser Leu Gln Asn Glu

Tyr His Phe Thr Thr Ile Phe Ile Thr His Asp Leu Gly Val Val Ala

Ser Ile Ala Asp Lys Val Ala Val Met Tyr Ala Gly Glu Ile Val Glu

Tyr Gly Thr Val Glu Glu Val Phe Tyr Asp Pro Arg His Pro Tyr Thr

Ser Leu Leu Ser Ser Leu Pro Gln Leu Ala Asp Asp Lys Gly Asp

Leu Tyr Ser Ile Pro Gly Thr Pro Pro Ser Leu Tyr Thr Asp Leu Lys 275 280 285

Gly Asp Ala Phe Ala Leu Arg Ser Asp Tyr Ala Met Gln Ile Asp Phe 290 295 300

Glu Gln Lys Ala Pro Gln Phe Ser Val Ser Glu Thr His Trp Ala Lys 305 310 315 320

Thr Trp Leu Leu His Glu Asp Ala Pro Lys Val Glu Lys Pro Ala Val 325 330 335

Ile Ala Asn Leu His Asp Lys Ile Arg Glu Lys Met Gly Phe Ala His 340 345 350

Leu Ala Asp 355

<210> 220

<211> 659

<212> PRT

<213> Streptococcus pneumoniae

<400> 220

Met Lys Lys Asn Arg Val Phe Ala Thr Ala Gly Leu Val Leu Leu Ala 10 15

Ala Gly Val Leu Ala Ala Cys Ser Ser Ser Lys Ser Ser Asp Ser Ser Ser 20 25 30

Ala Pro Lys Ala Tyr Gly Tyr Val Tyr Thr Ala Asp Pro Glu Thr Leu 35 40 45

	As	p Ty	۷r (	.eu	I]	e Se	r Se	г Ly 55	str s As	pnei n Se	lmon er Th	iae ir T	pate hr v 6	ntii al.\ 0	n.s ⁄al	T25	r Se	: Asn	· · · · · · · · · · · · · · · · · · ·	
	G] 65	/ Il	le A	sp	GΊχ	/ Le	u Ph 70	e Thi	As	n As	p As	in Ty 75	/r G	ly A	sn	Lei	u A7	Pro 80		
······································	A1a	va	1 A	la -	G7u	85 85	o Tr	G]ı	ı Va	l Se	r Ly 90	/S AS	sp G	ly ∟	eu	Thi	т Ту 95	Thr		
	Tyr	· Ly	s I	1e	Arg 100	Lys	G G Ty	/ Val	Lys	Tr <sub>1</sub>	p Ph 5	еTh	ır se	er A	sp	G]y	′ G](	Glu	<u> </u>	<del></del>
	Tyr	A]	a G 1	] u 15	٧a٦	Thr	· Ala	Lys	Asp 120	Phe	e Va	l As	n Gl	y L	eu 25	Lys	Hi:	Ala		
	ΑΊa	As <sub>1</sub>	p Ly	ys	Lys	Ser	G]L	Ala 135	Met	Tyr	· Le	ra u	a Gl 14	<b>u</b> A:	sn	Ser	' Va]	Lys		
•	Gly 145	Lei	ı A	la ,	Asp	Tyr	Leu 150	Ser	Gly	Thr	` Sei	r Th 15	r As 5	p Pł	1e	Ser	Thr	Val 160		
	Gly	Val	L	/S A	41a	Va 1 165	Asp	Asp	Tyr	Thr	Lei 17(	ı Glı	ту	r Th	r (	Leu	Asn 175	Gln		
	Pro	Glu	ı Pr	9 O'	he L80	Trp	Asn	Ser	Lys	Leu 185	Thr	` Туі	se.	r Il	e i	Phe 190	Trp	Pro		
	Leu	Asn	G] 19	u 6	มโน	Phe	Glu	Thr	Ser 200	Lys	Gly	' Ser	· Asj	Ph 20	e #	47a	Lys	Pro		
•	Thr	Asp 210	Pr	о т	hr	Ser	Leu	Leu 215	Tyr	Asn	Gly	Pro	Phe 220	e Le	u L	.eu	Lys	gly		
• !	Leu 225	Thr	ΑŢ	a L	ys	Ser	Ser 230	Val	Glu	Phe	۷a٦	Lys 235	Asr	ı Gl	u G	i]n	Tyr	Γrp 240		
A	Asp	Lys	Gli	J A	sn '	Va1 245	His	Leu	Asp	Thr	Ile 250	Asn	Leu	ı Ala	аТ	yr	Tyr 255	Asp		
G	ily :	Ser	Asp	2 G	ln ( 60	31u	Ser	Leu	Glu	Arg 265	Asn	Phe	Thr	Sei	G 2	1y 70	Ala	yr		
S	er T	Гуг	A1a 275	A A I	rg l	.eu	Tyr	Pro ;	Thr 280	Ser	Ser	Asn	Tyr	Ser 285	L	ys '	val	la		
G	Tu o	ilu !90	Tyr	. F?	/S A	sp /	Asn :	Tle 1 295	ryr '	Tyr	Thr	Gln	Ser 300	Gly	' Se	er (	sly	le		
A 3	la G 05	lly	Leu	Gl	y V	'al A	Asn : 310	tle A	sp A	Arg (	G]n	Ser 315	Tyr	Asn	رד.	/r 7		er 20		

str pneumoniae patentin.ST25
Lys Thr Thr Asp Ser Glu Lys Val Ala Thr Lys Lys Ala Leu Leu Asn
325 330 335 Lys Asp Phe Arg Gln Ala Leu Asn Phe Ala Leu Asp Arg Ser Ala Tyr 340 Ser Ala Gln Ile Asn Gly Lys Asp Gly Ala Ala Leu Ala Val Arg Asn 355 360 365 Leu Phe Val Lys Pro Asp Phe Val Ser Ala Gly Glu Lys Thr Phe Gly 370 380 Asp Leu Val Ala Ala Gln Leu Pro Ala Tyr Gly Asp Glu Trp Lys Gly 385 390 395 Val Asn Leu Ala Asp Gly Gln Asp Gly Leu Phe Asn Ala Asp Lys Ala 405 415 Lys Ala Glu Phe Ala Lys Ala Lys Lys Ala Leu Glu Ala Asp Gly Val 420 425 430 Gln Phe Pro Ile His Leu Asp Val Pro Val Asp Gln Ala Ser Lys Asn 435 440 445 Tyr Ile Ser Arg Ile Gln Ser Phe Lys Gln Ser Val Glu Thr Val Leu 450 455 460 Gly Val Glu Asn Val Val Val Asp Ile Gln Gln Met Thr Ser Asp Glu 465 470 475 Phe Leu Asn Ile Thr Tyr Tyr Ala Ala Asn Ala Ser Ser Glu Asp Trp 485 490 495 Asp Val Ser Gly Gly Val Ser Trp Gly Pro Asp Tyr Gln Asp Pro Ser 500 510 Thr Tyr Leu Asp Ile Leu Lys Thr Thr Ser Ser Glu Thr Thr Lys Thr 515 525 Tyr Leu Gly Phe Asp Asn Pro Asn Ser Pro Ser Val Val Gln Val Gly 530 540 Leu Lys Glu Tyr Asp Lys Leu Val Asp Glu Ala Ala Arg Glu Thr Ser 545 550 560 Asp Leu Asn Val Arg Tyr Glu Lys Tyr Ala Ala Ala Gln Ala Trp Leu 565 570 Thr Asp Ser Ser Leu Phe Ile Pro Ala Met Ala Ser Ser Gly Ala Ala 580 585 str pneumoniae patentin.sT25
Pro Val Leu Ser Arg Ile Val Pro Phe Thr Gly Ala Ser Ala Gln Thr 605

Gly Ser Lys Gly Ser Asp Val Tyr Phe Lys Tyr Leu Lys Ser Gln Asp 610 620

Lys Val Val Thr Lys Glu Glu Tyr Glu Lys Ala Arg Glu Lys Trp Leu 625 630 640

Lys Glu Lys Ala Glu Ser Asn Glu Lys Ala Gln Lys Glu Leu Ala Ser 645 650 655

His Val Lys

<210> 221

<211> 318

<212> PRT

<213> Streptococcus pneumoniae

<400> 221

Met Glu Ile Asn Val Ser Lys Leu Arg Thr Asp Leu Pro Gln Val Gly
10 15

Val Gln Pro Tyr Arg Gln Val His Ala His Ser Thr Gly Asn Pro His 20 25 30

Ser Thr Val Gln Asn Glu Ala Asp Tyr His Trp Arg Lys Asp Pro Glu 35 40 45

Leu Gly Phe Phe Ser His Ile Val Gly Asn Gly Cys Ile Met Gln Val 50 60

Gly Pro Val Asp Asn Gly Ala Trp Asp Val Gly Gly Gly Trp Asn Ala 65 70 75 80

Glu Thr Tyr Ala Ala Val Glu Leu Ile Glu Ser His Ser Thr Lys Glu 85 90 95

Glu Phe Met Thr Asp Tyr Arg Leu Tyr Ile Glu Leu Leu Arg Asn Leu 100 105 110

Ala Asp Glu Ala Gly Leu Pro Lys Thr Leu Asp Thr Gly Ser Leu Ala 115 120 125

Gly Ile Lys Thr His Glu Tyr Cys Thr Asn Asn Gln Pro Asn Asn His 130 140 str pneumoniae patentin.ST25 Ser Asp His Val Asp Pro Tyr Pro Tyr Leu Ala Lys Trp Gly Ile Ser 145 150 155 160 Arg Glu Gln Phe Lys His Asp Ile Glu Asn Gly Leu Thr Ile Glu Thr 165 170 175 Gly Trp Gln Lys Asn Asp Thr Gly Tyr Trp Tyr Val His Ser Asp Gly 180 185 Ser Tyr Pro Lys Asp Lys Phe Glu Lys Ile Asn Gly Thr Trp Tyr Tyr 195 200 205 Phe Asp Ser Ser Gly Tyr Met Leu Ala Asp Arg Trp Arg Lys His Thr 210 220 Asp Gly Asn Trp Tyr Trp Phe Asp Asn Ser Gly Glu Met Ala Thr Gly 225 230 235 Trp Lys Lys Ile Ala Asp Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Ala 245 250 255 Met Lys Thr Gly Trp Val Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp 260 265 270 Ala Lys Glu Gly Ala Met Val Ser Asn Ala Phe Ile Gln Ser Ala Asp 275 285 Gly Thr Gly Trp Tyr Tyr Leu Lys Pro Asp Gly Thr Leu Ala Asp Lys 290 295 300 Pro Glu Phe Thr Val Glu Pro Asp Gly Leu Ile Thr Val Lys 305 310

<210> 222

<211> 467

<212> PRT

<213> Streptococcus pneumoniae

<400> 222

Met Lys Lys Lys Tyr Trp Thr Leu Ala Ile Leu Phe Phe Cys Leu Phe 10 15

Asn Asn Ser Val Thr Ala Gln Glu Ile Pro Lys Asn Leu Asp Gly Asn 20 25 30

Ile Thr His Thr Gln Thr Ser Glu Ser Phe Ser Glu Ser Asp Glu Lys

:	Gl	n va	l As	р Ту	r Se	r As	n Ly	str s Aş	pneu n G]	moni n Gl	ae p u Gl	u. va	.lAS	ST25 pG]	n. As	n. Lys
												00				p Lys 80
	Hi:	s Le	u G]	u Ly	s As 85	n Cys	s Cy	s Ly	s Lei	G]( 90	u Lei	u Gl	u Pro	o Gli	n I] 95	e Asn
	Ası	1 As	p Il	e Va 10	7 Ası 0	n Ser	· G7ı	u Se	r Asr 105	) Ası	n Lei	ı Lei	u Gly	y G]ı 110	ı Ası	) Asn
	Lei	ı Ası	P ASI 11!	n Ly:	s Ile	e Lys	G](	J ASI 120	val	Sei	r His	S Lei	1 ASI 12:	) Asr	ı Arg	g Gly
	Gly	/ Asi 13(	ı Ile )	e G7ı	ı His	s Asp	Lys 135	Asp	) Asn	Lei	ม Gไเ	Ser 140	Ser	·Ile	val	Arg
	Lys 145	Туг	· Glu	ı Trp	Asp	17e 150	Asp	Lys	val	Thr	Gly 155	Gly	∕ Gly	/ Glu	ı Ser	Туг 160
	Lys	Leu	ı Tyr	' Ser	Lys 165	Ser	Asn	Ser	' Lys	Val 170	Ser	Ile	Ala	Ile	Leu 175	Asp
	Ser	Gly	val	Asp 180	Leu	Gln	Asn	Thr	Gly 185	Leu	Leu	Lys	Asn	Leu 190	Ser	Asn
	His	Ser	Lys 195	Asn	Tyr	Val	Pro	Asn 200	Lys	Gly	Tyr	Leu	G]y 205	Lys	Glu	Glu
	Gly	Glu 210	Glu	Gly	Ile	Ile	Ser 215	Asp	Ile	Gln	Asp	Arg 220	Leu	Gly	His	Gly
	Thr 225	Ala	Val	٧a٦	Ala	G]n 230	Ile	٧a٦	Gly	Asp	Asp 235	Asn	Ile	Asn	GТу	Va1 240
	Asn	Pro	His	Val	Asn 245	Ile	Asn	Val	Tyr	Arg 250	Ile	Phe	Gly	Lys	Ser 255	Ser
	Ala	Ser	Pro	Asp 260	Тгр	Ile	۷al	Lys	Ala 265	Ile	Phe	Asp	Ala	Va1 270	Asp	Asp
	Gly	Asn	Asp 275	Ile	Ile	Asn	Leu	Ser 280	Thr	GТу	Gln	Tyr	Leu 285	Met	Ile	Asp
	Gly	G]u 290	Tyr	Glu	Asp	Gly	Thr 295	Asn	Asp	Phe	Glu	Thr 300	Phe	Leu	Lys	Tyr
	Lys 305	Lys	Ala	Ile	Asp	Tyr 310	Ala	Asn	Gln	Lys	G]y 315	Val	Ile	Ile	Val .	Ala 320

str pneumoniae patentin.ST25
Ala Leu Gly Asn Asp Ser Leu Asn Val Ser Asn Gln Ser Asp Leu Leu 335

Lys Leu Ile Ser Ser Arg Lys Lys Val Arg Lys Pro Gly Leu Val Val 340

Asp Val Pro Ser Tyr Phe Ser Ser Thr Ile Ser Val Gly Gly Ile Asp 355 360 365

Arg Leu Gly Asn Leu Ser Asp Phe Ser Asn Lys Gly Asp Ser Asp Ala 370 380

Ile Tyr Ala Pro Ala Gly Ser Thr Leu Ser Leu Ser Glu Leu Gly Leu 385 390 400

Asn Asn Phe Ile Asn Ala Glu Lys Tyr Lys Glu Asp Trp Ile Phe Ser 405 410 415

Ala Thr Leu Gly Gly Tyr Thr Tyr Leu Tyr Gly Asn Ser Phe Ala Ala 420 425 430

Pro Lys Val Ser Gly Ala Ile Ala Met Ile Ile Asp Lys Tyr Lys Leu 435 440 445

Lys Asp Gln Pro Tyr Asn Tyr Met Phe Val Lys Lys Phe Trp Lys Lys 450 460

His Tyr Gln 465

<210> 223

<211> 308

<212> PRT

<213> Streptococcus pneumoniae

<400> 223

Met Lys Lys Asp Glu Leu Phe Glu Gly Phe Tyr Leu Ile Lys Ser Ala 1 10 15

Asp Leu Arg Gln Thr Arg Ala Gly Lys Asn Tyr Leu Ala Phe Thr Phe 20 25 30

Gln Asp Asp Ser Gly Glu Ile Asp Gly Lys Leu Trp Asp Ala Gln Pro
35 40 45

His Asn Ile Glu Ala Phe Thr Ala Gly Lys Val Val His Met Lys Gly 50 60

	Arg 65_	Arc	g Glu	ı val	Ţyŗ	.Asn 70	. A <u>ş.</u> ņ	str p	neum Pro	G I.n	.va i	tent asn	in.s .Gln	T25 _Ile	The	Leu
	Arg	Leu	ı Pro	Gln	A]a 85	Gly	Glu	•				Ala	Asp	Phe	Lys 95	80 ∨a1
·=	Lys	Ser	Pro	Val 100	Asp	Val	Lys	Glu	Ile 105	Arg	Asp	Tyr	Met	Ser 110	Gln	Met
	Ile	Phe	Lys 115	Ile	Glu	Asn	Pro	Va7 120	Trp	Gln	Arg	Ile	Va1 125	Arg	Asn	Leu
	Tyr	Thr 130	Lys	Tyr	Asp	Lys	Glu 135	Phe	Tyr	Ser	Tyr	Pro 140	Ala	Ala	Lys	Thr
	Asn 145	His	His	Αla	Phe	G]u 150	Thr	Gly	Leu	Αla	Tyr 155	His	Thr	Аlа	Thr	Met 160
	val	Arg	Leu	Ala	Asp 165	Ala	Ile	Ser	Glu	Val 170	Туг	Pro	Gln	Leu	Asn 175	Lys
	Ser	Leu	Leu	Tyr 180	Ala	Gly	IJе	Met	Leu 185	His	Asp	Leu	Ala	Lys 190	Val	Ile
	Glu	Leu	Thr 195	GТу	Pro	Asp	Gln	Thr 200	Glu	Tyr	Thr	Val	Arg 205	Gly	Asn	Leu
	Leu	Gly 210	His	Ile	Ala	Leu	11e 215	Asp	Ser	Glu	Ile	Thr 220	Lys	Thr	۷a٦	Met
	G]u 225	Leu	Gly	Ile	Asp	Asp 230	Thr	Lys	Glu	Glu	Va1 235	Val	Leu	Leu	Arg	His 240
	Va1	Ile	Leu	Ser	Ніs 245	His	Gly	Leu	Leu	G]u 250	Tyr	Gly	Ser	Pro	Va1 255	Arg
	Pro	Arg	Ile	Met 260	Glu	Ala	Glu	Ile	Ile 265	His	Met	Ile	Asp	Asn 270	Leu	Asp
	Ala	ser	Met 275	Met	Met	Met	Ser	Thr 280	Ala	Leu	Ala	Leu	Val 285	Asp	Lys	G]y ·
	Glu	Met 290	Thr	Asn	Lys	Ile	Phe 295	Ala	Met	Asp	Asn	Arg 300	Ser	Phe	Tyr	Lys
	Pro 305	Asp	Leu	Asp												
	<210		24	-												
	<211	> 2	21													

str pneumoniae patentin.ST25

<212> PRT

<213> Streptococcus pneumoniae

<400> 224

Val Thr Ile Leu Gly Lys Asp Thr Val Gln Gln Ser Ala Lys Gly Glu 10 15

Ser Val Thr Glu Ala Thr Pro Glu Tyr Lys Leu Glu Asn Thr Pro 20 25 30

Gly Gly Asp Lys Gly Gly Asn Thr Gly Ser Ser Asp Ala Asn Ala Asn 40 45

Glu Gly Gly Ser Gln Ala Gly Gly Ser Ala His Thr Gly Ser Gln 50 55 60

Asn Ser Ala Gln Ser Gln Ala Ser Lys Gln Leu Ala Thr Glu Lys Glu 65 70 75 80

Ser Ala Lys Asn Ala Ile Glu Lys Ala Ala Lys Asp Lys Gln Asp Glu 85 90 95

Ile Lys Gly Ala Pro Leu Ser Asp Lys Glu Lys Ala Glu Leu Leu Ala 100 105

Arg Val Glu Ala Glu Lys Gln Ala Ala Leu Lys Glu Ile Glu Asn Ala 115 120 125

Lys Thr Met Glu Asp Val Lys Glu Ala Glu Thr Ile Gly Val Gln Ala 130 135 140

Ile Ala Met Val Thr Val Pro Lys Arg Pro Val Ala Pro Asn Ala Ala 145 150 155 160

Pro Lys Thr Thr Ser Ala Pro Gln Ala Thr Ala Gly Thr Met Gln Asp 165 170 175

Val Thr Tyr Gln Ser Pro Ala Gly Lys Gln Leu Pro Asn Thr Gly Ser 180 185 190

Ala Ser Ser Ala Ala Leu Ala Ser Leu Gly Leu Val Val Ala Thr Ser 195 200 205

Gly Phe Ala Leu Leu Gly Arg Lys Thr Arg Arg Arg Lys 210 220

<210> 225

<211> 336

## <213> Streptococcus pneumoniae

<400> 225

Met Asn Ala Asp Asp Thr Val Thr Ile Tyr Asp Val Ala Arg Glu Ala

10
15

Gly Val Ser Met Ala Thr Val Ser Arg Val Val Asn Gly Asn Lys Asn 20 25 30

Val Lys Glu Asn Thr Arg Lys Lys Val Leu Glu Val Ile Asp Arg Leu 35 40 45

Asp Tyr Arg Pro Asn Ala Val Ala Arg Gly Leu Ala Ser Lys Lys Thr 50 60

Thr Thr Val Gly Val Val Ile Pro Asn Ile Thr Asn Gly Tyr Phe Ser 75 75 80

Ser Leu Ala Lys Gly Ile Asp Asp Ile Ala Glu Met Tyr Lys Tyr Asn 90 95

Ile Val Leu Ala Asn Ser Asp Glu Asp Asn Glu Lys Glu Val Ser Val 100 105 110

Val Asn Thr Leu Phe Ser Lys Gln Val Asp Gly Ile Ile Tyr Met Gly
115 120 125

Tyr His Leu Thr Asp Lys Ile Arg Ser Glu Phe Ser Arg Ser Arg Thr 130 140

Pro Ile Val Leu Ala Gly Thr Val Asp Val Glu His Gln Leu Pro Ser 145 150 155 160

Val Asn Ile Asp Tyr Lys Gln Ala Thr Ile Asp Ala Val Ser Tyr Leu 165 170 175

Ala Lys Glu Asn Glu Arg Ile Ala Phe Val Ser Gly Pro Leu Val Asp 180 185 190

Asp Ile Asn Gly Lys Val Arg Leu Val Gly Tyr Lys Glu Thr Leu Lys 195 200 205

Lys Ala Gly Ile Thr Tyr Ser Glu Gly Leu Val Phe Glu Ser Lys Tyr 210 220

Ser Tyr Asp Asp Gly Tyr Ala Leu Ala Glu Arg Leu Ile Ser Ser Asn 225 230 235 240 Ala Thr Ala Ala Val Val Thr Gly Asp Glu Leu Ala Ala Gly Val Leu 255

Asn Gly Leu Ala Asp Lys Gly Val Ser Val Pro Glu Asp Phe Glu Ile 260

Ile Thr Ser Asp Asp Ser Gln Ile Ser Arg Phe Thr Arg Pro Asn Leu 275 . 280 . 285

Thr Thr Ile Ala Gln Pro Leu Tyr Asp Leu Gly Ala Ile Ser Met Arg 290 295 300

Met Leu Thr Lys Ile Met His Lys Glu Glu Leu Glu Glu Arg Glu Val 305 310 315 320

Leu Leu Pro His Gly Leu Thr Glu Arg Ser Ser Thr Arg Lys Arg Lys 325 330 335

<210> 226

<211> 469

<212> PRT

<213> Streptococcus pneumoniae

<400> 226

Met Lys Lys Leu Val Phe Pro Asn Leu Phe Trp Trp Gly Ala Ala 1 5 10 15

Ser Ser Gly Pro Gln Thr Glu Gly Gln Tyr Gly Lys Val His Glu Asn 20 25 30

val Met Asp Tyr Trp Phe Lys Thr His Pro Glu Asp Phe Phe Asp Asn 45

Val Gly Pro Leu Val Ala Ser Asn Phe Phe His Thr Tyr Thr Glu Asp  $50 \hspace{1cm} 55 \hspace{1cm} 60$ 

Phe His Leu Met Lys Glu Ile Gly Val Asn Ser Phe Arg Thr Ser Ile 65 70 75 80

Gln Trp Ser Arg Leu Ile Lys Asn Leu Glu Thr Gly Glu Pro Asp Pro 85 90 95

Lys Gly Ile Ala Phe Tyr Asn Ala Ile Ile Glu Glu Ala Lys Lys Asn 100 105 110

Gln Met Asp Leu Val Met Asn Leu His His Phe Asp Leu Pro Val Glu 115 120 125

÷ :	Le	u Le	u Gl	n Ly	s Ty	r_G])	/ G]	str j y Trp	oneur D_G] (	moni u Se	ae p	aten	tin. S.Va	ST25 1va:	l67ı	Leu-
			<u> </u>				,1,3,	5				_14(	)			
	Pho 14	e Va 5	7 гу	s Ph	e Ala	150	Th:	r Ala	. Ph€	e Thi	r Cys	5 Phe	e Gly	y Asp	) Lys	5 Val 160
~ * * *	His	5 Ty	r Trı	o Th		Phe		า Glu	Pro	Me1 17(	t Val	Ιle	Pro	o Glu	1 Ala	Gly .
	Туі	r Lei	и Туі	r Ala 180	a Phe	His	Tyr	Pro	Asn 185	Leu	ı Lys	G]y	' Lys	6 Gly 190	Lys	Glu
	Ala	a Va	l G]r 195	va]	lle	: Tyr	Asr	Leu 200	Asn	Leu	ı Ala	Ser	Ala 205	Lys	Val	Ile
	Gln	Lei 210	ı Tyr )	` Arg	, Ser	Leu	G]u 215	Leu	Asp	Gly	' Lys	Ile 220	Gly	'Ile	Ile	Leu
•	Asn 225	Leu	ı Thr	Pro	Ala	Tyr 230	Pro	Arg	Ser	Asn	Ser 235	Pro	Glu	Asp	Leu	G]u 240
	Ala	Ser	' Arg	) Phe	Thr 245	Asp	Asp	Phe	Phe	Asn 250	Lys	۷a٦	Phe	Leu	Asn 255	Pro
	Αla	Va]	Lys	Gly 260	Thr	Phe	Pro	Glu	Arg 265	Leu	Val	Lys	Gln	Leu 270	Glu	Arg
	Asp	Gly	Val 275	Leu	Trp	Ser	His	Thr 280	Glu	Lys	Glu	Leu	G]n 285	Leu	Met	Lys
	Ser	Asn 290	Thr	Val	Asp	Phe	Leu 295	Gly	٧a٦	Asn	Tyr	Tyr 300	His	Pro	Lys	Arg
	Va1 305	Gln	Ala	Gln	Аlа	Asn 310	Pro	Glu	Glu	Tyr	Gln 315	Thr	Pro	Trp	Met	Pro 320
	Asp	Gln	Tyr	Phe	Lys 325	Glu	Tyr	Glu	Trp	Leu 330	Glu	Arg	Arg	Met	Asn 335	Pro
	Tyr	Arg	Gly	Trp 340	Glu	Ile	Phe	Pro	Lys 345	Ala	Ile	Tyr	Asp	Ile 350	Ala	Met
	Ile	Val	Lys 355	Glu	Glu	Tyr	Gly	Asn 360	Ile	Pro-	Trp	Phe	Ile 365	Ser	Glu	Asn
	Gly	Met 370	Gly	Val	Glu	Asn	G1u 375	Ala	Arg	Phe	Ile	Asp 380	Glu	Asn	Gly	Val
	11e 385	Asp	Asp	Val	Tyr	Arg 390	Ile	Glu	Phe	Tyr	G]u 395	Glu	His	Leu .		Trp 400

str pneumoniae patentin.ST25 Leu His Lys Ala Ile Glu Glu Gly Ser His Cys Phe Gly Tyr His Ala 405 410 415

Trp Thr Ala Phe Asp Cys Trp Ser Trp Asn Asn Ala Tyr Lys Asn Arg 420 430

Tyr Gly Phe Ile Ser Val Asp Leu Glu Thr Gln Lys Arg Thr Ile Lys 435

Ser Ser Gly Arg Trp Tyr Arg Lys Val Ser Asp Asn Asn Gly Phe Glu 450 455 460

val Glu Ile Glu Glu 465

<210> 227

<211> 136

<212> PRT

<213> Streptococcus pneumoniae

<400> 227

Val Glu Asn Leu Thr Asn Phe Tyr Glu Lys Tyr Arg Val Tyr Leu Thr 1 10 15

Arg Pro Arg Leu Glu Leu Leu Ala Val Val Thr Ile Val Phe Cys Ala 20 25 30

Val Leu Val Phe Phe Leu Asn Ile Pro Gly Lys Gly Val Leu Lys Leu 35 40 45

Asp Asn Gly Thr Ile Val Tyr Asp Gly Ser Leu Val Arg Gly Lys Met 50 55

Asn Gly Gln Gly Thr Ile Thr Phe Gln Asn Gly Asp Gln Tyr Thr Gly 65 70 75 80

Gly Phe Asn Asn Gly Ala Phe Asn Gly Lys Gly Thr Phe Gln Ser Lys 85 90 95

Glu Gly Trp Thr Tyr Glu Gly Asp Phe Val Asn Gly Gln Ala Glu Gly 100 105 110

Lys Gly Lys Leu Thr Thr Glu Gln Glu Val Val Tyr Glu Gly Thr Phe 115 120 125

Lys Gln Gly Val Phe Gln Gln Lys 130 135 <210> 228

<211> 207

<212> PRT

<213> Streptococcus pneumoniae

<400>~=:228=

Met Leu Asn Lys Ile Arg Asp Tyr Leu Asp Phe Ala Gly Leu Gln Tyr 10 15

Arg Asn Pro Asp Lys Ala Gly Ala Glu Arg Glu Lys Met Leu Ala Phe 20 25 30

Arg His Lys Gly Gln Glu Ala Arg Lys Val Phe Thr Glu Leu Ala Lys 35 40 45

Ala Phe Gln Ala Ser His Pro Glu Trp Gln Leu Gln Gln Thr Ser Gln 50 60

Trp Met Asn Gln Ala Gln Arg Leu Arg Pro His Phe Trp Val Tyr Leu 65 70 75 80

Gln Arg Asp Gly Gln Val Thr Glu Pro Met Met Ala Leu Arg Leu Tyr

Gly Thr Ser Thr Asp Phe Gly Ile Ser Leu Glu Val Ser Phe Ile Glu 100 105

Arg Lys Lys Asp Glu Gln Thr Leu Gly Lys Gln Ala Lys Val Leu Asp 115 120 125

Ile Pro Thr Val Lys Gly Ile Tyr Tyr Leu Thr Tyr Ser Asn Gly Gln . 130 140

Ser Gln Arg Trp Glu Ala Asn Glu Glu Lys Arg Arg Thr Leu Arg Glu 145 150 160

Lys Val Arg Ser Gln Glu Val Arg Lys Val Leu Val Lys Val Asp Val 165 170 175

Pro Met Thr Glu Asn Ser Ser Glu Glu Glu Ile Val Glu Gly Leu Leu 180 185 190

Lys Ser Tyr Ser Lys Ile Leu Pro Tyr Tyr Leu Ala Thr Arg Lys 200 205

<210> 229

<211> 153

<212> PRT

<213> Streptococcus pneumoniae

<400> 229

Met Val Gln Asn Ser Cys Trp Gln Ser Lys Ser His Lys Val Lys Ala 1 10 15

Phe Thr Leu Leu Glu Ser Leu Leu Ala Leu Ile Val Ile Ser Gly Gly 20 25 30

Leu Leu Leu Phe Gln Ala Met Ser Gln Leu Leu Ile Ser Glu Val Arg

Tyr Gln Gln Ser Glu Gln Lys Glu Trp Leu Leu Phe Val Asp Gln 50 60

Leu Glu Val Glu Leu Asp Arg Ser Gln Phe Glu Lys Val Glu Gly Asn 65 70 75 80

Arg Leu Tyr Met Lys Gln Asp Gly Lys Asp Ile Ala Ile Gly Lys Ser

Lys Ser Asp Asp Phe Arg Lys Thr Asn Ala Arg Gly Arg Gly Tyr Gln 100 105

Pro Met Val Tyr Gly Leu Lys Ser Val Arg Ile Thr Glu Asp Asn Gln 115 120

Leu Val Arg Phe His Phe Gln Phe Gln Lys Gly Leu Glu Arg Glu Phe 130 135 140

Ile Tyr Arg Val Glu Lys Glu Lys Ser 145 150

<210> 230

<211> 108

<212> PRT

<213> Streptococcus pneumoniae

<400> 230

Met Lys Lys Met Met Thr Phe Leu Lys Lys Ala Lys Val Lys Ala Phe 10 15

Thr Leu Val Glu Met Leu Val Val Leu Leu Ile Ile Ser Val Leu Phe 20 25 30

Lys Gly Lys Ala Ala Val Val Lys Val Val Glu Ser Gln Ala Glu Leu 50 60

Tyr Ser Leu Glu Lys Asn Glu Asp Ala Ser Leu Arg Lys Leu Gln Ala 65 70 75 80

Asp Gly Arg Ile Thr Glu Glu Gln Ala Lys Ala Tyr Lys Glu Tyr Asn 85 90 95

Asp Lys Asn Gly Gly Ala Asn Arg Lys Val Asn Asp 100 105

<210> 231

<211> 299

<212> PRT

<213> Streptococcus pneumoniae

<400> 231

Met Thr Ser Lys Val Arg Lys Ala Val Ile Pro Ala Ala Gly Leu Gly 10 15

Thr Arg Phe Leu Pro Ala Thr Lys Ala Leu Ala Lys Glu Met Leu Pro 20 25 30

Ile Val Asp Lys Pro Thr Ile Gln Phe Ile Val Glu Glu Ala Leu Lys 35 40 45

Ser Gly Ile Glu Asp Ile Leu Val Val Thr Gly Lys Ser Lys Arg Ser 50 60

Ile Glu Asp His Phe Asp Ser Asn Phe Glu Leu Glu Tyr Asn Leu Lys 65 70 75 80

Glu Lys Gly Lys Thr Asp Leu Leu Lys Leu Val Asp Lys Thr Thr Asp 90 95

Met Arg Leu His Phe Ile Arg Gln Thr His Pro Arg Gly Leu Gly Asp 100 105 110

Ala Val Leu Gln Ala Lys Ala Phe Val Gly Asn Glu Pro Phe Val Val 115 120 125

Met Leu Gly Asp Asp Leu Met Asp Ile Thr Asp Glu Lys Ala Val Pro 130 140 Leu Thr Lys Gln Leu Met 150 Asp Asp Tyr Glu Arg Thr His Ala Ser Thr 160

Ile Ala Val Met Pro Val Pro His Asp Glu Val Ser Ala Tyr Gly Val Ile Ala Pro Gln Glu Gly Lys Asp Gly Leu Tyr Ser Val Glu Thr 190 Glu Thr 190 Glu Arg Tyr Ala Leu Lys Glu Asp Ala Pro Glu Ile Gly Leu Gly Lys Asp Ala Pro Glu Ile Gly Ile Leu Glu Lys 230 Asp Ala Pro Glu Ile Glu Phe Lys Gly Ala Arg Tyr Ala Leu Lys His Pro Glu Val Phe Met Lys Glu Phe Lys Gly Ala Cly Asp Ala Leu Lys Glu Lys Asp Ala Leu Lys Glu Lys Asp Ala Leu Gly Lys Glu Lys Asp Ala Leu Gly Lys Glu L

<210> 232

<211> 821

<212> PRT

<213> Streptococcus pneumoniae

<400> 232

Met Gln Asn Gln Leu Asn Glu Leu Lys Arg Lys Met Leu Glu Phe Phe Gln Gln Lys Gln Lys Asn Lys Lys Ser Ala Arg Pro Gly Lys Lys Gly Ser Ser Thr Lys Lys Ser Lys Thr Leu Asp Lys Ser Val Ile Phe Pro Ala Ile Leu Leu Ser Ile Lys Ala Leu Phe Asn Leu Leu Phe Val Leu Sov Lys Gly Sov Ser Lys Ala Leu Phe Asn Leu Phe Val Leu Phe Val Leu

	6	ly p	he ι	eu (	jy_c	31y <u>N</u>	1et L 20	str eu G	pne	umor Ja_c	niae Ly.	pa 11e 75-	ter Al	ntin a-L	.STZ	25 Sly	ту	r=Gly	 		**********	·2	***
										al p								u Val					
و المحمد و	As	n G	ln v	al L 1	ys A 00	sp I	le se	er se	er I 1(	le s	er (	37u 	<b>I</b> 70	e Tł	ır T	yr 10	_	Asp					
	G٦	у тһ	ir V	al I 15	le A	la s	er Il	e G1	lu se 20	er A	sp L	-eu	Lei	J Ar 12	g T	hr	Ser	·Ile	 	•			•
	Se	r Se 13	r G	lu G	ln I	le s	er Gl 13	u As 5	in Le	u Ly	ys L	.ys	A7a 140	1 I7	e I	le .	Αla	Thr					
	G1 14	u As 5	p G]	lu Hi	is Pl	ne Ly 1:	/s G] 50	u Hi	s Ly	's G	ly v 1	a1 55	۷a٦	Pr	O L	/S /	ΑΊa	Val 160				4	<b>.</b>
	Il	⊇ Ar	g Al	a Th	r Le	eu Gi 55	у Lу	s Ph	e Va	7 G1 17	у L О	eu	σΊу	' Se	r Se	r :	Ser 175	Gly					
							n Gl		_0.						19	U							
	Ala	Pro	7h 19	r Le 5	u Al	a Ar	g Lys	5 Ala 200	a Ala	a Gl	u Il	le v	√a1	Asp 205	) A]	a L	.eu	Ala					
	Leu	G1u 210	Arg	g Ala	a Me	t As	n Lys 215	Asp	G]ı	ı Il	e Le	eu 7	Thr 220	Thr	Ту	r L	.eu	Asn					
							g Asn				23							240					
							/ Ile			230	•					2	55					•	) .
							: Leu								2/0	ì							
							Thr						4	283									
	Glu	Ile 290	Gly	Leu	Arg	Arg	A7a 295	Lys	Ala	Val	Lei	ι Τ <u>γ</u> 3(	yr 9	ser	Met	Ту	/r /	Arg					
							Asp					,					3	20					
	Leu .	Lys	Gln	Asp	Phe 325	Leu	Pro	Ser	Gly	Thr 330	۷a٦	Th	ır G	Пy	Ile	Se 33	r A 5	rg					

str pneumoniae patentin.ST25 Asp Tyr Leu Tyr Phe Thr Thr Leu Ala Glu Ala Gln Glu Arg Met Tyr 340 345 350 Asp Tyr Leu Ala Gln Arg Asp Asn Val Ser Ala Lys Glu Leu Lys Asn 355 360 365 Glu Ala Thr Gln Lys Phe Tyr Arg Asp Leu Ala Ala Lys Glu Ile Glu 370 380 Asn Gly Gly Tyr Lys Ile Thr Thr Tle Asp Gln Lys Ile His Ser 385 390 395 Ala Met Gln Ser Ala Val Ala Asp Tyr Gly Tyr Leu Leu Asp Asp Gly
405 416 Thr Gly Arg Val Glu Val Gly Asn Val Leu Met Asp Asn Gln Thr Gly
420 425 430 Ala Ile Leu Gly Phe Val Gly Gly Arg Asn Tyr Gln Glu Asn Gln Asn 445 Asn His Ala Phe Asp Thr Lys Arg Ser Pro Ala Ser Thr Thr Lys Pro 450 460 Leu Leu Ala Tyr Gly Ile Ala Ile Asp Gln Gly Leu Met Gly Ser Glu 465 470 480 Thr Ile Leu Ser Asn Tyr Pro Thr Asn Phe Ala Asn Gly Asn Pro Ile 485 490 495 Met Tyr Ala Asn Ser Lys Gly Thr Gly Met Met Thr Leu Gly Glu Ala 500 505 Leu Asn Tyr Ser Trp Asn Ile Pro Ala Tyr Trp Thr Tyr Arg Met Leu 515 520 525 Arg Glu Lys Gly Val Asp Val Lys Gly Tyr Met Glu Lys Met Gly Tyr 530 540 Glu Ile Pro Glu Tyr Gly Ile Glu Ser Leu Pro Met Gly Gly Ile 545 550 550 560 Glu Val Thr Val Ala Gln His Thr Asn Gly Tyr Gln Thr Leu Ala Asn 565 570 575 Asn Gly Val Tyr His Gln Lys His Val Ile Ser Lys Ile Glu Ala Ala 580 585 590 Asp Gly Arg Val Val Tyr Glu Tyr Gln Asp Lys Pro Val Gln Val Tyr 595 600 605

.rr	Se	r Ly 61	/s A]	a Th	r Ala	a T <u>h</u> ı		str p	oneur Glr	nonia	ae pa	aten I- Lei 620	tin.s J-Arg	ST25 J. G](	ı∴Va]	1 · Leuwene meierie nweie je mie van ei voor
	Se 62	r Se 5	r Ar	g <sub>.</sub> Va	1 Thi	Thr 630	Thr	Phe	: Lys	Ser	' Asn 635	Leu	ı Thr	· Ser	. Fer	J Asn 640
	Pr( هد مند	⊃ Th	r Le	u Al	a Asr 645	Ala	Asp	Trp	Ile	G]y 650	Lys	Thr	Gly	Thr	Thr _655	Asn
	GÌr	1 As	p Gli	4 Asi 660	n Met	: Trp	Leu	Met	Leu 665	Ser	Thr	Pro	Arg	Leu 670	Thr	` Leu
	Gly	∕ Gl	y Tri 67:	) I]6	e Gly	His	Asp	Asp 680	Asn	His	Ser	Leu	Ser 685	Arg	Arg	Ala
_	G٦y	7 Tyl 690	r Ser )	' Asr	) Asn	Ser	Asn 695	Tyr	Met	Ala	His	Leu 700	۷a٦	Asn	Ala	Ile
	G1n 705	Glr	ı Ala	Ser	' Pro	Ser 710	Ile	Trp	Gly	Asn	G]u 715	Arg	Phe	Ala	Leu	Asp 720
	Pro	Ser	· Val	۷a٦	Lys 725	Ser	Glu	۷al	Leu	Lys 730	Ser	Thr	Gly	Gln	Lys 735	Pro
	Glu	Lys	Val	Ser 740	٧a٦	Glu	Gly	Lys	G1u 745	val	Glu	Val	Thr	G]y 750	Ser	Thr
	Val	Thr	Ser 755	Tyr	Trp	Ala	Asn	Lys 760	Ser	GТу	Ala	Pro	Ala 765	Thr	Ser	Tyr
	Arg	Phe 770	Ala	Ile	Gly	Gly	Ser 775	Asp	Ala	Asp	Tyr	Gln 780	Asn	Ala	Тгр	Ser
	Ser 785	Ile	Val	Gly	Ser	Leu 790	Pro '	Thr	Pro	Ser	Ser 795	Ser	Ser	Ser	Ser	Ser 800
	Ser	Ser	Ser	Ser	Asp 805	Ser	ser /	Asn	Ser	Ser 810	Thr	Thr	Arg	Pro	Ser 815	Ser
	Ser	Arg	Ala	Arg 820	Arg											
	<210	> 2	233													
	<211	> 4	123													
	<212	> F	PRT													
	<213	> S	trep	toco	ccus	pneı	ımoni	ae								
	<400	> 2	33						•							

str pneumoniae patentin.ST25
Met Ser Ser Lys Phe Met Lys Ser Ala Ala Val Leu Gly Thr Ala Thr
1 10 15 Leu Ala Ser Leu Leu Leu Val Ala Cys Gly Ser Lys Thr Ala Asp Lys
20 25 30 Pro Ala Asp Ser Gly Ser Ser Glu Val Lys Glu Leu Thr Val Tyr Val 45 Asp Glu Gly Tyr Lys Ser Tyr Ile Glu Glu Val Ala Lys Ala Tyr Glu 50 60 Lys Glu Ala Gly Val Lys Val Thr Leu Lys Thr Gly Asp Ala Leu Gly 65 70 75 80 Gly Leu Asp Lys Leu Ser Leu Asp Asn Gln Ser Gly Asn Val Pro Asp 85 90 95 Val Met Met Ala Pro Tyr Asp Arg Val Gly Ser Leu Gly Ser Asp Gly 100 105 Gln Leu Ser Glu Val Lys Leu Ser Asp Gly Ala Lys Thr Asp Asp Thr 115 120 125 Thr Lys Ser Leu Val Thr Ala Ala Asn Gly Lys Val Tyr Gly Ala Pro 130 140 Ala Val Ile Glu Ser Leu Val Met Tyr Tyr Asn Lys Asp Leu Val Lys 145 150 160 Asp Ala Pro Lys Thr Phe Ala Asp Leu Glu Asn Leu Ala Lys Asp Ser 165 170 175 Lys Tyr Ala Phe Ala Gly Glu Asp Gly Lys Thr Thr Ala Phe Leu Ala 180 185 Asp Trp Thr Asn Phe Tyr Tyr Thr Tyr Gly Leu Leu Ala Gly Asn Gly 195 205 Ala Tyr Val Phe Gly Gln Asn Gly Lys Asp Ala Lys Asp Ile Gly Leu 210 215 220 Ala Asn Asp Gly Ser Ile Val Gly Ile Asn Tyr Ala Lys Ser Trp Tyr 225 230 235 240 Glu Lys Trp Pro Lys Gly Met Gln Asp Thr Glu Gly Ala Gly Asn Leu 245 250 255 Ile Gln Thr Gln Phe Gln Glu Gly Lys Thr Ala Ala Ile Ile Asp Gly 260 265 270

Gly Val Ile Met Trp Val Leu Gly Phe Ile Leu Phe Met Ile Phe Phe 50 60

str pneumoniae patentin.ST25

Tyr Ser Asn Asn Ser Lys Lys Ile Lys Lys Leu Glu Asn Lys Ile Lys 65

Arg Leu Glu Arg Lys Glu Lys Gly Asn Ala Glu Met Ser Arg Leu Leu 95

Gln Glu Met Ile Gly Lys Glu Pro Ile Ile Thr Gly Val Tyr Ile Gly 100 105 110

Pro Asp Asn Trp Glu Val Val Asp Val Asp Glu Glu Trp Val Lys Leu 115 120 125

Arg Arg Val Asp Asn Thr Gly Lys Glu Lys Phe Lys Leu Gln Arg Ile 130 140

Glu Asp Ile Gln Thr Val Glu Phe Asp Gly Glu 145 150 155

<210> 235

<211> 285

<212> PRT

<213> Streptococcus pneumoniae

<400> 235

Met Ile Leu Ser Lys Asn Arg Glu Asp Gly Leu Arg Lys Phe Ala Thr 10 15

Asn Ile Arg Leu Asn Thr Leu Arg Thr Leu Asn His Leu Gly Phe Gly 20 25 30

His Tyr Gly Gly Ser Leu Ser Ile Val Glu Val Leu Ala Val Leu Tyr 35 40 45

Gly Glu Ile Met Pro Met Thr Pro Glu Ile Phe Ala Ala Arg Asp Arg 50 60

Asp Tyr Phe Ile Leu Ser Lys Gly His Gly Gly Pro Ala Leu Tyr Ser 65 70 75 80

Thr Leu Tyr Leu Asn Gly Phe Phe Asp Lys Glu Phe Leu Tyr Ser Leu 85 90 95

Asn Thr Asn Gly Thr Lys Leu Pro Ser His Pro Asp Arg Asn Leu Thr 100 105 110

Pro Gly Ile Asp Met Thr Thr Gly Ser Leu Gly Gln Gly Ile Ser Val

· 	Ala	_Thr	,_G])	/ Leu	Ala	Tyr	G1 <u>y</u>	str p /Glr	oneu L'Arg	moni g <u>-</u> I-]	ae p e≟Ar	aten g Ly	tin. s-Se	ST25	n-Ph	entyren eneman va men e
			<b>/</b>				1-3·5	)				14	0			- 1,1
	Thr 145	Tyr	'Ala	ıle	۷a٦	G]y 150	Asp	Gly	/ Glu	ı Lei	u Ası 15	n Gl	u Gl	y Gl	n Cys	5 Trp 160
<b>**</b> *	G]u	Ala	Ile	Gln	Phe 165	Ala	Ser	His	G]r	17(	Lei	ı Se	r Ası	n Le	u I]e	val
	Phe	۷a٦	Asp	Asp 180	Asn	Lys	Lys	GÌn	Leu 185	Asp	עום כ	/ Phe			s Asp	) Ile
	Cys	Asn	Pro 195	GТу	Asp	Phe	۷a٦	G]u 200	Lys	Phe	e Ser	· Ala	a Phe 205	e Gly	/ Phe	e Glu
	Ser	Ile 210	Arg	۷a٦	Lys	GТу	Ser 215	Asp	Ile	: Arg	ι Glu	1 I1€ 220	₹ Tyr	G]ı	ı Gly	'Ile
	Va1 225	Gln	Leu	Lys	Gln	Ser 230	Asn	Asn	Ser	Ser	Pro 235	Lys	Cys	; Il€	val	Leu 240
	Asp	Thr	Ile	Lys	Gly 245	Gln	Gly	Val	Gln	G]u 250	Leu	Glu	เ Gไน	ı Met	: Lys 255	Ser
	Asn	His	His	Leu 260	Arg	Pro	Thr	val	G]u 265	Glu	Lys	Gln	Met	: Leu 270	Thr	Ser
	Val	Val	Glu 275	Arg	Leu	Ser	Gln	G]u 280	Leu	Glu	Glu	Thr	G]u 285			
	<210	> 2	236													
	<211		521											·		
	<212	_	RT													
								_								
	<213	> 5	trep	toco	ccus	pne	umor	iiae								
	<400	> 2	36													
	Met 1	Lys	Lys	Thr	Thr 5	Ile	Leu	Ser	Leu	Thr 10	Thr	Ala	Ala	۷a٦	Ile 15	Leu
	Ala /	Ala i	Tyr	Val   20	Pro /	Asn	Glu	Pro	Ile 25	Leu	Ala	Asp	Thr	Pro 30	Ser	Ser
	Glu v	√a]	Ile 35	Lys (	s]u'	Thr	Lys	Va1 40	Gly	Ser	Ile	Ile	G]n 45	Gln	Asn	Asn
	Ile i	ys : 0	Tyr	Lys \	/al ı	_eu	Thr '	Va1	Glu	Gly	Asn	Ile 60	Gly	Thr	val	Gln

str pneumoniae patentin.ST25 Val Gly Asn Gly Val Thr Pro Val Glu Phe Glu Ala Gly Gln Asp Gly 65 70 75 80 Lys Pro Phe Thr Ile Pro Thr Lys Ile Thr Val Gly Asp Lys Val Phe 85 90 95 Thr Val Thr Glu Val Ala Ser Gln Ala Phe Ser Tyr Tyr Pro Asp Glu 100 105 110 Thr Gly Arg Ile Val Tyr Tyr Pro Ser Ser Ile Thr Ile Pro Ser Ser 115 120 125 Ile Lys Lys Ile Gln Lys Lys Gly Phe His Gly Ser Lys Ala Lys Thr 130 140 Ile Ile Phe Asp Lys Gly Ser Gln Leu Glu Lys Ile Glu Asp Arg Ala 145 150 155 160 Phe Asp Phe Ser Glu Leu Glu Glu Ile Glu Leu Pro Ala Ser Leu Glu 165 170 175 Tyr Ile Gly Thr Ser Ala Phe Ser Phe Ser Gln Lys Leu Lys Lys Leu 180 185 190 Thr Phe Ser Ser Ser Ser Lys Leu Glu Leu Ile Ser His Glu Ala Phe 195 200 Ala Asn Leu Ser Asn Leu Glu Lys Leu Thr Leu Pro Lys Ser Val Lys 210 220 Thr Leu Gly Ser Asn Leu Phe Arg Leu Thr Thr Ser Leu Lys His Val 225 230 235 240 Asp Val Glu Glu Gly Asn Glu Ser Phe Ala Ser Val Asp Gly Val Leu 245 250 255 Phe Ser Lys Asp Lys Thr Gln Leu Ile Tyr Tyr Pro Ser Gln Lys Asn 260 270 Asp Glu Ser Tyr Lys Thr Pro Lys Glu Thr Lys Glu Leu Ala Ser Tyr 275 280 285 Ser Phe Asn Lys Asn Ser Tyr Leu Lys Lys Leu Glu Leu Asn Glu Gly 290 295 300 Leu Glu Lys Ile Gly Thr Phe Ala Phe Ala Asp Ala Ile Lys Leu Glu 305 310 315 320 Glu Ile Ser Leu Pro Asn Ser Leu Glu Thr Ile Glu Arg Leu Ala Phe 325 330 335

				3	40					32	45	ا ابات		u P:/	-ОД	sp.	Asn 350	)∴Va )——	l::Lys===================================
															'S L				r Leu
Th	r 1	1e 70	G٦	y A	sn 	Asn	Ile	Asr 375	Se	r Le	u P	ro	Ser	' Ph _ 38	е Р 0	he L	.eu	Se	r Gly
Va 38:	] L	eu	Asp	) \$(	er	Leu	Lys 390	Glu	ılle	е ні	s I	1e	Lys 395	Ası	n Ly	ys s	er	Thi	Glu 400
Phe	e s	er	Val	l Ly	/5	Lys 405	Asp	Thr	Phe	e A];	a I <sup>*</sup>	le 10	Pro	G٦ι	J Th	יר ע	a1	Lys 415	Phe
Tyr	' V	a]	Thr	S€ 42	er (	Glu	His	Ile	Lys	42:	o Va 5	a7	Leu	Lys	s Se	r A 4	sn 30	Leu	Ser
Thr	Se	er	Asn 435	As	p I	Пe	Ile	Val	G]u 440	Lys	s Va	17	Asp	Asn	17 44	e L	ys	GÌn	Glu
Thr	A5	р 0	Val	ΑŢ	aι	.ys	Pro	Lys 455	Lys	Asn	) Se	r,	Asn	G]n 460	G٦	y Vä	a] '	۷a٦	Gly
													17 5						Ser 480
Met												•					2	195	
Glu										_						3 T	U		
Tyr															J ~ J				
Lys													2	740					
Trp \ 545												٠,	,,						560
Met A											<i>3.</i> 0						57	75	
Glu S	er	G٦	у S 5	er 80	Me	t A	lат	hr G	ly 1	rp '	Val	Th	ir V	al s	Ser	G]y 590	Ly	/s T	rp

str pneumoniae patentin.ST25
Asp Gly Tyr Arg Val Asn Ala Asn Gly Glu Trp Val Gly
610 615 620

<210> 237

<211> 626

<212> PRT

<213> Streptococcus pneumoniae

<400> 237

Met Val Arg Phe Thr Gly Leu Ser Leu Lys Gln Thr Gln Ala Ile Glu 1 10 15

Val Leu Lys Gly His Ile Ser Leu Pro Asp Val Glu Val Ala Val Thr 20 25 30

Gln Ser Asp Gln Ala Ser Ile Ser Ile Glu Gly Glu Glu Gly His Tyr 35 40 45

Gln Leu Thr Tyr Arg Lys Pro His Gln Leu Tyr Arg Ala Leu Ser Leu 50 60

Leu Val Thr Val Leu Ala Glu Ala Asp Lys Val Glu Ile Glu Glu Gln 65 70 75

Ala Ala Tyr Glu Asp Leu Ala Tyr Met Val Asp Cys Ser Arg Asn Ala 85 90 95

Val Leu Asn Val Ala Ser Ala Lys Gln Met Ile Glu Ile Leu Ala Leu 100 105 110

Met Gly Tyr Ser Thr Phe Glu Leu Tyr Met Glu Asp Thr Tyr Gln Ile 115 120 125

Glu Gly Gln Pro Tyr Phe Gly Tyr Phe Arg Gly Ala Tyr Ser Ala Glu 130 140

Glu Leu Gln Glu Ile Glu Ala Tyr Ala Gln Gln Phe Asp Val Thr Phe 145 150 160

Val Pro Cys Ile Gln Thr Leu Ala His Leu Ser Ala Phe Val Lys Trp 165 170 175

Gly Val Lys Glu Val Gln Glu Leu Arg Asp Val Glu Asp Ile Leu Leu 180 185

Ile Gly Glu Glu Lys Val Tyr Asp Leu Ile Asp Gly Met Phe Ala Thr 195 200 205

					٠.														
	Le.	u Se	er i	ys	Ļė	u Ly	s Th	IC/	و ۱ <u>۳۵</u>	str J.Ly	pneu s_Va	mon Jas	iae sn∴I	16~∂	ily	Me	ST25	; ;p: G]	u-Ala
													le L		.20				7 Asp 240
	Ar	g Se	r L	eu	Lei	J Me: 24	t Cy	s G	î În	His	Le	u G1 25	u Ai	g v	al	 Le	u As	p I1	e Ala 5
	Asj	p Ly	'S T	yr	G]) 260	/ Phe	e Hi	s C	ys	Gln	Me <sup>1</sup> 26!	t Tr 5	p Se	er A	sp	Me	t Ph	e Ph	e Lys
	Leu	и ме	t S	er 75	Ala	l Asp	GT:	y G	lη	Tyr 280	Ası	) Ar	g As	p V	a7	G] ( 28:	ı Ile	e Pro	o Glu
.1	Glu	Th 29	r A	rg	۷a٦	Tyr	. Fe	J A	sp 95	Arg	Leu	ı Ly	s As	р A 30	rg 00	۷a٦	Thi	r Lei	ı Val
	Tyr 305	Tr	p As	sp	Tyr	Tyr	G]r 310	1 A:	sp	Ser	G٦u	ı Gl	и Ly 31	s T) 5	/r	Asn	Arg	) Asr	Phe 320
	Arg	Asi	1 Н	is	нis	Lys 325	Ile	2 Se	er	His	Asp	Le:	IA L	a Pł	ie .	Аlа	Gly	′ G]y 335	Ala
	Trp	Lys	5 Tr	ʻq	Ile 340	Gly	Phe	: Th	ır	Pro	His 345	Asr	า หว่	s Pł	e	Ser	Arg 350	Leu	Va]
	Ala	Ile	e G7 35	u /	41a	Asn	Lys	ΑŢ	a	Cys 360	Arg	Αla	l Asi	ı Gl	n :	11e 365	Lys	Glu	Val
	Ile	Va1 370	Th	r(	ŝТу	Trp	Gly	As 37	р 5	Asn	Glу	GТу	G]ı	ı Th 38	r / 0	٩٦a	Gln	Phe	Ser
•	Ile 385	Leu	Pr	o S	Ser	Leu	G]n 390	ΙΊ	e '	Тгр	Ala	Glu	Let 395	Se	ר ז	Гуг	Arg	Asn	Asp 400
	Leu	Asp	GT:	y L	.eu	Ser 405	Ala	нi	s I	Phe	Lys	Thr 410	Asn	Th	r G	Пy	Leu	Thr 415	Val
	Glu	Asp	Pho	e M 4	et 20	Gln	Ile	As	рΙ	Leu	Ala 425	Asn	Leu	Lei	a P	ro	Asp 430	Leu	Pro
	Gly	Asn	Let 435	i S	er	Gly	Ile	Ası	1 F	Pro 140	Asn	Arg	Tyr	۷a	Р 4	he 45	Tyr	G7n	Asp
	Ile	Leu 450	Cys	P	ro .	Ile	Leu	Asr 455	5	in (	His	Met	Thr	Pro 460	G	٦u	G7n	Asp	Lys
	Pro 1 465	Ris	Phe	: A'	la (	Gln ,	Ala 470	Αla	ı G	ilu ji	Thr	Leu	A]a 475	Asn	I.	le	Lys	Glu	Lys 480

Ala Gly Asn Tyr Ala Tyr Leu Phe Glu Thr Gln Ala Gln Leu Asn Ala 485 Tyr Leu Phe Glu Thr Gln Ala Gln Leu Asn Ala 485 Ala Ile Leu Ser Ser Lys Val Asp Val Gly Arg Arg Ile Arg Gln Ala Tyr Gln Ala Asp Asp Lys Glu Ser Leu Gln Gln Ile Ala Arg Gln Glu Leu Phe Ser His 530 Leu Arg Ser Gln 535 Glu Asp Phe His Ala Leu Phe Ser His 545 Trp Leu Lys Glu Asn Lys Val Phe Gly Leu Asp Thr Val Asp 560 Arg Met Gly Gly Leu Gln Arg Ile Lys Arg Arg Ala Glu Ser Arg Ile Glu Val Tyr Leu Ala Gly Gln Leu Asp Phe Thr Asp Phe Tyr Ala Asp Lys Asp Phe Ala Ala Thr Thr Ala Asn Gln Trp His Thr Ile Ala Thr Ala Ser Thr Ile Tyr 610

Thr Thr 625

<210> 238

<211> 782

<212> PRT

<213> Streptococcus pneumoniae

<400> 238

Met Ser Asn Ser Phe Val Lys Leu Leu Val Ser Gln Leu Phe Ala Asn Leu Ala Asp Ile Phe Phe Arg Val Thr Ile Ile Ala Asn Ile Tyr Ile Ile Ser Lys Ser Val Ile Ala Thr Ser Leu Val Pro Ile Leu Ile Gly Ile Ser Ser Phe Val Ala Ser Leu Leu Val Pro Leu Val Thr Lys Arg 50

:	Le 65	u Al	a Le	u As	n Ar	g Va 70	l Lei	str u Se	pneu r Lei	moni u Se	ae p r Gli 75	aten 1 Ph	tin.	ST25	s . Thi	Ile 80
	Le	u Le	u Al	a Il	e Lei 85	u Va]	l Gly	/ Met	t Phe	• Thi	r Val	Met	G]	ı Sei	^ Val	Ala
•	Pro	) Le	u Va	7 Thi	Tyr	Leu	ı Phe	≥ Va]	Va] 105	l Ala	a Ile	. Ser	· Ile	Leu 11(	I Asp	Gly
	Phe	≘ Ala	a Ala 11	a Pro	Val	Ser	· Tyr	Ala 120	ı Ile	val	l Pro	Arg	Ty:	Ala	Thr	Asp
	Leu	1 G]) 13(	/ Lys	s Ala	ı Asn	Ser	Ala 135	Leu	ı Ser	· Met	: Thr	G]y	G]L	ı Ala	Va]	Gln
	Leu 145	ı Ile	e Gly	/ Trp	Gly	Leu 150	Gly	G]y	' Leu	Leu	Phe 155	Аlа	Thr	'Ile	Gly	Leu 160
•	Leu	Pro	Thr	Thr	Cys 165	Ile	Asn	Leu	Va]	Leu 170	Tyr	Ile	Ile	Ser	Ser 175	Phe
	Leu	Met	Leu	Phe 180	Leu	Pro	Asn	Ala	Glu 185	Val	Glu	۷al	Leu	Glu 190	Ser	Glu
	Thr	Asn	Leu 195	Glu	Ile	Leu	Leu	Lys 200	Gly	Trp	Lys	Leu	Va] 205	Ala	Arg	Asn
	Pro	Arg 210	Leu	Arg	Leu	Phe	Val 215	Ser	ΑΊа	Asn	Leu	Leu 220	Glu	Ile	Phe	Ser
	Asn 225	Thr	Ile	тгр	٧a٦	Ser 230	Ser	Ile	Ile	Leu	Va1 235	Phe	۷aΊ	Thr	Glu	Leu 240
	Leu	Asn	Lys	Thr	G]u 245	Ser	Tyr	Trp	GТу	Tyr 250	Ser	Asn	Thr	Ala	Tyr 255	Ser
	Ile	Gly	Ile	Ile 260	Ile	Ser	Gly	Leu	Ile 265	Ala	Phe	Arg	Leu	Ser 270	Glu	Lys
	Phe	Leu	Ala 275	Ala	Lys	Trp	Glu	Pro 280	Gln	Leu	Phe	Thr	Pro 285	Asn	Leu	Lys
	Thr	Ile 290	Gln	Asn	Pro	Cys	Leu 295	Ser	Leu	Asp	Pro	G]y 300	Trp	Phe	Leu	Phe
	Ser 305	Pro	Asn	Gly	Cys	Phe 310	Leu	Leu	Asp	Lys	Lys 315	Glu	Phe	Pro		Tyr 320
	Gly	Ile	Ser	Val	G]u 325	Lys .	Asn '	Thr	Lys	Arg 330	Lys .	Glu '	Thr	His	Met / 335	Asn

str pneumoniae patentin.ST25 Ser Leu Pro Asn His His Phe Gln Asn Lys Ser Phe Tyr Gln Leu Ser 340 345 350 Phe Asp Gly Gly His Leu Thr Gln Tyr Gly Gly Leu Ile Phe Phe Gln 355 360 365 Glu Leu Phe Ser Gln Leu Lys Leu Lys Glu Arg Ile Ser Lys Tyr Leu 370 380 Val Thr Asn Asp Gln Arg Arg Tyr Cys Arg Tyr Ser Asp Ser Asp Ile 385 390 395 400 Leu Val Gln Phe Leu Phe Gln Leu Leu Thr Gly Tyr Gly Thr Asp Tyr 405 410 415 Ala Cys Lys Glu Leu Ser Ala Asp Ala Tyr Phe Pro Lys Leu Leu Glu 420 430 Gly Gln Leu Ala Ser Gln Pro Thr Leu Ser Arg Phe Leu Ser Arg 435 440 445Thr Asp Glu Glu Thr Val His Ser Leu Arg Cys Leu Asn Leu Glu Leu 450 460 Val Glu Phe Phe Leu Gln Phe His Gln Leu Asn Gln Leu Ile Val Asp 465 470 475 480 Ile Asp Ser Thr His Phe Thr Thr Tyr Gly Lys Gln Glu Gly Val Ala 485 490 495 Tyr Asn Ala His Tyr Arg Ala His Gly Tyr His Pro Leu Tyr Ala Phe 500 510 Glu Gly Lys Thr Gly Tyr Cys Phe Asn Ala Gln Leu Arg Pro Gly Asn 515 520 525 Arg Tyr Cys Ser Glu Glu Ala Asp Ser Phe Ile Thr Pro Val Leu Glu 530 540 Arg Phe Asn Gln Leu Leu Phe Arg Met Asp Ser Gly Phe Ala Thr Pro 545 550 560 Lys Leu Tyr Asp Leu Ile Glu Lys Thr Gly Gln Tyr Tyr Leu Ile Lys 565 570 575 Leu Lys Lys Asn Thr Val Leu Ser Arg Leu Gly Asp Leu Ser Leu Pro 585 590 Cys Pro Gln Asp Glu Asp Leu Thr Ile Leu Pro His Ser Ala Tyr Ser 595 600 605

	G]	u Tł	ir. Le	eu Ty	r Gl	n Ala	a GT	str v se	pneu	moni	ae p	aten	tin.	ST25		Cys
		61					_61	5 <b>-</b>		P=-3e1	- H1:	620	Arc	-Arg	J-•Va ]	Cys
	G1 62	n Ph 5	ie Se	er Gl	u Ar	g Lys 630	Gli )	u Gl	y Ası	1 Leu	J Phe 635	Tyr	` Asp	Val	Ile	ser 640
	Le	u Va	7 Th	r As	n Met 645	Thr	Ser	G7	y Thr	Ser 650	Gln	Asp	Gln مد.	Phe	G]n 655	Leu
									4 Asn 665	•				670		
	Gly	/ Ph	e Ph 67	e G7 <sub>3</sub> 5	/ Asp	Lys	Thr	' Asp 680	Ser	Ser	Thr	Leu	Ile 685	Lys	Asn	Glu
	Val	69	) Me	t Met	Met	Ser	Cys 695	Ile	e Ala	Tyr	Asn	Leu 700	Tyr	Leu	Phe	Leu
•	Lys 705	His	. Lei	u Ala	Gly	G]y 710	Asp	Phe	e Gln	Thr	Leu 715	Thr	Ile	Lys	Arg	Phe 720
	Arg	His	Lei	ı Phe	Leu 725	Bis	Val	Va]	Gly	Lys 730	Суѕ	val	Arg	Thr	Gly 735	Arg
	Lys	Gln	Leu	1 Leu 740	Lys	Leu	Ser	Ser	Leu 745	Tyr	Ala	Tyr	Ser	<u></u> ցշս 750	Leu	Phe
	Ser	ΑΊа	Leu 755	Tyr	Ser	Arg	Ile	Arg 760	Lys	۷aΊ	Asn	Leu	Asn 765	Leu	Pro	Val
	Pro	Tyr 770	Glu	Pro	Pro	Arg	Arg 775	Lys	Ala	Ser	Leu	Met 780	Met	His		
	<210	)>	239													
	<211	<b>.</b>	693													
	<212	!> 1	PRT													
	<213	<b>&gt;</b>	Stre	ptoco	ccus	pne	umon	iae								
	<400	> 2	239				•									
	Met 1	Phe	Αla	Ser	Lys 5	Ser (	slu ,	Arg	Lys :	Val 1 10	His -	Tyr s	Ser I	lle A	lg μ	.ys
	Phe	Ser	Val	G]у 20	Val /	Ala s	Ser v	val :	Va] \ 25	val A	Ala s	Ser L	.eu \ 3	/al M 80	let d	IJ
	Ser \	∨al	Va1 35	His .	Ala -	Thr G	Slu A	Asn ( 10	Glu (	Sly A	Лат	hr G	iln v 5	'al P	ro T	hr

str pneumoniae patentin.ST25
Ser Ser Asn Arg Ala Asn Glu Ser Gln Ala Glu Gln Gly Glu Gln Pro
50 55 60 Lys Lys Leu Asp Ser Glu Arg Asp Lys Ala Arg Lys Glu Val Glu 65 70 75 80 Tyr Val Lys Lys Ile Val Gly Glu Ser Tyr Ala Lys Ser Thr Lys Lys Arg His Thr Ile Thr Val Ala Leu Val Asn Glu Leu Asn Asn Ile Lys
100 105 110 Asn Glu Tyr Leu Asn Lys Ile Val Glu Ser Thr Ser Glu Ser Gln Leu 115 120 125 Gln Ile Leu Met Met Glu Ser Arg Ser Lys Val Asp Glu Ala Val Ser 130 135 140 Lys Pro Glu Ala Ser Asp Thr Ala Lys Pro Asn Lys Pro Thr Glu Pro 165 170 175 Gly Glu Lys Val Ala Glu Ala Lys Lys Lys Val Glu Glu Ala Glu Lys 180 185 190 Lys Ala Lys Asp Gln Lys Glu Glu Asp Arg Arg Asn Tyr Pro Thr Ile 195 200 205 Thr Tyr Lys Thr Leu Glu Leu Glu Ile Ala Glu Ser Asp Val Glu Val 210 220 Lys Lys Ala Glu Leu Glu Leu Val Lys Val Lys Ala Asn Glu Pro Arg 225 230 235 240 Asp Glu Gln Lys Ile Lys Gln Ala Glu Ala Glu Val Glu Ser Lys Gln 245 250 255 Ala Glu Ala Thr Arg Leu Lys Lys Ile Lys Thr Asp Arg Glu Glu Ala 260 265 270 Glu Glu Glu Ala Lys Arg Arg Ala Asp Ala Lys Glu Gln Gly Lys Pro 275 280 285 Lys Gly Arg Ala Lys Arg Gly Val Pro Gly Glu Leu Ala Thr Pro Asp 290 295 300 Lys Lys Glu Asn Asp Ala Lys Ser Ser Asp Ser Ser Val Gly Glu Glu 305 310 315 320

Str pneumoniae patentin.ST25 Thr Leu Pro Ser Pro Ser Leu Lys Pro Glu Lys Lys Val-Ala Glu-Ala Glu-Ala 325
325 330 Lys Lys Val-Ala Glu-Ala 335 335 335 335 335 335 335 335 335 33
Glu Lys Lys Val Glu Glu Ala Lys Lys Lys Ala Glu Asp Gln Lys Glu 340 345 350
Glu Asp Arg Arg Asn Tyr Pro Thr Asn Thr Tyr Lys Thr Leu Glu Leu 355 360 365
Glu Ile Ala Glu Ser Asp Val Glu Val Lys Lys Ala Glu Leu Glu Leu 370 375 380
Val Lys Glu Glu Ala Lys Glu Pro Arg Asn Glu Glu Lys Val Lys Gln 385 390 395 400
Ala Lys Ala Glu Val Glu Ser Lys Lys Ala Glu Ala Thr Arg Leu Glu 405 410 415
Lys Ile Lys Thr Asp Arg Lys Lys Ala Glu Glu Ala Lys Arg Lys 420 430
Ala Ala Glu Glu Asp Lys Val Lys Glu Lys Pro Ala Glu Gln Pro Gln 435 440 445
Pro Ala Pro Ala Pro Lys Ala Glu Lys Pro Ala Pro Ala Pro Lys Pro 450 . 455. 460
Glu Asn Pro Ala Glu Gln Pro Lys Ala Glu Lys Pro Ala Asp Gln Gln 465 470 475 480
Ala Glu Glu Asp Tyr Ala Arg Arg Ser Glu Glu Glu Tyr Asn Arg Leu 485 490 495
Thr Gln Gln Pro Pro Lys Thr Glu Lys Pro Ala Gln Pro Ser Thr 500 505
Pro Lys Thr Gly Trp Lys Gln Glu Asn Gly Met Trp Tyr Phe Tyr Asn 515 520 525
Thr Asp Gly Ser Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp 530 535 540
Tyr Tyr Leu Asn Ser Asn Gly Ala Met Ala Thr Gly Trp Leu Gln Asn 550 555 560
Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ser Met Ala Thr Gly 565 570 575
Trp Leu Gln Asn Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ser 580 585 590

The second of the second of the second

str pneumoniae patentin.ST25 Met Ala Thr Gly Trp Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn 595 600 605

Ala Asn Gly Ser Met Ala Thr Gly Trp Leu Gln Tyr Asn Gly Ser Trp 610 620

Tyr Tyr Leu Asn Ala Asn Gly Asp Met Ala Thr Gly Trp Val Lys Asp 625 630 635

Gly Asp Thr Trp Tyr Tyr Leu Glu Ala Ser Gly Ala Met Lys Ala Ser 645 655

Gln Trp Phe Lys Val Ser Asp Lys Trp Tyr Tyr Val Asn Gly Ser Gly 660 665

Ala Leu Ala Val Asn Thr Thr Val Asp Gly Tyr Gly Val Asn Ala Asn 675 680

Gly Glu Trp Val Asn 690

<210> 240

<211> 810

<212> PRT

<213> Streptococcus pneumoniae

<400> 240

Met Asn Tyr Ser Lys Ala Leu Asn Glu Cys Ile Glu Ser Ala Tyr Met  $1. \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$ 

Val Ala Gly His Phe Gly Ala Arg Tyr Leu Glu Ser Trp His Leu Leu 20 25 30

Ile Ala Met Ser Asn His Ser Tyr Ser Val Ala Gly Ala Thr Leu Asn 35 40 45

Asp Tyr Pro Tyr Glu Met Asp Arg Leu Glu Glu Val Ala Leu Glu Leu 50 60

Thr Glu Thr Asp Tyr Ser Gln Asp Glu Thr Phe Thr Glu Leu Pro Phe 65 70 75 80

Ser Arg Arg Leu Gln Val Leu Phe Asp Glu Ala Glu Tyr Val Ala Ser 85 90 95

Val Val His Ala Lys Val Leu Gly Thr Glu His Val Leu Tyr Ala Ile 100 105 110

a . ·	Le	eu H	is A 1	sp s 15	er A	sn A	la L	str eu A	рі 1а 20	neur Thr	oni Ar	ae p g_ <u>I</u> l	ater e Le	euG	lu-A	5 rg - Ai	la Gly
												. –		e A]			eu Arg
	Ar 14	g As 5	in L	eu G	lu G	lu Ai	rg A	la G	ly -	Trp	Thr	' Are	g G1	U As	p Le	u Ly	's Ala 160
	Le	u Ar	g G	In A	rg Hi 16	s Ai	•g ⊤l	hr Va	al .	- Ala	Asp 170	· ) Lys	6 G]	n As	n Se	r Me 17	t Ala
	Ası	п Ме	t Me	et G 18	ly Me 30	t Pr	o G	in Th	nr i	Pro 185	Ser	· Gly	/ G7:	y Le	u G] 19	u As <sub>i</sub> O	р Туг
_	Th	r Hi	s As 19	p Le	u Th	r Gl	u Gl	n A7	a /	Arg	Ser	Gly	' Lys	5 Lei 20	u Gl	u Pro	o Val
•	Ιle	210 210	y Ar D	g As	р Lу	s G7	u I] 21	e se .5	r /	Arg	Met	Ile	G]r 220	ı Ile	⊇ Le	u Sei	r Arg
	Lys 225	Thi	r Ly	s As	n Asi	n Pr 23	o Va O	l Le	u V	/al	Gly	Asp 235	Αla	G7y	⁄ Va	l Gly	/ Lys 240
	Thr	Ala	a Le	ra u	a Lei 24!	g G]	y Le	u Al	a G	iln	Arg 250	Ile	Ala	Ser	· G]	/ Asp 255	val
	Pro	Ala	G](	и Ме 26	t Ala	a Ly:	s Me	t Ar	g V 2	'a1 '65	Leu	Glu	Leu	Asp	Leu 270	Met	Asn
	Val	Val	A1a 275	G G T	/ Thr	` Arg	g Pho	e Aro 280	g G	lу,	Asp	Phe	Glu	G] u 285	Arg	Met	Asn
	Asn	17e 290	Ιle	Lys	s Asp	ıle	e Glu 295	i Glu	I A	sp (	ςΊу	Gln	Va7 300	Ile	Leu	Phe	Ile
_	Asp 305	Glu	Leu	His	Thr	1]e 310	Met	Gly	′ S(	er (	ЗÌу	Ser 315	Gly	Ile	Asp	Ser	Thr 320
	Leu	Asp	Ala	Аla	325	Ile	Leu	l Lys	Pi	ro A	17a 130	Leu	Ala	Arg	Gly	Thr 335	Leu
	Arg	Thr	Va1	Gly 340	Аlа	Thr	Thr	Gln	G1 34	lu G 15	ilu 1	Туг	Gln	Lys	His 350	Ile	Glu
	Lys	Asp	A]a 355	ΑΊа	Leu	Ser	Arg	Arg 360	Ph	ie A	Ла і	_ys '		Thr 365	Ile	Glu	Glu
	Pro	Ser 370	Va1	Ala	Asp <sub>.</sub>	Ser	Met 375	Thr	ΙΊ	e L	eu d	in o	31y 380	Leu	Lys	Ala	Thr .

str pneumoniae patentin.ST25 Tyr Glu Lys His His Arg Val Gln Ile Thr Asp Glu Ala Val Glu Thr 385 390 395 400 Ala Val Lys Met Ala His Arg Tyr Leu Thr Ser Arg His Leu Pro Asp 405 410 415 Ser Ala Ile Asp Leu Leu Asp Glu Ala Ala Ala Thr Val Gln Asn Lys 420 430 Ala Lys His Val Lys Ala Asp Asp Ser Asp Leu Ser Pro Ala Asp Lys 435 440 445 Ala Leu Met Asp Gly Lys Trp Lys Gln Ala Ala Gln Leu Ile Ala Lys 450 460 Glu Glu Glu Val Pro Val Tyr Lys Asp Leu Val Thr Glu Ser Asp Ile 465 470 480 Leu Thr Thr Leu Ser Arg Leu Ser Gly Ile Pro Val Gln Lys Leu Thr 485 490 495 Gln Thr Asp Ala Lys Lys Tyr Leu Asn Leu Glu Ala Glu Leu His Lys 500 510 Arg Val Ile Gly Gln Asp Gln Ala Val Ser Ser Ile Ser Arg Ala Ile 515 520 Arg Arg Asn Gln Ser Gly Ile Arg Ser His Lys Arg Pro Ile Gly Ser 530 540 Phe Met Phe Leu Gly Pro Thr Gly Val Gly Lys Thr Glu Leu Ala Lys 545 550 555 Ala Leu Ala Glu Val Leu Phe Asp Asp Glu Ser Ala Leu Ile Arg Phe 565 570 575 Asp Met Ser Glu Tyr Met Glu Lys Phe Ala Ala Ser Arg Leu Asn Gly 580 585 Ala Pro Pro Gly Tyr Val Gly Tyr Glu Glu Gly Gly Glu Leu Thr Glu 595 600 Lys Val Arg Asn Lys Pro Tyr Ser Val Leu Leu Phe Asp Glu Val Glu 610 620 Lys Ala His Pro Asp Ile Phe Asn Val Leu Leu Gln Val Leu Asp Asp 625 630 635 640 Gly Val Leu Thr Asp Ser Lys Gly Arg Lys Val Asp Phe Ser Asn Thr 645 650 655

str pneumoniae patentin.ST25  Ile Ile Ile Met Thr Ser Asn Leu Gly Ala Thr Ala Leu Arg Asp As 660 665 665 6670 670	p
	_

Lys Thr Val Gly Phe Gly Ala Lys Asp Ile Arg Phe Asp Gln Glu Asn 685

Met Glu Lys Arg Met Phe Glu Glu Leu Lys Lys Ala Tyr Arg Pro Glu 695 700

Phe Ile Asn Arg Ile Asp Glu Lys Val Val Phe His Ser Leu Ser Ser 705 710 715

Asp His Met Gln Glu Val Val Lys Ile Met Val Lys Pro Leu Val Ala 725 730 735

Ser Leu Thr Glu Lys Gly Ile Asp Leu Lys Leu Gln Ala Ser Ala Leu 740 750

Lys Leu Leu Ala Asn Gln Gly Tyr Asp Pro Glu Met Gly Ala Arg Pro
755 760 765

Leu Arg Arg Thr Leu Gln Thr Glu Val Glu Asp Lys Leu Ala Glu Leu 770 780

Leu Leu Lys Gly Asp Leu Val Ala Gly Ser Thr Leu Lys Ile Gly Val 785 790 795 800

Lys Ala Gly Gln Leu Lys Phe Asp Ile Ala 805 810

<210> 241

<211> 448

<212> PRT

<213> Streptococcus pneumoniae

<400> 241

Met Lys Ile Leu Pro Phe Ile Ala Arg Gly Thr Ser Tyr Tyr Leu Lys  $1 \hspace{1cm} 1 \hspace{1cm} 15$ 

Met Ser Val Lys Lys Leu Val Pro Phe Leu Val Val Gly Leu Met Leu 25 30

Ala Ala Gly Asp Ser Val Tyr Ala Tyr Ser Arg Gly Asn Gly Ser Ile 35 40 45

Ala Arg Gly Asp Asp Tyr Pro Ala Tyr Tyr Lys Asn Gly Ser Gln Glu 50 60 str pneumoniae patentin.ST25
Ile Asp Gln Trp Arg Met Tyr Ser Arg Gln Cys Thr Ser Phe Val Ala
65 70 75 80 Phe Arg Leu Ser Asn Val Asn Gly Phe Glu Ile Pro Ala Ala Tyr Gly 85 90 95 Asn Ala Asn Glu Trp Gly His Arg Ala Arg Arg Glu Gly Tyr Arg Val Asp Asn Thr Pro Thr Ile Gly Ser Ile Thr Trp Ser Thr Ala Gly Thr 115 120 125 Tyr Gly His Val Ala Trp Val Ser Asn Val Met Gly Asp Gln Ile Glu 130 140 Ile Glu Glu Tyr Asn Tyr Gly Tyr Thr Glu Ser Tyr Asn Lys Arg Val 145 150 155 160 Ile Lys Ala Asn Thr Met Thr Gly Phe Ile His Phe Lys Asp Leu Asp 165 170 175 Gly Gly Ser Val Gly Asn Ser Gln Ser Ser Thr Ser Thr Gly Gly Thr 180 185 His Tyr Phe Lys Thr Lys Ser Ala Ile Lys Thr Glu Pro Leu Ala Ser 195 200 205 Gly Thr Val Ile Asp Tyr Tyr Tyr Pro Gly Glu Lys Val His Tyr Asp 210 215 220 Gln Ile Leu Glu Lys Asp Gly Tyr Lys Trp Leu Ser Tyr Thr Ala Tyr 225 230 235 240 Asn Gly Ser Tyr Arg Tyr Val Gln Leu Glu Ala Val Asn Lys Asn Pro 245 250 255 Leu Gly Asn Ser Val Leu Ser Ser Thr Gly Gly Thr His Tyr Phe Lys 260 265 270 Thr Lys Ser Ala Ile Lys Thr Glu Pro Leu Val Ser Ala Thr Val Ile 275 280 285 Asp Tyr Tyr Pro Gly Glu Lys Val His Tyr Asp Gln Ile Leu Glu 290 300 Lys Asp Gly Tyr Lys Trp Leu Ser Tyr Thr Ala Tyr Asn Gly Ser Arg 305 310 315 320 Arg Tyr Ile Gln Leu Glu Gly Val Thr Ser Ser Gln Asn Tyr Gln Asn 325 330 335

				•						•					
 Gln	Ser	· G]	y Ası 34(	ı <u>ı</u> l	e Sei	r Se	str r.Ty	pneu r_Gly	moni <u>Y</u> _Se	ae p c_Hi	aten s. Se	tin. r Se	ST25	r <sub>≕-</sub> Th	r= Val
		٠											55	0	
Gly	Trp	35!	s Lys	5 Il€	⊇ Asr	ı Gly	y 5ei 360	r Trp	ту	r Hi:	s Ph	e Ly 36	s Se 5	r As	n Gly
 Ser	Lys 370	Sei	Thr	Gly	/ Trp	) Lei	Lys	S Asp	G [	y Sei	r Sei	r Tr	р Ту	г ту	r Leu
Lys 385	Leu	Ser	· Gly	Glu	Met 390	Glr	Thr	· Gly	/ Tri	2 Lei 39:	ı Lys	s Gl	u Ası	ı Gl	y Leu 400
Trp	Tyr	Tyr	` Leu	G]y 405	Ser	' Ser	· Gly	⁄ Ala	Me1 410	t Lys	5 Thi	r Gly	y Trp	7 Ty:	r Gln
Va]	Ser	Gly	' Lys 420	Trp	Tyr	Tyr	' Ser	Tyr 425	Ser	- Ser	· Gly	/ Ala	a Leu 430	ı Ala	a Val
Asn	Thr	Thr 435	' Val	Asp	Gly	Tyr	' Arg 440	Val	Asr	ser	' Asp	Gly 445	/ Glu	ı Arç	y Val
<210	)> 2	242													
<211	: حا	150													
<212	?> F	PRT													
<213	B> 5	Stre	ptoc	occu:	s pn	eumo	niae								
<400	)> 2	242													
			Tlo	nho		47-	•								
									~0					72	Gly
Glu	Ile	Lys	Glu 20	Va1	Pro	Thr	Gly	Tyr 25	Ala	Gln	Asn	Phe	Leu 30	Ile	Lys
Lys	Asn	Leu 35	Ala	Lys	Glu	Ala	Thr 40	ΑΊα	Gln	Ala	Val	G]y 45	Glu	Leu	Arg
Gly	Lys 50	Gln	Lys	Ser	Glu	G]u 55	Lys	Ala	His	Ala	G]u 60	Met	Ile	Ala	Glu
G]y   65	Lys /	Ala	Ile	Lys	Ala 70	Gln	Leu	Glu	Ala	G1u 75	Glu	Thr	Val	۷a٦	Glu 80
Phe \	√al (	Glu	Lys	Va1 85	Gly	Pro	Asp	Gly	Arg 90	Thr	Phe	Gly	Ser	Ile 95	Thr
Asn I	ys ı	Lys	Ile 100	Ala	Glu	Glu	Leu	G]n 105	Lys	Gln	Phe	G]y	Ile 110	Lys	Ile

str pneumoniae patentin.ST25
Asp Lys Arg His Ile Gln Val Gln Ala Pro Ile Arg Ala Val Gly Leu
115 120 125

Ile Asp Val Pro Val Lys Ile Tyr Gln Asp Ile Thr Ser Val Ile Asn 130 140

Leu Arg Val Lys Glu Gly 145 150

<210> 243

<211> 392

<212> PRT

<213> Streptococcus pneumoniae

<400> 243

Met Lys Lys Lys Ile Leu Ala Ser Leu Leu Leu Ser Thr Val Met Val 1 10 15

Ser Gln Val Ala Val Leu Thr Thr Ala His Ala Glu Thr Thr Asp Asp 20 25 30

Lys Ile Ala Ala Gln Asp Asn Lys Ile Ser Asn Leu Thr Ala Gln Gln 35 40 45

Gln Glu Ala Gln Lys Gln Val Asp Gln Ile Gln Glu Gln Val Ser Ala 50 60

Ile Gln Ala Glu Gln Ser Asn Leu Gln Ala Glu Asn Asp Arg Leu Gln 65 70 75 80

Ala Glu Ser Lys Leu Glu Gly Glu Ile Thr Glu Leu Ser Lys Asn 85 90 95

Ile Val Ser Arg Asn Gln Ser Leu Glu Lys Gln Ala Arg Ser Ala Gln
100 105 110

Thr Asn Gly Ala Val Thr Ser Tyr Ile Asn Thr Ile Val Asn Ser Lys
115 120 125

Ser Ile Thr Glu Ala Ile Ser Arg Val Ala Ala Met Ser Glu Ile Val 130 140

Ser Ala Asn Asn Lys Met Leu Glu Gln Gln Lys Ala Asp Lys Lys Ala 145 150 155 160

Ile Ser Glu Lys Gln Val Ala Asn Asn Asp Ala Ile Asn Thr Val Ile 165 170 175

	Ala	ASI	ı Glr	G] 18(	ı Lys	Lei	<u> </u>	str a Aşı	pneu p Asr 18	noni	ae p	aten n <u>A</u> la	tin.:	ST25 4Thi 1.90	ը Միկ	Lys
									ı Lei					Glu	,	. Ala
	Thr	A]a 210	Glu	G]y	Glu	Lys	A]a 215	Ser	Leu	Leu	G]ı	I G]n 220	Lys	: Ala	ı Ala	Ala
	G]u 225	Ala	Glu	Ala	Arg	A1a 230	Ala	Ala	Va1	Ala	G1u 235	Ala	Ala	Tyr	Lys	G]u 240
	Lys	Arg	Ala	Ser	G]n 245	Gln	Gln	Ser	Val	Leu 250	ΑΊа	Ser	Аlа	Asn	Thr 255	Asn
									-03			Ala		2/0		
												Αla	285			
							_					A7a 300				
	Asp 305										217					320
	Gly (									<b>J J J</b>					335	
	Asn A								J 1 J					350		
•	Thrī											•	000			
	Ile G								Asn I	Pro -	Thr :	Thr 7 380	Thr s	Ser (	Glu (	5 <b>1</b> y
	Phe V 385	al T	hr T	yr 1	le 1	yr 4 90	la /	Asp								
	<210>															
	<211> <212>	12														
	<213>	PR St		0000	CHC	nno	<b></b> ~~-									
		50	. <b>-</b> p		cus	hueu	เกษกา	ae								
	<400>	244	4													

str pneumoniae patentin.ST25
Met Val Lys Arg Arg Ile Arg Arg Gly Thr Arg Glu Pro Glu Lys Val
1 5 10 15 Val Val Pro Glu Gln Ser Ser Ile Pro Ser Tyr Pro Val Ser Val Thr 20 25 30 Ser Asn Gln Gly Thr Asp Val Ala Val Glu Pro Ala Lys Ala Val Ala 35 40 45 Pro Thr Thr Asp Trp Lys Gln Glu Asn Gly Met Trp Tyr Phe Tyr Asn 50 60Thr Asp Gly Ser Met Ala Thr Gly Trp Val Gln Val Asn Ser Ser Trp 65 70 75 80 Tyr Tyr Leu Asn Ser Asn Gly Ser Met Lys Val Asn Gln Trp Phe Gln 85 90 95 Val Gly Gly Lys Trp Tyr Tyr Val Asn Thr Ser Gly Glu Leu Ala Val 100 105 110

Asn Thr Ser Ile Asp Gly Tyr Arg Val Asn Asp Asn Gly Glu Trp Val

Arg

<210> 245

<21.1> 46

<212> **PRT** 

<213> Streptococcus pneumoniae

<400> 245

Glu Leu Arg Arg Leu Ser Arg Leu Val Asp Gln Glu Leu Tyr Phe Gly
1 10 15

Cys Gly Trp Arg Leu Ser Leu Glu Trp Leu Pro Ser Met Arg Lys Asp 20 25 30

Ser Trp Pro Ser Asn Thr Ala Pro Arg Thr Thr Met Val Gln 35 40 45

<210> 246

<211> 31

<212> PRT

<213> Streptococcus pneumoniae

## str pneumoniae patentin.ST25

от менения и и постоя и выполняться в предоставления в противования в предоставления в противования в поставления в поставления в противования в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в применения в

<400> 246

Asp Cys Ile Arg Lys Gln Pro Phe Thr Arg Asp Glu Pro Asn Lys Thr 10 15

Cys Arg Lys Thr Lys Pro Ser Lys Ser Tyr Cys Ser Tyr Arg Trp

<210> 247

<211> 26

<212> PRT

<213> Streptococcus pneumoniae

<400> 247

Gly Gln Arg Asn Pro Arg Arg Ile Glu Arg Val Ile Arg Met Ala Glu 10 15

Thr Lys Pro Arg Ile Ser Lys Lys Glu Gly 20 25

<210> 248

<211> 83

<212> PRT

<213> Streptococcus pneumoniae

<400> 248

Gln Arg Lys Leu Phe Lys Ile Phe His Leu Phe Gln Lys Lys Ser Gly 10 15

Trp Asn Gln Lys Ser Ser Cys Leu Lys Leu Asn Leu Asn Ser Leu Asn 20 25 30

Arg Lys Met Thr Gln Met Thr Lys Met Phe Arg Ser Ile Phe Gln Pro  $\frac{35}{40}$ 

Lys Lys Pro Leu Asn Thr Asn Phe Gln Ala Tyr Asn Ser Leu His Gln 50 60

Ile Asn Gln Lys Ile Ser Leu Lys Arg Arg Lys Leu Ser Glu Lys Ile 70 75 80

Ser Lys Ser

```
str pneumoniae patentin.ST25
```

<210> 249

<211> 104

<212> PRT

<213> Streptococcus pneumoniae

<400> 249

Leu Val Ile Ile Val Leu Lys Ile Gln Ser Lys Ser Glu Thr Asp Phe 10 15

Ile Phe Lys Thr Trp Pro Phe Ile Leu Leu Ser Lys Ile Ile Pro Leu 20 25 30

Met Val Leu Asp Cys Gln Val Ser Ile Ser Trp Thr Asn Arg Glu Thr 35 40 45

Val Ala Tyr Ser Lys Leu Leu Ala Ile Lys Thr Leu Lys Gly Asp Tyr 50 60

His Asp Gly Gln Ser Lys Lys Ile Arg Leu Ser His Ala Ser Arg Val 65 70 75 80

Arg Thr Pro Ser Trp Tyr Pro His Asp Met Ala Asp Ser Thr Arg Ile 85 90 95

Met Ala Phe Ser Arg Lys Gly Cys 100

<210> 250

<211> 30

<212> PRT

<213> Streptococcus pneumoniae

<400> 250

Glu Arg Leu Pro Ala Phe Pro Arg Ser Leu Ser Gly Arg Lys Leu Asp 10 15

Gln Gly Gly Thr Lys Glu Lys Gly Ser Asp Gly Arg Ser Pro 20 25 30

<210> 251

<211> 245

<212> PRT

<213> Streptococcus pneumoniae

<400>--251-

Arg Asn Cys Leu Ser Thr Trp Lys Ser Ser Ser Asn Tyr His Thr Glu
10
15

Ile Lys Arg Gly Thr Val Arg Gln Cys Leu Gly Lys Gly Arg Phe Lys

Glu Val Tyr Ser Ala Asp Tyr Ala Gln Gln Ser Tyr Glu Asn Asn Arg 35 40 45

Lys Arg Ser Val Lys Lys Ser Ser Leu Thr Lys Glu Leu Lys Glu Lys 50 60

Ile Leu His Tyr His Asn Gln Lys Phe Ser Pro Glu Met Met Val Met 65 70 75 80

Ala Lys Gly Val Asn Val Gly Ile Ser Thr Ile Tyr Tyr Trp Ile His 85 90 95

His Gly Lys Leu Gly Leu Ser Lys Gln Asp Leu Leu Tyr Pro Arg Lys

Gly Lys Ala Leu Lys Lys Gln Ala Ser Thr Asn Phe Lys Pro Ala Gly
115 120 125

Gln Ser Ile Glu Gln Arg Pro Glu Ala Ile Asn Leu Arg Leu Glu Asn 130 140

Gly His Tyr Glu Ile Asp Thr Val Leu Leu Thr Arg Ser Lys Asn Tyr 150 155 160

Cys Leu Ile Val Leu Thr Asp Arg Lys Ser Arg His Gln Ile Ile Arg 165 170 175

Leu Ile Pro Asn Lys Ser Ala Glu Val Val Asn Gln Ala Leu Lys Leu 180 185 190

Ile Leu Lys Gln His Lys Ile Leu Ser Ile Thr Ala Asp Asn Gly Thr 195 200 205

Glu Phe Asn Arg Leu Phe Asp Ile Phe Ser Glu Glu His Ile Tyr Tyr 210 220

Ala His Pro Tyr Ala Ser Trp Glu Arg Gly Thr Asn Glu Asn His Asn 230 235 240

Arg Leu Ile Arg Arg 245

```
str pneumoniae patentin.ST25
```

<210> 252

<211> 36

<212> PRT

<213> Streptococcus pneumoniae

<400> 252

Pro Val Met Thr Ile Ser Ser Pro Thr Met Lys Asn Met Asp Leu Ser 10

Thr Lys Ala Ser Pro Ser Gln Pro Leu Gln Gly Lys His Gly Met Ile 20 25 30

Trp Ser Gly Lys

<210> 253

<211> 28

<212> PRT

<213> Streptococcus pneumoniae

<400> 253

Thr Ser Ser Ile Arg Ile His Thr Arg Lys Ser Ser Pro Asn Trp Thr 10 15

Thr Thr Pro His Leu Ala Leu Ser Ala Glu Thr Asn 20 25

<210> 254

<211> 27

<212> PRT

<213> Streptococcus pneumoniae

<400> 254

Tyr Phe Leu Pro His Lys Tyr Ala Arg Glu Ser Leu Ser Leu Pro Ser 1 10 15

Thr Asn Lys Ile Leu His Arg Lys Gln Gly Ser 20 25

<210> 255

<211> 53

## <213>— Streptococcus pneumoniae

<400> 255

Ala Ala Phe Lys Lys Asp Gln Ile Asn Glu Arg Val Glu Lys Leu Gly
10 15

Lys Leu Lys Pro Ile Thr Ile Asn Tyr Asn Gly Lys Ser Glu Val Ile 20 30

Asp Ser Lys Glu Lys Leu Gln Glu Leu Met Asn Lys Ala Val Lys Asp 35 40 45

Glu Val Ala Gln Ile 50

<210> 256

<211> 33

<212> PRT

<213> Streptococcus pneumoniae

<400> 256

Ala Tyr Ala His Ser Lys Arg Ser Ala Gly Ser Gly Arg Ala Gly Gly 10 15

Arg Gln Cys Leu Cys Gln Cys Gln Asn Lys Cys Arg Arg Asp Phe Lys 20 25 30

Tyr

<210> 257

<211> 36

<212> PRT

<213> Streptococcus pneumoniae

<400> 257

His Gly Arg Pro Tyr His Lys Pro His Gln Pro His His Gly Phe 10 15

Pro Gln Gln Ser Tyr Asn Leu Leu Pro Pro Lys His Lys Pro Thr Leu 25 30

Cys Val Arg Arg 35

<210> 258

<211> 130

<212> PRT

<213> Streptococcus pneumoniae

<400> 258

Lys Gly Lys Ile Leu Leu Leu Pro Arg Leu Thr Thr Gln Arg Trp Gln 10 15

Arg Lys Ile Arg Pro Asp Ser Arg Lys Ser Ala Asn Asn Lys Ala Asn 20 25 30

Pro Asn Leu His Lys Asn Pro Ala Leu Leu Val His Ser Leu Ser Arg  $50 \hspace{1.5cm} 55 \hspace{1.5cm} 60$ 

Val Ile Ala Val Leu Leu Glu Leu Ser Pro Leu Gln Ala Tyr Ser Ile 65 70 75 80

Val Lys Phe Ser Pro Lys Glu Asp Asp Leu Ile His Asp Asp Ala Ile  $85 \hspace{1.5cm} 90 \hspace{1.5cm} 95$ 

Leu Val Arg Phe Gly Ile Leu Glu Val His Asp Ser Pro Tyr Glu Leu 100 105 110

Leu Leu Tyr His Thr His Ser Tyr Arg Phe Ser Cys Ser Ile Tyr 115 120 125

Leu Ser 130

<210> 259

<211> 144

<212> PRT

<213> Streptococcus pneumoniae

<400> 259

Phe Thr Val Ser His Val Phe Leu Leu Tyr Leu Ser Phe Asn Pro Arg 10 15

```
str pneumoniae patentin.ST25

Pro Lys Ser Met Ser Leu Ser Phe Thr Ser Ser Lys Leu Leu Arg Pro

20
25
30
      Arg Phe Arg Thr Phe Ile Ile Ser Ala Ser Asp Phe Ser Val Lys Ser
      Cys Thr Val Leu Ile Pro Ala Arg Phe Lys Gln Leu Tyr Glu Arg Thr 50 60
     Asp Lys Ser Ser Ser Ser Ile Val Arg Ser Lys Ile Arg Ser Ser Asp 70 75 80
     Ser Val Ser Ala Ser Phe Ile Thr Ser Val Asp Leu Ala Ile Ser Val
85 90 95
     Arg Phe Val Asn Lys Ser Arg Cys Ser Val Lys Ile Arg Ala Glu Ser
100 105 110
     Pro Lys Ala Ser Ser Gly Ile Ile Val Pro Phe Val Lys Ile Ser Arg
     Val Asn Leu Ser Lys Pro Ser Leu Leu Pro Thr Arg Ala Gly Ser Thr
130 135 140
     <210>
            260
     <211>
            18
     <212>
            PRT
            Streptococcus pneumoniae
    <400> 260
    Leu Val Cys Met Lys Asn Lys Gly Cys Tyr Lys Glu Arg Asn Asn Cys 10 15
    Cys His
    <210>
           261
    <211>
           58
    <212>
           PRT
           Streptococcus pneumoniae
   <400>
   Phe His Tyr Leu Ser Lys Tyr Phe Leu Val Ser Ala Ile Thr Thr Gly
10 15
```

str pneumoniae patentin.ST25
Asp Lys Thr Lys Arg Ala Ile Lys Phe Gly Arg Ala Ile Lys Ala Leu
20 25 30 Thr Ile Ser Ala Ile Ile Gln Thr Ile Ser Asn Ser Ile Asn Pro Pro  $\frac{35}{40}$ Asn Lys Thr Met Ser Thr Lys Thr Thr Arg 50 <210> 262 <211> 47 <212> PRT <213> Streptococcus pneumoniae <400> 262 Gly Lys Lys Val Phe Ile Lys Tyr Pro Leu Ser Arg Val Ser Ser Lys 10 15Thr Gly Pro Met Ile Thr Gly Arg Thr Lys Asp Lys Ile Val Asp Lys 20 25 30 Lys Val Gly Cys Pro Phe Glu Lys Ser Thr Val Lys Tyr Ser Ser 35 40 45 <210> 263 <211> 37 <212> PRT <213> Streptococcus pneumoniae <400> 263 Ser Ser Pro Val Phe Pro Lys Leu Val Met Val Ser Gly Ala Asn Lys 1 10 15 Pro Arg Glu Arg Arg Asn Phe Pro Phe Ser Ser Lys Met Ser Phe His. 20 25 30 Leu Thr Phe Val Leu <210> 264 <211> 77 <212> PRT <213> Streptococcus pneumoniae

<400>-264

Tyr Leu Thr Ser Phe Ser Val Pro Lys Ile Ala Ser Ser Lys Val Lys

Leu Thr Arg Tyr Trp Arg Ser Ser Pro Trp Arg Gly Ala Phe Gly Leu
25
30

Arg Glu Glu Pro Pro Pro Lys Lys Leu Glu Lys Ile Ser Ser Lys

Pro Pro Lys Pro Pro Ala Pro Leu Lys Pro Pro Lys Pro Pro Ala Pro 50 60

Pro Lys Pro Pro Leu Ala Pro Ala Ala Pro Tyr Trp Ser

<210> 265

<211> 89

<212> PRT

<213> Streptococcus pneumoniae

<400> 265

Gln Ser Trp Arg Pro Ile Pro Asp Ser Lys Cys Tyr Thr Gln Glu Lys 10 15

Leu Thr Ile Pro Ile Lys Arg Arg Lys Asp Ile Lys Asp Phe Tyr His  $\frac{25}{20}$ 

Asn Ser Ile Gln Arg His Lys Asn Ser His Lys Ser His Leu Leu Asp 45

Ser Tyr Arg Leu Ile Ile Thr Arg Leu Ala Glu Ile Val His Glu Asn 50 60

Lys Ile Leu Ile Val Leu Ile Leu Tyr Val Thr Asn Ile Pro Ser Arg 65 70 75 80

Ser Arg Arg Tyr Glu Val Asn Arg Val 85

<210> 266

<211> 60

<212> PRT

<213> Streptococcus pneumoniae

<400> 266

Leu Phe Arg Phe Tyr Arg Val Ile Val Leu Tyr Arg Gly Trp His Ile  $10 \ 15$ 

Tyr Leu Leu Ile Leu Val Asn Leu Gln Tyr Val Gln Asn Val Phe Arg

Lys Asp Arg Phe Leu Val Arg Gly Ala Gln Pro Phe Phe His Gly Glu 35 40 45

Arg Ser Ala Gly His Leu Val Leu Pro Tyr Val Leu 50 60

<210> 267

<211> 60

<212> PRT

<213> Streptococcus pneumoniae

<400> 267

Ile Thr His Pro Pro Leu Asn Pro Glu His Phe Val Ser Arg Val Phe  $10^{\circ}$  15

Ser Ser Leu Gly Leu Lys Ser Tyr Gln Pro Lys Asp Asp Arg Phe Leu 20 25 30

Arg Lys Pro Ser Asp Ser Arg His Pro Glu Ser Gly Asn Ser Gly Lys 35 40 45

Trp Gln Val Leu Asn Ser Pro Leu Val Ile Val Lys 50 55 60

<210> 268

<211> 30

<212> PRT

<213> Streptococcus pneumoniae

<400> 268

Thr Leu Ala Lys Ala Val Gly Leu Met Tyr Ser Pro Pro Ile Pro Pro 1 10 15

Lys Pro Phe Leu Gly Arg Ile Thr Thr Asp Ser Ser Ser Ile 20 25 30

<210> 269

<211>---83

<212> PRT

<213> Streptococcus pneumoniae

#### <400>\_\_.269

Pro Gly Ser Pro Phe Ser Glu Ile Ser Gly Ala Gly Phe Phe Gly Val 10 15

Ala Lys Arg Ile Phe Pro Arg Pro Pro Arg Pro Pro Trp Ala Thr Ile 20 25 30

Asn Ser Cys Pro Cys Ser Ile Lys Ser Val Lys Thr Leu Pro Val Ser

Ala Ser Arg Thr Val Val Pro Cys Gly Thr Arg Thr Leu Arg Ser Ser 50 60

Ala Pro Arg Pro Cys Ile Pro Leu Val Ile Pro Phe Ser Pro Glu Ser 65 70 75

Ala Leu Lys

<210> 270

<211> 111

<212> PRT

<213> Streptococcus pneumoniae

<400> 270

Ile Asn Ser Leu Thr Leu Ala Thr Ser Leu Ser Lys Arg Arg Ala Pro 10 15

Arg Lys Ala Ser Lys Ala Ser Pro Arg Met Val Ser Arg Leu Arg Pro 20 25 30

Pro Asp Phe Ser Ser Pro Leu Pro Asn Leu Ile Asn Trp Ser Asn Trp  $\frac{35}{40}$ 

Gln Ser Arg Ala Lys Pro Ala Lys Leu Ser Ser Arg Thr Ile Ile Ala 50 60

Arg Ser Phe Asp Arg Ser Pro Ser Gly Phe Leu Gly Tyr Phe Leu Tyr 75 70 80

```
str pneumoniae patentin.ST25
Arg Tyr Ser Glu Ile Asn Asn Cys Arg Thr Ala Ser Pro Lys Asn Ser
85
90
95
Lys Arg Ser Leu Cys Glu Ile Phe Lys Arg Arg Cys Ser Leu Ala
100 105 110
<210> 271
<211>
       49
<212>
<213> Streptococcus pneumoniae
<400> 271
Pro Ile Gly Lys Arg Asn Cys Lys Ala Glu Cys Gln Ser His His Leu
1 10 15
Leu Glu Lys Gln Lys Thr Phe Gln Ser Arg Lys Thr Lys Arg Tyr Gly 20 25 30
Ala Ser Pro Glu Pro Arg Tyr Arg Glu Ser Arg Lys Pro Arg Leu Ser 35 40 45
GĨ'n
<210>
        272
        58
<211>
<212>
        PRT
<213>
        Streptococcus pneumoniae
<400> 272
Gln Pro Leu Gly His Ser Lys Ala Glu Glu His Glu Thr Ile Cys Ser
1 5 10 15
His Thr Phe Asp Asn His Thr Thr Glu Thr Ile Pro Asn Gln Val Lys
20 25 30
Gly Arg Asp Met Thr Ser Ser Glu Thr Leu Pro Phe Pro Ser Lys Asn 40 45
Gln Asn Gln Gly Lys Ala Lys Gln Ile Pro
50 55
<210> 273
```

<211>

125

## <213> Streptococcus pneumoniae

<400> 273

Pro Cys Ser Leu Pro Asp Tyr Gly Leu Val Gly Ser Gly Tyr His Ser

10
15

Cys His Tyr Gln Ser Asn Asp Thr Arg Phe Leu Glu Ser His Gly Asn 20 25 30

Trp Arg Thr Leu Leu Tyr Ser Trp Ser Trp Ile Leu Cys Gln Glu Lys  $\frac{35}{40}$ 

Thr Leu Phe Pro His Asp Leu Ala Ser Leu Tyr Pro Ser Cys Val Arg 50 60

Thr Ser Ile His Arg Tyr Cys Leu Leu His Val Lys Lys Leu Arg Asn 70 75 80

Ser Ile Ser Thr Phe Phe Phe Thr His Ile Asp Lys Val Leu Val Gln 85 90 95

Ala His Ile Ile Ser Gln Phe Trp Met Lys Arg Thr Tyr Gln His Ile 100 105 110

Phe Phe Leu Gly Cys Asn Asn Leu Ile Val His Cys Cys 115 120 125

<210> 274

<211> 69

<212> PRT

<213> Streptococcus pneumoniae

<400> 274

Arg Val Lys Asp Asn His Leu Asp Lys Leu Val Lys Ala Leu Leu Lys 1 10 15

Arg Arg Ser Ser Thr Gln Tyr Tyr Ile His Gln Leu Leu Arg Lys Met 20 25 30

Ile Arg Leu Tyr Gly His Gln Gln Leu His Asn Asn Ser Glu Ile Leu 35 40 45

Val Tyr Ser Asp Tyr Gly His Val Asp Leu Leu Leu Glu Thr Asn 50 60

Lys Ile Pro Val Tyr 65

<210> 275

<211> 40

<212> PRT

<213> Streptococcus pneumoniae

<400> 275

Gln Val Ile Lys Ile Asp Ile Ala Thr Thr Asn Lys Thr Glu Ser Val 1 10 15

Lys Ser Gln Ser Glu Arg Glu Lys Lys Arg Leu Thr Ser Ser Asn Ile 20 25 30

Leu Lys Val Arg Gly Arg Pro Ile 35 40

<210> 276

<211> 32

<212> PRT

<213> Streptococcus pneumoniae

<400> 276

Ala Phe Lys Ser Ser Lys Val Pro Ser Leu Asp Pro Ser Ser Thr Lys 1 10 15

Thr Tyr Ser Ile Ser Val Ser Lys Ser Gly Ser Lys Ala Ser Arg Ala 20 25 30

<210> 277

<211> 69

<212> PRT

<213> Streptococcus pneumoniae

<400> 277

Asp Lys Thr Asp Pro Leu Ala Arg Lys Leu Pro Asp Lys Ser Lys Pro 10 15

Ser Thr Ser Phe Cys Thr Lys Ser Leu Ser Pro Val Asn Met Ala Ser 20 25 30

# str pneumoniae patentin.ST25 Leu Thr Ser Ala Lys Pro Ser Lys Thr Lys Ala Ser Leu Gly Ile Gys 40 40 40

Ser Pro Ala Asp Lys Arg Met Thr Ser Pro Ser Thr Asn Ser Ser Gly 50 60

Leu Arg Ala Thr Ser

<210> 278

<211> 38

<212> PRT

<213> Streptococcus pneumoniae

<400> 278

Leu Cys Arg Leu Gln Thr Gln Ala Arg Pro Arg Gly Ser Val Thr Asn 10 15

Leu Thr Lys Gln Asn Lys Val Tyr Arg Tyr Leu Asn Tyr Leu Arg Gln 25 30

Thr Gln Leu Ser Ala Met

<210> 279

<211> 110

<212> PRT

<213> Streptococcus pneumoniae

<400> 279

Cys Ile Gln Ser Ile Gly Asn Glu Gly Gln Cys Lys Gly Asn Ser Cys 10 15

Tyr Val Gly Lys Glu Ile His Leu Ala Pro Ile Ser Asp Ile Val Gly

His Lys Gly Lys Glu Glu Gly Asp Asp Gly Asn Asp Asp Gly Arg Gln 35 40 45

Phe Tyr Leu Phe Leu Ala His Leu Val Gly Ser Ala Phe Leu Arg Ser 50 60

Phe Pro Leu Leu Tyr Ser Lys Gly Ile Asn Glu Glu Gly Asp Gly Ile 65 75 75 80

str pneumoniae patentin.ST25
Gly Asn Asp Gly Arg Leu Ile Ser Lys Asp Ile Ile Asn Ser Thr Gly
85
90
95

Gln Asn Gly Ile Asn Asn Thr Lys Val Ile Ser Pro Phe Ala 100 105 110

<210> 280

<211> 121

<212> PRT

<213> Streptococcus pneumoniae

<400> 280

Thr Ser Thr Lys Leu Val Ile Asp Thr Thr Thr Phe Met Thr Phe Cys 10 15

Thr Asn Asn Thr Lys Ser Ser Lys Phe Thr Asn Thr Phe Thr Lys Leu 20 25 30

Asp Val Gly Thr Thr Arg His Val Gly Cys Asp Gly Asn Gly Thr 35 40 45

Thr Leu Thr Ser Ile His Asp Asp Leu Gly Phe Ser Ile Val Val Phe 50 60

Gly Ile Gln Asp Phe Val Arg Asn Thr Ser Cys Asn Gln Phe Leu Arg 65 70 75 80

Asn Val Val Thr Ser Phe Asn Arg Tyr Cys Thr Asn Gln Asp Arg Leu 85 90 95

Thr Leu Leu Val Thr Ser Leu Asn Val Phe Asp Asn Arg Phe Lys Leu 100 105 110

Arg Phe Asp Thr Cys Ile Lys Lys Val

<210> 281

<211> 27

<212> PRT

<213> Streptococcus pneumoniae

<400> 281

Ile Ser Thr Gly Val Pro Thr Cys Ser Met Tyr Pro Leu Leu Lys Thr 10 15

## str pneumoniae patentin.ST25 Ala Ile Leu Ser Asp Lys Val Lys Ala Ser Ser 20 25

<210> 282

<211> 34

<212> PRT

<213>--Streptococcus pneumoniae---

<400> 282

Leu Ser Thr Met Ser Ser Ile Lys Ser Ile Leu Cys Ser Leu Pro Thr 10 15

His Thr Ile Phe Ser Lys Ser Ala Ile Ser Pro Lys Arg Gly Ser Thr 20 25 30

Ala Ile

<210> 283

<211> 111

<212> PRT

<213> Streptococcus pneumoniae

<400> 283

Ser Cys Ser Tyr Ser Ser Thr Asn Ser Lys Ala Cys Ser Ile Val Gly 10 15

Leu Ser Lys Pro Thr Ile Phe Ile Cys Val Thr Pro Ile Ser Ala Ala 20 25 30

Lys Ala Ile Ser Ser Ala Ser Arg Pro Ala Asn Ser Ser Thr Phe Lys  $\frac{35}{40}$ 

Cys Val Cys Val Ser Lys Ile Ile Ser Ser Asn Leu Val Phe Tyr Leu 50 60

Leu Leu Tyr Gln Lys Arg Gly Gly Ala Pro Asn Phe Ser Val Ser Pro 65 70 75 80

Pro Leu Phe Asn Arg Glu Leu Phe Cys Tyr Leu Phe Tyr Pro Ile Leu  $85 \ 90 \ 95$ 

Pro Ile Ser Tyr Ser Thr Val Arg Asp Arg Arg Asp Trp Leu His 100 105 110

<210> 284

<211> 110

<212> PRT

<213> Streptococcus pneumoniae

<400> 284

Val Thr Ser Cys Ile Val Pro Ala Val Ala Cys Gly Ala Leu Val Val 1 10 15

Leu Gly Ala Ala Leu Gly Ala Thr Gly Leu Leu Gly Thr Val Thr Met 20 25 30

Ala Met Ala Cys Thr Pro Ile Val Ser Ala Ser Phe Thr Ser Ser Ile 35 40 45

Val Phe Ala Phe Ser Ile Ser Leu Arg Ala Ala Cys Phe Ser Ala Ser 50 60

Thr Leu Ala Lys Ser Ser Ala Phe Ser Leu Ser Glu Ser Gly Ala Pro 65 70 75 80

Leu Ile Ser Ser Cys Leu Ser Leu Ala Ala Phe Ser Met Ala Phe Leu 85 90 95

Ala Asp Ser Phe Ser Val Ala Asn Cys Leu Glu Ala Cys Asp 100 105 110

<210> 285

<211> 53

<212> PRT

<213> Streptococcus pneumoniae

<400> 285

Tyr Ser Pro Phe Asn His Ser Ile Leu Ile Arg Lys Thr Thr Lys Ile 5 10 15

Ile Asn Pro Asn Pro Lys Ala Pro Arg Met Asn Trp Arg Ser Lys Val

Trp Ser Asn Gln Pro Val Asn Ile Ser Thr Asn His Thr Lys Ser Asp  $\frac{35}{40}$ 

Arg Pro Ile Lys Lys 50

str pneumoniae patentin.ST25 <210> 286 <212> PRT <213> Streptococcus pneumoniae Asp Tyr Phe Lys Phe Arg Thr Thr Phe Thr Arg Phe Ser Thr Val Lys

10
15 Pro Tyr Ser Ala Asn Thr Phe Gly Ala Gly Ala Glu Ala Pro Lys Val 20 25 30 Ser Ile Pro Arg Thr Ala Pro Ser Arg Pro Thr Tyr Leu Tyr Gln Phe 35 40 45 <210> 287 <211> 74 <212> Streptococcus pneumoniae <400> 287 Arg Gly Arg Arg Gly Leu Cys Val Ala Arg Ile Lys Ala Pro Arg Leu 10 15 Val Ile Lys Pro Lys Arg Thr Ile Asp Pro Pro Thr Lys Asp Arg Tyr 20 25 30 Ser Pro Pro Leu Ser Ala Thr Ser Leu Ser Val Pro Lys Ser Pro Ile  $\frac{35}{40}$ Ile Ser Phe Pro Ala Lys Met Asp Lys Asn Pro Lys Arg Lys Leu Asn 50 60 Ser Lys Val Ile Phe Asn Ala Ser Val Thr 70 <210> 288 <211> 30 <212> PRT <213> Streptococcus pneumoniae

<400>

288

str pneumoniae patentin.ST25
Thr Pro Pro Tyr Thr Lys Ile Pro Ala Lys Thr Ala Ile Ile Pro Phe
1 5 10 15

Ile Ser Ala Gln Asp Phe Asn Gln Ala Gln Arg Leu Ser Gly 20 25 30

PCT/EP2004/003984

The second secon

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
Потиев.

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.